
<html lang="en"     class="pb-page"  data-request-id="45cfe3f3-473e-4e61-bc33-a146c10b1547"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01459;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-1;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development" /></meta><meta name="dc.Creator" content="Lu  Hou" /></meta><meta name="dc.Creator" content="Jian  Rong" /></meta><meta name="dc.Creator" content="Ahmed  Haider" /></meta><meta name="dc.Creator" content="Daisuke  Ogasawara" /></meta><meta name="dc.Creator" content="Cassis  Varlow" /></meta><meta name="dc.Creator" content="Michael A.  Schafroth" /></meta><meta name="dc.Creator" content="Linjing  Mu" /></meta><meta name="dc.Creator" content="Jiefeng  Gan" /></meta><meta name="dc.Creator" content="Hao  Xu" /></meta><meta name="dc.Creator" content="Christopher J.  Fowler" /></meta><meta name="dc.Creator" content="Ming-Rong  Zhang" /></meta><meta name="dc.Creator" content="Neil  Vasdev" /></meta><meta name="dc.Creator" content="Simon  Ametamey" /></meta><meta name="dc.Creator" content="Benjamin F.  Cravatt" /></meta><meta name="dc.Creator" content="Lu  Wang" /></meta><meta name="dc.Creator" content="Steven H.  Liang" /></meta><meta name="dc.Description" content="The endocannabinoid system (ECS) is involved in a wide range of biological functions and comprises cannabinoid receptors and enzymes responsible for endocannabinoid synthesis and degradation. Over ..." /></meta><meta name="Description" content="The endocannabinoid system (ECS) is involved in a wide range of biological functions and comprises cannabinoid receptors and enzymes responsible for endocannabinoid synthesis and degradation. Over ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 31, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01459" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01459" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01459" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01459" /></link>
        
    
    

<title>Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01459" /></meta><meta property="og:title" content="Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0007.jpeg" /></meta><meta property="og:description" content="The endocannabinoid system (ECS) is involved in a wide range of biological functions and comprises cannabinoid receptors and enzymes responsible for endocannabinoid synthesis and degradation. Over the past 2 decades, significant advances toward developing drugs and positron emission tomography (PET) tracers targeting different components of the ECS have been made. Herein, we summarized the recent development of PET tracers for imaging cannabinoid receptors 1 (CB1R) and 2 (CB2R) as well as the key enzymes monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), particularly focusing on PET neuroimaging applications. State-of-the-art PET tracers for the ECS will be reviewed including their chemical design, pharmacological properties, radiolabeling, as well as preclinical and human PET imaging. In addition, this review addresses the current challenges for ECS PET biomarker development and highlights the important role of PET ligands to study disease pathophysiology as well as to facilitate drug discovery." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01459"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01459">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01459&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01459&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01459&amp;href=/doi/10.1021/acs.jmedchem.0c01459" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 123-149</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01307" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01473" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Lu Hou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lu Hou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lu++Hou">Lu Hou</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Rong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Rong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Rong">Jian Rong</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ahmed Haider</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ahmed Haider</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ahmed++Haider">Ahmed Haider</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daisuke Ogasawara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daisuke Ogasawara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, SR107, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daisuke++Ogasawara">Daisuke Ogasawara</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cassis Varlow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cassis Varlow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, and Department of Psychiatry/Institute of Medical Science, University of Toronto, 250 College Street, Toronto, M5T 1R8 ON, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cassis++Varlow">Cassis Varlow</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael A. Schafroth</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael A. Schafroth</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, SR107, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Schafroth">Michael A. Schafroth</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5864-6766" title="Orcid link">http://orcid.org/0000-0002-5864-6766</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linjing Mu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linjing Mu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ, and Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linjing++Mu">Linjing Mu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiefeng Gan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiefeng Gan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiefeng++Gan">Jiefeng Gan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Xu">Hao Xu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath9">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher J. Fowler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. Fowler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87 Umeå, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Fowler">Christopher J. Fowler</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath10">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ming-Rong Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ming-Rong Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ming-Rong++Zhang">Ming-Rong Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath11">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3001-9605" title="Orcid link">http://orcid.org/0000-0002-3001-9605</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil Vasdev</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil Vasdev</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</div><div class="loa-info-affiliations-info">Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, and Department of Psychiatry/Institute of Medical Science, University of Toronto, 250 College Street, Toronto, M5T 1R8 ON, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil++Vasdev">Neil Vasdev</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath12">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2087-5125" title="Orcid link">http://orcid.org/0000-0002-2087-5125</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon Ametamey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon Ametamey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ, and Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Ametamey">Simon Ametamey</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath13">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4285-6731" title="Orcid link">http://orcid.org/0000-0003-4285-6731</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benjamin F. Cravatt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benjamin F. Cravatt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, SR107, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin+F.++Cravatt">Benjamin F. Cravatt</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath14">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5330-3492" title="Orcid link">http://orcid.org/0000-0001-5330-3492</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lu Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lu Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China</div><div class="loa-info-affiliations-info">Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</div></div><span class="conrtib-corresp"><strong>*</strong>L.W.: phone, +862038688994; email, <a href="/cdn-cgi/l/email-protection#b7dbe8c0d6d9d08687878ef7ddd9c299d2d3c299d4d9"><span class="__cf_email__" data-cfemail="c3af9cb4a2ada4f2f3f3fa83a9adb6eda6a7b6eda0ad">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lu++Wang">Lu Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath15">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8049-1991" title="Orcid link">http://orcid.org/0000-0002-8049-1991</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Steven H. Liang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven H. Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</div></div><span class="conrtib-corresp"><strong>*</strong>S.H.L.: phone, +16177266107; fax, +1-617-726-6165; email, <a href="/cdn-cgi/l/email-protection#b3dfdad2ddd49dc0c7d6c5d6ddf3ded4db9ddbd2c1c5d2c1d79dd6d7c6"><span class="__cf_email__" data-cfemail="08646169666f267b7c6d7e6d6648656f602660697a7e697a6c266d6c7d">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+H.++Liang">Steven H. Liang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath16">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1413-6315" title="Orcid link">http://orcid.org/0000-0003-1413-6315</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01459&amp;href=/doi/10.1021%2Facs.jmedchem.0c01459" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 123–149</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 30, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 August 2020</li><li><span class="item_label"><b>Published</b> online</span>31 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01459" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01459</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D123%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLu%2BHou%252C%2BJian%2BRong%252C%2BAhmed%2BHaider%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D1%26contentID%3Dacs.jmedchem.0c01459%26title%3DPositron%2BEmission%2BTomography%2BImaging%2Bof%2Bthe%2BEndocannabinoid%2BSystem%253A%2BOpportunities%2Band%2BChallenges%2Bin%2BRadiotracer%2BDevelopment%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D149%26publicationDate%3DJanuary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01459"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1237</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01459" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Lu&quot;,&quot;last_name&quot;:&quot;Hou&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Rong&quot;},{&quot;first_name&quot;:&quot;Ahmed&quot;,&quot;last_name&quot;:&quot;Haider&quot;},{&quot;first_name&quot;:&quot;Daisuke&quot;,&quot;last_name&quot;:&quot;Ogasawara&quot;},{&quot;first_name&quot;:&quot;Cassis&quot;,&quot;last_name&quot;:&quot;Varlow&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Schafroth&quot;},{&quot;first_name&quot;:&quot;Linjing&quot;,&quot;last_name&quot;:&quot;Mu&quot;},{&quot;first_name&quot;:&quot;Jiefeng&quot;,&quot;last_name&quot;:&quot;Gan&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Fowler&quot;},{&quot;first_name&quot;:&quot;Ming-Rong&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Vasdev&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Ametamey&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;F. Cravatt&quot;},{&quot;first_name&quot;:&quot;Lu&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;H. Liang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;123-149&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01459&quot;},&quot;abstract&quot;:&quot;The endocannabinoid system (ECS) is involved in a wide range of biological functions and comprises cannabinoid receptors and enzymes responsible for endocannabinoid synthesis and degradation. Over the past 2 decades, significant advances toward developing drugs and positron emission tomography (PET) tracers targeting different components of the ECS have been made. Herein, we summarized the recent development of PET tracers for imaging cannabinoid receptors 1 (CB1R) and 2 (CB2R) as well as the key enzymes monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), particularly focusing on PET neuroimaging applications. State-of-the-art PET tracers for the ECS will be reviewed including their chemical design, pharmacological properties, radiolabeling, as well as preclinical and human PET imaging. In addition, this review addresses the current challenges for ECS PET biomarker development and highlights the important role of PET ligands to study disease pathophysiology as well as to facilitate drug disc&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01459&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01459" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01459&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01459" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01459&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01459" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01459&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01459&amp;href=/doi/10.1021/acs.jmedchem.0c01459" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01459" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01459" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01459%26sid%3Dliteratum%253Aachs%26pmid%3D33379862%26genre%3Darticle%26aulast%3DHou%26date%3D2021%26atitle%3DPositron%2BEmission%2BTomography%2BImaging%2Bof%2Bthe%2BEndocannabinoid%2BSystem%253A%2BOpportunities%2Band%2BChallenges%2Bin%2BRadiotracer%2BDevelopment%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D1%26spage%3D123%26epage%3D149%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291663" title="Positron emission tomography">Positron emission tomography</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/jmcmar.2021.64.issue-1/20210114/jmcmar.2021.64.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The endocannabinoid system (ECS) is involved in a wide range of biological functions and comprises cannabinoid receptors and enzymes responsible for endocannabinoid synthesis and degradation. Over the past 2 decades, significant advances toward developing drugs and positron emission tomography (PET) tracers targeting different components of the ECS have been made. Herein, we summarized the recent development of PET tracers for imaging cannabinoid receptors 1 (CB1R) and 2 (CB2R) as well as the key enzymes monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), particularly focusing on PET neuroimaging applications. State-of-the-art PET tracers for the ECS will be reviewed including their chemical design, pharmacological properties, radiolabeling, as well as preclinical and human PET imaging. In addition, this review addresses the current challenges for ECS PET biomarker development and highlights the important role of PET ligands to study disease pathophysiology as well as to facilitate drug discovery.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25283" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25283" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The endocannabinoid system (ECS) constitutes a lipid-based signaling system in the human central nervous system (CNS), which includes primarily two cannabinoid receptors (CB1R and CB2R), their endogenous ligands, and enzymes responsible for ligand synthesis and degradation. In the brain, 2-arachidonoylglycerol (2-AG) and <i>N</i>-arachidonoylethanolamine (AEA), the most well-known endogenous ligands for cannabinoid receptors, are produced by the postsynaptic membrane as “on-demand” to stimulate adjacent CB1 receptors. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> depicts a general model for the ECS signaling in the CNS. This model, whereby postsynaptic endocannabinoid synthesis in response to a presynaptic signal acts presynaptically to depress the release of the presynaptic neurotransmitter, has been suggested to provide a protective negative feedback mechanism against overactivity of the presynaptic nerves.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Peripheral roles of the endocannabinoid system in the regulation of processes as diverse as gut function and bone turnover are also well-described.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> These endogenous cannabinoids are mainly synthesized by membrane phospholipids on the postsynaptic membrane.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Several catabolic pathways responsible for the termination of endocannabinoid signaling have been described.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Among all hydrolytic enzymes, fatty acid amide hydrolase (FAAH) is the main metabolic enzyme of AEA, while monoacylglycerol lipase (MAGL) is the primary metabolic enzyme of 2-AG in the brain.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> Nonetheless, other serine hydrolases α/β hydrolase domain-6 (ABHD6) and α/β hydrolase domain-12 (ABHD12) may be more important for endocannabinoid metabolism in microglial cells.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Additional catabolic pathways, such as oxidation catalyzed by cyclooxygenase-2 and by some members of the cytochrome P450 (CYP) family of enzymes, have also been reported and yield biologically active products<a onclick="showRef(event, 'ref4 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref8">(4,8)</a> but are outside the scope of the present article.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Model for the ECS Signaling in the Nervous System</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ECS regulates important physiological processes such as pain, emotion, stress, exercise, and cognition functions.<a onclick="showRef(event, 'ref2 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref2 ref9 ref10">(2,9,10)</a> Accordingly, cannabinoid receptors have become promising targets for the management of numerous pathologies including, but not limited to, chronic pain, epilepsy, anxiety, depression, Alzheimer disease (AD), Parkinson’s syndrome (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), drug dependence, osteoporosis, and liver, kidney, intestine, and cardiovascular dysfunction (CVD).<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15 ref16">(11−16)</a> Cannabinoids, particularly phytocannabinoid preparations, also have a wide off-label use in the treatment of chronic pain, despite modest evidence of efficacy in rigorous randomized clinical trials and a high incidence of unwanted effects.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">Positron emission tomography (PET) is a noninvasive and highly sensitive molecular imaging technique that allows <i>in vivo</i> quantification of biochemical and pharmacological processes under healthy and diseased conditions.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> By use of radioactive PET tracers, <i>in vivo</i> imaging can be achieved at the molecular level to obtain quantitative information on target engagement and the degree of receptor occupancy at a given drug dose. PET scanning equipment and PET probes are just like the relationship between pistol and bullet. The bullet can accurately target <i>in vivo</i> biomarkers and provide real-time information on tracer accumulation in the area of interest, which plays a crucial role in precision medicine and quantitative pharmacokinetic research.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Such information is invaluable and harbors enormous potential to accelerate drug development,<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> especially in phase 0 clinical trials.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23−26)</a> Over the past decades, while many PET probes targeting endogenous cannabinoid receptors (CB1R and CB2R) and hydrolases (FAAH and MAGL) have substantially advanced our understanding of the ECS,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> the vast majority of reported reviews are confined to one specific ECS component such as CB1R<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> or CB2R.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Previous reviews of CNS PET did not cover the radiotracers targeting cannabinoid receptors and MAGL.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In contrast, this review provides a comprehensive summary of PET-based ECS imaging, thereby covering CB1R-, CB2R-, FAAH-, and MAGL-targeted probes, as well as presenting challenges in drug discovery, radioligand development, and medical imaging applications. For each ECS component, representative PET probes will be introduced with their pharmacological properties, radiolabeling techniques, and PET imaging in rodents/non-human primates (NHPs)/human subjects.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  Receptor Targeting PET Tracers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02730" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02730" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Both CB1R and CB2R are members of the G-protein-coupled receptor (GPCR) superfamily containing seven transmembrane structures.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> CB1R density is high in the human brain, especially in the substantia nigra, globus pallidus, putamen, hippocampus, and cerebellum.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33−35)</a> CB1R is also abundantly expressed in peripheral nerves and tissues though in a region-specific manner.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> For example, in the gastrointestinal system, CB1R can regulate intestinal peristalsis and the secretion of gastric acid and neurotransmitter, which in turn affects appetite and digestion.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In the cardiovascular system, CB1R is significantly upregulated under pathological conditions and promotes disease progression.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> CB1R expression has also been detected in adipose tissue, bone, skin, as well as several cancer cells.<a onclick="showRef(event, 'ref36 ref40'); return false;" href="javascript:void(0);" class="ref ref36 ref40">(36,40)</a></div><div class="NLM_p">Although CB2R and CB1R share 44% structural homology, their distribution patterns in the mammalian system are fundamentally different.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Indeed, CB2R is predominantly found in peripheral organs harboring large numbers of immune cells such as the spleen and tonsils. Further, moderate expression can be found in the cardiovascular system, bone marrow, and reproductive organs.<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41−43)</a> Recently, the crystal structures of CB1R and CB2R have been revealed.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Hua et al.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> uncovered the structures of the inactivated, intermediate, and activated states of CB1R and CB2R, respectively, which provides more accurate molecule models and theoretical support for drug and ligand discovery.</div><div class="NLM_p">Due to the diverse regulatory effects by chronic therapeutic exposure and the presence of genetic splice variants, cannabinoid receptors have unique pharmacological and physiological effects and have been considered as an attractive drug target for over 20 years. CB1R plays an important role in normal physiology (cognition, appetite, memory)<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and is closely related to several neuropsychiatric<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and metabolic diseases.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> CB1R agonists and inverse agonists have been extensively developed but are accompanied by side effects impairing cognitive function and the ECS reward system.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> A well-known example is rimonabant (SR141716A), a potent and selective CB1R inverse agonist developed by Sanofi-Synthelabo.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> It was found to improve lipid and glucose metabolism and became one of the most promising weight-loss drugs. However, rimonabant was later linked to rare but severe cases of depression and suicide, resulting in its withdrawal from the market in 2008.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Currently approved drugs by the FDA include tetrahydrocannabinol, cannabidiol, and their analogs or compositions, such as Marinol (dronabinol),<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> Cesamet (nabilone),<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Sativex (nabiximols),<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and Epidiolex (cannabidiol).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> CB1 negative allosteric modulators, dronabinol, and nabilone are mainly used to treat nausea, vomiting, and weight loss when traditional therapeutics are ineffective and for the treatment of spasticity and pain in MS as combination therapy (nabiximols). Cannabidiol is used to treat epilepsy associated with Lennox–Gastaut syndrome (LGS) and Dravet syndrome (DS). In order to avoid CNS side effects, drugs that act on peripheral CB1R alone have been developed and demonstrated promising results. NEO1940 (ART27.13), a peripheral CB1R and CB2R agonist for the treatment of cancer-related anorexia and weight loss, has entered a phase II clinical trial.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> CRB-4001(JD-5037) is a peripheral CB1R inverse agonist in a phase I clinical trial, which was intended for the treatment of nonalcoholic steatohepatitis.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> CB2R regulation is disrupted in peripheral inflammation, neurological diseases, cancer, and atherosclerosis.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> Of note, CB2R activation is associated with anti-inflammatory and protective effects in the CNS and periphery.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> In several neurodegenerative disease models such as AD or PD, treatment with selective CB2R agonists is effective in attenuating proinflammatory cytokine release and migratory activity of immune system cells.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> Thus, the effects of CB2R agonists may offer a new therapeutic approach for the treatment of neurodegenerative disorders, taking advantage of the notion that CB2R activation does not elicit the psychoactive side effects frequently observed with brain penetrating CB1R agonists.<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68,69)</a></div><div class="NLM_p">CB2 agonist JBT-101 (lenabasum) is currently in a phase III clinical trial for treating diffuse skin systemic sclerosis and dermatomyositis and in a phase II clinical trial for treating cystic fibrosis, systemic sclerosis, and systemic lupus erythematosus.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> CB2 agonist APD371 (olorinab) entered phase II trials for the treatment of gastrointestinal pain.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> As mentioned above, the development of PET radiotracers for cannabinoid receptors facilitates our understanding of the ECS under normal physiological and disease states and has played an important role in the design and evaluation of promising drugs that target the receptors. Several research groups have made substantial efforts toward the development of CB1R or CB2R PET radioligands, highlighting applications in CNS diseases.</div><div class="NLM_p">Given the diversity of ECS-targeted drug discovery, the clinical availability of suitable PET probes is crucial to guide drug development as well as to identify and validate novel disease areas, where the ECS can be exploited as a pharmacological target. As such, several research groups have made substantial efforts toward the development of CB1R or CB2R PET radioligands.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  PET Tracers for Imaging CB1R</h3><div class="NLM_p">Endogenous CB1R ligands have moderate affinity and are highly lipophilic, rendering them unsuitable for PET or SPECT (single photon emission computed tomography) tracer development. By reducing their lipophilicity and retaining their high affinity, researchers synthesized a series of compounds for imaging CB1R in the CNS. On the basis of selective CB1 antagonists, PET tracers have been widely developed and selected structures are shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. A summary of the relevant parameters for selected CB1R specific PET tracers is presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative chemical structures for CB1R-specific PET tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Radiolabeling and PET Imaging Application of CB1R Specific Tracers<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">PET imaging study</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">radioligand (RCY)</th><th class="colsep0 rowsep0" align="center">subject</th><th class="colsep0 rowsep0" align="center">brain uptake</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>5</b> (16 ± 5%<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents: obesity (myocardial imaging)</td><td class="colsep0 rowsep0" align="left">Mouse: 6.6 %ID/g (striatum, 15 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NHP</td><td class="colsep0 rowsep0" align="left">Baboon: BP, 1.3 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: SZ; obesity (myocardial imaging); alcohol dependence</td><td class="colsep0 rowsep0" align="left">Human: <i>V</i><sub>T</sub> = 1.35 ± 0.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: SUV<sub>max</sub> = 1.75 ± 0.35 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: <i>V</i><sub>T</sub> = 0.72 ± 0.07 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>6</b> (2.5% ± 1.1%<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Monkey: <i>V</i><sub>T</sub> = 24.3 (mL/m<sup>3</sup>, striatum)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: SZ</td><td class="colsep0 rowsep0" align="left">Human: <i>V</i><sub>T</sub> = 29.1 ± 17.4 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: SUV<sub>max</sub> = 3.5 ± 0.5 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>7</b> (16.5%<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Rat: high BBB permeability, high specificity to CB1R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 3.3 (30 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8</b> (7.92 ± 2.16%<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Rat: high BBB permeability, high specificly to CB1R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 2.75 ± 0.75 (15 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>9</b> (5.92% ± 1.34%<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Rat: high BBB permeability, high specificity to CB1R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 5.75 ± 0.75 (20 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>10</b> (7.93 ± 2.48%<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">Rodents: AD; BAT</td><td class="colsep0 rowsep0" align="left">Mouse: 1.5%ID/mL (BAT)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NHP</td><td class="colsep0 rowsep0" align="left">Monkey:SUV<sub>max</sub> = 5.5 ± 1.0 (20 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: chronic cannabis smokers; alcohol-dependent; SZ; psychosis</td><td class="colsep0 rowsep0" align="left">Monkey: <i>V</i><sub>T</sub>: 35.4 (mL/m<sup>3</sup>, striatum)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: SUV<sub>max</sub> = 3.5 ± 0.5 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: <i>V</i><sub>T</sub>: 24.3 ± 7.2 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>11</b> (−)</td><td class="colsep0 rowsep0" align="left">Rodents: HD; PD</td><td class="colsep0 rowsep0" align="left">Rat, monkey: high BBB permeability, high specificity to CB1R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NHP</td><td class="colsep0 rowsep0" align="left">Human: SUV<sub>max</sub> = 1.5 ± 0.2 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: anorexia and bulimia nervosa; episodic migraine; epilepsy; HD</td><td class="colsep0 rowsep0" align="left">Human: <i>V</i><sub>T</sub> = 25.1 ± 13.3 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>12</b> (50%<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP, human</td><td class="colsep0 rowsep0" align="left">Monkey: <i>V</i><sub>T</sub> = 2.36 (mL/m<sup>3</sup>, striatum)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: SUV<sub>max</sub> = 2.35 ± 0.65 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: <i>V</i><sub>T</sub> = 3.15 ± 0.70 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>15</b> (7.35 ± 4.25%<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">NHP</td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 2.2 ± 0.5 (120 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>16</b> (3.55 ± 2.05%<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">NHP</td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 1.8 (240 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>17</b> (17 ± 8%)</td><td class="colsep0 rowsep0" align="left">Rodents: BAT</td><td class="colsep0 rowsep0" align="left">Mouse: 2.8 %ID/mL (BAT)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">The data of PET imaging are listed only in the control group.</p></div><div class="footnote" id="t1fn1"><sup><sup>b</sup></sup><p class="last">Non-decay-corrected RCYs.</p></div><div class="footnote" id="t1fn2"><sup><sup>c</sup></sup><p class="last">Decay-corrected RCYs.</p></div></div></div><div class="NLM_p">Initially, a series of PET tracers ([<sup>18</sup>F]<b>1</b>–[<sup>11</sup>C]<b>4</b>) based on rimonabant were developed for CB1R imaging and preliminary biological evaluations were carried out. However, these tracers had either high lipophilicity (log <i>D</i> > 4), resulting in nonspecific binding, or poor brain permeability that is not suitable for CNS imaging.<a onclick="showRef(event, 'ref71 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73">(71−73)</a> To improve the binding affinity of rimonabant (<i>K</i><sub>i</sub> hCB1R = 46.2 nM, cLogD = 6.0), Fan et al. synthesized OMAR/JHU5528 (<i>K</i><sub>i</sub> hCB1R = 11 ± 7 nM, cLogD = 4.3) and its analogs by introducing cyano groups. OMAR is a CB1R antagonist, demonstrating higher specificity than earlier CB1R antagonists with decreased lipophilicity and significantly increased <i>B</i><sub>max</sub>/<i>K</i><sub>i</sub> ratio to 91, indicating great potential for successful <i>in vivo</i> imaging.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> Further, PET evaluations in mouse and baboons demonstrated that [<sup>11</sup>C]OMAR ([<sup>11</sup>C]<b>5</b>) readily entered the brain, specifically and selectively visualizing cerebral CB1 receptors. In the biodistribution experiment, the radioactive accumulation reached its maximum value (6.6 %ID/g in the striatum) at 15 min; radioactivity in the baboon brain reached its peak at about 10 min, and the ratio of CB1-rich regions to CB1-poor regions was up to 2.5, and the highest binding potential (BP) value was 1.3 in the putamen.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Wong et al.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> presented the first human studies by using [<sup>11</sup>C]<b>5</b>, which successfully displayed the distribution of CB1R in the healthy controls and SZ patients. Maximum standard uptake value (SUV<sub>max</sub>) in controls reached 1.4–2.1 at about 20 min postinjection and average volume of distributions <i>(V</i><sub>T</sub>) ranged from 1.0 to 1.7. Compared with control siubjects, regional total <i>V</i><sub>T</sub> values of [<sup>11</sup>C]<b>5</b> were higher in SZ patients, especially in the pons (0.93 vs 0.72, <i>P</i> < 0.05). Another study comparing the availability of CB1R between male SZ patients and healthy controls highlighted that CB1R availability of male SZ patients was moderately and globally reduced, and the use of antipsychotics and tobacco increased CB1R availability in patients.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a><i>In vitro</i> studies have shown that the ECS plays a vital role in alcohol dependence.<a onclick="showRef(event, 'ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82">(80−82)</a> Neumeister et al. used [<sup>11</sup>C]<b>5</b> to carry out the first <i>in vivo</i> experiment to demonstrate this correlation. <i>V</i><sub>T</sub> in alcohol-dependent patients administered [<sup>11</sup>C]<b>5</b> was approximately 20% (<i>P</i> = 0.023) higher than that of healthy controls.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">Compound [<sup>11</sup>C]<b>5</b> was not only used to image CB1R in the CNS but was also successfully employed to assess peripheral cardiovascular CB1R expression. Valenta et al. demonstrated that the retention rate of [<sup>11</sup>C]<b>5</b> in the myocardium of obese mice was significantly higher than that of normal-weight mice.<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84,85)</a> These results may provide a theoretical basis for further clinical testing of CB1R targeted molecular imaging in cardiac metabolic diseases. However, due to the moderate lipophilicity of [<sup>11</sup>C]<b>5</b>, it tends to accumulate in the liver, which may hamper accurate quantitative assessment.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_p">Similarly, on the basis of the structure of SR141716, Yasuno et al. reported the synthesis of [<sup>11</sup>C]MePPEP ([<sup>11</sup>C]<b>6</b>) (<i>K</i><sub>i</sub> hCB1R = 0.11 nM, <i>K</i><sub>b</sub> = 0.57 nM, log <i>D</i><sub>7.4</sub> = 4.8, <i>K</i><sub>b</sub> represents an <i>in vitro</i> efficacy constant that is calculated using the following equation <i>K</i><sub>b</sub> = IC<sub>50</sub>/[1 + [agonist]/EC<sub>50</sub>], which is derived from the Cheng–Prusoff relationship<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a>) by the reaction of the <i>O</i>-desmethyl precursor with [<sup>11</sup>C]CH<sub>3</sub>I. Compared to PET imaging of [<sup>11</sup>C]<b>5</b> in baboon brain, the uptake kinetics of the two tracers were similar, but the peak uptake of [<sup>11</sup>C]<b>6</b> was higher and SUV<sub>max</sub> almost reached 6.0 within 10–20 min postinjection.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Subsequently, Donohue et al. synthesized [<sup>11</sup>C]<b>6</b> and its four analogs [<sup>11</sup>F]FMePPEP ([<sup>11</sup>C]<b>7</b>, <i>K</i><sub>b</sub> = 0.22 nM, log <i>D</i><sub>7.4</sub> = 5.7), [<sup>18</sup>F]FEPEP ([<sup>18</sup>F]<b>8</b>, <i>K</i><sub>b</sub> = 0.42 nM, log <i>D</i><sub>7.4</sub> = 5.8), [<sup>18</sup>F]FMPEP ([<sup>18</sup>F]<b>9</b>, <i>K</i><sub>b</sub> = 0.19 nM, log <i>D</i><sub>7.4</sub> = 5.7), and [<sup>18</sup>F]FMPEP-<i>d</i><sub>2</sub> ([<sup>18</sup>F]<b>10</b>, <i>K</i><sub>i</sub> hCB1R = 0.11 nM, log <i>D</i> = 4.24)<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> and demonstrated that [<sup>11</sup>C]<b>6</b>-<b>7</b> and [<sup>18</sup>F]<b>8</b>-<b>9</b> crossed the blood–brain barrier adequately and exhibited high specificity to CB1R in rat brain tissues. Terry et al. further evaluated these four imaging agents ([<sup>11</sup>C]<b>7</b>, [<sup>18</sup>F]<b>8</b>–<b>10</b>) in monkeys, and SUV<sub>max</sub> in the brain were 3.3 by 30 min, 2–3.5 at 15 min, 5–6.5 at 20 min, 4.5–6.5 by 20 min, respectively. And then they advanced the most promising agent [<sup>18</sup>F]<b>10</b> to humans.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> [<sup>18</sup>F]<b>10</b> uptake in the human brain was similar to [<sup>11</sup>C]<b>6</b>, and the peak SUV in the putamen ranged from 3.0 to 4.0; however, the retest variability of [<sup>11</sup>C]<b>6</b> in plasma was relatively large (58%), as compared to [<sup>18</sup>F]<b>10</b> (16%), and [<sup>18</sup>F]<b>10</b> had a good retest variability of <i>V</i><sub>T</sub> (14%), which had previously been reported by Terry et al.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> In subsequent studies, [<sup>11</sup>C]<b>6</b> was used as a CB1R imaging agent to study the anxiogenic effects of cannabis in humans, which proved that this effect was closely related to the activation of CB1Rs on the amygdala.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> [<sup>18</sup>F]<b>10</b> has been used to demonstrate a reversible downregulation of CB1Rs in chronic cannabis smokers,<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> and in alcohol-dependent patients,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> [<sup>18</sup>F]<b>10</b> demonstrated reduced CB1R binding that did not recover after 2–4 weeks of abstinence. It is worth noting that in CB1R imaging of alcohol-dependent patients with [<sup>18</sup>F]<b>10</b>, the results were contradictory to the findings obtained from the aforementioned study with  [<sup>11</sup>C]<b>5</b>. Differences in experimental design or patient selection may have contributed to these divergent findings. In addition, [<sup>18</sup>F]<b>10</b> has been used to study mental illnesses. Borgan et al. designed a cross-sectional, case-controlled study in patients with first-episode psychosis, demonstrating that CB1 receptors are viable therapeutic targets in psychosis.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Besides CNS-targeted CB1R imaging, [<sup>18</sup>F]<b>10</b> has been used to quantitatively monitor the density of CB1R in brown adipose tissue (BAT). Eriksson et al. and Lahesmaa et al. confirmed that [<sup>18</sup>F]<b>10</b> showed specicific binding to BAT in rodents and humans, respectively.<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97,98)</a></div><div class="NLM_p">Using taranabant as a lead compound, Merck research laboratories synthesized [<sup>18</sup>F]MK-9470 ([<sup>18</sup>F]<b>11</b>, IC<sub>50(human)</sub> CB1R = 0.7 nM, IC<sub>50(human)</sub> CB2R = 44 nM), a new potent CB1R inverse agonist, with a high affinity for CB1R.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a><i>In vivo</i> brain imaging and autoradiography distribution studies in rhesus monkeys have demonstrated reversible binding to CB1R with reasonable binding specificity. The occupancy of CB1R in the human brain has low test–retest (TRT) variability (ca. 7%), as determined by the area under curve (AUC) of the respective time–activity curve. However, <i>in vivo</i> radioactive distribution of CB1R is inconsistent with <i>ex vivo</i> findings in the post-mortem research, an inconsistency which was suggested to be related to the different properties (agonists and inverse agonists) of radioligands.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Subsequently, Van et al. analyzed the distribution of [<sup>18</sup>F]<b>11</b> in 50 healthy individuals.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> In women, as the age increased, radiotracer–receptor binding increased in the basal ganglia, the lateral iliac crest, and the limbic system, especially in the hippocampus. Men do not have these age-related characteristic changes, but men show higher [<sup>18</sup>F]<b>11</b> binding in the limbic system and cortical–thalamic–cortical loop cluster.</div><div class="NLM_p">Compound [<sup>18</sup>F]<b>11</b> has been used in imaging studies of various neurological diseases: anorexia nervosa patients demonstrated increased [<sup>18</sup>F]<b>11</b> uptake (24.5%, <i>P</i> = 0.0003) in the brain compared to healthy controls;<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> a study investigating [<sup>18</sup>F]<b>11</b> in female with episodic migraine showed that there was an increased interictal binding (average gray matter difference of +16%, <i>P</i> = 0.009), indicating a low level of competing endogenous cannabinoids in this area;<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> in patients with epilepsy of temporal lobe due to hippocampal sclerosis, [<sup>18</sup>F]<b>11</b> uptake increased in the ipsilateral temporal lobe.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> In the premanifest phase of the HD, the PBA-HD (problem behavior assessment for HD) scores inversely correlated with CB1R binding in prefrontal regions and cingulate cortex.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Imaging studies of [<sup>18</sup>F]<b>11</b> performed in the brains of PD patients showed that the reduced availability of CB1R is associated with various cognitive impairments.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Although the CB1R inverse agonist PET tracers highlighted above have been used in clinical research to study receptor availability in several neurological disorders, rimonabant and taranabant development was discontinued in 2008 due to neurological side effects.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><div class="NLM_p">Donohue et al. developed a new selective CB1 receptor antagonist, [<sup>11</sup>C]SD5024 ([<sup>11</sup>C]<b>12</b>, <i>K</i><sub>i</sub> hCB1R = 0.47 nM, log <i>D</i><sub>7.4</sub> = 3.79), which demonstrated high specific binding in the cynomolgus monkey brain.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The brain uptake reached a peak SUV of 2.0 at 24 min and declined to 1.5 at 90 min. Tsujikawa et al. evaluated this radioligand <i>in vitro</i> and <i>in vivo</i> and compared it with the following ligands: [<sup>11</sup>C]<b>6</b> (<i>K</i><sub>i</sub> hCB1R = 0.11 nM, log <i>D</i><sub>7.4</sub> = 4.77), [<sup>11</sup>C]<b>5</b> (<i>K</i><sub>i</sub> hCB1R = 2.05 nM), [<sup>18</sup>F]<b>11</b> (<i>K</i><sub>i</sub> hCB1R = 0.10 nM), and [<sup>18</sup>F]<b>10</b> (<i>K</i><sub>i</sub> hCB1R = 0.11 nM, log <i>D</i><sub>7.4</sub> = 4.24).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> [<sup>11</sup>C]<b>12</b> demonstrated optimal lipophilicity and precise measurement accuracy in terms of intersubject variability (22%) for <i>V</i><sub>T</sub>. It is worth noting that Hjorth et al.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> employed [<sup>11</sup>C]<b>12</b> in NHP imaging to obtain the pharmacokinetic profile, calculate the occupancy rate, and explore the optimal dose of three novel selective CB1R antagonists developed by AstraZeneca (AZ).<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Compound [<sup>11</sup>C]<b>13</b>, a similar structure to [<sup>11</sup>C]<b>12</b>, was reported by Donohue et al. in an abstract, and it showed high specificity in the monkey brain;<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> however, no further studies have been reported.</div><div class="NLM_p">WIN 55212-2 is a cannabinoid receptor agonist that belongs to the aminoalkylindoles (AAI) family. This type of compound has been radiolabeled for PET or SPECT imaging but exhibited poor brain permeability and specificity.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> An important example of this compound class is [<sup>18</sup>F]<b>14</b>.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Following these studies, Allen et al. synthesized a new array of arylsulfonyl-substituted indoles as CB1R inverse agonists.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Finnema et al. and Donohue et al. radiolabeled PipISB (<i>K</i><sub>b</sub> = 1.5 nM, cLogD = 5.1) with <sup>18</sup>F and <sup>11</sup>C, to afford [<sup>11</sup>C]<b>15</b> and [<sup>18</sup>F]<b>16</b>, respectively, and further evaluated them in rhesus and cynomolgus monkeys. [<sup>11</sup>C]<b>15</b> and [<sup>18</sup>F]<b>16</b> crossed the blood–brain barrier (BBB) and exhibited CB1R specific and displaceable binding in monkeys.<a onclick="showRef(event, 'ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref116 ref117">(116,117)</a></div><div class="NLM_p last">On the basis of the previous research,<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Yamasaki et al.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> modified 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1) to synthesize compound [<sup>11</sup>C]<b>17</b> (<i>K</i><sub>D</sub> = 15.3 μM, log <i>D</i> = 3.76) and conducted PET imaging where this radiotracer demonstrated high specificity in the mouse BAT (2.8 %ID/mL). Zanato et al.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> labeled a fluorinated tetrahydrocannabinol (THC) analog HU-210F with <sup>18</sup>F ([<sup>18</sup>F]<b>18</b> (<i>K</i><sub>i</sub> hCB1R = 0.98 nM, <i>K</i><sub>i</sub> hCB2R = 3.83 nM) as a potential imaging agent, but further biological evaluation has not been carried out. The latest CB1R imaging probe [<sup>18</sup>F]<b>19</b> was reported by Chang et al.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> by modifying DBPR211; however, the uptake of this tracer in the mouse brain was low (<1%).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.2.  PET Tracers for Imaging CB2R</h3><div class="NLM_p">Although CB2R expression is limited in the healthy CNS, there is a consensus that CB2R is upregulated on activated microglial cells upon neuroinflammation.<a onclick="showRef(event, 'ref63 ref122'); return false;" href="javascript:void(0);" class="ref ref63 ref122">(63,122)</a> Thus, the CB2 receptor is regarded as an exceptionally promising target to exploit for neuroinflammation manifested in AD, PD, and ALS.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Despite strenuous efforts by several research groups worldwide, CB2R-targeted PET radioligand development has only moderately progressed in recent years. Reported probes have mainly been hampered by nonspecific binding due to high lipophilicity, metabolic instability, inappropriate pharmacokinetics, and lack of selectivity over CB1R or other CNS targets. The search for suitable CB2R PET radioligands is further hampered by the lack of reliable information on CB2R <i>B</i><sub>max</sub> values in the CNS as well as the lack of a highly selective CB2R antibody to confirm autoradiographic findings by histological assessment. Nonetheless, some promising examples with potential for clinical translation have emerged and will be discussed in this chapter. The structural scaffolds for CB2R PET ligands include oxoquinoline, pyridine, thiazole, triazine, and oxadiazole derivatives (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). A summary of the relevant parameters for selected CB2R specific PET tracers is presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative chemical structures for CB2R-specific PET tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Radiolabeling and PET Imaging Application of CB2R Specific Tracers</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">PET imaging study</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">radioligand (RCY)</th><th class="colsep0 rowsep0" align="center">subject</th><th class="colsep0 rowsep0" align="center">brain uptake</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>20</b> (32 ± 11%, 40 ± 12%)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Mouse: SUV<sub>max</sub> = 1.2 (2 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: AD</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> = 1.4 (1.5 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 1.5 (1.5 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: low CB2R availability in AD patients</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>21</b> (33%<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a>)</td><td class="colsep0 rowsep0" align="left"><i>Rodents: neuroinflammation, atherosclerosis</i></td><td class="colsep0 rowsep0" align="left">Rat: high BBB permeability specificly to CB2R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: ALS (spinal cord tissues), atherosclerosis (specimen)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>22</b> (∼6%,<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> 12.0 ± 2.7%<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a>)</td><td class="colsep0 rowsep0" align="left">Rodents: HD</td><td class="colsep0 rowsep0" align="left">Rat: not sensitive to the CB2R overexpression</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: ALS (spinal cord tissues)</td><td class="colsep0 rowsep0" align="left">Human: no specificly to CB2R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>23</b> (41.7 ± 8.7%<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a>)</td><td class="colsep0 rowsep0" align="left">Human: ALS (spinal cord tissues)</td><td class="colsep0 rowsep0" align="left">Human: specificly to CB2R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>26</b> (−)</td><td class="colsep0 rowsep0" align="left">Rodents: neuroinflammation</td><td class="colsep0 rowsep0" align="left">Rat: specificly to CB2R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>27</b> (11 ± 4%<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> = 2.7 ± 0.3 (2 min, spleen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: ALS (spinal cord tissues)</td><td class="colsep0 rowsep0" align="left">Human: specifically to CB2R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>30</b> (26 ± 2%<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents: neuroinflammation, AD, cerebral ischemia</td><td class="colsep0 rowsep0" align="left">Mice: sensitive to the CB2R overexpression in the AD mice</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>31</b> (0.95 ± 0.65%)</td><td class="colsep0 rowsep0" align="left">NHP: neuroinflammation</td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 0.85 ± 0.15 (brain)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Non-decay-corrected RCYs.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Decay-corrected RCYs</p></div></div></div><div class="NLM_p">Oxoquinoline derivatives have been exploited for their suitability as CB2R PET radioligands. As such, the most extensively studied candidate in this class of compounds, [<sup>11</sup>C]NE40 (<sup>[11</sup>C]<b>20</b>), was successfully synthesized via O-methylation of the respective phenolic precursor using either [<sup>11</sup>C]CH<sub>3</sub>I or [<sup>11</sup>C]methyl triflate.<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124,125)</a> With a binding affinity (<i>K</i><sub>i</sub> CB2R) of 9.6 nM and a selectivity factor of ∼100 over CB1R, [<sup>11</sup>C]<b>20</b> proved to be specific for CB2R in the rodent spleen while concurrently exhibiting a fast washout from the CB2R-deficient healthy brain.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Moreover, preclinical evaluation of [<sup>11</sup>C]<b>20</b> revealed specific and reversible binding to human CB2R (hCB2R) in a rat model with local hCB<sub>2</sub>R overexpression in the right striatum.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> In the same study, the authors reported a high brain uptake (SUV<sub>max</sub> = 1.5 at 90 s) in rhesus monkeys, confirming that the tracer is able to penetrate the brain in non-human primates. In a subsequent clinical study, [<sup>11</sup>C]<b>20</b> did not detect the anticipated CB2R upregulation in the brain of AD patients, thus raising concerns about the suitability of the tracer for CB2R imaging in AD.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Particularly, given the high abundancy of CB1R in the human brain, a selectivity factor of ∼100 might have been insufficient to avoid off-target binding of [<sup>11</sup>C]<b>20</b> to CB1R. Along this line, no relationship was found between regional or global amyloid load and [<sup>11</sup>C]<b>20</b> uptakes.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></div><div class="NLM_p">Slavilk et al.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> used anisidine and diethyl 2-(ethoxymethylene)malonate to synthesize a series of novel 4-oxoquinoline derivatives based on the structure of KD2 (<i>K</i><sub>i</sub> CB2R = 1.7 nM, log <i>D</i><sub>7.4</sub> = 3.3).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> RS-016 (<b>21</b>) emerged as most suitable candidate, exhibiting an improved affinity (<i>K</i><sub>i</sub> = 0.7 nM) and lipophilicity (log <i>D</i><sub>7.4</sub> = 2. 8).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Dynamic brain PET scans of [<sup>11</sup>C]RS-016 ([<sup>11</sup>C]<b>21</b>) in a murine neuroinflammation model induced by lipopolysaccharide (LPS) application showed higher CB2R expression level in different brain regions including the cortex, hippocampus, and cerebellum. Further, [<sup>11</sup>C]<b>21</b> was used to visualize the CB2R in human and mouse atherosclerotic lesions.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> To overcome the limitation of the short half-life of carbon-11, Slavik et al.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> developed a radiofluorinated analog of [<sup>11</sup>C]<b>21</b>, code-named [<sup>18</sup>F]RS-126 ([<sup>18</sup>F]<b>22</b>). Although the <i>in vitro</i> results with [<sup>18</sup>F]<b>22</b> were encouraging, no CB2R expression was detected in the brain of LPS-treated mice. The latter was attributed to the low specific activity of [<sup>18</sup>F]<b>22</b>. In addition, [<sup>18</sup>F]<b>22</b> was rapidly metabolized in mice. Haider et al.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> improved the synthesis strategy to obtain higher radiochemical yields (RCYs) and molar activities of [<sup>18</sup>F]<b>22</b>. In the transgenic R6/2 mouse model for HD, [<sup>18</sup>F]<b>22</b> was not sensitive to the CB2R overexpression, although CB2R mRNA upregulation was detected by qPCR in the same tissue. Further, due to high nonspecific neuronal tissue binding, [<sup>18</sup>F]<b>22</b> did not show specific CB2R binding in human ALS spinal cord sections. In sharp contrast, the newly developed hydroxylated derivative, [<sup>11</sup>C]RS-028 ([<sup>11</sup>C]<b>23</b>), exhibited a significantly reduced lipophilicity, thus leading to less nonspecific binding and allowing the detection of CB2R upregulation in post-mortem human ALS spinal cord tissue. Notably, the spleen uptake of [<sup>11</sup>C]<b>23</b> was relatively low compared to its predecessors and was accompanied by a rapid washout <i>in vivo</i>, potentially owing to enzymatic degradation. To investigate the influence of the <i>O</i>-alkyl chain length and oxygen position on metabolic stability, [<sup>18</sup>F]AH-040 and [<sup>18</sup>F]AH-043 ([<sup>18</sup>F]<b>24</b> and [<sup>18</sup>F]<b>25</b>) were synthesized. Although these probes showed improved stability to liver enzymes, their selectivity over CB1R was substantially reduced, impeding their further development.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><div class="NLM_p">Among the reported structural scaffolds of CB2R PET radioligands, 2,5,6-trisubstituted pyridines (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) have been thoroughly assessed and currently constitute the most promising candidates for clinical translation. Indeed, initial studies with [<sup>11</sup>C]RSR-056 ([<sup>11</sup>C]<b>26</b>, <i>K</i><sub>i</sub> hCB2R = 2.5 nM, log <i>D</i><sub>7.4</sub> = 1.94) revealed significantly increased brain uptake following LPS-induced neuroinflammation in mice. Nonetheless, it should be noted that only part of the increased [<sup>11</sup>C]<b>26</b> accumulation in the brain was attributed to CB2R-specificity, as evidenced by the weak signal reduction under blockade conditions.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The latter can be, at least in part, explained by inflammation-induced damage to the blood–brain barrier, which would ultimately result in an increased tracer delivery to the brain, independent of CB2R.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Due to the short physical half-life of carbon-11, which confines the use of [<sup>11</sup>C]<b>26</b> to facilities with an on-site cyclotron, the authors synthesized a series of fluorinated derivatives via structural modifications at positions 2 and 5 of the pyridine core. These efforts led to the development of the radiofluorinated analog [<sup>18</sup>F]<b>27</b>,<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> with a prolonged half-life of 109.8 min, a binding affinity of 6 nM, and a selectivity factor of ∼600 over CB1R. [<sup>18</sup>F]<b>27</b> proved to be CB2R-specific by <i>in vitro</i> autoradiography experiments of the rodent spleen. Further, CB2R receptor upregulation in post-mortem spinal cord tissues of ALS patients was confirmed with [<sup>18</sup>F]<b>27</b>. Notwithstanding the promising <i>in vitro</i> results obtained with [<sup>18</sup>F]<b>27</b>, <i>in vivo</i> specificity for the CB2R-rich rodent spleen was only modest. To overcome this limitation, the authors studied the influence of structural modifications at position 6 of the pyridine core, which ultimately led to the discovery of [<sup>18</sup>F]RoSMA-18 ([<sup>18</sup>F]<b>28</b>), a ligand with subnanomolar affinity (<i>K</i><sub>i</sub> hCB2R = 0.7 nM) and a remarkable selectivity factor of >12 000.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> [<sup>18</sup>F]<b>28</b> revealed exceptional specificities for the CB2R-positive rodent spleen by <i>in vitro</i> autoradiography (71 ± 2%) and <i>ex vivo</i> biodistribution (86 ± 2%), which was superior to any previously reported CB2R-targeted PET probe. Indeed, the outstanding specificity was further elegantly corroborated in the CB2R knockout mouse spleen. [<sup>18</sup>F]<b>28</b> was sensitive in detecting CB2R upregulation in post-mortem human ALS spinal cord tissue by <i>in vitro</i> autoradiography. Further, PET experiments confirmed the specific and reversible CB2R binding of [<sup>18</sup>F]<b>28</b> in the CB2-positive rat spleen. The authors found only intact [<sup>18</sup>F]<b>28</b> in the rat brain following intravenous tracer injection. Nonetheless, <i>in vivo</i> defluorination was noted by substantial skull uptake, which was circumvented by replacing the hydrogen atoms in the fluoropropyl side chain with deuterium atoms to afford [<sup>18</sup>F]RoSMA-18-<i>d</i><sub>6</sub> ([<sup>18</sup>F]<b>29</b>), in which case no radioactivity accumulation in the skull was observed. [<sup>18</sup>F]<b>29</b> is currently considered a promising candidate for clinical translation.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><div class="NLM_p">A-836339 is a highly potent and selective CB2R agonist (<i>K</i><sub>i</sub> CB2R = 0.7 nM, <i>K</i><sub>i</sub> CB1R = 270 nM), which is based on a thiazole core structure.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Horti et al. radiolabeled [<sup>11</sup>C]A-836339 ([<sup>11</sup>C]<b>30</b>) via its desmethyl precursor and performed PET imaging in LPS-treated CD1 mice, APP/PS1 transgenic mice (mouse model for AD), and wild-type control animals.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Whole body time–activity curves (TACs) for the control mice revealed a fast tracer washout from the brain, while CB2R specific binding was observed in the spleen. In LPS-treated mice, [<sup>11</sup>C]<b>30</b> uptake was significantly increased in the brain (SUV<sub>max</sub> = 2.3), as compared to the control group (SUV<sub>max</sub> = 0.5), after 5 days of LPS treatment. Similarly, higher brain uptake was found in transgenic APP/PS1 strains compared to wild-type littermates, and the regional distribution was consistent with the distribution of Aβ amyloid plaques. AM630 blocking showed 29–36% specific binding in the cerebellum, brainstem, and cortex. Attempts to develop a radiofluorinated analog of [<sup>11</sup>C]<b>30</b> led to an improved CB2R affinity with <i>K</i><sub>i</sub> of 0.4 nM for CB2R and 380 nM for CB1R. Nonetheless, the rapid metabolism of this <sup>18</sup>F analog following intravenous injection as well as the presence of radiometabolites in the brain hampered further evaluation.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Savonenko et al. further investigated the utility of [<sup>11</sup>C]<b>30</b> as a PET biomarker for neuroinflammation in AD mice.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> The authors found an increased tracer uptake in AD mice, which was blocked by the commercially available CB2R inverse agonist AM630. In sharp contrast, Pottier et al. did not detect CB2R upregulation with [<sup>11</sup>C]<b>30</b> PET in two distinct rat models of cerebral ischemia.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div><div class="NLM_p">Triazine scaffolds have been evaluated for CB2R-targeted PET imaging by Hortala et al.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> The authors reported on the development of [<sup>18</sup>F]<b>31</b>, demonstrating brain penetration in rhesus macaques and baboons. Baboon pretreatment with LPS led to <i>V</i><sub>T</sub> increase of about 30%, confirming previous observations with other CB2R PET probes in mice. In another study by Yrjola et al., the best performing triazine derivative, [<sup>18</sup>F]<b>32</b> (EC<sub>50</sub> = 0.60 nM), was found to suffer from rapid metabolism and elimination, rendering its pharmacokinetic properties unsuitable for <i>in vivo</i> PET.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><div class="NLM_p last">MA2 and MA3 are the analogs of the highly potent CB2 agonist <i>N</i>-arylamide oxadiazole.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Tissue distribution of [<sup>11</sup>C]<b>33</b> and [<sup>18</sup>F]<b>34</b> demonstrated high brain uptake at 2 min postinjection. Notably, [<sup>18</sup>F]<b>34</b> was found to specifically accumulate in brain regions with overexpression of the human CB2R in rats; however, no specific binding of [<sup>18</sup>F] <b>34</b> to the CB2 receptor was observed in PET scans in non-human primates.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">3.  Hydrolase Targeting PET Tracers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28708" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28708" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is known that drugs that act as direct agonists or antagonists on the endocannabinoid receptors can cause drug dependence or addiction.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Hence, as an alternative approach to achieve therapeutic effects, drugs/tool compounds that inhibit the hydrolases that metabolize AEA and 2-AG have been developed. The two main hydrolases involved in the hydrolytic metabolism of these endocannabinoids are FAAH and MAGL. FAAH is a 60 kDa integral membrane hydrolytic enzyme that is highly expressed in the mammalian brain, along with liver and kidney, which is responsible for terminating the endogenous cannabinoid signaling of AEA by hydrolysis of the amide bond.<a onclick="showRef(event, 'ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref146 ref147">(146,147)</a> MAGL is a 33 kDa serine hydrolase with high expression in the brain, BAT, adrenal glands, liver, and kidneys and acts as a critical degradative enzyme responsible for ca. 85% of 2-AG metabolism in the brain, generating glycerol and arachidonic acid (AA).<a onclick="showRef(event, 'ref148 ref149 ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref148 ref149 ref150 ref151">(148−151)</a> As shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, systemic or local inhibition of FAAH or MAGL increases levels of AEA or 2-AG while concurrently decreasing arachidonic acid level, respectively. These changes also affect endocannabinoid signaling and suppresses eicosanoid production. Increasing levels of AEA exert effects of antianxiety, antidepression, and treating addiction and withdrawal symptoms.<a onclick="showRef(event, 'ref152 ref153'); return false;" href="javascript:void(0);" class="ref ref152 ref153">(152,153)</a> Similarly, increasing the level of 2-AG in the brain has effects of antianxiolytic, antidepression, antiemetic, anti-inflammation, and neuroprotection.<a onclick="showRef(event, 'ref154 ref155'); return false;" href="javascript:void(0);" class="ref ref154 ref155">(154,155)</a> Moreover, inhibition of MAGL (genetically/pharmacologically) has therapeutic implications for some metabolic diseases.<a onclick="showRef(event, 'ref156 ref157'); return false;" href="javascript:void(0);" class="ref ref156 ref157">(156,157)</a> Numerous studies have demonstrated that FAAH and MAGL are potential therapeutic targets for a variety of human pathologies including pain, depression, (neuro)inflammatory diseases, and cancer.<a onclick="showRef(event, 'ref149 ref155 ref158 ref159 ref160'); return false;" href="javascript:void(0);" class="ref ref149 ref155 ref158 ref159 ref160">(149,155,158−160)</a> For several of these indications proof-of-concept studies have been performed in several animal models with the respective knockout animals.<a onclick="showRef(event, 'ref8 ref157 ref161'); return false;" href="javascript:void(0);" class="ref ref8 ref157 ref161">(8,157,161)</a> It is worthy of note that <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> only captures main features of FAAH and MAGL in the ECS since both FAAH and MAGL can metabolize other related lipids: in the case of FAAH, blockade of its hydrolysis activity for <i>N</i>-palmitoylethanolamine is an interesting pharmacological approach, given the anti-inflammatory effects of this endogenous lipid.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> In the case of MAGL, it has been shown that it promotes cancer cell growth by providing long chain fatty acids from their corresponding monoacylglycerols<a onclick="showRef(event, 'ref163 ref164'); return false;" href="javascript:void(0);" class="ref ref163 ref164">(163,164)</a> and to provide arachidonic acid for prostaglandin synthesis in neuroinflammation.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Pharmacological Properties of FAAH and MALG Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Currently, a variety of FAAH and MAGL inhibitors have been developed, characterized in animal models of disease and assessed at various stages of clinical trials.<a onclick="showRef(event, 'ref165 ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref165 ref166 ref167">(165−167)</a> Initial clinical studies with FAAH inhibitors PF-04457845,<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> V158866,<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> and JNJ-42165279<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> indicated that the compounds were well-tolerated (<i>vide infra</i> for a discussion with respect to FAAH inhibitor BIA10-2474<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a>), although PF-04457845 was not efficacious in a study of osteoarthritic pain. Recently, Fazio et al. reviewed newly developed single- and dual-target FAAH inhibitors in the literature and proposed that multitarget inhibition may be a promising strategy for the development of new effective inhibitors. Future drug design and medicinal chemistry could also take advantage of the recently disclosed human FAAH crystal structure.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Among MAGL inhibitors, ABX-1431 has entered clinical phase II studies for neurological disorders. In this context, PET ligand development toward FAAH and MAGL has also made considerable progress for target engagement studies in drug discovery and studying pathophysiological changes during disease states.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.1.  FAAH Inhibitor Based PET Tracers</h3><div class="NLM_p">A major clinical trial incident occurred in January 2016,<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> which led to the death of one of the participants during the study with a FAAH inhibitor code-named BIA 10-2474. Following the incident, there has been a solid body of evidence that the drug exhibited an off-target effect.<a onclick="showRef(event, 'ref174 ref175 ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref174 ref175 ref176 ref177">(174−177)</a> The tragic results of this trial emphasized that it is especially important to fully understand the pharmacological effects, metabolism, and pharmacokinetic–pharmacodynamic (PK–PD) relationship of drugs in the body before conducting clinical trials. Using PET probes is uniquely well suited for <i>in vivo</i> drug evaluation to assess target engagement and correlate therapeutic dose–target occupancy relationship accurately in humans via a phase 0 study. Currently, several PET tracers for imaging FAAH have been disclosed and can be classified into two categories, namely, irreversible and reversible tracers, based on different binding kinetics, as shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. We also summarize the pharmacological and imaging properties of FAAH PET tracers in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative chemical structures for FAAH-specific PET tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Radiolabeling and PET Imaging Application of FAAH Specific Tracers<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">PET imaging study</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">radioligand (RCY)</th><th class="colsep0 rowsep0" align="center">subject</th><th class="colsep0 rowsep0" align="center">brain uptake</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>36</b> (4%<a class="ref internalNav" href="#t3fn1" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, human: cannabis addiction, alcohol use disorders, psychiatric, borderline personality disorder</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> = 2 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: SUV<sub>max</sub> = 4.3 ± 0.8 (putamen)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>43</b> (20 ± 4.6%<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> ∼ 1.5 (cerebellar nucleus)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 2.0 (occipital cortex)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>44</b> (19.5 ± 2.5%<a class="ref internalNav" href="#t3fn1" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> = 4.55 ± 0.57 (cortex)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Baboon: SUV<sub>max</sub> = 2.1 (whole brain, 55 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>45</b> (15 ± 5%<a class="ref internalNav" href="#t3fn1" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> = 7.8 ± 0.1 (cortex, 40 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>46</b> (4.5 ± 1.3%<a class="ref internalNav" href="#t3fn1" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> = 2.8 ± 1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>47</b> (10.7 ± 4.4%<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">SUV ∼ 0.8 (cortex, 90 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>50</b> (−)</td><td class="colsep0 rowsep0" align="left">NHP, human</td><td class="colsep0 rowsep0" align="left">Monkey: BP = 0.7 ± 0.3, <i>V</i><sub>T</sub> = 3.5 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> > 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Human: <i>V</i><sub>T</sub> = 17 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>51</b> (13%<a class="ref internalNav" href="#t3fn1" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">Mice: SUV<sub>max</sub> = 0.87 (cerebellar nuclei, 1.5 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>52</b> (17 ± 6%<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">9.2 %ID/g</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">The data of PET imaging are listed only in the control group.</p></div><div class="footnote" id="t3fn1"><sup><sup>b</sup></sup><p class="last">Non-decay-corrected RCYs.</p></div><div class="footnote" id="t3fn2"><sup><sup>c</sup></sup><p class="last">Decay-corrected RCYs.</p></div></div></div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">3.1.1.  Irreversible FAAH Radiotracers</h4><div class="NLM_p">URB597 (IC<sub>50</sub> = 4.6 nM, cLogD = 3.6) is a classic FAAH inhibitor based on <i>O</i>-aryl carbamate scaffold with potentially useful activity in an animal model of anxiety.<a onclick="showRef(event, 'ref178 ref179 ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref178 ref179 ref180 ref181">(178−181)</a> A <sup>11</sup>C-labeled URB597 analog biphenyl-3-yl [<sup>11</sup>C]-4-methoxyphenylcarbamate ([<sup>11</sup>C]<b>35</b>) was the first radiolabeled FAAH inhibitor for PET imaging studies in rodents.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Although the log <i>D</i> value (2.27) was suitable for brain penetration, a continuous washout was observed after rapid peak brain uptake, which indicated no covalent binding to FAAH.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> However, it represented a reasonable starting point for the design of radiolabeled FAAH inhibitors.</div><div class="NLM_p">CURB (IC<sub>50</sub> = 30 nM, log <i>D</i><sub>7.4</sub> = 2.8), also named URB694, is an active and selective irreversible inhibitor of FAAH with improved brain penetration and plasma stability, as compared to URB597.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> As such, [<sup>11</sup>C]CURB ([<sup>11</sup>C]<b>36</b>) was the first reported successful irreversible PET tracer to image FAAH.<a onclick="showRef(event, 'ref184 ref185'); return false;" href="javascript:void(0);" class="ref ref184 ref185">(184,185)</a> [<sup>11</sup>C]<b>36</b> displayed similar <i>ex vivo</i> biodistribution to FAAH in the rat brain, with higher brain uptake in the cortex and lower signal in the hypothalamus. The radioactivity peaked at 5 min (SUV<sub>max</sub> = 1.6–2.4), and no significant washout was observed, consistent with the suggested irreversible binding mechanism. High dose pretreatment using URB597 showed high specificity of binding. A polar metabolite was detected in blood, which has little effect on the imaging results as it is not blood–brain barrier permeable.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> On the basis of these promising preclinical studies, [<sup>11</sup>C]<b>36</b> became the first PET tracer for mapping FAAH activity in the human brain.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> By performing 90 min PET scans with arterial blood sampling on six healthy volunteers, λ<i>k</i><sub>3</sub> was identified as the optimal parameter for quantifying FAAH binding, and SUV reached its peak (4.3 ± 0.8) 30 min postinjection. For the kinetic modeling of irreversible inhibitors, λ<i>k</i><sub>3</sub> can be calculated by the equation <i>K</i><sub>1</sub>/<i>k</i><sub>2</sub><i>× k</i><sub>3</sub> and constitutes a key parameter of kinetic modeling for two-tissue compartment models. Of note, λ is the ratio between the two rate constants, <i>K</i><sub>1</sub> and <i>k</i><sub>2</sub>, and represents the equilibrium distribution volume of the ligand in the plasma and the organ of interest, in this case the brain. Moreover, <i>k</i><sub>3</sub> describes the influx of [<sup>11</sup>C]<b>36</b> from the free and nonspecific compartment to the specifically bound compartment.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Recently, [<sup>11</sup>C]<b>36</b> has been applied in neuroimaging application of several neurological disorders, particularly in addictive diseases, such as cannabis addiction,<a onclick="showRef(event, 'ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref188 ref189">(188,189)</a> alcohol use disorders,<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> and psychiatric<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> and borderline personality disorder,<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> which further proves that FAAH could be a promising therapeutic target for a variety of CNS diseases.</div><div class="NLM_p">Moreover, a series of [<sup>11</sup>C-carbonyl]-radiolabeled <i>O</i>-aryl carbamates were synthesized ([<sup>11</sup>C]<b>37</b>–[<sup>11</sup>C]<b>42</b>) and evaluated as radiotracers for imaging FAAH with PET by Wilson et al.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> All six radiotracers showed moderate to excellent brain uptake, good regional distribution (cortex > hypothalamus), and excellent specificity (80–95% blocking via pretreatments with URB597) for FAAH in the rat brain. Brain kinetics showed that [<sup>11</sup>C]dihydrooxazole carbamates ([<sup>11</sup>C]<b>40</b>–<b>42</b>) had much higher uptake (3.0–4.5 SUV in the cortex at 2 min) than [<sup>11</sup>C]biphenyl carbamates ([<sup>11</sup>C]<b>36</b>–<b>39</b>, 0.8–2.7 SUV in the cortex at 2 min).</div><div class="NLM_p">2-Methylpyridin-3-yl-4-(5-(2-fluorophenyl)-4<i>H</i>-1,2,4-triazol-3-yl)piperidine-1-carboxylate (MFTC) is a high-affinity, selective FAAH ligand (IC<sub>50</sub> = 0.34 nM for human FAAH)<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> with moderate lipophilicity (cLogD = 3.6). <i>In vitro</i> studies demonstrated a similar binding affinity for FAAH as URB597 and CURB.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> [<sup>11</sup>C]MFTC ([<sup>11</sup>C])<b>43</b>) was successfully synthesized using bis(2-methylpyridin-3-yl)-[<sup>11</sup>C]carbonate as a new radioactive intermediate.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> PET studies of this ligand in rat brain demonstrated high uptake (SUV<sub>max</sub> ∼ 1.5 in the cerebellar nucleeus), and the distribution of radioactivity corresponded to FAAH expression. The accumulation of [<sup>11</sup>C]<b>43</b> in the brain was successfully blocked by pretreatment with nonradioactive MFTC and URB597. Furthermore, PET imaging of monkey brains demonstrated heterogeneous distribution and radioactivity accumulation was highest in the occipital cortex (SUV<sub>max</sub>= 2.0); however, [<sup>11</sup>C]<b>43</b> did not show high specific binding in the striatum, which was in contrast to [<sup>11</sup>C]<b>36</b> and [<sup>11</sup>C]MK-3168 (a reversible inhibitor of FAAH, <i>vide infra</i>). In addition, NHP PET imaging showed that the tracer was gradually washed out in all regions and no plateau was reached during the 90 min scan period, suggesting that total binding in the monkey brain might be affected by nonspecific binding to some extent.</div><div class="NLM_p"><sup>18</sup>F-Labeled PET tracers based on the dihydrooxazole scaffold have also been developed. [<sup>18</sup>F]DOPP ([<sup>18</sup>F]<b>44</b>) was synthesized via a multistep automated synthesis, as a potent, selective FAAH ligand with an IC<sub>50</sub> value of 0.82 nM for rat FAAH and a log <i>D</i> value of 2.33. <i>In vitro</i> assays showed that DOPP inhibited FAAH in a time-dependent manner. <i>Ex vivo</i> biodistribution studies demonstrated excellent brain uptake (>4 SUV) and a distribution pattern consistent with FAAH patterns in the rat brain. Autoradiography of [<sup>18</sup>F]<b>44</b> in the rat brain also showed high bound activity in FAAH rich regions. In addition, heterogeneous binding of [<sup>18</sup>F]<b>44</b> was displaced by pretreatment with the FAAH inhibitors CURB or PF-04457845, indicating that the radiotracer bound specifically to FAAH <i>in vitro.</i><a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> PET/magnetic resonance imaging (MRI) studies in baboons demonstrated that [<sup>18</sup>F]<b>44</b> rapidly crossed the blood–brain barrier with SUV<sub>peak</sub> of 2.1 and that the kinetic modeling parameter λ<i>k</i><sub>3</sub> was appropirate for FAAH quantification.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> As a proof-of-concept, [<sup>18</sup>F]<b>44</b> was employed to evaluate the potency of BIA 10-2472 <i>in vivo</i> in the brain, which may be useful for providing a rational approach to dose selection in clinical trials and avoiding severe adverse events.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a></div><div class="NLM_p">Another <sup>18</sup>F-labeled FAAH radiotracer, [<sup>18</sup>F]FCHC ([<sup>18</sup>F]<b>45</b>, IC<sub>50</sub> = 1.2 nM), was also evaluated in rodents.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Similar to previous results,<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> [<sup>18</sup>F]<b>45</b> demonstrated high brain penetration (SUV<sub>peak</sub> = 4.6), excellent specificity, and appropriate biodistribution in rodents, warranting further evaluation in higher species.</div><div class="NLM_p">Two urea-based irreversible tracers [<sup>11</sup>C]PF-04457845 ([<sup>11</sup>C]<b>46</b>, IC<sub>50</sub> = 3.2 nM, log <i>D</i><sub>7.4</sub> = 3.48) and [<sup>18</sup>F]PF-9811 ([<sup>18</sup>F]<b>47</b>, IC<sub>50</sub> = 16 nM, log <i>P</i> = 3.14) have been developed. The compounds interacted with FAAH in an analogous irreversible mechanism like other carbamate-based inhibitors.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Due to its high brain penetration, high selectivity, and safety profile in humans,<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> PF-04457845 was chosen as a promising candidate to be labeled with <sup>11</sup>C via the [<sup>11</sup>C]CO<sub>2</sub> fixation strategy.<a onclick="showRef(event, 'ref200 ref202'); return false;" href="javascript:void(0);" class="ref ref200 ref202">(200,202)</a><i>Ex vivo</i> biodistribution of [<sup>11</sup>C]PF-04457845 ([<sup>11</sup>C]<b>46</b>) in the rat brain was consistent with the known expression of FAAH, and the highest uptake (4.4 SUV) was observed in the cortex. In addition, pretreatment with URB597 resulted in a 71–81% reduction of bound activity in all areas of the brain, demonstrating high specificity for FAAH.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> [<sup>18</sup>F]PF-9811 ([<sup>18</sup>F]<b>47</b>) was designed based on the scaffold of PF-04457845, in which the trifluoromethyl group was replaced by a fluoroethoxy functionality to facilitate the incorporation of a fluorine-18 radiolabel.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Biodistribution experiments in rats showed good heterogeneous brain uptake, with high SUVs in the cortex, hippocampus, and cerebellum (ca. 0.8 SUV at 90 min) and specific to nonspecific binding ratios of 2.3 to 2.6. Pretreatment experiments proved irreversible binding in the brain. After 90 min, the radioactivity of all brain regions decreased to 37–73%, but the signal in the blood increased by a factor of 12. The authors claimed that this may have been related to irreversible binding in the brain and peripheral organs.</div><div class="NLM_p last">Dahl et al.<a onclick="showRef(event, 'ref205 ref206'); return false;" href="javascript:void(0);" class="ref ref205 ref206">(205,206)</a> introduced a new and efficient fully automated [<sup>11</sup>C]CO<sub>2</sub>-fixation apparatus and used this method to synthesize two FAAH radiotracers [<sup>11</sup>C]JNJ1661010 ([<sup>11</sup>C]<b>48</b>, IC<sub>50</sub> = 12 nM) and [<sup>11</sup>C]<b>49</b>, with significantly increased nonisolated RCY. This method can help to produce various <sup>11</sup>C-carbonyl compounds in a highly efficient manner to facilitate rapid screening of potential FAAH PET ligands <i>in vivo</i>.</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">3.1.2.  Reversible FAAH Radiotracers</h4><div class="NLM_p">On the basis of the binding mechanism, tissue uptake of irreversible PET tracers is frequently governed by perfusion, which is why they are described as flow limited tracers. As such, a flow limited PET tracer with irreversible binding mechanism may reveal information that is substantially confounded by organ perfusion rather than reflecting the density/activity of the biological target. Indeed, kinetic parameters from <i>in vivo</i> PET quantifications, including <i>K</i><sub>1</sub>, <i>k</i><sub>2</sub>, <i>k</i><sub>3</sub>, <i>V</i><sub>T</sub>, and BP<sub>ND</sub>, can be affected by the binding mechanism of a given tracer.<a onclick="showRef(event, 'ref207 ref208'); return false;" href="javascript:void(0);" class="ref ref207 ref208">(207,208)</a> Examples of irreversible PET tracers that were shown to be spared from significant flow limiting effects include [<sup>11</sup>C]CURB<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> and [<sup>18</sup>F]DOPP.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Thus, recent research has focused on the development of reversible binding PET tracers for FAAH in order to obtain a comprehensive quantitative assessment of FAAH distribution, concentration, and availability in the brain. Currently, a limited number of reversible FAAH inhibitor PET probes have been disclosed based on pyrazole or α-ketoheterocyclic scaffolds.</div><div class="NLM_p">A systematical evaluation of a library of FAAH inhibitors based on a pyrazole scaffold was conducted at Merck. Attributed to excellent potency (IC<sub>50(human)</sub> = 1.0 ± 0.6 nM) and selectivity, reasonable lipophilicity (log <i>D</i> = 3.3), and amenability for radiolabeling, [<sup>11</sup>C]MK-3168 ([<sup>11</sup>C]<b>50</b>) was prepared as the first reported reversible PET tracer for imaging FAAH. <i>In vivo</i> PET imaging studies were performed under baseline and blocking conditions in rhesus monkeys, demonstrating consistent regional heterogeneous distribution (accumulation in the frontal cortex/striatum/hippocampus regions), good brain uptake (SUV > 1), and high specific binding (total/nonspecific signal ∼2:1).<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> According to an abstract, the two tissue compartment model well simulated the [<sup>11</sup>C]<b>50</b> TAC in monkey and human, and values of binding potential (BP<sub>ND</sub>) and <i>V</i><sub>T</sub> were 0.4–1 and 3–4 in the monkey, respectively, and the <i>V</i><sub>T</sub> value in the human was between 14 and 20.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> [<sup>11</sup>C]<b>50</b> has been applied to determine the optimal dose for FAAH inhibitior JNJ-42165279 in the human brain.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a></div><div class="NLM_p">FAAH inhibitors based on an α-ketoheterocyclic scaffold were comprehensively studied by Boger and co-workers.<a onclick="showRef(event, 'ref212 ref213'); return false;" href="javascript:void(0);" class="ref ref212 ref213">(212,213)</a> These inhibitors exhibited reversible binding toward FAAH and other serine hydrolases. On the basis of the structure of OL-135 (a potent and selective FAAH inhibitor, <i>K</i><sub>i</sub> = 4.7 nM),<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> Wang et al. designed two positron-emitting analogs, <sup>18</sup>F- and <sup>11</sup>C-labeled MPPO ([<sup>11</sup>C]<b>51</b> represents the <sup>11</sup>C-analog), with communal pyridinyl oxazole ring.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> PET imaging of <sup>18</sup>F-analog showed rapid defluorination and high bone uptake <i>in vivo</i> and failed to show sufficient brain permeability. MPPO, which exhibited an excellent potency (IC<sub>50</sub> = 10 nM, <i>K</i><sub>i</sub> = 5.8 nM) to FAAH and selectivity over other enzymes,<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> was selected as a candidate as it was amenable for <sup>11</sup>C-labeling. The <i>ex vivo</i> biodistribution studies in mice indicated that the distribution of [<sup>11</sup>C]<b>51</b> was consistent with the distribution of FAAH. However, only moderate brain uptake (0.8 SUV) was observed. PET imaging studies showed low-to-moderate specific binding to FAAH. Subsequent PET imaging in P-glycoprotein (PgP)/breast cancer resistance protein (Bcrp) knockout mice indicated that this tracer was not likely a substrate for Pgp/Bcrp. It should be noted here that [<sup>11</sup>C]<b>51</b> showed a steady washout in the brain, indicating that the α-ketoheterocyclic scaffold indeed provided a promising lead for further investigation of reversible FAAH radiotracers.</div><div class="NLM_p last">Recently, Chen et al.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> discovered an improved FAAH inhibitor with a novel heterocyclic scaffold, and the corresponding PET tracer [<sup>11</sup>C]FAAH-1906 ([<sup>11</sup>C]<b>52</b>, IC<sub>50(mice)</sub> = 11 nM, log <i>D</i> = 2.9) was further studied. <i>Ex vivo</i> biodistribution studies demonstrated that [<sup>11</sup>C]<b>52</b> possessed high brain penetration (9.2 %ID/g), reversible binding kinetics, and moderate specificity. Further development of this tracer and close analogs is underway to validate this class of compounds in higher species.</div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.2.  MAGL Inhibitor Based PET Tracers</h3><div class="NLM_p">MAGL is responsible for about 85% of 2-AG hydrolysis in the brain,<a onclick="showRef(event, 'ref5 ref217 ref218'); return false;" href="javascript:void(0);" class="ref ref5 ref217 ref218">(5,217,218)</a> and significant efforts have been made, thus contributing to the discovery of several MAGL inhibitors. So far, most MAGL inhibitors are irreversible based on carbamate and urea-bearing scaffolds, involving the formation of a covalent bond between the Ser122 of MAGL and the carbonyl group of the inhibitor. Recently, a limited number of reversible MAGL inhibitors were disclosed with high binding affinity and advanced to potential PET tracers for imaging quantification ([<sup>11</sup>C]<b>61</b>–<b>64</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Pharmacological and imaging properties of MAGL PET tracers are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representative chemical structures of MAGL-specific PET tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Radiolabeling and PET Imaging Application of MAGL Specific Tracers</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">PET imaging study</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">radioligand (RCY)</th><th class="colsep0 rowsep0" align="center">subject</th><th class="colsep0 rowsep0" align="center">brain uptake</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>53</b> (4.5 ± 1.5%,<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> 20%<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> = 1.75 (cerebral cortex and striatum)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 0.93 (occipital cortex)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>54</b> (19%<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> = 0.43 (cerebellum)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>55</b> (40%)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Mice, rat: high BBB permeability, specificity to MAGL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> ∼ 4.2, 2.5 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>56</b> (11%)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> > 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> = 1.7 (occipital cortex)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>57</b> (2.5 ± 0.4%<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> = 2.26 (3.5 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>58</b> (15.0 ± 6.8%<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">Rat: SUV<sub>max</sub> > 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>11</sup>C]<b>59</b> (25%)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Rat: high BBB permeability, specificity to MAGL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> ∼ 3.5 (40 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>60</b> (8%<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a>)</td><td class="colsep0 rowsep0" align="left">Rodents</td><td class="colsep0 rowsep0" align="left">Mice: SUV<sub>max</sub> = 1.75 (2.5 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>63</b> (13.0%)</td><td class="colsep0 rowsep0" align="left">Rodents, BAT</td><td class="colsep0 rowsep0" align="left">BAT: 21.4 %ID/g</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>64</b> (21.7 ± 3.0%<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Rodents, NHP</td><td class="colsep0 rowsep0" align="left">Mice: 1.0 ± 0.1 %ID/g (biod,1 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Monkey: SUV<sub>max</sub> > 1.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Non-decay-corrected RCYs.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Decay-corrected RCYs.</p></div></div></div><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">3.2.1.  Irreversible MAGL Radiotracers</h4><div class="NLM_p">The first reported MAGL PET probe was described by Hicks et al. in 2014,<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> where carbamate based inhibitors ([<sup>11</sup>C]JW642, [<sup>11</sup>C]KML29) and two urea based inhibitors ([<sup>11</sup>C]ML30, [<sup>11</sup>C]JJKK-0048) were synthesized. However, all these inhibitors showed poor brain penetration and were not suitable as MAGL PET radioligands.</div><div class="NLM_p">SAR127303 is a highly potent and selective carbamate-based inhibitor of MAGL developed by Sanofi, with IC50 values of 3.8 and 29 nM for mouse and human MAGL, respectively. SAR127303 has shown therapeutic effect by relieving inflammatory pain and epilepsy symptoms in mice.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> In 2016, Wang et al.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> synthesized [<sup>11</sup>C]SAR127303 ([<sup>11</sup>C]<b>53</b>) and employed this novel MAGL imaging agent in rodents. PET imaging of [<sup>11</sup>C]<b>53</b> in rats showed 48% reduction during blocking conditions. Independently, Wang et al.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> screened MAGL inhibitors from a series of sulfonamido-based carbamates and urea-based compounds. Among them, the most potent candidates, SAR127303 (IC<sub>50</sub> = 39.3 nM) and TZPU (IC<sub>50</sub> = 35.9 nM), were labeled with [<sup>11</sup>C]COCl<sub>2</sub> to afford [<sup>11</sup>C]<b>53</b> and [<sup>11</sup>C]TZPU ([<sup>11</sup>C]<b>54</b>). [<sup>11</sup>C]<b>53</b> showed a high level of brain permeability (1.5 SUV for rats and ca. 1 SUV for NHP) and heterogeneous regional brain distribution, which was consistent with the distribution of MAGL in the brain. The uptake of radioactivity was almost 4 times higher than [<sup>11</sup>C]<b>54</b> in the rat brain.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> To further assess PET quantification of [<sup>11</sup>C]<b>53</b> in the rat brain, Yamasaki et al.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> successfully used an irreversible two-tissue compartment model (2-TCMi, <i>k</i><sub>4</sub> = 0) to quantify the concentration distribution of MAGL in different brain regions. Among the kinetic parameters (<i>k</i><sub>3</sub>, <i>K</i><sub>i</sub>, and λ<i>k</i><sub>3</sub>) they have obtained, the correlation between <i>K</i><sub>i</sub> value and <i>in vitro</i> binding of [<sup>11</sup>C]<b>53</b> was the highest.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></div><div class="NLM_p">In 2017, Ahamed et al.<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> reported on a novel MAGL PET tracer, [<sup>11</sup>C]MA-PB-1 ([<sup>11</sup>C]<b>55</b>), which was modified from JW642 by replacing the phenoxy group with a methoxy group. The initial uptake of [<sup>11</sup>C]<b>55</b> in mouse and rat brain was comparable with that of [<sup>11</sup>C]<b>53</b>. However, significant washout was observed after reaching peak uptake in the rat brain, and the radioactivity remained stable after 1 h. One explanation could be species differences postulated by the authors. Self-blocking experiments and chasing studies with MJN110 (a structurally distinct MAGL inhibitor) confirmed [<sup>11</sup>C]<b>55</b> as a specific irreversible MAGL tracer. In rhesus monkey PET imaging of [<sup>11</sup>C]<b>55</b>, initial high brain uptake reached ∼4.2 SUV at 2.5 min and a steady state (2.5 SUV) was reached after 20 min. This result further underlined the irreversible binding characteristics of [<sup>11</sup>C]<b>55</b>.</div><div class="NLM_p">In the same year, Butler et al. disclosed a series of MAGL inhibitors bearing an azetidine scaffold to reduce the lipophilicity and increase the binding specificity.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> Subsequently, Cheng et al. further developed an array of azetidinyl carbamate-based MAGL inhibitors. Among them, the most promising candidate, MAGL-0519, was labeled with [<sup>11</sup>C]COCl<sub>2</sub> or [<sup>11</sup>C]CH<sub>3</sub>I at two different positions and evaluated in rodents and rhesus monkeys.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> In rodent PET imaging, [<sup>11</sup>C]MAGL-0519 ([<sup>11</sup>C]<b>56</b>) had a high binding specificity and selectivity as well as a heterogeneous distribution with high brain uptake (SUV<sub>max</sub> is up to 1.5), which was consistent with the distribution of MAGL. An unexpected clearance of [<sup>11</sup>C]<b>56</b> in rat brain may be caused by the metabolism of the linkage between carbonyl group of the tracer and the serine residue of MAGL <i>in vivo</i>. In PET imaging studies with rhesus monkey, [<sup>11</sup>C]<b>56</b> also had a heterogeneous distribution with peak brain uptake greater than 1.5 SUV as well as an unexpected clearance.</div><div class="NLM_p">In 2019, Chen  et al.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> developed a novel array of reversible and irreversible MAGL inhibitors with a “tail switching” strategy on a piperazinyl azetidine scaffold.<a onclick="showRef(event, 'ref227 ref228 ref229'); return false;" href="javascript:void(0);" class="ref ref227 ref228 ref229">(227−229)</a> Among them, three promising MAGL inhibitors were labeled and evaluated in rodents, including the irreversible inhibitor [<sup>11</sup>C]MAGL-2-11 ([<sup>11</sup>C]<b>57</b>, IC<sub>50</sub> = 0.88 nM, log <i>D</i> = 1.9) and two reversible inhibitors [<sup>18</sup>F]MAGL-4-11 ([<sup>18</sup>F]<b>61</b>, IC<sub>50</sub> = 11.7 nM, log <i>D</i> = 2.7) and [<sup>11</sup>C]PAD ([<sup>11</sup>C]<b>62</b>, IC<sub>50</sub> = 2.7 nM, log <i>D</i> = 3.4). [<sup>11</sup>C]<b>57</b> showed good brain permeability with a maximum brain SUV of 2.26 at 3.5 min postinjection, and no significant washout was observed during a PET scan. The distribution of [<sup>11</sup>C]<b>57</b> in the rat brain was heterogeneous and consistent with MAGL distribution. However, BBB permeability of two reversible tracers ([<sup>11</sup>C]PAD ([<sup>11</sup>C]<b>62</b>) and [<sup>18</sup>F]MAGL-4-11 ([<sup>18</sup>F]<b>61</b>)) was poor (0.3–0.4 SUV<sub>max</sub>), which may be related to Pgp and Bcrp efflux. This hypothesis was validated in an experiment with Pgp/Bcrp knockout mice. Further studies in higher species are underway to verify if species difference exists for brain penetration.</div><div class="NLM_p">In the same year, Mori et al.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> reported a novel irreversible MAGL inhibitor [<sup>11</sup>C]<b>58</b> based on azetidine scaffold with a hexafluoroisopropyl (HFIP) alcohol leaving group. [<sup>11</sup>C]<b>58</b> has a high MAGL potency (IC<sub>50</sub> = 0.4 nM) and a suitable lipophilicity (cLogD = 3.29). [<sup>11</sup>C]<b>58</b> was labeled with [<sup>11</sup>C]COCl<sub>2</sub> and evaluated in rodents. [<sup>11</sup>C]<b>58</b> exhibited a good brain permeability with a maximum brain uptake of 1.5 SUV and specific and irreversible binding to MAGL.</div><div class="NLM_p">Recently, an azabicyclo[3.1.0]hexane scaffold-based irreversible MAGL inhibitor, PF-06809247, with a unique trifluoromethyl glycol leaving group was labeled with carbon-11 to assess its potential as a MAGL radioligand both <i>in vitro</i> and <i>in vivo.</i><a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> [<sup>11</sup>C]PF-06809247 ([<sup>11</sup>C]<b>59</b>) exhibited good MAGL potency (IC<sub>50</sub> = 13 nM, cLogD = 2.7), high permeability, and high specific binding in the frontal cortex, hippocampus, and cerebellum in the brain. In NHP PET imaging, [<sup>11</sup>C]<b>59</b> showed high brain uptake with SUV<sub>max</sub> of ca. 3.5. Although its target occupancy and pharmacokinetics in NHP have not yet been reported, [<sup>11</sup>C]<b>59</b> has entered clinical trials.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> This will provide the basis for the development of MAGL targeting therapeutics and further understanding of MAGL-related pathologies <i>in vivo</i>.</div><div class="NLM_p last">In parallel, Chen et al.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> reported another azabicyclo[3.1.0]hexane scaffold-based MAGL PET tracer [<sup>18</sup>F]PF06795071 ([<sup>18</sup>F]<b>60</b>). PF06795071 is a promising MAGL inhibitor developed by McAllister et al. with excellent MAGL potency (IC<sub>50</sub> = 3 nM) and excellent serine hydrolase selectivity.<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> [<sup>18</sup>F]<b>60</b> was <sup>18</sup>F-labeled via spirocyclic iodonium ylide (SCIDY) strategy<a onclick="showRef(event, 'ref235 ref236 ref237 ref238'); return false;" href="javascript:void(0);" class="ref ref235 ref236 ref237 ref238">(235−238)</a> and further evaluated in rodents. By <i>in vitro</i> autoradiography, [<sup>18</sup>F]<b>60</b> exhibited excellent binding specificity and heterogeneous regional brain uptake in rodent brain, consistent with MAGL distribution. In addition, [<sup>18</sup>F]<b>60</b> readily crossed the BBB (SUV<sub>max</sub> = 1.8 at 2.5 min) and exhibited heterogeneous regional brain uptake in rat PET imaging. PET evaluation in NHP is underway to verify its translation potential for human use.</div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">3.2.2.  Reversible MAGL Radiotracers</h4><div class="NLM_p last">A limited number of reversible MAGL radiotracers have been reported as shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Of note, [<sup>18</sup>F]<b>61</b> and [<sup>11</sup>C]<b>62</b> exhibited limited brain penetration, which was shown to be dependent on the activity of ABC efflux transporters.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> Subsequently, Chen et al.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> developed a novel reversible MAGL PET probe, [<sup>18</sup>F]FEPAD ([<sup>18</sup>F]<b>63</b>), based on the structure of [<sup>11</sup>C]<b>62</b>. [<sup>18</sup>F]<b>63</b> showed excellent MAGL potency (IC<sub>50</sub> = 23.8 nM) and target selectivity (>100-fold) among other major serine hydrolases. As a proof-of-concept, [<sup>18</sup>F]<b>63</b> was used to differentiate brown and white adipose tissue in the lipid network. Indeed, [<sup>18</sup>F]<b>63</b> had much higher uptake in BAT (peak value of 21.4 %ID/g) than white adipose tissue (WAT, 3.5 %ID/g). Recently Hattori et al.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a> developed a novel MAGL PET tracer [<sup>18</sup>F]T-401 ([<sup>18</sup>F]<b>64</b>, IC<sub>50(human)</sub> = 4.0 nM, log <i>D</i> = 1.86) based on the piperazinyl pyrrolidine-2-one scaffold reported by Takeda Pharmaceuticals. [<sup>18</sup>F]<b>64</b> exhibited the highest uptake in the frontal cortex, followed by the striatum, and these results were consistent with the distribution of MAGL. The rhesus monkey PET imaging with [<sup>18</sup>F]<b>64</b> exhibited reversible binding characteristics, and brain uptake of [<sup>18</sup>F]<b>64</b> peaked immediately (SUV<sub>max</sub> > 1.5) postinjection and subsequently decreased to 30–40% of the maximum at the end of a 120 min scan.</div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">4.  Perspectives and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.1.  Opportunities in Developing ECS PET Tracers Based on Allosteric Modulation</h3><div class="NLM_p last">CB1R ligand development has proven challenging due to severe psychoactive adverse events observed with the majority of orthosteric CB1R ligands. The latter has prompted the focus toward allosteric CB1R modulators, providing an enhanced subtype-selectivity and reducing receptor downregulation as well as inter-receptor promiscuity, two detrimental effects observed with classical orthosteric CB1R ligands.<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(241)</a> Both CB1R and CB2R contain several allosteric binding sites.<a onclick="showRef(event, 'ref242 ref243'); return false;" href="javascript:void(0);" class="ref ref242 ref243">(242,243)</a> Over the past few years, a number of synthetic or natural compounds were characterized as CB1R allosteric modulators.<a onclick="showRef(event, 'ref244 ref245 ref246 ref247'); return false;" href="javascript:void(0);" class="ref ref244 ref245 ref246 ref247">(244−247)</a> A detailed review on the pharmacological properties and therapeutic potential of these allosteric modulators has recently been reported by Khurana et al.<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a> Similarly, by computational modeling and molecular dynamics simulation, Dainese et al.<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a> demonstrated that the FAAH function can be fine-tuned by allosteric modulation. This discovery provided new concepts for the regulation of FAAH activity and the synthesis of allosteric FAAH inhibitors. Notably, the contemporary focus on allosteric modulators of the ECS has implications not only for therapeutic strategies but also for the development of ECS-targeted PET radioligands. Given that PET probes are crucial to facilitate drug development via target validation experiments, receptor occupancy, and proper dose-finding studies, it is not surprising that there is a growing interest in radioligands that bind to allosteric sites of CB1R and CB2R. Indeed, allosteric binding sites are yet to be exploited in future tracer development programs and harbor a huge potential to improve our understanding of the ECS and to facilitate drug discovery on allosteric modulation.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.2.  Opportunities in Developing PET Tracers for Important Yet Understudied Biological Targets within ECS</h3><div class="NLM_p">Other serine hydrolases, in addition to FAAH and MAGL, are involved in the biosynthesis and metabolism of endocannabinoids and other lipids. For some of these serine hydrolases, covalent and/or reversible inhibitors have been reported, which could potentially provide a starting point for developing PET tracers. For example, ABHD12 and ABHD6 have been shown to contribute to total brain 2-AG hydrolysis activity and may make more specialized contributions to this process, especially in cell types with low MAGL expression. In this regard, ABHD6 and ABHD12 both show distinct cellular and subcellular expression patterns compared to MAGL and may regulate different 2-AG pools.<a onclick="showRef(event, 'ref7 ref250'); return false;" href="javascript:void(0);" class="ref ref7 ref250">(7,250)</a> Development of PET tracers for ABHD6 and ABHD12 may facilitate an understanding of the potentially distinct roles played by these enzymes in 2-AG metabolism and signaling. There are several highly selective inhibitors available for ABHD6 and ABHD12 such as KT182, an orally active irreversible ABHD6 inhibitor,<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> and DO264, an orally active reversible ABHD12 inhibitor.<a onclick="showRef(event, 'ref252'); return false;" href="javascript:void(0);" class="ref ref252">(252)</a></div><div class="NLM_p">The integral membrane serine hydrolases diacylglycerol lipase α (DAGLα) and DAGLβ have been identified as DAG lipases involved in the biosynthesis of 2-AG.<a onclick="showRef(event, 'ref253'); return false;" href="javascript:void(0);" class="ref ref253">(253)</a> Different isoform-selective and nonselective DAGL inhibitors have been reported, including KT109 (DAGLβ isoform-selective, non-CNS active)<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> and DO34 and DH376 (DAGLα/β dual, CNS active).<a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">(255)</a> Beyond serine hydrolases, other lipases of interest include NAPE-PLD, which converts NAPEs into NAEs and is involved in the biosynthesis of AEA. Recently, a CNS-active NAPE-PLD inhibitor, LEI-401, has been reported and characterized in mice.<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a></div><div class="NLM_p last">Development of PET-tracers based on inhibitors of key enzymes involved in eCB metabolism is an important step in the development and characterization of new drug candidates for ECS-related diseases.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">5.  Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">During the past decades, a variety of CB1R radioligands have been synthesized and evaluated. Several tracers have been transitioned into clinical research studies, of which [<sup>11</sup>C]<b>5</b> and [<sup>18</sup>F]<b>10</b> have provided promising results in mental disorders, such as schizophrenia and addiction disorder. PET radioligands for CB2R have shown promise in neuroinflammatory animal models and post-mortem human tissues of ALS patients. It should be noted that CB2R tracer development has been plagued by the lack of a suitable antibody/ligand, which would allow the validation of autoradiographic findings and determination of CB2R <i>B</i><sub>max</sub> in the CNS. Now that the crystal structure of CB2R has been resolved, it is envisioned that computational modeling may aid the development of a selective antibody/ligand, thereby facilitating appropriate validation of PET probes in the pipeline.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Since a major clinical trial tragedy in 2016, few attempts have been made to develop new FAAH radiotracers, which represents a current unmet clinical need. Conversely, the development of PET probes for MAGL has recently received growing attention with a plethora of structurally distinct radiolabeled MAGL inhibitors evaluated in vivo. Reversible inhibitor PET probes for MAGL, albeit in the nascent stage, will continue to be of interest in the future.</div><div class="NLM_p last">Overall, the development of PET radioligands for ECS targets is a very energetic research field, which will lay the foundation for the research of diseases and the drugs related to the ECS. Nonetheless, only a few PET tracers displayed suitable lipophilicity and specificity from <i>in vivo</i> studies. Apart from improving the physical properties of the target compound, there are two primary areas of improvement needed. First of all, <sup>18</sup>F-labeled tracers should be more actively developed because of its longer half-life than <sup>11</sup>C, which potentially allows for longer scan times, diverse radiolabeling procedures, and remote regional distribution. The second important improvement is to develop and apply radiotracers with diverse binding character (reversible and irreversible binding) to obtain comprehensive biological knowledge for quantification of the receptor in human subjects.<a onclick="showRef(event, 'ref257'); return false;" href="javascript:void(0);" class="ref ref257">(257)</a> Moreover, tracer validation requires continuous improvement of animal models, particularly regarding neuroinflammatory models that would accurately reflect alterations in the human ECS. Finally, advances in novel radiochemical technology,<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a> including [<sup>11</sup>C]CO<sub>2</sub> fixation<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> and SCIDY<a onclick="showRef(event, 'ref235 ref237 ref258'); return false;" href="javascript:void(0);" class="ref ref235 ref237 ref258">(235,237,258)</a> for radiofluorination, will enable the discovery and access to novel, innovative PET tracers and may ultimately improve the current standard of diagnostic and therapeutic options for patients.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01459" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40751" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40751" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lu Wang</span> - <span class="hlFld-Affiliation affiliation">Center
of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine
and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China</span>; 
    <span class="hlFld-Affiliation affiliation">Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital,
and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8049-1991" title="Orcid link">http://orcid.org/0000-0002-8049-1991</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f894a78f99969fc9c8c8c1b892968dd69d9c8dd69b96"><span class="__cf_email__" data-cfemail="ed81b29a8c838adcddddd4ad878398c3888998c38e83">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven H. Liang</span> - <span class="hlFld-Affiliation affiliation">Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital,
and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1413-6315" title="Orcid link">http://orcid.org/0000-0003-1413-6315</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#422e2b232c256c31362734272c022f252a6c2a2330342330266c272637"><span class="__cf_email__" data-cfemail="402c29212e276e33342536252e002d27286e282132362132246e252435">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lu Hou</span> - <span class="hlFld-Affiliation affiliation">Center
of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine
and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Rong</span> - <span class="hlFld-Affiliation affiliation">Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital,
and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ahmed Haider</span> - <span class="hlFld-Affiliation affiliation">Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital,
and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daisuke Ogasawara</span> - <span class="hlFld-Affiliation affiliation">The
Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, SR107, 10550 North Torrey Pines
Road, La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cassis Varlow</span> - <span class="hlFld-Affiliation affiliation">Azrieli
Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre
for Addiction and Mental Health, and Department of Psychiatry/Institute
of Medical Science, University of Toronto, 250 College Street, Toronto, M5T 1R8 ON, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Schafroth</span> - <span class="hlFld-Affiliation affiliation">The
Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, SR107, 10550 North Torrey Pines
Road, La Jolla, California 92037, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5864-6766" title="Orcid link">http://orcid.org/0000-0002-5864-6766</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linjing Mu</span> - <span class="hlFld-Affiliation affiliation">Center
for Radiopharmaceutical Sciences of ETH, PSI, and USZ, and Institute
of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiefeng Gan</span> - <span class="hlFld-Affiliation affiliation">Center
of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine
and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Xu</span> - <span class="hlFld-Affiliation affiliation">Center
of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine
and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Fowler</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87 Umeå, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming-Rong Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Radiopharmaceuticals Development, National
Institute of Radiological Sciences, National Institutes for Quantum
and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3001-9605" title="Orcid link">http://orcid.org/0000-0002-3001-9605</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Vasdev</span> - <span class="hlFld-Affiliation affiliation">Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital,
and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Azrieli
Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre
for Addiction and Mental Health, and Department of Psychiatry/Institute
of Medical Science, University of Toronto, 250 College Street, Toronto, M5T 1R8 ON, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2087-5125" title="Orcid link">http://orcid.org/0000-0002-2087-5125</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Ametamey</span> - <span class="hlFld-Affiliation affiliation">Center
for Radiopharmaceutical Sciences of ETH, PSI, and USZ, and Institute
of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4285-6731" title="Orcid link">http://orcid.org/0000-0003-4285-6731</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin F. Cravatt</span> - <span class="hlFld-Affiliation affiliation">The
Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, SR107, 10550 North Torrey Pines
Road, La Jolla, California 92037, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5330-3492" title="Orcid link">http://orcid.org/0000-0001-5330-3492</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>L.H., J.R., and A.H. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02603" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02603" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Lu Hou</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4635-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lu Hou</b> is a third-year graduate student at Jinan University (JNU), majoring in imaging medicine and nuclear medicine under the guidance of Dr. Hao Xu and Dr. Lu Wang. Her main research interests are the imaging of the central nervous system and the clinical evaluation and transformation of new PET probes.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Jian Rong</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4640-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jian Rong</b> obtained his B.Sc. degrees in Chemistry and Biology with Professor Wen-Jing Xiao in Central China Normal University (CCNU) in 2012, followed by his Ph.D. in Organic Chemistry with Professor Jinbo Hu in Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences (CAS) in 2017. After that, he continued his postdoctoral research with Professor Steven H. Liang at Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS). His research interests include <sup>18</sup>F-labeling methodologies and development of PET tracers for the central and peripheral nervous system.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Ahmed Haider</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4648-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ahmed Haider</b> obtained his M.S. in Pharmaceutical Sciences at ETH Zurich, Switzerland, where he subsequently earned his Ph.D. in Radiochemistry and Molecular Imaging with Professor Simon M. Ametamey in 2018. In the same year, he moved to the Department of Nuclear Medicine at the University Hospital Zurich, working with Prof. Catherine Gebhard to advance cardiovascular gender medicine with particular focus on preclinical and clinical cardiovascular PET imaging. Recently Dr. Haider joined Professor Steven H. Liang’s research group at the Division of Nuclear Medicine and Molecular Imaging at Harvard Medical School and Massachusetts General Hospital in Boston, U.S..</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Daisuke Ogasawara</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4653-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Daisuke Ogasawara</b> received his B.S. in 2011 and M.S. in 2013 in Pharmaceutical Sciences from Nagoya City University. He then joined the research group of Prof. Benjamin F. Cravatt at The Scripps Research Institute, where he conducted his doctoral study focusing on development of chemical tools for serine hydrolases involved in metabolism of signaling lipids. After receiving his Ph.D. in Chemistry in 2019, he joined the research group of Prof. Stuart L. Schreiber as a JSPS Overseas Research Fellow.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Cassis Varlow</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4658-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Cassis Varlow</b> received her B.Sc. in Chemical Biology from McMaster University in 2019. She continued her education at the University of Toronto in Dr. Neil Vasdev’s lab at the Centre for Addiction and Mental Health (CAMH) Brain Health Imaging Centre as an M.Sc. candidate and a prospective Ph.D. student. Her research interests include <i>in vitro</i> radioligand characterization to derisk the development of successful PET radiotracers for preclinical and human translation, for the study of neurodegenerative diseases.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Michael A. Schafroth</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4666-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Michael A. Schafroth</b> received his B.Sc. in Chemistry in 2010 and M.Sc. in Interdisciplinary Sciences in 2012 from ETH Zürich. He then joined the research group of Prof. Erick M. Carreira, where he worked on the design and development of asymmetric iridium-catalyzed allylic substitution reactions, applications of stereodivergent methods to the synthesis of cannabinoids, and development of novel tools to study interactions of small molecules with the cell surface proteome. After receiving his Ph.D. in Chemistry in 2017, he joined the research group of Prof. Ben Cravatt at Scripps Research as a SNSF sponsored postdoctoral research associate. He currently works on the synthesis of small molecule inhibitors for serine hydrolases and is developing novel chemoprotoemic probes to modulate protein function in different biological arenas.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Linjing Mu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4671-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lingjing Mu</b> received her Ph.D. in Chemistry from Nankai University, China, in 1996. She worked as a postdoctoral fellow at the University of Basel and Center for Radiopharmaceutical Sciences (CRS) in Switzerland. In 2004, she was appointed as the team leader for PET chemistry at CRS. She is the Research Head of Radiopharmacy since 2010 and has working places at both University Hospital and ETH Zurich. Her research interests focus on PET tracer development and the development of new <sup>18</sup>F-radiolabeling methods as well as the translation of new PET tracers into the clinic.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Jiefeng Gan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4679-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jiefeng Gan</b> is a third-year graduate student at Jinan University with the major of nuclear medicine under the supervision of Dr. Lu Wang. Her research focuses on preliminary evaluation of novel PET tracers in rodents and non-human primates.</p></figure></div><div class="bio" rid="ath9"><figure id="ath9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Hao Xu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4684-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hao Xu</b> received his Ph.D. in Nuclear Medicine from Humboldt University of Berlin in 1996. Dr. Xu is currently the Director of the Nuclear Medicine Department and PET/CT-MRI Center at the First Affiliated Hospital of Jinan University (JNUH) and the Executive Vice Director of the Institute of Molecular and Functional Imaging at JNU. Dr. Xu’s research interests are clinical nuclear medicine and molecular imaging of cancer and neurological diseases.</p></figure></div><div class="bio" rid="ath10"><figure id="ath10" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Christopher J. Fowler</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4689-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher J. Fowler</b> obtained his B.A. at Cambridge University in 1975, followed by his Ph.D. in Pharmacology at the same university in 1978. Following postdoctoral posts in Sweden, Ireland, and France, he was a researcher at Astra Läkemedel (now part of AstraZeneca) from 1982 to 1994. He was thereafter appointed Professor of Pharmaology at Umeå University in Sweden and took up his appointment there in 1995. Dr. Fowler’s current research interests concern the pharmacology of the endocannabinoid system. Dr. Fowler was recognized as a highly cited researcher 2019 by the Web of Science group.</p></figure></div><div class="bio" rid="ath11"><figure id="ath11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Ming-Rong Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4694-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ming-Rong Zhang</b> received his B.S. at China Pharmaceutical University in 1985, followed by his Ph.D. in Medicinal Chemistry with Professor Masatoshi Yamato in Okayama University in 1993. Then he joined the Molecular Probe Program in National Institute of Radiological Sciences (NIRS) of Japan in 1998 and was promoted to Leader of Radiochemistry Team in 2006 and Director of Molecular Probe Program of NIRS in 2012. Dr. Zhang is currently the Director of Department of Advanced Nuclear Medicine Sciences, NIRS, QST of Japan. Dr. Zhang’s research interests include radiochemistry, radiotracer, and radiotherapy development, as well as clinical translation.</p></figure></div><div class="bio" rid="ath12"><figure id="ath12" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Neil Vasdev</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4700-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Neil Vasdev</b> received his Ph.D. in Chemistry from McMaster University, followed by a NSERC postdoc at Berkeley National Labs in 2003. He is the Director of the CAMH Brain Health Imaging Centre and the Azrieli Centre for Neuro-Radiochemistry. He is an endowed Chaired Professor at the University of Toronto and Canada Research Chair in Radiochemistry and Nuclear Medicine. He began his faculty career in Toronto in 2004 and was the Director of Radiochemistry at MGH and an Associate Professor at HMS (2011–2017). His research interests include applying novel radiochemistry methods with <sup>11</sup>C and <sup>18</sup>F to human PET imaging.</p></figure></div><div class="bio" rid="ath13"><figure id="ath13" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Simon Ametamey</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4711-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Simon M. Ametamey</b> obtained his M.S. in Chemistry from the Technical University of Merseburg, Germany, in 1985. He earned his doctorate degree in Organic Chemistry from the University of Zurich, Switzerland, under the supervision of Prof. H. H. Heimgartner. Following a postdoctoral fellowship with Prof. K. Bernhard at Hoffmann La Roche (Basel, Switzerland), he joined the Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ in Villigen, Switzerland, in 1991. In 1995, he became the group leader and was appointed Titularprofessor in 2006. Since then, he has coheaded the Animal Imaging Center-PET at the Institute of Pharmaceutical Sciences at ETH Zurich.</p></figure></div><div class="bio" rid="ath14"><figure id="ath14" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Benjamin F. Cravatt</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4716-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Benjamin F. Cravatt</b> obtained his undergraduate education at Stanford University, receiving a B.S. in Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Dr. Cravatt is a Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease, especially as they pertain to the nervous system and cancer.</p></figure></div><div class="bio" rid="ath15"><figure id="ath15" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Lu Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4721-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lu Wang</b> received his B.S. in Pharmacy from the Ocean University of China in 2010, followed by his Ph.D. in Chemical Genomics from Peking University in 2016. Dr. Wang was a Senior Visiting Scholar at HMS/MGH (2014–2016) and has been a Visiting Research Fellow at NIRS (2017 to now). Dr. Wang is currently the Vice Director of the Center of Cyclotron and PET Radiopharmaceuticals (CCPR) in JNUH. Dr. Wang’s research interests include radiochemistry, PET tracer development, and clinical translational studies.</p></figure></div><div class="bio" rid="ath16"><figure id="ath16" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Steven H. Liang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=BIO-d7e4726-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Steven H. Liang</b> obtained his B.S. at Tianjin University in 2003, followed by his Ph.D. in Chemistry with Professor Marco Ciufolini at the University of British Columbia in 2010. Then he started as a NSERC Fellow with Professor E. J. Corey at Harvard University. In 2012, Dr. Liang accepted a junior faculty position at HMS and MGH. Dr. Liang is currently the Director of Radiochemistry and Biomarker Development, Nuclear Medicine and Molecular Imaging at MGH, and Associate Professor of Radiology at HMS. Dr. Liang’s research interests include radiochemistry, imaging biomarker and radiotherapy development, and clinical translation.</p></figure></div><div class="ack" id="ACK-d7e4734-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56126" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56126" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">L.W. and H.X. are thankful of the support of K. C. Wong Education Foundation, the National Natural Science Foundation of China (Grants 81701751 and 81871383), the Guangdong Basic and Applied Basic Research Foundation (Grant 2020A1515011192), the Fundamental Research Funds for the Central Universities (Grant 21619104), and the Project of Innovative Team for the Guangdong University (Grant 2018KCXTD001). The following funding support from the NIH (Grants DA038000 and DA043507 to S.H.L., Grants AG054473 and AG052414 to N.V., and Grant DA033760 to B.F.C.), the Azrieli Foundation, Canada Foundation for Innovation, Ontario Research Fund and the Canada Research Chairs Program (to N.V.), and Swiss National Science Foundation (Grant P2EZP3_175137 to M.A.S) is also gratefully acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviation Used</td></tr><tr><td class="NLM_term">AA</td><td class="NLM_def"><p class="first last">arachidonic acid</p></td></tr><tr><td class="NLM_term">AAI</td><td class="NLM_def"><p class="first last">aminoalkylindole</p></td></tr><tr><td class="NLM_term">ABHD6</td><td class="NLM_def"><p class="first last">α/β hydrolase domain-6</p></td></tr><tr><td class="NLM_term">ABHD12</td><td class="NLM_def"><p class="first last">α/β hydrolase domain-12</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer disease</p></td></tr><tr><td class="NLM_term">ALS</td><td class="NLM_def"><p class="first last">amyotrophic lateral sclerosis</p></td></tr><tr><td class="NLM_term">AEA</td><td class="NLM_def"><p class="first last"><i>N</i>-arachidonoylethanolamine</p></td></tr><tr><td class="NLM_term">BAT</td><td class="NLM_def"><p class="first last">brown adipose tissue</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">BP</td><td class="NLM_def"><p class="first last">binding potential</p></td></tr><tr><td class="NLM_term">CB1R</td><td class="NLM_def"><p class="first last">cannabinoid receptor 1</p></td></tr><tr><td class="NLM_term">CB2R</td><td class="NLM_def"><p class="first last">cannabinoid receptor 2</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CVD</td><td class="NLM_def"><p class="first last">cardiovascular dysfunction</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DS</td><td class="NLM_def"><p class="first last">Dravet syndrome</p></td></tr><tr><td class="NLM_term">ECS</td><td class="NLM_def"><p class="first last">endocannabinoid system</p></td></tr><tr><td class="NLM_term">FAAH</td><td class="NLM_def"><p class="first last">fatty acid amide hydrolase</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">HD</td><td class="NLM_def"><p class="first last">Huntington’s disease</p></td></tr><tr><td class="NLM_term">LGS</td><td class="NLM_def"><p class="first last">Lennox–Gastaut syndrome</p></td></tr><tr><td class="NLM_term">MAGL</td><td class="NLM_def"><p class="first last">monoacylglycerol lipase</p></td></tr><tr><td class="NLM_term">MRI</td><td class="NLM_def"><p class="first last">magnetic resonance imaging</p></td></tr><tr><td class="NLM_term">NHP</td><td class="NLM_def"><p class="first last">non-human primate</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s syndrome</p></td></tr><tr><td class="NLM_term">PBA-HD</td><td class="NLM_def"><p class="first last">problem behavior assessment for Huntington’s disease</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">PgP/Bcrp</td><td class="NLM_def"><p class="first last">P-glycoprotein/breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">PK–PD</td><td class="NLM_def"><p class="first last">pharmacokinetic–pharmacodynamic</p></td></tr><tr><td class="NLM_term">RCY</td><td class="NLM_def"><p class="first last">radiochemical yield</p></td></tr><tr><td class="NLM_term">SCIDY</td><td class="NLM_def"><p class="first last">spirocyclic iodonium ylide</p></td></tr><tr><td class="NLM_term">SPECT</td><td class="NLM_def"><p class="first last">single photon emission computed tomography</p></td></tr><tr><td class="NLM_term">SUV</td><td class="NLM_def"><p class="first last">standard uptake value</p></td></tr><tr><td class="NLM_term">TRT</td><td class="NLM_def"><p class="first last">test–retest</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>T</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">2-AG</td><td class="NLM_def"><p class="first last">2-arachidonoylglycerol</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54582" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54582" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 258 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, T. F.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid signaling as a synaptic circuit breaker in neurological disease</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1038/nm.f.1869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnm.f.1869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18776886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVyms7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=923-930&author=I.+Katonaauthor=T.+F.+Freund&title=Endocannabinoid+signaling+as+a+synaptic+circuit+breaker+in+neurological+disease&doi=10.1038%2Fnm.f.1869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid signaling as a synaptic circuit breaker in neurological disease</span></div><div class="casAuthors">Katona, Istvan; Freund, Tamas F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">923-930</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cannabis sativa is one of the oldest herbal plants in the history of medicine.  It was used in various therapeutic applications from pain to epilepsy, but its psychotropic effect has reduced its usage in recent medical practice.  However, renewed interest has been fueled by major discoveries revealing that cannabis-derived compds. act through a signaling pathway in the human body.  Here we review recent advances showing that endocannabinoid signaling is a key regulator of synaptic communication throughout the central nervous system.  Its underlying mol. architecture is highly conserved in synapses from the spinal cord to the neocortex, and as a neg. feed-back signal, it provides protection against excess presynaptic activity.  The endocannabinoid signaling machinery operates on demand in a synapse-specific manner; therefore, its modulation offers new therapeutic opportunities for the selective control of deleterious neuronal activity in several neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0yon-a5eEWbVg90H21EOLACvtfcHk0lh9E08SYGEUPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVyms7vM&md5=3e29744bd103a145e6be7ad48277ae6e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnm.f.1869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.f.1869%26sid%3Dliteratum%253Aachs%26aulast%3DKatona%26aufirst%3DI.%26aulast%3DFreund%26aufirst%3DT.%2BF.%26atitle%3DEndocannabinoid%2520signaling%2520as%2520a%2520synaptic%2520circuit%2520breaker%2520in%2520neurological%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D923%26epage%3D930%26doi%3D10.1038%2Fnm.f.1869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petrocellis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span> <span> </span><span class="NLM_article-title">From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1659</span>, <span class="refDoi"> DOI: 10.1152/physrev.00002.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1152%2Fphysrev.00002.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27630175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFGhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2016&pages=1593-1659&author=A.+Ligrestiauthor=L.+De+Petrocellisauthor=V.+Di+Marzo&title=From+phytocannabinoids+to+cannabinoid+receptors+and+endocannabinoids%3A+pleiotropic+physiological+and+pathological+roles+through+complex+pharmacology&doi=10.1152%2Fphysrev.00002.2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology</span></div><div class="casAuthors">Ligresti, Alessia; De Petrocellis, Luciano; Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1593-1659</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Apart from having been used and misused for at least four millennia for, among others, recreational and medicinal purposes, the cannabis plant and its most peculiar chem. components, the plant cannabinoids (phytocannabinoids), have the merit to have led humanity to discover one of the most intriguing and pleiotropic endogenous signaling systems, the endocannabinoid system (ECS).  This review article aims to describe and critically discuss, in the most comprehensive possible manner, the multifaceted aspects of 1) the pharmacol. and potential impact on mammalian physiol. of all major phytocannabinoids, and not only of the most famous one δ9-tetrahydrocannabinol, and 2) the adaptive prohomeostatic physiol., or maladaptive pathol., roles of the ECS in mammalian cells, tissues, and organs.  In doing so, we have respected the chronol. order of the milestones of the millennial route from medicinal/recreational cannabis to the ECS and beyond, as it is now clear that some of the early steps in this long path, which were originally neglected, are becoming important again.  The emerging picture is rather complex, but still supports the belief that more important discoveries on human physiol., and new therapies, might come in the future from new knowledge in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgrvObOREtBLVg90H21EOLACvtfcHk0lh9E08SYGEUPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFGhsrw%253D&md5=47a9345b26cdcf8a8a4b73bf7a3744c6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00002.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00002.2016%26sid%3Dliteratum%253Aachs%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DDe%2BPetrocellis%26aufirst%3DL.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DFrom%2520phytocannabinoids%2520to%2520cannabinoid%2520receptors%2520and%2520endocannabinoids%253A%2520pleiotropic%2520physiological%2520and%2520pathological%2520roles%2520through%2520complex%2520pharmacology%26jtitle%3DPhysiol.%2520Rev.%26date%3D2016%26volume%3D96%26spage%3D1593%26epage%3D1659%26doi%3D10.1152%2Fphysrev.00002.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno-Shosaku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimotodani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, M.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoids and retrograde modulation of synaptic transmission</span>. <i>Neuroscientist</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1177/1073858410397377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1177%2F1073858410397377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21531987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslCmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=119-132&author=T.+Ohno-Shosakuauthor=A.+Tanimuraauthor=Y.+Hashimotodaniauthor=M.+Kano&title=Endocannabinoids+and+retrograde+modulation+of+synaptic+transmission&doi=10.1177%2F1073858410397377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoids and retrograde modulation of synaptic transmission</span></div><div class="casAuthors">Ohno-Shosaku, Takako; Tanimura, Asami; Hashimotodani, Yuki; Kano, Masanobu</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscientist</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-132</span>CODEN:
                <span class="NLM_cas:coden">NROSFJ</span>;
        ISSN:<span class="NLM_cas:issn">1073-8584</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Since the first reports of endocannabinoid-mediated retrograde signaling in 2001, great advances have been made toward understanding the mol. basis and functions of the endocannabinoid system.  Electrophysiol. studies have revealed that the endocannabinoid system is functional at various types of synapses throughout the brain.  Basic mechanisms have been clarified as to how endocannabinoids are produced and released from postsynaptic neurons and regulate neurotransmitter release through activating presynaptic cannabinoid CB1 receptors, although there remain unsolved questions and some discrepancies.  In addn. to this major function, recent studies suggest diverse functions of endocannabinoids, including control of other endocannabinoid-independent forms of synaptic plasticity, regulation of neuronal excitability, stimulation of glia-neuron interaction, and induction of CB1R-independent plasticity.  Using recently developed pharmacol. and genetic tools, behavioral studies have elucidated the roles of the endocannabinoid system in various aspects of neural functions.  In this review, we make a brief overview of mol. mechanisms underlying the endocannabinoid-mediated synaptic modulation and also summarize recent findings, which shed new light on a diversity of functional roles of endocannabinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlLctJDRHFp7Vg90H21EOLACvtfcHk0lh9E08SYGEUPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslCmtrw%253D&md5=c5ac84fa4044ee03c08b2fd985644f5f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1177%2F1073858410397377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1073858410397377%26sid%3Dliteratum%253Aachs%26aulast%3DOhno-Shosaku%26aufirst%3DT.%26aulast%3DTanimura%26aufirst%3DA.%26aulast%3DHashimotodani%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DM.%26atitle%3DEndocannabinoids%2520and%2520retrograde%2520modulation%2520of%2520synaptic%2520transmission%26jtitle%3DNeuroscientist%26date%3D2012%26volume%3D18%26spage%3D119%26epage%3D132%26doi%3D10.1177%2F1073858410397377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uyama, T.</span></span> <span> </span><span class="NLM_article-title">Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">1874</span>– <span class="NLM_lpage">1894</span>, <span class="refDoi"> DOI: 10.1111/febs.12152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Ffebs.12152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23425575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFWgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=1874-1894&author=N.+Uedaauthor=K.+Tsuboiauthor=T.+Uyama&title=Metabolism+of+endocannabinoids+and+related+N-acylethanolamines%3A+canonical+and+alternative+pathways&doi=10.1111%2Ffebs.12152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of endocannabinoids and related N-acylethanolamines: Canonical and alternative pathways</span></div><div class="casAuthors">Ueda, Natsuo; Tsuboi, Kazuhito; Uyama, Toru</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1874-1894</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Endocannabinoids are endogenous ligands of the cannabinoid receptors CB1 and CB2.  Two arachidonic acid derivs., arachidonoylethanolamide (anandamide) and 2-arachidonoyl glycerol, are considered to be physiol. important endocannabinoids.  In the known metabolic pathway in mammals, anandamide and other bioactive N-acylethanolamines, such as palmitoylethanolamide and oleoylethanolamide, are biosynthesized from glycerophospholipids by a combination of Ca2+-dependent N-acyltransferase and N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D, and are degraded by fatty acid amide hydrolase.  However, recent studies have shown the involvement of other enzymes and pathways, which include the members of the tumor suppressor HRASLS family (the phospholipase A/acyltransferase family) functioning as Ca2+-independent N-acyltransferases, N-acyl-phosphatidylethanolamine-hydrolyzing phospholipaseD-independent multistep pathways via N-acylated lysophospholipid, and N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme that preferentially hydrolyzes palmitoylethanolamide.  Although their physiol. significance is poorly understood, these new enzymes/pathways may serve as novel targets for the development of therapeutic drugs.  For example, selective N-acylethanolamine-hydrolyzing acid amidase inhibitors are expected to be new anti-inflammatory and analgesic drugs.  In this minireview, we focus on advances in the understanding of these enzymes/pathways.  In addn., recent findings on 2-arachidonoyl glycerol metab. are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXGslrDcd7BrVg90H21EOLACvtfcHk0lj5n3o0xqs9EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFWgur4%253D&md5=8ad15d152019255551ab6e5bac9817d1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Ffebs.12152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.12152%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DN.%26aulast%3DTsuboi%26aufirst%3DK.%26aulast%3DUyama%26aufirst%3DT.%26atitle%3DMetabolism%2520of%2520endocannabinoids%2520and%2520related%2520N-acylethanolamines%253A%2520canonical%2520and%2520alternative%2520pathways%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D1874%26epage%3D1894%26doi%3D10.1111%2Ffebs.12152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensi, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathuria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Brain monoglyceride lipase participating in endocannabinoid enactivation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">10819</span>– <span class="NLM_lpage">10824</span>, <span class="refDoi"> DOI: 10.1073/pnas.152334899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.152334899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12136125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmt1ChtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=10819-10824&author=T.+P.+Dinhauthor=D.+Carpenterauthor=F.+M.+Leslieauthor=T.+F.+Freundauthor=I.+Katonaauthor=S.+L.+Sensiauthor=S.+Kathuriaauthor=D.+Piomelli&title=Brain+monoglyceride+lipase+participating+in+endocannabinoid+enactivation&doi=10.1073%2Fpnas.152334899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Brain monoglyceride lipase participating in endocannabinoid inactivation</span></div><div class="casAuthors">Dinh, T. P.; Carpenter, D.; Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">10819-10824</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The endogenous cannabinoids (endocannabinoids) are lipid mols. that may mediate retrograde signaling at central synapses and other forms of short-range neuronal communication.  The monoglyceride 2-arachidonoylglycerol (2-AG) meets several criteria of an endocannabinoid substance: (i) it activates cannabinoid receptors; (ii) it is produced by neurons in an activity-dependent manner; and (iii) it is rapidly eliminated.  2-AG inactivation is only partially understood, but it may occur by transport into cells and enzymic hydrolysis.  Here we tested the hypothesis that monoglyceride lipase (MGL), a serine hydrolase that converts monoglycerides to fatty acid and glycerol, participates in 2-AG inactivation.  We cloned MGL by homol. from a rat brain cDNA library.  Its cDNA sequence encoded for a 303-aa protein with a calcd. mol. wt. of 33,367 Da.  Northern blot and in situ hybridization analyses revealed that MGL mRNA is heterogeneously expressed in the rat brain, with highest levels in regions where CB1 cannabinoid receptors are also present (hippocampus, cortex, anterior thalamus, and cerebellum).  Immunohistochem. studies in the hippocampus showed that MGL distribution has striking laminar specificity, suggesting a presynaptic localization of the enzyme.  Adenovirus-mediated transfer of MGL cDNA into rat cortical neurons increased MGL expression and attenuated N-methyl-D-aspartate/carbachol-induced 2-AG accumulation in these cells.  No such effect was obsd. on the accumulation of anandamide, another endocannabinoid lipid.  The results suggest that hydrolysis by means of MGL is a primary mechanism for 2-AG inactivation in intact neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_r8g9sR9CB7Vg90H21EOLACvtfcHk0lj5n3o0xqs9EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmt1ChtLs%253D&md5=10f14e9625b33d9283d13fa8b9705478</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.152334899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.152334899%26sid%3Dliteratum%253Aachs%26aulast%3DDinh%26aufirst%3DT.%2BP.%26aulast%3DCarpenter%26aufirst%3DD.%26aulast%3DLeslie%26aufirst%3DF.%2BM.%26aulast%3DFreund%26aufirst%3DT.%2BF.%26aulast%3DKatona%26aufirst%3DI.%26aulast%3DSensi%26aufirst%3DS.%2BL.%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBrain%2520monoglyceride%2520lipase%2520participating%2520in%2520endocannabinoid%2520enactivation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D10819%26epage%3D10824%26doi%3D10.1073%2Fpnas.152334899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Marzo, V.</span></span> <span> </span><span class="NLM_article-title">New approaches and challenges to targeting the endocannabinoid system</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrd.2018.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30116049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFans73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=623-639&author=V.+Di%0AMarzo&title=New+approaches+and+challenges+to+targeting+the+endocannabinoid+system&doi=10.1038%2Fnrd.2018.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">New approaches and challenges to targeting the endocannabinoid system</span></div><div class="casAuthors">Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">623-639</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid signalling system was discovered because receptors in this system are the targets of compds. present in psychotropic prepns. of Cannabis sativa.  The search for new therapeutics that target endocannabinoid signalling is both challenging and potentially rewarding, as endocannabinoids are implicated in numerous physiol. and pathol. processes.  Hundreds of mediators chem. related to the endocannabinoids, often with similar metabolic pathways but different targets, have complicated the development of inhibitors of endocannabinoid metabolic enzymes but have also stimulated the rational design of multi-target drugs.  Meanwhile, drugs based on botanical cannabinoids have come to the clin. forefront, synthetic agonists designed to bind cannabinoid receptor 1 with very high affinity have become a societal threat and the gut microbiome has been found to signal in part through the endocannabinoid network.  The current development of drugs that alter endocannabinoid signalling and how this complex system could be pharmacol. manipulated in the future are described in this Opinion article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsITgIPYFrrVg90H21EOLACvtfcHk0lj5n3o0xqs9EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFans73O&md5=7a48b4e8a8c27a5da3e8ba0f80222a32</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.115%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DNew%2520approaches%2520and%2520challenges%2520to%2520targeting%2520the%2520endocannabinoid%2520system%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D623%26epage%3D639%26doi%3D10.1038%2Fnrd.2018.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saario, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, J.</span></span> <span> </span><span class="NLM_article-title">The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors</span>. <i>Acta Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1111/j.1748-1716.2011.02280.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1748-1716.2011.02280.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21418147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1eiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2012&pages=267-276&author=J.+Savinainenauthor=S.+Saarioauthor=J.+Laitinen&title=The+serine+hydrolases+MAGL%2C+ABHD6+and+ABHD12+as+guardians+of+2-arachidonoylglycerol+signalling+through+cannabinoid+receptors&doi=10.1111%2Fj.1748-1716.2011.02280.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors</span></div><div class="casAuthors">Savinainen, J. R.; Saario, S. M.; Laitinen, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Physiologica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-276</span>CODEN:
                <span class="NLM_cas:coden">APCHC4</span>;
        ISSN:<span class="NLM_cas:issn">1748-1708</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid 2-arachidonoylglycerol (2-AG) is a lipid mediator involved in various physiol. processes.  In response to neural activity, 2-AG is synthesized post-synaptically, then activates pre-synaptic cannabinoid CB1 receptors (CB1Rs) in a retrograde manner, resulting in transient and long-lasting redn. of neurotransmitter release.  The signalling competence of 2-AG is tightly regulated by the balanced action between "on demand" biosynthesis and degrdn.  We review recent research on monoacylglycerol lipase (MAGL), ABHD6 and ABHD12, three serine hydrolases that together account for approx. 99% of brain 2-AG hydrolase activity.  MAGL is responsible for approx. 85% of 2-AG hydrolysis and colocalizes with CB1R in axon terminals.  It is therefore ideally positioned to terminate 2-AG-CB1R signalling regardless of the source of this endocannabinoid.  Its acute pharmacol. inhibition leads to 2-AG accumulation and CB1R-mediated behavioral responses.  Chronic MAGL inactivation results in 2-AG overload, desensitization of CB1R signalling and behavioral tolerance.  ABHD6 accounts for approx. 4% of brain 2-AG hydrolase activity but in neurons it rivals MAGL in efficacy.  Neuronal ABHD6 resides post-synaptically, often juxtaposed with CB1Rs, and its acute inhibition leads to activity-dependent accumulation of 2-AG.  In cortical slices, selective ABHD6 blockade facilitates CB1R-dependent long-term synaptic depression.  ABHD6 is therefore positioned to guard intracellular pools of 2-AG at the site of generation.  ABHD12 is highly expressed in microglia and accounts for approx. 9% of total brain 2-AG hydrolysis.  Mutations in ABHD12 gene are causally linked to a neurodegenerative disease called PHARC.  Whether ABHD12 qualifies as a bona fide member to the endocannabinoid system remains to be established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIBgLJavyxUbVg90H21EOLACvtfcHk0lhP6b4aQlzjpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1eiuro%253D&md5=399f8c1e38ae5fd12886573245bec0ba</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1748-1716.2011.02280.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1748-1716.2011.02280.x%26sid%3Dliteratum%253Aachs%26aulast%3DSavinainen%26aufirst%3DJ.%26aulast%3DSaario%26aufirst%3DS.%26aulast%3DLaitinen%26aufirst%3DJ.%26atitle%3DThe%2520serine%2520hydrolases%2520MAGL%252C%2520ABHD6%2520and%2520ABHD12%2520as%2520guardians%2520of%25202-arachidonoylglycerol%2520signalling%2520through%2520cannabinoid%2520receptors%26jtitle%3DActa%2520Physiol.%26date%3D2012%26volume%3D204%26spage%3D267%26epage%3D276%26doi%3D10.1111%2Fj.1748-1716.2011.02280.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Torres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutando, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Torre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valjent, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaita, A.</span></span> <span> </span><span class="NLM_article-title">Monoacylglycerol lipase blockade impairs fine motor coordination and triggers cerebellar neuroinflammation through cyclooxygenase-2</span>. <i>Brain, Behav., Immun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/j.bbi.2019.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bbi.2019.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31251974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yrs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2019&pages=399-409&author=S.+Mart%C3%ADnez-Torresauthor=L.+Cutandoauthor=A.+Pastorauthor=A.+Katoauthor=K.+Sakimuraauthor=R.+de+la+Torreauthor=E.+Valjentauthor=R.+Maldonadoauthor=M.+Kanoauthor=A.+Ozaita&title=Monoacylglycerol+lipase+blockade+impairs+fine+motor+coordination+and+triggers+cerebellar+neuroinflammation+through+cyclooxygenase-2&doi=10.1016%2Fj.bbi.2019.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacylglycerol lipase blockade impairs fine motor coordination and triggers cerebellar neuroinflammation through cyclooxygenase-2</span></div><div class="casAuthors">Martinez-Torres, Sara; Cutando, Laura; Pastor, Antoni; Kato, Ako; Sakimura, Kenji; de la Torre, Rafael; Valjent, Emmanuel; Maldonado, Rafael; Kano, Masanobu; Ozaita, Andres</div><div class="citationInfo"><span class="NLM_cas:title">Brain, Behavior, and Immunity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">399-409</span>CODEN:
                <span class="NLM_cas:coden">BBIMEW</span>;
        ISSN:<span class="NLM_cas:issn">0889-1591</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is the main enzyme implicated in the degrdn. of the most abundant endocannabinoid in the brain, 2-arachidonoylglycerol (2-AG), producing arachidonic acid (AA) and glycerol.  MAGL pharmacol. inhibition with JZL184 or genetic deletion results in an exacerbated 2-AG signaling and reduced synthesis of prostaglandins (PGs), due to the reduced AA precursor levels.  We found that acute JZL184 administration, previously described to exert anti-inflammatory effects, and MAGL knockout (KO) mice display cerebellar, but not hippocampal, microglial reactivity, accompanied with increased expression of the mRNA levels of neuroinflammatory markers, such as cyclooxygenase-2 (COX-2).  Notably, this neuroinflammatory phenotype correlated with relevant motor coordination impairment in the beam-walking and the footprint tests.  Treatment with the COX-2 inhibitor NS398 during 5 days prevented the deficits in cerebellar function and the cerebellar microglia reactivity in MAGL KO, without affecting hippocampal reactivity.  Altogether, this study reveals the brain region-specific response to MAGL inhibition, with an important role of COX-2 in the cerebellar deficits assocd., which should be taken into account for the use of MAGL inhibitors as anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65TtmesmDJrVg90H21EOLACvtfcHk0lhP6b4aQlzjpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yrs7vK&md5=8fdf43cec6c49e3a6487dae16f9fc263</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2019.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2019.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez-Torres%26aufirst%3DS.%26aulast%3DCutando%26aufirst%3DL.%26aulast%3DPastor%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DA.%26aulast%3DSakimura%26aufirst%3DK.%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DR.%26aulast%3DValjent%26aufirst%3DE.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DKano%26aufirst%3DM.%26aulast%3DOzaita%26aufirst%3DA.%26atitle%3DMonoacylglycerol%2520lipase%2520blockade%2520impairs%2520fine%2520motor%2520coordination%2520and%2520triggers%2520cerebellar%2520neuroinflammation%2520through%2520cyclooxygenase-2%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2019%26volume%3D81%26spage%3D399%26epage%3D409%26doi%3D10.1016%2Fj.bbi.2019.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schelling, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campolongo, P.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system and post traumatic stress disorder (PTSD): from preclinical findings to innovative therapeutic approaches in clinical settings</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.phrs.2016.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27456243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=668-678&author=A.+Berardiauthor=G.+Schellingauthor=P.+Campolongo&title=The+endocannabinoid+system+and+post+traumatic+stress+disorder+%28PTSD%29%3A+from+preclinical+findings+to+innovative+therapeutic+approaches+in+clinical+settings&doi=10.1016%2Fj.phrs.2016.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings</span></div><div class="casAuthors">Berardi, Andrea; Schelling, Gustav; Campolongo, Patrizia</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">668-678</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Post-Traumatic Stress Disorder (PTSD) is a psychiatric chronic disease developing in individuals after the experience of an intense and life-threatening traumatic event.  The post-traumatic symptomatol. encompasses alterations in memory processes, mood, anxiety and arousal.  There is now consensus in considering the disease as an aberrant adaptation to traumatic stress.  Pharmacol. research, aimed at the discovery of new potential effective treatments, has lately directed its attention towards the "so-called" cognitive enhancers.  This class of substances, by modulating cognitive processes involved in the development and/or persistence of the post-traumatic symptomatol., could be of great help in improving the outcome of psychotherapies and patients' prognosis.  In this perspective, drugs acting on the endocannabinoid system are receiving great attention due to their dual ability to modulate memory processes on one hand, and to reduce anxiety and depression on the other.  The purpose of the present review is to offer a thorough overview of both animal and human studies investigating the effects of cannabinoids on memory processes.  First, we will briefly describe the characteristics of the endocannabinoid system and the most commonly used animal models of learning and memory.  Then, studies investigating cannabinoid modulatory influences on memory consolidation, retrieval and extinction will be sep. presented, and the potential benefits assocd. with each approach will be discussed.  In the final section, we will review literature data reporting beneficial effects of cannabinoid drugs in PTSD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb-PWPhgS1wLVg90H21EOLACvtfcHk0lhP6b4aQlzjpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygtrfL&md5=7fa5b94ff602c40853b26fcc197ac298</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DBerardi%26aufirst%3DA.%26aulast%3DSchelling%26aufirst%3DG.%26aulast%3DCampolongo%26aufirst%3DP.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520post%2520traumatic%2520stress%2520disorder%2520%2528PTSD%2529%253A%2520from%2520preclinical%2520findings%2520to%2520innovative%2520therapeutic%2520approaches%2520in%2520clinical%2520settings%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D668%26epage%3D678%26doi%3D10.1016%2Fj.phrs.2016.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, H. D.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid signaling in health and disease</span>. <i>Can. J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1139/cjpp-2016-0346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1139%2Fcjpp-2016-0346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28263083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsl2gtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2017&pages=311-327&author=Y.+Luauthor=H.+D.+Anderson&title=Cannabinoid+signaling+in+health+and+disease&doi=10.1139%2Fcjpp-2016-0346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid signaling in health and disease</span></div><div class="casAuthors">Lu, Yan; Anderson, Hope D.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-327</span>CODEN:
                <span class="NLM_cas:coden">CJPPA3</span>;
        ISSN:<span class="NLM_cas:issn">0008-4212</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">Cannabis sativa has long been used for medicinal purposes.  To improve safety and efficacy, compds. from C.sativa were purified or synthesized and named under an umbrella group as cannabinoids.  Currently, several cannabinoids may be prescribed in Canada for a variety of indications such as nausea and pain.  More recently, an increasing no. of reports suggest other salutary effects assocd. with endogenous cannabinoid signaling including cardioprotection.  The therapeutic potential of cannabinoids is therefore extended; however, evidence is limited and mechanisms remain unclear.  In addn., the use of cannabinoids clin. has been hindered due to pronounced psychoactive side effects.  This review provides an overview on the endocannabinoid system, including known physiol. roles, and conditions in which cannabinoid receptor signaling has been implicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsd9MesiR56LVg90H21EOLACvtfcHk0liuEZ5nbUFOeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsl2gtb8%253D&md5=e3e1c0f219bd9e0d44c0c063dd61626d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1139%2Fcjpp-2016-0346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fcjpp-2016-0346%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DAnderson%26aufirst%3DH.%2BD.%26atitle%3DCannabinoid%2520signaling%2520in%2520health%2520and%2520disease%26jtitle%3DCan.%2520J.%2520Physiol.%2520Pharmacol.%26date%3D2017%26volume%3D95%26spage%3D311%26epage%3D327%26doi%3D10.1139%2Fcjpp-2016-0346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulugol, A.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system as a potential therapeutic target for pain modulation</span>. <i>Balk. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.5152/balkanmedj.2014.13103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.5152%2Fbalkanmedj.2014.13103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25207181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=115-120&author=A.+Ulugol&title=The+endocannabinoid+system+as+a+potential+therapeutic+target+for+pain+modulation&doi=10.5152%2Fbalkanmedj.2014.13103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as a potential therapeutic target for pain modulation</span></div><div class="casAuthors">Ulugol, Ahmet</div><div class="citationInfo"><span class="NLM_cas:title">Balkan Medical Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-120, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">BMJAB7</span>;
        ISSN:<span class="NLM_cas:issn">2146-3131</span>.
    
            (<span class="NLM_cas:orgname">AVES</span>)
        </div><div class="casAbstract">A review.  Although cannabis has been used for pain management for millennia, very few approved cannabinoids are indicated for the treatment of pain and other medical symptoms.  Cannabinoid therapy re-gained attention only after the discovery of endocannabinoids and fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the enzymes playing a role in endocannabinoid metab.  Nowadays, research has focused on the inhibition of these degradative enzymes and the elevation of endocannabinoid tonus locally; special emphasis is given on multi-target analgesia compds., where one of the targets is the endocannabinoid degrading enzyme.  In this review, I provide an overview of the current understanding about the processes accounting for the biosynthesis, transport and metab. of endocannabinoids, and pharmacol. approaches and potential therapeutic applications in this area, regarding the use of drugs elevating endocannabinoid levels in pain conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_qeLQOWMa7Vg90H21EOLACvtfcHk0liuEZ5nbUFOeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egtL3I&md5=b3401e563d92777405a1ef6c8569cb41</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.5152%2Fbalkanmedj.2014.13103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5152%252Fbalkanmedj.2014.13103%26sid%3Dliteratum%253Aachs%26aulast%3DUlugol%26aufirst%3DA.%26atitle%3DThe%2520endocannabinoid%2520system%2520as%2520a%2520potential%2520therapeutic%2520target%2520for%2520pain%2520modulation%26jtitle%3DBalk.%2520Med.%2520J.%26date%3D2014%26volume%3D31%26spage%3D115%26epage%3D120%26doi%3D10.5152%2Fbalkanmedj.2014.13103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bedse, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavecchia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, S.</span></span> <span> </span><span class="NLM_article-title">The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1136</span>, <span class="refDoi"> DOI: 10.3233/JAD-141635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3233%2FJAD-141635" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1115-1136&author=G.+Bedseauthor=A.+Romanoauthor=A.+M.+Lavecchiaauthor=T.+Cassanoauthor=S.+Gaetani&title=The+role+of+endocannabinoid+signaling+in+the+molecular+mechanisms+of+neurodegeneration+in+alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-141635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3233%2FJAD-141635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-141635%26sid%3Dliteratum%253Aachs%26aulast%3DBedse%26aufirst%3DG.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DLavecchia%26aufirst%3DA.%2BM.%26aulast%3DCassano%26aufirst%3DT.%26aulast%3DGaetani%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520endocannabinoid%2520signaling%2520in%2520the%2520molecular%2520mechanisms%2520of%2520neurodegeneration%2520in%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2014%26volume%3D43%26spage%3D1115%26epage%3D1136%26doi%3D10.3233%2FJAD-141635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhams, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neugebauer, V.</span></span> <span> </span><span class="NLM_article-title">The cannabinoid system and pain</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuropharm.2017.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28625720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGnsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=105-120&author=S.+G.+Woodhamsauthor=V.+Chapmanauthor=D.+P.+Finnauthor=A.+G.+Hohmannauthor=V.+Neugebauer&title=The+cannabinoid+system+and+pain&doi=10.1016%2Fj.neuropharm.2017.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The cannabinoid system and pain</span></div><div class="casAuthors">Woodhams, Stephen G.; Chapman, Victoria; Finn, David P.; Hohmann, Andrea G.; Neugebauer, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105-120</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic pain states are highly prevalent and yet poorly controlled by currently available analgesics, representing an enormous clin., societal, and economic burden.  Existing pain medications have significant limitations and adverse effects including tolerance, dependence, gastrointestinal dysfunction, cognitive impairment, and a narrow therapeutic window, making the search for novel analgesics ever more important.  In this article, we review the role of an important endogenous pain control system, the endocannabinoid (EC) system, in the sensory, emotional, and cognitive aspects of pain.  Herein, we briefly cover the discovery of the EC system and its role in pain processing pathways, before concg. on three areas of current major interest in EC pain research; 1.  Pharmacol. enhancement of endocannabinoid activity (via blockade of EC metab. or allosteric modulation of CB1receptors); 2.  The EC System and stress-induced modulation of pain; and 3.  The EC system & medial prefrontal cortex (mPFC) dysfunction in pain states.  While we focus predominantly on the preclin. data, we also include extensive discussion of recent clin. failures of endocannabinoid-related therapies, the future potential of these approaches, and important directions for future research on the EC system and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdKeLMGIq96bVg90H21EOLACvtfcHk0liuEZ5nbUFOeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGnsbfO&md5=dbe8590a0cc4e110f80de7f2267347cf</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhams%26aufirst%3DS.%2BG.%26aulast%3DChapman%26aufirst%3DV.%26aulast%3DFinn%26aufirst%3DD.%2BP.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26aulast%3DNeugebauer%26aufirst%3DV.%26atitle%3DThe%2520cannabinoid%2520system%2520and%2520pain%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D124%26spage%3D105%26epage%3D120%26doi%3D10.1016%2Fj.neuropharm.2017.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toczek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinowska, B.</span></span> <span> </span><span class="NLM_article-title">Enhanced endocannabinoid tone as a potential target of pharmacotherapy</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2018.04.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.lfs.2018.04.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29729263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1Khsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2018&pages=20-45&author=M.+Toczekauthor=B.+Malinowska&title=Enhanced+endocannabinoid+tone+as+a+potential+target+of+pharmacotherapy&doi=10.1016%2Fj.lfs.2018.04.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced endocannabinoid tone as a potential target of pharmacotherapy</span></div><div class="casAuthors">Toczek, Marek; Malinowska, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-45</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system is up-regulated in numerous pathophysiol. states such as inflammatory, neurodegenerative, gastrointestinal, metabolic and cardiovascular diseases, pain, and cancer.  It has been suggested that this phenomenon primarily serves an autoprotective role in inhibiting disease progression and/or diminishing signs and symptoms.  Accordingly, enhancement of endogenous endocannabinoid tone by inhibition of endocannabinoid degrdn. represents a promising therapeutic approach for the treatment of many diseases.  Importantly, this allows for the avoidance of unwanted psychotropic side effects that accompany exogenously administered cannabinoids.  The effects of endocannabinoid metabolic pathway modulation are complex, as endocannabinoids can exert their actions directly or via numerous metabolites.  The two main strategies for blocking endocannabinoid degrdn. are inhibition of endocannabinoid-degrading enzymes and inhibition of endocannabinoid cellular uptake.  To date, the most investigated compds. are inhibitors of fatty acid amide hydrolase (FAAH), an enzyme that degrades the endocannabinoid anandamide.  However, application of FAAH inhibitors (and consequently other endocannabinoid degrdn. inhibitors) in medicine became questionable due to a lack of therapeutic efficacy in clin. trials and serious adverse effects evoked by one specific compd.  In this paper, we discuss multiple pathways of endocannabinoid metab., changes in endocannabinoid levels across numerous human diseases and corresponding exptl. models, pharmacol. strategies for enhancing endocannabinoid tone and potential therapeutic applications including multi-target drugs with addnl. targets outside of the endocannabinoid system (cyclooxygenase-2, cholinesterase, TRPV1, and PGF2α-EA receptors), and currently used medicines or medicinal herbs that addnl. enhance endocannabinoid levels.  Ultimately, further clin. and preclin. studies are warranted to develop medicines for enhancing endocannabinoid tone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHpA_mUdMumrVg90H21EOLACvtfcHk0lg4bEl11tzufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1Khsbo%253D&md5=0cc869bf43372400169d7ab1f29d4227</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2018.04.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2018.04.054%26sid%3Dliteratum%253Aachs%26aulast%3DToczek%26aufirst%3DM.%26aulast%3DMalinowska%26aufirst%3DB.%26atitle%3DEnhanced%2520endocannabinoid%2520tone%2520as%2520a%2520potential%2520target%2520of%2520pharmacotherapy%26jtitle%3DLife%2520Sci.%26date%3D2018%26volume%3D204%26spage%3D20%26epage%3D45%26doi%3D10.1016%2Fj.lfs.2018.04.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tambaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives</span>. <i>Recent Pat. CNS Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.2174/157488912798842269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2174%2F157488912798842269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22280339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFSqt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=25-40&author=S.+Tambaroauthor=M.+Bortolato&title=Cannabinoid-related+agents+in+the+treatment+of+anxiety+disorders%3A+current+knowledge+and+future+perspectives&doi=10.2174%2F157488912798842269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives</span></div><div class="casAuthors">Tambaro, Simone; Bortolato, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on CNS Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>CODEN:
                <span class="NLM_cas:coden">RPCDC9</span>;
        ISSN:<span class="NLM_cas:issn">1574-8898</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Rich evidence has shown that cannabis products exert a broad gamut of effects on emotional regulation.  The main psychoactive ingredient of hemp, Δ9-tetrahydrocannabinol (THC), and its synthetic cannabinoid analogs have been reported to either attenuate or exacerbate anxiety and fear-related behaviors in humans and exptl. animals.  The heterogeneity of cannabis-induced psychol. outcomes reflects a complex network of mol. interactions between the key neurobiol. substrates of anxiety and fear and the endogenous cannabinoid system, mainly consisting of the arachidonic acid derivs. anandamide and 2-arachidonoylglycerol (2-AG) and two receptors, resp. termed CB1 and CB2.  The high degree of interindividual variability in the responses to cannabis is contributed by a wide spectrum of factors, including genetic and environmental determinants, as well as differences in the relative concns. of THC and other alkaloids (such as cannabidiol) within the plant itself.  The present article reviews the currently available knowledge on the herbal, synthetic and endogenous cannabinoids with respect to the modulation of anxiety responses, and high-lights the challenges that should be overcome to harness the therapeutic potential of some of these compds., all the while limiting the side effects assocd. with cannabis consumption.  In addn. the article presents some promising patents on cannabinoid-related agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp70n73araPC7Vg90H21EOLACvtfcHk0lg4bEl11tzufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFSqt78%253D&md5=b2e628adb3168a86ca29318cc899267f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F157488912798842269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488912798842269%26sid%3Dliteratum%253Aachs%26aulast%3DTambaro%26aufirst%3DS.%26aulast%3DBortolato%26aufirst%3DM.%26atitle%3DCannabinoid-related%2520agents%2520in%2520the%2520treatment%2520of%2520anxiety%2520disorders%253A%2520current%2520knowledge%2520and%2520future%2520perspectives%26jtitle%3DRecent%2520Pat.%2520CNS%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D25%26epage%3D40%26doi%3D10.2174%2F157488912798842269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3363</span>, <span class="refDoi"> DOI: 10.1098/rstb.2011.0381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1098%2Frstb.2011.0381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23108552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKgtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=3353-3363&author=R.+G.+Pertwee&title=Targeting+the+endocannabinoid+system+with+cannabinoid+receptor+agonists%3A+pharmacological+strategies+and+therapeutic+possibilities&doi=10.1098%2Frstb.2011.0381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities</span></div><div class="casAuthors">Pertwee, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1607</span>),
    <span class="NLM_cas:pages">3353-3363</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Human tissues express cannabinoid CB1 and CB2 receptors that can be activated by endogenously released 'endocannabinoids' or exogenously administered compds. in a manner that reduces the symptoms or opposes the underlying causes of several disorders in need of effective therapy.  Three medicines that activate cannabinoid CB1/CB2 receptors are now in the clinic: Cesamet (nabilone), Marinol (dronabinol; Δ9-tetrahydrocannabinol (Δ9-THC)) and Sativex (Δ9-THC with cannabidiol).  These can be prescribed for the amelioration of chemotherapy-induced nausea and vomiting (Cesamet and Marinol), stimulation of appetite (Marinol) and symptomatic relief of cancer pain and/or management of neuropathic pain and spasticity in adults with multiple sclerosis (Sativex).  This review mentions several possible addnl. therapeutic targets for cannabinoid receptor agonists.  These include other kinds of pain, epilepsy, anxiety, depression, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders.  It also describes potential strategies for improving the efficacy and/or benefit-to-risk ratio of these agonists in the clinic.  These are strategies that involve (i) targeting cannabinoid receptors located outside the blood-brain barrier, (ii) targeting cannabinoid receptors expressed by a particular tissue, (iii) targeting upregulated cannabinoid receptors, (iv) selectively targeting cannabinoid CB2 receptors, and/or (v) adjunctive 'multi-targeting'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Q3tFouTow7Vg90H21EOLACvtfcHk0lg4bEl11tzufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKgtL3L&md5=520dda552cdeb306560444cf7c5932f6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1098%2Frstb.2011.0381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2011.0381%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DTargeting%2520the%2520endocannabinoid%2520system%2520with%2520cannabinoid%2520receptor%2520agonists%253A%2520pharmacological%2520strategies%2520and%2520therapeutic%2520possibilities%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2012%26volume%3D367%26spage%3D3353%26epage%3D3363%26doi%3D10.1098%2Frstb.2011.0381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockings, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murnion, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, L.</span></span> <span> </span><span class="NLM_article-title">Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">1932</span>– <span class="NLM_lpage">1954</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000001293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1097%2Fj.pain.0000000000001293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29847469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslGnsrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2018&pages=1932-1954&author=E.+Stockingsauthor=G.+Campbellauthor=W.+D.+Hallauthor=S.+Nielsenauthor=D.+Zagicauthor=R.+Rahmanauthor=B.+Murnionauthor=M.+Farrellauthor=M.+Weierauthor=L.+Degenhardt&title=Cannabis+and+cannabinoids+for+the+treatment+of+people+with+chronic+noncancer+pain+conditions%3A+a+systematic+review+and+meta-analysis+of+controlled+and+observational+studies&doi=10.1097%2Fj.pain.0000000000001293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies</span></div><div class="casAuthors">Stockings, Emily; Campbell, Gabrielle; Hall, Wayne D.; Nielsen, Suzanne; Zagic, Dino; Rahman, Rakin; Murnion, Bridin; Farrell, Michael; Weier, Megan; Degenhardt, Louisa</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1932-1954</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines.  MEDLINE, Embase, PsycINFO, CENTRAL, and clinicaltrials.gov were searched in July 2017.  Analyses were conducted using Revman 5.3 and Stata 15.0.  A total of 91 publications contg. 104 studies were eligible (n = 9958 participants), including 47 randomised controlled trials (RCTs) and 57 observational studies.  Forty-eight studies examd. neuropathic pain, 7 studies examd. fibromyalgia, 1 rheumatoid arthritis, and 48 other CNCP (13 multiple sclerosis-related pain, 6 visceral pain, and 29 samples with mixed or undefined CNCP).  Across RCTs, pooled event rates (PERs) for 30% redn. in pain were 29.0% (cannabinoids) vs 25.9% (placebo); significant effect for cannabinoids was found; no. needed to treat to benefit was 24 (95% confidence interval [CI] 15-61); for 50% redn. in pain, PERs were 18.2% vs 14.4%; no significant difference was obsd.  Pooled change in pain intensity (standardised mean difference: -0.14, 95% CI -0.20 to -0.08) was equiv. to a 3 mm redn. on a 100 mm visual analog scale greater than placebo groups.  In RCTs, PERs for all-cause adverse events were 81.2% vs 66.2%; no. needed to treat to harm: 6 (95% CI 5-8).  There were no significant impacts on phys. or emotional functioning, and low-quality evidence of improved sleep and patient global impression of change.  Evidence for effectiveness of cannabinoids in CNCP is limited.  Effects suggest that no. needed to treat to benefit is high, and no. needed to treat to harm is low, with limited impact on other domains.  It seems unlikely that cannabinoids are highly effective medicines for CNCP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmM2l_gv8dtLVg90H21EOLACvtfcHk0ljzcYwl7N70QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslGnsrvL&md5=b135acedade4757309f4edca9dfbda74</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000001293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000001293%26sid%3Dliteratum%253Aachs%26aulast%3DStockings%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DG.%26aulast%3DHall%26aufirst%3DW.%2BD.%26aulast%3DNielsen%26aufirst%3DS.%26aulast%3DZagic%26aufirst%3DD.%26aulast%3DRahman%26aufirst%3DR.%26aulast%3DMurnion%26aufirst%3DB.%26aulast%3DFarrell%26aufirst%3DM.%26aulast%3DWeier%26aufirst%3DM.%26aulast%3DDegenhardt%26aufirst%3DL.%26atitle%3DCannabis%2520and%2520cannabinoids%2520for%2520the%2520treatment%2520of%2520people%2520with%2520chronic%2520noncancer%2520pain%2520conditions%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520controlled%2520and%2520observational%2520studies%26jtitle%3DPain%26date%3D2018%26volume%3D159%26spage%3D1932%26epage%3D1954%26doi%3D10.1097%2Fj.pain.0000000000001293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">Translational PET imaging research</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2013.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nbd.2013.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24055214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FgtVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=32-38&author=R.+J.+Hargreavesauthor=E.+A.+Rabiner&title=Translational+PET+imaging+research&doi=10.1016%2Fj.nbd.2013.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Translational PET imaging research</span></div><div class="casAuthors">Hargreaves Richard J; Rabiner Eugenii A</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The goal of any early central nervous system (CNS) drug development program is always to test the mechanism and not the molecule in order to support additional research investments in late phase clinical trials.  Confirmation that drugs reach their targets using translational positron emission tomography (PET) imaging markers of engagement is central to successful clinical proof-of-concept testing and has become an important feature of most neuropsychiatric drug development programs.  CNS PET imaging can also play an important role in the clinical investigation of the neuropharmacological basis of psychiatric disease and the optimization of drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUu9pmPSXkA0g6wdEZmT2rfW6udTcc2eaZY62NE7rlnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FgtVGlsg%253D%253D&md5=84b76b18c4006d60f1b420ae0ebeb903</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2013.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2013.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DTranslational%2520PET%2520imaging%2520research%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2014%26volume%3D61%26spage%3D32%26epage%3D38%26doi%3D10.1016%2Fj.nbd.2013.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suridjan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">The application of positron emission tomography (PET) imaging in CNS drug development</span>. <i>Brain Imaging Behav.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1007/s11682-018-9967-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs11682-018-9967-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30259405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3czjtF2htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=354-365&author=I.+Suridjanauthor=R.+A.+Comleyauthor=E.+A.+Rabiner&title=The+application+of+positron+emission+tomography+%28PET%29+imaging+in+CNS+drug+development&doi=10.1007%2Fs11682-018-9967-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The application of positron emission tomography (PET) imaging in CNS drug development</span></div><div class="casAuthors">Suridjan Ivonne; Comley Robert A; Rabiner Eugenii A; Rabiner Eugenii A</div><div class="citationInfo"><span class="NLM_cas:title">Brain imaging and behavior</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-365</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As drug discovery and development in Neuroscience push beyond symptom management to disease modification, neuroimaging becomes a key area of translational research that enables measurements of the presence of drugs and downstream physiological consequences of drug action within the living brain.  As such, neuroimaging can be used to help optimize decision-making processes throughout the various phases of drug development.  Positron Emission Tomography (PET) is a functional imaging technique that allows the quantification and visualization of biochemical processes, by monitoring the time dependent distribution of molecules labelled with short-lived positron-emitting isotopes.  This review focuses on the application of PET to support CNS drug development, particularly in the early clinical phases, by allowing us to measure tissue exposure, target engagement, and pharmacological activity.  We will also discuss the application of PET imaging as tools to image the pathological hallmarks of disease and evaluate the potential disease-modifying effect of candidate drugs in slowing disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7fE6UVIccHDMsgLhIoICsfW6udTcc2eaZY62NE7rlnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czjtF2htA%253D%253D&md5=60ba9d81f4ee2f24c3767b5cf75ef3bc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs11682-018-9967-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11682-018-9967-0%26sid%3Dliteratum%253Aachs%26aulast%3DSuridjan%26aufirst%3DI.%26aulast%3DComley%26aufirst%3DR.%2BA.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DThe%2520application%2520of%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520imaging%2520in%2520CNS%2520drug%2520development%26jtitle%3DBrain%2520Imaging%2520Behav.%26date%3D2019%26volume%3D13%26spage%3D354%26epage%3D365%26doi%3D10.1007%2Fs11682-018-9967-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waaijer, S. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisses, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalving, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lub-de Hooge, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G. E.</span></span> <span> </span><span class="NLM_article-title">Molecular Imaging in cancer drug development</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.2967/jnumed.116.188045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.116.188045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29371402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWhurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=726-732&author=S.+J.+H.+Waaijerauthor=I.+C.+Kokauthor=B.+Eissesauthor=C.+P.+Schr%C3%B6derauthor=M.+Jalvingauthor=A.+H.+Brouwersauthor=M.+N.+Lub-de+Hoogeauthor=E.+G.+E.+de+Vries&title=Molecular+Imaging+in+cancer+drug+development&doi=10.2967%2Fjnumed.116.188045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular imaging in cancer drug development</span></div><div class="casAuthors">Waaijer, Stijn J. H.; Kok, Iris C.; Eisses, Bertha; Schroeder, Carolina P.; Jalving, Mathilde; Brouwers, Adrienne H.; Hooge, Marjolijn N. Lub-de; de Vries, Elisabeth G. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">726-732</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">A review.  Development of new oncol. drugs has increased since the improved understanding of cancer's complex biol.  The oncol. field has become the top therapeutic research area for new drugs.  However, only a limited no. of drugs entering clin. trials will be approved for use as the std. of care for cancer patients.  Mol. imaging is increasingly perceived as a tool to support go/no-go decisions early during drug development.  It encompasses a wide range of techniques that include radiolabeling a compd. of interest followed by visualization with SPECT or PET.  Radiolabeling can be performed using a variety of radionuclides, which are preferably matched to the compd. on the basis of size and half-life.  Imaging can provide information on drug behavior in vivo, whole-body drug target visualization, and heterogeneity in drug target expression.  This review focuses on current applications of mol. imaging in the development of small mols., antibodies, and antihormonal anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb8D8OZd-hCLVg90H21EOLACvtfcHk0lgoTbWmZS4Q_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWhurzN&md5=ebc90092c8f856d65d9b17d86dd65004</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.116.188045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.116.188045%26sid%3Dliteratum%253Aachs%26aulast%3DWaaijer%26aufirst%3DS.%2BJ.%2BH.%26aulast%3DKok%26aufirst%3DI.%2BC.%26aulast%3DEisses%26aufirst%3DB.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DC.%2BP.%26aulast%3DJalving%26aufirst%3DM.%26aulast%3DBrouwers%26aufirst%3DA.%2BH.%26aulast%3DLub-de%2BHooge%26aufirst%3DM.%2BN.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%2BE.%26atitle%3DMolecular%2520Imaging%2520in%2520cancer%2520drug%2520development%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D726%26epage%3D732%26doi%3D10.2967%2Fjnumed.116.188045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of PET radiopharmaceuticals at the academia-industry interface</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2017.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ddtec.2017.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29233263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC1MzgslClug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=19-26&author=V.+Bernard-Gauthierauthor=T.+L.+Collierauthor=S.+H.+Liangauthor=N.+Vasdev&title=Discovery+of+PET+radiopharmaceuticals+at+the+academia-industry+interface&doi=10.1016%2Fj.ddtec.2017.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PET radiopharmaceuticals at the academia-industry interface</span></div><div class="casAuthors">Bernard-Gauthier Vadim; Liang Steven H; Collier Thomas L; Vasdev Neil</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today. Technologies</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Project-specific collaborations between academia and pharmaceutical partners are a growing phenomenon within molecular imaging and in particular in the positron emission tomography (PET) radiopharmaceutical community.  This cultural shift can be attributed in part to decreased public funding in academia in conjunction with the increased reliance on outsourcing of chemistry, radiochemistry, pharmacology and molecular imaging studies by the pharmaceutical industry.  This account highlights some of our personal experiences working with industrial partners to develop new PET radiochemistry methodologies for drug discovery and neuro-PET research studies.  These symbiotic academic-industrial partnerships have not only led to novel radiotracers for new targets but also to the application of new carbon-11 and fluorine-18 labeling methodologies and technologies to label previously unprecedented compounds for in vivo evaluations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAVgLDs8Vgmsjl5L8hwNX0fW6udTcc2eYQ7jLgKbvb9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzgslClug%253D%253D&md5=6bd1480c177f95675f332391d2118945</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2017.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2017.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520PET%2520radiopharmaceuticals%2520at%2520the%2520academia-industry%2520interface%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2017%26volume%3D25%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.ddtec.2017.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevigny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span> <span> </span><span class="NLM_article-title">Optimizing central nervous system drug development using molecular imaging</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1002/cpt.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fcpt.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25869938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOms7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2015&pages=47-60&author=R.+J.+Hargreavesauthor=J.+Hoppinauthor=J.+Sevignyauthor=S.+Patelauthor=P.+Chiaoauthor=M.+Klimasauthor=A.+Verma&title=Optimizing+central+nervous+system+drug+development+using+molecular+imaging&doi=10.1002%2Fcpt.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing Central Nervous System Drug Development Using Molecular Imaging</span></div><div class="casAuthors">Hargreaves, R. J.; Hoppin, J.; Sevigny, J.; Patel, S.; Chiao, P.; Klimas, M.; Verma, A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Advances in multimodality fusion imaging technologies promise to accelerate the understanding of the systems biol. of disease and help in the development of new therapeutics.  The use of mol. imaging biomarkers has been proven to shorten cycle times for central nervous system (CNS) drug development and thereby increase the efficiency and return on investment from research.  Imaging biomarkers can be used to help select the mols., doses, and patients most likely to test therapeutic hypotheses by stopping those that have little chance of success and accelerating those with potential to achieve beneficial clin. outcomes.  CNS imaging biomarkers have the potential to drive new medical care practices for patients in the latent phases of progressive neurodegenerative disorders by enabling the detection, preventative treatment, and tracking of disease in a paradigm shift from today's approaches that have to see the overt symptoms of disease before treating it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA4Jc_IBQ4E7Vg90H21EOLACvtfcHk0lgoTbWmZS4Q_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOms7fM&md5=90f5ace142f1c053385568e541c65a23</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fcpt.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.132%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26aulast%3DHoppin%26aufirst%3DJ.%26aulast%3DSevigny%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DChiao%26aufirst%3DP.%26aulast%3DKlimas%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DA.%26atitle%3DOptimizing%2520central%2520nervous%2520system%2520drug%2520development%2520using%2520molecular%2520imaging%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2015%26volume%3D98%26spage%3D47%26epage%3D60%26doi%3D10.1002%2Fcpt.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qijun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinghao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weijian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiaosong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhihua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhidong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span> <span> </span><span class="NLM_article-title">Positron emission tomography (PET) application in the phase 0 clinical trials in drug development</span>. <i>Pharmacy Today (Chinese)</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=99-105&author=H.+Luauthor=C.+Qijunauthor=W.+Luauthor=W.+Jinghaoauthor=Y.+Weijianauthor=W.+Xiaosongauthor=Z.+Zhihuaauthor=Z.+Zhidongauthor=X.+Hao&title=Positron+emission+tomography+%28PET%29+application+in+the+phase+0+clinical+trials+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DQijun%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DJinghao%26aufirst%3DW.%26aulast%3DWeijian%26aufirst%3DY.%26aulast%3DXiaosong%26aufirst%3DW.%26aulast%3DZhihua%26aufirst%3DZ.%26aulast%3DZhidong%26aufirst%3DZ.%26aulast%3DHao%26aufirst%3DX.%26atitle%3DPositron%2520emission%2520tomography%2520%2528PET%2529%2520application%2520in%2520the%2520phase%25200%2520clinical%2520trials%2520in%2520drug%2520development%26jtitle%3DPharmacy%2520Today%2520%2528Chinese%2529%26date%3D2020%26volume%3D30%26spage%3D99%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Guangdong
Province Pharmaceutical Association.</span> <span> </span><span class="NLM_article-title">Consensus on phase 0 clinical trial application for
positron radiopharmaceuticals</span>. <i>Pharmacy Today
(Chinese)</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">798</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=793-798&author=Guangdong%0AProvince+Pharmaceutical+Association.&title=Consensus+on+phase+0+clinical+trial+application+for%0Apositron+radiopharmaceuticals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DConsensus%2520on%2520phase%25200%2520clinical%2520trial%2520application%2520for%250Apositron%2520radiopharmaceuticals%26jtitle%3DPharmacy%2520Today%250A%2528Chinese%2529%26date%3D2020%26volume%3D30%26spage%3D793%26epage%3D798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wildt, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span> <span> </span><span class="NLM_article-title">Microdosing and other phase 0 clinical trials: facilitating translation in drug development</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1111/cts.12390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fcts.12390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26918865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC28jks1Giug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=74-88&author=T.+Burtauthor=K.+Yoshidaauthor=G.+Lappinauthor=L.+Vuongauthor=C.+Johnauthor=S.+N.+de+Wildtauthor=Y.+Sugiyamaauthor=M.+Rowland&title=Microdosing+and+other+phase+0+clinical+trials%3A+facilitating+translation+in+drug+development&doi=10.1111%2Fcts.12390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development</span></div><div class="casAuthors">Burt T; Yoshida K; John C; Yoshida K; Lappin G; Vuong L; Vuong L; de Wildt S N; Sugiyama Y; Rowland M; Rowland M</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">74-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A number of drivers and developments suggest that microdosing and other phase 0 applications will experience increased utilization in the near-to-medium future.  Increasing costs of drug development and ethical concerns about the risks of exposing humans and animals to novel chemical entities are important drivers in favor of these approaches, and can be expected only to increase in their relevance.  An increasing body of research supports the validity of extrapolation from the limited drug exposure of phase 0 approaches to the full, therapeutic exposure, with modeling and simulations capable of extrapolating even non-linear scenarios.  An increasing number of applications and design options demonstrate the versatility and flexibility these approaches offer to drug developers including the study of PK, bioavailability, DDI, and mechanistic PD effects.  PET microdosing allows study of target localization, PK and receptor binding and occupancy, while Intra-Target Microdosing (ITM) allows study of local therapeutic-level acute PD coupled with systemic microdose-level exposure.  Applications in vulnerable populations and extreme environments are attractive due to the unique risks of pharmacotherapy and increasing unmet healthcare needs.  All phase 0 approaches depend on the validity of extrapolation from the limited-exposure scenario to the full exposure of therapeutic intent, but in the final analysis the potential for controlled human data to reduce uncertainty about drug properties is bound to be a valuable addition to the drug development process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB4hk6rM5szw20zIbnCCI3fW6udTcc2eY25IybWL2qO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jks1Giug%253D%253D&md5=2852c3bb726cf87599926e6352f2eec0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fcts.12390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12390%26sid%3Dliteratum%253Aachs%26aulast%3DBurt%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DLappin%26aufirst%3DG.%26aulast%3DVuong%26aufirst%3DL.%26aulast%3DJohn%26aufirst%3DC.%26aulast%3Dde%2BWildt%26aufirst%3DS.%2BN.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DRowland%26aufirst%3DM.%26atitle%3DMicrodosing%2520and%2520other%2520phase%25200%2520clinical%2520trials%253A%2520facilitating%2520translation%2520in%2520drug%2520development%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2016%26volume%3D9%26spage%3D74%26epage%3D88%26doi%3D10.1111%2Fcts.12390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCartt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combes, R.</span></span> <span> </span><span class="NLM_article-title">Phase 0, including microdosing approaches: applying the three rs and increasing the efficiency of human drug development</span>. <i>ATLA, Altern. Lab. Anim.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1177/026119291804600603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1177%2F026119291804600603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30657329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3cjivVaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=335-346&author=T.+Burtauthor=L.+T.+Vuongauthor=E.+Bakerauthor=G.+C.+Youngauthor=A.+D.+McCarttauthor=M.+Bergstromauthor=Y.+Sugiyamaauthor=R.+Combes&title=Phase+0%2C+including+microdosing+approaches%3A+applying+the+three+rs+and+increasing+the+efficiency+of+human+drug+development&doi=10.1177%2F026119291804600603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development</span></div><div class="casAuthors">Burt Tal; Vuong Le Thuy; Baker Elizabeth; Young Graeme C; McCartt A Daniel; Bergstrom Mats; Sugiyama Yuichi; Combes Robert</div><div class="citationInfo"><span class="NLM_cas:title">Alternatives to laboratory animals : ATLA</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">335-346</span>
        ISSN:<span class="NLM_cas:issn">0261-1929</span>.
    </div><div class="casAbstract">Phase 0 approaches, including microdosing, involve the use of sub-therapeutic exposures to the tested drugs, thus enabling safer, more-relevant, quicker and cheaper first-in-human (FIH) testing.  These approaches also have considerable potential to limit the use of animals in human drug development.  Recent years have witnessed progress in applications, methodology, operations, and drug development culture.  Advances in applications saw an expansion in therapeutic areas, developmental scenarios and scientific objectives, in, for example, protein drug development and paediatric drug development.  In the operational area, the increased sensitivity of Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS), expansion of the utility of Positron Emission Tomography (PET) imaging, and the introduction of Cavity Ring-Down Spectroscopy (CRDS), have led to the increased accessibility and utility of Phase 0 approaches, while reducing costs and exposure to radioactivity.  PET has extended the application of microdosing, from its use as a predominant tool to record pharmacokinetics, to a method for recording target expression and target engagement, as well as cellular and tissue responses.  Advances in methodology include adaptive Phase 0/Phase 1 designs, cassette and cocktail microdosing, and Intra-Target Microdosing (ITM), as well as novel modelling opportunities and simulations.  Importantly, these methodologies increase the predictive power of extrapolation from microdose to therapeutic level exposures.  However, possibly the most challenging domain in which progress has been made, is the culture of drug development.  One of the main potential values of Phase 0 approaches is the opportunity to terminate development early, thus not only applying the principle of 'kill-early-kill-cheap' to enhance the efficiency of drug development, but also obviating the need for the full package of animal testing required for therapeutic level Phase 1 studies.  Finally, we list developmental scenarios that utilised Phase 0 approaches in novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9jWzpjX7CeTEC-75aqa5AfW6udTcc2eY25IybWL2qO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjivVaksg%253D%253D&md5=87e5688bfbd89c6315d2b6eb0cf6545a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F026119291804600603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F026119291804600603%26sid%3Dliteratum%253Aachs%26aulast%3DBurt%26aufirst%3DT.%26aulast%3DVuong%26aufirst%3DL.%2BT.%26aulast%3DBaker%26aufirst%3DE.%26aulast%3DYoung%26aufirst%3DG.%2BC.%26aulast%3DMcCartt%26aufirst%3DA.%2BD.%26aulast%3DBergstrom%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DCombes%26aufirst%3DR.%26atitle%3DPhase%25200%252C%2520including%2520microdosing%2520approaches%253A%2520applying%2520the%2520three%2520rs%2520and%2520increasing%2520the%2520efficiency%2520of%2520human%2520drug%2520development%26jtitle%3DATLA%252C%2520Altern.%2520Lab.%2520Anim.%26date%3D2018%26volume%3D46%26spage%3D335%26epage%3D346%26doi%3D10.1177%2F026119291804600603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varlow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Classics in neuroimaging: imaging the endocannabinoid pathway with PET</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.0c00305</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.0c00305" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtF2ksb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1855-1862&author=C.+Varlowauthor=I.+Boileauauthor=H.+Y.+Weyauthor=S.+H.+Liangauthor=N.+Vasdev&title=Classics+in+neuroimaging%3A+imaging+the+endocannabinoid+pathway+with+PET&doi=10.1021%2Facschemneuro.0c00305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Classics in Neuroimaging: Imaging the Endocannabinoid Pathway with PET</span></div><div class="casAuthors">Varlow, Cassis; Boileau, Isabelle; Wey, Hsiao-Ying; Liang, Steven H.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1855-1862</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Viewpoint aims to highlight positron emission tomog. (PET) research studies that have shaped our understanding of the endocannabinoid system (ECS) through radiopharmaceutical targeting of cannabinoid receptors 1 and 2 (CB1 and CB2), and the enzyme fatty acid amide hydrolase (FAAH), in several brain health illnesses including addiction, schizophrenia, eating disorders, and post-traumatic stress disorder.  Advances in radiochem., including 11C-carbonylation and radiofluorination of nonactivated arom. rings, are accelerating the translation of radiotracers with optimal kinetics, bringing us closer to clin. PET research studies to image the enzyme monoacylglycerol lipase (MAGL) and enabling the imaging of unexplored targets in the ECS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDv-Ls4H_44bVg90H21EOLACvtfcHk0li8yfYDlhNW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtF2ksb7N&md5=bb436524423c85a3b8c7fac6f69c357b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.0c00305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.0c00305%26sid%3Dliteratum%253Aachs%26aulast%3DVarlow%26aufirst%3DC.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DWey%26aufirst%3DH.%2BY.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DClassics%2520in%2520neuroimaging%253A%2520imaging%2520the%2520endocannabinoid%2520pathway%2520with%2520PET%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2020%26volume%3D11%26spage%3D1855%26epage%3D1862%26doi%3D10.1021%2Facschemneuro.0c00305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span> <span> </span><span class="NLM_article-title">In vivo imaging of the cannabinoid CB1 receptor with positron emission tomography</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1002/cpt.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fcpt.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25788235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFKrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=565-567&author=J.+Hirvonen&title=In+vivo+imaging+of+the+cannabinoid+CB1+receptor+with+positron+emission+tomography&doi=10.1002%2Fcpt.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo imaging of the cannabinoid CB1 receptor with positron emission tomography</span></div><div class="casAuthors">Hirvonen, J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-567</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Positron emission tomog. (PET) can visualize and quantify receptors and other targets in the living human brain, and recent progress in radioligand development has enabled measurement of cannabinoid type-1 (CB1) receptors.  Cannabinoid CB1 receptors have been implicated in multiple human diseases, such as obesity, mood disorders, and addiction.  First in vivo human studies have shown distinctive spatial and temporal alterations in cannabinoid CB1 receptor binding in addictive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBVyRtIVRdxLVg90H21EOLACvtfcHk0li8yfYDlhNW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFKrtr4%253D&md5=3c58f9046300d21011364a5255336d0b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcpt.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.116%26sid%3Dliteratum%253Aachs%26aulast%3DHirvonen%26aufirst%3DJ.%26atitle%3DIn%2520vivo%2520imaging%2520of%2520the%2520cannabinoid%2520CB1%2520receptor%2520with%2520positron%2520emission%2520tomography%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2015%26volume%3D97%26spage%3D565%26epage%3D567%26doi%3D10.1002%2Fcpt.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S.</span></span> <span> </span><span class="NLM_article-title">Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0035-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41401-018-0035-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29921889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOmsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=351-357&author=R.+Niauthor=L.+Muauthor=S.+Ametamey&title=Positron+emission+tomography+of+type+2+cannabinoid+receptors+for+detecting+inflammation+in+the+central+nervous+system&doi=10.1038%2Fs41401-018-0035-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system</span></div><div class="casAuthors">Ni, Ruiqing; Mu, Linjing; Ametamey, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-357</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cannabinoid receptor CB2 (CB2R) is upregulated on activated microglia and astrocytes in the brain under inflammatory conditions and plays important roles in many neurol. diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke.  The advent of positron emission tomog. (PET) using CB2R radiotracers has enabled the visualization of CB2R distribution in vivo in animal models of central nervous system inflammation, however translation to humans has been less successful.  Several novel CB2R radiotracers have been developed and evaluated to quantify microglial activation.  In this review, we summarize the recent preclin. and clin. imaging results of CB2R PET tracers and discuss the prospects of CB2R imaging using PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVQSh6Ru_9q7Vg90H21EOLACvtfcHk0li8yfYDlhNW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOmsrzF&md5=2244385624a23d12167e7ee37c187720</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0035-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0035-5%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DAmetamey%26aufirst%3DS.%26atitle%3DPositron%2520emission%2520tomography%2520of%2520type%25202%2520cannabinoid%2520receptors%2520for%2520detecting%2520inflammation%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D351%26epage%3D357%26doi%3D10.1038%2Fs41401-018-0035-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1002/jlcr.3579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjlcr.3579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29110331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=299-308&author=F.+Spinelliauthor=L.+Muauthor=S.+M.+Ametamey&title=Radioligands+for+positron+emission+tomography+imaging+of+cannabinoid+type+2+receptor&doi=10.1002%2Fjlcr.3579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor</span></div><div class="casAuthors">Spinelli, Francesco; Mu, Linjing; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-308</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  The cannabinoid type 2 (CB2) receptor is an immunomodulatory receptor mainly expressed in peripheral cells and organs of the immune system.  The expression level of CB2 in the central nervous system under physiol. conditions is negligible, however under neuroinflammatory conditions an upregulation of CB2 protein or mRNA mainly colocalized with activated microglial cells has been reported.  Consequently, CB2 agonists have been confirmed to play a role in neuroprotective and anti-inflammatory processes.  A suitable positron emission tomog. radioligand for imaging CB2 would provide an invaluable research tool to explore the role of CB2 receptor expression in inflammatory disorders.  In this review, we provide a summary of so far published CB2 radioligands as well as their in vitro and in vivo binding characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6zEMOTJW1t7Vg90H21EOLACvtfcHk0ljDi6g8JidpMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kruw%253D%253D&md5=618a65ba969379132659149f2c4fa9bb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3579%26sid%3Dliteratum%253Aachs%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DRadioligands%2520for%2520positron%2520emission%2520tomography%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptor%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2018%26volume%3D61%26spage%3D299%26epage%3D308%26doi%3D10.1002%2Fjlcr.3579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plisson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O.</span></span> <span> </span><span class="NLM_article-title">Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1007/s00259-019-04488-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00259-019-04488-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31541283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWkur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2020&pages=451-489&author=S.+P.+McCluskeyauthor=C.+Plissonauthor=E.+A.+Rabinerauthor=O.+Howes&title=Advances+in+CNS+PET%3A+the+state-of-the-art+for+new+imaging+targets+for+pathophysiology+and+drug+development&doi=10.1007%2Fs00259-019-04488-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development</span></div><div class="casAuthors">McCluskey, Stuart P.; Plisson, Christophe; Rabiner, Eugenii A.; Howes, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">451-489</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Purpose: A limit on developing new treatments for a no. of central nervous system (CNS) disorders has been the inadequate understanding of the in vivo pathophysiol. underlying neurol. and psychiatric disorders and the lack of in vivo tools to det. brain penetrance, target engagement, and relevant mol. activity of novel drugs.  Mol. neuroimaging provides the tools to address this.  This article aims to provide a state-of-the-art review of new PET tracers for CNS targets, focusing on developments in the last 5 years for targets recently available for in-human imaging.  Methods: We provide an overview of the criteria used to evaluate PET tracers.  We then used the National Institute of Mental Health Research Priorities list to identify the key CNS targets.  We conducted a PubMed search (search period 1st of Jan. 2013 to 31st of Dec. 2018), which yielded 40 new PET tracers across 16 CNS targets which met our selectivity criteria.  For each tracer, we summarised the evidence of its properties and potential for use in studies of CNS pathophysiol. and drug evaluation, including its target selectivity and affinity, inter and intra-subject variability, and pharmacokinetic parameters.  We also consider its potential limitations and missing characterization data, but not specific applications in drug development.  Where multiple tracers were present for a target, we provide a comparison of their properties.  Results and conclusions: Our review shows that multiple new tracers have been developed for proteinopathy targets, particularly tau, as well as the purinoceptor P2X7, phosphodiesterase enzyme PDE10A, and synaptic vesicle glycoprotein 2A (SV2A), amongst others.  Some of the most promising of these include 18F-MK-6240 for tau imaging, 11C-UCB-J for imaging SV2A, 11C-CURB and 11C-MK-3168 for characterization of fatty acid amide hydrolase, 18F-FIMX for metabotropic glutamate receptor 1, and 18F-MNI-444 for imaging adenosine 2A.  Our review also identifies recurrent issues within the field.  Many of the tracers discussed lack in vivo blocking data, reducing confidence in selectivity.  Addnl., late-stage identification of substantial off-target sites for multiple tracers highlights incomplete pre-clin. characterization prior to translation, as well as human disease state studies carried out without confirmation of test-retest reproducibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY0u-7Ko8uWbVg90H21EOLACvtfcHk0ljDi6g8JidpMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWkur%252FK&md5=277c998059c613ad478913f51eb81ae3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs00259-019-04488-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-019-04488-0%26sid%3Dliteratum%253Aachs%26aulast%3DMcCluskey%26aufirst%3DS.%2BP.%26aulast%3DPlisson%26aufirst%3DC.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26aulast%3DHowes%26aufirst%3DO.%26atitle%3DAdvances%2520in%2520CNS%2520PET%253A%2520the%2520state-of-the-art%2520for%2520new%2520imaging%2520targets%2520for%2520pathophysiology%2520and%2520drug%2520development%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2020%26volume%3D47%26spage%3D451%26epage%3D489%26doi%3D10.1007%2Fs00259-019-04488-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shahbazi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trant, J. F.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids and cannabinoid receptors: the story so far</span>. <i>iScience</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">101301</span>, <span class="refDoi"> DOI: 10.1016/j.isci.2020.101301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.isci.2020.101301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32629422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSisrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2020&pages=101301&author=F.+Shahbaziauthor=V.+Grandiauthor=A.+Banerjeeauthor=J.+F.+Trant&title=Cannabinoids+and+cannabinoid+receptors%3A+the+story+so+far&doi=10.1016%2Fj.isci.2020.101301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids and Cannabinoid Receptors: The Story so Far</span></div><div class="casAuthors">Shahbazi, Fred; Grandi, Victoria; Banerjee, Abhinandan; Trant, John F.</div><div class="citationInfo"><span class="NLM_cas:title">iScience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">101301</span>CODEN:
                <span class="NLM_cas:coden">ISCICE</span>;
        ISSN:<span class="NLM_cas:issn">2589-0042</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Like most modern mol. biol. and natural product chem., understanding cannabinoid pharmacol. centers around mol. interactions, in this case, between the cannabinoids and their putative targets, the G-protein coupled receptors (GPCRs) cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).  Understanding the complex structure and interplay between the partners in this mol. dance is required to understand the mechanism of action of synthetic, endogenous, and phytochem. cannabinoids.  This review, with 91 refs., surveys our understanding of the structural biol. of the cannabinoids and their target receptors including both a crit. comparison of the extant crystal structures and the computationally derived homol. models, as well as an in-depth discussion about the binding modes of the major cannabinoids.  The aim is to assist in situating structural biochemists, synthetic chemists, and mol. biologists who are new to the field of cannabis research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsxpectYVbRbVg90H21EOLACvtfcHk0ljDi6g8JidpMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSisrjK&md5=20e40dcafb7fd6ed6f15ce9d09c119e4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.isci.2020.101301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.isci.2020.101301%26sid%3Dliteratum%253Aachs%26aulast%3DShahbazi%26aufirst%3DF.%26aulast%3DGrandi%26aufirst%3DV.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DTrant%26aufirst%3DJ.%2BF.%26atitle%3DCannabinoids%2520and%2520cannabinoid%2520receptors%253A%2520the%2520story%2520so%2520far%26jtitle%3DiScience%26date%3D2020%26volume%3D23%26spage%3D101301%26doi%3D10.1016%2Fj.isci.2020.101301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragunow, M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1016/S0306-4522(96)00428-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0306-4522%2896%2900428-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=9472392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK2sXhs1Gms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1997&pages=299-318&author=M.+Glassauthor=R.+Faullauthor=M.+Dragunow&title=Cannabinoid+receptors+in+the+human+brain%3A+a+detailed+anatomical+and+quantitative+autoradiographic+study+in+the+fetal%2C+neonatal+and+adult+human+brain&doi=10.1016%2FS0306-4522%2896%2900428-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain</span></div><div class="casAuthors">Glass, M.; Dragunow, M.; Faull, R. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-318</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The anatomical distribution and d. of cannabinoid receptors in the human brain was studied in one fetal (33 wk gestation), two neonatal (aged three to six \months) and eight adult (aged 21-81 yr) human cases using quant. receptor autoradiog. following in vitro labeling of sections with the synthetic cannabinoid agonist [3H]CP55,940.  Cannabinoid receptors were distributed in a heterogeneous fashion throughout the adult human brain and spinal cord.  The allocortex contained very high concns. of cannabinoid receptor binding sites in the dentate gyrus, Ammons's horn and subiculum of the hippocampal formation; high concns. of receptor were also present in the entorhinal cortex and amygdaloid complex.  Cannabinoid receptor binding sites were also present throughout all regions of the neocortex, where they showed a marked variation in d. between the primary, secondary and associational cortical regions: the greatest densities of receptors were present in the associational cortical regions of the frontal and limbic lobes, with moderate densities in the secondary sensory and motor cortical regions, and with the lowest densities of receptors in the primary sensory and motor cortical regions.  Relatively high concns. of cannabinoid receptors were consistently seen in cortical regions of the left (dominant) hemisphere, known to be assocd. with verbal language functions.  In all of the cortical regions, the pattern and d. of receptor labeling followed the neocortical laminar organization, with the greatest d. of receptors localized in two discrete bands-a clearly delineated narrow superficial band which coincided with lamina I and a deeper broader, conspicuous band of labeling which corresponded to laminae V and VI.  Labeling in the intervening cortical laminae (II-IV) showed lower densities, with a well delineated narrow band of label in the middle of laminae IV in the associational cortical regions.  The thalamus showed a distinctive heterogeneous distribution of cannabinoid receptors, with the highest concn. of receptors localized in the mediodorsal nucleus, anterior nuclear complex, and in the midline and intralaminar complex of nuclei, i.e. in thalamic nuclei which have connectional affiliations with the associational cortical areas.  The basal ganglia showed a distinctive heterogeneous pattern of receptor binding, with the very highest concns. in the globus pallidus internus, moderate concns. in the globus pallidus externus and ventral pallidum, and moderately low levels of binding throughout the striatal complex.  In the midbrain, some of the highest levels of cannabinoid receptor binding sites in the human brain were present in the substantia nigra pars reticulata, with very low levels of labeling in all other midbrain areas.  The highest densities of cannabinoid receptor binding in the hindbrain were localized in the mol. layer of the cerebellar cortex and the dorsal motor nucleus of the vagus, with moderate densities of receptors in the nucleus of the solitary tract.  The spinal cord showed very low levels of receptor binding.  Studies on the distribution of cannabinoid receptors in the fetal and neonatal human brain showed similar patterns of receptor distribution to that obsd. in the adult human brain, except that the d. of receptor binding was generally markedly higher, esp. in the basal ganglia and substantia nigra.  The pattern of cannabinoid receptor labeling in the striatum showed a striking patchy pattern of organization which was esp. conspicuous in the fetal brain.  These results show that cannabinoid receptor binding sites in the human brain are localized mainly in: forebrain areas assocd. with higher cognitive functions; forebrain, midbrain and hindbrain areas assocd. with the control of movement; and in hindbrain areas assocd. with the control of motor and sensory functions of the autonomic nervous system.  The possible role of these receptors is discussed with respect to the known behavioral and psychomotor effects of cannabinoids in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphwrS-2VBdCLVg90H21EOLACvtfcHk0lj-4TrtPxSccQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhs1Gms7w%253D&md5=998c8c209c7d0a72d745be7f3946e2b9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2896%2900428-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252896%252900428-9%26sid%3Dliteratum%253Aachs%26aulast%3DGlass%26aufirst%3DM.%26aulast%3DFaull%26aufirst%3DR.%26aulast%3DDragunow%26aufirst%3DM.%26atitle%3DCannabinoid%2520receptors%2520in%2520the%2520human%2520brain%253A%2520a%2520detailed%2520anatomical%2520and%2520quantitative%2520autoradiographic%2520study%2520in%2520the%2520fetal%252C%2520neonatal%2520and%2520adult%2520human%2520brain%26jtitle%3DNeuroscience%26date%3D1997%26volume%3D77%26spage%3D299%26epage%3D318%26doi%3D10.1016%2FS0306-4522%2896%2900428-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herkenham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynn, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melvin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor localization in brain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1932</span>– <span class="NLM_lpage">1936</span>, <span class="refDoi"> DOI: 10.1073/pnas.87.5.1932</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.87.5.1932" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=2308954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFWktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=1932-1936&author=M.+Herkenhamauthor=A.+B.+Lynnauthor=M.+D.+Littleauthor=M.+R.+Johnsonauthor=L.+S.+Melvinauthor=B.+R.+De+Costaauthor=K.+C.+Rice&title=Cannabinoid+receptor+localization+in+brain&doi=10.1073%2Fpnas.87.5.1932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor localization in brain</span></div><div class="casAuthors">Herkenham, Miles; Lynn, Allison B.; Little, Mark D.; Johnson, M. Ross; Melvin, Lawrence S.; De Costa, Brian R.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1932-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">[3H]CP 55,940, a radiolabeled synthetic cannabinoid, which is 10-100 times more potent in vivo than Δ9-tetrahydrocannabinol, was used to characterize and localize a specific cannabinoid receptor in brain sections.  The potencies of a series of natural and synthetic cannabinoids as competitors of [3H]CP 55,940 binding correlated closely with their relative potencies in several biol. assays, suggesting that the receptor characterized in this in vitro assay is the same receptor that mediates behavioral and pharmacol. effects of cannabinoids, including human subjective experience.  Autoradiog. of cannabinoid receptors in brain sections from several mammalian species, including man, reveals a unique and conserved distribution; binding is most dense in outflow nuclei of the basal ganglia (the substantia nigra pars reticulata and globus pallidus) and in the hippocampus and cerebellum.  Generally high densities in forebrain and cerebellum implicate roles for cannabinoids in cognition and movement.  Sparse densities in lower brainstem areas controlling cardiovascular and respiratory functions may explain why high doses of Δ9-tetrahydrocannabinol are not lethal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFR443WjQM47Vg90H21EOLACvtfcHk0lj-4TrtPxSccQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFWktLs%253D&md5=59c7c3cebae57b8563f4c04af7aca7ef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.5.1932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.5.1932%26sid%3Dliteratum%253Aachs%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DLynn%26aufirst%3DA.%2BB.%26aulast%3DLittle%26aufirst%3DM.%2BD.%26aulast%3DJohnson%26aufirst%3DM.%2BR.%26aulast%3DMelvin%26aufirst%3DL.%2BS.%26aulast%3DDe%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DCannabinoid%2520receptor%2520localization%2520in%2520brain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26spage%3D1932%26epage%3D1936%26doi%3D10.1073%2Fpnas.87.5.1932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptors: where they are and what they do</span>. <i>J. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2826.2008.01671.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1365-2826.2008.01671.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18426493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsl2itbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=10-14&author=K.+Mackie&title=Cannabinoid+receptors%3A+where+they+are+and+what+they+do&doi=10.1111%2Fj.1365-2826.2008.01671.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors: where they are and what they do</span></div><div class="casAuthors">Mackie, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">10-14</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system consists of the endogenous cannabinoids (endocannabinoids), cannabinoid receptors and the enzymes that synthesize and degrade endocannabinoids.  Many of the effects of cannabinoids and endocannabinoids are mediated by two G protein-coupled receptors (GPCRs), CB1 and CB2, although addnl. receptors may be involved.  CB1 receptors are present in very high levels in several brain regions and in lower amts. in a more wide-spread fashion.  These receptors mediate many of the psychoactive effects of cannabinoids.  CB2 receptors have a more restricted distribution, being found in a no. of immune cells and in a few neurons.  Both CB1 and CB2 couple primarily to inhibitory G proteins and are subject to the same pharmacol. influences as other GPCRs.  Thus, partial agonism, functional selectivity and inverse agonism all play important roles in detg. the cellular response to specific cannabinoid receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE3tJevcn32LVg90H21EOLACvtfcHk0lj-4TrtPxSccQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsl2itbs%253D&md5=e87a4821e2475ef50f57f26507c2dc7f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2008.01671.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2008.01671.x%26sid%3Dliteratum%253Aachs%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DCannabinoid%2520receptors%253A%2520where%2520they%2520are%2520and%2520what%2520they%2520do%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2008%26volume%3D20%26spage%3D10%26epage%3D14%26doi%3D10.1111%2Fj.1365-2826.2008.01671.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bab, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bíró, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konje, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, A.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid signaling at the periphery: 50 years after THC</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.tips.2015.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25796370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFehur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=277-296&author=M.+Maccarroneauthor=I.+Babauthor=T.+B%C3%ADr%C3%B3author=G.+A.+Cabralauthor=S.+K.+Deyauthor=V.+Di+Marzoauthor=J.+C.+Konjeauthor=G.+Kunosauthor=R.+Mechoulamauthor=P.+Pacherauthor=K.+A.+Sharkeyauthor=A.+Zimmer&title=Endocannabinoid+signaling+at+the+periphery%3A+50+years+after+THC&doi=10.1016%2Fj.tips.2015.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid signaling at the periphery: 50 years after THC</span></div><div class="casAuthors">Maccarrone, Mauro; Bab, Itai; Biro, Tamas; Cabral, Guy A.; Dey, Sudhansu K.; Di Marzo, Vincenzo; Konje, Justin C.; Kunos, George; Mechoulam, Raphael; Pacher, Pal; Sharkey, Keith A.; Zimmer, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">277-296</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In 1964, the psychoactive ingredient of Cannabis sativa, Δ9-tetrahydrocannabinol (THC), was isolated.  Nearly 30 years later the endogenous counterparts of THC, collectively termed endocannabinoids (eCBs), were discovered: N-arachidonoylethanolamine (anandamide) (AEA) in 1992 and 2-arachidonoylglycerol (2-AG) in 1995.  Since then, considerable research has shed light on the impact of eCBs on human health and disease, identifying an ensemble of proteins that bind, synthesize, and degrade them and that together form the eCB system (ECS). eCBs control basic biol. processes including cell choice between survival and death and progenitor/stem cell proliferation and differentiation.  Unsurprisingly, in the past two decades eCBs have been recognized as key mediators of several aspects of human pathophysiol. and thus have emerged to be among the most widespread and versatile signaling mols. ever discovered.  Here some of the pioneers of this research field review the state of the art of crit. eCB functions in peripheral organs.  Our community effort is aimed at establishing consensus views on the relevance of the peripheral ECS for human health and disease pathogenesis, as well as highlighting emerging challenges and therapeutic hopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliBLJSeUEKLVg90H21EOLACvtfcHk0lhpd3Q8x7mH7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFehur4%253D&md5=a06cc2d98beb8bd8e42336b5c9c7a278</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DMaccarrone%26aufirst%3DM.%26aulast%3DBab%26aufirst%3DI.%26aulast%3DB%25C3%25ADr%25C3%25B3%26aufirst%3DT.%26aulast%3DCabral%26aufirst%3DG.%2BA.%26aulast%3DDey%26aufirst%3DS.%2BK.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DKonje%26aufirst%3DJ.%2BC.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26aulast%3DZimmer%26aufirst%3DA.%26atitle%3DEndocannabinoid%2520signaling%2520at%2520the%2520periphery%253A%252050%2520years%2520after%2520THC%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D277%26epage%3D296%26doi%3D10.1016%2Fj.tips.2015.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, K. A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids and the gut: new developments and emerging concepts</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.pharmthera.2009.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20117132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1Kgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=21-38&author=A.+A.+Izzoauthor=K.+A.+Sharkey&title=Cannabinoids+and+the+gut%3A+new+developments+and+emerging+concepts&doi=10.1016%2Fj.pharmthera.2009.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids and the gut: New developments and emerging concepts</span></div><div class="casAuthors">Izzo, Angelo A.; Sharkey, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-38</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric infections and inflammatory conditions to disorders of motility, emesis and abdominal pain.  The mechanistic basis of these treatments emerged after the discovery of Δ9-tetrahydrocannabinol as the major constituent of Cannabis.  Further progress was made when the receptors for Δ9-tetrahydrocannabinol were identified as part of an endocannabinoid system, that consists of specific cannabinoid receptors, endogenous ligands and their biosynthetic and degradative enzymes.  Anatomical, physiol. and pharmacol. studies have shown that the endocannabinoid system is widely distributed throughout the gut, with regional variation and organ-specific actions.  It is involved in the regulation of food intake, nausea and emesis, gastric secretion and gastroprotection, GI motility, ion transport, visceral sensation, intestinal inflammation and cell proliferation in the gut.  Cellular targets have been defined that include the enteric nervous system, epithelial and immune cells.  Mol. targets of the endocannabinoid system include, in addn. to the cannabinoid receptors, transient receptor potential vanilloid 1 receptors, peroxisome proliferator-activated receptor alpha receptors and the orphan G-protein coupled receptors, GPR55 and GPR119.  Pharmacol. agents that act on these targets have been shown in preclin. models to have therapeutic potential.  Here, we discuss cannabinoid receptors and their localization in the gut, the proteins involved in endocannabinoid synthesis and degrdn. and the presence of endocannabinoids in the gut in health and disease.  We focus on the pharmacol. actions of cannabinoids in relation to GI disorders, highlighting recent data on genetic mutations in the endocannabinoid system in GI disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSuvBS54QzJbVg90H21EOLACvtfcHk0lhpd3Q8x7mH7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1Kgs7g%253D&md5=97a1de4d71ab7c738bf84c85e7c37764</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DIzzo%26aufirst%3DA.%2BA.%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26atitle%3DCannabinoids%2520and%2520the%2520gut%253A%2520new%2520developments%2520and%2520emerging%2520concepts%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D126%26spage%3D21%26epage%3D38%26doi%3D10.1016%2Fj.pharmthera.2009.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montecucco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span> <span> </span><span class="NLM_article-title">At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2012.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.tips.2012.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22503477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFCkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=331-340&author=F.+Montecuccoauthor=V.+Di+Marzo&title=At+the+heart+of+the+matter%3A+the+endocannabinoid+system+in+cardiovascular+function+and+dysfunction&doi=10.1016%2Fj.tips.2012.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction</span></div><div class="casAuthors">Montecucco, Fabrizio; Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">331-340</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Starting from the well-documented effects of marijuana smoking on heart rate and blood pressure, the cardiovascular effects of Δ9-tetrahydrocannabinol (THC, the main psychotropic ingredient of Cannabis) and endocannabinoids [THC endogenous counterparts that activate cannabinoid receptor type 1 (CB1) and 2 (CB2)] have been thoroughly investigated.  These studies were mostly aimed at establishing the mol. bases of the hypotensive actions of THC, endocannabinoids and related mols., but also evaluated their therapeutic potential in cardiac injury protection, metabolic cardiovascular risk factors and atherosclerotic plaque vulnerability.  The results of these investigations, reviewed here, also served to highlight some of the most peculiar aspects of endocannabinoid signaling, such as redundancy in endocannabinoid targets and the often dualistic role of CB1 and CB2 receptors during pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojs2zPa3fwB7Vg90H21EOLACvtfcHk0lhpd3Q8x7mH7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFCkt7o%253D&md5=e3301962ac762719220b2366e96a7854</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DMontecucco%26aufirst%3DF.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DAt%2520the%2520heart%2520of%2520the%2520matter%253A%2520the%2520endocannabinoid%2520system%2520in%2520cardiovascular%2520function%2520and%2520dysfunction%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D331%26epage%3D340%26doi%3D10.1016%2Fj.tips.2012.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2017.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrcardio.2017.130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28905873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2isLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=151-166&author=P.+Pacherauthor=S.+Steffensauthor=G.+Hask%C3%B3author=T.+H.+Schindlerauthor=G.+Kunos&title=Cardiovascular+effects+of+marijuana+and+synthetic+cannabinoids%3A+the+good%2C+the+bad%2C+and+the+ugly&doi=10.1038%2Fnrcardio.2017.130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly</span></div><div class="casAuthors">Pacher, Pal; Steffens, Sabine; Hasko, Gyorgy; Schindler, Thomas H.; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dysregulation of the endogenous lipid mediators endocannabinoids and their G-protein-coupled cannabinoid receptors 1 and 2 (CB1R and CB2R) has been implicated in a variety of cardiovascular pathologies.  Activation of CB1R facilitates the development of cardiometabolic disease, whereas activation of CB2R (expressed primarily in immune cells) exerts anti-inflammatory effects.  The psychoactive constituent of marijuana, Δ9-tetrahydrocannabinol (THC), is an agonist of both CB1R and CB2R, and exerts its psychoactive and adverse cardiovascular effects through the activation of CB1R in the central nervous and cardiovascular systems.  The past decade has seen a nearly tenfold increase in the THC content of marijuana as well as the increased availability of highly potent synthetic cannabinoids for recreational use.  These changes have been accompanied by the emergence of serious adverse cardiovascular events, including myocardial infarction, cardiomyopathy, arrhythmias, stroke, and cardiac arrest.  In this Review, we summarize the role of the endocannabinoid system in cardiovascular disease, and critically discuss the cardiovascular consequences of marijuana and synthetic cannabinoid use.  With the legalization of marijuana for medicinal purposes and/or recreational use in many countries, physicians should be alert to the possibility that the use of marijuana or its potent synthetic analogs might be the underlying cause of severe cardiovascular events and pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoctXDjzQtJ-bVg90H21EOLACvtfcHk0lhyPvOq1wPGAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2isLnN&md5=9f1ce4c6c3173e5c9c4dc19a307c99d0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2017.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2017.130%26sid%3Dliteratum%253Aachs%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSteffens%26aufirst%3DS.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26aulast%3DSchindler%26aufirst%3DT.%2BH.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DCardiovascular%2520effects%2520of%2520marijuana%2520and%2520synthetic%2520cannabinoids%253A%2520the%2520good%252C%2520the%2520bad%252C%2520and%2520the%2520ugly%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2018%26volume%3D15%26spage%3D151%26epage%3D166%26doi%3D10.1038%2Fnrcardio.2017.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembovler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrosino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casap, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shteyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yirmiya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shohami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bab, I.</span></span> <span> </span><span class="NLM_article-title">The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1096/fj.06-7957com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1096%2Ffj.06-7957com" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17704191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=285-294&author=J.+Tamauthor=V.+Trembovlerauthor=V.+Di+Marzoauthor=S.+Petrosinoauthor=G.+Leoauthor=A.+Alexandrovichauthor=E.+Regevauthor=N.+Casapauthor=A.+Shteyerauthor=C.+Ledentauthor=M.+Karsakauthor=A.+Zimmerauthor=R.+Mechoulamauthor=R.+Yirmiyaauthor=E.+Shohamiauthor=I.+Bab&title=The+cannabinoid+CB1+receptor+regulates+bone+formation+by+modulating+adrenergic+signaling&doi=10.1096%2Ffj.06-7957com"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling</span></div><div class="casAuthors">Tam, Joseph; Trembovler, Victoria; Di Marzo, Vincenzo; Petrosino, Stefania; Leo, Gabriella; Alexandrovich, Alex; Regev, Eran; Casap, Nardy; Shteyer, Arie; Ledent, Catherine; Karsak, Meliha; Zimmer, Andreas; Mechoulam, Raphael; Yirmiya, Raz; Shohami, Esther; Bab, Itai</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">285-294, 10.1096/fj.06-7957com</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">We have recently reported that in bone the cannabinoid CB1 receptor is present in sympathetic terminals.  Here we show that traumatic brain injury (TBI), which in humans enhances peripheral osteogenesis and fracture healing, acutely stimulates bone formation in a distant skeletal site.  At this site we demonstrate (i) a high level of the main endocannabinoid, 2-arachidonoylglycerol (2-AG), and expression of diacylglycerol lipases, enzymes essential for 2-AG synthesis; (ii) that the TBI-induced increase in bone formation is preceded by elevation of the 2-AG and a decrease in norepinephrine (NE) levels.  The TBI stimulation of bone formation was absent in CB1-null mice.  In wild-type animals it could be mimicked, including the suppression of NE levels, by 2-AG administration.  The TBI- and 2-AG-induced stimulation of osteogenesis was restrained by the β-adrenergic receptor agonist isoproterenol.  NE from sympathetic terminals is known to tonically inhibit bone formation by activating osteoblastic β2-adrenergic receptors.  The present findings further demonstrate that the sympathetic control of bone formation is regulated through 2-AG activation of prejunctional CB1.  Elevation of bone 2-AG apparently suppresses NE release from bone sympathetic terminals, thus alleviating the inhibition of bone formation.  The involvement of osteoblastic CB2 signaling in this process is minimal, if any.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHBWEs2cC3IrVg90H21EOLACvtfcHk0lhyPvOq1wPGAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslWmsw%253D%253D&md5=18848f3beebb92be4b7a354ba8d4ea4f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1096%2Ffj.06-7957com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.06-7957com%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DTrembovler%26aufirst%3DV.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DPetrosino%26aufirst%3DS.%26aulast%3DLeo%26aufirst%3DG.%26aulast%3DAlexandrovich%26aufirst%3DA.%26aulast%3DRegev%26aufirst%3DE.%26aulast%3DCasap%26aufirst%3DN.%26aulast%3DShteyer%26aufirst%3DA.%26aulast%3DLedent%26aufirst%3DC.%26aulast%3DKarsak%26aufirst%3DM.%26aulast%3DZimmer%26aufirst%3DA.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DYirmiya%26aufirst%3DR.%26aulast%3DShohami%26aufirst%3DE.%26aulast%3DBab%26aufirst%3DI.%26atitle%3DThe%2520cannabinoid%2520CB1%2520receptor%2520regulates%2520bone%2520formation%2520by%2520modulating%2520adrenergic%2520signaling%26jtitle%3DFASEB%2520J.%26date%3D2008%26volume%3D22%26spage%3D285%26epage%3D294%26doi%3D10.1096%2Ffj.06-7957com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Shaar, M.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of a peripheral receptor for cannabinoids</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1038/365061a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2F365061a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=7689702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=1993&pages=61-65&author=S.+Munroauthor=K.+L.+Thomasauthor=M.+Abu-Shaar&title=Molecular+characterization+of+a+peripheral+receptor+for+cannabinoids&doi=10.1038%2F365061a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of a peripheral receptor for cannabinoids</span></div><div class="casAuthors">Munro, Sean; Thomas, Kerrie L.; Abu-Shaar, Muna</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">6441</span>),
    <span class="NLM_cas:pages">61-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The major active ingredient of marijuana, Δ9-tetrahydrocannabinol (Δ-THC), has been used as a psychoactive agent for thousands of years.  Marijuana, and Δ9-THC, also exert a wide range of other effects including analgesia, anti-inflammation, immunosuppression, anticonvulsion, alleviation of intraocular pressure in glaucoma, and attenuation of vomiting.  The clin. application of cannabinoids has, however, been limited by their psychoactive effects, and this has led to interest in the biochem. bases of their action.  Progress stemmed initially from the synthesis of potent derivs. of Δ9-THC4,5, and more recently from the cloning of a gene encoding a G-protein-coupled receptor for cannabinoids.  This receptor is expressed in the brain but not in the periphery, except for a low level in testes.  It has been proposed that the nonpsychoactive effects of cannabinoids are either mediated centrally or through direct interaction with other, non-receptor proteins.  Here the authors report the cloning of a receptor for cannabinoids that is not expressed in the brain but rather in macrophages in the marginal zone of spleen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHsq4vy1XH17Vg90H21EOLACvtfcHk0lhyPvOq1wPGAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D&md5=476435b57bd0f24483e2f24b813cc32f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2F365061a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F365061a0%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DK.%2BL.%26aulast%3DAbu-Shaar%26aufirst%3DM.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520peripheral%2520receptor%2520for%2520cannabinoids%26jtitle%3DNature%26date%3D1993%26volume%3D365%26spage%3D61%26epage%3D65%26doi%3D10.1038%2F365061a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casellas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devane, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herkenham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">International union of pharmacology. XXVII. classification of cannabinoid receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1124/pr.54.2.161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlettauthor=F.+Barthauthor=T.+I.+Bonnerauthor=G.+Cabralauthor=P.+Casellasauthor=W.+A.+Devaneauthor=C.+C.+Felderauthor=M.+Herkenhamauthor=K.+Mackieauthor=B.+R.+Martinauthor=R.+Mechoulamauthor=R.+G.+Pertwee&title=International+union+of+pharmacology.+XXVII.+classification+of+cannabinoid+receptors&doi=10.1124%2Fpr.54.2.161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0lio31HFfJ3cRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DDevane%26aufirst%3DW.%2BA.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XXVII.%2520classification%2520of%2520cannabinoid%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202%26doi%3D10.1124%2Fpr.54.2.161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Sickle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingsley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouihate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, J. S.</span></span> <span> </span><span class="NLM_article-title">Identification and functional characterization of brainstem cannabinoid CB2 receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1126/science.1115740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1126%2Fscience.1115740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16224028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2hurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2005&pages=329-332&author=M.+D.+Van%0ASickleauthor=M.+Duncanauthor=P.+J.+Kingsleyauthor=A.+Mouihateauthor=P.+Urbaniauthor=K.+Mackieauthor=N.+Stellaauthor=A.+Makriyannisauthor=D.+Piomelliauthor=J.+S.+Davison&title=Identification+and+functional+characterization+of+brainstem+cannabinoid+CB2+receptors&doi=10.1126%2Fscience.1115740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and functional characterization of brainstem cannabinoid CB2 receptors</span></div><div class="casAuthors">Van Sickle, Marja D.; Duncan, Marnie; Kingsley, Philip J.; Mouihate, Abdeslam; Urbani, Paolo; Mackie, Ken; Stella, Nephi; Makriyannis, Alexandros; Piomelli, Daniele; Davison, Joseph S.; Marnett, Lawrence J.; Di Marzo, Vincenzo; Pittman, Quentin J.; Patel, Kamala D.; Sharkey, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">5746</span>),
    <span class="NLM_cas:pages">329-332</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The presence and function of CB2 receptors in central nervous system (CNS) neurons are controversial.  The authors report the expression of CB2 receptor mRNA and protein localization on brainstem neurons.  These functional CB2 receptors in the brainstem were activated by a CB2 receptor agonist, 2-arachidonoylglycerol, and by elevated endogenous levels of endocannabinoids, which also act at CB1 receptors.  CB2 receptors represent an alternative site of action of endocannabinoids that opens the possibility of nonpsychotropic therapeutic interventions using enhanced endocannabinoid levels in localized brain areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriWgg6LDIT0bVg90H21EOLACvtfcHk0lio31HFfJ3cRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2hurvL&md5=ab457ab0bd1b8e30ea927a1e61366323</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscience.1115740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1115740%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BSickle%26aufirst%3DM.%2BD.%26aulast%3DDuncan%26aufirst%3DM.%26aulast%3DKingsley%26aufirst%3DP.%2BJ.%26aulast%3DMouihate%26aufirst%3DA.%26aulast%3DUrbani%26aufirst%3DP.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DStella%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DDavison%26aufirst%3DJ.%2BS.%26atitle%3DIdentification%2520and%2520functional%2520characterization%2520of%2520brainstem%2520cannabinoid%2520CB2%2520receptors%26jtitle%3DScience%26date%3D2005%26volume%3D310%26spage%3D329%26epage%3D332%26doi%3D10.1126%2Fscience.1115740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human cannabinoid receptor CB1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2016.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27768894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=750-762&author=T.+Huaauthor=K.+Vemuriauthor=M.+Puauthor=L.+Quauthor=G.+W.+Hanauthor=Y.+Wuauthor=S.+Zhaoauthor=W.+Shuiauthor=S.+Liauthor=A.+Kordeauthor=R.+B.+Laprairieauthor=E.+L.+Stahlauthor=J.+H.+Hoauthor=N.+Zvonokauthor=H.+Zhouauthor=I.+Kufarevaauthor=B.+Wuauthor=Q.+Zhaoauthor=M.+A.+Hansonauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.+J.+Liu&title=Crystal+structure+of+the+human+cannabinoid+receptor+CB1&doi=10.1016%2Fj.cell.2016.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB1</span></div><div class="casAuthors">Hua, Tian; Vemuri, Kiran; Pu, Mengchen; Qu, Lu; Han, Gye Won; Wu, Yiran; Zhao, Suwen; Shui, Wenqing; Li, Shanshan; Korde, Anisha; Laprairie, Robert B.; Stahl, Edward L.; Ho, Jo-Hao; Zvonok, Nikolai; Zhou, Han; Kufareva, Irina; Wu, Beili; Zhao, Qiang; Hanson, Michael A.; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-762.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) is the principal target of Δ9-tetrahydrocannabinol (THC), a psychoactive chem. from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use.  CB1 is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders.  Here, the authors present the 2.8 Å crystal structure of human CB1 in complex with AM6538, a stabilizing antagonist, synthesized and characterized for this structural study.  The structure of the CB1-AM6538 complex reveals key features of the receptor and crit. interactions for antagonist binding.  In combination with functional studies and mol. modeling, the structure provides insight into the binding mode of naturally occurring CB1 ligands, such as THC, and synthetic cannabinoids.  This enhances the understanding of the mol. basis for the physiol. functions of CB1 and provides new opportunities for the design of next-generation CB1-targeting pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAuMgAfmO22bVg90H21EOLACvtfcHk0lio31HFfJ3cRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI&md5=f4862c31391550ee2b83ef198c9c7b17</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DShui%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKorde%26aufirst%3DA.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DHo%26aufirst%3DJ.%2BH.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB1%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D750%26epage%3D762%26doi%3D10.1016%2Fj.cell.2016.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human cannabinoid receptor CB2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2018.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30639103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=459-467&author=X.+Liauthor=T.+Huaauthor=K.+Vemuriauthor=J.+H.+Hoauthor=Y.+Wuauthor=L.+Wuauthor=P.+Popovauthor=O.+Benchamaauthor=N.+Zvonokauthor=K.+Lockeauthor=L.+Quauthor=G.+W.+Hanauthor=M.+R.+Iyerauthor=R.+Cinarauthor=N.+J.+Coffeyauthor=J.+Wangauthor=M.+Wuauthor=V.+Katritchauthor=S.+Zhaoauthor=G.+Kunosauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.+J.+Liu&title=Crystal+structure+of+the+human+cannabinoid+receptor+CB2&doi=10.1016%2Fj.cell.2018.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB2</span></div><div class="casAuthors">Li, Xiaoting; Hua, Tian; Vemuri, Kiran; Ho, Jo-Hao; Wu, Yiran; Wu, Lijie; Popov, Petr; Benchama, Othman; Zvonok, Nikolai; Locke, K'ara; Qu, Lu; Han, Gye Won; Iyer, Malliga R.; Cinar, Resat; Coffey, Nathan J.; Wang, Jingjing; Wu, Meng; Katritch, Vsevolod; Zhao, Suwen; Kunos, George; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-467.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cannabinoid receptor CB2 is predominately expressed in the immune system, and selective modulation of CB2 without the psychoactivity of CB1 has therapeutic potential in inflammatory, fibrotic, and neurodegenerative diseases.  Here, we report the crystal structure of human CB2 in complex with a rationally designed antagonist, AM10257, at 2.8 Å resoln.  The CB2-AM10257 structure reveals a distinctly different binding pose compared with CB1.  However, the extracellular portion of the antagonist-bound CB2 shares a high degree of conformational similarity with the agonist-bound CB1, which led to the discovery of AM10257's unexpected opposing functional profile of CB2 antagonism vs. CB1 agonism.  Further structural anal. using mutagenesis studies and mol. docking revealed the mol. basis of their function and selectivity for CB2 and CB1.  Addnl. analyses of our designed antagonist and agonist pairs provide important insight into the activation mechanism of CB2.  The present findings should facilitate rational drug design toward precise modulation of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFwNUEO0q03LVg90H21EOLACvtfcHk0lgCv4HyDmHBLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFKktw%253D%253D&md5=90ee72a6dc13b74b84fb6799c3aa0471</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DJ.%2BH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DBenchama%26aufirst%3DO.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DLocke%26aufirst%3DK.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DCoffey%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB2%26jtitle%3DCell%26date%3D2019%26volume%3D176%26spage%3D459%26epage%3D467%26doi%3D10.1016%2Fj.cell.2018.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliopoulos-Tsoutsouvas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikas, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span> <span> </span><span class="NLM_article-title">Activation and signaling mechanism revealed by cannabinoid receptor-G(i) complex structures</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2020.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32004463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFeqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=655-665&author=T.+Huaauthor=X.+Liauthor=L.+Wuauthor=C.+Iliopoulos-Tsoutsouvasauthor=Y.+Wangauthor=M.+Wuauthor=L.+Shenauthor=C.+A.+Johnstonauthor=S.+P.+Nikasauthor=F.+Songauthor=X.+Songauthor=S.+Yuanauthor=Q.+Sunauthor=Y.+Wuauthor=S.+Jiangauthor=T.+W.+Grimauthor=O.+Benchamaauthor=E.+L.+Stahlauthor=N.+Zvonokauthor=S.+Zhaoauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=Z.+J.+Liu&title=Activation+and+signaling+mechanism+revealed+by+cannabinoid+receptor-G%28i%29+complex+structures&doi=10.1016%2Fj.cell.2020.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures</span></div><div class="casAuthors">Hua, Tian; Li, Xiaoting; Wu, Lijie; Iliopoulos-Tsoutsouvas, Christos; Wang, Yuxia; Wu, Meng; Shen, Ling; Johnston, Christina A.; Nikas, Spyros P.; Song, Feng; Song, Xiyong; Yuan, Shuguang; Sun, Qianqian; Wu, Yiran; Jiang, Shan; Grim, Travis W.; Benchama, Othman; Stahl, Edward L.; Zvonok, Nikolai; Zhao, Suwen; Bohn, Laura M.; Makriyannis, Alexandros; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-665.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human endocannabinoid systems modulate multiple physiol. processes mainly through the activation of cannabinoid receptors CB1 and CB2.  Their high sequence similarity, low agonist selectivity, and lack of activation and G protein-coupling knowledge have hindered the development of therapeutic applications.  Importantly, missing structural information has significantly held back the development of promising CB2-selective agonist drugs for treating inflammatory and neuropathic pain without the psychoactivity of CB1.  Here, we report the cryoelectron microscopy structures of synthetic cannabinoid-bound CB2 and CB1 in complex with Gi, as well as agonist-bound CB2 crystal structure.  Of important scientific and therapeutic benefit, our results reveal a diverse activation and signaling mechanism, the structural basis of CB2-selective agonists design, and the unexpected interaction of cholesterol with CB1, suggestive of its endogenous allosteric modulating role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgy9tDrt9HArVg90H21EOLACvtfcHk0lgCv4HyDmHBLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFeqtbc%253D&md5=b9d4dd05094f3bae76b315a41a11c21b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DIliopoulos-Tsoutsouvas%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DJohnston%26aufirst%3DC.%2BA.%26aulast%3DNikas%26aufirst%3DS.%2BP.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DBenchama%26aufirst%3DO.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3DActivation%2520and%2520signaling%2520mechanism%2520revealed%2520by%2520cannabinoid%2520receptor-G%2528i%2529%2520complex%2520structures%26jtitle%3DCell%26date%3D2020%26volume%3D180%26spage%3D655%26epage%3D665%26doi%3D10.1016%2Fj.cell.2020.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">The molecular logic of endocannabinoid signalling</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1038/nrn1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrn1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=14595399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=873-884&author=D.+Piomelli&title=The+molecular+logic+of+endocannabinoid+signalling&doi=10.1038%2Fnrn1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular logic of endocannabinoid signalling</span></div><div class="casAuthors">Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">873-884</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The endocannabinoids are a family of lipid messengers that engage the cell surface receptors that are targeted by Δ9-tetrahydrocannabinol, the active principle in marijuana (Cannabis).  They are made on demand through cleavage of membrane precursors and are involved in various short-range signaling processes.  In the brain, they combine with CB1 cannabinoid receptors on axon terminals to regulate ion channel activity and neurotransmitter release.  Their ability to modulate synaptic efficacy has a wide range of functional consequences and provides unique therapeutic possibilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUrtdaKTjDoLVg90H21EOLACvtfcHk0lgCv4HyDmHBLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOktrY%253D&md5=d4af135f5309e6551bdb1f8ade45b565</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrn1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1247%26sid%3Dliteratum%253Aachs%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DThe%2520molecular%2520logic%2520of%2520endocannabinoid%2520signalling%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2003%26volume%3D4%26spage%3D873%26epage%3D884%26doi%3D10.1038%2Fnrn1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eggan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, D. A.</span></span> <span> </span><span class="NLM_article-title">Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">772</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.65.7.772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1001%2Farchpsyc.65.7.772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18606950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD1cvjs1CqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=772-784&author=S.+M.+Egganauthor=T.+Hashimotoauthor=D.+A.+Lewis&title=Reduced+cortical+cannabinoid+1+receptor+messenger+RNA+and+protein+expression+in+schizophrenia&doi=10.1001%2Farchpsyc.65.7.772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia</span></div><div class="casAuthors">Eggan Stephen M; Hashimoto Takanori; Lewis David A</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">772-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Cannabis use is associated with both impaired cognitive functions, including working memory, and an increased risk of schizophrenia.  Schizophrenia is characterized by impairments in working memory that are associated with reduced gamma-aminobutyric acid (GABA) neurotransmission in the dorsolateral prefrontal cortex.  The cannabinoid 1 receptor (CB1R) is highly expressed in the dorsolateral prefrontal cortex, is contained in the axon terminals of a subpopulation of perisomatic-targeting GABA neurons, and, when activated, suppresses the release of GABA.  OBJECTIVE:  To determine the potential relationship between CB1R signaling and altered GABA neurotransmission in schizophrenia by evaluating CB1R messenger RNA (mRNA) and protein expression in the dorsolateral prefrontal cortex.  DESIGN:  In situ hybridization and immunocytochemistry techniques were used to examine the cortical levels of CB1R mRNA and protein, respectively.  SETTING:  Brain specimens were obtained from autopsies conducted at the Allegheny County Medical Examiner's Office, Pittsburgh, Pennsylvania.  PARTICIPANTS:  Postmortem brain specimens from 23 pairs of subjects with schizophrenia and age-, sex-, and postmortem interval-matched comparison subjects, as well as brain specimens from 18 macaque monkeys with long-term exposure to haloperidol, olanzapine, or placebo.  MAIN OUTCOME MEASURES:  Optical density measures of CB1R mRNA expression and protein levels and correlations with previously reported glutamic acid decarboxylase 67 and cholecystokinin mRNA measures.  RESULTS:  Levels of CB1R mRNA were significantly lower by 14.8% in the subjects with schizophrenia.  Similarly, CB1R protein levels, assessed by radioimmunocytochemistry and standard immunocytochemistry, were significantly decreased by 11.6% and 13.9%, respectively.  Group differences in CB1R mRNA levels were significantly correlated with those in glutamic acid decarboxylase 67 and cholecystokinin mRNA levels.  Expression of CB1R mRNA was not changed in antipsychotic-exposed monkeys, and neither CB1R mRNA levels nor protein levels were affected by potential confounding factors in the subjects with schizophrenia.  CONCLUSIONS:  This combination of findings suggests the testable hypothesis that reduced CB1R mRNA and protein levels in schizophrenia represent a compensatory mechanism to increase GABA transmission from perisomatic-targeting cholecystokinin interneurons with impaired GABA synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX7QVJCUq_ngHqQV89nF-2fW6udTcc2ea5zR-cUfy7Z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvjs1CqtA%253D%253D&md5=847a7b6301f8194010fbb7db075e7a24</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.65.7.772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.65.7.772%26sid%3Dliteratum%253Aachs%26aulast%3DEggan%26aufirst%3DS.%2BM.%26aulast%3DHashimoto%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DD.%2BA.%26atitle%3DReduced%2520cortical%2520cannabinoid%25201%2520receptor%2520messenger%2520RNA%2520and%2520protein%2520expression%2520in%2520schizophrenia%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2008%26volume%3D65%26spage%3D772%26epage%3D784%26doi%3D10.1001%2Farchpsyc.65.7.772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gazzerro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notarnicola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misciagna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span> <span> </span><span class="NLM_article-title">Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population</span>. <i>Int. J. Obes.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1038/sj.ijo.0803510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fsj.ijo.0803510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlslCqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2007&pages=908-912&author=P.+Gazzerroauthor=M.+Carusoauthor=M.+Notarnicolaauthor=G.+Misciagnaauthor=V.+Guerraauthor=C.+Laezzaauthor=M.+Bifulco&title=Association+between+cannabinoid+type-1+receptor+polymorphism+and+body+mass+index+in+a+southern+Italian+population&doi=10.1038%2Fsj.ijo.0803510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population</span></div><div class="casAuthors">Gazzerro, P.; Caruso, M. G.; Notarnicola, M.; Misciagna, G.; Guerra, V.; Laezza, C.; Bifulco, M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">908-912</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Endocannabinoids control food intake via both central and peripheral mechanisms, and cannabinoid type-1 receptor (CB1) modulates lipogenesis in primary adipocyte cell cultures and in animal models of obesity.  We aimed to evaluate, at the population level, the frequency of a genetic polymorphism of CB1 and to study its correlation with body mass index.  Healthy subjects from a population survey carried out in southern Italy examd. in 1992-1993 and older than 65 years (n = 419, M = 237, F = 182) were divided into quintiles by body mass index (BMI).  Two hundred and ten subjects were randomly sampled from the first, third and fifth quintile of BMI (BMI, resp.: 16.2-23.8 = normal, 26.7-28.4 = overweight, 31.6-49.7 = obese) to reach a total of 70 per quintile.  Their serum and white cells from the biol. bank were used to measure the genotype and the blood variables for the study.  Anthropometric parameters, blood pressure, serum glucose and lipid levels were measured with std. methods; genotyping for the CB1 1359G/A polymorphism was performed using multiplex PCR.  Statistical methods included χ2 for trend, binomial and multinomial multiple logistic regression to model BMI on the genotype, controlling for potential confounders.  We found a clear trend of increasing relative frequency of the CB1 wild-type genotype with the increase of BMI (P = 0.03) and, using a multiple logistic regression model, wild-type genotype, female gender, age, glycemia and triglycerides were directly assocd. with both overweight (third quintile of BMI) and obesity (fifth quintile of BMI).  Although performed in a limited no. of subjects, our results show that the presence of the CB1 polymorphic allele was significantly assocd. with a lower BMI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa4x_YKKxHP7Vg90H21EOLACvtfcHk0ljZa4q6a9NfLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlslCqs78%253D&md5=f4bda104c88560d24b08b5e15ce91aba</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fsj.ijo.0803510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ijo.0803510%26sid%3Dliteratum%253Aachs%26aulast%3DGazzerro%26aufirst%3DP.%26aulast%3DCaruso%26aufirst%3DM.%26aulast%3DNotarnicola%26aufirst%3DM.%26aulast%3DMisciagna%26aufirst%3DG.%26aulast%3DGuerra%26aufirst%3DV.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DBifulco%26aufirst%3DM.%26atitle%3DAssociation%2520between%2520cannabinoid%2520type-1%2520receptor%2520polymorphism%2520and%2520body%2520mass%2520index%2520in%2520a%2520southern%2520Italian%2520population%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2007%26volume%3D31%26spage%3D908%26epage%3D912%26doi%3D10.1038%2Fsj.ijo.0803510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubler, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalla, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagotto, U.</span></span> <span> </span><span class="NLM_article-title">Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1574</span>– <span class="NLM_lpage">1581</span>, <span class="refDoi"> DOI: 10.1210/en.2005-1649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1210%2Fen.2005-1649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17194743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjvVOhtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2007&pages=1574-1581&author=D.+Cotaauthor=M.-A.+Steinerauthor=G.+Marsicanoauthor=C.+Cervinoauthor=J.+P.+Hermanauthor=Y.+Grublerauthor=J.+Stallaauthor=R.+Pasqualiauthor=B.+Lutzauthor=G.+K.+Stallaauthor=U.+Pagotto&title=Requirement+of+cannabinoid+receptor+type+1+for+the+basal+modulation+of+hypothalamic-pituitary-adrenal+axis+function&doi=10.1210%2Fen.2005-1649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function</span></div><div class="casAuthors">Cota, Daniela; Steiner, Michel-Alexander; Marsicano, Giovanni; Cervino, Cristina; Herman, James P.; Gruebler, Yvonne; Stalla, Johanna; Pasquali, Renato; Lutz, Beat; Stalla, Guenter K.; Pagotto, Uberto</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1574-1581</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The endocannabinoid system affects the neuroendocrine regulation of hormone secretion, including the activity of the hypothalamus-pituitary-adrenal (HPA) axis.  However, the mechanisms by which endocannabinoids regulate HPA axis function have remained unclear.  Here we demonstrate that mice lacking cannabinoid receptor type 1 (CB1-/-) display a significant dysregulation of the HPA axis.  Although circadian HPA axis responsiveness is preserved, CB1-/- mice are characterized by an enhanced circadian drive on the HPA axis, resulting in elevated plasma corticosterone concns. at the onset of the dark as compared with wild-type (CB1+/+) littermates.  Moreover, CB1-/--derived pituitary cells respond with a significantly higher ACTH secretion to CRH and forskolin challenges as compared with pituitary cells derived from CB1+/+ mice.  Both CBL-/- and CB1+/+ mice properly respond to a high-dose dexamethasone test, but response to low-dose dexamethasone is influenced by genotype.  In addn., CB1-/- mice show increased CRH mRNA levels in the paraventricular nucleus of the hypothalamus but not in other extrahypothalamic areas, such as the amygdala and piriform cortex, in which CB1 and CRH mRNA have been colocalized.  Finally, CB1-/- mice have selective glucocorticoid receptor mRNA down-regulation in the CA1 region of the hippocampus but not in the dentate gyrus or paraventricular nucleus.  Conversely, mineralocorticoid receptor mRNA expression levels were found unchanged in these brain areas.  In conclusion, our findings indicate that CB1 deficiency enhances the circadian HPA axis activity peak and leads to central impairment of glucocorticoid feedback, thus further outlining the essential role of the endocannabinoid system in the modulation of neuroendocrine functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXUtiTQEiXILVg90H21EOLACvtfcHk0ljZa4q6a9NfLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjvVOhtr4%253D&md5=450b95cdc96f3897b1ccda5f76234896</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1210%2Fen.2005-1649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2005-1649%26sid%3Dliteratum%253Aachs%26aulast%3DCota%26aufirst%3DD.%26aulast%3DSteiner%26aufirst%3DM.-A.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DCervino%26aufirst%3DC.%26aulast%3DHerman%26aufirst%3DJ.%2BP.%26aulast%3DGrubler%26aufirst%3DY.%26aulast%3DStalla%26aufirst%3DJ.%26aulast%3DPasquali%26aufirst%3DR.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DStalla%26aufirst%3DG.%2BK.%26aulast%3DPagotto%26aufirst%3DU.%26atitle%3DRequirement%2520of%2520cannabinoid%2520receptor%2520type%25201%2520for%2520the%2520basal%2520modulation%2520of%2520hypothalamic-pituitary-adrenal%2520axis%2520function%26jtitle%3DEndocrinology%26date%3D2007%26volume%3D148%26spage%3D1574%26epage%3D1581%26doi%3D10.1210%2Fen.2005-1649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puighermanal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busquets-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaita, A.</span></span> <span> </span><span class="NLM_article-title">Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">3254</span>– <span class="NLM_lpage">3263</span>, <span class="refDoi"> DOI: 10.1098/rstb.2011.0384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1098%2Frstb.2011.0384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23108544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKgtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=3254-3263&author=E.+Puighermanalauthor=A.+Busquets-Garciaauthor=R.+Maldonadoauthor=A.+Ozaita&title=Cellular+and+intracellular+mechanisms+involved+in+the+cognitive+impairment+of+cannabinoids&doi=10.1098%2Frstb.2011.0384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids</span></div><div class="casAuthors">Puighermanal, Emma; Busquets-Garcia, Arnau; Maldonado, Rafael; Ozaita, Andres</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1607</span>),
    <span class="NLM_cas:pages">3254-3263</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Exogenous cannabinoids, such as delta9-tetrahydrocannabinol (THC), as well as the modulation of endogenous cannabinoids, affect cognitive function through the activation of cannabinoid receptors.  Indeed, these compds. modulate a no. of signalling pathways critically implicated in the deleterious effect of cannabinoids on learning and memory.  Thus, the involvement of the mammalian target of rapamycin pathway and extracellular signal-regulated kinases, together with their consequent regulation of cellular processes such as protein translation, play a crit. role in the amnesic-like effects of cannabinoids.  In this study, we summarize the cellular and mol. mechanisms reported in the modulation of cognitive function by the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDaAZkvCfWcrVg90H21EOLACvtfcHk0lgiBWdiyIyDlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKgtLzF&md5=2e29a221700879d7f07d33a2b38bb916</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1098%2Frstb.2011.0384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2011.0384%26sid%3Dliteratum%253Aachs%26aulast%3DPuighermanal%26aufirst%3DE.%26aulast%3DBusquets-Garcia%26aufirst%3DA.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DOzaita%26aufirst%3DA.%26atitle%3DCellular%2520and%2520intracellular%2520mechanisms%2520involved%2520in%2520the%2520cognitive%2520impairment%2520of%2520cannabinoids%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2012%26volume%3D367%26spage%3D3254%26epage%3D3263%26doi%3D10.1098%2Frstb.2011.0384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, Y. L.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid signalling in reward and addiction</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1038/nrn4004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrn4004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26373473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWls7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=579-594&author=L.+H.+Parsonsauthor=Y.+L.+Hurd&title=Endocannabinoid+signalling+in+reward+and+addiction&doi=10.1038%2Fnrn4004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid signaling in reward and addiction</span></div><div class="casAuthors">Parsons, Loren H.; Hurd, Yasmin L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">579-594</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Brain endocannabinoid (eCB) signaling influences the motivation for natural rewards (such as palatable food, sexual activity and social interaction) and modulates the rewarding effects of addictive drugs.  Pathol. forms of natural and drug-induced reward are assocd. with dysregulated eCB signaling that may derive from pre-existing genetic factors or from prolonged drug exposure.  Impaired eCB signaling contributes to dysregulated synaptic plasticity, increased stress responsivity, neg. emotional states and cravings that propel addiction.  Understanding the contributions of eCB disruptions to behavioral and physiol. traits provides insight into the eCB influence on addiction vulnerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2s5P4XZrYGbVg90H21EOLACvtfcHk0lgiBWdiyIyDlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWls7%252FF&md5=0a7180790eba188007435ec107c6a2a9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrn4004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn4004%26sid%3Dliteratum%253Aachs%26aulast%3DParsons%26aufirst%3DL.%2BH.%26aulast%3DHurd%26aufirst%3DY.%2BL.%26atitle%3DEndocannabinoid%2520signalling%2520in%2520reward%2520and%2520addiction%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2015%26volume%3D16%26spage%3D579%26epage%3D594%26doi%3D10.1038%2Fnrn4004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaulme, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calandra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neliat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caput, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breliere, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Fur, G.</span></span> <span> </span><span class="NLM_article-title">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(94)00773-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2F0014-5793%2894%2900773-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=8070571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1994&pages=240-244&author=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=M.+Heaulmeauthor=D.+Shireauthor=B.+Calandraauthor=C.+Congyauthor=S.+Martinezauthor=J.+Maruaniauthor=G.+Neliatauthor=D.+Caputauthor=P.+Ferraraauthor=P.+Soubrieauthor=J.+C.+Breliereauthor=G.+Le+Fur&title=SR141716A%2C+a+potent+and+selective+antagonist+of+the+brain+cannabinoid+receptor&doi=10.1016%2F0014-5793%2894%2900773-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span></div><div class="casAuthors">Rinaldi-Carmona, Murielle; Barth, Francis; Heaulme, Michel; Shire, David; Calandra, Bernard; Congy, Christian; Martinez, Serge; Maruani, Jeanne; Neliat, Gervais; et al.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">240-4</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor.  This compd. displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor.  In vitro, SR141716A antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes.  After i.p. or oral administration, SR141716A antagonizes classical pharmacol. and behavioral effects of cannabinoid receptor agonists.  This compd. should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLJ59LaZb2cbVg90H21EOLACvtfcHk0lgiBWdiyIyDlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D&md5=1eebdfec28d2dde64729cddb859aa6c8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2900773-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252900773-X%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DHeaulme%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DCalandra%26aufirst%3DB.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DMaruani%26aufirst%3DJ.%26aulast%3DNeliat%26aufirst%3DG.%26aulast%3DCaput%26aufirst%3DD.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DBreliere%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BFur%26aufirst%3DG.%26atitle%3DSR141716A%252C%2520a%2520potent%2520and%2520selective%2520antagonist%2520of%2520the%2520brain%2520cannabinoid%2520receptor%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D350%26spage%3D240%26epage%3D244%26doi%3D10.1016%2F0014-5793%2894%2900773-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sam, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghatei, M. A.</span></span> <span> </span><span class="NLM_article-title">Rimonabant: from RIO to ban</span>. <i>J. Obes.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">432607</span>, <span class="refDoi"> DOI: 10.1155/2011/432607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1155%2F2011%2F432607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21773005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnps1SnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=432607&author=A.+H.+Samauthor=V.+Salemauthor=M.+A.+Ghatei&title=Rimonabant%3A+from+RIO+to+ban&doi=10.1155%2F2011%2F432607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant: From RIO to Ban</span></div><div class="casAuthors">Sam Amir H; Salem Victoria; Ghatei Mohammad A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of obesity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">432607</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century.  The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome.  However, the drug was quickly withdrawn due to the emergence of significant side effects-notably severe mood disorders.  This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgmzv1LvwoEZSWdIdmEou5fW6udTcc2ebYa1BqXOS_srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnps1SnsQ%253D%253D&md5=03967572404bd633a2298bd1a62baff1</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1155%2F2011%2F432607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F432607%26sid%3Dliteratum%253Aachs%26aulast%3DSam%26aufirst%3DA.%2BH.%26aulast%3DSalem%26aufirst%3DV.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26atitle%3DRimonabant%253A%2520from%2520RIO%2520to%2520ban%26jtitle%3DJ.%2520Obes.%26date%3D2011%26volume%3D2011%26spage%3D432607%26doi%3D10.1155%2F2011%2F432607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beal, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yangco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plasse, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, K. V.</span></span> <span> </span><span class="NLM_article-title">Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS</span>. <i>J. Pain Symptom Manage.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/0885-3924(94)00117-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2F0885-3924%2894%2900117-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=7730690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADyaK2M3kvVWluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1995&pages=89-97&author=J.+E.+Bealauthor=R.+Olsonauthor=L.+Laubensteinauthor=J.+O.+Moralesauthor=P.+Bellmanauthor=B.+Yangcoauthor=L.+Lefkowitzauthor=T.+F.+Plasseauthor=K.+V.+Shepard&title=Dronabinol+as+a+treatment+for+anorexia+associated+with+weight+loss+in+patients+with+AIDS&doi=10.1016%2F0885-3924%2894%2900117-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS</span></div><div class="casAuthors">Beal J E; Olson R; Laubenstein L; Morales J O; Bellman P; Yangco B; Lefkowitz L; Plasse T F; Shepard K V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pain and symptom management</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-97</span>
        ISSN:<span class="NLM_cas:issn">0885-3924</span>.
    </div><div class="casAbstract">The effects of dronabinol on appetite and weight were evaluated in 139 patients with AIDS-related anorexia and > or = 2.3 kg weight loss in a multi-institutional study.  Patients were randomized to receive 2.5 mg dronabinol twice daily or placebo.  Patients rated appetite, mood, and nausea by using a 100-mm visual analogue scale 3 days weekly.  Efficacy was evaluable in 88 patients.  Dronabinol was associated with increased appetite above baseline (38% vs 8% for placebo, P = 0.015), improvement in mood (10% vs -2%, P = 0.06), and decreased nausea (20% vs 7%; P = 0.05).  Weight was stable in dronabinol patients, while placebo recipients had a mean loss of 0.4 kg (P = 0.14).  Of the dronabinol patients, 22% gained > or = 2 kg, compared with 10.5% of placebo recipients (P = 0.11).  Side effects were mostly mild to moderate in severity (euphoria, dizziness, thinking abnormalities); there was no difference in discontinued therapy between dronabinol (8.3%) and placebo (4.5%) recipients.  Dronabinol was found to be safe and effective for anorexia associated with weight loss in patients with AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1ELU2l20LmzdblLE_E9PWfW6udTcc2ebYa1BqXOS_srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3kvVWluw%253D%253D&md5=d1fa3546d61c4151d74607a321db1fc8</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2F0885-3924%2894%2900117-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0885-3924%252894%252900117-4%26sid%3Dliteratum%253Aachs%26aulast%3DBeal%26aufirst%3DJ.%2BE.%26aulast%3DOlson%26aufirst%3DR.%26aulast%3DLaubenstein%26aufirst%3DL.%26aulast%3DMorales%26aufirst%3DJ.%2BO.%26aulast%3DBellman%26aufirst%3DP.%26aulast%3DYangco%26aufirst%3DB.%26aulast%3DLefkowitz%26aufirst%3DL.%26aulast%3DPlasse%26aufirst%3DT.%2BF.%26aulast%3DShepard%26aufirst%3DK.%2BV.%26atitle%3DDronabinol%2520as%2520a%2520treatment%2520for%2520anorexia%2520associated%2520with%2520weight%2520loss%2520in%2520patients%2520with%2520AIDS%26jtitle%3DJ.%2520Pain%2520Symptom%2520Manage.%26date%3D1995%26volume%3D10%26spage%3D89%26epage%3D97%26doi%3D10.1016%2F0885-3924%2894%2900117-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badowski, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanful, P. K.</span></span> <span> </span><span class="NLM_article-title">Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S126849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2147%2FTCRM.S126849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29670357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKlu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=643-651&author=M.+E.+Badowskiauthor=P.+K.+Yanful&title=Dronabinol+oral+solution+in+the+management+of+anorexia+and+weight+loss+in+AIDS+and+cancer&doi=10.2147%2FTCRM.S126849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer</span></div><div class="casAuthors">Badowski, Melissa E.; Yanful, Paa Kwesi</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">643-651</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The true incidence of anorexia secondary to human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and cancer is not well classified owing to the fact that there is a lack of standardized definitions and recent clin. data in these settings.  Dronabinol, or Δ-9-tetrahydrocannabinol, is a synthetic mol. that closely mimics the action of Cannabis sativa L., a naturally occurring compd. activated in the central nervous system by cannabinoid receptors.  Dronabinol exerts its effects by directly acting on the vomiting and appetite control centers in the brain, which in turn increases appetite and prevents vomiting.  In the USA, dronabinol is currently available in two dosage formulations - oral capsule and oral soln.  While the oral capsule was initially approved by the US Food and Drug Administration in 1985, the recent approval of the oral soln. in 2016 presents an "easy-to-swallow" alternative for patients using or intending to use dronabinol.  Dronabinol is indicated in adult patients with HIV/AIDS for the treatment of anorexia and wt. loss.  However, there is no approved indication in the setting of cancer-related anorexia and wt. loss.  This review aims at presenting available data on the use of oral dronabinol in the management of anorexia and wt. loss in HIV/AIDS and cancer, as well as characterizing and highlighting the pharmaco-therapeutic considerations of the newest formulation of dronabinol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9hcSlGt-jtbVg90H21EOLACvtfcHk0lgDTKiF4gkzIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKlu77J&md5=aebbe7ff76bcc9f93490727b707d6a3a</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S126849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S126849%26sid%3Dliteratum%253Aachs%26aulast%3DBadowski%26aufirst%3DM.%2BE.%26aulast%3DYanful%26aufirst%3DP.%2BK.%26atitle%3DDronabinol%2520oral%2520solution%2520in%2520the%2520management%2520of%2520anorexia%2520and%2520weight%2520loss%2520in%2520AIDS%2520and%2520cancer%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2018%26volume%3D14%26spage%3D643%26epage%3D651%26doi%3D10.2147%2FTCRM.S126849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pergolizzi, J. V.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeQuang, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampogna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, R. B.</span></span> <span> </span><span class="NLM_article-title">Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1007/s00280-017-3257-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00280-017-3257-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28235999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVGnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2017&pages=467-477&author=J.+V.+Pergolizziauthor=R.+Taylorauthor=J.+A.+LeQuangauthor=G.+Zampognaauthor=R.+B.+Raffa&title=Concise+review+of+the+management+of+iatrogenic+emesis+using+cannabinoids%3A+emphasis+on+nabilone+for+chemotherapy-induced+nausea+and+vomiting&doi=10.1007%2Fs00280-017-3257-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Pergolizzi, Joseph V., Jr.; Taylor, Robert; Le Quang, Jo Ann; Zampogna, Gianpietro; Raffa, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">467-477</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Chemotherapy-induced nausea and vomiting (CINV) is a prevalent, distressing, and burdensome side effect of cancer chemotherapy.  It is estd. to affect the majority of patients receiving certain anti-cancer drug regimens and can be treatment-limiting, even for life-saving medications.  Despite seemingly numerous options, such as antimuscarinic anticholinergics, antihistamines, 5-HT3 receptor antagonists, dopamine receptor antagonists, and neurokinin-1 receptor antagonists, preventative therapies are often inadequately effective, particularly for "delayed CINV"-leaving an important unmet clin. need.  Cannabinoid receptor agonists, by virtue of their unique mechanism of action and efficacy and safety data reported in clin. trials, appear to offer a useful addnl. option.  The mechanistic value of cannabinoids has been well known for many years, but these agents may have been underutilized in the past because of the notoriety and legal status of marijuana.  While botanical marijuana contains nearly 500 components, including the psychoactive tetrahydrocannabinol (THC), nabilone is an established, single-entity synthetic cannabinoid receptor agonist that has become the focus of renewed interest.  We review the basic pharmacol. and clin. trial data of nabilone for use in prophylaxis and treatment of CINV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOLNktdc8JTrVg90H21EOLACvtfcHk0lhFfZcoi6gGEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVGnt70%253D&md5=d23853821db49c80c62166d8787b7beb</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs00280-017-3257-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-017-3257-1%26sid%3Dliteratum%253Aachs%26aulast%3DPergolizzi%26aufirst%3DJ.%2BV.%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DLeQuang%26aufirst%3DJ.%2BA.%26aulast%3DZampogna%26aufirst%3DG.%26aulast%3DRaffa%26aufirst%3DR.%2BB.%26atitle%3DConcise%2520review%2520of%2520the%2520management%2520of%2520iatrogenic%2520emesis%2520using%2520cannabinoids%253A%2520emphasis%2520on%2520nabilone%2520for%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2017%26volume%3D79%26spage%3D467%26epage%3D477%26doi%3D10.1007%2Fs00280-017-3257-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novotna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mares, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratcliffe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapletalova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzilli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cefaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelmasiak, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis</span>. <i>Eur. J. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1111/j.1468-1331.2010.03328.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1468-1331.2010.03328.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21362108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC3MfltlehsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1122-1131&author=A.+Novotnaauthor=J.+Maresauthor=S.+Ratcliffeauthor=I.+Novakovaauthor=M.+Vachovaauthor=O.+Zapletalovaauthor=C.+Gasperiniauthor=C.+Pozzilliauthor=L.+Cefaroauthor=G.+Comiauthor=P.+Rossiauthor=Z.+Amblerauthor=Z.+Stelmasiakauthor=A.+Erdmannauthor=X.+Montalbanauthor=A.+Klimekauthor=P.+Davies&title=A+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel-group%2C+enriched-design+study+of+nabiximols*+%28Sativex%29%2C+as+add-on+therapy%2C+in+subjects+with+refractory+spasticity+caused+by+multiple+sclerosis&doi=10.1111%2Fj.1468-1331.2010.03328.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis</span></div><div class="casAuthors">Novotna A; Mares J; Ratcliffe S; Novakova I; Vachova M; Zapletalova O; Gasperini C; Pozzilli C; Cefaro L; Comi G; Rossi P; Ambler Z; Stelmasiak Z; Erdmann A; Montalban X; Klimek A; Davies P</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1122-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:    Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition.  We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design.  METHODS:    A 19-week follow-up, multicentre, double-blind, randomized, placebo-controlled, parallel-group study in subjects with multiple sclerosis spasticity not fully relieved with current antispasticity therapy.  Subjects were treated with nabiximols, as add-on therapy, in a single-blind manner for 4weeks, after which those achieving an improvement in spasticity of ≥20% progressed to a 12-week randomized, placebo-controlled phase.  RESULTS:    Of the 572 subjects enrolled, 272 achieved a ≥20% improvement after 4weeks of single-blind treatment, and 241 were randomized.  The primary end-point was the difference between treatments in the mean spasticity Numeric Rating Scale (NRS) in the randomized, controlled phase of the study.  Intention-to-treat (ITT) analysis showed a highly significant difference in favour of nabiximols (P=0.0002).  Secondary end-points of responder analysis, Spasm Frequency Score, Sleep Disturbance NRS Patient, Carer and Clinician Global Impression of Change were all significant in favour of nabiximols.  CONCLUSIONS:    The enriched study design provides a method of determining the efficacy and safety of nabiximols in a way that more closely reflects proposed clinical practice, by limiting exposure to those patients who are likely to benefit from it.  Hence, the difference between active and placebo should be a reflection of efficacy and safety in the population intended for treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWbubnBKIFBK-9TkgmBqTqfW6udTcc2ebW8nrgfFJibLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfltlehsA%253D%253D&md5=c9b0a9c9f24acfed4b383390f77dd9cd</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1331.2010.03328.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1331.2010.03328.x%26sid%3Dliteratum%253Aachs%26aulast%3DNovotna%26aufirst%3DA.%26aulast%3DMares%26aufirst%3DJ.%26aulast%3DRatcliffe%26aufirst%3DS.%26aulast%3DNovakova%26aufirst%3DI.%26aulast%3DVachova%26aufirst%3DM.%26aulast%3DZapletalova%26aufirst%3DO.%26aulast%3DGasperini%26aufirst%3DC.%26aulast%3DPozzilli%26aufirst%3DC.%26aulast%3DCefaro%26aufirst%3DL.%26aulast%3DComi%26aufirst%3DG.%26aulast%3DRossi%26aufirst%3DP.%26aulast%3DAmbler%26aufirst%3DZ.%26aulast%3DStelmasiak%26aufirst%3DZ.%26aulast%3DErdmann%26aufirst%3DA.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DKlimek%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DP.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel-group%252C%2520enriched-design%2520study%2520of%2520nabiximols%252A%2520%2528Sativex%2529%252C%2520as%2520add-on%2520therapy%252C%2520in%2520subjects%2520with%2520refractory%2520spasticity%2520caused%2520by%2520multiple%2520sclerosis%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2011%26volume%3D18%26spage%3D1122%26epage%3D1131%26doi%3D10.1111%2Fj.1468-1331.2010.03328.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devinsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verducci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filloux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szaflarski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzer, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wechsler, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, D.</span></span> <span> </span><span class="NLM_article-title">Open-label use of highly purified CBD (Epidiolex) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes</span>. <i>Epilepsy Behav.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/j.yebeh.2018.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.yebeh.2018.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30006259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FotVSqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2018&pages=131-137&author=O.+Devinskyauthor=C.+Verducciauthor=E.+A.+Thieleauthor=L.+C.+Lauxauthor=A.+D.+Patelauthor=F.+Fillouxauthor=J.+P.+Szaflarskiauthor=A.+Wilfongauthor=G.+D.+Clarkauthor=Y.+D.+Parkauthor=L.+E.+Seltzerauthor=E.+M.+Bebinauthor=R.+Flaminiauthor=R.+T.+Wechslerauthor=D.+Friedman&title=Open-label+use+of+highly+purified+CBD+%28Epidiolex%29+in+patients+with+CDKL5+deficiency+disorder+and+Aicardi%2C+Dup15q%2C+and+Doose+syndromes&doi=10.1016%2Fj.yebeh.2018.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes</span></div><div class="casAuthors">Devinsky Orrin; Verducci Chloe; Friedman Daniel; Thiele Elizabeth A; Laux Linda C; Patel Anup D; Filloux Francis; Szaflarski Jerzy P; Wilfong Angus; Clark Gary D; Park Yong D; Seltzer Laurie E; Bebin E Martina; Flamini Robert; Wechsler Robert T</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy & behavior : E&B</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">131-137</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  We studied our collective open-label, compassionate use experience in using cannabidiol (CBD) to treat epilepsy in patients with CDKL5 deficiency disorder and Aicardi, Doose, and Dup15q syndromes.  METHODS:  We included patients aged 1-30 years with severe childhood-onset epilepsy who received CBD for ≥10 weeks as part of multiple investigator-initiated expanded access or state access programs for a compassionate prospective interventional study: CDKL5 deficiency disorder (n = 20), Aicardi syndrome (n = 19), Dup15q syndrome (n = 8), and Doose syndrome (n = 8).  These patients were treated at 11 institutions from January 2014 to December 2016.  RESULTS:  The percent change in median convulsive seizure frequency for all patients taking CBD in the efficacy group decreased from baseline [n = 46] to week 12 (51.4% [n = 35], interquartile range (IQR): 9-85%) and week 48 (59.1% [n = 27], IQR: 14-86%).  There was a significant difference between the percent changes in monthly convulsive seizure frequency during baseline and week 12, χ(2)(2) = 22.9, p = 0.00001, with no difference in seizure percent change between weeks 12 and 48.  Of the 55 patients in the safety group, 15 (27%) withdrew from extended observation by week 144: 4 due to adverse effects, 9 due to lack of efficacy, 1 withdrew consent, and 1 was lost to follow-up.  SIGNIFICANCE:  This open-label drug trial provides class III evidence for the long-term safety and efficacy of CBD administration in patients with treatment-resistant epilepsy (TRE) associated with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.  Adjuvant therapy with CBD showed similar safety and efficacy for these four syndromes as reported in a diverse population of TRE etiologies.  This study extended analysis of the prior report from 12 weeks to 48 weeks of efficacy data and suggested that placebo-controlled randomized trials should be conducted to formally assess the safety and efficacy of CBD in these epileptic encephalopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAJZ0hazDFZrFU0A1HOshhfW6udTcc2ebW8nrgfFJibLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FotVSqsA%253D%253D&md5=65776f247230dd73a7696bce00f9f034</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.yebeh.2018.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yebeh.2018.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DDevinsky%26aufirst%3DO.%26aulast%3DVerducci%26aufirst%3DC.%26aulast%3DThiele%26aufirst%3DE.%2BA.%26aulast%3DLaux%26aufirst%3DL.%2BC.%26aulast%3DPatel%26aufirst%3DA.%2BD.%26aulast%3DFilloux%26aufirst%3DF.%26aulast%3DSzaflarski%26aufirst%3DJ.%2BP.%26aulast%3DWilfong%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%2BD.%26aulast%3DPark%26aufirst%3DY.%2BD.%26aulast%3DSeltzer%26aufirst%3DL.%2BE.%26aulast%3DBebin%26aufirst%3DE.%2BM.%26aulast%3DFlamini%26aufirst%3DR.%26aulast%3DWechsler%26aufirst%3DR.%2BT.%26aulast%3DFriedman%26aufirst%3DD.%26atitle%3DOpen-label%2520use%2520of%2520highly%2520purified%2520CBD%2520%2528Epidiolex%2529%2520in%2520patients%2520with%2520CDKL5%2520deficiency%2520disorder%2520and%2520Aicardi%252C%2520Dup15q%252C%2520and%2520Doose%2520syndromes%26jtitle%3DEpilepsy%2520Behav.%26date%3D2018%26volume%3D86%26spage%3D131%26epage%3D137%26doi%3D10.1016%2Fj.yebeh.2018.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span>Artelo
BIOSCIENCES. <a href="http://artelobio.com/pipeline" class="extLink">http://artelobio.com/pipeline</a> (accessed Oct 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Artelo%0ABIOSCIENCES.+http%3A%2F%2Fartelobio.com%2Fpipeline+%28accessed+Oct+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span>CORBUS
Pharmaceuticals. <a href="https://www.corbuspharma.com/our-science/crb-4001" class="extLink">https://www.corbuspharma.com/our-science/crb-4001</a> (accessed Oct 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CORBUS%0APharmaceuticals.+https%3A%2F%2Fwww.corbuspharma.com%2Four-science%2Fcrb-4001+%28accessed+Oct+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kale, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zmarowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparrow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorospe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorvat, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terse, P. S.</span></span> <span> </span><span class="NLM_article-title">Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">104483</span>, <span class="refDoi"> DOI: 10.1016/j.yrtph.2019.104483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.yrtph.2019.104483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31580887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCktrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2019&pages=104483&author=V.+P.+Kaleauthor=S.+Gibbsauthor=J.+A.+Taylorauthor=A.+Zmarowskiauthor=J.+Novakauthor=K.+Pattonauthor=B.+Sparrowauthor=J.+Gorospeauthor=S.+Anandauthor=R.+Cinarauthor=G.+Kunosauthor=R.+J.+Chorvatauthor=P.+S.+Terse&title=Preclinical+toxicity+evaluation+of+JD5037%2C+a+peripherally+restricted+CB1+receptor+inverse+agonist%2C+in+rats+and+dogs+for+treatment+of+nonalcoholic+steatohepatitis&doi=10.1016%2Fj.yrtph.2019.104483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis</span></div><div class="casAuthors">Kale, Vijay Pralhad; Gibbs, Seth; Taylor, John A.; Zmarowski, Amy; Novak, Joseph; Patton, Kristin; Sparrow, Barney; Gorospe, Jenni; Anand, Satheesh; Cinar, Resat; Kunos, George; Chorvat, Robert J.; Terse, Pramod S.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104483</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">JD5037 is a novel peripherally restricted CB1 receptor (CB1R) inverse agonist being developed for the treatment of visceral obesity and its metabolic complications, including nonalcoholic fatty liver disease and dyslipidemia.  JD5037 was administered by oral gavage at 10, 40, and 150 mg/kg/day dose levels for up to 34 days to Sprague Dawley rats, and at 5, 20, and 75 mg/kg/day dose levels for 28 consecutive days to Beagle dogs.  In rats, higher incidences of stereotypic behaviors were obsd. in 10 mg/kg females and 40 mg/kg males, and slower responses for reflex and sensory tests were obsd. only in males at 10 and 40 mg/kg during neurobehavioral testing.  Sporadic minimal incidences of decreased activity (males) and seizures (both sexes) were obsd. in rats during daily clin. observations, without any clear dose-relationship.  Male dogs at 75 mg/kg during treatment period, but not recovery period, had an increased incidence of gut assocd. lymphoid tissue hyperplasia and inflammation in the intestine.  In both species, highest dose resulted in lower AUCs indicative of non-linear kinetics.  Free access to food increased the plasma AUC∞ by ∼4.5-fold at 20 mg/kg in dogs, suggesting presence of food may help in systemic absorption of JD5037 in dogs.  Based on the study results, 150 mg/kg/day in rats, and 20 and 75 mg/kg/day doses in male and female dogs, resp., were detd. to be the no-obsd.-adverse-effect-levels (NOAELs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtyXBEwV_5Z7Vg90H21EOLACvtfcHk0lg0ula67eVAeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCktrjM&md5=680bce0e87639dc009d7bdd541b42e88</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2019.104483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2019.104483%26sid%3Dliteratum%253Aachs%26aulast%3DKale%26aufirst%3DV.%2BP.%26aulast%3DGibbs%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DJ.%2BA.%26aulast%3DZmarowski%26aufirst%3DA.%26aulast%3DNovak%26aufirst%3DJ.%26aulast%3DPatton%26aufirst%3DK.%26aulast%3DSparrow%26aufirst%3DB.%26aulast%3DGorospe%26aufirst%3DJ.%26aulast%3DAnand%26aufirst%3DS.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DTerse%26aufirst%3DP.%2BS.%26atitle%3DPreclinical%2520toxicity%2520evaluation%2520of%2520JD5037%252C%2520a%2520peripherally%2520restricted%2520CB1%2520receptor%2520inverse%2520agonist%252C%2520in%2520rats%2520and%2520dogs%2520for%2520treatment%2520of%2520nonalcoholic%2520steatohepatitis%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2019%26volume%3D109%26spage%3D104483%26doi%3D10.1016%2Fj.yrtph.2019.104483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maresz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponomarev, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittel, B. N.</span></span> <span> </span><span class="NLM_article-title">Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2005.03380.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1471-4159.2005.03380.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16086683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFegu7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2005&pages=437-445&author=K.+Mareszauthor=E.+J.+Carrierauthor=E.+D.+Ponomarevauthor=C.+J.+Hillardauthor=B.+N.+Dittel&title=Modulation+of+the+cannabinoid+CB2+receptor+in+microglial+cells+in+response+to+inflammatory+stimuli&doi=10.1111%2Fj.1471-4159.2005.03380.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli</span></div><div class="casAuthors">Maresz, Katarzyna; Carrier, Erica J.; Ponomarev, Eugene D.; Hillard, Cecilia J.; Dittel, Bonnie N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">437-445</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The cannabinoid system is known to be important in neuronal regulation, but is also capable of modulating immune function.  Although the CNS resident microglial cells have been shown to express the CB2 subtype of cannabinoid receptor during non-immune-mediated pathol. conditions, little is known about the expression of the cannabinoid system during immune-mediated CNS pathol.  To examine this question, the authors measured CB2 receptor mRNA expression in the CNS of mice with exptl. autoimmune encephalomyelitis (EAE) and, by real-time PCR, found a 100-fold increase in CB2 receptor mRNA expression during EAE onset.  The authors next detd. whether microglial cells specifically express the CB2 receptor during EAE, and found that activated microglial cells expressed 10-fold more CB2 receptor than microglia in the resting state.  To det. the signals required for the up-regulation of the CB2 receptor, the authors cultured microglial cells with combinations of γ-interferon (IFN-γ) and granulocyte) macrophage-colony stimulating factor (GM-CSF), which both promote microglial cell activation and are expressed in the CNS during EAE, and found that they synergized, resulting in an eight to 10-fold increase in the CB2 receptor.  The authors found no difference in the amt. of the CB2 receptor ligand, 2-arachidonylglycerol (2-AG), in the spinal cord during EAE.  These data demonstrate that microglial cell activation is accompanied by CB2 receptor up-regulation, suggesting that this receptor plays an important role in microglial cell function in the CNS during autoimmune-induced inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9PXl5k5Q8SbVg90H21EOLACvtfcHk0lg0ula67eVAeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFegu7jM&md5=a7c0e744aa03f3769eddc96c6dfc81dc</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2005.03380.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2005.03380.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaresz%26aufirst%3DK.%26aulast%3DCarrier%26aufirst%3DE.%2BJ.%26aulast%3DPonomarev%26aufirst%3DE.%2BD.%26aulast%3DHillard%26aufirst%3DC.%2BJ.%26aulast%3DDittel%26aufirst%3DB.%2BN.%26atitle%3DModulation%2520of%2520the%2520cannabinoid%2520CB2%2520receptor%2520in%2520microglial%2520cells%2520in%2520response%2520to%2520inflammatory%2520stimuli%26jtitle%3DJ.%2520Neurochem.%26date%3D2005%26volume%3D95%26spage%3D437%26epage%3D445%26doi%3D10.1111%2Fj.1471-4159.2005.03380.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano-Cabral, F.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptors in microglia of the central nervous system: immune functional relevance</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1192</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1189/jlb.0405216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1189%2Fjlb.0405216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16204639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtleksL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2005&pages=1192-1197&author=G.+Cabralauthor=F.+Marciano-Cabral&title=Cannabinoid+receptors+in+microglia+of+the+central+nervous+system%3A+immune+functional+relevance&doi=10.1189%2Fjlb.0405216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors in microglia of the central nervous system: Immune functional relevance</span></div><div class="casAuthors">Cabral, G. A.; Marciano-Cabral, F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1192-1197</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Microglia, resident macrophages of the brain, function as immune effector and accessory cells.  Paradoxically, they not only play a role in host defense and tissue repair but also have been implicated in a variety of neuropathol. processes.  Microglia, in addn. to exhibiting phenotypic markers for macrophages, express CB1 and CB2 cannabinoid receptors.  Recent studies suggest the existence of a third, yet-to-be cloned, non-CB1, non-CB2 cannabinoid receptor.  These receptors appear to be functionally relevant within defined windows of microglial activation state and have been implicated as linked to cannabinoid modulation of chemokine and cytokine expression.  The recognition that microglia express cannabinoid receptors and that their activation results in modulation of select cellular activities suggests that they may be amenable to therapeutic manipulation for ablating untoward inflammatory responses in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXknErGXGXdLVg90H21EOLACvtfcHk0lg0ula67eVAeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtleksL3L&md5=c856712600eb54f8d8a1482626fb6c7c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0405216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0405216%26sid%3Dliteratum%253Aachs%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DMarciano-Cabral%26aufirst%3DF.%26atitle%3DCannabinoid%2520receptors%2520in%2520microglia%2520of%2520the%2520central%2520nervous%2520system%253A%2520immune%2520functional%2520relevance%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2005%26volume%3D78%26spage%3D1192%26epage%3D1197%26doi%3D10.1189%2Fjlb.0405216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolon, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 receptors in human brain inflammation</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fsj.bjp.0707505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17934510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFCktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=277-285&author=C.+Benitoauthor=R.+M.+Tolonauthor=M.+R.+Pazosauthor=E.+Nunezauthor=A.+I.+Castilloauthor=J.+Romero&title=Cannabinoid+CB2+receptors+in+human+brain+inflammation&doi=10.1038%2Fsj.bjp.0707505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors in human brain inflammation</span></div><div class="casAuthors">Benito, C.; Tolon, R. M.; Pazos, M. R.; Nunez, E.; Castillo, A. I.; Romero, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-285</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The presence of functional cannabinoid CB2 receptors in the CNS has provoked considerable controversy over the past few years.  Formerly considered as an exclusively peripheral receptor, it is now accepted that it is also present in limited amts. and distinct locations in the brain of several animal species, including humans.  Furthermore, the inducible nature of these receptors under neuroinflammatory conditions, in contrast to CB1, makes them attractive targets for the development of novel therapeutic approaches.  In fact, the undesired psychoactive effects caused by CB1 activation have largely limited the clin. use of cannabinoid-related compds. that act on these receptors.  In this review some recent findings on the antiinflammatory properties of CB2 receptors are presented, as well as new perspectives that have been obtained based on studies of human postmortem brain samples.  In addn., various working hypotheses are also proposed and discussed.  British Journal of Pharmacol. (2008) 153, 277-285; doi:10.1038/sj.bjp.0707505; published online 15 Oct. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy1sC3kUak-7Vg90H21EOLACvtfcHk0ljuRdoloU6jeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFCktg%253D%253D&md5=acc7f2244e1db16d66e5953eadecb381</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707505%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DC.%26aulast%3DTolon%26aufirst%3DR.%2BM.%26aulast%3DPazos%26aufirst%3DM.%2BR.%26aulast%3DNunez%26aufirst%3DE.%26aulast%3DCastillo%26aufirst%3DA.%2BI.%26aulast%3DRomero%26aufirst%3DJ.%26atitle%3DCannabinoid%2520CB2%2520receptors%2520in%2520human%2520brain%2520inflammation%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D277%26epage%3D285%26doi%3D10.1038%2Fsj.bjp.0707505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchet, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laviolette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamand, N.</span></span> <span> </span><span class="NLM_article-title">The CB2 receptor and its role as a regulator of inflammation</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4449</span>– <span class="NLM_lpage">4470</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2300-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00018-016-2300-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27402121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCrtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=4449-4470&author=C.+Turcotteauthor=M.+R.+Blanchetauthor=M.+Lavioletteauthor=N.+Flamand&title=The+CB2+receptor+and+its+role+as+a+regulator+of+inflammation&doi=10.1007%2Fs00018-016-2300-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The CB2 receptor and its role as a regulator of inflammation</span></div><div class="casAuthors">Turcotte, Caroline; Blanchet, Marie-Renee; Laviolette, Michel; Flamand, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4449-4470</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">The CB2 receptor is the peripheral receptor for cannabinoids.  It is mainly expressed in immune tissues, highlighting the possibility that the endocannabinoid system has an immunomodulatory role.  In this respect, the CB2 receptor was shown to modulate immune cell functions, both in cellulo and in animal models of inflammatory diseases.  In this regard, numerous studies have reported that mice lacking the CB2 receptor have an exacerbated inflammatory phenotype.  This suggests that therapeutic strategies aiming at modulating CB2 signaling could be promising for the treatment of various inflammatory conditions.  Herein, we review the pharmacol. of the CB2 receptor, its expression pattern, and the signaling pathways induced by its activation.  We next examine the regulation of immune cell functions by the CB2 receptor and the evidence obtained from primary human cells, immortalized cell lines, and animal models of inflammation.  Finally, we discuss the possible therapies targeting the CB2 receptor and the questions that remain to be addressed to det. whether this receptor could be a potential target to treat inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa70FJsUK5IbVg90H21EOLACvtfcHk0ljuRdoloU6jeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCrtLrN&md5=572eaca44428863b1c69dde0bca87662</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2300-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2300-4%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DC.%26aulast%3DBlanchet%26aufirst%3DM.%2BR.%26aulast%3DLaviolette%26aufirst%3DM.%26aulast%3DFlamand%26aufirst%3DN.%26atitle%3DThe%2520CB2%2520receptor%2520and%2520its%2520role%2520as%2520a%2520regulator%2520of%2520inflammation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D4449%26epage%3D4470%26doi%3D10.1007%2Fs00018-016-2300-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capparelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span> <span> </span><span class="NLM_article-title">Perspectives of cannabinoid type 2 receptor (CB2R) ligands in neurodegenerative disorders: structure-affinity relationship (SAfiR) and structure-activity relationship (SAR) studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9913</span>– <span class="NLM_lpage">9931</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9913-9931&author=F.+Spinelliauthor=E.+Capparelliauthor=C.+Abateauthor=N.+A.+Colabufoauthor=M.+Contino&title=Perspectives+of+cannabinoid+type+2+receptor+%28CB2R%29+ligands+in+neurodegenerative+disorders%3A+structure-affinity+relationship+%28SAfiR%29+and+structure-activity+relationship+%28SAR%29+studies&doi=10.1021%2Facs.jmedchem.7b00155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Spinelli, Francesco; Capparelli, Elena; Abate, Carmen; Colabufo, Nicola A.; Contino, Marialessandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9913-9931</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Up-regulation of CB2R on activated microglial cells, the first step in neurodegeneration, has been widely demonstrated, and this finding makes the receptor a promising target in the early diagnosis and treatment of several neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and multiple sclerosis (MS).  The development of CB2R PET ligands could help demonstrate the neurodegenerative pathogenesis, thus providing useful tools for characterizing the role of neuroinflammation in the progression of these disorders.  CB2R agonists and inverse agonists have emerged as neuroprotective agents and CB2R agonists have entered several clin. trials.  CB2R ligands have therefore received great attention and different mol. scaffolds have been selected to target CB2R subtypes.  This perspective is focused on structure-activity relationship (SAR) and structure-affinity relationship (SAfiR) studies performed on different scaffolds with the aim to identify the mol. features useful for the design of both therapeutic and diagnostic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy3g8MJz6QjbVg90H21EOLACvtfcHk0li8PeK1VcfoqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisbY%253D&md5=e4dfd58a0cb94a9d00203a8f32de43f8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00155%26sid%3Dliteratum%253Aachs%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DCapparelli%26aufirst%3DE.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DContino%26aufirst%3DM.%26atitle%3DPerspectives%2520of%2520cannabinoid%2520type%25202%2520receptor%2520%2528CB2R%2529%2520ligands%2520in%2520neurodegenerative%2520disorders%253A%2520structure-affinity%2520relationship%2520%2528SAfiR%2529%2520and%2520structure-activity%2520relationship%2520%2528SAR%2529%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9913%26epage%3D9931%26doi%3D10.1021%2Facs.jmedchem.7b00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T.</span></span> <span> </span><span class="NLM_article-title">Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid receptor ligands</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.2174/09298673113206660296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2174%2F09298673113206660296" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=187-203&author=T.+Nevalainen&title=Recent+development+of+CB2+selective+and+peripheral+CB1%2FCB2+cannabinoid+receptor+ligands&doi=10.2174%2F09298673113206660296"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2174%2F09298673113206660296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113206660296%26sid%3Dliteratum%253Aachs%26aulast%3DNevalainen%26aufirst%3DT.%26atitle%3DRecent%2520development%2520of%2520CB2%2520selective%2520and%2520peripheral%2520CB1%252FCB2%2520cannabinoid%2520receptor%2520ligands%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D187%26epage%3D203%26doi%3D10.2174%2F09298673113206660296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. Q.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the human cannabinoid receptor CB2-Gi signaling complex</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2020.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32004460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFequr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=645-654&author=C.+Xingauthor=Y.+Zhuangauthor=T.+H.+Xuauthor=Z.+Fengauthor=X.+E.+Zhouauthor=M.+Chenauthor=L.+Wangauthor=X.+Mengauthor=Y.+Xueauthor=J.+Wangauthor=H.+Liuauthor=T.+F.+McGuireauthor=G.+Zhaoauthor=K.+Melcherauthor=C.+Zhangauthor=H.+E.+Xuauthor=X.+Q.+Xie&title=Cryo-EM+structure+of+the+human+cannabinoid+receptor+CB2-Gi+signaling+complex&doi=10.1016%2Fj.cell.2020.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex</span></div><div class="casAuthors">Xing, Changrui; Zhuang, Youwen; Xu, Ting-Hai; Feng, Zhiwei; Zhou, X. Edward; Chen, Maozi; Wang, Lei; Meng, Xing; Xue, Ying; Wang, Junmei; Liu, Heng; McGuire, Terence Francis; Zhao, Gongpu; Melcher, Karsten; Zhang, Cheng; Xu, H. Eric; Xie, Xiang-Qun</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">645-654.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drugs selectively targeting CB2 hold promise for treating neurodegenerative disorders, inflammation, and pain while avoiding psychotropic side effects mediated by CB1.  The mechanisms underlying CB2 activation and signaling are poorly understood but crit. for drug design.  Here we report the cryo-EM structure of the human CB2-Gi signaling complex bound to the agonist WIN 55,212-2.  The 3D structure reveals the binding mode of WIN 55,212-2 and structural determinants for distinguishing CB2 agonists from antagonists, which are supported by a pair of rationally designed agonist and antagonist.  Further structural analyses with computational docking results uncover the differences between CB2 and CB1 in receptor activation, ligand recognition, and Gi coupling.  These findings are expected to facilitate rational structure-based discovery of drugs targeting the cannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxe6yMtfE8RbVg90H21EOLACvtfcHk0li8PeK1VcfoqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFequr8%253D&md5=2c54b7bd90e2f9b33b141adb36e57688</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DC.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DT.%2BH.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DX.%2BE.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMcGuire%26aufirst%3DT.%2BF.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DH.%2BE.%26aulast%3DXie%26aufirst%3DX.%2BQ.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB2-Gi%2520signaling%2520complex%26jtitle%3DCell%26date%3D2020%26volume%3D180%26spage%3D645%26epage%3D654%26doi%3D10.1016%2Fj.cell.2020.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span>ARENA
Pharmaceuticals. <a href="https://www.arenapharm.com/pipeline/apd371/#" class="extLink">https://www.arenapharm.com/pipeline/apd371/#</a> (accessed Oct 8, 2010).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ARENA%0APharmaceuticals.+https%3A%2F%2Fwww.arenapharm.com%2Fpipeline%2Fapd371%2F%23+%28accessed+Oct+8%2C+2010%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musachio, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of [<sup>18</sup>F]SR144385: A selective radioligand for positron emission tomographic studies of brain cannabinoid receptors</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1099-1344(199906)42:6<589::AID-JLCR219>3.0.CO;2-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2F%28SICI%291099-1344%28199906%2942%3A6%3C589%3A%3AAID-JLCR219%3E3.0.CO%3B2-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK1MXjvVKitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=589-596&author=W.+B.+Mathewsauthor=H.+T.+Ravertauthor=J.+L.+Musachioauthor=R.+A.+Frankauthor=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=R.+F.+Dannals&title=Synthesis+of+%5B18F%5DSR144385%3A+A+selective+radioligand+for+positron+emission+tomographic+studies+of+brain+cannabinoid+receptors&doi=10.1002%2F%28SICI%291099-1344%28199906%2942%3A6%3C589%3A%3AAID-JLCR219%3E3.0.CO%3B2-B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of [18F] SR144385: a selective radioligand for positron emission tomographic studies of brain cannabinoid receptors</span></div><div class="casAuthors">Mathews, William B.; Ravert, Hayden T.; Musachio, John L.; Frank, Richard A.; Rinaldi-Carmona, Murielle; Barth, Francis; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds & Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">589-596</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A cannabinoid receptor antagonist, SR144385, has been labeled with fluorine-18.  [18F] SR144385 was synthesized in a multi-step reaction in which fluorine-18 was introduced by nucleophilic halogen displacement on a bromo precursor.  The fluorine-18 labeled intermediate was deprotected and coupled with 1-aminopiperidine to give [18F] SR144385.  The time for radiosynthesis, HPLC purifn., and formulation was 2 h from end-of-bombardment.  [18F] SR144385 of high radiochem. purity was obtained at end-of-synthesis with an av. (n = 11) specific radioactivity of 1852 mCi/μmol and an av. isolated, non-decay cor. radiochem. yield of 4% from potassium [18F] fluoride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrenpEX6Zf6C7Vg90H21EOLACvtfcHk0lhuZC3-e67rDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvVKitro%253D&md5=cbf9d68fe17657cbd2b13dba4245ce92</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291099-1344%28199906%2942%3A6%3C589%3A%3AAID-JLCR219%3E3.0.CO%3B2-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291099-1344%2528199906%252942%253A6%253C589%253A%253AAID-JLCR219%253E3.0.CO%253B2-B%26sid%3Dliteratum%253Aachs%26aulast%3DMathews%26aufirst%3DW.%2BB.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DMusachio%26aufirst%3DJ.%2BL.%26aulast%3DFrank%26aufirst%3DR.%2BA.%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520of%2520%255B18F%255DSR144385%253A%2520A%2520selective%2520radioligand%2520for%2520positron%2520emission%2520tomographic%2520studies%2520of%2520brain%2520cannabinoid%2520receptors%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D1999%26volume%3D42%26spage%3D589%26epage%3D596%26doi%3D10.1002%2F%28SICI%291099-1344%28199906%2942%3A6%3C589%3A%3AAID-JLCR219%3E3.0.CO%3B2-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">Biodistribution of [<sup>18</sup>F] SR144385 and [<sup>18</sup>F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1016/S0969-8051(00)00152-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0969-8051%2800%2900152-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=11150708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVWltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=757-762&author=W.+B.+Mathewsauthor=U.+Scheffelauthor=P.+Finleyauthor=H.+T.+Ravertauthor=R.+A.+Frankauthor=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=R.+F.+Dannals&title=Biodistribution+of+%5B18F%5D+SR144385+and+%5B18F%5D+SR147963%3A+selective+radioligands+for+positron+emission+tomographic+studies+of+brain+cannabinoid+receptors&doi=10.1016%2FS0969-8051%2800%2900152-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors</span></div><div class="casAuthors">Mathews, W. B.; Scheffel, U.; Finley, P.; Ravert, H. T.; Frank, R. A.; Rinaldi-Carmona, M.; Barth, F.; Dannals, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">757-762</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">[18F]SR144385 and [18F]SR147963 were synthesized in a multistep reaction in which fluorine-18 was introduced by nucleophilic halogen displacement on a bromo precursor.  The fluorine-18-labeled intermediate was deprotected and coupled with the appropriate alkyl amine to give the final products.  Both radioligands had appropriate regional brain distribution for cannabinoid receptors with a target to nontarget ratio of 1.7 for [18F] SR147963 and 2.5 for [18F] SR144385 at 60 and 90 min postinjection, resp.  The uptake of both tracers was blocked with a 1 mg/kg dose of SR141716A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpar4_s-xCqsrVg90H21EOLACvtfcHk0lhuZC3-e67rDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVWltA%253D%253D&md5=74b77f6263aa1d057034a00153033434</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0969-8051%2800%2900152-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-8051%252800%252900152-9%26sid%3Dliteratum%253Aachs%26aulast%3DMathews%26aufirst%3DW.%2BB.%26aulast%3DScheffel%26aufirst%3DU.%26aulast%3DFinley%26aufirst%3DP.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DFrank%26aufirst%3DR.%2BA.%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DBiodistribution%2520of%2520%255B18F%255D%2520SR144385%2520and%2520%255B18F%255D%2520SR147963%253A%2520selective%2520radioligands%2520for%2520positron%2520emission%2520tomographic%2520studies%2520of%2520brain%2520cannabinoid%2520receptors%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2000%26volume%3D27%26spage%3D757%26epage%3D762%26doi%3D10.1016%2FS0969-8051%2800%2900152-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauseo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellames, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">Carbon-11 labeled radioligands for imaging brain cannabinoid receptors</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/S0969-8051(02)00308-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0969-8051%2802%2900308-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12234592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVeisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2002&pages=671-677&author=W.+B.+Mathewsauthor=U.+Scheffelauthor=P.+A.+Rauseoauthor=H.+T.+Ravertauthor=R.+A.+Frankauthor=G.+J.+Ellamesauthor=J.+M.+Herbertauthor=F.+Barthauthor=M.+Rinaldi-Carmonaauthor=R.+F.+Dannals&title=Carbon-11+labeled+radioligands+for+imaging+brain+cannabinoid+receptors&doi=10.1016%2FS0969-8051%2802%2900308-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Carbon-11 labeled radioligands for imaging brain cannabinoid receptors</span></div><div class="casAuthors">Mathews, William B.; Scheffel, Ursula; Rauseo, Paige A.; Ravert, Hayden T.; Frank, Richard A.; Ellames, George J.; Herbert, John M.; Barth, Francis; Rinaldi-Carmona, Murielle; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Two radioligands, [11C] SR149080 and its morpholino analog [11C] SR149568, were synthesized by reaction of the resp. phenolic precursors with [11C] Me iodide.  Both radioligands had appropriate regional brain distribution for cannabinoid receptors in mice with peak target to non-target ratios of 2.2 for [11C] SR149080 and 1.6 for [11C] SR149568 at 90 and 30 min post-injection resp.  The uptake of both tracers was blocked with a 1 mg/kg dose of SR141716A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJHhYCFQ1OybVg90H21EOLACvtfcHk0liR2wqtg0Q2cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVeisL8%253D&md5=975e6cd40f1731fa39fad1ebd2ddc428</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0969-8051%2802%2900308-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-8051%252802%252900308-6%26sid%3Dliteratum%253Aachs%26aulast%3DMathews%26aufirst%3DW.%2BB.%26aulast%3DScheffel%26aufirst%3DU.%26aulast%3DRauseo%26aufirst%3DP.%2BA.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DFrank%26aufirst%3DR.%2BA.%26aulast%3DEllames%26aufirst%3DG.%2BJ.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DCarbon-11%2520labeled%2520radioligands%2520for%2520imaging%2520brain%2520cannabinoid%2520receptors%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2002%26volume%3D29%26spage%3D671%26epage%3D677%26doi%3D10.1016%2FS0969-8051%2802%2900308-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 1-(2,4-dichlorophenyl)-4-cyano-5-(4-11C-methoxyphenyl)-N-(piperidin-1-y l)-1H-pyrazole-3-carboxamide (11C-JHU75528) and 1-(2bromophenyl)-4-cyano-5-(4- 11C methoxyphenyl)-N-(piperidin-1-yl)-1H -pyrazole-3-carboxamide ( 11C JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1002/jlcr.1125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjlcr.1125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12hu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1021-1036&author=H.+Fanauthor=H.+T.+Ravertauthor=D.+P.+Holtauthor=R.+F.+Dannalsauthor=A.+G.+Horti&title=Synthesis+of+1-%282%2C4-dichlorophenyl%29-4-cyano-5-%284-11C-methoxyphenyl%29-N-%28piperidin-1-y+l%29-1H-pyrazole-3-carboxamide+%2811C-JHU75528%29+and+1-%282bromophenyl%29-4-cyano-5-%284-+11C+methoxyphenyl%29-N-%28piperidin-1-yl%29-1H+-pyrazole-3-carboxamide+%28+11C+JHU75575%29+as+potential+radioligands+for+PET+imaging+of+cerebral+cannabinoid+receptor&doi=10.1002%2Fjlcr.1125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 1-(2,4-dichlorophenyl)-4-cyano-5-(4-[11C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([11C]JHU75528) and 1-(2-bromophenyl)-4-cyano-5-(4-[11C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([11C]JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor</span></div><div class="casAuthors">Fan, Hong; Ravert, Hayden T.; Holt, Daniel P.; Dannals, Robert F.; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1021-1036</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Two novel ligands for cerebral cannabinoid receptor (CB1), 1-(2,4-dichlorophenyl)-4-cyano-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (JHU75528) and 1-(2-bromophenyl)-4-cyano-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (JHU75575) have been synthesized.  Both JHU75528 and JHU75575 display a combination of higher binding affinity and lower lipophilicity than those of Rimonabant (SR141716), a high affinity CB1 selective antagonist, and AM281, the only available ligand for emission tomog. imaging of CB1 in human subjects.  Radiolabeled [11C]JHU75528 and [11C]JHU75575 were prepd. by reaction of [11C]methyl iodide with nor-Me precursors.  The av. radiochem. yield, specific radioactivity, and radiochem. purity of [11C]JHU75528 were 16%, 235 GBq/μmol (6360 mCi/μmol), and 99%, resp.; those of [11C]JHU75575 were 8%, 196 GBq/μmol (5308 mCi/μmol), and 99%, resp.  Both ligands hold promise as PET radioligands for imaging CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP3er6g9CD-bVg90H21EOLACvtfcHk0liR2wqtg0Q2cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12hu7zO&md5=d012863379858aa0eaa2e074ef4a0407</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.1125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.1125%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DH.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DHolt%26aufirst%3DD.%2BP.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DSynthesis%2520of%25201-%25282%252C4-dichlorophenyl%2529-4-cyano-5-%25284-11C-methoxyphenyl%2529-N-%2528piperidin-1-y%2520l%2529-1H-pyrazole-3-carboxamide%2520%252811C-JHU75528%2529%2520and%25201-%25282bromophenyl%2529-4-cyano-5-%25284-%252011C%2520methoxyphenyl%2529-N-%2528piperidin-1-yl%2529-1H%2520-pyrazole-3-carboxamide%2520%2528%252011C%2520JHU75575%2529%2520as%2520potential%2520radioligands%2520for%2520PET%2520imaging%2520of%2520cerebral%2520cannabinoid%2520receptor%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2006%26volume%3D49%26spage%3D1021%26epage%3D1036%26doi%3D10.1002%2Fjlcr.1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotsikorou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CBI): Development of ligands with optimized lipophilicity and binding affinity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.03.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejmech.2008.03.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18511157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlWjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=593-608&author=H.+Fanauthor=E.+Kotsikorouauthor=A.+F.+Hoffmanauthor=H.+T.+Ravertauthor=D.+Holtauthor=D.+P.+Hurstauthor=C.+R.+Lupicaauthor=P.+H.+Reggioauthor=R.+F.+Dannalsauthor=A.+G.+Horti&title=Analogs+of+JHU75528%2C+a+PET+ligand+for+imaging+of+cerebral+cannabinoid+receptors+%28CBI%29%3A+Development+of+ligands+with+optimized+lipophilicity+and+binding+affinity&doi=10.1016%2Fj.ejmech.2008.03.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): Development of ligands with optimized lipophilicity and binding affinity</span></div><div class="casAuthors">Fan, Hong; Kotsikorou, Evangelia; Hoffman, Alexander F.; Ravert, Hayden T.; Holt, Daniel; Hurst, Dow P.; Lupica, Carl R.; Reggio, Patricia H.; Dannals, Robert F.; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">593-608</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Cyano analogs of Rimonabant with high binding affinity for the cerebral cannabinoid receptor (CB1) and with optimized lipophilicity have been synthesized as potential positron emission tomog. (PET) ligands.  The best ligands of the series are optimal targets for the future radiolabeling with PET isotopes and in vivo evaluation as radioligands with enhanced properties for PET imaging of CB1 receptors in human subjects.  Extracellular electrophysiol. recordings in rodent brain slices demonstrated that JHU75528, 4, the lead compd. of the new series, has functional CB antagonist properties that are consistent with its structural relationship to Rimonabant.  Mol. modeling anal. revealed an important role of the binding of the cyano group with the CB1 binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOiNlgowGkprVg90H21EOLACvtfcHk0lg6i4RoF_oMbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlWjs74%253D&md5=556955be52dd2f5d1ba57fbbee84bce9</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.03.040%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DH.%26aulast%3DKotsikorou%26aufirst%3DE.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DHolt%26aufirst%3DD.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DAnalogs%2520of%2520JHU75528%252C%2520a%2520PET%2520ligand%2520for%2520imaging%2520of%2520cerebral%2520cannabinoid%2520receptors%2520%2528CBI%2529%253A%2520Development%2520of%2520ligands%2520with%2520optimized%2520lipophilicity%2520and%2520binding%2520affinity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D593%26epage%3D608%26doi%3D10.1016%2Fj.ejmech.2008.03.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1696</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17015906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKjtrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=1689-1696&author=A.+G.+Hortiauthor=H.+Fanauthor=H.+Kuwabaraauthor=J.+Hiltonauthor=H.+T.+Ravertauthor=D.+P.+Holtauthor=M.+Alexanderauthor=A.+Kumarauthor=A.+Rahmimauthor=U.+Scheffelauthor=D.+F.+Wongauthor=R.+F.+Dannals&title=11C-JHU75528%3A+a+radiotracer+for+PET+imaging+of+CB1+cannabinoid+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors</span></div><div class="casAuthors">Horti, Andrew G.; Fan, Hong; Kuwabara, Hiroto; Hilton, John; Ravert, Hayden T.; Holt, Daniel P.; Alexander, Mohab; Kumar, Anil; Rahmim, Arman; Scheffel, Ursula; Wong, Dean F.; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1689-1696</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">The development of the radioligands for PET imaging of the cerebral cannabinoid receptor (CB1) is of great importance for studying its role in neuropsychiatric disorders, obesity, and drug dependence.  None of the currently available radioligands for CB1 are suitable for quant. PET, primarily because of their insufficient binding potential (BP) in brain or low penetration through the blood-brain barrier (BBB).  The goal of this study was to evaluate 11C-JHU75528, an analog of the selective CB1 antagonist rimonabant, in vivo as a potential CB1 radioligand for PET.  Methods: The brain regional distribution and pharmacol. of 11C-JHU75528 have been evaluated in vivo in mice (dissection) and baboons (PET).  Results: 11C-JHU75528 readily entered the mouse and baboon brain and specifically and selectively labeled cerebral CB1 receptors.  The ratio of striatum to brain stem in mice and the binding potential (BP) in the baboon putamen were 3.4 and 1.3-1.5, resp.  The specific binding of 11C-JHU75528 in vivo was blocked by preinjection of nonlabeled JHU75528.  Administration of rimonabant (1 mg/kg, i.v.) also blocked the specific binding of 11C-JHU75528 binding in the mouse and baboon brain, whereas various central non-cannabinoid drugs did not significantly reduce the 11C-JHU75528 binding in the mouse brain.  11C-JHU75528 formed several hydrophilic metabolites, but only a minute fraction of metabolic radioactivity penetrated the BBB.  Conclusion: 11C-JHU75528 holds promise as a radiotracer with suitable imaging properties for quantification of CB1 receptors in the human brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKZkkvcJ8HULVg90H21EOLACvtfcHk0lg6i4RoF_oMbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKjtrbK&md5=3edbf9ef5616ae6c5927cefe7b69448f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorti%26aufirst%3DA.%2BG.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DHilton%26aufirst%3DJ.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DHolt%26aufirst%3DD.%2BP.%26aulast%3DAlexander%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DRahmim%26aufirst%3DA.%26aulast%3DScheffel%26aufirst%3DU.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3D11C-JHU75528%253A%2520a%2520radiotracer%2520for%2520PET%2520imaging%2520of%2520CB1%2520cannabinoid%2520receptors%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D1689%26epage%3D1696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascella, N.</span></span> <span> </span><span class="NLM_article-title">PET Imaging of cannabinoid CB1 type receptors in healthy humans and patients with schizophrenia using [<sup>11</sup>C]OMAR</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">T51</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2008.04.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2008.04.225" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=T51&author=D.+F.+Wongauthor=H.+Kuwabaraauthor=A.+Hortiauthor=A.+Kumarauthor=J.+Brasicauthor=W.+Yeauthor=M.+Alexanderauthor=V.+Raymontauthor=J.+Galeckiauthor=M.+Charlotteauthor=N.+Cascella&title=PET+Imaging+of+cannabinoid+CB1+type+receptors+in+healthy+humans+and+patients+with+schizophrenia+using+%5B11C%5DOMAR&doi=10.1016%2Fj.neuroimage.2008.04.225"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2008.04.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2008.04.225%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DHorti%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DBrasic%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DAlexander%26aufirst%3DM.%26aulast%3DRaymont%26aufirst%3DV.%26aulast%3DGalecki%26aufirst%3DJ.%26aulast%3DCharlotte%26aufirst%3DM.%26aulast%3DCascella%26aufirst%3DN.%26atitle%3DPET%2520Imaging%2520of%2520cannabinoid%2520CB1%2520type%2520receptors%2520in%2520healthy%2520humans%2520and%2520patients%2520with%2520schizophrenia%2520using%2520%255B11C%255DOMAR%26jtitle%3DNeuroImage%26date%3D2008%26volume%3D41%26spage%3DT51%26doi%3D10.1016%2Fj.neuroimage.2008.04.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guevara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grachev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascella, N.</span></span> <span> </span><span class="NLM_article-title">Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [<sup>11</sup>C]OMAR</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1513</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2010.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2010.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20406692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVGnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=1505-1513&author=D.+F.+Wongauthor=H.+Kuwabaraauthor=A.+G.+Hortiauthor=V.+Raymontauthor=J.+Brasicauthor=M.+Guevaraauthor=W.+Yeauthor=R.+F.+Dannalsauthor=H.+T.+Ravertauthor=A.+Nandiauthor=A.+Rahmimauthor=J.+E.+Mingauthor=I.+Grachevauthor=C.+Royauthor=N.+Cascella&title=Quantification+of+cerebral+cannabinoid+receptors+subtype+1+%28CB1%29+in+healthy+subjects+and+schizophrenia+by+the+novel+PET+radioligand+%5B11C%5DOMAR&doi=10.1016%2Fj.neuroimage.2010.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR</span></div><div class="casAuthors">Wong, Dean F.; Kuwabara, Hiroto; Horti, Andrew G.; Raymont, Vanessa; Brasic, James; Guevara, Maria; Ye, Weiguo; Dannals, Robert F.; Ravert, Hayden T.; Nandi, Ayon; Rahmim, Arman; Ming, Jeffrey E.; Grachev, Igor; Roy, Christine; Cascella, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1505-1513</span>CODEN:
                <span class="NLM_cas:coden">NEIMEF</span>;
        ISSN:<span class="NLM_cas:issn">1053-8119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Several studies have examd. the link between the cannabinoid CB1 receptor and several neuropsychiatric illnesses, including schizophrenia.  As such, there is a need for in vivo imaging tracers so that the relationship between CB1 and schizophrenia (SZ) can be further studied.  In this paper, we present our first human studies in both healthy control patients and patients with schizophrenia using the novel PET tracer, [11C]OMAR (JHU75528), we have shown its utility as a tracer for imaging human CB1 receptors and to investigate normal aging and the differences in the cannabinoid system of healthy controls vs. patients with schizophrenia.  A total of ten healthy controls and nine patients with schizophrenia were included and studied with high specific activity [11C]OMAR.  The CB1 binding (expressed as the distribution vol.; VT) was highest in the globus pallidus and the cortex in both controls and patients with schizophrenia.  Controls showed a correlation with the known distribution of CB1 and decline of [11C]OMAR binding with age, most significantly in the globus pallidus.  Overall, we obsd. elevated mean binding in patients with schizophrenia across all regions studied, and this increase was statistically significant in the pons (p < 0.05), by the Students t-test.  When we ran a regression of the control subjects VT values with age and then compared the patient data to 95% prediction limits of the linear regression, three patients fell completely outside for the globus pallidus, and in all other regions there were at least 1-3 patients outside of the prediction intervals.  There was no statistically significant correlations between PET measures and the individual Brief Psychiatry Rating Score (BPRS) subscores (r = 0.49), but there was a significant correlation between VT and the ratio of the BPRS psychosis to withdrawal score in the frontal lobe (r = 0.60), and middle and posterior cingulate regions (r = 0.71 and r = 0.79 resp.).  In conclusion, we found that [11C]OMAR can image human CB1 receptors in normal aging and schizophrenia.  In addn., our initial data in subjects with schizophrenia seem to suggest an assocn. of elevated binding specific brain regions and symptoms of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOEH2Wkw4jW7Vg90H21EOLACvtfcHk0lg6i4RoF_oMbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVGnt70%253D&md5=6f7bf8d2410075a00b7f7f1969106823</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2010.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2010.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26aulast%3DRaymont%26aufirst%3DV.%26aulast%3DBrasic%26aufirst%3DJ.%26aulast%3DGuevara%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DNandi%26aufirst%3DA.%26aulast%3DRahmim%26aufirst%3DA.%26aulast%3DMing%26aufirst%3DJ.%2BE.%26aulast%3DGrachev%26aufirst%3DI.%26aulast%3DRoy%26aufirst%3DC.%26aulast%3DCascella%26aufirst%3DN.%26atitle%3DQuantification%2520of%2520cerebral%2520cannabinoid%2520receptors%2520subtype%25201%2520%2528CB1%2529%2520in%2520healthy%2520subjects%2520and%2520schizophrenia%2520by%2520the%2520novel%2520PET%2520radioligand%2520%255B11C%255DOMAR%26jtitle%3DNeuroImage%26date%3D2010%26volume%3D52%26spage%3D1505%26epage%3D1513%26doi%3D10.1016%2Fj.neuroimage.2010.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Briones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurnauer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planeta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skosnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaree, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, D. C.</span></span> <span> </span><span class="NLM_article-title">Reduced brain cannabinoid receptor availability in schizophrenia</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1005</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2015.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.biopsych.2015.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26432420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2hu7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=997-1005&author=M.+Ranganathanauthor=J.+Cortes-Brionesauthor=R.+Radhakrishnanauthor=H.+Thurnauerauthor=B.+Planetaauthor=P.+Skosnikauthor=H.+Gaoauthor=D.+Labareeauthor=A.+Neumeisterauthor=B.+Pittmanauthor=T.+Surtiauthor=Y.+Huangauthor=R.+E.+Carsonauthor=D.+C.+D%E2%80%99Souza&title=Reduced+brain+cannabinoid+receptor+availability+in+schizophrenia&doi=10.1016%2Fj.biopsych.2015.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced Brain Cannabinoid Receptor Availability In Schizophrenia</span></div><div class="casAuthors">Ranganathan, Mohini; Cortes-Briones, Jose; Radhakrishnan, Rajiv; Thurnauer, Halle; Planeta, Beata; Skosnik, Patrick; Gao, Hong; Labaree, David; Neumeister, Alexander; Pittman, Brian; Surti, Toral; Huang, Yiyun; Carson, Richard E.; D'Souza, Deepak Cyril</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">997-1005</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BACKGROUND: Several lines of evidence suggest the presence of abnormalities in the endocannabinoid (eCB) system in schizophrenia (SCZ).  However, there are limited in vivo measures of the eCB system in SCZ.  METHODS: Twenty five male SCZ subjects (SCZs) (18 antipsychotic treated and 7 antipsychotic free) were compared with 18 age-matched male healthy control subjects (HCs).  Subjects underwent one positron emission tomog. scan each with the cannabinoid receptor-1 (CB1R) selective radiotracer [11C]OMAR on the high resoln. research tomog. scanner.  Regional vol. of distribution (VT) values were detd. using kinetic modeling of positron emission tomog. data as a measure of CB1R availability.  Group differences in mean composite [11C]OMAR VT values were compared between SCZs and HCs.  Exploratory comparisons of CB1R availability within 15 brain regions were also conducted.  All analyses were covaried for age and body mass index.  RESULTS: SCZs showed significantly (p = .02) lower composite [11C]OMAR VT relative to HCs (∼12% difference, effect size d = .73). [11C]OMAR VT was significantly (all ps < .05) lower in SCZs in the amygdala, caudate, posterior cingulate cortex, hippocampus, hypothalamus, and insula.  Composite [11]OMAR VT was HCs > antipsychotic treated SZCs > antipsychotic free SZCs.  Furthermore, composite [11C]OMAR VT was greater in HCs than SCZ smokers (n = 11) and SCZ nonsmokers (n = 14).  CONCLUSIONS: CB1R availability is lower in male SCZ subjects compared with HCs.  Furthermore, antipsychotics and tobacco use may increase CB1R availability in this population.  The findings of the study provide further evidence supporting the hypothesis that alterations in the eCB system might contribute to the pathophysiol. of SCZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBZyqsE12WArVg90H21EOLACvtfcHk0ljy-LfBEyO3RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2hu7vE&md5=820e1afd3acd95bac1b0470a061e26bd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2015.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2015.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DCortes-Briones%26aufirst%3DJ.%26aulast%3DRadhakrishnan%26aufirst%3DR.%26aulast%3DThurnauer%26aufirst%3DH.%26aulast%3DPlaneta%26aufirst%3DB.%26aulast%3DSkosnik%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DLabaree%26aufirst%3DD.%26aulast%3DNeumeister%26aufirst%3DA.%26aulast%3DPittman%26aufirst%3DB.%26aulast%3DSurti%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26atitle%3DReduced%2520brain%2520cannabinoid%2520receptor%2520availability%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D2016%26volume%3D79%26spage%3D997%26epage%3D1005%26doi%3D10.1016%2Fj.biopsych.2015.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hungund, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szakall, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavarajappa, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadasz, C.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2003.01576.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1046%2Fj.1471-4159.2003.01576.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12562514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1amsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2003&pages=698-704&author=B.+L.+Hungundauthor=I.+Szakallauthor=A.+Adamauthor=B.+S.+Basavarajappaauthor=C.+Vadasz&title=Cannabinoid+CB1+receptor+knockout+mice+exhibit+markedly+reduced+voluntary+alcohol+consumption+and+lack+alcohol-induced+dopamine+release+in+the+nucleus+accumbens&doi=10.1046%2Fj.1471-4159.2003.01576.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens</span></div><div class="casAuthors">Hungund, Basalingappa L.; Szakall, Istvan; Adam, Agota; Basavarajappa, Balapal S.; Vadasz, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">698-704</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The mechanisms underlying predisposition to alc. abuse and alcoholism are poorly understood.  In this study, we evaluated the role of cannabinoid (CB1) receptors in (i) voluntary alc. consumption, and (ii) acute alc.-induced dopamine (DA) release in the nucleus accumbens, using mice that lack the CB1 receptor gene (CB1-/-).  CB1-/- mice exhibited dramatically reduced voluntary alc. consumption, and completely lacked alc.-induced DA release in the nucleus accumbens, as compared to wild-type mice.  The gender difference, with female mice consuming significantly more alc. than wild-type male mice, was obsd. in wild-type mice, whereas this gender difference was nonexistent in CB1 mutant male and female mice.  There was also a significant gender difference, with the wild-type, heterozygous, and mutant females consuming significantly more liq. and food than wild-type, heterozygous and mutant males.  However, the total vol. of fluid consumption and food intake did not differ between wild-type, heterozygous, and mutant mice.  These results strongly suggest that the CB1 receptor system plays an important role in regulating the pos. reinforcing properties of alc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc8YMoO8pzH7Vg90H21EOLACvtfcHk0ljy-LfBEyO3RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1amsbo%253D&md5=f33e9f29974662aafbc7460ecfc22980</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2003.01576.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2003.01576.x%26sid%3Dliteratum%253Aachs%26aulast%3DHungund%26aufirst%3DB.%2BL.%26aulast%3DSzakall%26aufirst%3DI.%26aulast%3DAdam%26aufirst%3DA.%26aulast%3DBasavarajappa%26aufirst%3DB.%2BS.%26aulast%3DVadasz%26aufirst%3DC.%26atitle%3DCannabinoid%2520CB1%2520receptor%2520knockout%2520mice%2520exhibit%2520markedly%2520reduced%2520voluntary%2520alcohol%2520consumption%2520and%2520lack%2520alcohol-induced%2520dopamine%2520release%2520in%2520the%2520nucleus%2520accumbens%26jtitle%3DJ.%2520Neurochem.%26date%3D2003%26volume%3D84%26spage%3D698%26epage%3D704%26doi%3D10.1046%2Fj.1471-4159.2003.01576.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basavarajappa, B. S.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid system and alcohol abuse disorders</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1162</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1007/978-3-030-21737-2_6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2F978-3-030-21737-2_6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31332736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVGrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1162&publication_year=2019&pages=89-127&author=B.+S.+Basavarajappa&title=Endocannabinoid+system+and+alcohol+abuse+disorders&doi=10.1007%2F978-3-030-21737-2_6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid System and Alcohol Abuse Disorders</span></div><div class="casAuthors">Basavarajappa, Balapal S.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1162</span>
        (<span class="NLM_cas:issue">Recent Advances in Cannabinoid Physiology and Pathology</span>),
    <span class="NLM_cas:pages">89-127</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Δ9 -tetrahydrocannabinol (Δ9 -THC), the primary active component in Cannabis sativa prepns. such as hashish and marijuana, signals by binding to cell surface receptors.  Two types of receptors have been cloned and characterized as cannabinoid (CB) receptors.  CB1 receptors (CB1R) are ubiquitously present in the central nervous system (CNS) and are present in both inhibitory interneurons and excitatory neurons at the presynaptic terminal.  CB2 receptors (CB2R) are demonstrated in microglial cells, astrocytes, and several neuron subpopulations and are present in both pre- and postsynaptic terminals.  The majority of studies on these receptors have been conducted in the past two and half decades after the identification of the mol. constituents of the endocannabinoid (eCB) system that started with the characterization of CB1R.  Subsequently, the seminal discovery was made, which suggested that alc. (ethanol) alters the eCB system, thus establishing the contribution of the eCB system in the motivation to consume ethanol.  Several preclin. studies have provided evidence that CB1R significantly contributes to the motivational and reinforcing properties of ethanol and that the chronic consumption of ethanol alters eCB transmitters and CB1R expression in the brain nuclei assocd. with addiction pathways.  Addnl., recent seminal studies have further established the role of the eCB system in the development of ethanol-induced developmental disorders, such as fetal alc. spectrum disorders (FASD).  These results are augmented by in vitro and ex vivo studies, showing that acute and chronic treatment with ethanol produces physiol. relevant alterations in the function of the eCB system during development and in the adult stage.  This chapter provides a current and comprehensive review of the literature concerning the role of the eCB system in alc. abuse disorders (AUD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1JfwQRXQR2LVg90H21EOLACvtfcHk0ljy-LfBEyO3RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVGrsLo%253D&md5=9166c5636e0dfaa614a9ae07e27348a2</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-21737-2_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-030-21737-2_6%26sid%3Dliteratum%253Aachs%26aulast%3DBasavarajappa%26aufirst%3DB.%2BS.%26atitle%3DEndocannabinoid%2520system%2520and%2520alcohol%2520abuse%2520disorders%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2019%26volume%3D1162%26spage%3D89%26epage%3D127%26doi%3D10.1007%2F978-3-030-21737-2_6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Femenia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Gutierrez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzanares, J.</span></span> <span> </span><span class="NLM_article-title">CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats</span>. <i>Alcohol.: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1111/j.1530-0277.2009.01074.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1530-0277.2009.01074.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19860799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVyrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=131-141&author=T.+Femeniaauthor=M.+S.+Garcia-Gutierrezauthor=J.+Manzanares&title=CB1+receptor+blockade+decreases+ethanol+intake+and+associated+neurochemical+changes+in+fawn-hooded+rats&doi=10.1111%2Fj.1530-0277.2009.01074.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats</span></div><div class="casAuthors">Femenia, Teresa; Garcia-Gutierrez, Maria S.; Manzanares, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical & Experimental Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-141</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: This study was undertaken to identify the neurochem. changes underlying the attenuation of voluntary ethanol intake induced by the cannabinoid CB1 receptor antagonist AM251 in fawn-hooded rats.  Methods: Rats were exposed to the 2-bottle-choice paradigm (ethanol 10% vol./vol. or water) for 15 days.  After this period, rats received AM251 (3 to 6 mg/kg, i.p.) or vehicle.  Results: Voluntary ethanol intake decreased (30%) with the administration of incremental dosages of AM251 (3 mg/kg, 5 days and 6 mg/kg, 5 days) in rats with acquired high preferring ethanol consumption (> 3.5 g of ethanol/kg/d).  Ethanol intake significantly decreased proopiomelanocortin expression in the arcuate nucleus (38.31%) and μ-opioid-DAMGO-stimulated [35S]-GTPγ binding in the caudate-putamen (40%), nucleus accumbens core (AccC) (32.87%), and shell (AccS) (34.21%).  Moreover, ethanol intake increased tyrosine hydroxylase (TH) gene expression in the substantia nigra (24%) and ventral tegmental area (23%) and corticotrophin-releasing gene expression in the paraventricular hypothalamic nucleus (41.6%).  The redn. of ethanol intake induced by AM251 was assocd. with blockade or significant redn. of the changes produced by ethanol in the expression of these genes in key regions related to drug dependence.  Interestingly, treatment with AM251 reduced (20%) TH gene expression in rats drinking only water.  In this respect, the action of AM251 in reducing TH gene expression may not be specific.  Conclusion: Taken together, these results revealed that blockade of cannabinoid CB1 receptors (CB1r) decreased voluntary ethanol intake in ethanol-habituated rats by normalizing the neurochem. alterations induced by ethanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoePE2DgCm0jLVg90H21EOLACvtfcHk0lj5tHg2F4hcfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVyrtL0%253D&md5=e2a94f2d7702dccd914b1c2cce6b47ad</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2009.01074.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2009.01074.x%26sid%3Dliteratum%253Aachs%26aulast%3DFemenia%26aufirst%3DT.%26aulast%3DGarcia-Gutierrez%26aufirst%3DM.%2BS.%26aulast%3DManzanares%26aufirst%3DJ.%26atitle%3DCB1%2520receptor%2520blockade%2520decreases%2520ethanol%2520intake%2520and%2520associated%2520neurochemical%2520changes%2520in%2520fawn-hooded%2520rats%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2010%26volume%3D34%26spage%3D131%26epage%3D141%26doi%3D10.1111%2Fj.1530-0277.2009.01074.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normandin, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galatzer-Levy, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potenza, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span> <span> </span><span class="NLM_article-title">Positron emission tomography shows elevated cannabinoid CB 1 receptor binding in men with alcohol dependence</span>. <i>Alcohol.: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2104</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1111/j.1530-0277.2012.01815.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1530-0277.2012.01815.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22551199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=2104-2109&author=A.+Neumeisterauthor=M.+D.+Normandinauthor=J.+W.+Murroughauthor=S.+Henryauthor=C.+R.+Baileyauthor=D.+A.+Luckenbaughauthor=K.+Tuitauthor=M.-Q.+Zhengauthor=I.+R.+Galatzer-Levyauthor=R.+Sinhaauthor=R.+E.+Carsonauthor=M.+N.+Potenzaauthor=Y.+Huang&title=Positron+emission+tomography+shows+elevated+cannabinoid+CB+1+receptor+binding+in+men+with+alcohol+dependence&doi=10.1111%2Fj.1530-0277.2012.01815.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence</span></div><div class="casAuthors">Neumeister, Alexander; Normandin, Marc D.; Murrough, James W.; Henry, Shannan; Bailey, Christopher R.; Luckenbaugh, David A.; Tuit, Keri; Zheng, Ming-Qiang; Galatzer-Levy, Isaac R.; Sinha, Rajita; Carson, Richard E.; Potenza, Marc N.; Huang, Yiyun</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical & Experimental Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2104-2109</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Several lines of evidence link cannabinoid (CB) type 1 (CB1) receptor-mediated endogenous CB (eCB) signaling to the etiol. of alc. dependence (AD).  However, to date, only peripheral measures of eCB function have been collected in living humans with AD and no human in vivo data on the potentially crit. role of the brain CB1 receptor in AD have been published.  This is an important gap in the literature, because recent therapeutic developments suggest that these receptors could be targeted for the treatment for AD.  Methods: Medication-free participants were scanned during early abstinence 4 wk after their last drink.  Using positron emission tomog. (PET) with a high-resoln. research tomograph and the CB1 receptor selective radiotracer [11C]OMAR, we detd. [11C]OMAR vol. of distribution (VT) values, a measure of CB1 receptor d., in a priori selected brain regions in men with AD (n = 8, age 37.4 ± 7.9 years; 5 smokers) and healthy control (HC) men (n = 8, age 32.5 ± 6.9 years; all nonsmokers).  PET images reconstructed using the MOLAR algorithm with hardware motion correction were rigidly aligned to the subject-specific magnetic resonance (MR) image, which in turn was warped to an MR template.  Time-activity curves (TACs) were extd. from the dynamic PET data using a priori selected regions of interest delineated in the MR template space.  Results: In AD relative to HC, [11C]OMAR VT values were elevated by approx. 20% (p = 0.023) in a circuit, including the amygdala, hippocampus, putamen, insula, anterior and posterior cingulate cortices, and orbitofrontal cortex.  Age, body mass index, or smoking status did not influence the outcome.  Conclusions: These findings agree with preclin. evidence and provide the first, albeit still preliminary in vivo evidence suggesting a role for brain CB1 receptors in AD.  The current study design does not answer the important question of whether elevated CB1 receptors are a preexisting vulnerability factor for AD or whether elevations develop as a consequence of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIlr91KkxuGrVg90H21EOLACvtfcHk0lj5tHg2F4hcfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCjtbk%253D&md5=dd5ac94acc4060ffea6578362adf96d2</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2012.01815.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2012.01815.x%26sid%3Dliteratum%253Aachs%26aulast%3DNeumeister%26aufirst%3DA.%26aulast%3DNormandin%26aufirst%3DM.%2BD.%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DHenry%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DC.%2BR.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DTuit%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DM.-Q.%26aulast%3DGalatzer-Levy%26aufirst%3DI.%2BR.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DPotenza%26aufirst%3DM.%2BN.%26aulast%3DHuang%26aufirst%3DY.%26atitle%3DPositron%2520emission%2520tomography%2520shows%2520elevated%2520cannabinoid%2520CB%25201%2520receptor%2520binding%2520in%2520men%2520with%2520alcohol%2520dependence%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D2104%26epage%3D2109%26doi%3D10.1111%2Fj.1530-0277.2012.01815.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valenta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T. H.</span></span> <span> </span><span class="NLM_article-title">Feasibility evaluation of myocardial cannabinoid type 1 receptor imaging in obesity: a translational approach</span>. <i>JACC Cardiovasc. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1016/j.jcmg.2017.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.jcmg.2017.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29413441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvos1aqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=320-332&author=I.+Valentaauthor=Z.+V.+Vargaauthor=H.+Valentineauthor=R.+Cinarauthor=A.+Hortiauthor=W.+B.+Mathewsauthor=R.+F.+Dannalsauthor=K.+Steeleauthor=G.+Kunosauthor=R.+L.+Wahlauthor=M.+G.+Pomperauthor=D.+F.+Wongauthor=P.+Pacherauthor=T.+H.+Schindler&title=Feasibility+evaluation+of+myocardial+cannabinoid+type+1+receptor+imaging+in+obesity%3A+a+translational+approach&doi=10.1016%2Fj.jcmg.2017.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach</span></div><div class="casAuthors">Valenta Ines; Valentine Heather; Horti Andrew; Mathews William B; Dannals Robert F; Pomper Martin G; Wong Dean F; Varga Zoltan V; Cinar Resat; Kunos George; Steele Kimberley; Wahl Richard L; Pacher Pal; Schindler Thomas H</div><div class="citationInfo"><span class="NLM_cas:title">JACC. Cardiovascular imaging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2 Pt 2</span>),
    <span class="NLM_cas:pages">320-332</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The aim of this study was to evaluate the feasibility of targeted imaging of myocardial cannabinoid type 1 receptor (CB1-R) and its potential up-regulation in obese mice with translation to humans using [(11)C]-OMAR and positron emission tomography (PET)/computed tomography (CT).  BACKGROUND:  Activation of myocardial CB1-R by endocannabinoids has been implicated in cardiac dysfunction in diabetic mice.  Obesity may lead to an up-regulation of myocardial CB1-R, potentially providing a mechanistic link between obesity and the initiation and/or progression of cardiomyopathy.  METHODS:  Binding specificity of [(11)C]-OMAR to CB1-R was investigated by blocking studies with rimonabant in mice.  The heart was harvested from each mouse, and its radioactivity was determined by γ-counter.  Furthermore, [(11)C]-OMAR dynamic micro-PET/CT was carried out in obese and normal-weight mice.  Ex vivo validation was performed by droplet digital polymerase chain reaction (absolute quantification) and RNAscope Technology (an in situ ribonucleic acid analysis platform).  Subsequently, myocardial CB1-R expression was probed noninvasively with intravenous injection of CB1-R ligand [(11)C]-OMAR and PET/CT in humans with advanced obesity and normal-weight human control subjects, respectively.  RESULTS:  Rimonabant significantly blocked OMAR uptake in the heart muscle compared with vehicle, signifying specific binding of OMAR to the CB1-R in the myocardium.  The myocardial OMAR retention quantified by micro-PET/CT in mice was significantly higher in obese compared with normal-weight mice.  Absolute quantification of CB1-R gene expression with droplet digital polymerase chain reaction and in situ hybridization confirmed CB1-R up-regulation in all major myocardial cell types (e.g., cardiomyocytes, endothelium, vascular smooth muscle cells, and fibroblasts) of obese mice.  Obese mice also had elevated myocardial levels of endocannabinoids anandamide and 2-arachidonoylglycerol compared with lean mice.  Translation to humans revealed higher myocardial OMAR retention in advanced obesity compared with normal-weight subjects.  CONCLUSIONS:  Noninvasive imaging of cardiac CB1-R expression in obesity is feasible applying [(11)C]-OMAR and PET/CT.  These results may provide a rationale for further clinical testing of CB1-R-targeted molecular imaging in cardiometabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjuViowtDkaX6HPRus0rAafW6udTcc2eaftfA87gIBX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvos1aqtw%253D%253D&md5=0613321cb418452cbb16c8bb38e15207</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmg.2017.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmg.2017.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DValenta%26aufirst%3DI.%26aulast%3DVarga%26aufirst%3DZ.%2BV.%26aulast%3DValentine%26aufirst%3DH.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DHorti%26aufirst%3DA.%26aulast%3DMathews%26aufirst%3DW.%2BB.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DSteele%26aufirst%3DK.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DWahl%26aufirst%3DR.%2BL.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%2BH.%26atitle%3DFeasibility%2520evaluation%2520of%2520myocardial%2520cannabinoid%2520type%25201%2520receptor%2520imaging%2520in%2520obesity%253A%2520a%2520translational%2520approach%26jtitle%3DJACC%2520Cardiovasc.%2520Imaging%26date%3D2018%26volume%3D11%26spage%3D320%26epage%3D332%26doi%3D10.1016%2Fj.jcmg.2017.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valenta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilsizian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T. H.</span></span> <span> </span><span class="NLM_article-title">Novel myocardial PET/CT receptor imaging and potential therapeutic targets</span>. <i>Curr. Cardiol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">55</span>, <span class="refDoi"> DOI: 10.1007/s11886-019-1148-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs11886-019-1148-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31104205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ntlSisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=55&author=I.+Valentaauthor=P.+Pacherauthor=V.+Dilsizianauthor=T.+H.+Schindler&title=Novel+myocardial+PET%2FCT+receptor+imaging+and+potential+therapeutic+targets&doi=10.1007%2Fs11886-019-1148-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Myocardial PET/CT Receptor Imaging and Potential Therapeutic Targets</span></div><div class="casAuthors">Valenta Ines; Schindler Thomas H; Pacher Pal; Dilsizian Vasken</div><div class="citationInfo"><span class="NLM_cas:title">Current cardiology reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF THE REVIEW:  Activation of myocardial cannabinoid type 1 receptors (CB1-R) and/or angiotensin II type 1 receptors (AT1-R) likely plays an important mechanistic role in determining the left-ventricular remodeling process in systolic heart failure.  We provide an overview on novel radiotracer probes and positron emission tomography (PET)/computed tomography (CT) imaging to noninvasively probe the expression of myocardial CB1-R and/or AT1-R.  RECENT FINDINGS:  Recent translational investigations have demonstrated the feasibility of (11)C-OMAR or (11)C-KR31173 and PET/CT to image and quantify myocardial CB1-R and/or AT1-R expression, respectively.  There is an increasing understanding of the mechanisms of activated myocardial CB1-R and/or AT1-R to influence the left-ventricular remodeling process in systolic heart failure in different disease entities.  The review summarizes contributions of PET to image myocardial CB1-R and AT1-R expression that may have the potential to serve as a target to tailor preventive medical care in the individual patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2g3e0fpt8hb7NkxioyDXTfW6udTcc2ebvnw-ZnaKoArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ntlSisw%253D%253D&md5=577fd6635ffba5422de3845412c3ffd5</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2Fs11886-019-1148-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11886-019-1148-2%26sid%3Dliteratum%253Aachs%26aulast%3DValenta%26aufirst%3DI.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DDilsizian%26aufirst%3DV.%26aulast%3DSchindler%26aufirst%3DT.%2BH.%26atitle%3DNovel%2520myocardial%2520PET%252FCT%2520receptor%2520imaging%2520and%2520potential%2520therapeutic%2520targets%26jtitle%3DCurr.%2520Cardiol.%2520Rep.%26date%3D2019%26volume%3D21%26spage%3D55%26doi%3D10.1007%2Fs11886-019-1148-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fish, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajjar, R. J.</span></span> <span> </span><span class="NLM_article-title">Myocardial cannabinoid receptor imaging in obesity</span>. <i>JACC Cardiovasc. imaging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1016/j.jcmg.2017.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.jcmg.2017.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29413442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvos1aqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=333-335&author=K.+M.+Fishauthor=R.+J.+Hajjar&title=Myocardial+cannabinoid+receptor+imaging+in+obesity&doi=10.1016%2Fj.jcmg.2017.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Myocardial Cannabinoid Receptor Imaging in Obesity</span></div><div class="casAuthors">Fish Kenneth M; Hajjar Roger J</div><div class="citationInfo"><span class="NLM_cas:title">JACC. Cardiovascular imaging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2 Pt 2</span>),
    <span class="NLM_cas:pages">333-335</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjuViowtDkaQwxfk_AGB-EfW6udTcc2ebvnw-ZnaKoArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvos1aqtA%253D%253D&md5=9db693742957a67c8ed8099e3370938e</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmg.2017.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmg.2017.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DFish%26aufirst%3DK.%2BM.%26aulast%3DHajjar%26aufirst%3DR.%2BJ.%26atitle%3DMyocardial%2520cannabinoid%2520receptor%2520imaging%2520in%2520obesity%26jtitle%3DJACC%2520Cardiovasc.%2520imaging%26date%3D2018%26volume%3D11%26spage%3D333%26epage%3D335%26doi%3D10.1016%2Fj.jcmg.2017.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. C.</span></span> <span> </span><span class="NLM_article-title">The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/S1056-8719(02)00166-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS1056-8719%2802%2900166-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12481843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslKhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=61-71&author=H.+C.+Cheng&title=The+power+issue%3A+determination+of+KB+or+Ki+from+IC50.+A+closer+look+at+the+Cheng-Prusoff+equation%2C+the+Schild+plot+and+related+power+equations&doi=10.1016%2FS1056-8719%2802%2900166-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations</span></div><div class="casAuthors">Cheng, Hsien C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-71</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Introduction: The Cheng-Prusoff equation (1973) is often applied to the detn. of equil. dissocn. const. (KB) of a competitive receptor antagonist when the IC50 value is available.  The purpose of this study is to illustrate that the slope function (K) of an agonist concn.-response curve is crit. to the detn. of KB values.  Methods: The article describes new equations, which incorporate the slope function, consequently yielding more accurate estn. of KB values for antagonists, and tests them using simulated data.  The value of KB was calcd. according to the following new power equation: KB=IC50/(1+AK/KP)=IC50/[1+(A/EC50)K], where IC50 is the concn. of the antagonist producing 50% inhibition, A is the concn. of the agonist against which the IC50 is being detd. and KP is the apparent equil. dissocn. const. of the agonist.  Results: The new equation is the same as the Cheng-Prusoff equation when the slope function K is exactly unity.  Application of the equation avoids errors inherent in the use of the Cheng-Prusoff equation when the slope function of the agonist concn.-response curve deviates from unity.  The new equation was applicable to slope functions less than, equal to or greater than unity.  All inhibition curves have a neg. slope function of 1, indicating that there is only one single receptor population even though different slope functions of agonist concn.-response curves are involved.  The importance of the power function in the Schild plot is illustrated by using the equation: log (xK-1)=log B-log KB, where x is the concn. ratio and B is the concn. of the antagonist.  Discussion: This investigation illustrates the application of six power equations for accurate estn. of KB values covering situations with different slope functions of the agonist concn.-response curves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWVFwIc5R1grVg90H21EOLACvtfcHk0ljHWWarHfLK2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslKhtr8%253D&md5=ac48f20214a292284c03533088118d7f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2802%2900166-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252802%252900166-1%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%2BC.%26atitle%3DThe%2520power%2520issue%253A%2520determination%2520of%2520KB%2520or%2520Ki%2520from%2520IC50.%2520A%2520closer%2520look%2520at%2520the%2520Cheng-Prusoff%2520equation%252C%2520the%2520Schild%2520plot%2520and%2520related%2520power%2520equations%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2001%26volume%3D46%26spage%3D61%26epage%3D71%26doi%3D10.1016%2FS1056-8719%2802%2900166-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesterfield, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladding, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">The PET radioligand [<sup>11</sup>C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1301402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fsj.npp.1301402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17392732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=259-269&author=F.+Yasunoauthor=A.+K.+Brownauthor=S.+S.+Zoghbiauthor=J.+H.+Krushinskiauthor=E.+Chernetauthor=J.+Tauscherauthor=J.+M.+Schausauthor=L.+A.+Phebusauthor=A.+K.+Chesterfieldauthor=C.+C.+Felderauthor=R.+L.+Gladdingauthor=J.+Hongauthor=C.+Halldinauthor=V.+W.+Pikeauthor=R.+B.+Innis&title=The+PET+radioligand+%5B11C%5DMePPEP+binds+reversibly+and+with+high+specific+signal+to+cannabinoid+CB1+receptors+in+nonhuman+primate+brain&doi=10.1038%2Fsj.npp.1301402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain</span></div><div class="casAuthors">Yasuno, Fumihiko; Brown, Amira K.; Zoghbi, Sami S.; Krushinski, Joseph H.; Chernet, Eyassu; Tauscher, Johannes; Schaus, John M.; Phebus, Lee A.; Chesterfield, Amy K.; Felder, Christian C.; Gladding, Robert L.; Hong, Jinsoo; Halldin, Christer; Pike, Victor W.; Innis, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-269</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The cannabinoid CB1 receptor is one of the most abundant G protein-coupled receptors in the brain and is a promising target of therapeutic drug development.  Success of drug development for neuropsychiatric indications is significantly enhanced with the ability to directly measure spatial and temporal binding of compds. to receptors in central compartments.  We assessed the utility of a new positron emission tomog. (PET) radioligand to image CB1 receptors in monkey brain. [11C]MePPEP ((3R,5R)-5-(3-methoxy-phenyl)-3-((R)-1-phenyl-ethylamino)-1-(4-trifluoromethyl-phenyl)-pyrrolidin-2-one) has high CB1 affinity (Kb = 0.574 ± 0.207 nM) but also moderately high lipophilicity (measured LogD7.4 = 4.8).  After i.v. injection of [11C]MePPEP, brain activity reached high levels of almost 600% standardized uptake value (SUV) within 10-20 min.  The regional uptake was consistent with the distribution of CB1 receptors, with high radioactivity in striatum and cerebellum and low in thalamus and pons.  Injection of pharmacol. doses of CB1-selective agents confirmed that the tracer doses of [11C]MePPEP reversibly labeled CB1 receptors.  Preblockade or displacement with two CB1 selective agents (ISPB; (4-(3-cyclopentyl-indole-1-sulfonyl)-N-(tetrahydro-pyran-4-ylmethyl)-benzamide) and rimonabant) showed that the majority (>89%) of brain uptake in regions with high receptor densities was specific and reversibly bound to CB1 receptors in the high binding regions. [11C]MePPEP was rapidly removed from arterial plasma.  Regional brain uptake could be quantified as distribution vol. relative to the concn. of parent radiotracer in plasma.  The P-glycoprotein (P-gp) inhibitor DCPQ ((R)-4-[(1a,6,10b)-1,1-dichloro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-[(5-quinolinyloxy)methyl]-1-piperazineethanol) did not significantly increase brain uptake of [11C]MePPEP, suggesting it is not a substrate for this efflux transporter at the blood-brain barrier. [11C]MePPEP is a radioligand with high brain uptake, high specific signal to CB1 receptors, and adequately fast washout from brain that allows quantification with 11C (half-life=20 min).  These promising results in monkey justify studying this radioligand in human subjects.  Neuropsychopharmacol. (2008) 33, 259-269; doi:10.1038/sj.npp.1301402; published online 28 March 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7SzUHk8qx9rVg90H21EOLACvtfcHk0lhpn6CYm-4kJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSktrrI&md5=bbad5e8f87edbec604c0e5e38ef91568</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301402%26sid%3Dliteratum%253Aachs%26aulast%3DYasuno%26aufirst%3DF.%26aulast%3DBrown%26aufirst%3DA.%2BK.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DChernet%26aufirst%3DE.%26aulast%3DTauscher%26aufirst%3DJ.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DPhebus%26aufirst%3DL.%2BA.%26aulast%3DChesterfield%26aufirst%3DA.%2BK.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DGladding%26aufirst%3DR.%2BL.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DThe%2520PET%2520radioligand%2520%255B11C%255DMePPEP%2520binds%2520reversibly%2520and%2520with%2520high%2520specific%2520signal%2520to%2520cannabinoid%2520CB1%2520receptors%2520in%2520nonhuman%2520primate%2520brain%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D259%26epage%3D269%26doi%3D10.1038%2Fsj.npp.1301402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesterfield, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5833</span>– <span class="NLM_lpage">5842</span>, <span class="refDoi"> DOI: 10.1021/jm800416m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800416m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVChsL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5833-5842&author=S.+R.+Donohueauthor=J.+H.+Krushinskiauthor=V.+W.+Pikeauthor=E.+Chernetauthor=L.+Phebusauthor=A.+K.+Chesterfieldauthor=C.+C.+Felderauthor=C.+Halldinauthor=J.+M.+Schaus&title=Synthesis%2C+ex+vivo+evaluation%2C+and+radiolabeling+of+potent+1%2C5-diphenylpyrrolidin-2-one+cannabinoid+subtype-1+receptor+ligands+as+candidates+for+in+vivo+imaging&doi=10.1021%2Fjm800416m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Ex Vivo Evaluation, and Radiolabeling of Potent 1,5-Diphenylpyrrolidin-2-one Cannabinoid Subtype-1 Receptor Ligands as Candidates for In Vivo Imaging</span></div><div class="casAuthors">Donohue, Sean R.; Krushinski, Joseph H.; Pike, Victor W.; Chernet, Eyassu; Phebus, Lee; Chesterfield, Amy K.; Felder, Christian C.; Halldin, Christer; Schaus, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5833-5842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have reported that [methyl-11C] (3R,5R)-5-(3-methoxyphenyl)-3-[(R)-1-phenylethylamino]-1-(4-trifluoromethylphenyl)pyrrolidin-2-one (I, R = OC11H3) binds with high selectivity to cannabinoid type-1 (CB1) receptors in monkey brain in vivo.  We now describe the synthesis of I (R = OCH3) and four analogs, namely, the 4-fluorophenyl, 3-fluoromethoxy, 3-fluoromethoxy-d2, and 3-fluoroethoxy analogs, and report their activity in an ex vivo model designed to identify compds. suitable for use as positron emission tomog. (PET) ligands.  These ligands exhibited high, selective potency at CB1 receptors in vitro (Kb < 1 nM).  Each ligand (30 μg/kg, iv) was injected into rats under baseline and pretreatment conditions and quantified at later times in frontal cortex ex vivo with liq. chromatog.-mass spectrometry (LC-MS) detection.  Maximal ligand uptakes were high (22.6-48.0 ng/g).  Under pretreatment, maximal brain uptakes were greatly reduced (6.5-17.3 ng/g).  Since each ligand readily entered brain and bound with high selectivity to CB1 receptors, we then established and here describe methods for producing I (R = OC11H3) as well as other [11C]- and [18F]-labeled ligands in adequate activities for evaluation as candidate PET radioligands in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBPuzDtuODnLVg90H21EOLACvtfcHk0lhpn6CYm-4kJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVChsL3E&md5=f25e5b4f2a9bf02aa5967f3a1b852510</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm800416m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800416m%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DChernet%26aufirst%3DE.%26aulast%3DPhebus%26aufirst%3DL.%26aulast%3DChesterfield%26aufirst%3DA.%2BK.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26atitle%3DSynthesis%252C%2520ex%2520vivo%2520evaluation%252C%2520and%2520radiolabeling%2520of%2520potent%25201%252C5-diphenylpyrrolidin-2-one%2520cannabinoid%2520subtype-1%2520receptor%2520ligands%2520as%2520candidates%2520for%2520in%2520vivo%2520imaging%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5833%26epage%3D5842%26doi%3D10.1021%2Fjm800416m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladding, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using 18F-labeled inverse agonist radioligands</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.2967/jnumed.109.067074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.109.067074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20008988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=112-120&author=G.+E.+Terryauthor=J.+Hirvonenauthor=J.+S.+Liowauthor=S.+S.+Zoghbiauthor=R.+Gladdingauthor=J.+T.+Tauscherauthor=J.+M.+Schausauthor=L.+Phebusauthor=C.+C.+Felderauthor=C.+L.+Morseauthor=S.+R.+Donohueauthor=V.+W.+Pikeauthor=C.+Halldinauthor=R.+B.+Innis&title=Imaging+and+quantitation+of+cannabinoid+CB1+receptors+in+human+and+monkey+brains+using+18F-labeled+inverse+agonist+radioligands&doi=10.2967%2Fjnumed.109.067074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using 18F-labeled inverse agonist radioligands</span></div><div class="casAuthors">Terry, Garth E.; Hirvonen, Jussi; Liow, Jeih-San; Zoghbi, Sami S.; Gladding, Robert; Tauscher, Johannes T.; Schaus, John M.; Phebus, Lee; Felder, Christian C.; Morse, Cheryl L.; Donohue, Sean R.; Pike, Victor W.; Halldin, Christer; Innis, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-120</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">We recently demonstrated that 11C-MePPEP, a PET ligand for CB1 receptors, has such high uptake in the human brain that it can be imaged for 210 min and that receptor d. can be quantified as distribution vol. (VT) using the gold std. of compartmental modeling.  However, 11C-MePPEP had relatively poor retest and intersubject variabilities, which were likely caused by errors in the measurements of radioligand in plasma at low concns. by 120 min.  We sought to find an analog of 11C-MePPEP that would provide more accurate plasma measurements.  We evaluated several promising analogs in the monkey brain and chose the 18F-di-deutero fluoromethoxy analog (18F-FMPEP-d2) to evaluate further in the human brain.  Methods: 11C-FMePPEP, 18F-FEPEP, 18F-FMPEP, and 18F-FMPEP-d2 were studied in 5 monkeys with 10 PET scans.  We calcd. VT using compartmental modeling with serial measurements of unchanged parent radioligand in arterial plasma and radioactivity in the brain.  Nonspecific binding was detd. by administering a receptor-satg. dose of rimonabant, an inverse agonist at the CB1 receptor.  Nine healthy human subjects participated in 17 PET scans using 18F-FMPEP-d2, with 8 subjects having 2 PET scans to assess retest variability.  To identify sources of error, we compared intersubject and retest variability of brain uptake, arterial plasma measurements, and VT.  Results: 18F-FMPEP-d2 had high uptake in the monkey brain, with greater than 80% specific binding, and yielded less radioactivity uptake in bone than did 18F-FMPEP.  High brain uptake with 18F-FMPEP-d2 was also obsd. in humans, in whom VT was well identified within approx. 60 min.  Retest variability of plasma measurements was good (16%); consequently, VT had a good retest variability (14%), intersubject variability (26%), and intraclass correlation coeff. (0.89).  VT increased after 120 min, suggesting an accumulation of radiometabolites in the brain.  Radioactivity accumulated in the skull throughout the entire scan but was thought to be an insignificant source of data contamination.  Conclusion: Studies in monkeys facilitated our development and selection of 18F-FMPEP-d2, com- pared with 18F-FMPEP, as a radioligand demonstrating high brain uptake, high percentage of specific binding, and reduced uptake in bone.  Retest anal. in human subjects showed that 18F-FMPEP-d2 has greater precision and accuracy than 11C-MePPEP, allowing smaller sample sizes to detect a significant difference between groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEIsZPKGaLO7Vg90H21EOLACvtfcHk0lhpn6CYm-4kJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCrsbs%253D&md5=148e9549eef03cd8e45f739656b13414</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.109.067074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.109.067074%26sid%3Dliteratum%253Aachs%26aulast%3DTerry%26aufirst%3DG.%2BE.%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DLiow%26aufirst%3DJ.%2BS.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DGladding%26aufirst%3DR.%26aulast%3DTauscher%26aufirst%3DJ.%2BT.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DPhebus%26aufirst%3DL.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DMorse%26aufirst%3DC.%2BL.%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DImaging%2520and%2520quantitation%2520of%2520cannabinoid%2520CB1%2520receptors%2520in%2520human%2520and%2520monkey%2520brains%2520using%252018F-labeled%2520inverse%2520agonist%2520radioligands%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2010%26volume%3D51%26spage%3D112%26epage%3D120%26doi%3D10.2967%2Fjnumed.109.067074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farris, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2009.06.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2009.06.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19573609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD1MrntVylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=362-370&author=G.+E.+Terryauthor=J.+S.+Liowauthor=S.+S.+Zoghbiauthor=J.+Hirvonenauthor=A.+G.+Farrisauthor=A.+Lernerauthor=J.+T.+Tauscherauthor=J.+M.+Schausauthor=L.+Phebusauthor=C.+C.+Felderauthor=C.+L.+Morseauthor=J.+S.+Hongauthor=V.+W.+Pikeauthor=C.+Halldinauthor=R.+B.+Innis&title=Quantitation+of+cannabinoid+CB1+receptors+in+healthy+human+brain+using+positron+emission+tomography+and+an+inverse+agonist+radioligand&doi=10.1016%2Fj.neuroimage.2009.06.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand</span></div><div class="casAuthors">Terry Garth E; Liow Jeih-San; Zoghbi Sami S; Hirvonen Jussi; Farris Amanda G; Lerner Alicja; Tauscher Johannes T; Schaus John M; Phebus Lee; Felder Christian C; Morse Cheryl L; Hong Jinsoo S; Pike Victor W; Halldin Christer; Innis Robert B</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">362-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">[11C]MePPEP is a high affinity, CB1 receptor-selective, inverse agonist that has been studied in rodents and monkeys.  We examined the ability of [11C]MePPEP to quantify CB1 receptors in human brain as distribution volume calculated with the "gold standard" method of compartmental modeling and compared results with the simple measure of brain uptake.  A total of 17 healthy subjects participated in 26 positron emission tomography (PET) scans, with 8 having two PET scans to assess retest variability.  After injection of [11C]MePPEP, brain uptake of radioactivity was high (e.g., 3.6 SUV in putamen at approximately 60 min) and washed out very slowly.  A two-tissue compartment model yielded values of distribution volume (which is proportional to receptor density) that were both well identified (SE 5%) and stable between 60 and 210 min.  The simple measure of brain uptake (average concentration of radioactivity between 40 and 80 min) had good retest variability ( approximately 8%) and moderate intersubject variability (16%, coefficient of variation).  In contrast, distribution volume had two-fold greater retest variability ( approximately 15%) and, thus, less precision.  In addition, distribution volume had three-fold greater intersubject variability ( approximately 52%).  The decreased precision of distribution volume compared to brain uptake was likely due to the slow washout of radioactivity from brain and to noise in measurements of the low concentrations of [11C]MePPEP in plasma.  These results suggest that brain uptake can be used for within subject studies (e.g., to measure receptor occupancy by medications) but that distribution volume remains the gold standard for accurate measurements between groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh0yJMiTh8SMuCWE5mhx1RfW6udTcc2eZyhG0n7SBzK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrntVylsQ%253D%253D&md5=2270ceaed417a38df15bdff660ca95bb</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2009.06.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2009.06.059%26sid%3Dliteratum%253Aachs%26aulast%3DTerry%26aufirst%3DG.%2BE.%26aulast%3DLiow%26aufirst%3DJ.%2BS.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DFarris%26aufirst%3DA.%2BG.%26aulast%3DLerner%26aufirst%3DA.%26aulast%3DTauscher%26aufirst%3DJ.%2BT.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DPhebus%26aufirst%3DL.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DMorse%26aufirst%3DC.%2BL.%26aulast%3DHong%26aufirst%3DJ.%2BS.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DQuantitation%2520of%2520cannabinoid%2520CB1%2520receptors%2520in%2520healthy%2520human%2520brain%2520using%2520positron%2520emission%2520tomography%2520and%2520an%2520inverse%2520agonist%2520radioligand%26jtitle%3DNeuroImage%26date%3D2009%26volume%3D48%26spage%3D362%26epage%3D370%26doi%3D10.1016%2Fj.neuroimage.2009.06.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharyya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egerton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riano Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brammer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkheimer, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, P.</span></span> <span> </span><span class="NLM_article-title">Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15025</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-14203-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41598-017-14203-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29101333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC1M7nsFygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=15025&author=S.+Bhattacharyyaauthor=A.+Egertonauthor=E.+Kimauthor=L.+Rossoauthor=D.+Riano+Barrosauthor=A.+Hammersauthor=M.+Brammerauthor=F.+E.+Turkheimerauthor=O.+D.+Howesauthor=P.+McGuire&title=Acute+induction+of+anxiety+in+humans+by+delta-9-tetrahydrocannabinol+related+to+amygdalar+cannabinoid-1+%28CB1%29+receptors&doi=10.1038%2Fs41598-017-14203-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors</span></div><div class="casAuthors">Bhattacharyya Sagnik; Egerton Alice; Howes Oliver D; McGuire Philip; Kim Euitae; Rosso Lula; Howes Oliver D; Riano Barros Daniela; Hammers Alexander; Brammer Michael; Turkheimer Federico E</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15025</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Use of Cannabis, the most widely used illicit drug worldwide, is associated with acute anxiety, and anxiety disorders following regular use.  The precise neural and receptor basis of these effects have not been tested in man.  Employing a combination of functional MRI (fMRI) and positron emission tomography (PET), we investigated whether the effects of delta-9-tetrahydrocannabinol (delta-9-THC), the main psychoactive ingredient of cannabis, on anxiety and on amygdala response while processing fearful stimuli were related to local availability of its main central molecular target, cannabinoid-1 (CB1) receptors in man.  Fourteen healthy males were studied with fMRI twice, one month apart, following an oral dose of either delta-9-THC (10 mg) or placebo, while they performed a fear-processing task.  Baseline availability of the CB1 receptor was studied using PET with [(11)C]MePPEP, a CB1 inverse agonist radioligand.  Relative to the placebo condition, delta-9-THC induced anxiety and modulated right amygdala activation while processing fear.  Both these effects were positively correlated with CB1 receptor availability in the right amygdala.  These results suggest that the acute effects of cannabis on anxiety in males are mediated by the modulation of amygdalar function by delta-9-THC and the extent of these effects are related to local availability of CB1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWW6OSv3swrOkdrW1FkXG-fW6udTcc2eZyhG0n7SBzK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7nsFygtA%253D%253D&md5=97db42b3e015b7298cfc7910e80c54d3</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-14203-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-14203-4%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharyya%26aufirst%3DS.%26aulast%3DEgerton%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DRosso%26aufirst%3DL.%26aulast%3DRiano%2BBarros%26aufirst%3DD.%26aulast%3DHammers%26aufirst%3DA.%26aulast%3DBrammer%26aufirst%3DM.%26aulast%3DTurkheimer%26aufirst%3DF.%2BE.%26aulast%3DHowes%26aufirst%3DO.%2BD.%26aulast%3DMcGuire%26aufirst%3DP.%26atitle%3DAcute%2520induction%2520of%2520anxiety%2520in%2520humans%2520by%2520delta-9-tetrahydrocannabinol%2520related%2520to%2520amygdalar%2520cannabinoid-1%2520%2528CB1%2529%2520receptors%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D15025%26doi%3D10.1038%2Fs41598-017-14203-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">Approaches to quantify radioligands that wash out slowly from target organs</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1007/s00259-010-1426-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00259-010-1426-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20358196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC3c3lvVOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=917-919&author=J.+Hirvonenauthor=G.+E.+Terryauthor=C.+Halldinauthor=V.+W.+Pikeauthor=R.+B.+Innis&title=Approaches+to+quantify+radioligands+that+wash+out+slowly+from+target+organs&doi=10.1007%2Fs00259-010-1426-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to quantify radioligands that wash out slowly from target organs</span></div><div class="casAuthors">Hirvonen Jussi; Terry Garth E; Halldin Christer; Pike Victor W; Innis Robert B</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">917-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTps0oEc91oVb5oR8RchjrrfW6udTcc2eZyhG0n7SBzK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3lvVOlug%253D%253D&md5=8165e589d3b290a23db51533b562ff1a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs00259-010-1426-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-010-1426-0%26sid%3Dliteratum%253Aachs%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DTerry%26aufirst%3DG.%2BE.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DApproaches%2520to%2520quantify%2520radioligands%2520that%2520wash%2520out%2520slowly%2520from%2520target%2520organs%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2010%26volume%3D37%26spage%3D917%26epage%3D919%26doi%3D10.1007%2Fs00259-010-1426-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R.</span></span> <span> </span><span class="NLM_article-title">Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1038/mp.2011.82</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fmp.2011.82" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21747398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1Sktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=642-649&author=J.+Hirvonenauthor=R.+Goodwinauthor=C.-T.+Liauthor=G.+Terryauthor=S.+Zoghbiauthor=C.+Morseauthor=V.+Pikeauthor=N.+Volkowauthor=M.+Huestisauthor=R.+Innis&title=Reversible+and+regionally+selective+downregulation+of+brain+cannabinoid+CB+1+receptors+in+chronic+daily+cannabis+smokers&doi=10.1038%2Fmp.2011.82"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers</span></div><div class="casAuthors">Hirvonen, J.; Goodwin, R. S.; Li, C.-T.; Terry, G. E.; Zoghbi, S. S.; Morse, C.; Pike, V. W.; Volkow, N. D.; Huestis, M. A.; Innis, R. B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">642-649</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic cannabis (marijuana, hashish) smoking can result in dependence.  Rodent studies show reversible downregulation of brain cannabinoid CB1 (cannabinoid receptor type 1) receptors after chronic exposure to cannabis.  However, whether downregulation occurs in humans who chronically smoke cannabis is unknown.  Here we show, using positron emission tomog. imaging, reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in human subjects who chronically smoke cannabis.  Downregulation correlated with years of cannabis smoking and was selective to cortical brain regions.  After ∼4 wk of continuously monitored abstinence from cannabis on a secure research unit, CB1 receptor d. returned to normal levels.  This is the first direct demonstration of cortical cannabinoid CB1 receptor downregulation as a neuroadaptation that may promote cannabis dependence in human brain.  Mol. Psychiatry (2012) 17, 642-649; doi:10.1038/mp.2011.82; published online 12 July 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSq7vDYUA3N7Vg90H21EOLACvtfcHk0ljpa0x3CKWWig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1Sktrc%253D&md5=81dbbb04565fdd12aad5646c9dcc2cae</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fmp.2011.82&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2011.82%26sid%3Dliteratum%253Aachs%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DGoodwin%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DC.-T.%26aulast%3DTerry%26aufirst%3DG.%26aulast%3DZoghbi%26aufirst%3DS.%26aulast%3DMorse%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%26aulast%3DVolkow%26aufirst%3DN.%26aulast%3DHuestis%26aufirst%3DM.%26aulast%3DInnis%26aufirst%3DR.%26atitle%3DReversible%2520and%2520regionally%2520selective%2520downregulation%2520of%2520brain%2520cannabinoid%2520CB%25201%2520receptors%2520in%2520chronic%2520daily%2520cannabis%2520smokers%26jtitle%3DMol.%2520Psychiatry%26date%3D2012%26volume%3D17%26spage%3D642%26epage%3D649%26doi%3D10.1038%2Fmp.2011.82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti-Fregonara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umhau, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rallis-Frutos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyoo, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, M.</span></span> <span> </span><span class="NLM_article-title">Reduced cannabinoid CB 1 receptor binding in alcohol dependence measured with positron emission tomography</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1038/mp.2012.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fmp.2012.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22776901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1SlsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=916-921&author=J.+Hirvonenauthor=P.+Zanotti-Fregonaraauthor=J.+C.+Umhauauthor=D.+T.+Georgeauthor=D.+Rallis-Frutosauthor=C.+H.+Lyooauthor=C.-T.+Liauthor=C.+S.+Hinesauthor=H.+Sunauthor=G.+E.+Terryauthor=C.+Morseauthor=S.+S.+Zoghbiauthor=V.+W.+Pikeauthor=R.+B.+Innisauthor=M.+Heilig&title=Reduced+cannabinoid+CB+1+receptor+binding+in+alcohol+dependence+measured+with+positron+emission+tomography&doi=10.1038%2Fmp.2012.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography</span></div><div class="casAuthors">Hirvonen, J.; Zanotti-Fregonara, P.; Umhau, J. C.; George, D. T.; Rallis-Frutos, D.; Lyoo, C. H.; Li, C.-T.; Hines, C. S.; Sun, H.; Terry, G. E.; Morse, C.; Zoghbi, S. S.; Pike, V. W.; Innis, R. B.; Heilig, M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">916-921</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Brain cannabinoid CB1 receptors contribute to alc.-related behaviors in exptl. animals, but their potential role in humans with alc. dependence is poorly understood.  We measured CB1 receptors in alc. dependent patients in early and protracted abstinence, and in comparison with control subjects without alc. use disorders, using positron emission tomog. and [18F]FMPEP-d2, a radioligand for CB1 receptors.  We scanned 18 male in-patients with alc. dependence twice, within 3-7 days of admission from ongoing drinking, and after 2-4 wk of supervised abstinence.  Imaging data were compared with those from 19 age-matched healthy male control subjects.  Data were also analyzed for potential influence of a common functional variation (rs2023239) in the CB1 receptor gene (CNR1) that may moderate CB1 receptor d.  On the first scan, CB1 receptor binding was 20-30% lower in patients with alc. dependence than in control subjects in all brain regions and was neg. correlated with years of alc. abuse.  After 2-4 wk of abstinence, CB1 receptor binding remained similarly reduced in these patients.  Irresp. of the diagnostic status, C allele carriers at rs2023239 had higher CB1 receptor binding compared with non-carriers.  Alc. dependence is assocd. with a widespread redn. of cannabinoid CB1 receptor binding in the human brain and this redn. persists at least 2-4 wk into abstinence.  The correlation of reduced binding with years of alc. abuse suggests an involvement of CB1 receptors in alc. dependence in humans.  Mol. Psychiatry (2013) 18, 916-921; doi:10.1038/mp.2012.100; published online 10 July 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC5CLHcqpwmLVg90H21EOLACvtfcHk0ljpa0x3CKWWig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1SlsbjE&md5=90de4a2b558c2f6d65833a6cebd14258</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fmp.2012.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2012.100%26sid%3Dliteratum%253Aachs%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DZanotti-Fregonara%26aufirst%3DP.%26aulast%3DUmhau%26aufirst%3DJ.%2BC.%26aulast%3DGeorge%26aufirst%3DD.%2BT.%26aulast%3DRallis-Frutos%26aufirst%3DD.%26aulast%3DLyoo%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DC.-T.%26aulast%3DHines%26aufirst%3DC.%2BS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DTerry%26aufirst%3DG.%2BE.%26aulast%3DMorse%26aufirst%3DC.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DHeilig%26aufirst%3DM.%26atitle%3DReduced%2520cannabinoid%2520CB%25201%2520receptor%2520binding%2520in%2520alcohol%2520dependence%2520measured%2520with%2520positron%2520emission%2520tomography%26jtitle%3DMol.%2520Psychiatry%26date%3D2013%26volume%3D18%26spage%3D916%26epage%3D921%26doi%3D10.1038%2Fmp.2012.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borgan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurikainen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaparanta-Solin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahoun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogdaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salokangas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karukivi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Forti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkheimer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hietala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O.</span></span> <span> </span><span class="NLM_article-title">In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis</span>. <i>JAMA Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1074</span>– <span class="NLM_lpage">1084</span>, <span class="refDoi"> DOI: 10.1001/jamapsychiatry.2019.1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1001%2Fjamapsychiatry.2019.1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31268519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3Mzjs1Khuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2019&pages=1074-1084&author=F.+Borganauthor=H.+Laurikainenauthor=M.+Veroneseauthor=T.+R.+Marquesauthor=M.+Haaparanta-Solinauthor=O.+Solinauthor=T.+Dahounauthor=M.+Rogdakiauthor=R.+K.+Salokangasauthor=M.+Karukiviauthor=M.+Di+Fortiauthor=F.+Turkheimerauthor=J.+Hietalaauthor=O.+Howes&title=In+vivo+availability+of+cannabinoid+1+receptor+levels+in+patients+with+first-episode+psychosis&doi=10.1001%2Fjamapsychiatry.2019.1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis</span></div><div class="casAuthors">Borgan Faith; Marques Tiago Reis; Di Forti Marta; Howes Oliver; Borgan Faith; Marques Tiago Reis; Dahoun Tarik; Rogdaki Maria; Howes Oliver; Laurikainen Heikki; Haaparanta-Solin Merja; Solin Olof; Hietala Jarmo; Laurikainen Heikki; Salokangas Raimo Kr; Hietala Jarmo; Veronese Mattia; Turkheimer Federico; Dahoun Tarik; Howes Oliver; Dahoun Tarik; Karukivi Max</div><div class="citationInfo"><span class="NLM_cas:title">JAMA psychiatry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1074-1084</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis.  However, whether CB1R levels are altered in the early stages of psychosis and whether they are linked to cognitive function or symptom severity remain unknown.  Objective:  To investigate CB1R availability in first-episode psychosis (FEP) without the confounds of illness chronicity or the use of illicit substances or antipsychotics.  Design, Setting, and Participants:  This cross-sectional, case-control study of 2 independent samples included participants receiving psychiatric early intervention services at 2 independent centers in Turku, Finland (study 1) and London, United Kingdom (study 2).  Study 1 consisted of 18 volunteers, including 7 patients with affective or nonaffective psychoses taking antipsychotic medication and 11 matched controls; study 2, 40 volunteers, including 20 antipsychotic-naive or antipsychotic-free patients with schizophrenia or schizoaffective disorder and 20 matched controls.  Data were collected from January 5, 2015, through September 26, 2018, and analyzed from June 20, 2016, through February 12, 2019.  Main Outcomes and Measures:  The availability of CB1R was indexed using the distribution volume (VT, in milliliters per cubic centimeter) of 2 CB1R-selective positron emission tomography radiotracers: fluoride 18-labeled FMPEP-d2 (study 1) and carbon 11-labeled MePPEP (study 2).  Cognitive function was measured using the Wechsler Digit Symbol Coding Test.  Symptom severity was measured using the Brief Psychiatric Rating Scale for study 1 and the Positive and Negative Syndrome Scale for study 2.  Results:  A total of 58 male individuals were included in the analyses (mean [SD] age of controls, 27.16 [5.93] years; mean [SD] age of patients, 26.96 [4.55] years).  In study 1, 7 male patients with FEP (mean [SD] age, 26.80 [5.40] years) were compared with 11 matched controls (mean [SD] age, 27.18 [5.86] years); in study 2, 20 male patients with FEP (mean [SD] age, 27.00 [5.06] years) were compared with 20 matched controls (mean [SD] age, 27.15 [6.12] years).  In study 1, a significant main effect of group on [18F]FMPEP-d2 VT was found in the anterior cingulate cortex (ACC) (t16 = -4.48; P < .001; Hedges g = 1.2), hippocampus (t16 = -2.98; P = .006; Hedges g = 1.4), striatum (t16 = -4.08; P = .001; Hedges g = 1.9), and thalamus (t16 = -4.67; P < .001; Hedges g = 1.4).  In study 2, a significant main effect of group on [11C]MePPEP VT was found in the ACC (Hedges g = 0.8), hippocampus (Hedges g = 0.5), striatum (Hedges g = 0.4), and thalamus (Hedges g = 0.7).  In patients, [11C]MePPEP VT in the ACC was positively associated with cognitive functioning (R = 0.60; P = .01), and [11C]MePPEP VT in the hippocampus was inversely associated with Positive and Negative Syndrome Scale total symptom severity (R = -0.50; P = .02).  Conclusions and Relevance:  The availability of CB1R was lower in antipsychotic-treated and untreated cohorts relative to matched controls.  Exploratory analyses indicated that greater reductions in CB1R levels were associated with greater symptom severity and poorer cognitive functioning in male patients.  These findings suggest that CB1R may be a potential target for the treatment of psychotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsgVim5oaKgUQ0lWbKiCflfW6udTcc2eYJBCkpCVwFjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mzjs1Khuw%253D%253D&md5=765b732632f557ca57db9573b9d11343</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2019.1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2019.1427%26sid%3Dliteratum%253Aachs%26aulast%3DBorgan%26aufirst%3DF.%26aulast%3DLaurikainen%26aufirst%3DH.%26aulast%3DVeronese%26aufirst%3DM.%26aulast%3DMarques%26aufirst%3DT.%2BR.%26aulast%3DHaaparanta-Solin%26aufirst%3DM.%26aulast%3DSolin%26aufirst%3DO.%26aulast%3DDahoun%26aufirst%3DT.%26aulast%3DRogdaki%26aufirst%3DM.%26aulast%3DSalokangas%26aufirst%3DR.%2BK.%26aulast%3DKarukivi%26aufirst%3DM.%26aulast%3DDi%2BForti%26aufirst%3DM.%26aulast%3DTurkheimer%26aufirst%3DF.%26aulast%3DHietala%26aufirst%3DJ.%26aulast%3DHowes%26aufirst%3DO.%26atitle%3DIn%2520vivo%2520availability%2520of%2520cannabinoid%25201%2520receptor%2520levels%2520in%2520patients%2520with%2520first-episode%2520psychosis%26jtitle%3DJAMA%2520Psychiatry%26date%3D2019%26volume%3D76%26spage%3D1074%26epage%3D1084%26doi%3D10.1001%2Fjamapsychiatry.2019.1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuominen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsback, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaparanta-Solin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hietala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuutila, P.</span></span> <span> </span><span class="NLM_article-title">The cannabinoid receptor-1 is an imaging biomarker of brown adipose tissue</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1941</span>, <span class="refDoi"> DOI: 10.2967/jnumed.115.156422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.115.156422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26359260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XntV2htL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=1937-1941&author=O.+Erikssonauthor=K.+Mikkolaauthor=D.+Espesauthor=L.+Tuominenauthor=K.+Virtanenauthor=S.+Forsbackauthor=M.+Haaparanta-Solinauthor=J.+Hietalaauthor=O.+Solinauthor=P.+Nuutila&title=The+cannabinoid+receptor-1+is+an+imaging+biomarker+of+brown+adipose+tissue&doi=10.2967%2Fjnumed.115.156422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The cannabinoid receptor-1 is an imaging biomarker of brown adipose tissue</span></div><div class="casAuthors">Eriksson, Olof; Mikkola, Kirsi; Espes, Daniel; Tuominen, Lauri; Virtanen, Kirsi; Forsback, Sarita; Haaparanta-Solin, Merja; Hietala, Jarmo; Solin, Olof; Nuutila, Pirjo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1937-1941</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Recently, the existence of significant deposits of brown adipose tissue (BAT) in human adults was confirmed.  Its role in the human metab. is unknown but could be substantial.  Inhibition of the cannabinoid receptor-1 (CB1) by the antagonist rimonabant (SR141716) has been assocd. with activation of BAT thermogenesis and wt. loss in mice and rats.  The role of peripheral and central CB1 in the activation of BAT merits further investigation.  Here we developed a technique for quantifying CB1 in BAT by PET.  Sections of rat BAT and s.c. white adipose tissue (WAT) were stained for CB1 and uncoupling protein-1 by immunofluorescent staining.  Binding of the radiolabeled CB1 antagonist (3R,5R)-5-(3-(18F-fluoromethoxy)phenyl)-3-(((R)-1-phenylethyl)amino)-1-(4-(trifluoromethyl)-phenyl)pyrrolidin-2-one (18F-FMPEP-d2) to BAT in vivo and in vitro was assessed in rats by PET.  We found that CB1 was colocalized with uncoupling protein-1 in BAT, but neither protein was found in WAT.  Binding of the radiotracer to BAT sections (but not WAT) in vitro was high and displaceable by pretreatment with rimonabant.  Deposits of BAT in rats had significant binding of 18F-FMPEP-d2 in vivo, indicating high CB1 d.  WAT deposits were neg. for 18F-FMPEP-d2, consistent with the immunofluorescent staining and in vitro results.  Conclusion:18F-FMPEP-d2 PET can quantify CB1 d. noninvasively in vivo in rats.  CB1 is therefore a promising surrogate imaging biomarker for assessing the presence of BAT deposits as well as for elucidating the mechanism of CB1 antagonist-mediated wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOYHvJSreG5LVg90H21EOLACvtfcHk0lgczhRMt-3G0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntV2htL0%253D&md5=2d88732d8a0fedcde52560f88b76f66e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.115.156422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.115.156422%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DO.%26aulast%3DMikkola%26aufirst%3DK.%26aulast%3DEspes%26aufirst%3DD.%26aulast%3DTuominen%26aufirst%3DL.%26aulast%3DVirtanen%26aufirst%3DK.%26aulast%3DForsback%26aufirst%3DS.%26aulast%3DHaaparanta-Solin%26aufirst%3DM.%26aulast%3DHietala%26aufirst%3DJ.%26aulast%3DSolin%26aufirst%3DO.%26aulast%3DNuutila%26aufirst%3DP.%26atitle%3DThe%2520cannabinoid%2520receptor-1%2520is%2520an%2520imaging%2520biomarker%2520of%2520brown%2520adipose%2520tissue%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26spage%3D1937%26epage%3D1941%26doi%3D10.2967%2Fjnumed.115.156422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahesmaa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikonen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskensalo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teuho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taittonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahdenpohja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">U Din, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaparanta-Solin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuutila, P.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid type 1 receptors are upregulated during acute activation of brown adipose tissue</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1226</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.2337/db17-1366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2337%2Fdb17-1366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29650773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktleqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2018&pages=1226-1236&author=M.+Lahesmaaauthor=O.+Erikssonauthor=T.+Gnadauthor=V.+Oikonenauthor=M.+Bucciauthor=J.+Hirvonenauthor=K.+Koskensaloauthor=J.+Teuhoauthor=T.+Niemiauthor=M.+Taittonenauthor=S.+Lahdenpohjaauthor=M.+U+Dinauthor=M.+Haaparanta-Solinauthor=A.+Pfeiferauthor=K.+A.+Virtanenauthor=P.+Nuutila&title=Cannabinoid+type+1+receptors+are+upregulated+during+acute+activation+of+brown+adipose+tissue&doi=10.2337%2Fdb17-1366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid Type 1 Receptors Are Upregulated During Acute Activation of Brown Adipose Tissue</span></div><div class="casAuthors">Lahesmaa, Minna; Eriksson, Olof; Gnad, Thorsten; Oikonen, Vesa; Bucci, Marco; Hirvonen, Jussi; Koskensalo, Kalle; Teuho, Jarmo; Niemi, Tarja; Taittonen, Markku; Lahdenpohja, Salla; Din, Mueez U.; Haaparanta-Solin, Merja; Pfeifer, Alexander; Virtanen, Kirsi A.; Nuutila, Pirjo</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1226-1236</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Activating brown adipose tissue (BAT) could provide a potential approach for the treatment of obesity and metabolic disease in humans.  Obesity is assocd. with upregulation of the endocannabinoid system, and blocking the cannabinoid type 1 receptor (CB1R) has been shown to cause wt. loss and to decrease cardiometabolic risk factors.  These effects may be mediated partly via increased BAT metab., since there is evidence that CB1R antagonism activates BAT in rodents.  To investigate the significance of CB1R in BAT function, we quantified the d. of CB1R in human and rodent BAT using the positron emission tomog. radioligand [18F]FMPEP-d2 and measured BAT activation in parallel with the glucose analog [18F]-fluorodeoxyglucose.  Activation by cold exposure markedly increased CB1R d. and glucose uptake in the BAT of lean men.  Similarly, β3-receptor agonism increased CB1R d. in the BAT of rats.  In contrast, overweight men with reduced BAT activity exhibited decreased CB1R in BAT, reflecting impaired endocannabinoid regulation.  Image-guided biopsies confirmed CB1R mRNA expression in human BAT.  Furthermore, CB1R blockade increased glucose uptake and lipolysis of brown adipocytes.  Our results highlight that CB1Rs are significant for human BAT activity, and the CB1Rs provide a novel therapeutic target for BAT activation in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrld9meZDX3-7Vg90H21EOLACvtfcHk0lgczhRMt-3G0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktleqsLc%253D&md5=a0c46b08748f0e0aa391b47502ab3988</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2337%2Fdb17-1366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb17-1366%26sid%3Dliteratum%253Aachs%26aulast%3DLahesmaa%26aufirst%3DM.%26aulast%3DEriksson%26aufirst%3DO.%26aulast%3DGnad%26aufirst%3DT.%26aulast%3DOikonen%26aufirst%3DV.%26aulast%3DBucci%26aufirst%3DM.%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DKoskensalo%26aufirst%3DK.%26aulast%3DTeuho%26aufirst%3DJ.%26aulast%3DNiemi%26aufirst%3DT.%26aulast%3DTaittonen%26aufirst%3DM.%26aulast%3DLahdenpohja%26aufirst%3DS.%26aulast%3DU%2BDin%26aufirst%3DM.%26aulast%3DHaaparanta-Solin%26aufirst%3DM.%26aulast%3DPfeifer%26aufirst%3DA.%26aulast%3DVirtanen%26aufirst%3DK.%2BA.%26aulast%3DNuutila%26aufirst%3DP.%26atitle%3DCannabinoid%2520type%25201%2520receptors%2520are%2520upregulated%2520during%2520acute%2520activation%2520of%2520brown%2520adipose%2520tissue%26jtitle%3DDiabetes%26date%3D2018%26volume%3D67%26spage%3D1226%26epage%3D1236%26doi%3D10.2337%2Fdb17-1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burns, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanabria-Bohorquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamill, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lepeleire, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoch, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagmann, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesdiener, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Hoon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortelmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span> <span> </span><span class="NLM_article-title">[<sup>18</sup>F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">9800</span>– <span class="NLM_lpage">9805</span>, <span class="refDoi"> DOI: 10.1073/pnas.0703472104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.0703472104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17535893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFSmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=9800-9805&author=H.+D.+Burnsauthor=K.+Van+Laereauthor=S.+Sanabria-Bohorquezauthor=T.+G.+Hamillauthor=G.+Bormansauthor=W.+S.+Engauthor=R.+Gibsonauthor=C.+Ryanauthor=B.+Connollyauthor=S.+Patelauthor=S.+Krauseauthor=A.+Vankoauthor=A.+Van+Heckenauthor=P.+Dupontauthor=I.+De+Lepeleireauthor=P.+Rothenbergauthor=S.+A.+Stochauthor=J.+Coteauthor=W.+K.+Hagmannauthor=J.+P.+Jewellauthor=L.+S.+Linauthor=P.+Liuauthor=M.+T.+Gouletauthor=K.+Gottesdienerauthor=J.+A.+Wagnerauthor=J.+de+Hoonauthor=L.+Mortelmansauthor=T.+M.+Fongauthor=R.+J.+Hargreaves&title=%5B18F%5DMK-9470%2C+a+positron+emission+tomography+%28PET%29+tracer+for+in+vivo+human+PET+brain+imaging+of+the+cannabinoid-1+receptor&doi=10.1073%2Fpnas.0703472104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor</span></div><div class="casAuthors">Burns, H. Donald; Van Laere, Koen; Sanabria-Bohorquez, Sandra; Hamill, Terence G.; Bormans, Guy; Eng, Wai-Si; Gibson, Ray; Ryan, Christine; Connolly, Brett; Patel, Shil; Krause, Stephen; Vanko, Amy; Van Hecken, Anne; Dupont, Patrick; De Lepeleire, Inge; Rothenberg, Paul; Stoch, S. Aubrey; Cote, Josee; Hagmann, William K.; Jewell, James P.; Lin, Linus S.; Liu, Ping; Goulet, Mark T.; Gottesdiener, Keith; Wagner, John A.; de Hoon, Jan; Mortelmans, Luc; Fong, Tung M.; Hargreaves, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9800-9805</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">[18F]MK-9470 is a selective, high-affinity, inverse agonist (human IC50, 0.7 nM) for the cannabinoid CB1 receptor (CB1R) that has been developed for use in human brain imaging.  Autoradiog. studies in rhesus monkey brain showed that [18F]MK-9470 binding is aligned with the reported distribution of CB1 receptors with high specific binding in the cerebral cortex, cerebellum, caudate/putamen, globus pallidus, substantia nigra, and hippocampus.  Positron emission tomog. (PET) imaging studies in rhesus monkeys showed high brain uptake and a distribution pattern generally consistent with that seen in the autoradiog. studies.  Uptake was blocked by pretreatment with a potent CB1 inverse agonist, MK-0364.  The ratio of total to nonspecific binding in putamen was 4-5:1, indicative of a strong specific signal that was confirmed to be reversible via displacement studies with MK-0364.  Baseline PET imaging studies in human research subject demonstrated behavior of [18F]MK-9470 very similar to that seen in monkeys, with very good test-retest variability (7%).  Proof of concept studies in healthy young male human subjects showed that MK-0364, given orally, produced a dose-related redn. in [18F]MK-9470 binding reflecting CB1R receptor occupancy by the drug.  Thus, [18F]MK-9470 has the potential to be a valuable, noninvasive research tool for the in vivo study of CB1R biol. and pharmacol. in a variety of neuropsychiatric disorders in humans.  In addn., it allows demonstration of target engagement and noninvasive dose-occupancy studies to aid in dose selection for clin. trials of CB1R inverse agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8neFicpfiT7Vg90H21EOLACvtfcHk0lhcpiaD9tQ3cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFSmsLc%253D&md5=d8bca5f5cbbc743319c3df462dc8972c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0703472104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0703472104%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DH.%2BD.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DSanabria-Bohorquez%26aufirst%3DS.%26aulast%3DHamill%26aufirst%3DT.%2BG.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DEng%26aufirst%3DW.%2BS.%26aulast%3DGibson%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DC.%26aulast%3DConnolly%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DKrause%26aufirst%3DS.%26aulast%3DVanko%26aufirst%3DA.%26aulast%3DVan%2BHecken%26aufirst%3DA.%26aulast%3DDupont%26aufirst%3DP.%26aulast%3DDe%2BLepeleire%26aufirst%3DI.%26aulast%3DRothenberg%26aufirst%3DP.%26aulast%3DStoch%26aufirst%3DS.%2BA.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DLin%26aufirst%3DL.%2BS.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DGoulet%26aufirst%3DM.%2BT.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BHoon%26aufirst%3DJ.%26aulast%3DMortelmans%26aufirst%3DL.%26aulast%3DFong%26aufirst%3DT.%2BM.%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26atitle%3D%255B18F%255DMK-9470%252C%2520a%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520tracer%2520for%2520in%2520vivo%2520human%2520PET%2520brain%2520imaging%2520of%2520the%2520cannabinoid-1%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D9800%26epage%3D9805%26doi%3D10.1073%2Fpnas.0703472104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kent, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=6104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADyaL3c3gvFKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1980&pages=14-23&author=R.+S.+Kentauthor=A.+De+Leanauthor=R.+J.+Lefkowitz&title=A+quantitative+analysis+of+beta-adrenergic+receptor+interactions%3A+resolution+of+high+and+low+affinity+states+of+the+receptor+by+computer+modeling+of+ligand+binding+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data</span></div><div class="casAuthors">Kent R S; De Lean A; Lefkowitz R J</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-23</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvtQ56tMYqkK69lAbTj9rGfW6udTcc2eZ1Om54H_27qLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3c3gvFKqtQ%253D%253D&md5=70f9116fd24d17e34229d48137cafa4e</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKent%26aufirst%3DR.%2BS.%26aulast%3DDe%2BLean%26aufirst%3DA.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520beta-adrenergic%2520receptor%2520interactions%253A%2520resolution%2520of%2520high%2520and%2520low%2520affinity%2520states%2520of%2520the%2520receptor%2520by%2520computer%2520modeling%2520of%2520ligand%2520binding%2520data%26jtitle%3DMol.%2520Pharmacol.%26date%3D1980%26volume%3D17%26spage%3D14%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortelmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Hoon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span> <span> </span><span class="NLM_article-title">Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [<sup>18</sup>F]MK-9470 PET</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1533</span>– <span class="NLM_lpage">1541</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2007.10.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2007.10.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18077184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FovFSqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2008&pages=1533-1541&author=K.+Van+Laereauthor=K.+Goffinauthor=C.+Casteelsauthor=P.+Dupontauthor=L.+Mortelmansauthor=J.+de+Hoonauthor=G.+Bormans&title=Gender-dependent+increases+with+healthy+aging+of+the+human+cerebral+cannabinoid-type+1+receptor+binding+using+%5B18F%5DMK-9470+PET&doi=10.1016%2Fj.neuroimage.2007.10.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET</span></div><div class="casAuthors">Van Laere Koen; Goffin Karolien; Casteels Cindy; Dupont Patrick; Mortelmans Luc; de Hoon Jan; Bormans Guy</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1533-41</span>
        ISSN:<span class="NLM_cas:issn">1053-8119</span>.
    </div><div class="casAbstract">The endocannabinoid system (ECS) is implicated as a regulator of homeostasis of several cerebral functions and is a novel target for drug treatment of neuropyschiatric disorders.  So far, the cerebral cannabinoid-type 1 receptor (CB1R) has only been studied using in vitro, animal model, electrophysiological and post-mortem data.  We have used positron emission tomography (PET) using a high-affinity, subtype-selective radioligand, [(18)F]MK-9470, to assess the in vivo cerebral CB1R distribution and its variation with healthy aging and gender.  Fifty healthy volunteers (25 M/25 F, 18-69 years) underwent [(18)F]MK-9470 PET.  Parametric [(18)F]MK-9470 binding maps were constructed, corrected for partial volume effects and analyzed using statistical parametric mapping in a combined categorical (gender) and covariate (age) design.  We found that [(18)F]MK-9470 binding to CB1R increased with aging but only in women (p(FWE)<0.05, corrected for multiple comparisons); this was most pronounced in the basal ganglia, lateral temporal cortex and limbic system, especially in the hippocampus.  Men showed higher [(18)F]MK-9470 binding then women (p<0.001, uncorrected), in clusters of the limbic system and cortico-striato-thalamic-cortical circuit.  Region-dependent and gender-related upregulation of [(18)F]MK-9470 binding with aging is in line with ex vivo findings in rodent studies and may be associated with a changing homeostatic capacity or compensation mechanisms in the ECS that is modulated by sex hormones.  In vivo PET of the CB1R will likely improve our understanding of the ECS in several neurological and psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRkebs6x3EJPcsfMJQC1ZdfW6udTcc2eZ1Om54H_27qLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FovFSqtQ%253D%253D&md5=6c7b114e4cbfe1da00d79d74de5d39c2</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2007.10.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2007.10.053%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DGoffin%26aufirst%3DK.%26aulast%3DCasteels%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DP.%26aulast%3DMortelmans%26aufirst%3DL.%26aulast%3Dde%2BHoon%26aufirst%3DJ.%26aulast%3DBormans%26aufirst%3DG.%26atitle%3DGender-dependent%2520increases%2520with%2520healthy%2520aging%2520of%2520the%2520human%2520cerebral%2520cannabinoid-type%25201%2520receptor%2520binding%2520using%2520%255B18F%255DMK-9470%2520PET%26jtitle%3DNeuroImage%26date%3D2008%26volume%3D39%26spage%3D1533%26epage%3D1541%26doi%3D10.1016%2Fj.neuroimage.2007.10.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gérard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2011.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.biopsych.2011.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21718968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GntrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=777-784&author=N.+G%C3%A9rardauthor=G.+Pietersauthor=K.+Goffinauthor=G.+Bormansauthor=K.+Van+Laere&title=Brain+type+1+cannabinoid+receptor+availability+in+patients+with+anorexia+and+bulimia+nervosa&doi=10.1016%2Fj.biopsych.2011.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Type 1 Cannabinoid Receptor Availability in Patients with Anorexia and Bulimia Nervosa</span></div><div class="casAuthors">Gerard, Nathalie; Pieters, Guido; Goffin, Karolien; Bormans, Guy; Van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">777-784</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The endocannabinoid system is a possible target in the treatment of eating disorders.  We used positron emission tomog. to investigate the type 1 cannabinoid receptor (CB1R) in bulimic and anorectic patients.  We investigated 16 female bulimia nervosa patients (BN) (age = 23.8 ± 7.1 years) and 14 female anorexia nervosa patients (AN) (age = 20.5 ± 3.6 years) using the selective CB1R ligand [18F]MK-9470.  The control group consisted of 19 age-matched women (age = 25.2 ± 8.5 years).  Statistical parametric mapping (p family-wise error < .05) and vol.-of-interest analyses of CB1R availability were performed.  Global CB1R availability was significantly increased in cortical and subcortical brain areas in AN patients compared with healthy control subjects (+24.5%, p = .0003).  Regionally, CB1R availability was increased in the insula in both AN and BN patients (p = .01 and p = .0004) and the inferior frontal and temporal cortex in AN patients only (p = .02).  Global CB1R upregulation in AN patients is a possible long-term compensatory mechanism to an underactive endocannabinoid system in anorectic conditions.  There is a similarity in CB1R dysregulation both in AN and BN in the insular cortex, which is involved in the integration of interoceptive information, gustatory information, reward, and emotion processing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAhT1tF1-SpbVg90H21EOLACvtfcHk0ljuYXdAPO7-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GntrnJ&md5=2d48bfa7bea48333e632d83c5c2a477e</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2011.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2011.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25A9rard%26aufirst%3DN.%26aulast%3DPieters%26aufirst%3DG.%26aulast%3DGoffin%26aufirst%3DK.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DBrain%2520type%25201%2520cannabinoid%2520receptor%2520availability%2520in%2520patients%2520with%2520anorexia%2520and%2520bulimia%2520nervosa%26jtitle%3DBiol.%2520Psychiatry%26date%3D2011%26volume%3D70%26spage%3D777%26epage%3D784%26doi%3D10.1016%2Fj.biopsych.2011.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van der Schueren, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gérard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Hoon, J. N.</span></span> <span> </span><span class="NLM_article-title">Interictal type 1 cannabinoid receptor binding is increased in female migraine patients</span>. <i>Headache</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1111/j.1526-4610.2011.02030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1526-4610.2011.02030.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22077199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC383pvVyntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=433-440&author=B.+J.+Van+der+Schuerenauthor=K.+Van+Laereauthor=N.+G%C3%A9rardauthor=G.+Bormansauthor=J.+N.+De+Hoon&title=Interictal+type+1+cannabinoid+receptor+binding+is+increased+in+female+migraine+patients&doi=10.1111%2Fj.1526-4610.2011.02030.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Interictal type 1 cannabinoid receptor binding is increased in female migraine patients</span></div><div class="casAuthors">Van der Schueren Bart J; Van Laere Koen; Gerard Nathalie; Bormans Guy; De Hoon Jan N</div><div class="citationInfo"><span class="NLM_cas:title">Headache</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">433-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To compare binding of the type 1 cannabinoid receptor (CB1R) between migraine patients and healthy volunteers.  BACKGROUND:  It has been suggested that endocannabinoid deficiency may play a role in the pathophysiology of migraine.  Nonetheless, biochemical studies substantiating this idea remain scarce and are faced with methodological shortcomings partly because of the difficulty to perform measurements of endocannabinoids within the central nervous system itself.  METHODS:  An observational cross-sectional study was conducted in 20 female migraine patients and 18 healthy women matched for age and body mass index.  Positron emission tomography acquisition was performed 90 minutes after intravenous injection of the radioligand [(18)F]MK-9470 to assess binding of [(18)F]MK-9470 to CB1R.  RESULTS:  Binding of CB1 R was globally increased in migraine patients vs healthy controls (average gray matter difference +16%; P = .009, 2-sample 2-sided Student's t-test).  There were no correlations between CB1R binding and any predefined migraine characteristics.  Increases in CB1R binding were most pronounced in the anterior cingulate, mesial temporal, prefrontal, and superior frontal cortices.  CONCLUSION:  The increased interictal CB1R binding, especially in brain regions that exert top-down influences to modulate pain, supports the idea that endocannibinoid deficiency is present in female patients suffering from episodic migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLXDtqzqQ_X0kUaC_kzhvyfW6udTcc2eZ-NEptR0ucN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383pvVyntA%253D%253D&md5=b063478758937ca9eb0bd7d43dd3dc60</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1526-4610.2011.02030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1526-4610.2011.02030.x%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BSchueren%26aufirst%3DB.%2BJ.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DG%25C3%25A9rard%26aufirst%3DN.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DDe%2BHoon%26aufirst%3DJ.%2BN.%26atitle%3DInterictal%2520type%25201%2520cannabinoid%2520receptor%2520binding%2520is%2520increased%2520in%2520female%2520migraine%2520patients%26jtitle%3DHeadache%26date%3D2012%26volume%3D52%26spage%3D433%26epage%3D440%26doi%3D10.1111%2Fj.1526-4610.2011.02030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Paesschen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.1093/brain/awq385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1093%2Fbrain%2Fawq385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21303859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC3Mvgt12gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2011&pages=1033-1040&author=K.+Goffinauthor=W.+Van+Paesschenauthor=K.+Van+Laere&title=In+vivo+activation+of+endocannabinoid+system+in+temporal+lobe+epilepsy+with+hippocampal+sclerosis&doi=10.1093%2Fbrain%2Fawq385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis</span></div><div class="casAuthors">Goffin Karolien; Van Paesschen Wim; Van Laere Koen</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">Pt 4</span>),
    <span class="NLM_cas:pages">1033-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The endocannabinoid system modulates neuronal excitability, protects neurons against hyperexcitability and is involved in epileptogenesis in animal models of mesial temporal lobe epilepsy with hippocampal sclerosis.  We performed in vivo positron emission tomography imaging of the type 1 cannabinoid receptor in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.  Twelve patients with refractory mesial temporal lobe epilepsy due to hippocampal sclerosis received a [(18)F]MK-9470 scan to assess type 1 cannabinoid receptor availability in vivo.  Parametric modified standard uptake values were used as quantitative measure of type 1 cannabinoid receptor availability and images were spatially normalized to standard space.  Voxel-based analysis was performed comparing patients with hippocampal sclerosis to controls and correlations between type 1 cannabinoid receptor status and seizure characteristics were done using volumes of interest.  Type 1 cannabinoid receptor positron emission tomography was co-registered with subtraction ictal single photon emission computed tomography co-registered to magnetic resonance imaging of a complex partial seizure (n = 9).  An increased type 1 cannabinoid receptor availability in the ipsilateral temporal lobe was observed, which correlated negatively with the latency since last seizure before scanning and positively to the number of seizures in the month before scanning.  A decreased type 1 cannabinoid receptor availability was present in the superior insular cortex, ipsilateral more than contralateral.  The ipsilateral insular region displayed a mild ictal hyperperfusion in the transition zone of subtraction ictal single photon emission computed tomography co-registered to magnetic resonance imaging temporal lobe hyperperfusion-frontal lobe hypoperfusion during complex partial seizures.  Type 1 cannabinoid receptor availability showed opposite changes in different brain regions that are involved during complex partial seizures in refractory mesial temporal lobe epilepsy with hippocampal sclerosis.  The increase in type 1 cannabinoid receptor availability at the seizure onset zone might be a protective mechanism of neurons against hyperexcitability and seizure activity, or contribute to the process of epileptogenesis, or both.  The decreased type 1 cannabinoid receptor availability in the insula may play a role in surround inhibition and prevention of seizure propagation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMoXID3BH1GEbxh97K6Vt6fW6udTcc2eZ-NEptR0ucN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mvgt12gsw%253D%253D&md5=862b151f793157cdb1017597a293c379</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawq385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawq385%26sid%3Dliteratum%253Aachs%26aulast%3DGoffin%26aufirst%3DK.%26aulast%3DVan%2BPaesschen%26aufirst%3DW.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DIn%2520vivo%2520activation%2520of%2520endocannabinoid%2520system%2520in%2520temporal%2520lobe%2520epilepsy%2520with%2520hippocampal%2520sclerosis%26jtitle%3DBrain%26date%3D2011%26volume%3D134%26spage%3D1033%26epage%3D1040%26doi%3D10.1093%2Fbrain%2Fawq385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Vliet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbulcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Behavioral symptoms in premanifest huntington disease correlate with reduced frontal CB1R levels</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.2967/jnumed.118.210393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.118.210393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29934407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOmu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=115-121&author=J.+Ceccariniauthor=R.+Ahmadauthor=L.+Van+de+Vlietauthor=C.+Casteelsauthor=M.+Vandenbulckeauthor=W.+Vandenbergheauthor=K.+Van+Laere&title=Behavioral+symptoms+in+premanifest+huntington+disease+correlate+with+reduced+frontal+CB1R+levels&doi=10.2967%2Fjnumed.118.210393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral symptoms in premanifest huntington disease correlate with reduced frontal CB1R levels</span></div><div class="casAuthors">Ceccarini, Jenny; Ahmad, Rawaha; Van de Vliet, Laura; Casteels, Cindy; Vandenbulcke, Mathieu; Vandenberghe, Wim; Van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-121</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Many Huntington disease (HD) mutation carriers already have cognitive and psychiatric symptoms in the premanifest (premotor) phase of the disease (pre-HD), but the mol. underpinnings of these symptoms are not well understood.  Previous work has shown reduced availability of the cerebral type 1 cannabinoid receptor (CB1R) in manifest HD.  Here, we investigated whether CB1R binding is related to cognitive and psychiatric symptoms in pre-HD mutation carriers.  Methods: CB1R binding was measured with 18F-MK-9470 (N-[(2S,3S)-3-(3-cyanophenyl)-4-(4-ethoxyphenyl)butan-2-yl]-2-methyl-2-(5-methylpyridin-2-yl)oxypropanamide) PET in 15 pre-HD subjects (8 men, 7 women; age, 39.3 ± 9.9 y), 15 gene-neg. controls from HD families (9 men, 6 women; age, 37.0 ± 10.6 y), and 12 community controls (6 men and 6 women; age, 39.9 ± 15.1 y).  All subjects also underwent extensive assessment of motor and cognitive function, as well as a behavioral test battery including the Problem Behavior Assessment for HD (PBA-HD), and MRI.  Parametric binding images of 18F-MK-9470 were cor. for partial-vol. effect.  Results: There was no difference in CB1R binding, gray matter vol., cognitive function, or psychiatric scores between gene-neg. controls from HD families and community controls, which were therefore pooled to one control group.  Compared with controls, pre-HD subjects showed striatal atrophy, a decrease in CB1R binding in the prefrontal cortex, and higher PBA-HD scores on depression, apathy, and irritability (range, P = 0.01-0.005).  The PBA-HD scores inversely correlated with CB1R binding in prefrontal regions and cingulate cortex in pre-HD (range: r = -0.64 to -0.72; P = 0.01-0.008).  Conclusion: The assocn. between behavioral symptoms and reduced prefrontal CB1R levels may provide new insight into the mol. basis of neuropsychiatric symptoms in pre-HD and suggest new therapeutic avenues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL33qq-XJBJbVg90H21EOLACvtfcHk0lg1mlKWPzctMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOmu7bM&md5=98f9c4984ecfeda0cf9e67c10c0579b7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.210393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.210393%26sid%3Dliteratum%253Aachs%26aulast%3DCeccarini%26aufirst%3DJ.%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DVan%2Bde%2BVliet%26aufirst%3DL.%26aulast%3DCasteels%26aufirst%3DC.%26aulast%3DVandenbulcke%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DW.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DBehavioral%2520symptoms%2520in%2520premanifest%2520huntington%2520disease%2520correlate%2520with%2520reduced%2520frontal%2520CB1R%2520levels%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D115%26epage%3D121%26doi%3D10.2967%2Fjnumed.118.210393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabbé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Vliet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaute, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbulcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson’s disease</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2348</span>– <span class="NLM_lpage">2357</span>, <span class="refDoi"> DOI: 10.1007/s00259-019-04445-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00259-019-04445-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31342135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVCht7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2019&pages=2348-2357&author=J.+Ceccariniauthor=C.+Casteelsauthor=R.+Ahmadauthor=M.+Crabb%C3%A9author=L.+Van+de+Vlietauthor=H.+Vanhauteauthor=M.+Vandenbulckeauthor=W.+Vandenbergheauthor=K.+Van+Laere&title=Regional+changes+in+the+type+1+cannabinoid+receptor+are+associated+with+cognitive+dysfunction+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs00259-019-04445-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease</span></div><div class="casAuthors">Ceccarini, Jenny; Casteels, Cindy; Ahmad, Rawaha; Crabbe, Melissa; Van de Vliet, Laura; Vanhaute, Heleen; Vandenbulcke, Mathieu; Vandenberghe, Wim; Van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2348-2357</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The endocannabinoid system plays a regulatory role in a no. of physiol. functions, including motor control but also mood, emotion, and cognition.  A no. of preclin. studies in Parkinson's disease (PD) models demonstrated that modulating the type 1 cannabinoid receptor (CB1R) may improve motor symptoms and components of cognitive processing.  However, the relation between CB1R, cognitive decline and behavioral symptoms has not been investigated in PD patients so far.  The aim of this study was to examine whether CB1R availability is assocd. with measures of cognitive and behavioral function in PD patients.  Methods: Thirty-eight PD patients and ten age- and gender-matched controls underwent a [18F]MK-9470 PET scan to assess CB1R availability, as well as volumetric MR imaging.  Neuropsychol. symptoms were evaluated using an extensive cognitive and behavioral battery covering the five cognitive domains, depression, anxiety, apathy, and psychiatric complications, and were correlated to CB1R availability using vowel-wise regression anal. (P < 0.05, cor. for family-wise error).  Results: PD patients with poorer performance in episodic memory, executive functioning, speed and mental flexibility (range P 0.003-0.03) showed lower CB1R availability in predominantly the midcingulate cortex and middle to superior frontal gyrus (Tpeak-level > 4.0).  Also, PD patients with more severe visuospatial dysfunction showed decreased CB1R availability in the precuneus, midcingulate, supplementary motor cortex, inferior orbitofrontal gyrus and thalamus (Tpeak-level = 5.5).  These correlations were not related to cortical gray matter atrophy.  No relationship was found between CB1R availability and mood or behavioral symptom scores.  Conclusions: Decreased CB1R availability in the prefrontal and midcingulate cortex in PD patients is strongly correlated with disturbances in executive functioning, episodic memory, and visuospatial functioning.  Further investigation of regional CB1R expression in groups of PD patients with mild cognitive impairment or dementia is warranted in order to further investigate the role of CB1R expression in different levels of cognitive impairment in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0x0S4EDHDR7Vg90H21EOLACvtfcHk0lg1mlKWPzctMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVCht7bL&md5=c8153c6b49172901b13fbff26460a461</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs00259-019-04445-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-019-04445-x%26sid%3Dliteratum%253Aachs%26aulast%3DCeccarini%26aufirst%3DJ.%26aulast%3DCasteels%26aufirst%3DC.%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DCrabb%25C3%25A9%26aufirst%3DM.%26aulast%3DVan%2Bde%2BVliet%26aufirst%3DL.%26aulast%3DVanhaute%26aufirst%3DH.%26aulast%3DVandenbulcke%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DW.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DRegional%2520changes%2520in%2520the%2520type%25201%2520cannabinoid%2520receptor%2520are%2520associated%2520with%2520cognitive%2520dysfunction%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2019%26volume%3D46%26spage%3D2348%26epage%3D2357%26doi%3D10.1007%2Fs00259-019-04445-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span> <span> </span><span class="NLM_article-title">End of the line for cannabinoid receptor 1 as an anti-obesity target?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1038/nrd2775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrd2775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19043439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVenurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=961-962&author=D.+Jones&title=End+of+the+line+for+cannabinoid+receptor+1+as+an+anti-obesity+target%3F&doi=10.1038%2Fnrd2775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">End of the line for cannabinoid receptor 1 as an anti-obesity target?</span></div><div class="casAuthors">Jones, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">961-962</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A wave of terminations of development programs for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters.  Nevertheless, lessons learned might help salvage something for future such approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnUVPwDEhXwrVg90H21EOLACvtfcHk0lg1mlKWPzctMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVenurbO&md5=e9f31da702da5a058d2ece7ab08be3c0</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnrd2775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2775%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DD.%26atitle%3DEnd%2520of%2520the%2520line%2520for%2520cannabinoid%2520receptor%25201%2520as%2520an%2520anti-obesity%2520target%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D961%26epage%3D962%26doi%3D10.1038%2Fnrd2775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnema, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vivo evaluation of a new PET radioligand for imaging the cannabinoid type-1 (CB1) receptors</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">T50</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2006.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2006.04.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=T50&author=S.+Donohueauthor=C.+Halldinauthor=S.+Finnemaauthor=B.+Gulyasauthor=V.+Pike&title=Synthesis+and+in+vivo+evaluation+of+a+new+PET+radioligand+for+imaging+the+cannabinoid+type-1+%28CB1%29+receptors&doi=10.1016%2Fj.neuroimage.2006.04.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2006.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2006.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DS.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DFinnema%26aufirst%3DS.%26aulast%3DGulyas%26aufirst%3DB.%26aulast%3DPike%26aufirst%3DV.%26atitle%3DSynthesis%2520and%2520in%2520vivo%2520evaluation%2520of%2520a%2520new%2520PET%2520radioligand%2520for%2520imaging%2520the%2520cannabinoid%2520type-1%2520%2528CB1%2529%2520receptors%26jtitle%3DNeuroImage%26date%3D2006%26volume%3D31%26spage%3DT50%26doi%3D10.1016%2Fj.neuroimage.2006.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsujikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenko, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladding, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of 11C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2013.09.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2013.09.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24076222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWju7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2014&pages=733-741&author=T.+Tsujikawaauthor=S.+S.+Zoghbiauthor=J.+Hongauthor=S.+R.+Donohueauthor=K.+J.+Jenkoauthor=R.+L.+Gladdingauthor=C.+Halldinauthor=V.+W.+Pikeauthor=R.+B.+Innisauthor=M.+Fujita&title=In+vitro+and+in+vivo+evaluation+of+11C-SD5024%2C+a+novel+PET+radioligand+for+human+brain+imaging+of+cannabinoid+CB1+receptors&doi=10.1016%2Fj.neuroimage.2013.09.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo evaluation of 11C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors</span></div><div class="casAuthors">Tsujikawa, Tetsuya; Zoghbi, Sami S.; Hong, Jinsoo; Donohue, Sean R.; Jenko, Kimberly J.; Gladding, Robert L.; Halldin, Christer; Pike, Victor W.; Innis, Robert B.; Fujita, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">733-741</span>CODEN:
                <span class="NLM_cas:coden">NEIMEF</span>;
        ISSN:<span class="NLM_cas:issn">1053-8119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We recently developed a novel cannabinoid subtype-1 (CB1) receptor radioligand 11C-SD5024 for brain imaging.  This study aimed to evaluate 11C-SD5024 both in vitro and in vivo and compare it with the other CB1 receptor ligands previously used in humans, i.e., 11C-MePPEP, 11C-OMAR, 18F-MK-9470, and 18F-FMPEP-d2.  In vitro expts. were performed to measure dissocn. const. (Ki) in the human brain and to measure the lipophilicity of the five CB1 receptor ligands listed above.  In vivo specific binding in monkeys was measured by comparing total distribution vol. (VT) at baseline and after full receptor blockade.  The kinetics of 11C-SD5024 in humans were evaluated in seven healthy subjects with compartmental modeling.  SD5024 showed Ki = 0.47 nM, which was at an intermediate level among the five CB1 receptor ligands.  Lipophilicity (LogD7.4) was 3.79, which is appropriate for brain imaging.  Monkey scans showed high proportion of specific binding: ∼ 80̂ of VT.  In humans, 11C-SD5024 showed peak brain uptake of 1.5-3 standardized uptake value, which was slightly higher than that of 11C-OMAR and 18F-MK-9470.  One-compartment model showed good fitting, consistent with the vast majority of brain uptake being specific binding found in the monkey.  Regional VT values were consistent with known distribution of CB1 receptors.  VT calcd. from 80 and 120 min of scan data was strongly correlated (R2 = 0.97), indicating that 80 min provided adequate information for quantitation and that the influence of radiometabolites was low.  Intersubject variability for VT of 11C-SD5024 was 22̂, which was low among the five radioligands and indicated precise measurement.  In conclusion, 11C-SD5024 has appropriate affinity and lipophilicity, high specific binding, moderate brain uptake, and provides good precision to measure the binding.  The results suggest that 11C-SD5024 is slightly better than or equiv. to 11C-OMAR and that both are suitable for clin. studies, esp. those that involve two scans in one day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSuJxTjY4PkLVg90H21EOLACvtfcHk0ljksWxEBmr9Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWju7fJ&md5=b4427668202331ff0a1357cb0ecf09b3</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2013.09.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2013.09.043%26sid%3Dliteratum%253Aachs%26aulast%3DTsujikawa%26aufirst%3DT.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DJenko%26aufirst%3DK.%2BJ.%26aulast%3DGladding%26aufirst%3DR.%2BL.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DFujita%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%252011C-SD5024%252C%2520a%2520novel%2520PET%2520radioligand%2520for%2520human%2520brain%2520imaging%2520of%2520cannabinoid%2520CB1%2520receptors%26jtitle%3DNeuroImage%26date%3D2014%26volume%3D84%26spage%3D733%26epage%3D741%26doi%3D10.1016%2Fj.neuroimage.2013.09.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hjorth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jucaite, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahlby Hamren, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstrom, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farde, L.</span></span> <span> </span><span class="NLM_article-title">A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuropharm.2015.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25791528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVSku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=519-530&author=S.+Hjorthauthor=C.+Karlssonauthor=A.+Jucaiteauthor=K.+Varnasauthor=U.+Wahlby+Hamrenauthor=P.+Johnstromauthor=B.+Gulyasauthor=S.+R.+Donohueauthor=V.+W.+Pikeauthor=C.+Halldinauthor=L.+Farde&title=A+PET+study+comparing+receptor+occupancy+by+five+selective+cannabinoid+1+receptor+antagonists+in+non-human+primates&doi=10.1016%2Fj.neuropharm.2015.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates</span></div><div class="casAuthors">Hjorth, Stephan; Karlsson, Cecilia; Jucaite, Aurelija; Varnaes, Katarina; Waehlby Hamren, Ulrika; Johnstroem, Peter; Gulyas, Balazs; Donohue, Sean R.; Pike, Victor W.; Halldin, Christer; Farde, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519-530</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is a medical need for safe and efficacious anti-obesity drugs with acceptable side effect profiles.  To mitigate the challenge posed by translating target interaction across species and balancing beneficial vs. adverse effects, a positron emission tomog. (PET) approach could help guide clin. dose optimization.  Thus, as part of a compd. differentiation effort, three novel selective CB1 receptor (CB1R) antagonists, developed by AstraZeneca (AZ) for the treatment of obesity, were compared with two clin. tested ref. compds., rimonabant and taranabant, with regard to receptor occupancy relative to dose and exposure.  A total of 42 PET measurements were performed in 6 non-human primates using the novel CB1R antagonist radioligand [11C]SD5024.  The AZ CB1R antagonists bound in a saturable manner to brain CB1R with in vivo affinities similar to that of rimonabant and taranabant, compds. with proven wt. loss efficacy in clin. trials.  Interestingly, it was found that exposures corresponding to those needed for optimal clin. efficacy of rimonabant and taranabant resulted in a CB1R occupancy typically around ∼20-30%, thus much lower than what would be expected for classical G-protein coupled receptor (GPCR) antagonists in other therapeutic contexts.  These findings are also discussed in relation to emerging literature on the potential usefulness of 'neutral' vs. 'classical' CB1R (inverse agonist) antagonists.  The study addnl. highlighted the usefulness of the radioligand [11C]SD5024 as a specific tracer for CB1R in the primate brain, though an arterial input function would ideally be required in future studies to further assure accurate quant. anal. of specific binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsy3zXkro_77Vg90H21EOLACvtfcHk0ljksWxEBmr9Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVSku7k%253D&md5=8c81c21f73e6b3cdd988b23d160fe576</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DHjorth%26aufirst%3DS.%26aulast%3DKarlsson%26aufirst%3DC.%26aulast%3DJucaite%26aufirst%3DA.%26aulast%3DVarnas%26aufirst%3DK.%26aulast%3DWahlby%2BHamren%26aufirst%3DU.%26aulast%3DJohnstrom%26aufirst%3DP.%26aulast%3DGulyas%26aufirst%3DB.%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DFarde%26aufirst%3DL.%26atitle%3DA%2520PET%2520study%2520comparing%2520receptor%2520occupancy%2520by%2520five%2520selective%2520cannabinoid%25201%2520receptor%2520antagonists%2520in%2520non-human%2520primates%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D101%26spage%3D519%26epage%3D530%26doi%3D10.1016%2Fj.neuropharm.2015.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjorth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapham, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span> <span> </span><span class="NLM_article-title">Binding properties of antagonists to cannabinoid receptors in intact cells</span>. <i>Fundam. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1111/j.1472-8206.2010.00843.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1472-8206.2010.00843.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20608998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=200-210&author=M.+Wennerbergauthor=L.+Chengauthor=S.+Hjorthauthor=J.+C.+Claphamauthor=A.+Balendranauthor=G.+Vauquelin&title=Binding+properties+of+antagonists+to+cannabinoid+receptors+in+intact+cells&doi=10.1111%2Fj.1472-8206.2010.00843.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Binding properties of antagonists to Cannabinoid receptors in intact cells</span></div><div class="casAuthors">Wennerberg, Marie; Cheng, Leifeng; Hjorth, Stephan; Clapham, John C.; Balendran, Anudharan; Vauquelin, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-210</span>CODEN:
                <span class="NLM_cas:coden">FCPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">0767-3981</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The implication of the cannabinoid receptor 1 (CB1 receptor) in several pathophysiol. states has sparked the development of selective antagonists.  Here we compare binding of the antagonists [3H]-AZ12491187, [3H]-taranabant and [3H]-rimonabant to intact human embryonic kidney cells stably expressing recombinant human CB1 receptors (CB1r cells).  Unlabeled ligands decreased the total binding of the three radioligands with closely the same order of potency: i.e. AZ12288553 ∼ AZ12491187 ∼ taranabant > rimonabant.  Nondisplaceable (i.e. nonspecific) binding to the CB1R cells was the same as total binding to the wells contg. untransfected cells and it was more pronounced for [3H]-AZ12491187 and [3H]-rimonabant than for [3H]-taranabant.  [3H]-Rimonabant and (to a lesser extent) [3H]-AZ12491187 were also prone to bind nonspecifically to the walls of the wells.  Compared to the other radioligands, [3H]-rimonabant displayed lower potency for the CB1 receptors in satn. binding studies and faster assocn. and dissocn. in kinetic expts.  When dissocd., the three radioligands also showed prominent rebinding to the cells in medium only.  This could be relieved by the presence of excess of unlabeled ligand and of bovine serum albumin (BSA) but a combination thereof was most efficient.  The long "residence time" of AZ12491187 at the CB1 receptor (because of slow dissocn. and prominent rebinding) and its pronounced incorporation into the membranes of the cells could contribute to long-lasting in vivo CB1 receptor blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7r6I6kbyu17Vg90H21EOLACvtfcHk0lgVpGBrrih0xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOqs7w%253D&md5=a110cb216c5f73757e9de57e7ceef0a9</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fj.1472-8206.2010.00843.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1472-8206.2010.00843.x%26sid%3Dliteratum%253Aachs%26aulast%3DWennerberg%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DHjorth%26aufirst%3DS.%26aulast%3DClapham%26aufirst%3DJ.%2BC.%26aulast%3DBalendran%26aufirst%3DA.%26aulast%3DVauquelin%26aufirst%3DG.%26atitle%3DBinding%2520properties%2520of%2520antagonists%2520to%2520cannabinoid%2520receptors%2520in%2520intact%2520cells%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D25%26spage%3D200%26epage%3D210%26doi%3D10.1111%2Fj.1472-8206.2010.00843.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnema, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyás, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span> <span> </span><span class="NLM_article-title">Discovery and labeling of a homochiral high affinity 3,4-diarylpyrazoline as a candidate radioligand for in vivo imaging of cannabinoid type-1 receptors</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">T90</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2008.04.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2008.04.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=T90&author=S.+R.+Donohueauthor=S.+J.+Finnemaauthor=P.+Truongauthor=J.+Anderssonauthor=B.+Guly%C3%A1sauthor=V.+W.+Pikeauthor=C.+Halldin&title=Discovery+and+labeling+of+a+homochiral+high+affinity+3%2C4-diarylpyrazoline+as+a+candidate+radioligand+for+in+vivo+imaging+of+cannabinoid+type-1+receptors&doi=10.1016%2Fj.neuroimage.2008.04.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2008.04.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2008.04.059%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DFinnema%26aufirst%3DS.%2BJ.%26aulast%3DTruong%26aufirst%3DP.%26aulast%3DAndersson%26aufirst%3DJ.%26aulast%3DGuly%25C3%25A1s%26aufirst%3DB.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520labeling%2520of%2520a%2520homochiral%2520high%2520affinity%25203%252C4-diarylpyrazoline%2520as%2520a%2520candidate%2520radioligand%2520for%2520in%2520vivo%2520imaging%2520of%2520cannabinoid%2520type-1%2520receptors%26jtitle%3DNeuroImage%26date%3D2008%26volume%3D41%26spage%3DT90%26doi%3D10.1016%2Fj.neuroimage.2008.04.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willis, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlova, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chefer, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaupel, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5813</span>– <span class="NLM_lpage">5822</span>, <span class="refDoi"> DOI: 10.1021/jm0502743</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0502743" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVertbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5813-5822&author=P.+G.+Willisauthor=O.+A.+Pavlovaauthor=S.+I.+Cheferauthor=D.+B.+Vaupelauthor=A.+G.+Mukhinauthor=A.+G.+Horti&title=Synthesis+and+structure-activity+relationship+of+a+novel+series+of+aminoalkylindoles+with+potential+for+imaging+the+neuronal+cannabinoid+receptor+by+positron+emission+tomography&doi=10.1021%2Fjm0502743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationship of a Novel Series of Aminoalkylindoles with Potential for Imaging the Neuronal Cannabinoid Receptor by Positron Emission Tomography</span></div><div class="casAuthors">Willis, Peter G.; Pavlova, Olga A.; Chefer, Svetlana I.; Vaupel, D. Bruce; Mukhin, Alexey G.; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5813-5822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of CB1 ligands I (R = 4-Me-1-naphthyl, 2-IC6H4, 1-naphthylamino, etc.) with high binding affinity (Ki = 0.7-100 nM) and moderate lipophilicity (cLogD7.4) in the range of 2.1-4.5 has been synthesized.  A structure-activity relationship study demonstrated that for the studied set of aminoalkylindoles, the mol. dipole of the ground state conformation within the series was inversely related to the affinity.  The racemic ligand with highest affinity (0.7 nM), I (R = 4-fluoro-1-naphthyl), was radiolabeled with 18F.  This radioligand specifically labeled CB1 receptors in mouse brain and accumulated in regions of high vs. low CB1 receptor d. in a ratio of 1.6.  The displaceable radioactivity of one enantiomer in the brains of mice detd. in a pretreatment study using the CB1 antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) was nearly double that of the racemate for the same detn.; therefore, the active enantiomer is a candidate for PET studies in animals.  A pretreatment study for the other enantiomer found no displaceable radioactivity in the same group of mice; this result suggested the enantiomer was inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSeOt9IGNWf7Vg90H21EOLACvtfcHk0lgVpGBrrih0xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVertbs%253D&md5=02a724ee78558e62f9c3176231c9670c</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm0502743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0502743%26sid%3Dliteratum%253Aachs%26aulast%3DWillis%26aufirst%3DP.%2BG.%26aulast%3DPavlova%26aufirst%3DO.%2BA.%26aulast%3DChefer%26aufirst%3DS.%2BI.%26aulast%3DVaupel%26aufirst%3DD.%2BB.%26aulast%3DMukhin%26aufirst%3DA.%2BG.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%2520a%2520novel%2520series%2520of%2520aminoalkylindoles%2520with%2520potential%2520for%2520imaging%2520the%2520neuronal%2520cannabinoid%2520receptor%2520by%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5813%26epage%3D5822%26doi%3D10.1021%2Fjm0502743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhawan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinfeleye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruneus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimaio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gifford, A. N.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[<sup>125</sup>/<sup>131</sup>I] AM2233</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1002/syn.20277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fsyn.20277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16715483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFChu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=93-101&author=J.+Dhawanauthor=H.+Dengauthor=S.+J.+Gatleyauthor=A.+Makriyannisauthor=T.+Akinfeleyeauthor=M.+Bruneusauthor=A.+A.+Dimaioauthor=A.+N.+Gifford&title=Evaluation+of+the+in+vivo+receptor+occupancy+for+the+behavioral+effects+of+cannabinoids+using+a+radiolabeled+cannabinoid+receptor+agonist%2C+R-%5B125%2F131I%5D+AM2233&doi=10.1002%2Fsyn.20277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233</span></div><div class="casAuthors">Dhawan, Jasbeer; Deng, Hongfeng; Gatley, S. John; Makriyannis, Alexandros; Akinfeleye, Tolulope; Bruneus, Magalie; Dimaio, Alexis A.; Gifford, Andrew N.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-101</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">G-protein coupled receptors exist in both high and low agonist affinity conformations, with tracer levels of agonist radioligands preferentially binding to the former.  The goal of the present study was to characterize the in vivo binding of the amino-alkyindole-based, CB1 receptor agonist, R-[125/131I]AM2233 ((2-[125/131I]iodo-phenyl)-[1-(1-methyl-piperidin-2-yl-methyl)-1H-indol-3-yl]-methanone), and to use this radiotracer to selectively measure the receptor occupancy by the related CB1 receptor agonist, WIN55212-2, to the agonist-preferring affinity state of the receptor.  In mouse locomotor assays, both WIN55212-2 and AM2233 (racemic) produced an ∼60% redn. in activity at 1 mg/kg, (i.v.) and completely inhibited activity at 3 mg/kg, confirming their agonist nature.  In ex vivo autoradiog., preferential uptake of R-[131I]AM2233 was apparent in CB1 receptor-rich areas, including globus pallidus, substantia nigra, striatum, cerebellum, and hippocampus.  Overall brain uptake of R-[131I]AM2233 was 1.3% injected activity/g at 5 min in mice.  Coinjection of 3 mg/kg (i.v.) SR141716A, a CB1 receptor antagonist, with R-[125I]AM2233 inhibited the radiotracer binding almost to nonspecific levels in the striatum, globus pallidus, and substantia nigra, although residual binding to a non-CB1 receptor remained in the hippocampus.  In contrast to the effect of SR141716A, coinjection of 10 mg/kg (i.v.) WIN55212-2, a high dose that produced an immediate and profound immobility and catalepsy in the mice, reduced CB1 receptor-specific binding of R-[125I]AM2233 in CB1 receptor-rich areas by only 21-43%.  These observations suggest that the behavioral effects of CB1 receptor agonists are manifested with a relatively small fraction of the agonist-preferring affinity state of the receptor occupied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriXfFfDmY9PLVg90H21EOLACvtfcHk0lhtAHV41G8VNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFChu74%253D&md5=f1f9670cec72b23ee2676989e081e28d</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20277%26sid%3Dliteratum%253Aachs%26aulast%3DDhawan%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DGatley%26aufirst%3DS.%2BJ.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DAkinfeleye%26aufirst%3DT.%26aulast%3DBruneus%26aufirst%3DM.%26aulast%3DDimaio%26aufirst%3DA.%2BA.%26aulast%3DGifford%26aufirst%3DA.%2BN.%26atitle%3DEvaluation%2520of%2520the%2520in%2520vivo%2520receptor%2520occupancy%2520for%2520the%2520behavioral%2520effects%2520of%2520cannabinoids%2520using%2520a%2520radiolabeled%2520cannabinoid%2520receptor%2520agonist%252C%2520R-%255B125%252F131I%255D%2520AM2233%26jtitle%3DSynapse%26date%3D2006%26volume%3D60%26spage%3D93%26epage%3D101%26doi%3D10.1002%2Fsyn.20277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. B.</span>; <span class="NLM_string-name">Amegadzie, K. M.</span>; <span class="NLM_string-name">Gardiner, G. S.</span>; <span class="NLM_string-name">Hitchcock, A.</span>; <span class="NLM_string-name">Hoogestraat, W. J.</span></span> <span> </span><span class="NLM_article-title">CB1 Modulator Compounds</span>. Patent <span class="NLM_patent">WO2005/066126A1</span>, Jul 21, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+B.+Allen&author=K.+M.+Amegadzie&author=G.+S.+Gardiner&author=A.+Hitchcock&author=W.+J.+Hoogestraat&title=CB1+Modulator+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BB.%26atitle%3DCB1%2520Modulator%2520Compounds%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardinier, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruley, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span> <span> </span><span class="NLM_article-title">Radiolabeling of a high potency cannabinoid subtype-1 receptor ligand, N-(4-fluoro-benzyl)-4-(3-(piperidin-1-yl)-indole-1-sulfonyl)benzamide (PipISB), with carbon-11 or fluorine-18</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1002/jlcr.1491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjlcr.1491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVKgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=146-152&author=S.+R.+Donohueauthor=C.+Halldinauthor=M.+Schouauthor=J.+Hongauthor=L.+Phebusauthor=E.+Chernetauthor=S.+A.+Hitchcockauthor=K.+M.+Gardinierauthor=K.+M.+Ruleyauthor=J.+H.+Krushinskiauthor=J.+Schausauthor=V.+W.+Pike&title=Radiolabeling+of+a+high+potency+cannabinoid+subtype-1+receptor+ligand%2C+N-%284-fluoro-benzyl%29-4-%283-%28piperidin-1-yl%29-indole-1-sulfonyl%29benzamide+%28PipISB%29%2C+with+carbon-11+or+fluorine-18&doi=10.1002%2Fjlcr.1491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Radiolabeling of a high potency cannabinoid subtype-1 receptor ligand, N-(4-fluoro-benzyl)-4-(3-(piperidin-1-yl)-indole-1-sulfonyl)benzamide (PipISB), with carbon-11 or fluorine-18</span></div><div class="casAuthors">Donohue, Sean R.; Halldin, Christer; Schou, Magnus; Hong, Jinsoo; Phebus, Lee; Chernet, Eyassu; Hitchcock, Stephen A.; Gardinier, Kevin M.; Ruley, Kevin M.; Krushinski, Joseph H.; Schaus, John; Pike, Victor W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">146-152</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">PipISB [N-(4-fluorobenzyl)-4-(3-(piperidin-1-yl)indole-1-sulfonyl)benzamide, I] was identified as a selective high potency CB1 receptor ligand.  Here we describe the labeling of I with positron-emitters to provide candidate radioligands for imaging brain CB1 receptors with positron emission tomog. (PET).  The radiolabeling of I was achieved by two methods, method A with carbon-11 and method B with fluorine-18.  In method A, [11C]I was prepd. in one step from [11C]carbon monoxide, itself prepd. from cyclotron-produced [11C]carbon dioxide.  In method B, [18F]I was prepd. from cyclotron-produced [18F]fluoride ion in a two-stage, four-step synthesis with [18F]4-fluorobenzyl bromide as a labeling agent.  The radiosynthesis time for method A was 44 min; decay-cor. radiochem. yields (RCYs) from [11C]carbon monoxide ranged from 3.1 to 11.6% and specific radioactivities ranged from 21 to 67 GBq/μmol.  The radiosynthesis time for method B was 115 min; RCYs from [18F]fluoride ion ranged from 1.5 to 5.6% and specific radioactivities ranged from 200 to 348 GBq/μmol.  With these methods, [11C]I and [18F]I may be prepd. with adequate activity and quality for future evaluation as PET radioligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHbhAoO0U7qrVg90H21EOLACvtfcHk0lhtAHV41G8VNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVKgtrY%253D&md5=7c46eed40e9ff3fff9412da9af01581f</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.1491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.1491%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DSchou%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DPhebus%26aufirst%3DL.%26aulast%3DChernet%26aufirst%3DE.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DGardinier%26aufirst%3DK.%2BM.%26aulast%3DRuley%26aufirst%3DK.%2BM.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DSchaus%26aufirst%3DJ.%26aulast%3DPike%26aufirst%3DV.%2BW.%26atitle%3DRadiolabeling%2520of%2520a%2520high%2520potency%2520cannabinoid%2520subtype-1%2520receptor%2520ligand%252C%2520N-%25284-fluoro-benzyl%2529-4-%25283-%2528piperidin-1-yl%2529-indole-1-sulfonyl%2529benzamide%2520%2528PipISB%2529%252C%2520with%2520carbon-11%2520or%2520fluorine-18%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2008%26volume%3D51%26spage%3D146%26epage%3D152%26doi%3D10.1002%2Fjlcr.1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnema, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of [<sup>11</sup>C]PipISB and [<sup>18</sup>F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1002/syn.20578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fsyn.20578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18925657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD1cnpsVamtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2009&pages=22-30&author=S.+J.+Finnemaauthor=S.+R.+Donohueauthor=S.+S.+Zoghbiauthor=A.+K.+Brownauthor=B.+Gulyasauthor=R.+B.+Innisauthor=C.+Halldinauthor=V.+W.+Pike&title=Evaluation+of+%5B11C%5DPipISB+and+%5B18F%5DPipISB+in+monkey+as+candidate+radioligands+for+imaging+brain+cannabinoid+type-1+receptors+in+vivo&doi=10.1002%2Fsyn.20578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo</span></div><div class="casAuthors">Finnema Sjoerd J; Donohue Sean R; Zoghbi Sami S; Brown Amira K; Gulyas Balazs; Innis Robert B; Halldin Christer; Pike Victor W</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">N-(4-Fluorobenzyl)-4-[3-(piperidin-1-yl)indole-1-sulfonyl]benzamide] (PipISB, 3) is a selective and high-potency cannabinoid subtype-1 (CB1) receptor inverse agonist.  We have previously reported radiosyntheses of [11C]3 and [18F]3.  Here, we aimed to evaluate the uptake and CB(1) receptor-specific binding of each radioligand in monkey brain in vivo with positron emission tomography (PET). [11C]3 or [18F]3 was injected intravenously into rhesus or cynomolgus monkey, respectively, and examined with PET at baseline or after pretreatment with a receptor-saturating dose of CB1 receptor-selective ligand (3 for [11C]3 or 8 for [18F]3).  In one PET experiment, the dose of 3 was administered at 100 min after [11C]3.  Relative plasma concentrations of radioligand and radiometabolites were concurrently measured in baseline experiments with high-performance liquid chromatography.  Brain radioactivity uptake was highest in striatum and cerebellum, and it reached 170-270% standardized uptake value (SUV) at 120 min after injection of [11C]3 and 180% SUV at 240 min after injection of [18F]3.  Radioactivity was well retained in all CB1 receptor-rich regions.  No reference region could be identified for nonspecifically bound radioligand.  Under CB1 receptor pretreatment and displacement conditions, initial brain uptakes of radioactivity were similar to those at baseline.  Regional brain radioactivity concentrations then became homogeneous and diminished to between 70 and 80% SUV at 120 min after injection of [11C]3 and to 25% SUV at 240 min after injection of [18F]3. [18F]3 was not defluorinated but was metabolized to less lipophilic radiometabolites, as was [11C]3.  Hence, [11C]3 and [18F]3 showed high CB1 receptor-specific binding in monkey brain in vivo and merit further investigation as prospective PET radioligands in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlf8GQ8ajv6s-crCu0nI_sfW6udTcc2earc-qviEH5m7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnpsVamtQ%253D%253D&md5=6988fe4d33bc473e3c06163c92a64149</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20578%26sid%3Dliteratum%253Aachs%26aulast%3DFinnema%26aufirst%3DS.%2BJ.%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DBrown%26aufirst%3DA.%2BK.%26aulast%3DGulyas%26aufirst%3DB.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%2BW.%26atitle%3DEvaluation%2520of%2520%255B11C%255DPipISB%2520and%2520%255B18F%255DPipISB%2520in%2520monkey%2520as%2520candidate%2520radioligands%2520for%2520imaging%2520brain%2520cannabinoid%2520type-1%2520receptors%2520in%2520vivo%26jtitle%3DSynapse%26date%3D2009%26volume%3D63%26spage%3D22%26epage%3D30%26doi%3D10.1002%2Fsyn.20578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">German, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmour, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure–activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl) pyridin-2-yl] phenyl} urea (PSNCBAM-1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7758</span>– <span class="NLM_lpage">7769</span>, <span class="refDoi"> DOI: 10.1021/jm501042u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501042u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCnu7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7758-7769&author=N.+Germanauthor=A.+M.+Deckerauthor=B.+P.+Gilmourauthor=E.+A.+Gayauthor=J.+L.+Wileyauthor=B.+F.+Thomasauthor=Y.+Zhang&title=Diarylureas+as+allosteric+modulators+of+the+cannabinoid+CB1+receptor%3A+structure%E2%80%93activity+relationship+studies+on+1-%284-chlorophenyl%29-3-%7B3-%5B6-%28pyrrolidin-1-yl%29+pyridin-2-yl%5D+phenyl%7D+urea+%28PSNCBAM-1%29&doi=10.1021%2Fjm501042u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylureas as Allosteric Modulators of the Cannabinoid CB1 Receptor: Structure-Activity Relationship Studies on 1-(4-Chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)</span></div><div class="casAuthors">German, Nadezhda; Decker, Ann M.; Gilmour, Brian P.; Gay, Elaine A.; Wiley, Jenny L.; Thomas, Brian F.; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7758-7769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent discovery of allosteric modulators of the CB1 receptor including PSNCBAM-1 (4) has generated significant interest in CB1 receptor allosteric modulation.  Here in the first SAR study on 4, we have designed and synthesized a series of analogs focusing on modifications at two positions.  Pharmacol. evaluation in calcium mobilization and binding assays revealed the importance of alkyl substitution at the 2-aminopyridine moiety and electron deficient arom. groups at the 4-chlorophenyl position for activity at the CB1 receptor, resulting in several analogs with comparable potency to 4.  These compds. increased the specific binding of [3H]CP55,940, in agreement with previous reports.  Importantly, 4 and two analogs dose-dependently reduced the Emax of the agonist curve in the CB1 calcium mobilization assays, confirming their neg. allosteric modulator characteristics.  Given the side effects assocd. with CB1 receptor orthosteric antagonists, neg. allosteric modulators provide an alternative approach to modulate the pharmacol. important CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKoWK33ooy7Vg90H21EOLACvtfcHk0ljgaA25rQEgfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCnu7bE&md5=c7cfd8bd55b25d5861768a10496cca70</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm501042u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501042u%26sid%3Dliteratum%253Aachs%26aulast%3DGerman%26aufirst%3DN.%26aulast%3DDecker%26aufirst%3DA.%2BM.%26aulast%3DGilmour%26aufirst%3DB.%2BP.%26aulast%3DGay%26aufirst%3DE.%2BA.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiarylureas%2520as%2520allosteric%2520modulators%2520of%2520the%2520cannabinoid%2520CB1%2520receptor%253A%2520structure%25E2%2580%2593activity%2520relationship%2520studies%2520on%25201-%25284-chlorophenyl%2529-3-%257B3-%255B6-%2528pyrrolidin-1-yl%2529%2520pyridin-2-yl%255D%2520phenyl%257D%2520urea%2520%2528PSNCBAM-1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7758%26epage%3D7769%26doi%3D10.1021%2Fjm501042u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakizaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and evaluation of new PET ligands for peripheral cannabinoid receptor type 1 imaging</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4114</span>– <span class="NLM_lpage">4117</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.07.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmcl.2017.07.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28757061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GktbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4114-4117&author=T.+Yamasakiauthor=M.+Fujinagaauthor=Y.+Shimodaauthor=W.+Moriauthor=Y.+Zhangauthor=H.+Wakizakaauthor=M.+Ogawaauthor=M.+R.+Zhang&title=Radiosynthesis+and+evaluation+of+new+PET+ligands+for+peripheral+cannabinoid+receptor+type+1+imaging&doi=10.1016%2Fj.bmcl.2017.07.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and evaluation of new PET ligands for peripheral cannabinoid receptor type 1 imaging</span></div><div class="casAuthors">Yamasaki, Tomoteru; Fujinaga, Masayuki; Shimoda, Yoko; Mori, Wakana; Zhang, Yiding; Wakizaka, Hidekatsu; Ogawa, Masanao; Zhang, Ming-Rong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4114-4117</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of radiolabeled compds. I (X = Cl, Y = (CH3)2N; X = CN, Y = pyrrolidin-1-yl) using [11C]COCl2 and an evaluation of their potential as PET ligands for CB1 imaging using in vitro and in vivo techniques were reported.  Compds. I were successfully synthesized in two steps using [11C]COCl2.  The radiochem. yields of I were 17 ± 8% and 20 ± 9% (decay-cor. to the end of bombardment, based on [11C]CO2).  The specific activities of I were 42 ± 36 and 37 ± 13 GBq/μmol, resp.  The results of an in vitro binding assay using brown adipose tissue (BAT) homogenate showed that the binding affinity of 1-(4-Chloro-phenyl)-3-[3-(6-dimethylamino-pyridin-2-yl)-phenyl]-urea for CB1 (KD = 15.3 μM) was much higher than that of 1-(4-cyano-phenyl)-3-[3-(6-pyrrolidin-1-yl-pyridin-2-yl)-phenyl]-urea (KD = 26.0 μM).  PET studies with I (X = Cl; Y = (CH3)2N) showed a high uptake of radioactivity in BAT, which decreased in animals pretreated with AM281 (a selective antagonist for CB1).  In conclusion, I (X = Cl; Y = (CH3)2N) may be a useful PET ligand for imaging peripheral CB1 in BAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZyVetOisQH7Vg90H21EOLACvtfcHk0ljgaA25rQEgfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GktbnO&md5=2821e74fe07f3addb84bcbe8645c21f6</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.07.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.07.040%26sid%3Dliteratum%253Aachs%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWakizaka%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26atitle%3DRadiosynthesis%2520and%2520evaluation%2520of%2520new%2520PET%2520ligands%2520for%2520peripheral%2520cannabinoid%2520receptor%2520type%25201%2520imaging%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4114%26epage%3D4117%26doi%3D10.1016%2Fj.bmcl.2017.07.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelagalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marwick, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Angelo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinaci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardingham, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanda, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2096</span>, <span class="refDoi"> DOI: 10.1039/C6OB02796B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1039%2FC6OB02796B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28210722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1Whs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=2086-2096&author=C.+Zanatoauthor=A.+Pelagalliauthor=K.+F.+Marwickauthor=M.+Pirasauthor=S.+Dall%E2%80%99Angeloauthor=A.+Spinaciauthor=R.+G.+Pertweeauthor=D.+J.+Wyllieauthor=G.+E.+Hardinghamauthor=M.+Zanda&title=Synthesis%2C+radio-synthesis+and+in+vitro+evaluation+of+terminally+fluorinated+derivatives+of+HU-210+and+HU-211+as+novel+candidate+PET+tracers&doi=10.1039%2FC6OB02796B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers</span></div><div class="casAuthors">Zanato, Chiara; Pelagalli, Alessia; Marwick, Katie F. M.; Piras, Monica; Dall'Angelo, Sergio; Spinaci, Andrea; Pertwee, Roger G.; Wyllie, David J. A.; Hardingham, Giles E.; Zanda, Matteo</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2086-2096</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We report the synthesis of terminally fluorinated HU-210 and HU-211 analogs (HU-210F and HU-211F, resp.) and their biol. evaluation as ligands of cannabinoid receptors (CB1 and CB2) and N-Me D-aspartate receptor (NMDAR). [18F]-labeled HU-210F was radiosynthesised from the bromo-substituted precursor.  In vitro assays showed that both HU-210F and HU-211F retain the potent pharmacol. profile of HU-210 and HU-211, suggesting that [18F]-radiolabeled HU-210F and HU-211F could have potential as PET tracers for in vivo imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfDBpn2w-O2LVg90H21EOLACvtfcHk0ljk-wr9jellgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1Whs70%253D&md5=fa689a4c76b4d8fc6b057d373e2efb09</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1039%2FC6OB02796B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB02796B%26sid%3Dliteratum%253Aachs%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DPelagalli%26aufirst%3DA.%26aulast%3DMarwick%26aufirst%3DK.%2BF.%26aulast%3DPiras%26aufirst%3DM.%26aulast%3DDall%25E2%2580%2599Angelo%26aufirst%3DS.%26aulast%3DSpinaci%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DWyllie%26aufirst%3DD.%2BJ.%26aulast%3DHardingham%26aufirst%3DG.%2BE.%26aulast%3DZanda%26aufirst%3DM.%26atitle%3DSynthesis%252C%2520radio-synthesis%2520and%2520in%2520vitro%2520evaluation%2520of%2520terminally%2520fluorinated%2520derivatives%2520of%2520HU-210%2520and%2520HU-211%2520as%2520novel%2520candidate%2520PET%2520tracers%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2017%26volume%3D15%26spage%3D2086%26epage%3D2096%26doi%3D10.1039%2FC6OB02796B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K. S.</span></span> <span> </span><span class="NLM_article-title">Fluorine-18 isotope labeling for positron emission tomography imaging. Direct evidence for DBPR211 as a peripherally restricted CB1 inverse agonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.11.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmc.2018.11.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30528163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnu7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=216-223&author=C.+P.+Changauthor=H.+L.+Huangauthor=J.+K.+Huangauthor=M.+S.+Hungauthor=C.+H.+Wuauthor=J.+S.+Songauthor=C.+J.+Leeauthor=C.+S.+Yuauthor=K.+S.+Shia&title=Fluorine-18+isotope+labeling+for+positron+emission+tomography+imaging.+Direct+evidence+for+DBPR211+as+a+peripherally+restricted+CB1+inverse+agonist&doi=10.1016%2Fj.bmc.2018.11.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine-18 isotope labeling for positron emission tomography imaging. Direct evidence for DBPR211 as a peripherally restricted CB1 inverse agonist</span></div><div class="casAuthors">Chang, Chun-Ping; Huang, Ho-Lien; Huang, Jing-Kai; Hung, Ming-Shiu; Wu, Chien-Huang; Song, Jen-Shin; Lee, Chia-Jui; Yu, Chung-Shan; Shia, Kak-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">216-223</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The [18F] isotope-labeled CB1 inverse agonist 3 was elaborated and synthesized for positron emission tomog. scanning studies.  After immediate purifn. and calibration with its unlabeled counterpart, compd. 3 was i.v. injected in mice and revealed that its distribution percentage in brain over 90-min scans among five region of interests, including brain, liver, heart, thigh muscle and kidney was lower than 1%, thus providing direct evidence to justify itself as a peripherally restricted CB1 antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY2-c_Wr1LNLVg90H21EOLACvtfcHk0ljk-wr9jellgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnu7fE&md5=13a1edf2520bc1731960217b22282d8d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.11.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.11.043%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%2BP.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DHuang%26aufirst%3DJ.%2BK.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DC.%2BJ.%26aulast%3DYu%26aufirst%3DC.%2BS.%26aulast%3DShia%26aufirst%3DK.%2BS.%26atitle%3DFluorine-18%2520isotope%2520labeling%2520for%2520positron%2520emission%2520tomography%2520imaging.%2520Direct%2520evidence%2520for%2520DBPR211%2520as%2520a%2520peripherally%2520restricted%2520CB1%2520inverse%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D216%26epage%3D223%26doi%3D10.1016%2Fj.bmc.2018.11.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Cueto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ruiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagerovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span> <span> </span><span class="NLM_article-title">Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">406</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3389%2Ffnins.2016.00406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27679556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC2svktlSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=406&author=G.+Navarroauthor=P.+Moralesauthor=C.+Rodriguez-Cuetoauthor=J.+Fernandez-Ruizauthor=N.+Jagerovicauthor=R.+Franco&title=Targeting+cannabinoid+CB2+receptors+in+the+central+nervous+system.+Medicinal+chemistry+approaches+with+focus+on+neurodegenerative+disorders&doi=10.3389%2Ffnins.2016.00406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders</span></div><div class="casAuthors">Navarro Gemma; Franco Rafael; Morales Paula; Rodriguez-Cueto Carmen; Fernandez-Ruiz Javier; Jagerovic Nadine</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">406</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Endocannabinoids activate two types of specific G-protein-coupled receptors (GPCRs), namely cannabinoid CB1 and CB2.  Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 receptors appear as promising drugs to combat CNS diseases (Parkinson's disease, Huntington's chorea, cerebellar ataxia, amyotrohic lateral sclerosis).  Differential localization of CB2 receptors in neural cell types and upregulation in neuroinflammation are keys to understand the therapeutic potential in inter alia diseases that imply progressive neurodegeneration.  Medicinal chemistry approaches are now engaged to develop imaging tools to map receptors in the living human brain, to develop more efficacious agonists, and to investigate the possibility to develop allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3wLImrF0SGijiVMCqkKxVfW6udTcc2eabPTx_mdmGT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svktlSitg%253D%253D&md5=5301fd9e4c3411b77a0cc9809389aee8</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00406%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DRodriguez-Cueto%26aufirst%3DC.%26aulast%3DFernandez-Ruiz%26aufirst%3DJ.%26aulast%3DJagerovic%26aufirst%3DN.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DTargeting%2520cannabinoid%2520CB2%2520receptors%2520in%2520the%2520central%2520nervous%2520system.%2520Medicinal%2520chemistry%2520approaches%2520with%2520focus%2520on%2520neurodegenerative%2520disorders%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D406%26doi%3D10.3389%2Ffnins.2016.00406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. J.</span></span> <span> </span><span class="NLM_article-title">Role of neuroinflammation in neurodegenerative diseases (Review)</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3391</span>– <span class="NLM_lpage">3396</span>, <span class="refDoi"> DOI: 10.3892/mmr.2016.4948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3892%2Fmmr.2016.4948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26935478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12rsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=3391-3396&author=W.+W.+Chenauthor=X.+Zhangauthor=W.+J.+Huang&title=Role+of+neuroinflammation+in+neurodegenerative+diseases+%28Review%29&doi=10.3892%2Fmmr.2016.4948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Role of neuroinflammation in neurodegenerative diseases (Review)</span></div><div class="casAuthors">Chen, Wei-Wei; Zhang, Xia; Huang, Wen-Juan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3391-3396</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Neurodegeneration is a phenomenon that occurs in the central nervous system through the hallmarks assocg. the loss of neuronal structure and function.  Neurodegeneration is obsd. after viral insult and mostly in various so-called 'neurodegenerative diseases', generally obsd. in the elderly, such as Alzheimer's disease, multiple sclerosis, Parkinson's disease and amyotrophic lateral sclerosis that neg. affect mental and phys. functioning.  Causative agents of neurodegeneration have yet to be identified.  However, recent data have identified the inflammatory process as being closely linked with multiple neurodegenerative pathways, which are assocd. with depression, a consequence of neurodegenerative disease.  Accordingly, pro-inflammatory cytokines are important in the pathophysiol. of depression and dementia.  These data suggest that the role of neuroinflammation in neurodegeneration must be fully elucidated, since pro-inflammatory agents, which are the causative effects of neuroinflammation, occur widely, particularly in the elderly in whom inflammatory mechanisms are linked to the pathogenesis of functional and mental impairments.  In this review, we investigated the role played by the inflammatory process in neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp398nJGS8HIrVg90H21EOLACvtfcHk0lhxdXdzYVaHhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12rsL7E&md5=36d22b27436bea74776a33a373108e9d</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2016.4948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2016.4948%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%2BW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26atitle%3DRole%2520of%2520neuroinflammation%2520in%2520neurodegenerative%2520diseases%2520%2528Review%2529%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2016%26volume%3D13%26spage%3D3391%26epage%3D3396%26doi%3D10.3892%2Fmmr.2016.4948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raitio, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vepsäläinen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2022</span>– <span class="NLM_lpage">2027</span>, <span class="refDoi"> DOI: 10.1021/jm050879z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050879z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2022-2027&author=K.+H.+Raitioauthor=J.+R.+Savinainenauthor=J.+Veps%C3%A4l%C3%A4inenauthor=J.+T.+Laitinenauthor=A.+Posoauthor=T.+J%C3%A4rvinenauthor=T.+Nevalainen&title=Synthesis+and+SAR+studies+of+2-oxoquinoline+derivatives+as+CB2+receptor+inverse+agonists&doi=10.1021%2Fjm050879z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR Studies of 2-Oxoquinoline Derivatives as CB2 Receptor Inverse Agonists</span></div><div class="casAuthors">Raitio, Katri H.; Savinainen, Juha R.; Vepsaelaeinen, Jouko; Laitinen, Jarmo T.; Poso, Antti; Jaervinen, Tomi; Nevalainen, Tapio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2022-2027</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The highly CB2 selective cannabinoid receptor inverse agonist, N-benzo[1,3]dioxol-5-ylmethyl 7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide I (R = 1,3-benzodioxolan-5-ylmethyl) (JTE-907), served as the lead compd. for investigating the structure-activity relationships of its analogs and in the search for more potent and effective CB2 receptor inverse agonists.  A series of amides I [R = PhCH2, Ph(CH2)3, 4-O2NC6H4CH2CH2, 2-(3-indolyl)ethyl, etc.] was synthesized, and the CB2 receptor activities of the compds. were detd. by a [35S]GTPγS-binding assay using membranes of CHO cells stably transfected with the human CB2 receptor.  As a result, all the compds. were defined as full CB2 receptor inverse agonists, and addnl., except for I [R = 3,4-(HO)2C6H3(CH2)n; n = 1, 2], they were found to be equally potent as SR144528.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrzdBz_5pRFrVg90H21EOLACvtfcHk0lhxdXdzYVaHhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Grur8%253D&md5=e9a4a044d6ed3f8fbb2c2eb2f2623e2b</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fjm050879z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050879z%26sid%3Dliteratum%253Aachs%26aulast%3DRaitio%26aufirst%3DK.%2BH.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DVeps%25C3%25A4l%25C3%25A4inen%26aufirst%3DJ.%26aulast%3DLaitinen%26aufirst%3DJ.%2BT.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DT.%26aulast%3DNevalainen%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520SAR%2520studies%2520of%25202-oxoquinoline%2520derivatives%2520as%2520CB2%2520receptor%2520inverse%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2022%26epage%3D2027%26doi%3D10.1021%2Fjm050879z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houbrechts, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2009.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2009.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19423014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslWitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=455-465&author=N.+Evensauthor=G.+G.+Muccioliauthor=N.+Houbrechtsauthor=D.+M.+Lambertauthor=A.+M.+Verbruggenauthor=K.+Van+Laereauthor=G.+M.+Bormans&title=Synthesis+and+biological+evaluation+of+carbon-11-+and+fluorine-18-labeled+2-oxoquinoline+derivatives+for+type+2+cannabinoid+receptor+positron+emission+tomography+imaging&doi=10.1016%2Fj.nucmedbio.2009.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging</span></div><div class="casAuthors">Evens, Nele; Muccioli, Giulio G.; Houbrechts, Nele; Lambert, Didier M.; Verbruggen, Alfons M.; Van Laere, Koen; Bormans, Guy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">455-465</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: The type 2 cannabinoid (CB2) receptor is part of the endocannabinoid system and has been suggested as a mediator of several central and peripheral inflammatory processes.  Imaging of the CB2 receptor has been unsuccessful so far.  We synthesized and evaluated a carbon-11- and a fluorine-18-labeled 2-oxoquinoline deriv. as new PET tracers with high specificity and affinity for the CB2 receptor.  Methods: Two 2-oxoquinoline derivs. were synthesized and radiolabeled with either carbon-11 or fluorine-18.  Their affinity and selectivity for the human CB2 receptor were detd.  Biol. evaluation was done by biodistribution, radiometabolite and autoradiog. studies in mice.  Results: In vitro studies showed that both compds. are high affinity CB2-specific inverse agonists.  Biodistribution study of the tracers in mice showed a high in vivo initial brain uptake and fast brain washout, in accordance with the low CB2 receptor expression levels in normal brain.  A persistently high in vivo binding to the spleen was obsd., which was inhibited by pretreatment with two structurally unrelated CB2 selective inverse agonists.  In vitro autoradiog. studies with the radioligands confirmed CB2-specific binding to the mouse spleen.  Conclusion: We synthesized two novel CB2 receptor PET tracers that show high affinity/selectivity for CB2 receptors.  Both tracers show favorable characteristics as radioligands for central and peripheral in vivo visualization of the CB2 receptor and are promising candidates for primate and human CB2 PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvj-Yo-xj7b7Vg90H21EOLACvtfcHk0lhxdXdzYVaHhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslWitr4%253D&md5=215490676fd3fc7a7f96a22d0a67daf8</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2009.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2009.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DEvens%26aufirst%3DN.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DHoubrechts%26aufirst%3DN.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26aulast%3DVerbruggen%26aufirst%3DA.%2BM.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DBormans%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520carbon-11-%2520and%2520fluorine-18-labeled%25202-oxoquinoline%2520derivatives%2520for%2520type%25202%2520cannabinoid%2520receptor%2520positron%2520emission%2520tomography%2520imaging%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2009%26volume%3D36%26spage%3D455%26epage%3D465%26doi%3D10.1016%2Fj.nucmedbio.2009.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeputte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coolen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekelandt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G. M.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of [<sup>11</sup>C]NE40, a type 2 cannabinoid receptor PET tracer</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2011.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22154685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Oqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=389-399&author=N.+Evensauthor=C.+Vandeputteauthor=C.+Coolenauthor=P.+Janssenauthor=R.+Sciotauthor=V.+Baekelandtauthor=A.+M.+Verbruggenauthor=Z.+Debyserauthor=K.+Van+Laereauthor=G.+M.+Bormans&title=Preclinical+evaluation+of+%5B11C%5DNE40%2C+a+type+2+cannabinoid+receptor+PET+tracer&doi=10.1016%2Fj.nucmedbio.2011.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer</span></div><div class="casAuthors">Evens, Nele; Vandeputte, Caroline; Coolen, Charlotte; Janssen, Peter; Sciot, Raf; Baekelandt, Veerle; Verbruggen, Alfons M.; Debyser, Zeger; Van Laere, Koen; Bormans, Guy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-399</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Up-regulation of the type 2 cannabinoid receptor (CB2R) has been reported in (neuro)inflammatory diseases.  In this study, we report the preclin. evaluation of [11C]NE40 as positron emission tomog. (PET) radioligand for visualization of the CB2R.  The selectivity of NE40 for CB2R and its toxicity and mutagenicity were detd.  [11C]NE40 was evaluated by biodistribution and autoradiog. studies in normal rats and a microPET study in normal mice, rats and a rhesus monkey.  Specific in vivo binding of [11C]NE40 to human CB2R (hCB2R) was studied in a rat model with hCB2R overexpression.[11C]NE40 shows specific CB2R binding in the spleen and blood of normal rats and high brain uptake in rhesus monkey.  [11C]NE40 showed specific and reversible binding to hCB2R in vivo in a rat model with local hCB2R overexpression.  [11C]NE40 shows favorable characteristics as radioligand for in vivo visualization of the CB2R and is a promising candidate for hCB2R PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJz5-qNs-FbVg90H21EOLACvtfcHk0lhxdXdzYVaHhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Oqu7k%253D&md5=be1c9b2ff6196d6f7cbe5f4ab02150bb</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DEvens%26aufirst%3DN.%26aulast%3DVandeputte%26aufirst%3DC.%26aulast%3DCoolen%26aufirst%3DC.%26aulast%3DJanssen%26aufirst%3DP.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DBaekelandt%26aufirst%3DV.%26aulast%3DVerbruggen%26aufirst%3DA.%2BM.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DBormans%26aufirst%3DG.%2BM.%26atitle%3DPreclinical%2520evaluation%2520of%2520%255B11C%255DNE40%252C%2520a%2520type%25202%2520cannabinoid%2520receptor%2520PET%2520tracer%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2012%26volume%3D39%26spage%3D389%26epage%3D399%26doi%3D10.1016%2Fj.nucmedbio.2011.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postnov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versijpt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbulcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">2219</span>– <span class="NLM_lpage">2227</span>, <span class="refDoi"> DOI: 10.1007/s00259-016-3457-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00259-016-3457-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27488857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlansbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=2219-2227&author=R.+Ahmadauthor=A.+Postnovauthor=G.+Bormansauthor=J.+Versijptauthor=M.+Vandenbulckeauthor=K.+Van+Laere&title=Decreased+in+vivo+availability+of+the+cannabinoid+type+2+receptor+in+Alzheimer%E2%80%99s+disease&doi=10.1007%2Fs00259-016-3457-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease</span></div><div class="casAuthors">Ahmad, Rawaha; Postnov, Andrey; Bormans, Guy; Versijpt, Jan; Vandenbulcke, Mathieu; Van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2219-2227</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The cannabinoid type 2 receptor (CB2R) is expressed by immune cells such as monocytes and macrophages.  In the brain, CB2R is primarily found on microglia.  CB2R upregulation has been reported in animal models of Alzheimer's disease, with a preferential localization near amyloid beta (Aβ) plaques, and in patients post mortem.  We performed in vivo brain imaging and kinetic modeling of the CB2R tracer [11C]NE40 in healthy controls (HC) and in patients with Alzheimer's disease (AD) to investigate whether higher CB2R availability regionally colocalized to Aβ deposits is present in vivo.  Methods: Dynamic 90-min [11C]NE40 PET scans were performed in eight HC and nine AD patients with full kinetic modeling using arterial sampling and metabolite correction and partial vol. correction.  All AD patients received a static [11C]PIB scan 40 min after injection.  In four HC, a retest scan with [11C]NE40 PET was performed within 9 wk to investigate test-retest characteristics.  Results: [11C]NE40 was metabolized quickly leading to 50 % of intact tracer 20 min after injection and 20 % at 90 min.  A two-tissue kinetic model fitted most of the time-activity curves best; both binding potential (BPND) and distribution vol. (VT) parameters could be used.  Brain uptake was generally low with an av. K1 value of 0.07 mL/min/mL tissue.  VT and BPND were in the range of 0.7 - 1.8 and 0.6 - 1.6, resp.  Test values in HC were about 30 % for VT and BPND.  AD patients showed overall significantly lower CB2R binding.  No relationship was found between regional or global amyloid load and CB2R availability.  Conclusion: Kinetic modeling of [11C]NE40 is possible with a two-tissue reversible model.  In contrast to preclin. and post-mortem data, [11C]NE40 PET shows lower CB2R availability in vivo in AD patients, with no relationship to Aβ plaques.  A possible explanation for these findings is that [11C]NE40 binds to CB2R with lower affinity and/or selectivity than to CB1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8dZ0AOY_CYrVg90H21EOLACvtfcHk0li1dZE4zlLsyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlansbvI&md5=206d502f265b83e15c0f032499b08eb6</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3457-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3457-7%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DPostnov%26aufirst%3DA.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DVersijpt%26aufirst%3DJ.%26aulast%3DVandenbulcke%26aufirst%3DM.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DDecreased%2520in%2520vivo%2520availability%2520of%2520the%2520cannabinoid%2520type%25202%2520receptor%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2016%26volume%3D43%26spage%3D2219%26epage%3D2227%26doi%3D10.1007%2Fs00259-016-3457-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herde, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.01.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejmech.2015.01.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25599952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFGmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=554-564&author=R.+Slavikauthor=A.+M.+Herdeauthor=D.+Bieriauthor=M.+Weberauthor=R.+Schibliauthor=S.+D.+Kramerauthor=S.+M.+Ametameyauthor=L.+Mu&title=Synthesis%2C+radiolabeling+and+evaluation+of+novel+4-oxo-quinoline+derivatives+as+PET+tracers+for+imaging+cannabinoid+type+2+receptor&doi=10.1016%2Fj.ejmech.2015.01.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor</span></div><div class="casAuthors">Slavik, Roger; Herde, Adrienne Muller; Bieri, Daniel; Weber, Markus; Schibli, Roger; Kramer, Stefanie D.; Ametamey, Simon M.; Mu, Linjing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">554-564</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Our goal is to develop a highly specific and selective PET brain tracer for imaging CB2 expression in patients with neuroinflammatory diseases.  Based on our previous findings on a carbon-11 labeled 4-oxo-quinoline structure, designated KD2, further structural optimizations were performed, which led to the discovery of N-(1-adamantyl)-1-(2-ethoxyethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxamide of formula I (RS-016).  Compared to KD2, RS-016 exhibits a higher binding affinity towards CB2 (Ki = 0.7 nM) with a selectivity over CB1 of > 10,000 and lower lipophilicity (logD = 2.78). [11C]RS-016 was obtained in ≥ 99 % radiochem. purity and up to 850 GBq/μmol specific radioactivity at the end of synthesis.  In vitro autoradiog. on rodent spleen tissue showed high specific binding to CB2. [11C]RS-016 was stable in vitro in rodent and human plasma over 40 min, whereas 47 % intact compd. was found in vivo in rat blood plasma 20 min post injection (p.i.).  High specific binding to CB2 was obsd. in murine spleen tissues and postmortem ALS patient spinal cord tissues in vitro autoradiog., ex vivo biodistribution data confirmed the high and specific uptake of [11C]RS-016 in spleen region in rats.  In vivo specificity of [11C]RS-016 could also be shown in brain by PET imaging using a murine neuroinflammation model, which has higher CB2 receptor expression level in the brain induced by lipopolysaccharide (LPS) application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3_cA3WYogLVg90H21EOLACvtfcHk0li1dZE4zlLsyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFGmsQ%253D%253D&md5=9416c5ac46b4a73ab18ca7b8580eacb9</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.01.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.01.028%26sid%3Dliteratum%253Aachs%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DHerde%26aufirst%3DA.%2BM.%26aulast%3DBieri%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26aulast%3DMu%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520radiolabeling%2520and%2520evaluation%2520of%2520novel%25204-oxo-quinoline%2520derivatives%2520as%2520PET%2520tracers%2520for%2520imaging%2520cannabinoid%2520type%25202%2520receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D554%26epage%3D564%26doi%3D10.1016%2Fj.ejmech.2015.01.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drandarov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cermak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1111/jnc.12354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fjnc.12354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23795580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSqu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2013&pages=616-624&author=L.+Muauthor=D.+Bieriauthor=R.+Slavikauthor=K.+Drandarovauthor=A.+Mullerauthor=S.+Cermakauthor=M.+Weberauthor=R.+Schibliauthor=S.+D.+Kramerauthor=S.+M.+Ametamey&title=Radiolabeling+and+in+vitro+%2Fin+vivo+evaluation+of+N-%281-adamantyl%29-8-methoxy-4-oxo-1-phenyl-1%2C4-dihydroquinoline-3-carboxamide+as+a+PET+probe+for+imaging+cannabinoid+type+2+receptor&doi=10.1111%2Fjnc.12354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor</span></div><div class="casAuthors">Mu, Linjing; Bieri, Daniel; Slavik, Roger; Drandarov, Konstantin; Mueller, Adrienne; Cermak, Stjepko; Weber, Markus; Schibli, Roger; Kraemer, Stefanie D.; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">5&6</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The cannabinoid type 2 (CB2) receptor plays an important role in neuroinflammatory and neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease and is therefore a very promising target for therapeutic approaches as well as for imaging.  Based on the literature, we identified one 4-oxoquinoline deriv. (designated KD2) as the lead structure.  It was synthesized, radiolabeled and evaluated as a potential imaging tracer for CB2. [11C]KD2 was obtained in 99% radiochem. purity.  Moderate blood-brain barrier (BBB) passage was predicted for KD2 from an in vitro transport assay with P-glycoprotein-transfected Madin Darby canine kidney cells.  No efflux of KD2 by P-glycoprotein was detected.  In vitro autoradiog. of rat and mouse spleen slices demonstrated that [11C]KD2 exhibits high specific binding towards CB2.  High spleen uptake of [11C]KD2 was obsd. in dynamic positron emission tomog. (PET) studies with Wistar rats and its specificity was confirmed by displacement study with a selective CB2 agonist, GW405833.  A pilot autoradiog. study with post-mortem spinal cord slices from amyotrophic lateral sclerosis (ALS) patients with [11C]KD2 suggested the presence of CB2 receptors under disease conditions.  Specificity of [11C]KD2 binding could also be demonstrated on these human tissues.  In conclusion, [11C]KD2 shows good in vitro and in vivo properties as a potential PET tracer for CB2.  The cannabinoid type 2 receptor (CB2) plays an important role in neuroinflammatory and neuro-degenerative diseases. [11C]KD2, a new CB2 radioligand, exhibits selectivity towards CB2 receptor in vitro and in vivo in rat.  A pilot autoradiog. study with spinal cord slices from amyotrophic lateral sclerosis patients with [11C]KD2 suggested the presence of CB2 under disease conditions (Figure).  Selective CB2 agonist, GW405833.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5nK7DhzHrErVg90H21EOLACvtfcHk0lhZmJ_ZyIRp8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSqu7zN&md5=863e2ab5064c38648f1618a9a2424410</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12354%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DL.%26aulast%3DBieri%26aufirst%3DD.%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DDrandarov%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DA.%26aulast%3DCermak%26aufirst%3DS.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DRadiolabeling%2520and%2520in%2520vitro%2520%252Fin%2520vivo%2520evaluation%2520of%2520N-%25281-adamantyl%2529-8-methoxy-4-oxo-1-phenyl-1%252C4-dihydroquinoline-3-carboxamide%2520as%2520a%2520PET%2520probe%2520for%2520imaging%2520cannabinoid%2520type%25202%2520receptor%26jtitle%3DJ.%2520Neurochem.%26date%3D2013%26volume%3D126%26spage%3D616%26epage%3D624%26doi%3D10.1111%2Fjnc.12354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meletta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rancic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller
Herde, A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [<sup>11</sup>C]RS-016 targeting CB2 in atherosclerosis</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2017.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2017.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28104528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=31-43&author=R.+Melettaauthor=R.+Slavikauthor=L.+Muauthor=Z.+Rancicauthor=N.+Borelauthor=R.+Schibliauthor=S.+M.+Ametameyauthor=S.+D.+Kramerauthor=A.+Muller%0AHerde&title=Cannabinoid+receptor+type+2+%28CB2%29+as+one+of+the+candidate+genes+in+human+carotid+plaque+imaging%3A+Evaluation+of+the+novel+radiotracer+%5B11C%5DRS-016+targeting+CB2+in+atherosclerosis&doi=10.1016%2Fj.nucmedbio.2017.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evalu1ation of the novel radiotracer [11C]RS-016 targeting CB2 in atherosclerosis</span></div><div class="casAuthors">Meletta, Romana; Slavik, Roger; Mu, Linjing; Rancic, Zoran; Borel, Nicole; Schibli, Roger; Ametamey, Simon M.; Kramer, Stefanie D.; Muller Herde, Adrienne</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-43</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Endarterectomized human atherosclerotic plaques are a valuable basis for gene expression studies to disclose novel imaging biomarkers and therapeutic targets, such as the cannabinoid receptor type 2 (CB2).  In this work, CB2 is expressed on activated immune cells, which are abundant in inflamed plaques.  We evaluated the CB2-specific radiotracer [11C]RS-016 for imaging vascular inflammation in human and mouse atherosclerotic lesions.  Methods: The differential gene expression of microscopically classified human carotid plaques was evaluated using quant. polymerase chain reaction.  In addn., CB2 expression levels in human plaques were investigated by in vitro autoradiog.  As an appropriate animal model we used apolipoprotein E knockout mice (ApoE KO) with shear stress-induced atherosclerosis to evaluate CB2 levels in vivo.  Positron emission tomog. (PET) was performed with both the CB2 radioligand [11C]RS-016 and the metabolic radiotracer [18F]fluorodeoxyglucose ([18F]FDG) at various time points.  Retrospectively, carotids were dissected for histopathol. and gene expression anal.  Results: We identified 28 human genes differentially expressed in atherosclerotic plaques compared to normal arteries of which 12 were upregulated preferentially in vulnerable plaques.  The latter group included members of matrix metalloproteinase family and the T-lymphocyte activation antigens CD80 and CD86.  CB2 was upregulated by 2-fold in human atherosclerotic plaques correlating with CD68 expression levels.  Specific in vitro binding of [11C]RS-016 was predominantly obsd. to plaques.  In vivo PET imaging of ApoE KO mice revealed accumulation of [11C]RS-016 and [18F]FDG in atherosclerotic plaques.  Development of advanced plaques with elevated CB2 and CD68 levels were found in vitro in ApoE KO mice resembling human vulnerable plaques.  Conclusion: We identified human genes assocd. with plaque vulnerability, which potentially could serve as novel imaging or therapeutic targets.  The CB2-specific radiotracer [11C]RS-016 detected human plaques by in vitro autoradiog. and accumulated in vivo in plaques of ApoE KO mice, however not exclusively in vulnerable plaques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMl-qV7Q_iMLVg90H21EOLACvtfcHk0lhZmJ_ZyIRp8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ahs70%253D&md5=5b905f400a54ca39e4a0bda213987fdb</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2017.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2017.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DMeletta%26aufirst%3DR.%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DRancic%26aufirst%3DZ.%26aulast%3DBorel%26aufirst%3DN.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DMuller%2BHerde%26aufirst%3DA.%26atitle%3DCannabinoid%2520receptor%2520type%25202%2520%2528CB2%2529%2520as%2520one%2520of%2520the%2520candidate%2520genes%2520in%2520human%2520carotid%2520plaque%2520imaging%253A%2520Evaluation%2520of%2520the%2520novel%2520radiotracer%2520%255B11C%255DRS-016%2520targeting%2520CB2%2520in%2520atherosclerosis%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2017%26volume%3D47%26spage%3D31%26epage%3D43%26doi%3D10.1016%2Fj.nucmedbio.2017.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller Herde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1111/jnc.13716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fjnc.13716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27385045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gqt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=874-886&author=R.+Slavikauthor=A.+Muller+Herdeauthor=A.+Haiderauthor=S.+D.+Kramerauthor=M.+Weberauthor=R.+Schibliauthor=S.+M.+Ametameyauthor=L.+Mu&title=Discovery+of+a+fluorinated+4-oxo-quinoline+derivative+as+a+potential+positron+emission+tomography+radiotracer+for+imaging+cannabinoid+receptor+type+2&doi=10.1111%2Fjnc.13716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2</span></div><div class="casAuthors">Slavik, Roger; Mueller Herde, Adrienne; Haider, Ahmed; Kraemer, Stefanie D.; Weber, Markus; Schibli, Roger; Ametamey, Simon M.; Mu, Linjing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-886</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The cannabinoid receptor type 2 (CB2) is part of the endocannabinoid system and has gained growing attention in recent years because of its important role in neuroinflammatory/neurodegenerative diseases.  Recently, we reported on a carbon-11 labeled 4-oxo-quinoline deriv., designated RS-016, as a promising radiotracer for imaging CB2 using PET.  In this study, three novel fluorinated analogs of RS-016 were designed, synthesized, and pharmacol. evaluated.  The results of our efforts led to the identification of N-(1-adamantyl)-1-(2-(2-fluoroethoxy)ethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxamide (RS-126) as the most potent candidate for evaluation as a CB2 PET ligand. [18F]RS-126 was obtained in ≥ 99% radiochem. purity with an av. specific radioactivity of 98 GBq/μmol at the end of the radiosynthesis. [18F]RS-126 showed a logD7.4 value of 1.99 and is stable in vitro in rat and human plasma over 120 min, whereas 55% intact parent compd. was found in vivo in rat blood plasma at 10 min post injection.  In vitro autoradiog. studies with CB2-pos. rat spleen tissue revealed high and blockable binding which was confirmed in in vivo displacement expts. with rats by dynamic PET imaging.  Ex vivo biodistribution studies confirmed accumulation of [18F]RS-126 in rat spleen with a specificity of 79% under blocking conditions.  The moderate elevated CB2 levels in LPS-treated mice brain did not permit the detection of CB2 by [18F]RS-126 using PET imaging.  In summary, [18F]RS-126 demonstrated high specificity toward CB2 receptor in vitro and in vivo and is a promising radioligand for imaging CB2 receptor expression.  Cannabinoid receptor type 2 (CB2) is an interesting target for PET imaging.  Specific binding of [18F]RS-126 in CB2-pos. spleen tissue (white arrow head) was confirmed in in vivo displacement expts. with rats.  Time activity curve of [18F]RS-126 in the spleen after the addn. of GW405833 (CB2 specific ligand, green) demonstrates faster radiotracer elimination (blue) compared to the tracer only (red).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6l7D--J1F7Vg90H21EOLACvtfcHk0lhZmJ_ZyIRp8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gqt7rK&md5=2b51bf80bdb7a8743f315b3442e4166a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13716%26sid%3Dliteratum%253Aachs%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DMuller%2BHerde%26aufirst%3DA.%26aulast%3DHaider%26aufirst%3DA.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26aulast%3DMu%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520fluorinated%25204-oxo-quinoline%2520derivative%2520as%2520a%2520potential%2520positron%2520emission%2520tomography%2520radiotracer%2520for%2520imaging%2520cannabinoid%2520receptor%2520type%25202%26jtitle%3DJ.%2520Neurochem.%26date%3D2016%26volume%3D138%26spage%3D874%26epage%3D886%26doi%3D10.1111%2Fjnc.13716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herde, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margelisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejmech.2017.12.097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29353725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=746-759&author=A.+Haiderauthor=F.+Spinelliauthor=A.+M.+Herdeauthor=B.+Muauthor=C.+Kellerauthor=M.+Margelischauthor=M.+Weberauthor=R.+Schibliauthor=L.+Muauthor=S.+M.+Ametamey&title=Evaluation+of+4-oxo-quinoline-based+CB2+PET+radioligands+in+R6%2F2+chorea+huntington+mouse+model+and+human+ALS+spinal+cord+tissue&doi=10.1016%2Fj.ejmech.2017.12.097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue</span></div><div class="casAuthors">Haider, Ahmed; Spinelli, Francesco; Herde, Adrienne Muller; Mu, Boshuai; Keller, Claudia; Margelisch, Markus; Weber, Markus; Schibli, Roger; Mu, Linjing; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">746-759</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The cannabinoid receptor 2 (CB2) has been implicated in a series of neurodegenerative disorders and has emerged as an interesting biol. target for therapeutic as well as diagnostic purposes.  In the present work, we describe an improved radiosynthetic approach to obtain the previously reported CB2-specific PET radioligand [18F]RS-126 in higher radiochem. yields and molar activities.  Addnl., the study revealed that prolongation of the [18F]RS-126 fluoroalkyl side chain ultimately leads to an improved stability towards mouse liver enzymes but is accompanied by a redn. in selectivity over the cannabinoid receptor 1 (CB1).  Huntington-related phenotypic changes as well as striatal D2R downregulation were confirmed for the transgenic R6/2 mouse model.  CB2 upregulation in R6/2 Chorea Huntington mice was obsd. in hippocampus, cortex, striatum and cerebellum by qPCR, however, these results could not be confirmed at the protein level by PET imaging.  Furthermore, we evaluated the utility of the newly developed [11C]RS-028, a potent [18F]RS-126 deriv. with increased polarity and high selectivity over CB1 in post-mortem human ALS spinal cord and control tissue.  Applying in vitro autoradiog., the translational relevance of CB2 imaging was demonstrated by the specific binding of [11C]RS-028 to post-mortem human ALS spinal cord tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplQbODli8237Vg90H21EOLACvtfcHk0lh063R_vdWXqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOhsL0%253D&md5=12d0514c79a7a3e45b1aa751971af494</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.097%26sid%3Dliteratum%253Aachs%26aulast%3DHaider%26aufirst%3DA.%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DHerde%26aufirst%3DA.%2BM.%26aulast%3DMu%26aufirst%3DB.%26aulast%3DKeller%26aufirst%3DC.%26aulast%3DMargelisch%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DEvaluation%2520of%25204-oxo-quinoline-based%2520CB2%2520PET%2520radioligands%2520in%2520R6%252F2%2520chorea%2520huntington%2520mouse%2520model%2520and%2520human%2520ALS%2520spinal%2520cord%2520tissue%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D145%26spage%3D746%26epage%3D759%26doi%3D10.1016%2Fj.ejmech.2017.12.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller Herde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingerle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4266</span>– <span class="NLM_lpage">4277</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00283</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00283" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVSntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4266-4277&author=R.+Slavikauthor=U.+Gretherauthor=A.+Muller+Herdeauthor=L.+Gobbiauthor=J.+Fingerleauthor=C.+Ullmerauthor=S.+D.+Kramerauthor=R.+Schibliauthor=L.+Muauthor=S.+M.+Ametamey&title=Discovery+of+a+high+affinity+and+selective+pyridine+analog+as+a+potential+positron+emission+tomography+imaging+agent+for+cannabinoid+type+2+receptor&doi=10.1021%2Facs.jmedchem.5b00283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a High Affinity and Selective Pyridine Analog as a Potential Positron Emission Tomography Imaging Agent for Cannabinoid Type 2 Receptor</span></div><div class="casAuthors">Slavik, Roger; Grether, Uwe; Muller Herde, Adrienne; Gobbi, Luca; Fingerle, Jurgen; Ullmer, Christoph; Kramer, Stefanie D.; Schibli, Roger; Mu, Linjing; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4266-4277</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of our efforts to develop CB2 PET imaging agents, we investigated 2,5,6-substituted pyridines as a novel class of potential CB2 PET ligands.  A total of 21 novel compds. were designed, synthesized, and evaluated for their potency and binding properties toward human and rodent CB1 and CB2.  The most promising ligand 6a was radiolabeled with carbon-11 to yield 16 ([11C]RSR-056).  Specific binding of 16 to CB2-pos. spleen tissue of rats and mice was demonstrated by in vitro autogadiog. and verified in vivo in PET and biodistribution expts.  Furthermore, 16 was evaluated in a lipopolysaccharid (LPS) induced murine model of neuroinflammation.  Brain radioactivity was strikingly higher in the LPS-treated mice than the control mice.  Compd. 16 is a promising radiotracer for imaging CB2 in rodents.  It might serve as a tool for the investigation of CB2 receptor expression levels in healthy tissues and different neuroinflammatory disorders in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWUcSCaQyFerVg90H21EOLACvtfcHk0lh063R_vdWXqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVSntr8%253D&md5=ed007d65ae82025274ddc73ec0668220</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00283%26sid%3Dliteratum%253Aachs%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DGrether%26aufirst%3DU.%26aulast%3DMuller%2BHerde%26aufirst%3DA.%26aulast%3DGobbi%26aufirst%3DL.%26aulast%3DFingerle%26aufirst%3DJ.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%2520a%2520high%2520affinity%2520and%2520selective%2520pyridine%2520analog%2520as%2520a%2520potential%2520positron%2520emission%2520tomography%2520imaging%2520agent%2520for%2520cannabinoid%2520type%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4266%26epage%3D4277%26doi%3D10.1021%2Facs.jmedchem.5b00283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xaio, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niehoff, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, J. E.</span></span> <span> </span><span class="NLM_article-title">Effect of LPS on the permeability of the blood-brain barrier to insulin</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>896</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/S0006-8993(00)03247-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0006-8993%2800%2903247-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=11277970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitF2rsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=896&publication_year=2001&pages=36-42&author=H.+Xaioauthor=W.+A.+Banksauthor=M.+L.+Niehoffauthor=J.+E.+Morley&title=Effect+of+LPS+on+the+permeability+of+the+blood-brain+barrier+to+insulin&doi=10.1016%2FS0006-8993%2800%2903247-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of LPS on the permeability of the blood-brain barrier to insulin</span></div><div class="casAuthors">Xaio, H.; Banks, W. A.; Niehoff, M. L.; Morley, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">896</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">36-42</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Insulin has emerged as an important neuropeptide.  Central actions of insulin appear to oppose those in the periphery.  Insulin is transported across the blood-brain barrier (BBB) by a saturable transport system.  The permeability of the BBB to insulin is altered by various events, but no studies exist that have examd. the permeability of the BBB to insulin during infection or inflammation, states which can induce peripheral insulin resistance.  The authors looked at the effects of lipopolysaccharide (LPS), a bacterial endotoxin and a powerful cytokine releaser, on the permeability of the BBB to human insulin in CD-1 mice.  I.p. injections of LPS significantly increased the uptake by the brain of 131I-insulin and disrupted the BBB to 125I-albumin.  After subtraction of the brain/serum ratio for 125I-albumin, brain/serum ratios for insulin were increased: 10.38±0.70 μL/g (LPS) vs. 3.62±0.27 μL/g (no LPS), P<0.0001, showing that LPS increased the uptake of insulin independent of BBB disruption.  This increase in insulin uptake was due to enhanced saturable transport.  Pretreatment with indomethacin 10 min before LPS injections enhanced BBB disruption, but not insulin transport.  Pretreatment with the nitric oxide (NO) synthase inhibitor aminoguanidine had no effect on insulin or albumin uptake, but pretreatment with NG-nitro-L-arginine Me ester (L-NAME) enhanced insulin transport, but not BBB disruption.  Thus, LPS increases the saturable transport of insulin across the BBB independent of disruption and prostaglandins with potentiation by NO inhibition.  Such increased transport could potentiate the central effects of insulin and so contribute to the peripheral insulin resistance seen with infection and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodWLkGN_YapLVg90H21EOLACvtfcHk0lh063R_vdWXqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitF2rsbo%253D&md5=c22da3654f329faf70cab547681fe3b7</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2800%2903247-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252800%252903247-9%26sid%3Dliteratum%253Aachs%26aulast%3DXaio%26aufirst%3DH.%26aulast%3DBanks%26aufirst%3DW.%2BA.%26aulast%3DNiehoff%26aufirst%3DM.%2BL.%26aulast%3DMorley%26aufirst%3DJ.%2BE.%26atitle%3DEffect%2520of%2520LPS%2520on%2520the%2520permeability%2520of%2520the%2520blood-brain%2520barrier%2520to%2520insulin%26jtitle%3DBrain%2520Res.%26date%3D2001%26volume%3D896%26spage%3D36%26epage%3D42%26doi%3D10.1016%2FS0006-8993%2800%2903247-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartelmus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingerle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knuesel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herde, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies of pyridine-based ligands and identification of a fluorinated derivative for positron emission tomography imaging of cannabinoid type 2 receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">11165</span>– <span class="NLM_lpage">11181</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01280</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01280" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SnsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11165-11181&author=A.+Haiderauthor=J.+Kretzauthor=L.+Gobbiauthor=H.+Ahmedauthor=K.+Atzauthor=M.+Burklerauthor=C.+Bartelmusauthor=J.+Fingerleauthor=W.+Gubaauthor=C.+Ullmerauthor=M.+Honerauthor=I.+Knueselauthor=M.+Weberauthor=A.+Brinkauthor=A.+M.+Herdeauthor=C.+Kellerauthor=R.+Schibliauthor=L.+Muauthor=U.+Gretherauthor=S.+M.+Ametamey&title=Structure-activity+relationship+studies+of+pyridine-based+ligands+and+identification+of+a+fluorinated+derivative+for+positron+emission+tomography+imaging+of+cannabinoid+type+2+receptors&doi=10.1021%2Facs.jmedchem.9b01280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors</span></div><div class="casAuthors">Haider, Ahmed; Kretz, Julian; Gobbi, Luca; Ahmed, Hazem; Atz, Kenneth; Burkler, Markus; Bartelmus, Christian; Fingerle, Jurgen; Guba, Wolfgang; Ullmer, Christoph; Honer, Michael; Knuesel, Irene; Weber, Markus; Brink, Andreas; Herde, Adrienne Muller; Keller, Claudia; Schibli, Roger; Mu, Linjing; Grether, Uwe; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11165-11181</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cannabinoid type 2 (CB2) receptor has emerged as a valuable target for therapy and imaging of immune-mediated pathologies.  With the aim to find a suitable radiofluorinated analog of the previously reported CB2 positron emission tomog. (PET) radioligand [11C]RSR-056, 38 fluorinated derivs. were synthesized and tested by in vitro binding assays.  With a Ki (hCB2) of 6 nM and a selectivity factor of nearly 700 over cannabinoid type 1 receptors, target compd. 3 exhibited optimal in vitro properties and was selected for evaluation as a PET radioligand. [18F]3 was obtained in an av. radiochem. yield of 11 ± 4% and molar activities between 33 and 114 GBq/μmol.  Specific binding of [18F]3 to CB2 was demonstrated by in vitro autoradiog. and in vivo PET expts. using the CB2 ligand GW-405 833.  Metabolite anal. revealed only intact [18F]3 in the rat brain. [18F]3 detected CB2 upregulation in human amyotrophic lateral sclerosis spinal cord tissue and may thus become a candidate for diagnostic use in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-5mBBCTvMY7Vg90H21EOLACvtfcHk0liTdKGUWKHI8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SnsbzP&md5=2635e2a8659b53485ddcbabcf26afd18</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01280%26sid%3Dliteratum%253Aachs%26aulast%3DHaider%26aufirst%3DA.%26aulast%3DKretz%26aufirst%3DJ.%26aulast%3DGobbi%26aufirst%3DL.%26aulast%3DAhmed%26aufirst%3DH.%26aulast%3DAtz%26aufirst%3DK.%26aulast%3DBurkler%26aufirst%3DM.%26aulast%3DBartelmus%26aufirst%3DC.%26aulast%3DFingerle%26aufirst%3DJ.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DHoner%26aufirst%3DM.%26aulast%3DKnuesel%26aufirst%3DI.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DBrink%26aufirst%3DA.%26aulast%3DHerde%26aufirst%3DA.%2BM.%26aulast%3DKeller%26aufirst%3DC.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DGrether%26aufirst%3DU.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520pyridine-based%2520ligands%2520and%2520identification%2520of%2520a%2520fluorinated%2520derivative%2520for%2520positron%2520emission%2520tomography%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D11165%26epage%3D11181%26doi%3D10.1021%2Facs.jmedchem.9b01280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartelmus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knuesel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herde, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical development of a 2,5,6-trisubstituted fluorinated pyridine derivative as a radioligand for the positron emission tomography imaging of cannabinoid type 2 receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10287</span>– <span class="NLM_lpage">10306</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00778</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00778" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFOju7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10287-10306&author=A.+Haiderauthor=L.+C.+Gobbiauthor=J.+Kretzauthor=C.+Ullmerauthor=A.+Brinkauthor=M.+Honerauthor=T.+J.+Wolteringauthor=D.+Muriauthor=H.+Idingauthor=M.+B%C3%BCrklerauthor=M.+Binderauthor=C.+Bartelmusauthor=I.+Knueselauthor=P.+Pacherauthor=A.+M.+Herdeauthor=F.+Spinelliauthor=H.+Ahmedauthor=K.+Atzauthor=C.+Kellerauthor=M.+Weberauthor=R.+Schibliauthor=L.+Muauthor=U.+Gretherauthor=S.+M.+Ametamey&title=Identification+and+preclinical+development+of+a+2%2C5%2C6-trisubstituted+fluorinated+pyridine+derivative+as+a+radioligand+for+the+positron+emission+tomography+imaging+of+cannabinoid+type+2+receptors&doi=10.1021%2Facs.jmedchem.0c00778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors</span></div><div class="casAuthors">Haider, Ahmed; Gobbi, Luca; Kretz, Julian; Ullmer, Christoph; Brink, Andreas; Honer, Michael; Woltering, Thomas J.; Muri, Dieter; Iding, Hans; Burkler, Markus; Binder, Martin; Bartelmus, Christian; Knuesel, Irene; Pacher, Pal; Herde, Adrienne Muller; Spinelli, Francesco; Ahmed, Hazem; Atz, Kenneth; Keller, Claudia; Weber, Markus; Schibli, Roger; Mu, Linjing; Grether, Uwe; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10287-10306</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clin. routine.  In this work, we synthesized 15 fluorinated pyridine derivs. and tested their binding affinities toward CB2 and CB1.  With a sub-nanomolar affinity (Ki for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an av. radiochem. yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochem. purity > 99%). [18F]RoSMA-18-d6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiog., ex vivo biodistribution, and positron emission tomog. (PET).  Further, [18F]RoSMA-18-d6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues.  Overall, these results suggest that [18F]RoSMA-18-d6 is a promising CB2 PET radioligand for clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7gtOgThXrm7Vg90H21EOLACvtfcHk0liTdKGUWKHI8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFOju7rI&md5=52c2fc5eb0b41922de8cd959ba99dd4c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00778%26sid%3Dliteratum%253Aachs%26aulast%3DHaider%26aufirst%3DA.%26aulast%3DGobbi%26aufirst%3DL.%2BC.%26aulast%3DKretz%26aufirst%3DJ.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DBrink%26aufirst%3DA.%26aulast%3DHoner%26aufirst%3DM.%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DMuri%26aufirst%3DD.%26aulast%3DIding%26aufirst%3DH.%26aulast%3DB%25C3%25BCrkler%26aufirst%3DM.%26aulast%3DBinder%26aufirst%3DM.%26aulast%3DBartelmus%26aufirst%3DC.%26aulast%3DKnuesel%26aufirst%3DI.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DHerde%26aufirst%3DA.%2BM.%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DAhmed%26aufirst%3DH.%26aulast%3DAtz%26aufirst%3DK.%26aulast%3DKeller%26aufirst%3DC.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DGrether%26aufirst%3DU.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DIdentification%2520and%2520preclinical%2520development%2520of%2520a%25202%252C5%252C6-trisubstituted%2520fluorinated%2520pyridine%2520derivative%2520as%2520a%2520radioligand%2520for%2520the%2520positron%2520emission%2520tomography%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10287%26epage%3D10306%26doi%3D10.1021%2Facs.jmedchem.0c00778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savonenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biodistribution of [<sup>11</sup>C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5202</span>– <span class="NLM_lpage">5207</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.05.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmc.2010.05.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20554448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslagurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5202-5207&author=A.+G.+Hortiauthor=Y.+Gaoauthor=H.+T.+Ravertauthor=P.+Finleyauthor=H.+Valentineauthor=D.+F.+Wongauthor=C.+J.+Endresauthor=A.+V.+Savonenkoauthor=R.+F.+Dannals&title=Synthesis+and+biodistribution+of+%5B11C%5DA-836339%2C+a+new+potential+radioligand+for+PET+imaging+of+cannabinoid+type+2+receptors+%28CB2%29&doi=10.1016%2Fj.bmc.2010.05.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2)</span></div><div class="casAuthors">Horti, Andrew G.; Gao, Yongjun; Ravert, Hayden T.; Finley, Paige; Valentine, Heather; Wong, Dean F.; Endres, Christopher J.; Savonenko, Alena V.; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5202-5207</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, A-836339 [2,2,3,3-tetramethylcyclopropanecarboxylic acid [3-(2-methoxyethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]amide] (1) was reported to be a selective CB2 agonist with high binding affinity.  Here we describe the radiosynthesis of [11C]A-836339 ([11C]1) via its desmethyl precursor as a candidate radioligand for imaging CB2 receptors with positron-emission tomog. (PET).  Whole body and the regional brain distribution of [11C]1 in control CD1 mice demonstrated that this radioligand exhibits specific uptake in the CB2-rich spleen and little specific in vivo binding in the control mouse brain.  However, [11C]1 shows specific cerebral uptake in the lipopolysaccharide (LPS)-induced mouse model of neuroinflammation and in the brain areas with Aβ amyloid plaque deposition in a mouse model of Alzheimer's disease (APPswe/PS1dE9 mice).  These data establish a proof of principle that CB2 receptors binding in the neuroinflammation and related disorders can be measured in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrriR2pw_HawbVg90H21EOLACvtfcHk0lh87dlo5mVc-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslagurc%253D&md5=1baba739bf8db92d34ac41f16906482c</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.058%26sid%3Dliteratum%253Aachs%26aulast%3DHorti%26aufirst%3DA.%2BG.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DFinley%26aufirst%3DP.%26aulast%3DValentine%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DEndres%26aufirst%3DC.%2BJ.%26aulast%3DSavonenko%26aufirst%3DA.%2BV.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520and%2520biodistribution%2520of%2520%255B11C%255DA-836339%252C%2520a%2520new%2520potential%2520radioligand%2520for%2520PET%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptors%2520%2528CB2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D5202%26epage%3D5207%26doi%3D10.1016%2Fj.bmc.2010.05.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moldovan, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teodoro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Development of a high-affinity PET radioligand for imaging cannabinoid subtype 2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7840</span>– <span class="NLM_lpage">7855</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00554</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00554" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSms7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7840-7855&author=R.+P.+Moldovanauthor=R.+Teodoroauthor=Y.+Gaoauthor=W.+Deuther-Conradauthor=M.+Kranzauthor=Y.+Wangauthor=H.+Kuwabaraauthor=M.+Nakanoauthor=H.+Valentineauthor=S.+Fischerauthor=M.+G.+Pomperauthor=D.+F.+Wongauthor=R.+F.+Dannalsauthor=P.+Brustauthor=A.+G.+Horti&title=Development+of+a+high-affinity+PET+radioligand+for+imaging+cannabinoid+subtype+2+receptor&doi=10.1021%2Facs.jmedchem.6b00554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor</span></div><div class="casAuthors">Moldovan, Rares-Petru; Teodoro, Rodrigo; Gao, Yongjun; Deuther-Conrad, Winnie; Kranz, Mathias; Wang, Yuchuan; Kuwabara, Hiroto; Nakano, Masayoshi; Valentine, Heather; Fischer, Steffen; Pomper, Martin G.; Wong, Dean F.; Dannals, Robert F.; Brust, Peter; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7840-7855</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cannabinoid receptors type 2 (CB2) represent a target with increasing importance for neuroimaging due to its upregulation under various pathol. conditions.  Encouraged by preliminary results obtained with [11C](Z)-N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl-cyclopropanecarboxamide ([11C]A-836339, [11C]1) in a mouse model of acute neuroinflammation (induced by lipopolysaccharide, LPS), we designed a library of fluorinated analogs aiming for an [18F]-labeled radiotracer with improved CB2 binding affinity and selectivity.  Compd. (Z)-N-(3-(4-fluorobutyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl-cyclopropanecarboxamide (29) was selected as the ligand with the highest CB2 affinity (Ki = 0.39 nM) and selectivity over those of CB1 (factor of 1000). [18F]29 was prepd. starting from the bromo precursor (53).  Specific binding was shown in vitro, whereas fast metab. was obsd. in vivo in CD-1 mice.  Animal PET revealed a brain uptake comparable to that of [11C]1.  In the LPS-treated mice, a 20-30% higher uptake in brain was found in comparison to that in nontreated mice (n = 3, P < 0.05).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGoJDH-P8D8bVg90H21EOLACvtfcHk0lh87dlo5mVc-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSms7jM&md5=3fc2fc09c2f83aa7cd50458060e0128c</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00554%26sid%3Dliteratum%253Aachs%26aulast%3DMoldovan%26aufirst%3DR.%2BP.%26aulast%3DTeodoro%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DValentine%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DDevelopment%2520of%2520a%2520high-affinity%2520PET%2520radioligand%2520for%2520imaging%2520cannabinoid%2520subtype%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7840%26epage%3D7855%26doi%3D10.1021%2Facs.jmedchem.6b00554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savonenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnikova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pletnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncoso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 receptors in a mouse model of abeta amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0129618</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0129618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1371%2Fjournal.pone.0129618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26086915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWntLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0129618&author=A.+V.+Savonenkoauthor=T.+Melnikovaauthor=Y.+Wangauthor=H.+Ravertauthor=Y.+Gaoauthor=J.+Koppelauthor=D.+Leeauthor=O.+Pletnikovaauthor=E.+Choauthor=N.+Sayyidaauthor=A.+Hiattauthor=J.+Troncosoauthor=P.+Daviesauthor=R.+F.+Dannalsauthor=M.+G.+Pomperauthor=A.+G.+Horti&title=Cannabinoid+CB2+receptors+in+a+mouse+model+of+abeta+amyloidosis%3A+immunohistochemical+analysis+and+suitability+as+a+PET+biomarker+of+neuroinflammation&doi=10.1371%2Fjournal.pone.0129618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation</span></div><div class="casAuthors">Savonenko, Alena V.; Melnikova, Tatiana; Wang, Yuchuan; Ravert, Hayden; Gao, Yongjun; Koppel, Jeremy; Lee, Deidre; Pletnikova, Olga; Cho, Eugenia; Sayyida, Nuzhat; Hiatt, Andrew; Troncoso, Juan; Davies, Peter; Dannals, Robert F.; Pomper, Martin G.; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0129618/1-e0129618/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In Alzheimer's disease (AD), one of the early responses to Aβ amyloidosis is recruitment of microglia to areas of new plaque.  Microglial receptors such as cannabinoid receptor 2 (CB2) might be a suitable target for development of PET radiotracers that could serve as imaging biomarkers of Aβ-induced neuroinflammation.  Mouse models of amyloidosis (J20APPswe/ind and APPswe/PS1ΔE9) were used to investigate the cellular distribution of CB2 receptors.  Specificity of CB2 antibody (H60) was confirmed using J20APPswe/ind mice lacking CB2 receptors.  APPswe/PS1ΔE9 mice were used in small animal PET with a CB2-targeting radiotracer, [11C]A836339.  These studies revealed increased binding of [11C]A836339 in amyloid-bearing mice.  Specificity of the PET signal was confirmed in a blockade study with a specific CB2 antagonist, AM630.  Confocal microscopy revealed that CB2-receptor immunoreactivity was assocd. with astroglial (GFAP) and, predominantly, microglial (CD68) markers.  CB2 receptors were obsd., in particular, in microglial processes forming engulfment synapses with Aβ plaques.  In contrast to glial cells, neuron (NeuN)-derived CB2 signal was equal between amyloid-bearing and control mice.  The pattern of neuronal CB2 staining in amyloid-bearing mice was similar to that in human cases of AD.  The data collected in this study indicate that Aβ amyloidosis without concomitant tau pathol. is sufficient to activate CB2 receptors that are suitable as an imaging biomarker of neuroinflammation.  The main source of enhanced CB2 PET binding in amyloid-bearing mice is increased CB2 immunoreactivity in activated microglia.  The presence of CB2 immunoreactivity in neurons does not likely contribute to the enhanced CB2 PET signal in amyloid-bearing mice due to a lack of significant neuronal loss in this model.  However, significant loss of neurons as seen at late stages of AD might decrease the CB2 PET signal due to loss of neuronally-derived CB2.  Thus this study in mouse models of AD indicates that a CB2-specific radiotracer can be used as a biomarker of neuroinflammation in the early preclin. stages of AD, when no significant neuronal loss has yet developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAhB68J9FaFLVg90H21EOLACvtfcHk0lh87dlo5mVc-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWntLjP&md5=45755102bb41c0682c473a71082079b7</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0129618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0129618%26sid%3Dliteratum%253Aachs%26aulast%3DSavonenko%26aufirst%3DA.%2BV.%26aulast%3DMelnikova%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRavert%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DKoppel%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DPletnikova%26aufirst%3DO.%26aulast%3DCho%26aufirst%3DE.%26aulast%3DSayyida%26aufirst%3DN.%26aulast%3DHiatt%26aufirst%3DA.%26aulast%3DTroncoso%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DCannabinoid%2520CB2%2520receptors%2520in%2520a%2520mouse%2520model%2520of%2520abeta%2520amyloidosis%253A%2520immunohistochemical%2520analysis%2520and%2520suitability%2520as%2520a%2520PET%2520biomarker%2520of%2520neuroinflammation%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0129618%26doi%3D10.1371%2Fjournal.pone.0129618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pottier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Vallejo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisgard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkeler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span> <span> </span><span class="NLM_article-title">PET imaging of cannabinoid type 2 receptors with [<sup>11</sup>C]A-836339 did not evidence changes following neuroinflammation in rats</span>. <i>J. Cereb. Blood Flow Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1177/0271678X16685105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1177%2F0271678X16685105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28079433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1163-1178&author=G.+Pottierauthor=V.+Gomez-Vallejoauthor=D.+Padroauthor=R.+Boisgardauthor=F.+Dolleauthor=J.+Llopauthor=A.+Winkelerauthor=A.+Martin&title=PET+imaging+of+cannabinoid+type+2+receptors+with+%5B11C%5DA-836339+did+not+evidence+changes+following+neuroinflammation+in+rats&doi=10.1177%2F0271678X16685105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging of cannabinoid type 2 receptors with [11C]A-836339 did not evidence changes following neuroinflammation in rats</span></div><div class="casAuthors">Pottier, Geraldine; Gomez-Vallejo, Vanessa; Padro, Daniel; Boisgard, Raphael; Dolle, Frederic; Llop, Jordi; Winkeler, Alexandra; Martin, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1163-1178</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Cannabinoid type 2 receptors (CB2R) have emerged as promising targets for the diagnosis and therapy of brain pathologies.  However, no suitable radiotracers for accurate CB2R mapping have been found to date, limiting the investigation of the CB2 receptor expression using positron emission tomog. (PET) imaging.  In this work, we report the evaluation of the in vivo expression of CB2R with [11C]A-836339 PET after cerebral ischemia and in two rat models of neuroinflammation, first by intrastriatal LPS and then by AMPA injection.  PET images and in vitro autoradiog. showed a lack of specific [11C]A-836339 uptake in these animal models demonstrating the limitation of this radiotracer to image CB2 receptor under neuroinflammatory conditions.  Further, using immunohistochem., the CB2 receptor displayed a modest expression increase after cerebral ischemia, LPS and AMPA models.  Finally, [18F]DPA-714-PET and immunohistochem. demonstrated decreased neuroinflammation by a selective CB2R agonist, JWH133.  Taken together, these findings suggest that [11C]A-836339 is not a suitable radiotracer to monitor in vivo CB2R expression by using PET imaging.  Future studies will have to investigate alternative radiotracers that could provide an accurate binding to CB2 receptors following brain inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjVLRGvLaxgLVg90H21EOLACvtfcHk0lgeRNC5WQLgHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKns7k%253D&md5=2a64e3b77030906c9cbdc02c42bda307</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1177%2F0271678X16685105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0271678X16685105%26sid%3Dliteratum%253Aachs%26aulast%3DPottier%26aufirst%3DG.%26aulast%3DGomez-Vallejo%26aufirst%3DV.%26aulast%3DPadro%26aufirst%3DD.%26aulast%3DBoisgard%26aufirst%3DR.%26aulast%3DDolle%26aufirst%3DF.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DWinkeler%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DA.%26atitle%3DPET%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptors%2520with%2520%255B11C%255DA-836339%2520did%2520not%2520evidence%2520changes%2520following%2520neuroinflammation%2520in%2520rats%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2017%26volume%3D37%26spage%3D1163%26epage%3D1178%26doi%3D10.1177%2F0271678X16685105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hortala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oustric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oury-Donat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avenet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barret, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamagnan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmcl.2013.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24291040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOhs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=283-287&author=L.+Hortalaauthor=J.+Arnaudauthor=P.+Rouxauthor=D.+Oustricauthor=L.+Bouluauthor=F.+Oury-Donatauthor=P.+Avenetauthor=T.+Rooneyauthor=D.+Alagilleauthor=O.+Barretauthor=G.+Tamagnanauthor=F.+Barth&title=Synthesis+and+preliminary+evaluation+of+a+new+fluorine-18+labelled+triazine+derivative+for+PET+imaging+of+cannabinoid+CB2+receptor&doi=10.1016%2Fj.bmcl.2013.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor</span></div><div class="casAuthors">Hortala, Laurent; Arnaud, Joelle; Roux, Pascale; Oustric, Didier; Boulu, Laurent; Oury-Donat, Florence; Avenet, Patrick; Rooney, Thomas; Alagille, David; Barret, Olivier; Tamagnan, Gilles; Barth, Francis</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-287</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cannabinoid CB2 PET tracers are considered as a promising alternative to PBR/TSPO tracers for the in-vivo imaging of neuroinflammation.  We describe here the synthesis and characterization of compd. I, a new potent and brain penetrating CB2 ligand based on an original triazine template.  The PET tracer [18F]-dideutero-I (II) was prepd. in a three steps radiosynthesis, and demonstrated significant uptake in rhesus macaque and baboon brain with a max. SUV of about 0.7-0.9 g/mL, followed by a moderate washout over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOttCEg3j-SLVg90H21EOLACvtfcHk0lgeRNC5WQLgHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOhs7zM&md5=280f4f22351c8468b1147c9dac62d766</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DHortala%26aufirst%3DL.%26aulast%3DArnaud%26aufirst%3DJ.%26aulast%3DRoux%26aufirst%3DP.%26aulast%3DOustric%26aufirst%3DD.%26aulast%3DBoulu%26aufirst%3DL.%26aulast%3DOury-Donat%26aufirst%3DF.%26aulast%3DAvenet%26aufirst%3DP.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DAlagille%26aufirst%3DD.%26aulast%3DBarret%26aufirst%3DO.%26aulast%3DTamagnan%26aufirst%3DG.%26aulast%3DBarth%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520preliminary%2520evaluation%2520of%2520a%2520new%2520fluorine-18%2520labelled%2520triazine%2520derivative%2520for%2520PET%2520imaging%2520of%2520cannabinoid%2520CB2%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D283%26epage%3D287%26doi%3D10.1016%2Fj.bmcl.2013.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yrjola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarparanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Airaksinen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hytti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauppinen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasonen-Seppanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adinolfi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keinanen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2014.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejps.2014.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25447744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCnt7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=85-96&author=S.+Yrjolaauthor=M.+Sarparantaauthor=A.+J.+Airaksinenauthor=M.+Hyttiauthor=A.+Kauppinenauthor=S.+Pasonen-Seppanenauthor=B.+Adinolfiauthor=P.+Nieriauthor=C.+Maneraauthor=O.+Keinanenauthor=A.+Posoauthor=T.+J.+Nevalainenauthor=T.+Parkkari&title=Synthesis%2C+in+vitro+and+in+vivo+evaluation+of+1%2C3%2C5-triazines+as+cannabinoid+CB2+receptor+agonists&doi=10.1016%2Fj.ejps.2014.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists</span></div><div class="casAuthors">Yrjola, Sari; Sarparanta, Mirkka; Airaksinen, Anu J.; Hytti, Maria; Kauppinen, Anu; Pasonen-Seppanen, Sanna; Adinolfi, Barbara; Nieri, Paola; Manera, Clementina; Keinanen, Outi; Poso, Antti; Nevalainen, Tapio J.; Parkkari, Teija</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-96</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cannabinoid receptors type 2 (CBR2) are attractive therapeutic targets of the endocannabinoid signaling system (ECS) as they are not displaying the undesired psychotropic and cardiovascular side-effects seen with cannabinoid receptor type 1 (CB1R) agonists.  In continuation of our previous work on 2,4,6-trisubstituted 1,3,5-triazines as potent CB2 agonists, we synthesized an addnl. series of more polar analogs (1-10), which were found to possess high CB2R agonist activity with enhanced water soly.  The most potent compd. in the series was N-(adamantan-1-yl)-4-ethoxy-6-(4-(2-fluoroethyl)piperazin-1-yl)-1,3,5-triazin-2-amine (9) with EC50 value of 0.60 nM.  To further evaluate the biol. effects of the compds., the selected compds. were tested in vitro against four different cell lines.  A human retinal pigment epithelial cell line (ARPE-19) was used to evaluate the cytotoxicity of the compds. whereas an androgen-sensitive human prostate adenocarcinoma cell line (LNCaP), a Jurkat leukemia cell line and a C8161 melanoma cell line were used to assess the antiproliferative activity of the compds.  The most interesting results were obtained for N-(adamantan-1-yl)-4-ethoxy-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (6), which induced cell viability decrease in prostate and leukemia cell lines, and diminished proliferation of C8161 melanoma cells.  The results could be reversed in leukemia cells with the selective CB2R antagonist AM630, whereas in prostate cells the AM630 induced a significant cell viability decrease with a mechanism probably unlinked to CB2 cannabinoid receptor.  The antiproliferative effect of 6 on the melanoma cells seemed not to be mediated via the CB1R or CB2R.  No cytotoxicity was detected against ARPE-19 cell line at concns. of 1 and 10 μM for compd. 6.  However, at 30 μM concn. the compd. 6 decreased the cell viability.  Finally, in order to est. in vivo behavior of these compds., 18F labeled PET ligand, N-cyclopentyl-4-ethoxy-6-(4-(2-fluoro-18-ethyl)piperazin-1-yl)-1,3,5-triazin-2-amine ([18F]5), was synthesized and its biodistribution was detd. in healthy male Sprague-Dawley rats.  As a result, the tracer showed a rapid (<15 min) elimination in urine accompanied by a slower excretion via the hepatobiliary route.  In conclusion, we further demonstrated that 1,3,5-triazine scaffold serves as a suitable template for the design of highly potent CB2R agonists with reasonable water soly. properties.  The compds. may be useful when studying the role of the endocannabinoid system in different diseases.  The triazine scaffold is also a promising candidate for the development of new CB2R PET ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_1aEvtEgaW7Vg90H21EOLACvtfcHk0lgeRNC5WQLgHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCnt7bL&md5=8153b8fd95235ae3541e6bf209eef499</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2014.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2014.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DYrjola%26aufirst%3DS.%26aulast%3DSarparanta%26aufirst%3DM.%26aulast%3DAiraksinen%26aufirst%3DA.%2BJ.%26aulast%3DHytti%26aufirst%3DM.%26aulast%3DKauppinen%26aufirst%3DA.%26aulast%3DPasonen-Seppanen%26aufirst%3DS.%26aulast%3DAdinolfi%26aufirst%3DB.%26aulast%3DNieri%26aufirst%3DP.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DKeinanen%26aufirst%3DO.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DNevalainen%26aufirst%3DT.%2BJ.%26aulast%3DParkkari%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%25201%252C3%252C5-triazines%2520as%2520cannabinoid%2520CB2%2520receptor%2520agonists%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D67%26spage%3D85%26epage%3D96%26doi%3D10.1016%2Fj.ejps.2014.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veghel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biodistribution and in vitro evaluation of brain permeable high affinity type 2 cannabinoid receptor agonists [<sup>11</sup>C]MA2 and [<sup>18</sup>F]MA3</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">431</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3389%2Ffnins.2016.00431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27713686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC2svnvFKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=431&author=M.+Ahamedauthor=D.+van+Veghelauthor=C.+Ullmerauthor=K.+Van+Laereauthor=A.+Verbruggenauthor=G.+M.+Bormans&title=Synthesis%2C+biodistribution+and+in+vitro+evaluation+of+brain+permeable+high+affinity+type+2+cannabinoid+receptor+agonists+%5B11C%5DMA2+and+%5B18F%5DMA3&doi=10.3389%2Ffnins.2016.00431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [(11)C]MA2 and [(18)F]MA3</span></div><div class="casAuthors">Ahamed Muneer; van Veghel Daisy; Verbruggen Alfons; Bormans Guy M; Ullmer Christoph; Van Laere Koen</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">431</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">The type 2 cannabinoid receptor (CB2) is a member of the endocannabinoid system and is known for its important role in (neuro)inflammation.  A PET-imaging agent that allows in vivo visualization of CB2 expression may thus allow quantification of neuroinflammation.  In this paper, we report the synthesis, radiosynthesis, biodistribution and in vitro evaluation of a carbon-11 ([(11)C]MA2) and a fluorine-18 ([(18)F]MA3) labeled analog of a highly potent N-arylamide oxadiazole CB2 agonist (EC50 = 0.015 nM).  MA2 and MA3 behaved as potent CB2 agonist (EC50: 3 nM and 0.1 nM, respectively) and their in vitro binding affinity for hCB2 was found to be 87 nM and 0.8 nM, respectively.  Also MA3 (substituted with a fluoro ethyl group) was found to have higher binding affinity and EC50 values when compared to the originally reported trifluoromethyl analog 12. [(11)C]MA2 and [(18)F]MA3 were successfully synthesized with good radiochemical yield, high radiochemical purity and high specific activity.  In mice, both tracers were efficiently cleared from blood and all major organs by the hepatobiliary pathway and importantly these compounds showed high brain uptake.  In conclusion, [(11)C]MA2 and [(18)F]MA3 are shown to be high potent CB2 agonists with good brain uptake, these favorable characteristics makes them potential PET probes for in vivo imaging of brain CB2 receptors.  However, in view of its higher affinity and selectivity, further detailed evaluation of MA3 as a PET tracer for CB2 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREdksh7qntkZNiNltV31zlfW6udTcc2ebLvdkcvDnDzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnvFKktg%253D%253D&md5=3240509303d6d5aa35daa26c7e8a59fb</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00431%26sid%3Dliteratum%253Aachs%26aulast%3DAhamed%26aufirst%3DM.%26aulast%3Dvan%2BVeghel%26aufirst%3DD.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DVerbruggen%26aufirst%3DA.%26aulast%3DBormans%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%252C%2520biodistribution%2520and%2520in%2520vitro%2520evaluation%2520of%2520brain%2520permeable%2520high%2520affinity%2520type%25202%2520cannabinoid%2520receptor%2520agonists%2520%255B11C%255DMA2%2520and%2520%255B18F%255DMA3%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D431%26doi%3D10.3389%2Ffnins.2016.00431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Attili, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haute, C. V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanduffel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of [<sup>18</sup>F]MA3: a CB2 receptor agonist radiotracer for PET</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1491</span>, <span class="refDoi"> DOI: 10.1111/bph.14564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fbph.14564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30588600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVyru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=1481-1491&author=B.+Attiliauthor=S.+Celenauthor=M.+Ahamedauthor=M.+Kooleauthor=C.+V.+D.+Hauteauthor=W.+Vanduffelauthor=G.+Bormans&title=Preclinical+evaluation+of+%5B18F%5DMA3%3A+a+CB2+receptor+agonist+radiotracer+for+PET&doi=10.1111%2Fbph.14564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of [18F]MA3: a CB2 receptor agonist radiotracer for PET</span></div><div class="casAuthors">Attili, Bala; Celen, Sofie; Ahamed, Muneer; Koole, Michel; Van Den Haute, Chris; Vanduffel, Wim; Bormans, Guy</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1481-1491</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Non-invasive in vivo imaging of cannabinoid CB2 receptors using PET is pursued to study neuroinflammation.  The purpose of this study is to evaluate the in vivo binding specificity of [18F]MA3, a CB2 receptor agonist, in a rat model with local overexpression of human (h) CB2 receptors.  [18F]MA3 was produced with good radiochem. yield and radiochem. purity.  The radiotracer was evaluated in rats with local overexpression of hCB2 receptors and in a healthy non-human primate using PET.  Ex vivo autoradiog. demonstrated CB2-specific binding of [18F]MA3 in rat hCB2 receptor vector injected striatum.  Further clin. evaluation of [18F]MA3 in patients with neuroinflammation is warranted.  Evaluation of [18F]MA3 in a rat model with local overexpression of hCB2 receptors showed CB2 receptor-specific and reversible tracer binding.  [18F]MA3 showed good brain uptake and subsequent washout in a healthy non-human primate, but no specific binding was obsd.  This study identified the utility of mutated inactive vector model for evaluation of CB2 receptor agonist PET tracers.  [18F]MA3 PET scans in the non-human primate showed good uptake and fast washout from brain, but no CB2 receptor-specific binding was obsd.  Binding in hCB2 receptor vector-injected striatum was blocked with a structurally non-related CB2 receptor inverse agonist, and a displacement study confirmed the reversibility of tracer binding.  In a PET study, increased tracer binding in the hCB2 receptor vector-injected striatum compared to the contralateral control vector-injected striatum was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnC8Wt9qbYfrVg90H21EOLACvtfcHk0lg5EX8pIIIInQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVyru74%253D&md5=8f8224cb59149a1a5df55a6424682438</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fbph.14564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14564%26sid%3Dliteratum%253Aachs%26aulast%3DAttili%26aufirst%3DB.%26aulast%3DCelen%26aufirst%3DS.%26aulast%3DAhamed%26aufirst%3DM.%26aulast%3DKoole%26aufirst%3DM.%26aulast%3DHaute%26aufirst%3DC.%2BV.%2BD.%26aulast%3DVanduffel%26aufirst%3DW.%26aulast%3DBormans%26aufirst%3DG.%26atitle%3DPreclinical%2520evaluation%2520of%2520%255B18F%255DMA3%253A%2520a%2520CB2%2520receptor%2520agonist%2520radiotracer%2520for%2520PET%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3D1481%26epage%3D1491%26doi%3D10.1111%2Fbph.14564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stasiulewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Znajdek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudzień, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawiński, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowska, A. J. I.</span></span> <span> </span><span class="NLM_article-title">A guide to targeting the endocannabinoid system in drug design</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2778</span>, <span class="refDoi"> DOI: 10.3390/ijms21082778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3390%2Fijms21082778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVCnt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=2778&author=A.+Stasiulewiczauthor=K.+Znajdekauthor=M.+Grudzie%C5%84author=T.+Pawi%C5%84skiauthor=A.+J.+I.+Sulkowska&title=A+guide+to+targeting+the+endocannabinoid+system+in+drug+design&doi=10.3390%2Fijms21082778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">A guide to targeting the endocannabinoid system in drug design</span></div><div class="casAuthors">Stasiulewicz, Adam; Znajdek, Katarzyna; Grudzien, Monika; Pawinski, Tomasz; Sulkowska, Joanna I.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2778</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  He endocannabinoid system (ECS) is one of the most crucial systems in the human organism, exhibiting multi-purpose regulatory character.  It is engaged in a vast array of physiol. processes, including nociception, mood regulation, cognitive functions, neurogenesis and neuroprotection, appetite, lipid metab., as well as cell growth and proliferation.  Thus, ECS proteins, including cannabinoid receptors and their endogenous ligands' synthesizing and degrading enzymes, are promising therapeutic targets.  Their modulation has been employed in or extensively studied as a treatment of multiple diseases.  However, due to a complex nature of ECS and its crosstalk with other biol. systems, the development of novel drugs turned out to be a challenging task.  In this , we summarize potential therapeutic applications for ECS-targeting drugs, esp. focusing on promising synthetic compds. and preclin. studies.  We put emphasis on modulation of specific proteins of ECS in different pathophysiol. areas.  In addn., we stress possible difficulties and risks and highlight proposed solns.  By presenting this , we point out information pivotal in the spotlight of ECS-targeting drug design, as well as provide an overview of the current state of knowledge on ECS-related pharmacodynamics and show possible directions for needed research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKa6x7jgTR7rVg90H21EOLACvtfcHk0lg5EX8pIIIInQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVCnt7jN&md5=ac09145f2e89c1b7e703f523e38ca497</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3390%2Fijms21082778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21082778%26sid%3Dliteratum%253Aachs%26aulast%3DStasiulewicz%26aufirst%3DA.%26aulast%3DZnajdek%26aufirst%3DK.%26aulast%3DGrudzie%25C5%2584%26aufirst%3DM.%26aulast%3DPawi%25C5%2584ski%26aufirst%3DT.%26aulast%3DSulkowska%26aufirst%3DA.%2BJ.%2BI.%26atitle%3DA%2520guide%2520to%2520targeting%2520the%2520endocannabinoid%2520system%2520in%2520drug%2520design%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D2778%26doi%3D10.3390%2Fijms21082778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gulyas, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracey, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, T. F.</span></span> <span> </span><span class="NLM_article-title">Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2004.03428.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1460-9568.2004.03428.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15233753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD2czjt1Gntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=441-458&author=A.+I.+Gulyasauthor=B.+F.+Cravattauthor=M.+H.+Braceyauthor=T.+P.+Dinhauthor=D.+Piomelliauthor=F.+Bosciaauthor=T.+F.+Freund&title=Segregation+of+two+endocannabinoid-hydrolyzing+enzymes+into+pre-+and+postsynaptic+compartments+in+the+rat+hippocampus%2C+cerebellum+and+amygdala&doi=10.1111%2Fj.1460-9568.2004.03428.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala</span></div><div class="casAuthors">Gulyas A I; Cravatt B F; Bracey M H; Dinh T P; Piomelli D; Boscia F; Freund T F</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-58</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) catalyse the hydrolysis of the endocannabinoids anandamide and 2-arachidonoyl glycerol.  We investigated their ultrastructural distribution in brain areas where the localization and effects of cannabinoid receptor activation are known.  In the hippocampus, FAAH was present in somata and dendrites of principal cells, but not in interneurons.  It was located mostly on the membrane surface of intracellular organelles known to store Ca(2+) (e.g. mitochondria, smooth endoplasmic reticulum), less frequently on the somatic or dendritic plasma membrane.  MGL immunoreactivity was found in axon terminals of granule cells, CA3 pyramidal cells and some interneurons.  In the cerebellum, Purkinje cells and their dendrites are intensively immunoreactive for FAAH, together with a sparse axon plexus at the border of the Purkinje cell/granule cell layers.  Immunostaining for MGL was complementary, the axons in the molecular layer were intensively labelled leaving the Purkinje cell dendrites blank.  FAAH distribution in the amygdala was similar to that of the CB(1) cannabinoid receptor: evident signal in neuronal somata and proximal dendrites in the basolateral nucleus, and hardly any labelling in the central nucleus.  MGL staining was restricted to axons in the neuropil, with similar relative signal intensities seen for FAAH in different nuclei.  Thus, FAAH is primarily a postsynaptic enzyme, whereas MGL is presynaptic.  FAAH is associated with membranes of cytoplasmic organelles.  The differential compartmentalization of the two enzymes suggests that anandamide and 2-AG signalling may subserve functional roles that are spatially segregated at least at the stage of metabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTW_4mkeOzg3z0O18WR3iAofW6udTcc2eY9_1jBiiAPkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czjt1Gntg%253D%253D&md5=8c77b186a775f898e85cda664263d81b</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2004.03428.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2004.03428.x%26sid%3Dliteratum%253Aachs%26aulast%3DGulyas%26aufirst%3DA.%2BI.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBracey%26aufirst%3DM.%2BH.%26aulast%3DDinh%26aufirst%3DT.%2BP.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DBoscia%26aufirst%3DF.%26aulast%3DFreund%26aufirst%3DT.%2BF.%26atitle%3DSegregation%2520of%2520two%2520endocannabinoid-hydrolyzing%2520enzymes%2520into%2520pre-%2520and%2520postsynaptic%2520compartments%2520in%2520the%2520rat%2520hippocampus%252C%2520cerebellum%2520and%2520amygdala%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2004%26volume%3D20%26spage%3D441%26epage%3D458%26doi%3D10.1111%2Fj.1460-9568.2004.03428.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Structure and function of fatty acid amide hydrolase</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.74.082803.133450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1146%2Fannurev.biochem.74.082803.133450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15952893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVensL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2005&pages=411-432&author=M.+K.+McKinneyauthor=B.+F.+Cravatt&title=Structure+and+function+of+fatty+acid+amide+hydrolase&doi=10.1146%2Fannurev.biochem.74.082803.133450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of fatty acid amide hydrolase</span></div><div class="casAuthors">McKinney, Michele K.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">411-432</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Fatty acid amide hydrolase (FAAH) is a mammalian integral membrane enzyme that degrades the fatty acid amide family of endogenous signaling lipids, which includes the endogenous cannabinoid, anandamide, and the sleep-inducing substance, oleamide.  FAAH belongs to a large and diverse class of enzymes referred to as the amidase signature (AS) family.  Investigations into the structure and function of FAAH, in combination with complementary studies of other AS enzymes, have engendered provocative mol. models to explain how this enzyme integrates into cell membranes and terminates fatty acid amide signaling in vivo.  These studies, as well as their biol. and therapeutic implications, are the subject of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprO7TpUTr6n7Vg90H21EOLACvtfcHk0li3et0BpohQEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVensL4%253D&md5=d28b43f14feb6894d48e907064087867</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.74.082803.133450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.74.082803.133450%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinney%26aufirst%3DM.%2BK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStructure%2520and%2520function%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2005%26volume%3D74%26spage%3D411%26epage%3D432%26doi%3D10.1146%2Fannurev.biochem.74.082803.133450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of monoacylglycerol lipase inhibitors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2012.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.lfs.2012.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23142242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKqsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2013&pages=492-497&author=M.+M.+Mulvihillauthor=D.+K.+Nomura&title=Therapeutic+potential+of+monoacylglycerol+lipase+inhibitors&doi=10.1016%2Fj.lfs.2012.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of monoacylglycerol lipase inhibitors</span></div><div class="casAuthors">Mulvihill, Melinda M.; Nomura, Daniel K.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">492-497</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Marijuana and aspirin have been used for millennia to treat a wide range of maladies including pain and inflammation.  Both cannabinoids, like marijuana, that exert anti-inflammatory action through stimulating cannabinoid receptors, and cyclooxygenase (COX) inhibitors, like aspirin, that suppress pro-inflammatory eicosanoid prodn. have shown beneficial outcomes in mouse models of neurodegenerative diseases and cancer.  Both cannabinoids and COX inhibitors, however, have untoward effects that discourage their chronic usage, including cognitive deficits and gastrointestinal toxicity, resp.  Recent studies have uncovered that the serine hydrolase monoacylglycerol lipase (MAGL) links the endocannabinoid and eicosanoid systems together through hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG) to provide the major arachidonic acid (AA) precursor pools for pro-inflammatory eicosanoid synthesis in specific tissues.  Studies in recent years have shown that MAGL inhibitors elicit anti-nociceptive, anxiolytic, and anti-emetic responses and attenuate pptd. withdrawal symptoms in addiction paradigms through enhancing endocannabinoid signaling.  MAGL inhibitors have also been shown to exert anti-inflammatory action in the brain and protect against neurodegeneration through lowering eicosanoid prodn.  In cancer, MAGL inhibitors have been shown to have anti-cancer properties not only through modulating the endocannabinoid-eicosanoid network, but also by controlling fatty acid release for the synthesis of protumorigenic signaling lipids.  Thus, MAGL serves as a crit. node in simultaneously coordinating multiple lipid signaling pathways in both physiol. and disease contexts.  This review will discuss the diverse (patho)physiol. roles of MAGL and the therapeutic potential of MAGL inhibitors in treating a vast array of complex human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpojyVx1YSerrVg90H21EOLACvtfcHk0li3et0BpohQEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKqsL7O&md5=cb44625201730a7849701df80fadb708</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DMulvihill%26aufirst%3DM.%2BM.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26atitle%3DTherapeutic%2520potential%2520of%2520monoacylglycerol%2520lipase%2520inhibitors%26jtitle%3DLife%2520Sci.%26date%3D2013%26volume%3D92%26spage%3D492%26epage%3D497%26doi%3D10.1016%2Fj.lfs.2012.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleu-Chavain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of fatty acid amide hydrolase, monoacylglycerol lipase, and N-acylethanolamine acid amidase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00538</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00538" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWjsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4-46&author=W.+Tuoauthor=N.+Leleu-Chavainauthor=J.+Spencerauthor=S.+Sansookauthor=R.+Milletauthor=P.+Chavatte&title=Therapeutic+potential+of+fatty+acid+amide+hydrolase%2C+monoacylglycerol+lipase%2C+and+N-acylethanolamine+acid+amidase+inhibitors&doi=10.1021%2Facs.jmedchem.6b00538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors</span></div><div class="casAuthors">Tuo, Wei; Leleu-Chavain, Natascha; Spencer, John; Sansook, Supojjanee; Millet, Regis; Chavatte, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-46</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Fatty acid ethanolamides (FAEs) and endocannabinoids (ECs) have been shown to alleviate pain and inflammation, regulate motility and appetite, and produce anti-cancer, anxiolytic, and neuroprotective efficacies via cannabinoid receptor type 1 (CB1) or type 2 (CB2), or via peroxisome proliferator-activated receptor α (PPAR-α) stimulation.  FAEs and ECs are synthesized by a series of endogenous enzymes, including N-acylphosphatidylethanolamine-phospholipase D (NAPE-PLD), diacylglycerol lipase (DAGL), or phospholipase C (PLC), and their metab. is mediated by several metabolic enzymes, including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL), N-acylethanolamine acid amidase (NAAA), or cyclooxygenase-2 (COX-2).  Over the last decades, increasing the concn. of FAEs and ECs through the inhibition of degrading enzymes has been considered to be a viable therapeutic approach to enhance their anti-nociceptive and anti-inflammatory effects, as well as protecting the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoamrYPCqYEIbVg90H21EOLACvtfcHk0li3et0BpohQEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWjsLzI&md5=dd509179171644767726a67cb42dd074</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00538%26sid%3Dliteratum%253Aachs%26aulast%3DTuo%26aufirst%3DW.%26aulast%3DLeleu-Chavain%26aufirst%3DN.%26aulast%3DSpencer%26aufirst%3DJ.%26aulast%3DSansook%26aufirst%3DS.%26aulast%3DMillet%26aufirst%3DR.%26aulast%3DChavatte%26aufirst%3DP.%26atitle%3DTherapeutic%2520potential%2520of%2520fatty%2520acid%2520amide%2520hydrolase%252C%2520monoacylglycerol%2520lipase%252C%2520and%2520N-acylethanolamine%2520acid%2520amidase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4%26epage%3D46%26doi%3D10.1021%2Facs.jmedchem.6b00538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.chembiol.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18096503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1347-1356&author=J.+L.+Blankmanauthor=G.+M.+Simonauthor=B.+F.+Cravatt&title=A+comprehensive+profile+of+brain+enzymes+that+hydrolyze+the+endocannabinoid+2-arachidonoylglycerol&doi=10.1016%2Fj.chembiol.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol</span></div><div class="casAuthors">Blankman, Jacqueline L.; Simon, Gabriel M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Endogenous ligands for cannabinoid receptors ("endocannabinoids") include the lipid transmitters anandamide and 2-arachidonoylglycerol (2-AG).  Endocannabinoids modulate a diverse set of physiol. processes and are tightly regulated by enzymic biosynthesis and degrdn.  Termination of anandamide signaling by fatty acid amide hydrolase (FAAH) is well characterized, but less is known about the inactivation of 2-AG, which can be hydrolyzed by multiple enzymes in vitro, including FAAH and monoacylglycerol lipase (MAGL).  Here, we have taken a functional proteomic approach to comprehensively map 2-AG hydrolases in the mouse brain.  Our data reveal that ∼85% of brain 2-AG hydrolase activity can be ascribed to MAGL, and that the remaining 15% is mostly catalyzed by two uncharacterized enzymes, ABHD6 and ABHD12.  Interestingly, MAGL, ABHD6, and ABHD12 display distinct subcellular distributions, suggesting that they may control different pools of 2-AG in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF_Kmd_7v5urVg90H21EOLACvtfcHk0li3et0BpohQEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE&md5=78c6355a3909bff3cbae25989ab6a956</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DSimon%26aufirst%3DG.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520comprehensive%2520profile%2520of%2520brain%2520enzymes%2520that%2520hydrolyze%2520the%2520endocannabinoid%25202-arachidonoylglycerol%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D1347%26epage%3D1356%26doi%3D10.1016%2Fj.chembiol.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">The metabolic serine hydrolases and their functions in mammalian physiology and disease</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">6022</span>– <span class="NLM_lpage">6063</span>, <span class="refDoi"> DOI: 10.1021/cr200075y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200075y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFagtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=6022-6063&author=J.+Z.+Longauthor=B.+F.+Cravatt&title=The+metabolic+serine+hydrolases+and+their+functions+in+mammalian+physiology+and+disease&doi=10.1021%2Fcr200075y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic serine hydrolases and their functions in mammalian physiology and disease</span></div><div class="casAuthors">Long, Jonathan Z.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6022-6063</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Serine hydrolases (SHs) consist of >200 enzymes in humans which are characterized by the presence of an active site Ser residue that is used for the hydrolysis of substrates.  The membership of this enzyme class is nearly equally split between serine proteases (trypsin/chymotrypsin/subtilisin enzymes) and "metabolic" SHs that cleave ester, amide, or thioester bonds in small mols., peptides, or proteins.  The focus of this review is on the metabolic SHs.  Here, the authors attempt to provide a comprehensive summary that captures the state of knowledge about metabolic SHs in their entirety, including those enzymes that remain mostly or completely uncharacterized.  Particular emphasis is placed on relating the biochem. and enzymol. of individual SHs to the physiol. substrates and products they regulate in living systems, and how SHs, through the regulation of specific metabolic pathways impact health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5UaSiI-yXi7Vg90H21EOLACvtfcHk0li9ReL_xb7Bmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFagtb8%253D&md5=c978f77bd911d5877df4ba97fc09e4b3</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fcr200075y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200075y%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DThe%2520metabolic%2520serine%2520hydrolases%2520and%2520their%2520functions%2520in%2520mammalian%2520physiology%2520and%2520disease%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26spage%3D6022%26epage%3D6063%26doi%3D10.1021%2Fcr200075y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2004.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.pain.2004.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15157693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1SltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2004&pages=319-327&author=A.+H.+Lichtmanauthor=C.+C.+Sheltonauthor=T.+Advaniauthor=B.+F.+Cravatt&title=Mice+lacking+fatty+acid+amide+hydrolase+exhibit+a+cannabinoid+receptor-mediated+phenotypic+hypoalgesia&doi=10.1016%2Fj.pain.2004.01.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia</span></div><div class="casAuthors">Lichtman, Aron H.; Shelton, Christopher C.; Advani, Tushar; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-327</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Although the N-arachidonoyl ethanolamine (anandamide) binds to cannabinoid receptors and has been implicated in the suppression of pain, its rapid catabolism in vivo by fatty acid amide hydrolase (FAAH) has presented a challenge in investigating the physiol. functions of this endogenous cannabinoid.  In order to test whether anandamide and other non-cannabinoid fatty amides modulate nociception, we compared FAAH (+/+) and (-/-) mice in the tail immersion, hot plate, and formalin tests, as well as for thermal hyperalgesia in the carrageenan and the chronic constriction injury (CCI) models.  FAAH (-/-) mice exhibited a CB1 receptor-mediated phenotypic hypoalgesia in thermal nociceptive tests.  These mice also exhibited CB1 receptor-mediated hypoalgesia in both phases of the formalin test accompanied with a phenotypic anti-edema effect, which was not blocked by either CB1 or CB2 antagonists.  Addnl., FAAH (-/-) mice displayed thermal anti-hyperalgesic and anti-inflammatory effects in the carrageenan model that were mediated, in part, by CB2, but not CB1 receptors.  In contrast, no genotype differences in pain behavior were evident following CCI, which was instead found to obliterate the phenotypic hypoalgesia displayed by FAAH (-/-) mice in the tail immersion and hot plate tests, suggesting that nerve injury may promote adaptive changes in these animals.  Collectively, these findings demonstrate a cannabinoid receptor-mediated analgesic phenotype in FAAH (-/-) mice.  In more general terms, these findings suggest that selective inhibitors of FAAH might represent a viable pharmacol. approach for the clin. treatment of pain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotqtNiSPx6jbVg90H21EOLACvtfcHk0li9ReL_xb7Bmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1SltL4%253D&md5=522ddc54fa86e8b181f751bbbb7903c3</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2004.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2004.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DShelton%26aufirst%3DC.%2BC.%26aulast%3DAdvani%26aufirst%3DT.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DMice%2520lacking%2520fatty%2520acid%2520amide%2520hydrolase%2520exhibit%2520a%2520cannabinoid%2520receptor-mediated%2520phenotypic%2520hypoalgesia%26jtitle%3DPain%26date%3D2004%26volume%3D109%26spage%3D319%26epage%3D327%26doi%3D10.1016%2Fj.pain.2004.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambico, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campolongo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgese, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debonnel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duranti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarzia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trezza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">18620</span>– <span class="NLM_lpage">18625</span>, <span class="refDoi"> DOI: 10.1073/pnas.0509591102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.0509591102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16352709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1yq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=18620-18625&author=G.+Gobbiauthor=F.+R.+Bambicoauthor=R.+Mangieriauthor=M.+Bortolatoauthor=P.+Campolongoauthor=M.+Solinasauthor=T.+Cassanoauthor=M.+G.+Morgeseauthor=G.+Debonnelauthor=A.+Durantiauthor=A.+Tontiniauthor=G.+Tarziaauthor=M.+Morauthor=V.+Trezzaauthor=S.+R.+Goldbergauthor=V.+Cuomoauthor=D.+Piomelli&title=Antidepressant-like+activity+and+modulation+of+brain+monoaminergic+transmission+by+blockade+of+anandamide+hydrolysis&doi=10.1073%2Fpnas.0509591102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis</span></div><div class="casAuthors">Gobbi, G.; Bambico, F. R.; Mangieri, R.; Bortolato, M.; Campolongo, P.; Solinas, M.; Cassano, T.; Morgese, M. G.; Debonnel, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Mor, M.; Trezza, V.; Goldberg, S. R.; Cuomo, V.; Piomelli, D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">18620-18625</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Although anecdotal reports suggest that cannabis may be used to alleviate symptoms of depression, the psychotropic effects and abuse liability of this drug prevent its therapeutic application.  The active constituent of cannabis, Δ9-tetrahydrocannabinol, acts by binding to brain CB1 cannabinoid receptors, but an alternative approach might be to develop agents that amplify the actions of endogenous cannabinoids by blocking their deactivation.  Here, we show that URB597, a selective inhibitor of the enzyme fatty-acid amide hydrolase, which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide, exerts potent antidepressant-like effects in the mouse tail-suspension test and the rat forced-swim test.  Moreover, URB597 increases firing activity of serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in the nucleus locus ceruleus.  These actions are prevented by the CB1 antagonist rimonabant, are accompanied by increased brain anandamide levels, and are maintained upon repeated URB597 administration.  Unlike direct CB1 agonists, URB597 does not exert rewarding effects in the conditioned place preference test or produce generalization to the discriminative effects of Δ9-tetrahydrocannabinol in rats.  The findings support a role for anandamide in mood regulation and point to fatty-acid amide hydrolase as a previously uncharacterized target for antidepressant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVtAcOEAiXh7Vg90H21EOLACvtfcHk0li9ReL_xb7Bmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1yq&md5=92475dd0b18fa1d1a3351cc3bf2f4a67</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0509591102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0509591102%26sid%3Dliteratum%253Aachs%26aulast%3DGobbi%26aufirst%3DG.%26aulast%3DBambico%26aufirst%3DF.%2BR.%26aulast%3DMangieri%26aufirst%3DR.%26aulast%3DBortolato%26aufirst%3DM.%26aulast%3DCampolongo%26aufirst%3DP.%26aulast%3DSolinas%26aufirst%3DM.%26aulast%3DCassano%26aufirst%3DT.%26aulast%3DMorgese%26aufirst%3DM.%2BG.%26aulast%3DDebonnel%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTrezza%26aufirst%3DV.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26aulast%3DCuomo%26aufirst%3DV.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DAntidepressant-like%2520activity%2520and%2520modulation%2520of%2520brain%2520monoaminergic%2520transmission%2520by%2520blockade%2520of%2520anandamide%2520hydrolysis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D18620%26epage%3D18625%26doi%3D10.1073%2Fpnas.0509591102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scalvini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span> <span> </span><span class="NLM_article-title">Monoglyceride lipase: Structure and inhibitors</span>. <i>Chem. Phys. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.chemphyslip.2015.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.chemphyslip.2015.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26216043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWgtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2016&pages=13-24&author=L.+Scalviniauthor=D.+Piomelliauthor=M.+Mor&title=Monoglyceride+lipase%3A+Structure+and+inhibitors&doi=10.1016%2Fj.chemphyslip.2015.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Monoglyceride lipase: Structure and inhibitors</span></div><div class="casAuthors">Scalvini, Laura; Piomelli, Daniele; Mor, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry and Physics of Lipids</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-24</span>CODEN:
                <span class="NLM_cas:coden">CPLIA4</span>;
        ISSN:<span class="NLM_cas:issn">0009-3084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Monoglyceride lipase (MGL), the main enzyme responsible for the hydrolytic deactivation of the endocannabinoid 2-arachidonoyl-sn-glycerol (2-AG), is an intracellular serine hydrolase that plays crit. roles in many physiol. and pathol. processes, such as pain, inflammation, neuroprotection and cancer.  The crystal structures of MGL that are currently available provide valuable information about how this enzyme might function and interact with site-directed small-mol. inhibitors.  On the other hand, its conformational equil. and the contribution of regulatory cysteine residues present within the substrate-binding pocket or on protein surface remain open issues.  Several classes of MGL inhibitors have been developed, from early reversible ones, such as URB602 and pristimerin, to carbamoylating agents that react with the catalytic serine, such as JZL184 and more recent O-hexafluoroisopropyl carbamates.  Other inhibitors that modulate MGL activity by interacting with conserved regulatory cysteines act through mechanisms that deserve to be more thoroughly investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo87N6IaURGmLVg90H21EOLACvtfcHk0liakRYoRex6WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWgtrfJ&md5=2caf6260d15d85af413b2235f1d46450</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.chemphyslip.2015.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemphyslip.2015.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DScalvini%26aufirst%3DL.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DMonoglyceride%2520lipase%253A%2520Structure%2520and%2520inhibitors%26jtitle%3DChem.%2520Phys.%2520Lipids%26date%3D2016%26volume%3D197%26spage%3D13%26epage%3D24%26doi%3D10.1016%2Fj.chemphyslip.2015.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcondes, M. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1126/science.1209200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1126%2Fscience.1209200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22021672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVagtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=809-813&author=D.+K.+Nomuraauthor=B.+E.+Morrisonauthor=J.+L.+Blankmanauthor=J.+Z.+Longauthor=S.+G.+Kinseyauthor=M.+C.+G.+Marcondesauthor=A.+M.+Wardauthor=Y.+K.+Hahnauthor=A.+H.+Lichtmanauthor=B.+Contiauthor=B.+F.+Cravatt&title=Endocannabinoid+Hydrolysis+Generates+Brain+Prostaglandins+That+Promote+Neuroinflammation&doi=10.1126%2Fscience.1209200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation</span></div><div class="casAuthors">Nomura, Daniel K.; Morrison, Bradley E.; Blankman, Jacqueline L.; Long, Jonathan Z.; Kinsey, Steven G.; Marcondes, Maria Cecilia G.; Ward, Anna M.; Hahn, Yun Kyung; Lichtman, Aron H.; Conti, Bruno; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6057</span>),
    <span class="NLM_cas:pages">809-813</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Phospholipase A2(PLA2) enzymes are considered the primary source of arachidonic acid for cyclooxygenase (COX)-mediated biosynthesis of prostaglandins.  Here, we show that a distinct pathway exists in brain, where monoacyl-glycerol lipase (MAGL) hydrolyzes the endocannabinoid 2-arachidonoylglycerol to generate a major arachidonate precursor pool for neuroinflammatory prostaglandins.  MAGL-disrupted animals show neuroprotection in a parkinsonian mouse model.  These animals are spared the hemorrhaging caused by COX inhibitors in the gut, where prostaglandins are instead regulated by cytosolic PLA2.  These findings identify MAGL as a distinct metabolic node that couples endocannabinoid to prostaglandin signaling networks in the nervous system and suggest that inhibition of this enzyme may be a new and potentially safer way to suppress the proinflammatory cascades that underlie neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPRRB-JEf2GrVg90H21EOLACvtfcHk0liakRYoRex6WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVagtrnJ&md5=17967f2d83876f57e4bc901df2e7dc68</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1126%2Fscience.1209200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1209200%26sid%3Dliteratum%253Aachs%26aulast%3DNomura%26aufirst%3DD.%2BK.%26aulast%3DMorrison%26aufirst%3DB.%2BE.%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DKinsey%26aufirst%3DS.%2BG.%26aulast%3DMarcondes%26aufirst%3DM.%2BC.%2BG.%26aulast%3DWard%26aufirst%3DA.%2BM.%26aulast%3DHahn%26aufirst%3DY.%2BK.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DConti%26aufirst%3DB.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DEndocannabinoid%2520Hydrolysis%2520Generates%2520Brain%2520Prostaglandins%2520That%2520Promote%2520Neuroinflammation%26jtitle%3DScience%26date%3D2011%26volume%3D334%26spage%3D809%26epage%3D813%26doi%3D10.1126%2Fscience.1209200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Ordonez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fontecha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Gutierrez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Rodriguez, M. L.</span></span> <span> </span><span class="NLM_article-title">Monoacylglycerol lipase (MAGL) as a promising therapeutic target</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.07.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bcp.2018.07.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30059673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVersL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=18-32&author=A.+Gil-Ordonezauthor=M.+Martin-Fontechaauthor=S.+Ortega-Gutierrezauthor=M.+L.+Lopez-Rodriguez&title=Monoacylglycerol+lipase+%28MAGL%29+as+a+promising+therapeutic+target&doi=10.1016%2Fj.bcp.2018.07.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacylglycerol lipase (MAGL) as a promising therapeutic target</span></div><div class="casAuthors">Gil-Ordonez, Ana; Martin-Fontecha, Mar; Ortega-Gutierrez, Silvia; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-32</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Monoacylglycerol lipase (MAGL) has been characterized as the main enzyme responsible for the inactivation of the most abundant brain endocannabinoid, 2-arachidonoylglycerol (2-AG).  Besides this role, MAGL has progressively acquired a growing importance as an integrative metabolic hub that controls not only the in vivo levels of 2-AG but also of other monoacylglycerides and, indirectly, the levels of free fatty acids derived from their hydrolysis as well as other lipids with pro-inflammatory or pro-tumorigenic effects, coming from the further metab. of fatty acids.  All these functions have only started to be elucidated in the last years due to the progress made in the knowledge of the structure of MAGL and in the development of genetic and chem. tools.  In this review the authors report the advances made in the field with a special focus on the last decade and how MAGL has become a promising therapeutic target for the treatment of several diseases that currently lack appropriate therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIoQ1x3SqqRrVg90H21EOLACvtfcHk0lhlEZs_eSIASA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVersL3L&md5=476dd950e4e1f221b0744dc0f7ede64f</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.07.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.07.036%26sid%3Dliteratum%253Aachs%26aulast%3DGil-Ordonez%26aufirst%3DA.%26aulast%3DMartin-Fontecha%26aufirst%3DM.%26aulast%3DOrtega-Gutierrez%26aufirst%3DS.%26aulast%3DLopez-Rodriguez%26aufirst%3DM.%2BL.%26atitle%3DMonoacylglycerol%2520lipase%2520%2528MAGL%2529%2520as%2520a%2520promising%2520therapeutic%2520target%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D157%26spage%3D18%26epage%3D32%26doi%3D10.1016%2Fj.bcp.2018.07.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habib, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chokr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro-Parenti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lettéron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouillet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Faouder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotersztajn, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2018-316137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1136%2Fgutjnl-2018-316137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30301768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFOns7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2019&pages=522-532&author=A.+Habibauthor=D.+Chokrauthor=J.+Wanauthor=P.+Hegdeauthor=M.+Mabireauthor=M.+Siebertauthor=L.+Ribeiro-Parentiauthor=M.+Le+Gallauthor=P.+Lett%C3%A9ronauthor=N.+Pilardauthor=A.+Mansouriauthor=A.+Brouilletauthor=M.+Tardelliauthor=E.+Weissauthor=P.+Le+Faouderauthor=H.+Guillouauthor=B.+F.+Cravattauthor=R.+Moreauauthor=M.+Traunerauthor=S.+Lotersztajn&title=Inhibition+of+monoacylglycerol+lipase%2C+an+anti-inflammatory+and+antifibrogenic+strategy+in+the+liver&doi=10.1136%2Fgutjnl-2018-316137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of monoacylglycerol lipase, an antiinflammatory and antifibrogenic strategy in the liver</span></div><div class="casAuthors">Habib, Aa; Chokr, Dina; Wan, JingHong; Hegde, Pushpa; Mabire, Morgane; Siebert, Matthieu; Ribeiro-Parenti, Lara; Gall, Maude Le; Letteron, Philippe; Pilard, Nathalie; Mansouri, Abdellah; Brouillet, Arthur; Tardelli, Matteo; Weiss, Emmanuel; Faouder, Pauline Le; Guillou, Herve; Cravatt, Benjamin F.; Moreau, Richard; Trauner, Michael; Lotersztajn, Sophie</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">522-532</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective Sustained inflammation originating from macrophages is a driving force of fibrosis progression and resoln.  Monoacylglycerol lipase (MAGL ) is the rate-limiting enzyme in the degrdn. of monoacylglycerols.  It is a proinflammatory enzyme that metabolises 2-arachidonoylglycerol, an endocannabinoid receptor ligand, into arachidonic acid.  Here, we investigated the impact of MAGL on inflammation and fibrosis during chronic liver injury.  Design C 57BL/6J mice and mice with global invalidation of MAGL (MAGL -/-), or myeloid-specific deletion of either MAGL (MAGL Mye-/-), ATG 5 (ATG Mye-/-) or CB2 (CB2Mye-/-), were used.  Fibrosis was induced by repeated carbon tetrachloride (CCl4) injections or bile duct ligation (BDL).  Studies were performed on peritoneal or bone marrow-derived macrophages and Kupffer cells.  Results MAGL -/- or MAGL Mye-/- mice exposed to CCl4 or subjected to BDL were more resistant to inflammation and fibrosis than wild-type counterparts.  Therapeutic intervention with MJN110, an MAGL inhibitor, reduced hepatic macrophage no. and inflammatory gene expression and slowed down fibrosis progression.  MAGL inhibitors also accelerated fibrosis regression and increased Ly-6Clow macrophage no.  Antifibrogenic effects exclusively relied on MAGL inhibition in macrophages, since MJN110 treatment of MAGL Mye-/- BDL mice did not further decrease liver fibrosis.  Cultured macrophages exposed to MJN110 or from MAGL Mye-/- mice displayed reduced cytokine secretion.  These effects were independent of the cannabinoid receptor 2, as they were preserved in CB2Mye-/- mice.  They relied on macrophage autophagy, since anti-inflammatory and antifibrogenic effects of MJN110 were lost in ATG 5Mye-/- BDL mice, and were assocd. with increased autophagic flux and autophagosome biosynthesis in macrophages when MAGL was pharmacol. or genetically inhibited.  Conclusion MAGL is an immunometabolic target in the liver.  MAGL inhibitors may show promising antifibrogenic effects during chronic liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHtyJlRmcarVg90H21EOLACvtfcHk0lg-KTZtvU6-DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFOns7jI&md5=bfa2ac283139753566804e4e2237ea3b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2018-316137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2018-316137%26sid%3Dliteratum%253Aachs%26aulast%3DHabib%26aufirst%3DA.%26aulast%3DChokr%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DHegde%26aufirst%3DP.%26aulast%3DMabire%26aufirst%3DM.%26aulast%3DSiebert%26aufirst%3DM.%26aulast%3DRibeiro-Parenti%26aufirst%3DL.%26aulast%3DLe%2BGall%26aufirst%3DM.%26aulast%3DLett%25C3%25A9ron%26aufirst%3DP.%26aulast%3DPilard%26aufirst%3DN.%26aulast%3DMansouri%26aufirst%3DA.%26aulast%3DBrouillet%26aufirst%3DA.%26aulast%3DTardelli%26aufirst%3DM.%26aulast%3DWeiss%26aufirst%3DE.%26aulast%3DLe%2BFaouder%26aufirst%3DP.%26aulast%3DGuillou%26aufirst%3DH.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DMoreau%26aufirst%3DR.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DLotersztajn%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520monoacylglycerol%2520lipase%252C%2520an%2520anti-inflammatory%2520and%2520antifibrogenic%2520strategy%2520in%2520the%2520liver%26jtitle%3DGut%26date%3D2019%26volume%3D68%26spage%3D522%26epage%3D532%26doi%3D10.1136%2Fgutjnl-2018-316137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dipasquale, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Righetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, V.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs</span>. <i>Int. Rev. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/S0074-7742(09)85005-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0074-7742%2809%2985005-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19607961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Wis7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=57-72&author=S.+Gaetaniauthor=P.+Dipasqualeauthor=A.+Romanoauthor=L.+Righettiauthor=T.+Cassanoauthor=D.+Piomelliauthor=V.+Cuomo&title=The+endocannabinoid+system+as+a+target+for+novel+anxiolytic+and+antidepressant+drugs&doi=10.1016%2FS0074-7742%2809%2985005-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs</span></div><div class="casAuthors">Gaetani, Silvana; Dipasquale, Pasqua; Romano, Adele; Righetti, Laura; Cassano, Tommaso; Piomelli, Daniele; Cuomo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">Advances in Neuropharmacology</span>),
    <span class="NLM_cas:pages">57-72</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Observational studies in humans suggest that exposure to marijuana and other cannabis-derived drugs produces a wide range of subjective effects on mood tone and emotionality.  These observations have their counterpart in animal studies, showing that cannabinoid agonists strongly affect emotional reactivity in directions that vary depending on dose and context.  Based on these evidence, the activation of central CB1 receptor has emerged as potential target for the development of antianxiety and antidepressant therapies.  However, the variable effects of exogenous cannabinoid agonists have gradually shifted the interest to the alternative approach of amplifying the effects of endogenous cannabinoids (EC), namely anandamide (AEA) and 2-arachidonoylglycerol (2-AG), by preventing their deactivation.  The enzyme fatty acid amide hydrolase (FAAH) has been the target of intense research efforts aimed at developing potent and selective inhibitors that might prolong AEA actions in vivo.  Among the inhibitors developed, the compd. URB597 was found to potently inhibit FAAH activity in vivo and cause brain AEA levels to increase.  Interestingly, the enhanced AEA tone produced by URB597 does not result in the behavioral effects typical of a direct-acting cannabinoid agonist.  Though URB597 does not elicit a full-fledged cannabinoid profile of behavioral responses, it does elicit marked anxiolytic-like and antidepressant-like effects in rats and mice.  Such effects involve the downstream activation of CB1 receptors, since they are attenuated by the CB1 antagonist SR141716 (rimonabant).  Parallel to FAAH inhibition, similar results can also be obsd. by pharmacol. blocking the AEA transport system, which is responsible of the intracellular uptake of AEA from the synaptic cleft.  The reason why FAAH inhibition approach produces a smaller set of cannabimimetic effects might depend on the mechanism of EC synthesis and release upon neuronal activation and on the target selectivity of the drug.  The mechanism of EC release is commonly referred to as "on request", since they are not synthesized and stored in synaptic vesicles, such as classical neurotransmitters, but are synthesized from membrane precursors and immediately released in the synaptic cleft following neuronal activation.  The neural stimulation in specific brain areas, for example, those involved in the regulation of mood tone and/or emotional reactivity, would result in an increased EC tone in these same areas, but not necessarily in others.  Therefore, inhibition of AEA metab. activity could amplify CB1 activation mainly where AEA release is higher.  Furthermore, the inhibition of FAAH causes an accumulation of AEA but not 2-AG, which, being 200-fold more abundant than AEA in the brain, might differently modulate CB1-mediated behavioral responses.  The evidence outlined above supports the hypothesis that the EC system plays an important role in anxiety and mood disorders and suggests that modulation of FAAH activity might be a pharmacol. target for novel anxiolytic and antidepressant therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoikIKJ9JJfGLVg90H21EOLACvtfcHk0lg-KTZtvU6-DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Wis7rL&md5=159980712c246a32cd127e61a98df686</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2FS0074-7742%2809%2985005-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0074-7742%252809%252985005-8%26sid%3Dliteratum%253Aachs%26aulast%3DGaetani%26aufirst%3DS.%26aulast%3DDipasquale%26aufirst%3DP.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DRighetti%26aufirst%3DL.%26aulast%3DCassano%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCuomo%26aufirst%3DV.%26atitle%3DThe%2520endocannabinoid%2520system%2520as%2520a%2520target%2520for%2520novel%2520anxiolytic%2520and%2520antidepressant%2520drugs%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D2009%26volume%3D85%26spage%3D57%26epage%3D72%26doi%3D10.1016%2FS0074-7742%2809%2985005-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerr, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, T. A.</span></span> <span> </span><span class="NLM_article-title">A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer’s disease</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2012.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.celrep.2012.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22813736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOrsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=617-623&author=J.+R.+Piroauthor=D.+I.+Benjaminauthor=J.+M.+Duerrauthor=Y.+Piauthor=C.+Gonzalesauthor=K.+M.+Woodauthor=J.+W.+Schwartzauthor=D.+K.+Nomuraauthor=T.+A.+Samad&title=A+dysregulated+endocannabinoid-eicosanoid+network+supports+pathogenesis+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.celrep.2012.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Piro, Justin R.; Benjamin, Daniel I.; Duerr, James M.; Pi, YeQing; Gonzales, Cathleen; Wood, Kathleen M.; Schwartz, Joel W.; Nomura, Daniel K.; Samad, Tarek A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">617-623</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although inflammation in the brain is meant as a defense mechanism against neurotoxic stimuli, increasing evidence suggests that uncontrolled, chronic, and persistent inflammation contributes to neurodegeneration.  Most neurodegenerative diseases have now been assocd. with chronic inflammation, including Alzheimer's disease (AD).  Whether anti-inflammatory approaches can be used to treat AD, however, is a major unanswered question.  We recently demonstrated that monoacylglycerol lipase (MAGL) hydrolyzes endocannabinoids to generate the primary arachidonic acid pool for neuroinflammatory prostaglandins.  In this study, we show that genetic inactivation of MAGL attenuates neuroinflammation and lowers amyloid β levels and plaques in an AD mouse model.  We also find that pharmacol. blockade of MAGL recapitulates the cytokine-lowering effects through reduced prostaglandin prodn., rather than enhanced endocannabinoid signaling.  Our findings thus reveal a role of MAGL in modulating neuroinflammation and amyloidosis in AD etiol. and put forth MAGL inhibitors as a potential next-generation strategy for combating AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhEmpHXwNVC7Vg90H21EOLACvtfcHk0lg-KTZtvU6-DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOrsrvM&md5=a84bec802e0b547d6e06052f39d1db0f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2012.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2012.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DPiro%26aufirst%3DJ.%2BR.%26aulast%3DBenjamin%26aufirst%3DD.%2BI.%26aulast%3DDuerr%26aufirst%3DJ.%2BM.%26aulast%3DPi%26aufirst%3DY.%26aulast%3DGonzales%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DK.%2BM.%26aulast%3DSchwartz%26aufirst%3DJ.%2BW.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26aulast%3DSamad%26aufirst%3DT.%2BA.%26atitle%3DA%2520dysregulated%2520endocannabinoid-eicosanoid%2520network%2520supports%2520pathogenesis%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCell%2520Rep.%26date%3D2012%26volume%3D1%26spage%3D617%26epage%3D623%26doi%3D10.1016%2Fj.celrep.2012.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Monoacylglycerol lipase is a therapeutic target for Alzheimer’s disease</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1339</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2012.09.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.celrep.2012.09.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23122958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWns77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1329-1339&author=R.+Chenauthor=J.+Zhangauthor=Y.+Wuauthor=D.+Wangauthor=G.+Fengauthor=Y.+P.+Tangauthor=Z.+Tengauthor=C.+Chen&title=Monoacylglycerol+lipase+is+a+therapeutic+target+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.celrep.2012.09.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease</span></div><div class="casAuthors">Chen, Rongqing; Zhang, Jian; Wu, Yan; Wang, Dongqing; Feng, Guoping; Tang, Ya-Ping; Teng, Zhaoqian; Chen, Chu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1329-1339</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common cause of dementia among older people.  There are no effective medications currently available to prevent and treat AD and halt disease progression.  Monoacylglycerol lipase (MAGL) is the primary enzyme metabolizing the endocannabinoid 2-arachidonoylglycerol in the brain.  We show here that inactivation of MAGL robustly suppressed prodn. and accumulation of β-amyloid (Aβ) assocd. with reduced expression of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) in a mouse model of AD.  MAGL inhibition also prevented neuroinflammation, decreased neurodegeneration, maintained integrity of hippocampal synaptic structure and function, and improved long-term synaptic plasticity, spatial learning, and memory in AD animals.  Although the mol. mechanisms underlying the beneficial effects produced by MAGL inhibition remain to be detd., our results suggest that MAGL, which regulates endocannabinoid and prostaglandin signaling, contributes to pathogenesis and neuropathol. of AD, and thus is a promising therapeutic target for the prevention and treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq66o3D4dpA5bVg90H21EOLACvtfcHk0ljNiRdkSUghHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWns77I&md5=ed129dd8f6b0222062777cb113060ad0</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2012.09.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2012.09.030%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DY.%2BP.%26aulast%3DTeng%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DMonoacylglycerol%2520lipase%2520is%2520a%2520therapeutic%2520target%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCell%2520Rep.%26date%3D2012%26volume%3D2%26spage%3D1329%26epage%3D1339%26doi%3D10.1016%2Fj.celrep.2012.09.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habib, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okorokov, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bras, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Drimmelen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houlden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. J.</span></span> <span> </span><span class="NLM_article-title">Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">e249</span>– <span class="NLM_lpage">e253</span>, <span class="refDoi"> DOI: 10.1016/j.bja.2019.02.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bja.2019.02.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30929760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2019&pages=e249-e253&author=A.+M.+Habibauthor=A.+L.+Okorokovauthor=M.+N.+Hillauthor=J.+T.+Brasauthor=M.+C.+Leeauthor=S.+Liauthor=S.+J.+Gossageauthor=M.+van+Drimmelenauthor=M.+Morenaauthor=H.+Houldenauthor=J.+D.+Ramirezauthor=D.+L.+H.+Bennettauthor=D.+Srivastavaauthor=J.+J.+Cox&title=Microdeletion+in+a+FAAH+pseudogene+identified+in+a+patient+with+high+anandamide+concentrations+and+pain+insensitivity&doi=10.1016%2Fj.bja.2019.02.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrationsand pain insensitivity</span></div><div class="casAuthors">Habib, Abdella M.; Okorokov, Andrei L.; Hill, Matthew N.; Bras, Jose T.; Lee, Man-Cheung; Li, Shengnan; Gossage, Samuel J.; van Drimmelen, Marie; Morena, Maria; Houlden, Henry; Ramirez, Juan D.; Bennett, David L. H.; Srivastava, Devjit; Cox, James J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e249-e253</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">1471-6771</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The study of rare families with inherited pain insensitivity can identify new human-validated analgesic drug targets.  Here, a 66-yr-old female presented with nil requirement for postoperative analgesia after a normally painful orthopaedic hand surgery (trapeziectomy).  Further investigations revealed a lifelong history of painless injuries, such as frequent cuts and burns, which were obsd. to heal quickly.  We report the causative mutations for this new pain insensitivity disorder: the co-inheritance of (i) a microdeletion in dorsal root ganglia and brain-expressed pseudogene, FAAH-OUT, which we cloned from the fatty-acid amide hydrolase (FAAH) chromosomal region; and (ii) a common functional single-nucleotide polymorphism in FAAH conferring reduced expression and activity.  Circulating concns. of anandamide and related fatty-acid amides (palmitoylethanolamide and oleoylethanolamine) that are all normally degraded by FAAH were significantly elevated in peripheral blood compared with normal control carriers of the hypomorphic single-nucleotide polymorphism.  The genetic findings and elevated circulating fatty-acid amides are consistent with a phenotype resulting from enhanced endocannabinoid signaling and a loss of function of FAAH.  Our results highlight previously unknown complexity at the FAAH genomic locus involving the expression of FAAH-OUT, a novel pseudogene and long non-coding RNA.  These data suggest new routes to develop FAAH-based analgesia by targeting of FAAH-OUT, which could significantly improve the treatment of postoperative pain and potentially chronic pain and anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXNQj7AwBRvLVg90H21EOLACvtfcHk0ljNiRdkSUghHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlOhtbs%253D&md5=a64125a64e7ce5733bdc3962ff34eb53</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bja.2019.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bja.2019.02.019%26sid%3Dliteratum%253Aachs%26aulast%3DHabib%26aufirst%3DA.%2BM.%26aulast%3DOkorokov%26aufirst%3DA.%2BL.%26aulast%3DHill%26aufirst%3DM.%2BN.%26aulast%3DBras%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGossage%26aufirst%3DS.%2BJ.%26aulast%3Dvan%2BDrimmelen%26aufirst%3DM.%26aulast%3DMorena%26aufirst%3DM.%26aulast%3DHoulden%26aufirst%3DH.%26aulast%3DRamirez%26aufirst%3DJ.%2BD.%26aulast%3DBennett%26aufirst%3DD.%2BL.%2BH.%26aulast%3DSrivastava%26aufirst%3DD.%26aulast%3DCox%26aufirst%3DJ.%2BJ.%26atitle%3DMicrodeletion%2520in%2520a%2520FAAH%2520pseudogene%2520identified%2520in%2520a%2520patient%2520with%2520high%2520anandamide%2520concentrations%2520and%2520pain%2520insensitivity%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2019%26volume%3D123%26spage%3De249%26epage%3De253%26doi%3D10.1016%2Fj.bja.2019.02.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo Verme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astarita, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calignano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1124/mol.104.006353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fmol.104.006353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15465922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt12ksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=15-19&author=J.+Lo+Vermeauthor=J.+Fuauthor=G.+Astaritaauthor=G.+La+Ranaauthor=R.+Russoauthor=A.+Calignanoauthor=D.+Piomelli&title=The+nuclear+receptor+peroxisome+proliferator-activated+receptor-alpha+mediates+the+anti-inflammatory+actions+of+palmitoylethanolamide&doi=10.1124%2Fmol.104.006353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide</span></div><div class="casAuthors">Lo Verme, Jesse; Fu, Jin; Astarita, Giuseppe; La Rana, Giovanna; Russo, Roberto; Calignano, Antonio; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-19</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Palmitoylethanolamide (PEA), the naturally occurring amide of palmitic acid and ethanolamine, reduces pain and inflammation through an as-yet-uncharacterized mechanism.  Here, we identify the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) as the mol. target responsible for the anti-inflammatory properties of PEA.  PEA selectively activates PPAR-α in vitro with an EC50 value of 3.1±0.4 μM and induces the expression of PPAR-α mRNA when applied topically to mouse skin.  In two animal models, carrageenan-induced paw edema and phorbol ester-induced ear edema, PEA attenuates inflammation in wild-type mice but has no effect in mice deficient in PPAR-α.  The natural PPAR-α agonist oleoylethanolamide (OEA) and the synthetic PPAR-α agonists GW7647 and Wy-14643 mimic these effects in a PPAR-α-dependent manner.  These findings indicate that PPAR-α mediates the anti-inflammatory effects of PEA and suggest that this fatty-acid ethanolamide may serve, like its analog OEA, as an endogenous ligand of PPAR-α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw2rfZ_7rANLVg90H21EOLACvtfcHk0lhHBcTcO_tPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt12ksA%253D%253D&md5=c6c20156b93828c507ecbdee107c7061</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1124%2Fmol.104.006353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.104.006353%26sid%3Dliteratum%253Aachs%26aulast%3DLo%2BVerme%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DAstarita%26aufirst%3DG.%26aulast%3DLa%2BRana%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DR.%26aulast%3DCalignano%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DThe%2520nuclear%2520receptor%2520peroxisome%2520proliferator-activated%2520receptor-alpha%2520mediates%2520the%2520anti-inflammatory%2520actions%2520of%2520palmitoylethanolamide%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D15%26epage%3D19%26doi%3D10.1124%2Fmol.104.006353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoover, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.11.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2009.11.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20079333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=49-61&author=D.+K.+Nomuraauthor=J.+Z.+Longauthor=S.+Niessenauthor=H.+S.+Hooverauthor=S.-W.+Ngauthor=B.+F.+Cravatt&title=Monoacylglycerol+lipase+regulates+a+fatty+acid+network+that+promotes+cancer+pathogenesis&doi=10.1016%2Fj.cell.2009.11.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis</span></div><div class="casAuthors">Nomura, Daniel K.; Long, Jonathan Z.; Niessen, Sherry; Hoover, Heather S.; Ng, Shu-Wing; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-61</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tumor cells display progressive changes in metab. that correlate with malignancy, including development of a lipogenic phenotype.  How stored fats are liberated and remodeled to support cancer pathogenesis, however, remains unknown.  Here, we show that the enzyme monoacylglycerol lipase (MAGL) is highly expressed in aggressive human cancer cells and primary tumors, where it regulates a fatty acid network enriched in oncogenic signaling lipids that promotes migration, invasion, survival, and in vivo tumor growth.  Overexpression of MAGL in nonaggressive cancer cells recapitulates this fatty acid network and increases their pathogenicity-phenotypes that are reversed by an MAGL inhibitor.  Impairments in MAGL-dependent tumor growth are rescued by a high-fat diet, indicating that exogenous sources of fatty acids can contribute to malignancy in cancers lacking MAGL activity.  Together, these findings reveal how cancer cells can co-opt a lipolytic enzyme to translate their lipogenic state into an array of protumorigenic signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJjx-809DEL7Vg90H21EOLACvtfcHk0lhHBcTcO_tPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWiurw%253D&md5=2eccd811b2e806e79215cc00c72b7d6a</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.11.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.11.027%26sid%3Dliteratum%253Aachs%26aulast%3DNomura%26aufirst%3DD.%2BK.%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DHoover%26aufirst%3DH.%2BS.%26aulast%3DNg%26aufirst%3DS.-W.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DMonoacylglycerol%2520lipase%2520regulates%2520a%2520fatty%2520acid%2520network%2520that%2520promotes%2520cancer%2520pathogenesis%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D49%26epage%3D61%26doi%3D10.1016%2Fj.cell.2009.11.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morbidelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aviello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imperatore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capasso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piscitelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, A. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.phrs.2017.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28193521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlyqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2017&pages=227-236&author=E.+Paganoauthor=F.+Borrelliauthor=P.+Orlandoauthor=B.+Romanoauthor=M.+Montiauthor=L.+Morbidelliauthor=G.+Avielloauthor=R.+Imperatoreauthor=R.+Capassoauthor=F.+Piscitelliauthor=L.+Buonoauthor=V.+Di+Marzoauthor=A.+A.+Izzo&title=Pharmacological+inhibition+of+MAGL+attenuates+experimental+colon+carcinogenesis&doi=10.1016%2Fj.phrs.2017.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis</span></div><div class="casAuthors">Pagano, Ester; Borrelli, Francesca; Orlando, Pierangelo; Romano, Barbara; Monti, Martina; Morbidelli, Lucia; Aviello, Gabriella; Imperatore, Roberta; Capasso, Raffaele; Piscitelli, Fabiana; Buono, Lorena; Di Marzo, Vincenzo; Izzo, Angelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">227-236</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Colorectal cancer (CRC) is a major health problem in Western countries.  The endocannabinoid 2-arachidonoyl-glycerol (2-AG) exerts antiproliferative actions in a no. of tumoral cell lines, including CRC cells.  Monoacylglycerol lipase (MAGL), a serine hydrolase that inactivates 2-AG, is highly expressed in aggressive human cancer cells.  Here, we investigated the role of MAGL in exptl. colon carcinogenesis.  The role of MAGL was assessed in vivo by using the xenograft and the azoxymethane models of colon carcinogenesis; MAGL expression was evaluated by RT-PCR and immunohistochem.; 2-AG levels were measured by liq. chromatog. mass spectrometry; angiogenesis was evaluated in tumor tissues [by microvessel counting and by investigating the expression of vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) proteins] as well as in human umbilical vein endothelial cells (HUVEC); cyclin D1 was evaluated by RT-PCR.  MAGL and 2-AG were strongly expressed in tumor tissues.  The MAGL inhibitor URB602 reduced xenograft tumor vol., this effect being assocd. to down-regulation of VEGF and FGF-2, redn. in the no. of vessels and down-regulation of cyclin D1.  In HUVEC, URB602 exerted a direct antiangiogenic effect by inhibiting FGF-2 induced proliferation and migration, and by modulating pro/anti-angiogenic agents.  In expts. aiming at investigating the role of MAGL in chemoprevention, URB602 attenuated azoxymethane-induced preneoplastic lesions, polyps and tumors.  MAGL, possibly through modulation of angiogenesis, plays a pivotal role in exptl. colon carcinogenesis.  Pharmacol. inhibition of MAGL could represent an innovative therapeutic approach to reduce colorectal tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXVAd5-AN_rVg90H21EOLACvtfcHk0lhHBcTcO_tPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlyqsL0%253D&md5=24855bcf178b5093b8310525358d11a7</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DE.%26aulast%3DBorrelli%26aufirst%3DF.%26aulast%3DOrlando%26aufirst%3DP.%26aulast%3DRomano%26aufirst%3DB.%26aulast%3DMonti%26aufirst%3DM.%26aulast%3DMorbidelli%26aufirst%3DL.%26aulast%3DAviello%26aufirst%3DG.%26aulast%3DImperatore%26aufirst%3DR.%26aulast%3DCapasso%26aufirst%3DR.%26aulast%3DPiscitelli%26aufirst%3DF.%26aulast%3DBuono%26aufirst%3DL.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DIzzo%26aufirst%3DA.%2BA.%26atitle%3DPharmacological%2520inhibition%2520of%2520MAGL%2520attenuates%2520experimental%2520colon%2520carcinogenesis%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D119%26spage%3D227%26epage%3D236%26doi%3D10.1016%2Fj.phrs.2017.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisogno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span> <span> </span><span class="NLM_article-title">Latest advances in the discovery of fatty acid amide hydrolase inhibitors</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.780021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1517%2F17460441.2013.780021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23488865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFWrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=509-522&author=T.+Bisognoauthor=M.+Maccarrone&title=Latest+advances+in+the+discovery+of+fatty+acid+amide+hydrolase+inhibitors&doi=10.1517%2F17460441.2013.780021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Latest advances in the discovery of fatty acid amide hydrolase inhibitors</span></div><div class="casAuthors">Bisogno, Tiziana; Maccarrone, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">509-522</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Fatty acid amide hydrolase (FAAH) is the major catabolic enzyme of the endocannabinoid N-arachidonoylethanolamine (anandamide) that, with different degrees of efficiency, also hydrolyzes other endogenous fatty acid ethanolamides.  FAAH is increasingly being considered a relevant therapeutic target, esp. in models of inflammatory pain.  The opportunity to selectively increase the endocannabinoid tone only in those tissues where such an enhancement can be beneficial might result in a therapeutic benefit with more limited side effects, compared to the use of direct agonists of anandamide-binding receptors.  Thus the research for selective FAAH inhibitors has become a hot topic in current drug discovery.  Areas covered: This review highlights the advances in the development of different compds. belonging to different chem. families that have been proposed as FAAH inhibitors.  Several classes of inhibitors have been reported so far, and they may be classified into two major classes: reversible and irreversible compds.  These inhibitors are reviewed herein with an emphasis on their potency and selectivity.  Expert opinion: In recent years, tremendous efforts have been made to develop the FAAH inhibitors, and consequently many novel chem. templates have been discovered.  It is still a major challenge to identify the first inhibitor of FAAH suitable for clin. exploitation that satisfies the requirements of potency, selectivity vs. proteins related to anandamide activity as well as other potential off-targets, reversibility vs. irreversibility, and efficacy toward rat vs. human FAAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaENSbBN0bAbVg90H21EOLACvtfcHk0liCZF0wh6lGUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFWrt7o%253D&md5=bb68fa44724b72d5e1b35e2e7b0c7b0c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.780021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.780021%26sid%3Dliteratum%253Aachs%26aulast%3DBisogno%26aufirst%3DT.%26aulast%3DMaccarrone%26aufirst%3DM.%26atitle%3DLatest%2520advances%2520in%2520the%2520discovery%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D509%26epage%3D522%26doi%3D10.1517%2F17460441.2013.780021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burston, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosburg, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavon, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selley, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1038/nchembio.129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnchembio.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19029917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWgsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=37-44&author=J.+Z.+Longauthor=W.+Liauthor=L.+Bookerauthor=J.+J.+Burstonauthor=S.+G.+Kinseyauthor=J.+E.+Schlosburgauthor=F.+J.+Pavonauthor=A.+M.+Serranoauthor=D.+E.+Selleyauthor=L.+H.+Parsonsauthor=A.+H.+Lichtmanauthor=B.+F.+Cravatt&title=Selective+blockade+of+2-arachidonoylglycerol+hydrolysis+produces+cannabinoid+behavioral+effects&doi=10.1038%2Fnchembio.129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects</span></div><div class="casAuthors">Long, Jonathan Z.; Li, Weiwei; Booker, Lamont; Burston, James J.; Kinsey, Steven G.; Schlosburg, Joel E.; Pavon, Franciso J.; Serrano, Antonia M.; Selley, Dana E.; Parsons, Loren H.; Lichtman, Aron H.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-44</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">2-Arachidonoylglycerol (2-AG) and anandamide are endocannabinoids that activate the cannabinoid receptors CB1 and CB2.  Endocannabinoid signaling is terminated by enzymic hydrolysis, a process that for anandamide is mediated by fatty acid amide hydrolase (FAAH), and for 2-AG is thought to involve monoacylglycerol lipase (MAGL).  FAAH inhibitors produce a select subset of the behavioral effects obsd. with CB1 agonists, which suggests a functional segregation of endocannabinoid signaling pathways in vivo.  Testing this hypothesis, however, requires specific tools to independently block anandamide and 2-AG metab.  Here, we report a potent and selective inhibitor of MAGL called JZL184 that, upon administration to mice, raises brain 2-AG by eight-fold without altering anandamide.  JZL184-treated mice exhibited a broad array of CB1-dependent behavioral effects, including analgesia, hypothermia and hypomotility.  These data indicate that 2-AG endogenously modulates several behavioral processes classically assocd. with the pharmacol. of cannabinoids and point to overlapping and unique functions for 2-AG and anandamide in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY1sK0ulYFK7Vg90H21EOLACvtfcHk0liCZF0wh6lGUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWgsr3F&md5=1ffee44019b0e52db5da38fe30a6e4d0</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.129%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DBooker%26aufirst%3DL.%26aulast%3DBurston%26aufirst%3DJ.%2BJ.%26aulast%3DKinsey%26aufirst%3DS.%2BG.%26aulast%3DSchlosburg%26aufirst%3DJ.%2BE.%26aulast%3DPavon%26aufirst%3DF.%2BJ.%26aulast%3DSerrano%26aufirst%3DA.%2BM.%26aulast%3DSelley%26aufirst%3DD.%2BE.%26aulast%3DParsons%26aufirst%3DL.%2BH.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DSelective%2520blockade%2520of%25202-arachidonoylglycerol%2520hydrolysis%2520produces%2520cannabinoid%2520behavioral%2520effects%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D37%26epage%3D44%26doi%3D10.1038%2Fnchembio.129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohnz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span> <span> </span><span class="NLM_article-title">Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">6859</span>– <span class="NLM_lpage">6869</span>, <span class="refDoi"> DOI: 10.1039/C4CS00047A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1039%2FC4CS00047A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24676249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2mtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=6859-6869&author=R.+A.+Kohnzauthor=D.+K.+Nomura&title=Chemical+approaches+to+therapeutically+target+the+metabolism+and+signaling+of+the+endocannabinoid+2-AG+and+eicosanoids&doi=10.1039%2FC4CS00047A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids</span></div><div class="casAuthors">Kohnz, Rebecca A.; Nomura, Daniel K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6859-6869</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system, most popularly known as the target of the psychoactive component of marijuana, Δ9-tetrahydrocannabinol (THC), is a signaling network that modulates a diverse range of physiol. processes including nociception, behavior, cognitive function, appetite, metab., motor control, memory formation, and inflammation.  While THC and its derivs. have garnered notoriety in the eyes of the public, the endocannabinoid system consists of two endogenous signaling lipids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anandamide), which activate cannabinoid receptors CB1 and CB2 in the nervous system and peripheral tissues.  This review will focus on the recent efforts to chem. manipulate 2-AG signaling through the development of inhibitors of the 2-AG-synthesizing enzyme diacylglycerol lipase (DAGL) or the 2-AG-degrading enzyme monoacylglycerol lipase (MAGL), and assessing the therapeutic potential of DAGL and MAGL inhibitors in pain, inflammation, degenerative diseases, tissue injury, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo061VrnQ7sP7Vg90H21EOLACvtfcHk0liCZF0wh6lGUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2mtrjM&md5=930d2e70ae5741c872c870860b61d5a7</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1039%2FC4CS00047A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CS00047A%26sid%3Dliteratum%253Aachs%26aulast%3DKohnz%26aufirst%3DR.%2BA.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26atitle%3DChemical%2520approaches%2520to%2520therapeutically%2520target%2520the%2520metabolism%2520and%2520signaling%2520of%2520the%2520endocannabinoid%25202-AG%2520and%2520eicosanoids%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2014%26volume%3D43%26spage%3D6859%26epage%3D6869%26doi%3D10.1039%2FC4CS00047A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huggins, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span> <span> </span><span class="NLM_article-title">An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">1837</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2012.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.pain.2012.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22727500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKnurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2012&pages=1837-1846&author=J.+P.+Hugginsauthor=T.+S.+Smartauthor=S.+Langmanauthor=L.+Taylorauthor=T.+Young&title=An+efficient+randomised%2C+placebo-controlled+clinical+trial+with+the+irreversible+fatty+acid+amide+hydrolase-1+inhibitor+PF-04457845%2C+which+modulates+endocannabinoids+but+fails+to+induce+effective+analgesia+in+patients+with+pain+due+to+osteoarthritis+of+the+knee&doi=10.1016%2Fj.pain.2012.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee</span></div><div class="casAuthors">Huggins, John P.; Smart, Trevor S.; Langman, Stephen; Taylor, Louise; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1837-1846</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A randomised, placebo-controlled clin. trial with PF-04457845, a novel irreversible fatty acid amide hydrolase-1 inhibitor, increases endocannabinoids, but does not induce analgesia in patients with osteoarthritis.  The effect of PF-04457845, a potent and selective fatty acid amide hydrolase-1 (FAAH1) inhibitor, on pain due to osteoarthritis of the knee was investigated in a randomised placebo and active-controlled clin. trial.  The trial involved 2 periods (sepd. by a 2-wk washout) consisting of a 1-wk wash-in phase followed by 2 wk double-blind treatment.  Patients received single-blind placebo throughout the wash-in and washout periods.  Patients were randomised to receive either 4 mg q.d.  PF-04457845 followed by placebo (or vice versa), or 500 mg b.i.d. naproxen followed by placebo (or vice versa).  The primary end point was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score.  The trial had predefined decision rules based on likelihood that PF-04457845 was better or worse than the std. of care (considered to be a 1.8 redn. in WOMAC pain score compared to placebo).  A total of 74 patients were randomised to 1 of 4 treatment sequences.  The mean differences (80% confidence intervals) from placebo in WOMAC pain score were 0.04 (-0.63 to 0.71) for PF-04457845 and -1.13 (-1.79 to -0.47) for naproxen, indicating that while naproxen seemed efficacious, PF-04457845 was not differentiated from placebo.  The study was stopped at the interim anal. for futility.  PF-04457845 decreased FAAH activity by >96% and substantially increased 4 endogenous substrates (fatty acid amides).  PF-04457845 was well tolerated in osteoarthritis patients, and there was no evidence of cannabinoid-type adverse events.  The lack of analgesic effect of FAAH1 inhibition in humans is in contrast to data from animal models.  This apparent disconnect between species needs further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbHcORiYgJbVg90H21EOLACvtfcHk0liEYlx1Lqs5tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKnurrF&md5=2b63f10426d6cacef059d972a5a825c1</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2012.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2012.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DHuggins%26aufirst%3DJ.%2BP.%26aulast%3DSmart%26aufirst%3DT.%2BS.%26aulast%3DLangman%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DAn%2520efficient%2520randomised%252C%2520placebo-controlled%2520clinical%2520trial%2520with%2520the%2520irreversible%2520fatty%2520acid%2520amide%2520hydrolase-1%2520inhibitor%2520PF-04457845%252C%2520which%2520modulates%2520endocannabinoids%2520but%2520fails%2520to%2520induce%2520effective%2520analgesia%2520in%2520patients%2520with%2520pain%2520due%2520to%2520osteoarthritis%2520of%2520the%2520knee%26jtitle%3DPain%26date%3D2012%26volume%3D153%26spage%3D1837%26epage%3D1846%26doi%3D10.1016%2Fj.pain.2012.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pawsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, S.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability and pharmacokinetics of FAAH inhibitor V158866: a double-blind, randomised, placebo-controlled phase I study in healthy volunteers</span>. <i>Drugs R&amp;D</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1007/s40268-016-0127-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs40268-016-0127-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26987975" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=181-191&author=S.+Pawseyauthor=M.+Woodauthor=H.+Browneauthor=K.+Donaldsonauthor=M.+Christieauthor=S.+Warrington&title=Safety%2C+tolerability+and+pharmacokinetics+of+FAAH+inhibitor+V158866%3A+a+double-blind%2C+randomised%2C+placebo-controlled+phase+I+study+in+healthy+volunteers&doi=10.1007%2Fs40268-016-0127-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1007%2Fs40268-016-0127-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40268-016-0127-y%26sid%3Dliteratum%253Aachs%26aulast%3DPawsey%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DBrowne%26aufirst%3DH.%26aulast%3DDonaldson%26aufirst%3DK.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DWarrington%26aufirst%3DS.%26atitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520FAAH%2520inhibitor%2520V158866%253A%2520a%2520double-blind%252C%2520randomised%252C%2520placebo-controlled%2520phase%2520I%2520study%2520in%2520healthy%2520volunteers%26jtitle%3DDrugs%2520R%2526amp%253BD%26date%3D2016%26volume%3D16%26spage%3D181%26epage%3D191%26doi%3D10.1007%2Fs40268-016-0127-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postnov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Hoon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hecken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Boer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannikos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Ark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Fatty acid amide hydrolase inhibition by JNJ-42165279: a multiple-ascending dose and a positron emission tomography study in healthy volunteers</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1111/cts.12548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fcts.12548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29575526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12mt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=397-404&author=A.+Postnovauthor=M.+E.+Schmidtauthor=D.+J.+Pembertonauthor=J.+de+Hoonauthor=A.+van+Heckenauthor=M.+van+den+Boerauthor=P.+Zannikosauthor=P.+van+der+Arkauthor=J.+A.+Palmerauthor=S.+Rassnickauthor=S.+Celenauthor=G.+Bormansauthor=K.+van+Laere&title=Fatty+acid+amide+hydrolase+inhibition+by+JNJ-42165279%3A+a+multiple-ascending+dose+and+a+positron+emission+tomography+study+in+healthy+volunteers&doi=10.1111%2Fcts.12548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers</span></div><div class="casAuthors">Postnov, Andrey; Schmidt, Mark E.; Pemberton, Darrel J.; de Hoon, Jan; van Hecken, Anne; van den Boer, Maarten; Zannikos, Peter; van der Ark, Peter; Palmer, James A.; Rassnick, Stef; Celen, Sofie; Bormans, Guy; van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-404</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Inhibition of fatty acid amide hydrolase (FAAH) potentiates endocannabinoid activity and is hypothesized to have therapeutic potential for mood and anxiety disorders and pain.  The clin. profile of JNJ-42165279, an oral selective FAAH inhibitor, was assessed by investigating the pharmacokinetics, pharmacodynamics, safety, and binding to FAAH in the brain of healthy human volunteers.  Concns. of JNJ-42165279 (plasma, cerebrospinal fluid (CSF), urine) and fatty acid amides (FAA; plasma, CSF), and FAAH activity in leukocytes was detd. in a phase I multiple ascending dose study.  A positron emission tomog. study with the FAAH tracer [11C]MK3168 was conducted to det. brain FAAH occupancy after single and multiple doses of JNJ-42165279.  JNJ-42165279 administration resulted in an increase in plasma and CSF FAA.  Significant blocking of brain FAAH binding of [11C]MK3168 was obsd. after pretreatment with JNJ-42165279.  JNJ-42165279 produces potent central and peripheral FAAH inhibition.  Satn. of brain FAAH occupancy occurred with doses ≥10 mg of JNJ-42165279.  No safety concerns were identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7z52Pfhrl_LVg90H21EOLACvtfcHk0liEYlx1Lqs5tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12mt73M&md5=2b389cf4f21d8ffdbf13b66e4ff18571</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fcts.12548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12548%26sid%3Dliteratum%253Aachs%26aulast%3DPostnov%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DM.%2BE.%26aulast%3DPemberton%26aufirst%3DD.%2BJ.%26aulast%3Dde%2BHoon%26aufirst%3DJ.%26aulast%3Dvan%2BHecken%26aufirst%3DA.%26aulast%3Dvan%2Bden%2BBoer%26aufirst%3DM.%26aulast%3DZannikos%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BArk%26aufirst%3DP.%26aulast%3DPalmer%26aufirst%3DJ.%2BA.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DCelen%26aufirst%3DS.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3Dvan%2BLaere%26aufirst%3DK.%26atitle%3DFatty%2520acid%2520amide%2520hydrolase%2520inhibition%2520by%2520JNJ-42165279%253A%2520a%2520multiple-ascending%2520dose%2520and%2520a%2520positron%2520emission%2520tomography%2520study%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2018%26volume%3D11%26spage%3D397%26epage%3D404%26doi%3D10.1111%2Fcts.12548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerbrat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillatre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronziere, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carsin-Nicol, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvrit, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tulzo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edan, G.</span></span> <span> </span><span class="NLM_article-title">Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1717</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1604221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1056%2FNEJMoa1604221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27806235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1717-1725&author=A.+Kerbratauthor=J.+C.+Ferreauthor=P.+Fillatreauthor=T.+Ronziereauthor=S.+Vannierauthor=B.+Carsin-Nicolauthor=S.+Lavoueauthor=M.+Verinauthor=J.+Y.+Gauvritauthor=Y.+Le+Tulzoauthor=G.+Edan&title=Acute+neurologic+disorder+from+an+inhibitor+of+fatty+acid+amide+hydrolase&doi=10.1056%2FNEJMoa1604221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase</span></div><div class="casAuthors">Kerbrat, Anne; Ferre, Jean-Christophe; Fillatre, Pierre; Ronziere, Thomas; Vannier, Stephane; Carsin-Nicol, Beatrice; Lavoue, Sylvain; Verin, Marc; Gauvrit, Jean-Yves; Le Tulzo, Yves; Edan, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1717-1725</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND A decrease in fatty acid amide hydrolase (FAAH) activity increases the levels of endogenous analogs of cannabinoids, or endocannabinoids.  FAAH inhibitors have shown analgesic and antiinflammatory activity in animal models, and some have been tested in phase 1 and 2 studies.  In a phase 1 study, BIA 10-2474, an orally administered reversible FAAH inhibitor, was given to healthy volunteers to assess safety.  METHODS Single doses (0.25 to 100 mg) and repeated oral doses (2.5 to 20 mg for 10 days) of BIA 10-2474 had been administered to 84 healthy volunteers in sequential cohorts; no severe adverse events had been reported.  Another cohort of participants was then assigned to placebo (2 participants) or 50 mg of BIA 10-2474 per day (6 participants).  This report focuses on neurol. adverse events in participants in this final cohort.  A total of 4 of the 6 participants who received active treatment consented to have their clin. and radiol. data included in this report.  RESULTS An acute and rapidly progressive neurol. syndrome developed in three of the four participants starting on the fifth day of drug administration.  The main clin. features were headache, a cerebellar syndrome, memory impairment, and altered consciousness.  Magnetic resonance imaging showed bilateral and sym. cerebral lesions, including microhemorrhages and hyperintensities on fluid-attenuated inversion recovery and diffusion-weighted imaging sequences predominantly involving the pons and hippocampi.  One patient became brain dead; the condition of two patients subsequently improved, but one patient had residual memory impairment, and the other patient had a residual cerebellar syndrome.  One patient remained asymptomatic.  CONCLUSIONS An unanticipated severe neurol. disorder occurred after ingestion of BIA 10-2474 at the highest dose level used in a phase 1 trial.  The underlying mechanism of this toxic cerebral syndrome remains unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGSymlUTX16LVg90H21EOLACvtfcHk0lhfcorytuVSkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrbJ&md5=55be96221464c92030a1a90b46e4afff</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1604221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1604221%26sid%3Dliteratum%253Aachs%26aulast%3DKerbrat%26aufirst%3DA.%26aulast%3DFerre%26aufirst%3DJ.%2BC.%26aulast%3DFillatre%26aufirst%3DP.%26aulast%3DRonziere%26aufirst%3DT.%26aulast%3DVannier%26aufirst%3DS.%26aulast%3DCarsin-Nicol%26aufirst%3DB.%26aulast%3DLavoue%26aufirst%3DS.%26aulast%3DVerin%26aufirst%3DM.%26aulast%3DGauvrit%26aufirst%3DJ.%2BY.%26aulast%3DLe%2BTulzo%26aufirst%3DY.%26aulast%3DEdan%26aufirst%3DG.%26atitle%3DAcute%2520neurologic%2520disorder%2520from%2520an%2520inhibitor%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D1717%26epage%3D1725%26doi%3D10.1056%2FNEJMoa1604221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fazio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscuolo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barboni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fezza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span> <span> </span><span class="NLM_article-title">Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold?</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1080/17460441.2020.1751118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1080%2F17460441.2020.1751118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32292082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVGhtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=765-778&author=D.+Fazioauthor=E.+Criscuoloauthor=A.+Piccoliauthor=B.+Barboniauthor=F.+Fezzaauthor=M.+Maccarrone&title=Advances+in+the+discovery+of+fatty+acid+amide+hydrolase+inhibitors%3A+what+does+the+future+hold%3F&doi=10.1080%2F17460441.2020.1751118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold</span></div><div class="casAuthors">Fazio, Domenico; Criscuolo, Emanuele; Piccoli, Alessandra; Barboni, Barbara; Fezza, Filomena; Maccarrone, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">765-778</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Fatty acid amide hydrolase (FAAH) is a membrane-bound enzyme, that inactivates endogenous signaling lipids of the fatty acid amide family, including the endocannabinoid anandamide (N-arachidonoylethanolamine, AEA).  The latter compd. has been shown to regulate a no. of important pathophysiol. conditions in humans, like feeding, obesity, immune response, reproductive events, motor coordination, and neurol. disorders.  Hence, direct manipulation of the endocannabinoid tone is thought to have therapeutic potential.  A new opportunity to develop effective drugs may arise from multi-target directed ligand (MTDL) strategies, which brings the concept that a single compd. can recognize different targets involved in the cascade of pathophysiol. events.  This review reports the latest advances in the development of new single targeted and dual-targeted FAAH inhibitors over the past 5 years.  In recent years, several FAAH inhibitors have been synthesized and investigated, yet to date none of them has reached the market as a systemic drug.  Due to the diligence of inherent redundancy and robustness in many biol. networks and pathways, multitarget inhibitors present a new prospect in the pharmaceutical industry for treatment of complex diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZjorYOeiGbrVg90H21EOLACvtfcHk0lhfcorytuVSkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVGhtLg%253D&md5=6bd1fe56ef4bf88286312b78e1ea2f46</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1080%2F17460441.2020.1751118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2020.1751118%26sid%3Dliteratum%253Aachs%26aulast%3DFazio%26aufirst%3DD.%26aulast%3DCriscuolo%26aufirst%3DE.%26aulast%3DPiccoli%26aufirst%3DA.%26aulast%3DBarboni%26aufirst%3DB.%26aulast%3DFezza%26aufirst%3DF.%26aulast%3DMaccarrone%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%253A%2520what%2520does%2520the%2520future%2520hold%253F%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2020%26volume%3D15%26spage%3D765%26epage%3D778%26doi%3D10.1080%2F17460441.2020.1751118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaway, E.</span></span> <span> </span><span class="NLM_article-title">Scientists in the dark after fatal french clinical trial</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>529</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nature.2016.19189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnature.2016.19189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26791697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=263-264&author=D.+Butlerauthor=E.+Callaway&title=Scientists+in+the+dark+after+fatal+french+clinical+trial&doi=10.1038%2Fnature.2016.19189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Scientists in the dark after French clinical trial proves fatal</span></div><div class="casAuthors">Butler, Declan; Callaway, Ewen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">263-264</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Knowledge about the drug's structure would help researchers understand what happened.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxsp23F3gJiLVg90H21EOLACvtfcHk0lhfcorytuVSkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oju7s%253D&md5=0fd9e8d7117ea49fc8593bdedc7cb95d</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fnature.2016.19189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature.2016.19189%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DD.%26aulast%3DCallaway%26aufirst%3DE.%26atitle%3DScientists%2520in%2520the%2520dark%2520after%2520fatal%2520french%2520clinical%2520trial%26jtitle%3DNature%26date%3D2016%26volume%3D529%26spage%3D263%26epage%3D264%26doi%3D10.1038%2Fnature.2016.19189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beliaev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loureiro, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, long-acting, and CNS-active inhibitor (BIA 10-2474) of fatty acid amide hydrolase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fcmdc.201800393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30113139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Ort73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2177-2188&author=L.+E.+Kissauthor=A.+Beliaevauthor=H.+S.+Ferreiraauthor=C.+P.+Rosaauthor=M.+J.+Bonifacioauthor=A.+I.+Loureiroauthor=N.+M.+Piresauthor=P.+N.+Palmaauthor=P.+Soares-da-Silva&title=Discovery+of+a+potent%2C+long-acting%2C+and+CNS-active+inhibitor+%28BIA+10-2474%29+of+fatty+acid+amide+hydrolase&doi=10.1002%2Fcmdc.201800393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase</span></div><div class="casAuthors">Kiss, Laszlo E.; Beliaev, Alexandre; Ferreira, Humberto S.; Rosa, Carla P.; Bonifacio, Maria Joao; Loureiro, Ana I.; Pires, Nuno M.; Palma, P. Nuno; Soares-da-Silva, Patricio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2177-2188</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) can be targeted for the treatment of pain assocd. with various medical conditions.  Herein we report the design and synthesis of a novel series of heterocyclic-N-carboxamide FAAH inhibitors that have a good alignment of potency, metabolic stability and selectivity for FAAH over monoacylglycerol lipase (MAGL) and carboxylesterases (CEs).  Lead optimization efforts carried out with benzotriazolyl- and imidazolyl-N-carboxamide series led to the discovery of clin. candidate 8 l (3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide; BIA 10-2474) as a potent and long-acting inhibitor of FAAH.  However, during a Phase I clin. trial with compd. 8l, unexpected and unpredictable serious neurol. adverse events occurred, affecting five healthy volunteers, including the death of one subject.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy1XH_cx1SxLVg90H21EOLACvtfcHk0lgiWomJu4_bng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Ort73J&md5=5cf530290c058e85e6fc7ced59770b9e</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800393%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DL.%2BE.%26aulast%3DBeliaev%26aufirst%3DA.%26aulast%3DFerreira%26aufirst%3DH.%2BS.%26aulast%3DRosa%26aufirst%3DC.%2BP.%26aulast%3DBonifacio%26aufirst%3DM.%2BJ.%26aulast%3DLoureiro%26aufirst%3DA.%2BI.%26aulast%3DPires%26aufirst%3DN.%2BM.%26aulast%3DPalma%26aufirst%3DP.%2BN.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520long-acting%252C%2520and%2520CNS-active%2520inhibitor%2520%2528BIA%252010-2474%2529%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D2177%26epage%3D2188%26doi%3D10.1002%2Fcmdc.201800393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaikin, P.</span></span> <span> </span><span class="NLM_article-title">The Bial 10-2474 Phase 1 Study-a drug development perspective and recommendations for future first-in-human trials</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1002/jcph.889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjcph.889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28387940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=690-703&author=P.+Chaikin&title=The+Bial+10-2474+Phase+1+Study-a+drug+development+perspective+and+recommendations+for+future+first-in-human+trials&doi=10.1002%2Fjcph.889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The Bial 10-2474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials</span></div><div class="casAuthors">Chaikin, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">690-703</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BIA 10-2474 (a fatty acid amide hydrolase inhibitor) was evaluated in a first-in-human phase 1 study in normal volunteers to assess safety/tolerability, pharmacokinetics, pharmacodynamics, and food effect.  The dose-escalation process consisted of a single-ascending-dose phase (SAD) and multiple-ascending-dose phase (MAD).  Prospective detn. of the starting dose and maximal escalated dose was consistent with the usual clin. pharmacol. principles for extrapolation of preclin. toxicol. data to human equiv. doses.  After only 5-6 days of multiple-dose administration of 50 mg daily in the MAD phase, several subjects became quite ill with central nervous system symptoms.  One subject progressed to brain death within several days of symptom onset.  Magnetic resonance imaging scans demonstrated signal abnormalities consistent with microbleeds affecting the hippocampus and pons, suggestive of possible cytotoxic or vasogenic edema compatible with a toxic/metabolic process.  There were no findings at lower MAD doses or during the SAD phase.  The toxicol. program carried out in 4 preclin. species (mouse, rat, dog, and monkey) did not demonstrate significant neurotoxicity.  The probable mechanism of neurol. toxicity demonstrated in humans at the 50-mg daily dose was inhibition of off-target cerebral receptors or through another mechanism.  Addnl. recommendations have been proposed for future first-in-human studies to maximize subject safety.  However, one must also accept the basic premise that, in general, first-in-human phase 1 studies are remarkably safe, and these rare events are not 100% avoidable during the drug development process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpTSyCaZuUtrVg90H21EOLACvtfcHk0lgiWomJu4_bng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7k%253D&md5=bdfe25f40f07efff9c9545fb9387282e</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2Fjcph.889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.889%26sid%3Dliteratum%253Aachs%26aulast%3DChaikin%26aufirst%3DP.%26atitle%3DThe%2520Bial%252010-2474%2520Phase%25201%2520Study-a%2520drug%2520development%2520perspective%2520and%2520recommendations%2520for%2520future%2520first-in-human%2520trials%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D57%26spage%3D690%26epage%3D703%26doi%3D10.1002%2Fjcph.889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A.</span></span> <span> </span><span class="NLM_article-title">Enzymology: Tracking off-targets</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">817</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnchembio.2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28853735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyisbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=817&author=A.+Farrell&title=Enzymology%3A+Tracking+off-targets&doi=10.1038%2Fnchembio.2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymology Tracking off-targets</span></div><div class="casAuthors">Farrell, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">817</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMdaf2xoivrVg90H21EOLACvtfcHk0lgiWomJu4_bng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyisbrO&md5=e00dea87da5f91cbea497d80372cd917</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2445%26sid%3Dliteratum%253Aachs%26aulast%3DFarrell%26aufirst%3DA.%26atitle%3DEnzymology%253A%2520Tracking%2520off-targets%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D817%26doi%3D10.1038%2Fnchembio.2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seneviratne, U. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cognetta, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">am
Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Global portrait of protein targets of metabolites of the neurotoxic compound BIA 10–2474</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b01097</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b01097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2it7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=192-197&author=Z.+Huangauthor=D.+Ogasawaraauthor=U.+I.+Seneviratneauthor=A.+B.+Cognettaauthor=C.+W.+am%0AEndeauthor=D.+M.+Nasonauthor=K.+Laphamauthor=J.+Litchfieldauthor=D.+S.+Johnsonauthor=B.+F.+Cravatt&title=Global+portrait+of+protein+targets+of+metabolites+of+the+neurotoxic+compound+BIA+10%E2%80%932474&doi=10.1021%2Facschembio.8b01097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Global Portrait of Protein Targets of Metabolites of the Neurotoxic Compound BIA 10-2474</span></div><div class="casAuthors">Huang, Zhen; Ogasawara, Daisuke; Seneviratne, Uthpala I.; Cognetta, Armand B., III; am Ende, Christopher W.; Nason, Deane M.; Lapham, Kimberly; Litchfield, John; Johnson, Douglas S.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">192-197</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin. investigation of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 resulted in serious adverse neurol. events.  Structurally unrelated FAAH inhibitors tested in humans have not presented safety concerns, suggesting that BIA 10-2474 has off-target activities.  A recent activity-based protein profiling (ABPP) study revealed that BIA 10-2474 and one of its major metabolites inhibit multiple members of the serine hydrolase class to which FAAH belongs.  Here, we extend these studies by performing a proteome-wide anal. of covalent targets of BIA 10-2474 metabolites.  Using alkynylated probes for click chem.-ABPP in human cells, we show that des-methylated metabolites of BIA 10-2474 covalently modify the conserved catalytic cysteine in aldehyde dehydrogenases, including ALDH2, which has been implicated in protecting the brain from oxidative stress-related damage.  These findings indicate that BIA 10-2474 and its metabolites have the potential to inhibit multiple mechanistically distinct enzyme classes involved in nervous system function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4x2mj4V6zUrVg90H21EOLACvtfcHk0lgiWomJu4_bng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2it7g%253D&md5=2760f9d1be5460939bf323135ae4b1a7</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b01097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b01097%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DSeneviratne%26aufirst%3DU.%2BI.%26aulast%3DCognetta%26aufirst%3DA.%2BB.%26aulast%3Dam%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DLitchfield%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DGlobal%2520portrait%2520of%2520protein%2520targets%2520of%2520metabolites%2520of%2520the%2520neurotoxic%2520compound%2520BIA%252010%25E2%2580%25932474%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D192%26epage%3D197%26doi%3D10.1021%2Facschembio.8b01097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadagopan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Becelaere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2009.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.chembiol.2009.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19389627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVCms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=411-420&author=K.+Ahnauthor=D.+S.+Johnsonauthor=M.+Mileniauthor=D.+Beidlerauthor=J.+Z.+Longauthor=M.+K.+McKinneyauthor=E.+Weerapanaauthor=N.+Sadagopanauthor=M.+Liimattaauthor=S.+E.+Smithauthor=S.+Lazerwithauthor=C.+Stiffauthor=S.+Kamtekarauthor=K.+Bhattacharyaauthor=Y.+Zhangauthor=S.+Swaneyauthor=K.+Van+Becelaereauthor=R.+C.+Stevensauthor=B.+F.+Cravatt&title=Discovery+and+characterization+of+a+highly+selective+FAAH+inhibitor+that+reduces+inflammatory+pain&doi=10.1016%2Fj.chembiol.2009.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain</span></div><div class="casAuthors">Ahn, Kay; Johnson, Douglas S.; Mileni, Mauro; Beidler, David; Long, Jonathan Z.; McKinney, Michele K.; Weerapana, Eranthie; Sadagopan, Nalini; Liimatta, Marya; Smith, Sarah E.; Lazerwith, Scott; Stiff, Cory; Kamtekar, Satwik; Bhattacharya, Keshab; Zhang, Yanhua; Swaney, Stephen; Van Becelaere, Keri; Stevens, Raymond C.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-420</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Endocannabinoids are lipid signaling mols. that regulate a wide range of mammalian behaviors, including pain, inflammation, and cognitive/emotional state.  The endocannabinoid anandamide is principally degraded by the integral membrane enzyme fatty acid amide hydrolase (FAAH), and there is currently much interest in developing FAAH inhibitors to augment endocannabinoid signaling in vivo.  Here, we report the discovery and detailed characterization of a highly efficacious and selective FAAH inhibitor, PF-3845.  Mechanistic and structural studies confirm that PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile.  PF-3845 selectively inhibits FAAH in vivo, as detd. by activity-based protein profiling; raises brain anandamide levels for up to 24 h; and produces significant cannabinoid receptor-dependent redns. in inflammatory pain.  These data thus designate PF-3845 as a valuable pharmacol. tool for in vivo characterization of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWANdntofbhbVg90H21EOLACvtfcHk0ljE4oNzNoIBvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVCms7w%253D&md5=c418dbdf626109415af7001db5a7cb93</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2009.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2009.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DMileni%26aufirst%3DM.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DMcKinney%26aufirst%3DM.%2BK.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DSadagopan%26aufirst%3DN.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DLazerwith%26aufirst%3DS.%26aulast%3DStiff%26aufirst%3DC.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DBhattacharya%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSwaney%26aufirst%3DS.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520highly%2520selective%2520FAAH%2520inhibitor%2520that%2520reduces%2520inflammatory%2520pain%26jtitle%3DChem.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D411%26epage%3D420%26doi%3D10.1016%2Fj.chembiol.2009.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarzia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duranti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasse, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaghan, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putman, D.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2006.00021.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1527-3458.2006.00021.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16834756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28Xos1yksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=21-38&author=D.+Piomelliauthor=G.+Tarziaauthor=A.+Durantiauthor=A.+Tontiniauthor=M.+Morauthor=T.+R.+Comptonauthor=O.+Dasseauthor=E.+P.+Monaghanauthor=J.+A.+Parrottauthor=D.+Putman&title=Pharmacological+profile+of+the+selective+FAAH+inhibitor+KDS-4103+%28URB597%29&doi=10.1111%2Fj.1527-3458.2006.00021.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)</span></div><div class="casAuthors">Piomelli, Daniele; Tarzia, Giorgio; Duranti, Andrea; Tontini, Andrea; Mor, Marco; Compton, Timothy R.; Dasse, Olivier; Monaghan, Edward P.; Parrott, Jeff A.; Putman, David</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-38</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  In the present article, we review the pharmacol. properties of KDS-4103 (URB597), a highly potent and selective inhibitor of the enzyme fatty-acid amide hydrolase (FAAH), which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide.  In vitro, KDS-4103 inhibits FAAH activity with median inhibitory concns. (IC50) of 5 nM in rat brain membranes and 3 nM in human liver microsomes.  In vivo, KDS-4103 inhibits rat brain FAAH activity after i.p. administration with a median ID (ID50) of 0.15 mg/kg.  The compd. does not significantly interact with other cannabinoid-related targets, including cannabinoid receptors and anandamide transport, or with a broad panel of receptors, ion channels, transporters and enzymes.  By i.p. administration to rats and mice KDS-4103 elicits significant, anxiolytic-like, anti-depressant-like and analgesic effects, which are prevented by treatment with CB1 receptor antagonists.  By contrast, at doses that significantly inhibit FAAH activity and substantially raise brain anandamide levels, KDS-4103 does not evoke classical cannabinoid-like effects (e.g., catalepsy, hypothermia, hyperphagia), does not cause place preference, and does not produce generalization to the discriminative effects of the active ingredient of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC).  These findings suggest that KDS-4103 acts by enhancing the tonic actions of anandamide on a subset of CB1 receptors, which may normally be engaged in controlling emotions and pain.  KDS-4103 is orally available in rats and cynomolgus monkeys.  Sub-chronic repeated dose studies (1500 mg/kg, per os) in these two species have not demonstrated systemic toxicity.  Likewise, no toxicity was noted in bacterial cytotoxicity tests in vitro and in the Ames test.  Furthermore, no deficits were obsd. in rats on the rotarod test after acute i.p. treatment with KDS-4103 at doses up to 5 mg/kg or in a functional observation battery after oral doses up to 1500 mg/kg.  The results suggest that KDS-4103 will offer a novel approach with a favorable therapeutic window for the treatment of anxiety, depression and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yDW3FkE5dbVg90H21EOLACvtfcHk0ljE4oNzNoIBvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xos1yksL0%253D&md5=3acddbfe31c13facb4d46fa35e8e4582</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2006.00021.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2006.00021.x%26sid%3Dliteratum%253Aachs%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DCompton%26aufirst%3DT.%2BR.%26aulast%3DDasse%26aufirst%3DO.%26aulast%3DMonaghan%26aufirst%3DE.%2BP.%26aulast%3DParrott%26aufirst%3DJ.%2BA.%26aulast%3DPutman%26aufirst%3DD.%26atitle%3DPharmacological%2520profile%2520of%2520the%2520selective%2520FAAH%2520inhibitor%2520KDS-4103%2520%2528URB597%2529%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2006%26volume%3D12%26spage%3D21%26epage%3D38%26doi%3D10.1111%2Fj.1527-3458.2006.00021.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">13019</span>– <span class="NLM_lpage">13030</span>, <span class="refDoi"> DOI: 10.1021/bi701378g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi701378g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyiurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=13019-13030&author=K.+Ahnauthor=D.+S.+Johnsonauthor=L.+R.+Fitzgeraldauthor=M.+Liimattaauthor=A.+Arendseauthor=T.+Stevensonauthor=E.+T.+Lundauthor=R.+A.+Nugentauthor=T.+K.+Nomanbhoyauthor=J.+P.+Alexanderauthor=B.+F.+Cravatt&title=Novel+mechanistic+class+of+fatty+acid+amide+hydrolase+inhibitors+with+remarkable+selectivity&doi=10.1021%2Fbi701378g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity</span></div><div class="casAuthors">Ahn, Kyunghye; Johnson, Douglas S.; Fitzgerald, Laura R.; Liimatta, Marya; Arendse, Andrea; Stevenson, Tracy; Lund, Eric. T.; Nugent, Richard A.; Nomanbhoy, Tyzoon K.; Alexander, Jessica P.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">13019-13030</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide.  Genetic or pharmacol. inactivation of FAAH leads to analgesic, anti-inflammatory, anxiolytic, and antidepressant phenotypes in rodents without showing the undesirable side effects obsd. with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for treatment of pain, inflammation, and other central nervous system disorders.  However, the FAAH inhibitors reported to date lack drug-like pharmacokinetic properties and/or selectivity.  Herein the authors describe piperidine/piperazine ureas represented by N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide (PF-750) and N-phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide (PF-622) as a novel mechanistic class of FAAH inhibitors.  PF-750 and PF-622 show higher in vitro potencies than previously established classes of FAAH inhibitors.  Rather unexpectedly based on the high chem. stability of the urea functional group, PF-750 and PF-622 were found to inhibit FAAH in a time-dependent manner by covalently modifying the enzyme's active site serine nucleophile.  Activity-based proteomic profiling revealed that PF-750 and PF-622 were completely selective for FAAH relative to other mammalian serine hydrolases.  The authors hypothesize that this remarkable specificity derives, at least in part, from FAAH's special ability to function as a C(O)-N bond hydrolase, which distinguishes it from the vast majority of metabolic serine hydrolases in mammals that are restricted to hydrolyzing esters and/or thioesters.  The piperidine/piperazine urea may thus represent a privileged chem. scaffold for the synthesis of FAAH inhibitors that display an unprecedented combination of potency and selectivity for use as potential analgesic and anxiolytic/antidepressant agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NGZiH1DJ-rVg90H21EOLACvtfcHk0lgcdI2CllCL3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyiurjM&md5=eb6f7945ff233b6fc0fea6b8677ecc87</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fbi701378g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi701378g%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DFitzgerald%26aufirst%3DL.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DArendse%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DT.%26aulast%3DLund%26aufirst%3DE.%2BT.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DAlexander%26aufirst%3DJ.%2BP.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DNovel%2520mechanistic%2520class%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%2520with%2520remarkable%2520selectivity%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D13019%26epage%3D13030%26doi%3D10.1021%2Fbi701378g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kathuria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duranti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarzia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calignano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giustino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tattoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Modulation of anxiety through blockade of anandamide hydrolysis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1038/nm803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnm803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12461523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivF2l" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=76-81&author=S.+Kathuriaauthor=S.+Gaetaniauthor=D.+Fegleyauthor=F.+Valinoauthor=A.+Durantiauthor=A.+Tontiniauthor=M.+Morauthor=G.+Tarziaauthor=G.+La+Ranaauthor=A.+Calignanoauthor=A.+Giustinoauthor=M.+Tattoliauthor=M.+Palmeryauthor=V.+Cuomoauthor=D.+Piomelli&title=Modulation+of+anxiety+through+blockade+of+anandamide+hydrolysis&doi=10.1038%2Fnm803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of anxiety through blockade of anandamide hydrolysis</span></div><div class="casAuthors">Kathuria, Satish; Gaetani, Silvana; Fegley, Darren; Valino, Fernando; Duranti, Andrea; Tontini, Andrea; Mor, Marco; Tarzia, Giorgio; La Rana, Giovanna; Calignano, Antonio; Giustino, Arcangela; Tattoli, Maria; Palmery, Maura; Cuomo, Vincenzo; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-81</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion.  But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists.  An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation.  Here, the authors describe a class of potent, selective, and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degrdn. of the endogenous cannabinoid anandamide.  Like clin. used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations.  These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade.  Apparently, anandamide participates in the modulation of emotional states and fatty acid amide hydrolase inhibition is an innovative approach to anti-anxiety therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbjKypjqxPcrVg90H21EOLACvtfcHk0lgcdI2CllCL3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivF2l&md5=350c8a5af97b6ea4e41e9f0c821231e4</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fnm803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm803%26sid%3Dliteratum%253Aachs%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DGaetani%26aufirst%3DS.%26aulast%3DFegley%26aufirst%3DD.%26aulast%3DValino%26aufirst%3DF.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DLa%2BRana%26aufirst%3DG.%26aulast%3DCalignano%26aufirst%3DA.%26aulast%3DGiustino%26aufirst%3DA.%26aulast%3DTattoli%26aufirst%3DM.%26aulast%3DPalmery%26aufirst%3DM.%26aulast%3DCuomo%26aufirst%3DV.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DModulation%2520of%2520anxiety%2520through%2520blockade%2520of%2520anandamide%2520hydrolysis%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D76%26epage%3D81%26doi%3D10.1038%2Fnm803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyffels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapanda, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span> <span> </span><span class="NLM_article-title">PET imaging of fatty acid amide hydrolase in the brain: synthesis and biological evaluation of an 11C-labelled URB597 analogue</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2010.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2010.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20610171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVyjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=665-675&author=L.+Wyffelsauthor=G.+G.+Muccioliauthor=C.+N.+Kapandaauthor=G.+Labarauthor=S.+De+Bruyneauthor=F.+De+Vosauthor=D.+M.+Lambert&title=PET+imaging+of+fatty+acid+amide+hydrolase+in+the+brain%3A+synthesis+and+biological+evaluation+of+an+11C-labelled+URB597+analogue&doi=10.1016%2Fj.nucmedbio.2010.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging of fatty acid amide hydrolase in the brain: synthesis and biological evaluation of an 11C-labelled URB597 analogue</span></div><div class="casAuthors">Wyffels, Leonie; Muccioli, Giulio G.; Kapanda, Coco N.; Labar, Geoffray; De Bruyne, Sylvie; De Vos, Filip; Lambert, Didier M.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">665-675</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Fatty acid amide hydrolase (FAAH) is part of the endocannabinoid system (ECS) and has been linked to the etiol. of several neurol. and neuropsychiatric disorders.  So far no useful PET or SPECT tracer for in vivo visualisation of FAAH has been reported.  We synthesized and evaluated a carbon-11-labeled URB597 analog, biphenyl-3-yl [11C]-4-methoxyphenylcarbamate or [11C]-1, as potential FAAH imaging agent.  Methods: The inhibitory activity of 1 was detd. in vitro using recombinant FAAH.  Radiosynthesis of [11C]-1 was performed by methylation using [11C]-CH3I, followed by HPLC purifn.  Biol. evaluation was done by biodistribution studies in wild-type and FAAH knock-out mice, and by ex vivo and in vivo metabolite anal.  The influence of URB597 pretreatment on the metabolisation profile was assessed.  Results: [11C]-1 was obtained in good yields and high radiochem. purity.  Biodistribution studies revealed high brain uptake in wild-type and FAAH knock-out mice, but no retention of radioactivity could be demonstrated.  Metabolite anal. and URB597 pretreatment confirmed the non-FAAH-mediated metabolisation of [11C]-1.  The inhibition mechanism was detd. to be reversible.  In addn., the inhibition of URB597 appeared slowly reversible.  Conclusions: Although [11C]-1 inhibits FAAH in vitro and displays high brain uptake, the inhibition mechanism seems to deviate from the proposed carbamylation mechanism.  Consequently, it does not covalently bind to FAAH and will not be useful for mapping the enzyme in vivo.  However, it represents a potential starting point for the development of in vivo FAAH imaging tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDMBRSTBX257Vg90H21EOLACvtfcHk0lgcdI2CllCL3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVyjsr0%253D&md5=c6d32ca4c9175799140aae2382759fbe</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2010.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2010.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DWyffels%26aufirst%3DL.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DKapanda%26aufirst%3DC.%2BN.%26aulast%3DLabar%26aufirst%3DG.%26aulast%3DDe%2BBruyne%26aufirst%3DS.%26aulast%3DDe%2BVos%26aufirst%3DF.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26atitle%3DPET%2520imaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520the%2520brain%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520an%252011C-labelled%2520URB597%2520analogue%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2010%26volume%3D37%26spage%3D665%26epage%3D675%26doi%3D10.1016%2Fj.nucmedbio.2010.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clapper, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duranti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarzia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1513</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fcmdc.200900210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19637155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKgtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1505-1513&author=J.+R.+Clapperauthor=F.+Vacondioauthor=A.+R.+Kingauthor=A.+Durantiauthor=A.+Tontiniauthor=C.+Silvaauthor=S.+Sanchiniauthor=G.+Tarziaauthor=M.+Morauthor=D.+Piomelli&title=A+second+generation+of+carbamate-based+fatty+acid+amide+hydrolase+inhibitors+with+improved+activity+in+vivo&doi=10.1002%2Fcmdc.200900210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">A Second Generation of Carbamate-Based Fatty Acid Amide Hydrolase Inhibitors with Improved Activity in vivo</span></div><div class="casAuthors">Clapper, Jason R.; Vacondio, Federica; King, Alvin R.; Duranti, Andrea; Tontini, Andrea; Silva, Claudia; Sanchini, Silvano; Tarzia, Giorgio; Mor, Marco; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1505-1513</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The fatty acid ethanolamides are a class of signaling lipids that include agonists at cannabinoid and α type peroxisome proliferator-activated receptors (PPARα).  In the brain, these compds. are primarily hydrolyzed by the intracellular serine enzyme fatty acid amide hydrolase (FAAH).  O-aryl carbamate FAAH inhibitors such as URB597 are being evaluated clin. for the treatment of pain and anxiety, but interactions with carboxylesterases in liver might limit their usefulness.  Here we explore two strategies aimed at overcoming this limitation.  Lipophilic N-terminal substitutions, which enhance FAAH recognition, yield potent inhibitors but render such compds. susceptible to attack by broad-spectrum hydrolases and inactive in vivo.  By contrast, polar electron-donating O-aryl substituents, which decrease carbamate reactivity, yield compds., such as URB694, that are highly potent FAAH inhibitors in vivo and less reactive with off-target carboxylesterases.  The results suggest that an approach balancing inhibitor reactivity with target recognition produces FAAH inhibitors that display significantly improved drug-likeness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLif0z6dIbyLVg90H21EOLACvtfcHk0ljDNDXmmu295g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKgtLnE&md5=fc73dbc173384549dfa0f319abb76479</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900210%26sid%3Dliteratum%253Aachs%26aulast%3DClapper%26aufirst%3DJ.%2BR.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DKing%26aufirst%3DA.%2BR.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DSanchini%26aufirst%3DS.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DA%2520second%2520generation%2520of%2520carbamate-based%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%2520with%2520improved%2520activity%2520in%2520vivo%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1505%26epage%3D1513%26doi%3D10.1002%2Fcmdc.200900210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">[<sup>11</sup>C]-URB694 for FAAH PET imaging: A novel radiotracer for a new target</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">S24</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2010.04.208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2010.04.208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=S24&author=A.+A.+Wilsonauthor=A.+Garciaauthor=S.+Houleauthor=N.+Vasdev&title=%5B11C%5D-URB694+for+FAAH+PET+imaging%3A+A+novel+radiotracer+for+a+new+target&doi=10.1016%2Fj.neuroimage.2010.04.208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2010.04.208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2010.04.208%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3D%255B11C%255D-URB694%2520for%2520FAAH%2520PET%2520imaging%253A%2520A%2520novel%2520radiotracer%2520for%2520a%2520new%2520target%26jtitle%3DNeuroImage%26date%3D2010%26volume%3D52%26spage%3DS24%26doi%3D10.1016%2Fj.neuroimage.2010.04.208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">[<sup>11</sup>C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2010.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2010.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21315280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFGqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=247-253&author=A.+A.+Wilsonauthor=A.+Garciaauthor=J.+Parkesauthor=S.+Houleauthor=J.+Tongauthor=N.+Vasdev&title=%5B11C%5DCURB%3A+Evaluation+of+a+novel+radiotracer+for+imaging+fatty+acid+amide+hydrolase+by+positron+emission+tomography&doi=10.1016%2Fj.nucmedbio.2010.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">[11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography</span></div><div class="casAuthors">Wilson, Alan A.; Garcia, Armando; Parkes, Jun; Houle, Sylvain; Tong, Junchao; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">247-253</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Fatty acid amide hydrolase (FAAH) is the enzyme responsible for metabolizing the endogenous cannabinoid, anandamide, and thus represents an important target for mol. imaging.  To date, no radiotracer has been shown to be useful for imaging of FAAH using either positron emission tomog. (PET) or single photon emission computed tomog. (SPECT).  We here det. the suitability of a novel carbon-11-labeled inhibitor of FAAH via ex vivo biodistribution studies in rat brain in conjunction with pharmacol. challenges.  Methods: A potent irreversible inhibitor of FAAH, URB694, radiolabeled with carbon-11 in the carbonyl position ([11C]CURB), was administered to male rats via tail-vein injection.  Rats were sacrificed at various time points postinjection, and tissue samples were dissected, counted and weighed.  Specific binding to FAAH was investigated by pretreatment of animals with URB694 or URB597.  For metab. and mechanism of binding studies, whole brains were excised post-radiotracer injection, homogenized and extd. exhaustively with 80% aq. acetonitrile to det. the time course and fraction of radioactivity that was irreversibly bound to brain parenchyma.  Results: Upon i.v. injection into rats, [11C]CURB showed high brain uptake [std. uptake value (SUV) of 1.6-2.4 at 5 min] with little washout over time, which is characteristic of irreversible binding.  Highest uptake of radioactivity was seen in the cortex, intermediate in the cerebellum and lowest in the hypothalamus, reflecting the reported distribution of FAAH.  Brain uptake of radioactivity was decreased in a dose-dependent manner by pretreatment with increasing amts. of URB694, demonstrating that binding was saturable.  Pretreatment with the well-characterized FAAH inhibitor, URB597, reduced binding in all brain regions by 70-80%.  Homogenised brain extn. expts. demonstrated unequivocally that [11C]CURB was irreversibly bound to FAAH.  Conclusions: The title radiotracer demonstrates favorable properties such as good brain uptake, regional heterogeneity and specificity of binding based on ex vivo biodistribution studies in conscious rat brain.  [11C]CURB represents a highly promising radiotracer for the imaging of FAAH using PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0P7jO28_d8rVg90H21EOLACvtfcHk0ljDNDXmmu295g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFGqtbc%253D&md5=b48b9f107ddd4580b3629b7fb3d8bab0</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2010.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2010.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3D%255B11C%255DCURB%253A%2520Evaluation%2520of%2520a%2520novel%2520radiotracer%2520for%2520imaging%2520fatty%2520acid%2520amide%2520hydrolase%2520by%2520positron%2520emission%2520tomography%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2011%26volume%3D38%26spage%3D247%26epage%3D253%26doi%3D10.1016%2Fj.nucmedbio.2010.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobaugh, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span> <span> </span><span class="NLM_article-title">Mapping human brain fatty acid amide hydrolase activity with PET</span>. <i>J. Cereb. Blood Flow Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1038/jcbfm.2012.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fjcbfm.2012.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23211960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVKkur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=407-414&author=P.+M.+Rusjanauthor=A.+A.+Wilsonauthor=R.+Mizrahiauthor=I.+Boileauauthor=S.+E.+Chavezauthor=N.+J.+Lobaughauthor=S.+J.+Kishauthor=S.+Houleauthor=J.+Tong&title=Mapping+human+brain+fatty+acid+amide+hydrolase+activity+with+PET&doi=10.1038%2Fjcbfm.2012.180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping human brain fatty acid amide hydrolase activity with PET</span></div><div class="casAuthors">Rusjan, Pablo M.; Wilson, Alan A.; Mizrahi, Romina; Boileau, Isabelle; Chavez, Sofia E.; Lobaugh, Nancy J.; Kish, Stephen J.; Houle, Sylvain; Tong, Junchao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Endocannabinoid tone has recently been implicated in a no. of prevalent neuropsychiatric conditions. [11C]CURB is the first available positron emission tomog. (PET) radiotracer for imaging fatty acid amide hydrolase (FAAH), the enzyme which metabolizes the prominent endocannabinoid anandamide.  Here, we sought to det. the most suitable kinetic modeling approach for quantifying [11C]CURB that binds selectively to FAAH.  Six healthy volunteers were scanned with arterial blood sampling for 90 min.  Kinetic parameters were estd. regionally using a one-tissue compartment model (TCM), a 2-TCM with and without irreversible trapping, and an irreversible 3-TCM.  The 2-TCM with irreversible trapping provided the best identifiability of PET outcome measures among the approaches studied (coeff. of variation (COV) of the net influx const. Ki and the composite parameter λk3 (λ=K1/k2) <5%, and COV(k3)<10%).  Reducing scan time to 60 min did not compromise the identifiability of rate consts.  Arterial spin labeling measures of regional cerebral blood flow were only slightly correlated with Ki, but not with k3 or λk3.  Our data suggest that λk3 is sensitive to changes in FAAH activity, therefore, optimal for PET quantification of FAAH activities with [11C]CURB.  Simulations showed that [11C]CURB binding in healthy subjects is far from a flow-limited uptake.  Journal of Cerebral Blood Flow & Metab. (2013) 33, 407-414; doi:10.1038/jcbfm.2012.180; published online 5 Dec. 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcOoWAfJlbbrVg90H21EOLACvtfcHk0ljDNDXmmu295g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVKkur8%253D&md5=7e7a12397411c12c9e14e2ce96c93214</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fjcbfm.2012.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjcbfm.2012.180%26sid%3Dliteratum%253Aachs%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DMizrahi%26aufirst%3DR.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DChavez%26aufirst%3DS.%2BE.%26aulast%3DLobaugh%26aufirst%3DN.%2BJ.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DJ.%26atitle%3DMapping%2520human%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%2520activity%2520with%2520PET%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2013%26volume%3D33%26spage%3D407%26epage%3D414%26doi%3D10.1038%2Fjcbfm.2012.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakizaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nengaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span> <span> </span><span class="NLM_article-title">First demonstration of in vivo mapping for regional brain monoacylglycerol lipase using PET with [<sup>11</sup>C]SAR127303</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2018.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2018.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29738910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1Knt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2018&pages=313-320&author=T.+Yamasakiauthor=W.+Moriauthor=Y.+Zhangauthor=A.+Hatoriauthor=M.+Fujinagaauthor=H.+Wakizakaauthor=Y.+Kuriharaauthor=L.+Wangauthor=N.+Nengakiauthor=T.+Ohyaauthor=S.+H.+Liangauthor=M.+R.+Zhang&title=First+demonstration+of+in+vivo+mapping+for+regional+brain+monoacylglycerol+lipase+using+PET+with+%5B11C%5DSAR127303&doi=10.1016%2Fj.neuroimage.2018.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">First demonstration of in vivo mapping for regional brain monoacylglycerol lipase using PET with [11C]SAR127303</span></div><div class="casAuthors">Yamasaki, Tomoteru; Mori, Wakana; Zhang, Yiding; Hatori, Akiko; Fujinaga, Masayuki; Wakizaka, Hidekatsu; Kurihara, Yusuke; Wang, Lu; Nengaki, Nobuki; Ohya, Tomoyuki; Liang, Steven H.; Zhang, Ming-Rong</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">313-320</span>CODEN:
                <span class="NLM_cas:coden">NEIMEF</span>;
        ISSN:<span class="NLM_cas:issn">1053-8119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a main regulator of the endocannabinoid system within the central nervous system (CNS).  Recently, [11C]SAR127303 was developed as a promising radioligand for MAGL imaging.  In this study, we aimed to quantify regional MAGL concns. in the rat brain using positron emission tomog. (PET) with [11C]SAR127303.  An irreversible two-tissue compartment model (2-TCMi, k4 = 0) anal. was conducted to est. quant. parameters (k3, K2-TCMii, and λk3).  These parameters were successfully obtained with high identifiability (<10 %COV) for the following regions ranked in order from highest to lowest: cingulate cortex > striatum > hippocampus > thalamus > cerebellum > hypothalamus ≈ pons.  In vitro autoradiographs using [11C]SAR127303 showed a heterogeneous distribution of radioactivity, as seen in the PET images.  The K2-TCMii and λk3 values correlated relatively highly with in vitro binding (r > 0.4, P < 0.005).  The K2-TCMii values showed high correlation and low underestimation (<10%) compared with the slope of a Patlak plot anal. with linear regression (KPatlaki).  In conclusion, we successfully estd. regional net uptake value of [11C]SAR127303 reflecting MAGL concns. in rat brain regions for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_WJ7neZ6JbVg90H21EOLACvtfcHk0li7WNvHGU-Xqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1Knt7o%253D&md5=6bb95add4389d8d2e607b6fc4373511f</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2018.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2018.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DWakizaka%26aufirst%3DH.%26aulast%3DKurihara%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNengaki%26aufirst%3DN.%26aulast%3DOhya%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26atitle%3DFirst%2520demonstration%2520of%2520in%2520vivo%2520mapping%2520for%2520regional%2520brain%2520monoacylglycerol%2520lipase%2520using%2520PET%2520with%2520%255B11C%255DSAR127303%26jtitle%3DNeuroImage%26date%3D2018%26volume%3D176%26spage%3D313%26epage%3D320%26doi%3D10.1016%2Fj.neuroimage.2018.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Silva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span> <span> </span><span class="NLM_article-title">Fatty acid amide hydrolase is lower in young cannabis users</span>. <i>Addict. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">e12872</span>, <span class="refDoi"> DOI: 10.1111/adb.12872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fadb.12872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31960544" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2021&pages=e12872&author=M.+R.+Jacobsonauthor=J.+J.+Wattsauthor=T.+Da+Silvaauthor=R.+F.+Tyndaleauthor=P.+M.+Rusjanauthor=S.+Houleauthor=A.+A.+Wilsonauthor=R.+A.+Rossauthor=I.+Boileauauthor=R.+Mizrahi&title=Fatty+acid+amide+hydrolase+is+lower+in+young+cannabis+users&doi=10.1111%2Fadb.12872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1111%2Fadb.12872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fadb.12872%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DM.%2BR.%26aulast%3DWatts%26aufirst%3DJ.%2BJ.%26aulast%3DDa%2BSilva%26aufirst%3DT.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DMizrahi%26aufirst%3DR.%26atitle%3DFatty%2520acid%2520amide%2520hydrolase%2520is%2520lower%2520in%2520young%2520cannabis%2520users%26jtitle%3DAddict.%2520Biol.%26date%3D2021%26volume%3D26%26spage%3De12872%26doi%3D10.1111%2Fadb.12872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payer, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span> <span> </span><span class="NLM_article-title">Fatty acid amide hydrolase binding in brain of cannabis users: imaging with the novel radiotracer [<sup>11</sup>C]CURB</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2016.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.biopsych.2016.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27345297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2gt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2016&pages=691-701&author=I.+Boileauauthor=E.+Mansouriauthor=B.+Williamsauthor=B.+Le+Follauthor=P.+Rusjanauthor=R.+Mizrahiauthor=R.+F.+Tyndaleauthor=M.+A.+Huestisauthor=D.+E.+Payerauthor=A.+A.+Wilsonauthor=S.+Houleauthor=S.+J.+Kishauthor=J.+Tong&title=Fatty+acid+amide+hydrolase+binding+in+brain+of+cannabis+users%3A+imaging+with+the+novel+radiotracer+%5B11C%5DCURB&doi=10.1016%2Fj.biopsych.2016.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB</span></div><div class="casAuthors">Boileau, Isabelle; Mansouri, Esmaeil; Williams, Belinda; Le Foll, Bernard; Rusjan, Pablo; Mizrahi, Romina; Tyndale, Rachel F.; Huestis, Marilyn A.; Payer, Doris E.; Wilson, Alan A.; Houle, Sylvain; Kish, Stephen J.; Tong, Junchao</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">691-701</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">One of the major mechanisms for terminating the actions of the endocannabinoid anandamide is hydrolysis by fatty acid amide hydrolase (FAAH), and inhibitors of the enzyme were suggested as potential treatment for human cannabis dependence.  However, the status of brain FAAH in cannabis use disorder is unknown.  Brain FAAH binding was measured with positron emission tomog. and [11C]CURB in 22 healthy control subjects and ten chronic cannabis users during early abstinence.  The FAAH genetic polymorphism (rs324420) and blood, urine, and hair levels of cannabinoids and metabolites were detd.  In cannabis users, FAAH binding was significantly lower by 14%-20% across the brain regions examd. than in matched control subjects (overall Cohen's d = 0.96).  Lower binding was neg. correlated with cannabinoid concns. in blood and urine and was assocd. with higher trait impulsiveness.  Lower FAAH binding levels in the brain may be a consequence of chronic and recent cannabis exposure and could contribute to cannabis withdrawal.  This effect should be considered in the development of novel treatment strategies for cannabis use disorder that target FAAH and endocannabinoids.  Further studies are needed to examine possible changes in FAAH binding during prolonged cannabis abstinence and whether lower FAAH binding predates drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph9pP9zUMIDrVg90H21EOLACvtfcHk0li7WNvHGU-Xqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2gt77N&md5=e7d5eb1531e5e5e43d1b157e33a8a0ea</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2016.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2016.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DMansouri%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DRusjan%26aufirst%3DP.%26aulast%3DMizrahi%26aufirst%3DR.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DHuestis%26aufirst%3DM.%2BA.%26aulast%3DPayer%26aufirst%3DD.%2BE.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DTong%26aufirst%3DJ.%26atitle%3DFatty%2520acid%2520amide%2520hydrolase%2520binding%2520in%2520brain%2520of%2520cannabis%2520users%253A%2520imaging%2520with%2520the%2520novel%2520radiotracer%2520%255B11C%255DCURB%26jtitle%3DBiol.%2520Psychiatry%26date%3D2016%26volume%3D80%26spage%3D691%26epage%3D701%26doi%3D10.1016%2Fj.biopsych.2016.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazinet, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagzdins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendershot, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span> <span> </span><span class="NLM_article-title">Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [<sup>11</sup>C] CURB</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1296</span>, <span class="refDoi"> DOI: 10.1038/s41386-020-0606-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41386-020-0606-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31910433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFOitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2020&pages=1289-1296&author=L.+M.+Bestauthor=B.+Williamsauthor=B.+Le+Follauthor=E.+Mansouriauthor=R.+P.+Bazinetauthor=L.+Linauthor=V.+De+Lucaauthor=D.+Lagzdinsauthor=P.+Rusjanauthor=R.+F.+Tyndaleauthor=A.+A.+Wilsonauthor=C.+S.+Hendershotauthor=M.+Heiligauthor=S.+Houleauthor=J.+Tongauthor=S.+J.+Kishauthor=I.+Boileau&title=Lower+brain+fatty+acid+amide+hydrolase+in+treatment-seeking+patients+with+alcohol+use+disorder%3A+a+positron+emission+tomography+study+with+%5B11C%5D+CURB&doi=10.1038%2Fs41386-020-0606-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB</span></div><div class="casAuthors">Best, Laura M.; Williams, Belinda; Le Foll, Bernard; Mansouri, Esmaeil; Bazinet, Richard P.; Lin, Lin; De Luca, Vincenzo; Lagzdins, Dina; Rusjan, Pablo; Tyndale, Rachel F.; Wilson, Alan A.; Hendershot, Christian S.; Heilig, Markus; Houle, Sylvain; Tong, Junchao; Kish, Stephen J.; Boileau, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1289-1296</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The endocannabinoid enzyme, fatty acid amide hydrolase (FAAH), has been proposed as a therapeutic target for alc. use disorder (AUD) and co-morbid psychiatric illnesses.  Investigating this target in the living human brain and its relationship to clin. outcome is a crit. step of informed drug development.  Our objective was to establish whether brain FAAH levels are low in individuals with AUD and related to drinking behavior.  In this pilot study, treatment-seeking patients with AUD completed two PET scans with the FAAH radiotracer [C-11]CURB after 3-7 days (n = 14) and 2-4 wk (n = 9) of monitored abstinence.  Healthy controls (n = 25) completed one scan.  FAAH genetic polymorphism (rs324420) and blood concns. of anandamide and other N-acylethanolamines metabolized by FAAH were detd. and AUD symptoms assessed.  In AUD, brain FAAH levels were globally lower than controls during early abstinence (F(1,36) = 5.447; p = 0.025) and FAAH substrates (anandamide, oleoylethanolamide, and N-docosahexaenoylethanolamide) were significantly elevated (30-67%).  No significant differences in FAAH or FAAH substrates were noted after 2-4 wk abstinence.  FAAH levels neg. correlated with drinks per wk (r = -0.57, p = 0.032) and plasma concns. of the three FAAH substrates (r > 0.57; p < 0.04).  Our findings suggest that early abstinence from alc. in AUD is assocd. with transiently low brain FAAH levels, which are inversely related to heavier alc. use and elevated plasma levels of FAAH substrates.  Whether low FAAH is an adaptive beneficial response to chronic alc. is unknown.  Therapeutic strategies focusing on FAAH inhibition should consider the possibility that low FAAH during early abstinence may be related to drinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5EKo2n_EFSbVg90H21EOLACvtfcHk0lhTX9T7HxhrVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFOitQ%253D%253D&md5=b0023050192aa9005471fd6d2f4a59de</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1038%2Fs41386-020-0606-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-020-0606-2%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DL.%2BM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DMansouri%26aufirst%3DE.%26aulast%3DBazinet%26aufirst%3DR.%2BP.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DDe%2BLuca%26aufirst%3DV.%26aulast%3DLagzdins%26aufirst%3DD.%26aulast%3DRusjan%26aufirst%3DP.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DHendershot%26aufirst%3DC.%2BS.%26aulast%3DHeilig%26aufirst%3DM.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DBoileau%26aufirst%3DI.%26atitle%3DLower%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520treatment-seeking%2520patients%2520with%2520alcohol%2520use%2520disorder%253A%2520a%2520positron%2520emission%2520tomography%2520study%2520with%2520%255B11C%255D%2520CURB%26jtitle%3DNeuropsychopharmacology%26date%3D2020%26volume%3D45%26spage%3D1289%26epage%3D1296%26doi%3D10.1038%2Fs41386-020-0606-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span> <span> </span><span class="NLM_article-title">Imaging brain fatty acid amide hydrolase in untreated patients with psychosis</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2020.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.biopsych.2020.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32387132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVegu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2020&pages=727-735&author=J.+J.+Wattsauthor=M.+R.+Jacobsonauthor=N.+Lalangauthor=I.+Boileauauthor=R.+F.+Tyndaleauthor=M.+Kiangauthor=R.+A.+Rossauthor=S.+Houleauthor=A.+A.+Wilsonauthor=P.+Rusjanauthor=R.+Mizrahi&title=Imaging+brain+fatty+acid+amide+hydrolase+in+untreated+patients+with+psychosis&doi=10.1016%2Fj.biopsych.2020.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis</span></div><div class="casAuthors">Watts, Jeremy J.; Jacobson, Maya R.; Lalang, Nittha; Boileau, Isabelle; Tyndale, Rachel F.; Kiang, Michael; Ross, Ruth A.; Houle, Sylvain; Wilson, Alan A.; Rusjan, Pablo; Mizrahi, Romina</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The brain's endocannabinoid system, the primary target of cannabis, has been implicated in psychosis.  The endocannabinoid anandamide is elevated in cerebrospinal fluid of patients with schizophrenia.  Fatty acid amide hydrolase (FAAH) controls brain anandamide levels; however, it is unknown if FAAH is altered in vivo in psychosis or related to pos. psychotic symptoms.  Twenty-seven patients with schizophrenia spectrum disorders and 36 healthy control subjects completed high-resoln. positron emission tomog. scans with the novel FAAH radioligand [11C]CURB and structural magnetic resonance imaging.  Data were analyzed using the validated irreversible 2-tissue compartment model with a metabolite-cor. arterial input function.  FAAH did not differ significantly between patients with psychotic disorders and healthy control subjects (F1,62.85 = 0.48, p = .49).  In contrast, lower FAAH predicted greater pos. psychotic symptom severity, with the strongest effect obsd. for the pos. symptom dimension, which includes suspiciousness, delusions, unusual thought content, and hallucinations (F1,26.69 = 12.42, p = .002; Cohen's f = 0.42, large effect).  Shorter duration of illness (F1,26.95 = 13.78, p = .001; Cohen's f = 0.39, medium to large effect) and duration of untreated psychosis predicted lower FAAH (F1,26.95 = 6.03, p = .021, Cohen's f = 0.27, medium effect).  These results were not explained by past cannabis exposure or current intake of antipsychotic medications.  FAAH exhibited marked differences across brain regions (F7,112.62 = 175.85, p < 1 x 10-56; Cohen's f > 1).  Overall, FAAH was higher in female subjects than in male subjects (F1,62.84 = 10.05, p = .002; Cohen's f = 0.37).  This first study of brain FAAH in psychosis indicates that FAAH may represent a biomarker of disease state of potential utility for clin. studies targeting psychotic symptoms or as a novel target for interventions to treat psychotic symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBQj1xFOipMbVg90H21EOLACvtfcHk0lhTX9T7HxhrVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVegu78%253D&md5=8826853f4031720264855e31be2f538a</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2020.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2020.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DWatts%26aufirst%3DJ.%2BJ.%26aulast%3DJacobson%26aufirst%3DM.%2BR.%26aulast%3DLalang%26aufirst%3DN.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DKiang%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DRusjan%26aufirst%3DP.%26aulast%3DMizrahi%26aufirst%3DR.%26atitle%3DImaging%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520untreated%2520patients%2520with%2520psychosis%26jtitle%3DBiol.%2520Psychiatry%26date%3D2020%26volume%3D88%26spage%3D727%26epage%3D735%26doi%3D10.1016%2Fj.biopsych.2020.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span> <span> </span><span class="NLM_article-title">Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [<sup>11</sup>C]CURB positron emission tomography study</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1834</span>– <span class="NLM_lpage">1841</span>, <span class="refDoi"> DOI: 10.1038/s41386-020-0731-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41386-020-0731-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32521537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Kgsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2020&pages=1834-1841&author=N.+J.+Kollaauthor=R.+Mizrahiauthor=K.+Karasauthor=C.+Wangauthor=R.+M.+Bagbyauthor=S.+McMainauthor=A.+I.+Simpsonauthor=P.+M.+Rusjanauthor=R.+Tyndaleauthor=S.+Houleauthor=I.+Boileau&title=Elevated+fatty+acid+amide+hydrolase+in+the+prefrontal+cortex+of+borderline+personality+disorder%3A+a+%5B11C%5DCURB+positron+emission+tomography+study&doi=10.1038%2Fs41386-020-0731-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study</span></div><div class="casAuthors">Kolla, N. J.; Mizrahi, R.; Karas, K.; Wang, C.; Bagby, R. M.; McMain, S.; Simpson, A. I.; Rusjan, P. M.; Tyndale, R.; Houle, S.; Boileau, I.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1834-1841</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Amygdala-prefrontal cortex (PFC) functional impairments have been linked to emotion dysregulation and aggression in borderline personality disorder (BPD).  Fatty acid amide hydrolase (FAAH), the major catabolic enzyme for the endocannabinoid anandamide, has been proposed as a key regulator of the amygdala-PFC circuit that subserves emotion regulation.  We tested the hypothesis that FAAH levels measured with [11C]CURB positron emission tomog. in amygdala and PFC would be elevated in BPD and would relate to hostility and aggression.  Twenty BPD patients and 20 healthy controls underwent FAAH genotyping (rs324420) and scanning with [11C]CURB.  BPD patients were medication-free and were not experiencing a current major depressive episode.  Regional differences in [11C]CURB binding were assessed using multivariate anal. of covariance with PFC and amygdala [11C]CURB binding as dependent variables, diagnosis as a fixed factor, and sex and genotype as covariates. [11C]CURB binding was marginally elevated across the PFC and amygdala in BPD (p = 0.08).  In a priori selected PFC, but not amygdala, [11C]CURB binding was significantly higher in BPD (11.0%, p = 0.035 vs. 10.6%, p = 0.29).  PFC and amygdala [11C]CURB binding was pos. correlated with measures of hostility in BPD (r > 0.4; p < 0.04).  This study is the first to provide preliminary evidence of elevated PFC FAAH binding in any psychiatric condition.  Findings are consistent with the model that lower endocannabinoid tone could perturb PFC circuitry that regulates emotion and aggression.  Replication of these findings could encourage testing of FAAH inhibitors as innovative treatments for BPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAO_EHMBKUwLVg90H21EOLACvtfcHk0lhTX9T7HxhrVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Kgsb3O&md5=27ce60a98633a51d985c17d796edc6cf</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1038%2Fs41386-020-0731-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-020-0731-y%26sid%3Dliteratum%253Aachs%26aulast%3DKolla%26aufirst%3DN.%2BJ.%26aulast%3DMizrahi%26aufirst%3DR.%26aulast%3DKaras%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DBagby%26aufirst%3DR.%2BM.%26aulast%3DMcMain%26aufirst%3DS.%26aulast%3DSimpson%26aufirst%3DA.%2BI.%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DTyndale%26aufirst%3DR.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DBoileau%26aufirst%3DI.%26atitle%3DElevated%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520the%2520prefrontal%2520cortex%2520of%2520borderline%2520personality%2520disorder%253A%2520a%2520%255B11C%255DCURB%2520positron%2520emission%2520tomography%2520study%26jtitle%3DNeuropsychopharmacology%26date%3D2020%26volume%3D45%26spage%3D1834%26epage%3D1841%26doi%3D10.1038%2Fs41386-020-0731-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and evaluation of [11C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1021/jm301492y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301492y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2mu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=201-209&author=A.+A.+Wilsonauthor=J.+W.+Hicksauthor=O.+Sadovskiauthor=J.+Parkesauthor=J.+Tongauthor=S.+Houleauthor=C.+J.+Fowlerauthor=N.+Vasdev&title=Radiosynthesis+and+evaluation+of+%5B11C-carbonyl%5D-labeled+carbamates+as+fatty+acid+amide+hydrolase+radiotracers+for+positron+emission+tomography&doi=10.1021%2Fjm301492y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and Evaluation of [11C-Carbonyl]-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography</span></div><div class="casAuthors">Wilson, Alan A.; Hicks, Justin W.; Sadovski, Oleg; Parkes, Jun; Tong, Junchao; Houle, Sylvain; Fowler, Christopher J.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-209</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) plays a key role in regulating the tone of the endocannabinoid system.  Radiotracers are required to image and quantify FAAH activity in vivo.  A series of potent FAAH inhibitors encompassing two classes of N-alkyl-O-arylcarbamates were synthesized and eight of them were radiolabeled with carbon-11.  The [11C-carbonyl]-radiotracers were evaluated in vitro and ex vivo in rats as potential FAAH imaging agents for positron emission tomog. (PET).  Both sets of [11C]O-arylcarbamates showed good to excellent brain penetration and an appropriate regional distribution.  Pre-treatments with a FAAH inhibitor demonstrated that 80-95% of brain uptake of radioactivity constituted binding of the radiotracers to FAAH.  Brain extn. measurements showed that binding to FAAH was irreversible and kinetically different for the two classes of carbamates.  These promising results are discussed in terms of the requirements of a suitable radiotracer for the in vivo imaging of FAAH using PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXOvMBW9txTbVg90H21EOLACvtfcHk0lioLehRBL1P_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2mu73M&md5=94d72f4c0c436168dc2192b2d2989cff</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Fjm301492y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301492y%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DHicks%26aufirst%3DJ.%2BW.%26aulast%3DSadovski%26aufirst%3DO.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DFowler%26aufirst%3DC.%2BJ.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DRadiosynthesis%2520and%2520evaluation%2520of%2520%255B11C-carbonyl%255D-labeled%2520carbamates%2520as%2520fatty%2520acid%2520amide%2520hydrolase%2520radiotracers%2520for%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D201%26epage%3D209%26doi%3D10.1021%2Fjm301492y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, A.</span>; <span class="NLM_string-name">Munagata, R.</span>; <span class="NLM_string-name">Kawano, N.</span>; <span class="NLM_string-name">Samizu, K.</span>; <span class="NLM_string-name">Oka, H.</span>; <span class="NLM_string-name">Ishii, T.</span></span> <span> </span><span class="NLM_article-title">Azole Compound</span>. U.S. Patent, <span class="NLM_patent">US8,207,199B2</span>, Jun 26, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Aoki&author=R.+Munagata&author=N.+Kawano&author=K.+Samizu&author=H.+Oka&author=T.+Ishii&title=Azole+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DA.%26atitle%3DAzole%2520Compound%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span> <span> </span><span class="NLM_article-title">Development of [<sup>11</sup>C]MFTC for PET imaging of fatty acid amide hydrolase in rat and monkey brains</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1021/cn500269g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500269g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=339-346&author=K.+Kumataauthor=J.+Yuiauthor=A.+Hatoriauthor=J.+Maedaauthor=L.+Xieauthor=M.+Ogawaauthor=T.+Yamasakiauthor=Y.+Nagaiauthor=Y.+Shimodaauthor=M.+Fujinagaauthor=K.+Kawamuraauthor=M.+R.+Zhang&title=Development+of+%5B11C%5DMFTC+for+PET+imaging+of+fatty+acid+amide+hydrolase+in+rat+and+monkey+brains&doi=10.1021%2Fcn500269g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Development of [11C]MFTC for PET Imaging of Fatty Acid Amide Hydrolase in Rat and Monkey Brains</span></div><div class="casAuthors">Kumata, Katsushi; Yui, Joji; Hatori, Akiko; Maeda, Jun; Xie, Lin; Ogawa, Masanao; Yamasaki, Tomoteru; Nagai, Yuji; Shimoda, Yoko; Fujinaga, Masayuki; Kawamura, Kazunori; Zhang, Ming-Rong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-346</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We developed 2-methylpyridin-3-yl-4-(5-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl)piperidine-1-[11C]carboxylate ([11C]MFTC) as a promising PET tracer for in vivo imaging of fatty acid amide hydrolase (FAAH) in rat and monkey brains. [11C]MFTC was synthesized by reacting 3-hydroxy-2-methylpyridine (2) with [11C]phosgene ([11C]COCl2), followed by reacting with 4-(5-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl)piperidine (3), with a 20 ± 4.6% radiochem. yield (decay-cor., n = 30) based on [11C]CO2 and 40 min synthesis time from the end of bombardment.  A biodistribution study in mice showed high uptake of radioactivity in FAAH-rich organs, including the lung, liver, and kidneys.  Positron emission tomog. (PET) summation images of rat brains showed high radioactivity in the frontal cortex, cerebellum, and hippocampus, which was consistent with the regional distribution pattern of FAAH in rodent brain.  Pretreatment with MFTC or FAAH-selective URB597 significantly reduced the uptake in the brain.  PET imaging of monkey brain showed relatively high uptake in the whole brain, particularly in the occipital cortex, which was also inhibited by treatment with MFTC or URB597.  More than 96% of the total radioactivity was irreversible in the brain homogenate of rats 5 min after the radiotracer injection.  The specific in vivo FAAH binding indicates that [11C]MFTC is a promising PET tracer for visualizing FAAH in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsICjWUI9PtbVg90H21EOLACvtfcHk0lioLehRBL1P_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsb7K&md5=59ea077964694b652c32790f82be982a</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Fcn500269g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500269g%26sid%3Dliteratum%253Aachs%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DYui%26aufirst%3DJ.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26atitle%3DDevelopment%2520of%2520%255B11C%255DMFTC%2520for%2520PET%2520imaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520rat%2520and%2520monkey%2520brains%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D339%26epage%3D346%26doi%3D10.1021%2Fcn500269g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobrega, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span> <span> </span><span class="NLM_article-title">Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4351</span>– <span class="NLM_lpage">4357</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.04.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmc.2013.04.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23712084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=4351-4357&author=O.+Sadovskiauthor=J.+W.+Hicksauthor=J.+Parkesauthor=R.+Raymondauthor=J.+Nobregaauthor=S.+Houleauthor=M.+Ciprianoauthor=C.+J.+Fowlerauthor=N.+Vasdevauthor=A.+A.+Wilson&title=Development+and+characterization+of+a+promising+fluorine-18+labelled+radiopharmaceutical+for+in+vivo+imaging+of+fatty+acid+amide+hydrolase&doi=10.1016%2Fj.bmc.2013.04.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase</span></div><div class="casAuthors">Sadovski, Oleg; Hicks, Justin W.; Parkes, Jun; Raymond, Roger; Nobrega, Jose; Houle, Sylvain; Cipriano, Mariateresa; Fowler, Christopher J.; Vasdev, Neil; Wilson, Alan A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4351-4357</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH), the enzyme responsible for terminating signaling by the endocannabinoid anandamide, plays an important role in the endocannabinoid system, and FAAH inhibitors are attractive drugs for pain, addiction, and neurol. disorders.  The synthesis, radiosynthesis, and evaluation, in vitro and ex vivo in rat, of an 18F-radiotracer designed to image FAAH using positron emission tomog. (PET) is described.  Fluorine-18 labeled 3-(4,5-dihydrooxazol-2-yl)phenyl (5-fluoropentyl)carbamate, [18F]5, was synthesized at high specific activity in a one-pot three step reaction using a com. module with a radiochem. yield of 17-22% (from [18F]fluoride).  In vitro assay using rat brain homogenates showed that 5 inhibited FAAH in a time-dependent manner, with an IC50 value of 0.82 nM after a preincubation of 60 min.  Ex vivo biodistribution studies and ex vivo autoradiog. in rat brain demonstrated that [18F]5 had high brain penetration with std. uptake values of up to 4.6 and had a regional distribution which correlated with reported regional FAAH enzyme activity.  Specificity of binding to FAAH with [18F]5 was high (>90%) as demonstrated by pharmacol. challenges with potent and selective FAAH inhibitors and was irreversible as demonstrated by radioactivity measurements on homogenized brain tissue exts  We infer from these results that [18F]5 is a highly promising candidate radiotracer with which to image FAAH in human subjects using PET and clin. studies are proceeding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Us6Ifw6o_7Vg90H21EOLACvtfcHk0lioLehRBL1P_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGmurk%253D&md5=367e67c5863b85854eeeebe2b02ee8d0</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.04.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.04.077%26sid%3Dliteratum%253Aachs%26aulast%3DSadovski%26aufirst%3DO.%26aulast%3DHicks%26aufirst%3DJ.%2BW.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DRaymond%26aufirst%3DR.%26aulast%3DNobrega%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DCipriano%26aufirst%3DM.%26aulast%3DFowler%26aufirst%3DC.%2BJ.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520a%2520promising%2520fluorine-18%2520labelled%2520radiopharmaceutical%2520for%2520in%2520vivo%2520imaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D4351%26epage%3D4357%26doi%3D10.1016%2Fj.bmc.2013.04.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoup, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">PET imaging of fatty acid amide hydrolase with [<sup>18</sup>F]DOPP in nonhuman primates</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3832</span>– <span class="NLM_lpage">3838</span>, <span class="refDoi"> DOI: 10.1021/mp500316h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500316h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=3832-3838&author=B.+H.+Rotsteinauthor=H.+Y.+Weyauthor=T.+M.+Shoupauthor=A.+A.+Wilsonauthor=S.+H.+Liangauthor=J.+M.+Hookerauthor=N.+Vasdev&title=PET+imaging+of+fatty+acid+amide+hydrolase+with+%5B18F%5DDOPP+in+nonhuman+primates&doi=10.1021%2Fmp500316h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">PET Imaging of Fatty Acid Amide Hydrolase with [18F]DOPP in Nonhuman Primates</span></div><div class="casAuthors">Rotstein, Benjamin H.; Wey, Hsiao-Ying; Shoup, Timothy M.; Wilson, Alan A.; Liang, Steven H.; Hooker, Jacob M.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3832-3838</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) regulates endocannabinoid signaling. [11C]CURB, an irreversibly binding FAAH inhibitor, has been developed for clin. research imaging with PET.  However, no fluorine-18 labeled radiotracer for FAAH has yet advanced to human studies. [18F]DOPP ([18F]3-(4,5-dihydrooxazol-2-yl)phenyl (5-fluoropentyl)carbamate) has been identified as a promising 18F-labeled analog based on rodent studies.  The goal of this work is to evaluate [18F]DOPP in nonhuman primates to support its clin. translation.  High specific activity [18F]DOPP (5-6 Ci·μmol-1) was administered i.v. (iv) to three baboons (2M/1F, 3-4 years old).  The distribution and pharmacokinetics were quantified following a 2 h dynamic imaging session using a simultaneous PET/MR scanner.  Pretreatment with the FAAH-selective inhibitor, URB597, was carried out at 200 or 300 μg/kg iv, 10 min prior to [18F]DOPP administration.  Rapid arterial blood sampling for the first 3 min was followed by interval sampling with metabolite anal. to provide a parent radiotracer plasma input function that indicated ∼95% baseline metab. at 60 min and a reduced rate of metab. after pretreatment with URB597.  Regional distribution data were analyzed with 1-, 2-, and 3-tissue compartment models (TCMs), with and without irreversible trapping since [18F]DOPP covalently links to the active site of FAAH.  Consistent with previous findings for [11C]CURB, the 2TCM with irreversible binding was found to provide the best fit for modeling the data in all regions.  The composite parameter λk3 was therefore used to evaluate whole brain (WB) and regional binding of [18F]DOPP.  Pretreatment studies showed inhibition of λk3 across all brain regions (WB baseline: 0.112 mL/cm3/min; 300 μg/kg URB597: 0.058 mL/cm3/min), suggesting that [18F]DOPP binding is specific for FAAH, consistent with previous rodent data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfComo4JWN7Vg90H21EOLACvtfcHk0litIGGFDofsRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtLvP&md5=026a7a53140bb381593d760d9cf67cc6</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fmp500316h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500316h%26sid%3Dliteratum%253Aachs%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DWey%26aufirst%3DH.%2BY.%26aulast%3DShoup%26aufirst%3DT.%2BM.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DPET%2520imaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520with%2520%255B18F%255DDOPP%2520in%2520nonhuman%2520primates%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D3832%26epage%3D3838%26doi%3D10.1021%2Fmp500316h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobrega, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of fatty acid amide hydrolase by BIA 10–2474 in rat brain</span>. <i>J. Cereb. Blood Flow Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3635</span>– <span class="NLM_lpage">3639</span>, <span class="refDoi"> DOI: 10.1177/0271678X16668890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1177%2F0271678X16668890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27650910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=3635-3639&author=J.+Tongauthor=R.+Mizrahiauthor=S.+Houleauthor=S.+J.+Kishauthor=I.+Boileauauthor=J.+Nobregaauthor=P.+M.+Rusjanauthor=A.+A.+Wilson&title=Inhibition+of+fatty+acid+amide+hydrolase+by+BIA+10%E2%80%932474+in+rat+brain&doi=10.1177%2F0271678X16668890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain</span></div><div class="casAuthors">Tong, Junchao; Mizrahi, Romina; Houle, Sylvain; Kish, Stephen J.; Boileau, Isabelle; Nobrega, Jose; Rusjan, Pablo M.; Wilson, Alan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3635-3639</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">In a recent clin. trial, the drug BIA 10-2474, a putative fatty acid amide hydrolase(FAAH) inhibitor, was responsible for severe adverse events (SAEs), including one death.  To date, there has been little reliable information divulged about the potency of BIA 10-2474 at FAAH in the central nervous system.  We synthesized BIA 10-2474 and detd. its ability to inhibit FAAH ex vivo in rat brain using a FAAH selective radiotracer.  BIA 10-2474 proved to be a potent FAAH inhibitor with IC50s of 50-70 μg/kg (i.p.) in various brain regions.  This information may be useful for detg. the cause of the SAEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX6sYwd9zuH7Vg90H21EOLACvtfcHk0litIGGFDofsRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKnu70%253D&md5=c0e494b3f946e6d22626462f9e6dd333</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1177%2F0271678X16668890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0271678X16668890%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DMizrahi%26aufirst%3DR.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DNobrega%26aufirst%3DJ.%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26atitle%3DInhibition%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520by%2520BIA%252010%25E2%2580%25932474%2520in%2520rat%2520brain%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2017%26volume%3D37%26spage%3D3635%26epage%3D3639%26doi%3D10.1177%2F0271678X16668890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoup, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonab, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of [<sup>18</sup>F]FCHC for neuroimaging of fatty acid amide hydrolase</span>. <i>Mol. Imaging. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1007/s11307-014-0789-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs11307-014-0789-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25273322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Smur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=257-263&author=T.+M.+Shoupauthor=A.+A.+Bonabauthor=A.+A.+Wilsonauthor=N.+Vasdev&title=Synthesis+and+preclinical+evaluation+of+%5B18F%5DFCHC+for+neuroimaging+of+fatty+acid+amide+hydrolase&doi=10.1007%2Fs11307-014-0789-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Preclinical Evaluation of [18F]FCHC for Neuroimaging of Fatty Acid Amide Hydrolase</span></div><div class="casAuthors">Shoup, Timothy M.; Bonab, Ali A.; Wilson, Alan A.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging and Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-263</span>CODEN:
                <span class="NLM_cas:coden">MIBOCZ</span>;
        ISSN:<span class="NLM_cas:issn">1860-2002</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The synthesis of a new fluorine-18-labeled FAAH inhibitor, trans-3-(4,5-dihydrooxazol-2-yl)phenyl-4-[18F]fluorocyclohexylcarbamate ([18F]FCHC), and its evaluation in rat brain were described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKabTPxYtktbVg90H21EOLACvtfcHk0ljVwHWA88lErg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Smur%252FL&md5=34ee9685d43115416e309c4be8687595</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1007%2Fs11307-014-0789-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-014-0789-1%26sid%3Dliteratum%253Aachs%26aulast%3DShoup%26aufirst%3DT.%2BM.%26aulast%3DBonab%26aufirst%3DA.%2BA.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520%255B18F%255DFCHC%2520for%2520neuroimaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DMol.%2520Imaging.%2520Biol.%26date%3D2015%26volume%3D17%26spage%3D257%26epage%3D263%26doi%3D10.1007%2Fs11307-014-0789-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesten, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadagopan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattachar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesten, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1021/ml100190t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100190t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVaisrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=91-96&author=D.+S.+Johnsonauthor=C.+Stiffauthor=S.+E.+Lazerwithauthor=S.+R.+Kestenauthor=L.+K.+Fayauthor=M.+Morrisauthor=D.+Beidlerauthor=M.+B.+Liimattaauthor=S.+E.+Smithauthor=D.+T.+Dudleyauthor=N.+Sadagopanauthor=S.+N.+Bhattacharauthor=S.+J.+Kestenauthor=T.+K.+Nomanbhoyauthor=B.+F.+Cravattauthor=K.+Ahn&title=Discovery+of+PF-04457845%3A+a+highly+potent%2C+orally+bioavailable%2C+and+selective+urea+FAAH+inhibitor&doi=10.1021%2Fml100190t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor</span></div><div class="casAuthors">Johnson, Douglas S.; Stiff, Cory; Lazerwith, Scott E.; Kesten, Suzanne R.; Fay, Lorraine K.; Morris, Mark; Beidler, David; Liimatta, Marya B.; Smith, Sarah E.; Dudley, David T.; Sadagopan, Nalini; Bhattachar, Shobha N.; Kesten, Stephen J.; Nomanbhoy, Tyzoon K.; Cravatt, Benjamin F.; Ahn, Kay</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-96</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide.  Genetic or pharmacol. inactivation of FAAH leads to analgesic and anti-inflammatory phenotypes in rodents without showing the undesirable side effects obsd. with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for the treatment of inflammatory pain and other nervous system disorders.  Herein, the discovery and characterization of a highly efficacious and selective FAAH inhibitor PF-04457845, N-(3-pyridazinyl)-4-(3-[5-trifluoromethyl-2-pyridinyloxy]benzylidene)piperidine-1-carboxamide (I), are reported.  This compd. inhibited FAAH by a covalent, irreversible mechanism involving carbamylation of the active-site serine nucleophile of FAAH with high in vitro potency (kinact/Ki and IC50 values of 40300 M-1 s-1 and 7.2 nM, resp., for human FAAH).  The compd. I had exquisite selectivity for FAAH relative to other members of the serine hydrolase superfamily as demonstrated by competitive activity-based protein profiling.  Oral administration of I at 0.1 mg/kg results in efficacy comparable to that of naproxen at 10 mg/kg in a rat model of inflammatory pain.  Compd. I is being evaluated in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoINP05KK-SNLVg90H21EOLACvtfcHk0ljVwHWA88lErg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVaisrfO&md5=c7ba2900e3abeda46f885d23bf1f76b8</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fml100190t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100190t%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DStiff%26aufirst%3DC.%26aulast%3DLazerwith%26aufirst%3DS.%2BE.%26aulast%3DKesten%26aufirst%3DS.%2BR.%26aulast%3DFay%26aufirst%3DL.%2BK.%26aulast%3DMorris%26aufirst%3DM.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DLiimatta%26aufirst%3DM.%2BB.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DSadagopan%26aufirst%3DN.%26aulast%3DBhattachar%26aufirst%3DS.%2BN.%26aulast%3DKesten%26aufirst%3DS.%2BJ.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DAhn%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520PF-04457845%253A%2520a%2520highly%2520potent%252C%2520orally%2520bioavailable%252C%2520and%2520selective%2520urea%2520FAAH%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D91%26epage%3D96%26doi%3D10.1021%2Fml100190t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadagopan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Becelaere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattachar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.180257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fjpet.111.180257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21505060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=114-124&author=K.+Ahnauthor=S.+E.+Smithauthor=M.+B.+Liimattaauthor=D.+Beidlerauthor=N.+Sadagopanauthor=D.+T.+Dudleyauthor=T.+Youngauthor=P.+Wrenauthor=Y.+Zhangauthor=S.+Swaneyauthor=K.+Van+Becelaereauthor=J.+L.+Blankmanauthor=D.+K.+Nomuraauthor=S.+N.+Bhattacharauthor=C.+Stiffauthor=T.+K.+Nomanbhoyauthor=E.+Weerapanaauthor=D.+S.+Johnsonauthor=B.+F.+Cravatt&title=Mechanistic+and+pharmacological+characterization+of+PF-04457845%3A+a+highly+potent+and+selective+fatty+acid+amide+hydrolase+inhibitor+that+reduces+inflammatory+and+noninflammatory+pain&doi=10.1124%2Fjpet.111.180257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain</span></div><div class="casAuthors">Ahn, Kay; Smith, Sarah E.; Liimatta, Marya B.; Beidler, David; Sadagopan, Nalini; Dudley, David T.; Young, Tim; Wren, Paul; Zhang, Yanhua; Swaney, Steven; Van Becelaere, Keri; Blankman, Jacqueline L.; Nomura, Daniel K.; Bhattachar, Shobha N.; Stiff, Cory; Nomanbhoy, Tyzoon K.; Weerapana, Eranthie; Johnson, Douglas S.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-124</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The endogenous cannabinoid (endocannabinoid) anandamide is principally degraded by the integral membrane enzyme fatty acid amide hydrolase (FAAH).  Pharmacol. blockade of FAAH has emerged as a potentially attractive strategy for augmenting endocannabinoid signaling and retaining the beneficial effects of cannabinoid receptor activation, while avoiding the undesirable side effects, such as wt. gain and impairments in cognition and motor control, obsd. with direct cannabinoid receptor 1 agonists.  Here, we report the detailed mechanistic and pharmacol. characterization of N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide (PF-04457845), a highly efficacious and selective FAAH inhibitor.  Mechanistic studies confirm that PF-04457845 is a time-dependent, covalent FAAH inhibitor that carbamylates FAAH's catalytic serine nucleophile.  PF-04457845 inhibits human FAAH with high potency (kinact/Ki = 40,300 M-1s-1; IC50 = 7.2 nM) and is exquisitely selective in vivo as detd. by activity-based protein profiling.  Oral administration of PF-04457845 produced potent antinociceptive effects in both inflammatory [complete Freund's adjuvant (CFA)] and noninflammatory (monosodium iodoacetate) pain models in rats, with a min. ED of 0.1 mg/kg (CFA model).  PF-04457845 displayed a long duration of action as a single oral administration at 1 mg/kg showed in vivo efficacy for 24 h with a concomitant near-complete inhibition of FAAH activity and maximal sustained elevation of anandamide in brain.  Significantly, PF-04457845-treated mice at 10 mg/kg elicited no effect in motility, catalepsy, and body temp.  Based on its exceptional selectivity and in vivo efficacy, combined with long duration of action and optimal pharmacokinetic properties, PF-04457845 is a clin. candidate for the treatment of pain and other nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd5BIw55W3OrVg90H21EOLACvtfcHk0ljVwHWA88lErg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiurY%253D&md5=b32df795c9df175bd6403fdd5672eae2</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.180257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.180257%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DLiimatta%26aufirst%3DM.%2BB.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DSadagopan%26aufirst%3DN.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DYoung%26aufirst%3DT.%26aulast%3DWren%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSwaney%26aufirst%3DS.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26aulast%3DBhattachar%26aufirst%3DS.%2BN.%26aulast%3DStiff%26aufirst%3DC.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DMechanistic%2520and%2520pharmacological%2520characterization%2520of%2520PF-04457845%253A%2520a%2520highly%2520potent%2520and%2520selective%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitor%2520that%2520reduces%2520inflammatory%2520and%2520noninflammatory%2520pain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D114%26epage%3D124%26doi%3D10.1124%2Fjpet.111.180257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">11CO2 fixation: a renaissance in PET radiochemistry</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5621</span>– <span class="NLM_lpage">5629</span>, <span class="refDoi"> DOI: 10.1039/c3cc42236d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1039%2Fc3cc42236d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23673726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVemsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=5621-5629&author=B.+H.+Rotsteinauthor=S.+H.+Liangauthor=J.+P.+Hollandauthor=T.+L.+Collierauthor=J.+M.+Hookerauthor=A.+A.+Wilsonauthor=N.+Vasdev&title=11CO2+fixation%3A+a+renaissance+in+PET+radiochemistry&doi=10.1039%2Fc3cc42236d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">11CO2 fixation: a renaissance in PET radiochemistry</span></div><div class="casAuthors">Rotstein, Benjamin H.; Liang, Steven H.; Holland, Jason P.; Collier, Thomas Lee; Hooker, Jacob M.; Wilson, Alan A.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">5621-5629</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Carbon-11 labeled carbon dioxide is the cyclotron-generated feedstock reagent for most positron emission tomog. (PET) tracers using this radionuclide.  Most carbon-11 labels, however, are installed using deriv. reagents generated from [11C]CO2.  In recent years, [11C]CO2 has seen a revival in applications for the direct incorporation of carbon-11 into functional groups such as ureas, carbamates, oxazolidinones, carboxylic acids, esters, and amides.  This review summarizes classical [11C]CO2 fixation strategies using organometallic reagents and then focuses on newly developed methods that employ strong org. bases to reversibly capture [11C]CO2 into soln., thereby enabling highly functionalized labeled compds. to be prepd.  Labeled compds. and radiopharmaceuticals that have been translated to the clinic are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxQyYB25RBbbVg90H21EOLACvtfcHk0lhcKEA_Pi1VkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVemsbo%253D&md5=555cd1c94c0e870cf268ff5db0578c0c</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1039%2Fc3cc42236d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc42236d%26sid%3Dliteratum%253Aachs%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DHolland%26aufirst%3DJ.%2BP.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3D11CO2%2520fixation%253A%2520a%2520renaissance%2520in%2520PET%2520radiochemistry%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26spage%3D5621%26epage%3D5629%26doi%3D10.1039%2Fc3cc42236d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2013.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2013.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23731552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslWmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=740-746&author=J.+W.+Hicksauthor=J.+Parkesauthor=O.+Sadovskiauthor=J.+Tongauthor=S.+Houleauthor=N.+Vasdevauthor=A.+A.+Wilson&title=Synthesis+and+preclinical+evaluation+of+%5B11C-carbonyl%5DPF-04457845+for+neuroimaging+of+fatty+acid+amide+hydrolase&doi=10.1016%2Fj.nucmedbio.2013.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase</span></div><div class="casAuthors">Hicks, Justin W.; Parkes, Jun; Sadovski, Oleg; Tong, Junchao; Houle, Sylvain; Vasdev, Neil; Wilson, Alan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">740-746</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) has a significant role in regulating endocannabinoid signaling in the central nervous system.  As such, FAAH inhibitors are being actively sought for pain, addiction, and other indications.  This has led to the recent pursuit of positron emission tomog. (PET) radiotracers targeting FAAH.  We report herein the prepn. and preclin. evaluation of [11C-carbonyl]PF-04457845, an isotopologue of the potent irreversible FAAH inhibitor.  PF-04457845 was radiolabeled at the carbonyl position via automated [11C]CO2-fixation.  Ex vivo brain biodistribution of [11C-carbonyl]PF-04457845 was carried out in conscious rats.  Specificity was detd. by pre-administration of PF-04457845 or URB597 prior to [11C-carbonyl]PF-04457845.  In a sep. expt., rats injected with the title radiotracer had whole brains excised, homogenized and extd. to examine irreversible binding to brain parenchyma.  The title compd. was prepd. in 5 ± 1% (n = 4) isolated radiochem. yield based on starting [11C]CO2 (decay uncorrected) within 25 min from end-of-bombardment in > 98% radiochem. purity and a specific activity of 73.5 ± 8.2 GBq/μmol at end-of-synthesis.  Uptake of [11C-carbonyl]PF-04457845 into the rat brain was high (range of 1.2-4.4 SUV), heterogeneous, and in accordance with reported FAAH distribution.  Saturable binding was demonstrated by a dose-dependent redn. in brain radioactivity uptake following pre-treatment with PF-04457845.  Pre-treatment with the prototypical FAAH inhibitor, URB597, reduced the brain radiotracer uptake in all regions by 71-81%, demonstrating specificity for FAAH.  The binding of [11C-carbonyl]PF-04457845 to FAAH at 40 min post injection was irreversible as 98% of the radioactivity in the brain could not be extd.  [11C-carbonyl]PF-04457845 was rapidly synthesized via an automated radiosynthesis.  Ex vivo biodistribution studies in conscious rodents demonstrate that [11C PF-04457845 is a promising candidate radiotracer for imaging FAAH in the brain with PET.  These results coupled with the known pharmacol. and toxicol. of PF-04457845 should facilitate clin. translation of this radiotracer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3VVfFVnooC7Vg90H21EOLACvtfcHk0lhcKEA_Pi1VkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslWmt7o%253D&md5=17ff0759bc57b31cd49887f5e30b3afa</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2013.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2013.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DJ.%2BW.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DSadovski%26aufirst%3DO.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520%255B11C-carbonyl%255DPF-04457845%2520for%2520neuroimaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2013%26volume%3D40%26spage%3D740%26epage%3D746%26doi%3D10.1016%2Fj.nucmedbio.2013.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skaddan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zasadny, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuszpit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niphakis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">The synthesis and in vivo evaluation of [<sup>18</sup>F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH)</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1058</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2012.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2012.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22571907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslynu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=1058-1067&author=M.+B.+Skaddanauthor=L.+Zhangauthor=D.+S.+Johnsonauthor=A.+Zhuauthor=K.+R.+Zasadnyauthor=R.+V.+Coelhoauthor=K.+Kuszpitauthor=G.+Currierauthor=K.+H.+Fanauthor=E.+M.+Beckauthor=L.+Chenauthor=S.+E.+Drozdaauthor=G.+Balanauthor=M.+Niphakisauthor=B.+F.+Cravattauthor=K.+Ahnauthor=T.+Bocanauthor=A.+Villalobos&title=The+synthesis+and+in+vivo+evaluation+of+%5B18F%5DPF-9811%3A+a+novel+PET+ligand+for+imaging+brain+fatty+acid+amide+hydrolase+%28FAAH%29&doi=10.1016%2Fj.nucmedbio.2012.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH)</span></div><div class="casAuthors">Skaddan, Marc B.; Zhang, Lei; Johnson, Douglas S.; Zhu, Aijun; Zasadny, Kenneth R.; Coelho, Richard V.; Kuszpit, Kyle; Currier, Gwen; Fan, Kuo-Hsien; Beck, Elizabeth M.; Chen, Laigao; Drozda, Susan E.; Balan, Gayatri; Niphakis, Micah; Cravatt, Benjamin F.; Ahn, Kay; Bocan, Thomas; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1058-1067</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) is responsible for the enzymic degrdn. of the fatty acid amide family of signaling lipids, including the endogenous cannabinoid (endocannabinoid) anandamide.  The involvement of the endocannabinoid system in pain and other nervous system disorders has made FAAH an attractive target for drug development.  Companion mol. imaging probes are needed, however, to assess FAAH inhibition in the nervous system in vivo.  We report here the synthesis and in vivo evaluation of [18F]PF-9811, a novel PET ligand for non-invasive imaging of FAAH in the brain.The potency and selectivity of unlabeled PF-9811 were detd. by activity-based protein profiling (ABPP) both in vitro and in vivo. [18F]PF-9811 was synthesized in a 3-step, one-pot reaction sequence, followed by HPLC purifn.  Biol. evaluation was performed by biodistribution and dynamic PET imaging studies in male rats.  The specificity of [18F]PF-9811 uptake was evaluated by pre-administration of PF-04457845, a potent and selective FAAH inhibitor, 1 h prior to radiotracer injection.Biodistribution studies show good uptake (SUV ~ 0.8 at 90 min) of [18F]PF-9811 in rat brain, with significant redn. of the radiotracer in all brain regions (37%-73% at 90 min) in blocking expts.  Dynamic PET imaging expts. in rat confirmed the heterogeneous uptake of [18F]PF-9811 in brain regions with high FAAH enzymic activity, as well as statistically significant redns. in signal following pre-administration of the blocking compd. PF-04457845.[18F]PF-9811 is a promising PET imaging agent for FAAH.  Biodistribution and PET imaging expts. show that the tracer has good uptake in brain, regional heterogeneity, and specific binding as detd. by blocking expts. with the highly potent and selective FAAH inhibitor, PF-04457845.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd02lQkPZjcLVg90H21EOLACvtfcHk0lhcKEA_Pi1VkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslynu7o%253D&md5=fe073d3c7b88670e8bef5ceb2412c0e3</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2012.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2012.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DSkaddan%26aufirst%3DM.%2BB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DZhu%26aufirst%3DA.%26aulast%3DZasadny%26aufirst%3DK.%2BR.%26aulast%3DCoelho%26aufirst%3DR.%2BV.%26aulast%3DKuszpit%26aufirst%3DK.%26aulast%3DCurrier%26aufirst%3DG.%26aulast%3DFan%26aufirst%3DK.%2BH.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DBalan%26aufirst%3DG.%26aulast%3DNiphakis%26aufirst%3DM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DBocan%26aufirst%3DT.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DThe%2520synthesis%2520and%2520in%2520vivo%2520evaluation%2520of%2520%255B18F%255DPF-9811%253A%2520a%2520novel%2520PET%2520ligand%2520for%2520imaging%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2012%26volume%3D39%26spage%3D1058%26epage%3D1067%26doi%3D10.1016%2Fj.nucmedbio.2012.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Design and prototype of an automated “in-loop” [<sup>11</sup>C] CO2-fixation apparatus</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">330</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=330-330&author=K.+Dahlauthor=T.+Collierauthor=X.+Zhangauthor=S.+Liangauthor=N.+Vasdev&title=Design+and+prototype+of+an+automated+%E2%80%9Cin-loop%E2%80%9D+%5B11C%5D+CO2-fixation+apparatus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DK.%26aulast%3DCollier%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DDesign%2520and%2520prototype%2520of%2520an%2520automated%2520%25E2%2580%259Cin-loop%25E2%2580%259D%2520%255B11C%255D%2520CO2-fixation%2520apparatus%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D330%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">“In-loop” [<sup>11</sup>C]CO2 fixation: Prototype and proof of concept</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1002/jlcr.3528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjlcr.3528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28600835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wlt7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=252-262&author=K.+Dahlauthor=T.+L.+Collierauthor=R.+Chengauthor=X.+Zhangauthor=O.+Sadovskiauthor=S.+H.+Liangauthor=N.+Vasdev&title=%E2%80%9CIn-loop%E2%80%9D+%5B11C%5DCO2+fixation%3A+Prototype+and+proof+of+concept&doi=10.1002%2Fjlcr.3528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">"In-loop" [11C]CO2 fixation: Prototype and proof of concept</span></div><div class="casAuthors">Dahl, Kenneth; Collier, Thomas L.; Cheng, Ran; Zhang, Xiaofei; Sadovski, Oleg; Liang, Steven H.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">252-262</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The development of an app. that takes advantage of "in-loop" technologies to facilitate robust and reproducible syntheses of 11C-carbonyl-based radiotracers by [11C]CO2-fixation was reported.  The "in-loop" [11C]CO2-fixation method was simple, efficient and proceeded smoothly at ambient pressure and temp.  The model 11C-carbonyl-labeled carbamates as well as sym. and unsym. ureas based on their widespread use in radiotracer design and clin. research interests was selected for proof of concept.  Utility of this method was demonstrated by the synthesis of a reversible radiopharmaceutical for monoamine oxidase B, [11C]SL25.1188 and 2 novel fatty acid amide hydrolase inhibitors.  These radiotracers were isolated and formulated (>3.5 GBq; 100 mCi) with radiochem. purities (>99%) and molar radioactivity (≥80 GBq/μmol; ≥2162 mCi/μmol).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8EB1T6TBx8rVg90H21EOLACvtfcHk0ljJnmXoTHhKhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wlt7jP&md5=c37196764c5f7f8a103e34c5b7f0b6f5</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3528%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DK.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSadovski%26aufirst%3DO.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3D%25E2%2580%259CIn-loop%25E2%2580%259D%2520%255B11C%255DCO2%2520fixation%253A%2520Prototype%2520and%2520proof%2520of%2520concept%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2018%26volume%3D61%26spage%3D252%26epage%3D262%26doi%3D10.1002%2Fjlcr.3528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">The assay of enzyme activity by positron emission tomography</span>. <i>Neuromethods</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1007/7657_2012_53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2F7657_2012_53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2012&pages=111-135&author=P.+Cummingauthor=N.+Vasdev&title=The+assay+of+enzyme+activity+by+positron+emission+tomography&doi=10.1007%2F7657_2012_53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">The Assay of Enzyme Activity by Positron Emission Tomography</span></div><div class="casAuthors">Cumming, Paul; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Neuromethods</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">Molecular Imaging in the Clinical Neurosciences</span>),
    <span class="NLM_cas:pages">111-135</span>CODEN:
                <span class="NLM_cas:coden">NUROE8</span>;
        ISSN:<span class="NLM_cas:issn">0893-2336</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  In a relatively small no. of instances, the activity in brain of specific enzymes can be measured with positron emission tomog. (PET) using radioactive enzyme substrates in conjunction with compartmental modeling.  Thus, the trapping of [11C]-labeled amino acids in brain protein was an early application of PET, which found particular use in the detection of brain tumors.  The most successful PET agent remains the glucose analog [18F]-fluoro-deoxyglucose (FDG), which is trapped in brain as FDG-phosphate, at a rate detd. by the local activity of the hexokinase enzyme.  The integrity of nigrostriatal dopamine innervations can be assessed with the DOPA decarboxylase tracer [18F]-fluoro-L-DOPA (FDOPA), whereas the rate of serotonin synthesis has been measured in PET studies with α-[14C]-methyl-L-tryptophan.  Monoamine oxidase, uniquely, can be assessed in PET studies with suicide substrates such as L-[11C]-deprenyl, where the rate of trapping in living tissue is a function of the local catalytic activity of MAO-B.  However, the abundance of MAO-A is most conveniently assessed with [11C]-harmine and other competitor ligands, which bind reversibly to the enzyme. [11C]-PMP and a no. of other substrates for acetylcholine esterase have been developed, based on the prodn. in situ of a nondiffusible hydrolysis product.  The activity of P-glycoprotein in the blood-brain barrier can be assessed only indirectly, by virtue of increased influx to brain of labeled substrates, following administration of P-glycoprotein inhibitors.  Positron-emitting inhibitors of phosphodiesterase enzymes have been described, which should herald the eventual development of a much wider array of tracers targeting signal transduction pathways.  Cell proliferation can be detected with [11C]-thymidine and synthetic nucleosides.  Very recently, it has become possible to measure the abundance in brain of aromatase, which catalyzes the synthesis of estrogen.  In general, the net influx of an enzyme substrate from blood to brain is calcd. by linear graphical anal., whereas individual steps in the non-uptake process can be estd. by compartmental anal.  When trapping of a PET tracer is catalyzed by the enzymic step, the magnitude of the corresponding rate const. (k 3; min-1) ranges from the lowest useful limit of 0.01 min-1 (α-[14C]-methyl-L-tryptophan) to >0.1 min-1 (L-[11C]-deprenyl, [11C]PMP).  Quantification is problematic at the lower end of this range due to low specific signal and also at the high end due to blood flow limiting effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKjqO1aeEBwLVg90H21EOLACvtfcHk0ljJnmXoTHhKhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWqu7g%253D&md5=2c863f2fadcb96d8354c71bce128085e</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1007%2F7657_2012_53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7657_2012_53%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DP.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DThe%2520assay%2520of%2520enzyme%2520activity%2520by%2520positron%2520emission%2520tomography%26jtitle%3DNeuromethods%26date%3D2012%26volume%3D71%26spage%3D111%26epage%3D135%26doi%3D10.1007%2F7657_2012_53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span> <span> </span><span class="NLM_article-title">PET radiotracers: crossing the blood-brain barrier and surviving metabolism</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2009.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.tips.2009.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19616318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1KgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=431-440&author=V.+W.+Pike&title=PET+radiotracers%3A+crossing+the+blood-brain+barrier+and+surviving+metabolism&doi=10.1016%2Fj.tips.2009.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">PET radiotracers: crossing the blood-brain barrier and surviving metabolism</span></div><div class="casAuthors">Pike, Victor W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">431-440</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Radiotracers for imaging protein targets in the living human brain with positron emission tomog. (PET) are increasingly useful in clin. research and in drug development.  Such radiotracers must fulfill many criteria, among which an ability to enter brain adequately and reversibly without contamination by troublesome radiometabolites is desirable for accurate measurement of the d. of a target protein (e.g. neuroreceptor, transporter, enzyme or plaque).  Candidate radiotracers can fail as a result of poor passive brain entry, rejection from brain by efflux transporters or undesirable metab.  These issues are reviewed.  Emerging PET radiotracers for measuring efflux transporter function and new strategies for ameliorating radiotracer metab. are discussed.  A growing understanding of the mol. features affecting the brain penetration, metab. and efflux transporter sensitivity of prospective radiotracers should ultimately lead to their more rational and efficient design, and also to their greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6ftMCpkOSmrVg90H21EOLACvtfcHk0ljJnmXoTHhKhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1KgsLg%253D&md5=97704995fecd968baf1e0892bf70324e</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DV.%2BW.%26atitle%3DPET%2520radiotracers%253A%2520crossing%2520the%2520blood-brain%2520barrier%2520and%2520surviving%2520metabolism%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D431%26epage%3D440%26doi%3D10.1016%2Fj.tips.2009.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamill, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellureficio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanabria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajdu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochnowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebetski, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holahan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posavec, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riffel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-3168: a PET tracer for imaging brain fatty acid amide hydrolase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1021/ml4000996</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000996" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ylu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=509-513&author=P.+Liuauthor=T.+G.+Hamillauthor=M.+Chiodaauthor=H.+Chobanianauthor=S.+Fungauthor=Y.+Guoauthor=L.+Changauthor=R.+Bakshiauthor=Q.+Hongauthor=J.+Dellureficioauthor=L.+S.+Linauthor=C.+Abbadieauthor=J.+Alexanderauthor=H.+Jinauthor=S.+Mandalaauthor=L.+L.+Shiaoauthor=W.+Liauthor=S.+Sanabriaauthor=D.+Williamsauthor=Z.+Zengauthor=R.+Hajduauthor=N.+Jochnowitzauthor=M.+Rosenbachauthor=B.+Karanamauthor=M.+Madeiraauthor=G.+Salituroauthor=J.+Powellauthor=L.+Xuauthor=J.+L.+Terebetskiauthor=J.+F.+Leoneauthor=P.+Millerauthor=J.+Cookauthor=M.+Holahanauthor=A.+Joshiauthor=S.+O%E2%80%99Malleyauthor=M.+Purcellauthor=D.+Posavecauthor=T.+B.+Chenauthor=K.+Riffelauthor=M.+Williamsauthor=R.+Hargreavesauthor=K.+A.+Sullivanauthor=R.+P.+Nargundauthor=R.+J.+DeVita&title=Discovery+of+MK-3168%3A+a+PET+tracer+for+imaging+brain+fatty+acid+amide+hydrolase&doi=10.1021%2Fml4000996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase</span></div><div class="casAuthors">Liu, Ping; Hamill, Terence G.; Chioda, Marc; Chobanian, Harry; Fung, Selena; Guo, Yan; Chang, Linda; Bakshi, Raman; Hong, Qingmei; Dellureficio, James; Lin, Linus S.; Abbadie, Catherine; Alexander, Jessica; Jin, Hong; Mandala, Suzanne; Shiao, Lin-Lin; Li, Wenping; Sanabria, Sandra; Williams, David; Zeng, Zhizhen; Hajdu, Richard; Jochnowitz, Nina; Rosenbach, Mark; Karanam, Bindhu; Madeira, Maria; Salituro, Gino; Powell, Joyce; Xu, Ling; Terebetski, Jenna L.; Leone, Joseph F.; Miller, Patricia; Cook, Jacquelynn; Holahan, Marie; Joshi, Aniket; O'Malley, Stacey; Purcell, Mona; Posavec, Diane; Chen, Tsing-Bau; Riffel, Kerry; Williams, Mangay; Hargreaves, Richard; Sullivan, Kathleen A.; Nargund, Ravi P.; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">509-513</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery of a fatty acid amide hydrolase (FAAH) positron emission tomog. (PET) tracer.  Starting from a pyrazole lead, medicinal chem. efforts directed toward reducing lipophilicity led to the synthesis of a series of imidazole analogs.  Compd. 6 was chosen for further profiling due to its appropriate phys. chem. properties and excellent FAAH inhibition potency across species. [11C]-6 (MK-3168) exhibited good brain uptake and FAAH-specific signal in rhesus monkeys and is a suitable PET tracer for imaging FAAH in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ7TcIehUa5rVg90H21EOLACvtfcHk0lhQTQMepP3fAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ylu7Y%253D&md5=a5ec9a3750ed61f576732b8dfd541026</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Fml4000996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000996%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DHamill%26aufirst%3DT.%2BG.%26aulast%3DChioda%26aufirst%3DM.%26aulast%3DChobanian%26aufirst%3DH.%26aulast%3DFung%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DBakshi%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DQ.%26aulast%3DDellureficio%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%2BS.%26aulast%3DAbbadie%26aufirst%3DC.%26aulast%3DAlexander%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DShiao%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSanabria%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DKaranam%26aufirst%3DB.%26aulast%3DMadeira%26aufirst%3DM.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DTerebetski%26aufirst%3DJ.%2BL.%26aulast%3DLeone%26aufirst%3DJ.%2BF.%26aulast%3DMiller%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DHolahan%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DS.%26aulast%3DPurcell%26aufirst%3DM.%26aulast%3DPosavec%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DRiffel%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DSullivan%26aufirst%3DK.%2BA.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-3168%253A%2520a%2520PET%2520tracer%2520for%2520imaging%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D509%26epage%3D513%26doi%3D10.1021%2Fml4000996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanabria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holahan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laere, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamill, T.</span></span> <span> </span><span class="NLM_article-title">Translational studies with [<sup>11</sup>C]MK-3168, a PET tracer for fatty acid amide hydrolase (FAAH)</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">S1</span>),  <span class="NLM_fpage">397</span>, <span class="refDoi"> DOI: 10.2967/jnumed.111.090340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.111.090340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=397&issue=S1&author=A.+Joshiauthor=W.+Liauthor=S.+Sanabriaauthor=M.+Holahanauthor=M.+Purcellauthor=R.+Declercqauthor=M.+Depreauthor=G.+Bormansauthor=K.+V.+Laereauthor=T.+Hamill&title=Translational+studies+with+%5B11C%5DMK-3168%2C+a+PET+tracer+for+fatty+acid+amide+hydrolase+%28FAAH%29&doi=10.2967%2Fjnumed.111.090340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.111.090340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.111.090340%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSanabria%26aufirst%3DS.%26aulast%3DHolahan%26aufirst%3DM.%26aulast%3DPurcell%26aufirst%3DM.%26aulast%3DDeclercq%26aufirst%3DR.%26aulast%3DDepre%26aufirst%3DM.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DLaere%26aufirst%3DK.%2BV.%26aulast%3DHamill%26aufirst%3DT.%26atitle%3DTranslational%2520studies%2520with%2520%255B11C%255DMK-3168%252C%2520a%2520PET%2520tracer%2520for%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2012%26volume%3D53%26issue%3DS1%26spage%3D397%26doi%3D10.2967%2Fjnumed.111.090340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postnov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecken, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannikos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoon, J. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laere, K. V.</span></span> <span> </span><span class="NLM_article-title">Kinetic modeling of fatty acid amide hydrolase (FAAH) enzyme occupancy after JNJ42165279 inhibition based on 11CMK3168 PET imaging of human brain</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">S3</span>),  <span class="NLM_fpage">362</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=362&issue=S3&author=A.+Postnovauthor=M.+Schmidtauthor=J.+Pensonauthor=A.+V.+Heckenauthor=P.+Zannikosauthor=D.+Pembertonauthor=J.+Palmerauthor=J.+d.+Hoonauthor=G.+Bormansauthor=K.+V.+Laere&title=Kinetic+modeling+of+fatty+acid+amide+hydrolase+%28FAAH%29+enzyme+occupancy+after+JNJ42165279+inhibition+based+on+11CMK3168+PET+imaging+of+human+brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPostnov%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DM.%26aulast%3DPenson%26aufirst%3DJ.%26aulast%3DHecken%26aufirst%3DA.%2BV.%26aulast%3DZannikos%26aufirst%3DP.%26aulast%3DPemberton%26aufirst%3DD.%26aulast%3DPalmer%26aufirst%3DJ.%26aulast%3DHoon%26aufirst%3DJ.%2Bd.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DLaere%26aufirst%3DK.%2BV.%26atitle%3DKinetic%2520modeling%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%2520enzyme%2520occupancy%2520after%2520JNJ42165279%2520inhibition%2520based%2520on%252011CMK3168%2520PET%2520imaging%2520of%2520human%2520brain%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26issue%3DS3%26spage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mileni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfunkle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">10497</span>– <span class="NLM_lpage">10506</span>, <span class="refDoi"> DOI: 10.1021/ja902694n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja902694n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot1Gnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=10497-10506&author=M.+Mileniauthor=J.+Garfunkleauthor=J.+K.+DeMartinoauthor=B.+F.+Cravattauthor=D.+L.+Bogerauthor=R.+C.+Stevens&title=Binding+and+inactivation+mechanism+of+a+humanized+fatty+acid+amide+hydrolase+by+alpha-ketoheterocycle+inhibitors+revealed+from+cocrystal+structures&doi=10.1021%2Fja902694n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Binding and Inactivation Mechanism of a Humanized Fatty Acid Amide Hydrolase by α-Ketoheterocycle Inhibitors Revealed from Cocrystal Structures</span></div><div class="casAuthors">Mileni, Mauro; Garfunkle, Joie; DeMartino, Jessica K.; Cravatt, Benjamin F.; Boger, Dale L.; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">10497-10506</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cocrystal x-ray structures of two isomeric α-ketooxazole inhibitors (1 (OL-135) and 2) bound to fatty acid amide hydrolase (FAAH), a key enzymic regulator of endocannabinoid signaling, are disclosed.  The active site catalytic Ser241 is covalently bound to the inhibitors' electrophilic carbonyl groups, providing the first structures of FAAH bound to an inhibitor as a deprotonated hemiketal mimicking the enzymic tetrahedral intermediate.  The work also offers a detailed view of the oxyanion hole and an exceptional "in-action" depiction of the unusual Ser-Ser-Lys catalytic triad.  These structures capture the first picture of inhibitors that span the active site into the cytosolic port providing new insights that help to explain FAAH's interaction with substrate leaving groups and their role in modulating inhibitor potency and selectivity.  The role for the activating central heterocycle is clearly defined and distinguished from that obsd. in prior applications with serine proteases, reconciling the large electronic effect of attached substituents found unique to this class of inhibitors with FAAH.  Addnl. striking active site flexibility is seen upon binding of the inhibitors, providing insights into the existence of a now well-defined membrane access channel with the disappearance of a spatially independent portion of the acyl chain-binding pocket.  Finally, comparison of the structures of OL-135 (1) and its isomer 2 indicates that they bind identically to FAAH, albeit with reversed orientations of the central activating heterocycle, revealing that the terminal 2-pyridyl substituent and the acyl chain Ph group provide key anchoring interactions and confirming the distinguishing role of the activating oxazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0VYXvkQBlWLVg90H21EOLACvtfcHk0liwerpb0NOprA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot1Gnurc%253D&md5=7acaa93a726e1d8fac4816aee62927e4</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1021%2Fja902694n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja902694n%26sid%3Dliteratum%253Aachs%26aulast%3DMileni%26aufirst%3DM.%26aulast%3DGarfunkle%26aufirst%3DJ.%26aulast%3DDeMartino%26aufirst%3DJ.%2BK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBoger%26aufirst%3DD.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DBinding%2520and%2520inactivation%2520mechanism%2520of%2520a%2520humanized%2520fatty%2520acid%2520amide%2520hydrolase%2520by%2520alpha-ketoheterocycle%2520inhibitors%2520revealed%2520from%2520cocrystal%2520structures%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D10497%26epage%3D10506%26doi%3D10.1021%2Fja902694n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otrubova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boger, D. L.</span></span> <span> </span><span class="NLM_article-title">α-Ketoheterocycle-based inhibitors of fatty acid amide hydrolase (FAAH)</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1021/cn2001206</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn2001206" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ChtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=340-348&author=K.+Otrubovaauthor=D.+L.+Boger&title=%CE%B1-Ketoheterocycle-based+inhibitors+of+fatty+acid+amide+hydrolase+%28FAAH%29&doi=10.1021%2Fcn2001206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">α-Ketoheterocycle-Based Inhibitors of Fatty Acid Amide Hydrolase (FAAH)</span></div><div class="casAuthors">Otrubova, Katerina; Boger, Dale L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">340-348</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A summary of the initial discovery and characterization of the enzyme fatty acid amide hydrolase (FAAH), and the subsequent advancement of an important class of competitive, reversible, potent, and selective inhibitors is presented.  Initially explored using substrate-inspired inhibitors bearing electrophilic carbonyls, the examn. of α-ketoheterocyle-based inhibitors of FAAH with the benefit of a unique activity-based protein-profiling (ABPP)-based proteome-wide selectivity assay, a powerful in vivo biomarker-based in vivo screen, and subsequent retrospective x-ray cocrystal structures with the enzyme, is summarized.  These efforts defined the impact of the central activating heterocycle and its key substituents, provided key simplifications in the C2 acyl side chain and clear interpretations for the unique role and subsequent optimization of the central activating heterocycle, and established the basis for the recent further conformational constraints in the C2 acyl side chain, providing potent, long-acting, orally active FAAH inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4v_VJgMuMirVg90H21EOLACvtfcHk0liwerpb0NOprA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ChtL3E&md5=e44d87e37c2f21bb7e7400bb1bc1f674</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1021%2Fcn2001206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn2001206%26sid%3Dliteratum%253Aachs%26aulast%3DOtrubova%26aufirst%3DK.%26aulast%3DBoger%26aufirst%3DD.%2BL.%26atitle%3D%25CE%25B1-Ketoheterocycle-based%2520inhibitors%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D340%26epage%3D348%26doi%3D10.1021%2Fcn2001206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardouin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayl, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boger, D. L.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3359</span>– <span class="NLM_lpage">3368</span>, <span class="refDoi"> DOI: 10.1021/jm061414r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061414r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Kru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3359-3368&author=C.+Hardouinauthor=M.+J.+Kelsoauthor=F.+A.+Romeroauthor=T.+J.+Raylauthor=D.+Leungauthor=I.+Hwangauthor=B.+F.+Cravattauthor=D.+L.+Boger&title=Structure-activity+relationships+of+alpha-ketooxazole+inhibitors+of+fatty+acid+amide+hydrolase&doi=10.1021%2Fjm061414r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase</span></div><div class="casAuthors">Hardouin, Christophe; Kelso, Michael J.; Romero, F. Anthony; Rayl, Thomas J.; Leung, Donmienne; Hwang, Inkyu; Cravatt, Benjamin F.; Boger, Dale L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3359-3368</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A systematic study of the structure-activity relationships of 2b (OL-135), a potent inhibitor of fatty acid amide hydrolase (FAAH), is detailed targeting the C2 acyl side chain.  A series of aryl replacements or substituents for the terminal Ph group provided effective inhibitors (e.g., 5c, aryl = 1-naphthyl, Ki = 2.6 nM), with 5hh (aryl = 3-ClPh, Ki = 900 pM) being 5-fold more potent than 2b.  Conformationally restricted C2 side chains were examd., and many provided exceptionally potent inhibitors, of which 11j (ethylbiphenyl side chain) was established to be a 750 pM inhibitor.  A systematic series of heteroatoms (O, NMe, S), electron-withdrawing groups (SO, SO2), and amides positioned within and hydroxyl substitutions on the linking side chain were investigated, which typically led to a loss in potency.  The most tolerant positions provided effective inhibitors (12p, 6-position S, Ki = 3 nM, or 13d, 2-position OH, Ki = 8 nM) comparable in potency to 2b.  Proteome-wide screening of selected inhibitors from the systematic series of >100 candidates prepd. revealed that they are selective for FAAH over all other mammalian serine proteases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFr5ELUCrPurVg90H21EOLACvtfcHk0liwerpb0NOprA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Kru70%253D&md5=6f64cd49c935c5aeaea5d0ba0d776bea</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Fjm061414r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061414r%26sid%3Dliteratum%253Aachs%26aulast%3DHardouin%26aufirst%3DC.%26aulast%3DKelso%26aufirst%3DM.%2BJ.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DRayl%26aufirst%3DT.%2BJ.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DHwang%26aufirst%3DI.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBoger%26aufirst%3DD.%2BL.%26atitle%3DStructure-activity%2520relationships%2520of%2520alpha-ketooxazole%2520inhibitors%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3359%26epage%3D3368%26doi%3D10.1021%2Fjm061414r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary PET imaging studies of a FAAH radiotracer ([<sup>11</sup>C]MPPO) based on alpha-ketoheterocyclic scaffold</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWltL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=109-118&author=L.+Wangauthor=J.+Yuiauthor=Q.+Wangauthor=Y.+Zhangauthor=W.+Moriauthor=Y.+Shimodaauthor=M.+Fujinagaauthor=K.+Kumataauthor=T.+Yamasakiauthor=A.+Hatoriauthor=B.+H.+Rotsteinauthor=T.+L.+Collierauthor=C.+Ranauthor=N.+Vasdevauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=Synthesis+and+preliminary+PET+imaging+studies+of+a+FAAH+radiotracer+%28%5B11C%5DMPPO%29+based+on+alpha-ketoheterocyclic+scaffold&doi=10.1021%2Facschemneuro.5b00248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Preliminary PET Imaging Studies of a FAAH Radiotracer ([11C]MPPO) Based on α-Ketoheterocyclic Scaffold</span></div><div class="casAuthors">Wang, Lu; Yui, Joji; Wang, Qifan; Zhang, Yiding; Mori, Wakana; Shimoda, Yoko; Fujinaga, Masayuki; Kumata, Katsushi; Yamasaki, Tomoteru; Hatori, Akiko; Rotstein, Benjamin H.; Collier, Thomas Lee; Ran, Chongzhao; Vasdev, Neil; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-118</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) is one of the principle enzymes for metabolizing endogenous cannabinoid neurotransmitters such as anandamide, and thus regulates endocannabinoid (eCB) signaling.  Selective pharmacol. blockade of FAAH has emerged as a potential therapy to discern the endogenous functions of anandamide-mediated eCB pathways in anxiety, pain, and addiction.  Quantification of FAAH in the living brain by positron emission tomog. (PET) would help our understanding of the endocannabinoid system in these conditions.  While most FAAH radiotracers operate by an irreversible ("suicide") binding mechanism, a FAAH tracer with reversibility would facilitate quant. anal.  We have identified and radiolabeled a reversible FAAH inhibitor, 7-(2-[11C]methoxyphenyl)-1-(5-(pyridin-2-yl)oxazol-2-yl)heptan-1-one ([11C]MPPO) in 13% radiochem. yield (nondecay cor.) with >99% radiochem. purity and 2 Ci/μmol (74 GBq/μmol) specific activity.  The tracer showed moderate brain uptake (0.8 SUV) with heterogeneous brain distribution.  However, blocking studies with a potent FAAH inhibitor URB597 demonstrated a low to modest specificity to the target.  Measurement of lipophilicity, metabolite, and efflux pathway anal. were also performed to study the pharmacokinetic profile of [11C]MPPO.  In all, we reported an efficient radiolabeling and preliminary evaluation of the first-in-class FAAH inhibitor [11C]MPPO with α-ketoheterocyclic scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpinihkxqhUKbVg90H21EOLACvtfcHk0ljR5x3-Tmkdag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWltL%252FP&md5=7fbd39323c54b80e222012094df4bce6</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00248%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYui%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DRan%26aufirst%3DC.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DSynthesis%2520and%2520preliminary%2520PET%2520imaging%2520studies%2520of%2520a%2520FAAH%2520radiotracer%2520%2528%255B11C%255DMPPO%2529%2520based%2520on%2520alpha-ketoheterocyclic%2520scaffold%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D109%26epage%3D118%26doi%3D10.1021%2Facschemneuro.5b00248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127513</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmcl.2020.127513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32860981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127513&author=Z.+Chenauthor=L.+Houauthor=J.+Ganauthor=Q.+Caiauthor=W.+Yeauthor=J.+Chenauthor=Z.+Tanauthor=C.+Zhengauthor=G.+Liauthor=H.+Xuauthor=C.+J.+Fowlerauthor=S.+H.+Liangauthor=L.+Wang&title=Synthesis+and+preliminary+evaluation+of+a+novel+positron+emission+tomography+%28PET%29+ligand+for+imaging+fatty+acid+amide+hydrolase+%28FAAH%29&doi=10.1016%2Fj.bmcl.2020.127513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH)</span></div><div class="casAuthors">Chen, Zhen; Hou, Lu; Gan, Jiefeng; Cai, Qijun; Ye, Weijian; Chen, Jiahui; Tan, Zhiqiang; Zheng, Chao; Li, Guocong; Xu, Hao; Fowler, Christopher J.; Liang, Steven H.; Wang, Lu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">127513</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) exerts its main function in the catabolism of the endogenous chem. messenger anandamide (AEA), thus modulating the endocannabinoid (eCB) pathway.  Inhibition of FAAH may serve as an effective strategy to relieve anxiety and possibly other central nervous system (CNS)-related disorders.  Positron emission tomog. (PET) would facilitate us to better understand the relationship between FAAH in certain disease conditions, and accelerate clin. translation of FAAH inhibitors by providing in vivo quant. information.  So far, most PET tracers show irreversible binding patterns with FAAH, which would result in complicated quant. processes.  Herein, we have identified a new FAAH inhibitor (1-((1-methyl-1H-indol-2-yl)methyl)piperidin-4-yl)(oxazol-2-yl)methanone (8) which inhibits the hydrolysis of AEA in the brain with high potency (IC50 value 11 nM at a substrate concn. of 0.5 μM), and without showing time-dependency.  The PET tracer [11C]8 (also called [11C]FAAH-1906) was successfully radiolabeled with [11C]MeI in 17 ± 6% decay-cor. radiochem. yield (n = 7) with >74.0 GBq/μmol (2 Ci/μmol) molar activity and >99% radiochem. purity.  Ex vivo biodistribution and blocking studies of [11C]8 in normal mice were also conducted, indicating good brain penetration, high brain target selectivity, and modest to excellent target selectivity in peripheral tissues.  Thus, [11C]8 is a potentially useful PET ligand with enzyme inhibitory and target binding properties consistent with a reversible mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo5IaDQQ8S_rVg90H21EOLACvtfcHk0ljR5x3-Tmkdag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsLrL&md5=95147be5650ba431674b3477e9be54f6</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127513%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DL.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DFowler%26aufirst%3DC.%2BJ.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520preliminary%2520evaluation%2520of%2520a%2520novel%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520ligand%2520for%2520imaging%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127513%26doi%3D10.1016%2Fj.bmcl.2020.127513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saario, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, R.</span></span> <span> </span><span class="NLM_article-title">Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1381</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2003.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bcp.2003.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15013854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVyhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2004&pages=1381-1387&author=S.+M.+Saarioauthor=J.+R.+Savinainenauthor=J.+T.+Laitinenauthor=T.+Jarvinenauthor=R.+Niemi&title=Monoglyceride+lipase-like+enzymatic+activity+is+responsible+for+hydrolysis+of+2-arachidonoylglycerol+in+rat+cerebellar+membranes&doi=10.1016%2Fj.bcp.2003.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes</span></div><div class="casAuthors">Saario, Susanna M.; Savinainen, Juha R.; Laitinen, Jarmo T.; Jarvinen, Tomi; Niemi, Riku</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1381-1387</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">2-Arachidonoylglycerol (2-AG) is an endogenous cannabinoid that binds to CB1 and CB2 cannabinoid receptors, inducing cannabimimetic effects.  However, the cannabimimetic effects of 2-AG are weak in vivo due to its rapid enzymic hydrolysis.  The enzymic hydrolysis of 2-AG has been proposed to mainly occur by monoglyceride lipase (monoacylglycerol lipase).  Fatty acid amide hydrolase (FAAH), the enzyme responsible for the hydrolysis of N-arachidonoylethanolamide (AEA), is also able to hydrolyze 2-AG.  In the present study, we investigated the hydrolysis of endocannabinoids in rat cerebellar membranes and obsd. that enzymic activity towards 2-AG was 50-fold higher than that towards AEA.  Furthermore, various inhibitors for 2-AG hydrolase activity were studied in rat cerebellar membranes.  2-AG hydrolysis was inhibited by Me arachidonylfluorophosphonate, hexadecylsulfonyl fluoride and phenylmethylsulfonyl fluoride with ic50 values of 2.2 nM, 241 nM and 155 μM, resp.  Potent FAAH inhibitors, such as OL-53 and URB597, did not inhibit the hydrolysis of 2-AG, suggesting that 2-AG is inactivated in rat cerebellar membranes by an enzyme distinct of FAAH.  The observation that the hydrolysis of 1(3)-AG and 2-AG occurred at equal rates supports the role of MGL in 2-AG inactivation.  This enzyme assay provides a useful method for future inhibition studies of 2-AG degrading enzyme(s) in brain membrane prepn. having considerably higher MGL-like activity when compared to FAAH activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi3kULx0FFRbVg90H21EOLACvtfcHk0ljR5x3-Tmkdag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVyhsLw%253D&md5=28b09b3dd9d8a19dc48196b737291fce</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2003.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2003.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DSaario%26aufirst%3DS.%2BM.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DLaitinen%26aufirst%3DJ.%2BT.%26aulast%3DJarvinen%26aufirst%3DT.%26aulast%3DNiemi%26aufirst%3DR.%26atitle%3DMonoglyceride%2520lipase-like%2520enzymatic%2520activity%2520is%2520responsible%2520for%2520hydrolysis%2520of%25202-arachidonoylglycerol%2520in%2520rat%2520cerebellar%2520membranes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D67%26spage%3D1381%26epage%3D1387%26doi%3D10.1016%2Fj.bcp.2003.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.chembiol.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18096503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1347-1356&author=J.+L.+Blankmanauthor=G.+M.+Simonauthor=B.+F.+Cravatt&title=A+comprehensive+profile+of+brain+enzymes+that+hydrolyze+the+endocannabinoid+2-arachidonoylglycerol&doi=10.1016%2Fj.chembiol.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol</span></div><div class="casAuthors">Blankman, Jacqueline L.; Simon, Gabriel M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Endogenous ligands for cannabinoid receptors ("endocannabinoids") include the lipid transmitters anandamide and 2-arachidonoylglycerol (2-AG).  Endocannabinoids modulate a diverse set of physiol. processes and are tightly regulated by enzymic biosynthesis and degrdn.  Termination of anandamide signaling by fatty acid amide hydrolase (FAAH) is well characterized, but less is known about the inactivation of 2-AG, which can be hydrolyzed by multiple enzymes in vitro, including FAAH and monoacylglycerol lipase (MAGL).  Here, we have taken a functional proteomic approach to comprehensively map 2-AG hydrolases in the mouse brain.  Our data reveal that ∼85% of brain 2-AG hydrolase activity can be ascribed to MAGL, and that the remaining 15% is mostly catalyzed by two uncharacterized enzymes, ABHD6 and ABHD12.  Interestingly, MAGL, ABHD6, and ABHD12 display distinct subcellular distributions, suggesting that they may control different pools of 2-AG in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF_Kmd_7v5urVg90H21EOLACvtfcHk0ljQLUGFjKRlhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE&md5=78c6355a3909bff3cbae25989ab6a956</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DSimon%26aufirst%3DG.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520comprehensive%2520profile%2520of%2520brain%2520enzymes%2520that%2520hydrolyze%2520the%2520endocannabinoid%25202-arachidonoylglycerol%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D1347%26epage%3D1356%26doi%3D10.1016%2Fj.chembiol.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and ex vivo evaluation of [11C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2014.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2014.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24969632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFentb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=688-694&author=J.+W.+Hicksauthor=J.+Parkesauthor=J.+Tongauthor=S.+Houleauthor=N.+Vasdevauthor=A.+A.+Wilson&title=Radiosynthesis+and+ex+vivo+evaluation+of+%5B11C-carbonyl%5Dcarbamate-+and+urea-based+monoacylglycerol+lipase+inhibitors&doi=10.1016%2Fj.nucmedbio.2014.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and ex vivo evaluation of [11C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors</span></div><div class="casAuthors">Hicks, Justin W.; Parkes, Jun; Tong, Junchao; Houle, Sylvain; Vasdev, Neil; Wilson, Alan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">688-694</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) are the two primary enzymes that regulate the tone of endocannabinoid signaling.  Although new PET radiotracers have been discovered for imaging FAAH in vivo, no such radiotracer exists for imaging MAGL.  Here we report the radiosynthesis of five candidate MAGL radiotracers and their ex vivo evaluations in mice and rats.Candidate carbamate and urea MAGL inhibitors were radiolabeled at the carbonyl position by [11C]CO2 fixation.  Radiotracers were administered (tail-vein injection) to rodents and brain uptake of radioactivity measured at early and late time points ex vivo.  Specificity of uptake was explored by pretreatment with unlabeled inhibitors (2 mg/kg, i.p.) 30 min prior to radiotracer administration.All five candidate MAGL radiotracers were prepd. in high specific activity (> 65 GBq/μmol) and radiochem. purity (> 98%).  Moderate brain uptake (0.2-0.8 SUV) was obsd. for each candidate while pretreatment did not reduce uptake for four of the five tested.  For two candidates ([11C]12 and [11C]14), high retention of radioactivity was obsd. in the blood (ca. 10 and 4 SUV at 40 min) which was blocked by pretreatment with unlabeled inhibitors.  The most promising candidate, [11C]18, demonstrated moderate brain uptake (ca. 0.8 SUV) which showed circa 50% blockade by pretreatment with unlabeled 18.One putative and four reported potent and selective MAGL inhibitors have been radiolabeled via [11C]CO2 fixation as radiotracers for this enzyme.  Despite the promising in vitro pharmacol. profile, none of the five candidate radiotracers exhibited in vivo behavior suitable for PET neuroimaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi4CWj3XLZqrVg90H21EOLACvtfcHk0ljQLUGFjKRlhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFentb3M&md5=dcedea3b995995c96c88e7fa130378fa</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2014.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2014.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DJ.%2BW.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26atitle%3DRadiosynthesis%2520and%2520ex%2520vivo%2520evaluation%2520of%2520%255B11C-carbonyl%255Dcarbamate-%2520and%2520urea-based%2520monoacylglycerol%2520lipase%2520inhibitors%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2014%26volume%3D41%26spage%3D688%26epage%3D694%26doi%3D10.1016%2Fj.nucmedbio.2014.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griebel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeske, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Even, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Grancha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstykh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederschain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergis, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avenet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escoubet, J.</span></span> <span> </span><span class="NLM_article-title">Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">7642</span>, <span class="refDoi"> DOI: 10.1038/srep07642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fsrep07642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25560837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGgurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=7642&author=G.+Griebelauthor=P.+Pichatauthor=S.+Beeskeauthor=T.+Leroyauthor=N.+Redonauthor=A.+Jacquetauthor=D.+Franconauthor=L.+Bertauthor=L.+Evenauthor=M.+Lopez-Granchaauthor=T.+Tolstykhauthor=F.+Sunauthor=Q.+Yuauthor=S.+Brittainauthor=H.+Arltauthor=T.+Heauthor=B.+Zhangauthor=D.+Wiederschainauthor=T.+Bertrandauthor=J.+Houtmannauthor=A.+Rakauthor=F.+Valleeauthor=N.+Michotauthor=F.+Augeauthor=V.+Menetauthor=O.+E.+Bergisauthor=P.+Georgeauthor=P.+Avenetauthor=V.+Mikolauthor=M.+Didierauthor=J.+Escoubet&title=Selective+blockade+of+the+hydrolysis+of+the+endocannabinoid+2-arachidonoylglycerol+impairs+learning+and+memory+performance+while+producing+antinociceptive+activity+in+rodents&doi=10.1038%2Fsrep07642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents</span></div><div class="casAuthors">Griebel, Guy; Pichat, Philippe; Beeske, Sandra; Leroy, Thibaud; Redon, Nicolas; Jacquet, Agnes; Francon, Dominique; Bert, Lionel; Even, Luc; Lopez-Grancha, Mati; Tolstykh, Tatiana; Sun, Fangxian; Yu, Qunyan; Brittain, Scott; Arlt, Heike; He, Timothy; Zhang, Bailin; Wiederschain, Dmitri; Bertrand, Thomas; Houtmann, Jacques; Rak, Alexey; Vallee, Francois; Michot, Nadine; Auge, Franck; Menet, Veronique; Bergis, Olivier E.; George, Pascal; Avenet, Patrick; Mikol, Vincent; Didier, Michel; Escoubet, Johanna</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7642</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) represents a primary degrdn. enzyme of the endogenous cannabinoid (eCB), 2-arachidonoyglycerol (2-AG).  This study reports a potent covalent MAGL inhibitor, SAR127303.  The compd. behaves as a selective and competitive inhibitor of mouse and human MAGL, which potently elevates hippocampal levels of 2-AG in mice.  In vivo, SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain.  In addn., the drug alters learning performance in several assays related to episodic, working and spatial memory.  Moreover, long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus, two hallmarks of memory function, are both decreased by SAR127303.  Although inactive in acute seizure tests, repeated administration of SAR127303 delays the acquisition and decreases kindled seizures in mice, indicating that the drug slows down epileptogenesis, a finding deserving further investigation to evaluate the potential of MAGL inhibitors as antiepileptics.  However, the observation that 2-AG hydrolysis blockade alters learning and memory performance, suggests that such drugs may have limited value as therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiPpgk18M26bVg90H21EOLACvtfcHk0ljQLUGFjKRlhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGgurrL&md5=4160ed016b730ea80abb5c093e66a284</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1038%2Fsrep07642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep07642%26sid%3Dliteratum%253Aachs%26aulast%3DGriebel%26aufirst%3DG.%26aulast%3DPichat%26aufirst%3DP.%26aulast%3DBeeske%26aufirst%3DS.%26aulast%3DLeroy%26aufirst%3DT.%26aulast%3DRedon%26aufirst%3DN.%26aulast%3DJacquet%26aufirst%3DA.%26aulast%3DFrancon%26aufirst%3DD.%26aulast%3DBert%26aufirst%3DL.%26aulast%3DEven%26aufirst%3DL.%26aulast%3DLopez-Grancha%26aufirst%3DM.%26aulast%3DTolstykh%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DBrittain%26aufirst%3DS.%26aulast%3DArlt%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWiederschain%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DHoutmann%26aufirst%3DJ.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DVallee%26aufirst%3DF.%26aulast%3DMichot%26aufirst%3DN.%26aulast%3DAuge%26aufirst%3DF.%26aulast%3DMenet%26aufirst%3DV.%26aulast%3DBergis%26aufirst%3DO.%2BE.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DAvenet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DDidier%26aufirst%3DM.%26aulast%3DEscoubet%26aufirst%3DJ.%26atitle%3DSelective%2520blockade%2520of%2520the%2520hydrolysis%2520of%2520the%2520endocannabinoid%25202-arachidonoylglycerol%2520impairs%2520learning%2520and%2520memory%2520performance%2520while%2520producing%2520antinociceptive%2520activity%2520in%2520rodents%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D7642%26doi%3D10.1038%2Fsrep07642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Placzek, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de
Bittner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">A novel radiotracer for imaging monoacylglycerol lipase in the brain using positron emission tomography</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=484-489&author=C.+Wangauthor=M.+S.+Placzekauthor=G.+C.+Van+de%0ABittnerauthor=F.+A.+Schroederauthor=J.+M.+Hooker&title=A+novel+radiotracer+for+imaging+monoacylglycerol+lipase+in+the+brain+using+positron+emission+tomography&doi=10.1021%2Facschemneuro.5b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Radiotracer for Imaging Monoacylglycerol Lipase in the Brain Using Positron Emission Tomography</span></div><div class="casAuthors">Wang, Changning; Placzek, Michael S.; Van de Bittner, Genevieve C.; Schroeder, Frederick A.; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">484-489</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a serine hydrolase that hydrolyzes monoacylglycerols to glycerol and fatty acid and plays an important role in neuroinflammation.  MAGL inhibitors are a class of mols. with therapeutic potential for human diseases of the central nervous system (CNS), in areas such as pain and inflammation, immunol. disorders, and neurol. and psychiatric conditions.  Development of a noninvasive imaging probe would elucidate the distribution and functional roles of MAGL in the brain and accelerate medical research and drug discovery in this domain.  Herein, we describe the synthesis and pilot rodent imaging of a novel MAGL imaging agent, [11C]SAR127303.  Our imaging results demonstrate the high specificity, good selectivity, and appropriate kinetics and distribution of [11C]SAR127303, validating its utility for imaging MAGL in the brain.  Our findings support the translational potential for human CNS MAGL imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwFMlYYqhfbVg90H21EOLACvtfcHk0ljgfBmApMbRpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7nP&md5=0cc854816045539b5ccb7b5d7819372b</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00293%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPlaczek%26aufirst%3DM.%2BS.%26aulast%3DVan%2Bde%2BBittner%26aufirst%3DG.%2BC.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DA%2520novel%2520radiotracer%2520for%2520imaging%2520monoacylglycerol%2520lipase%2520in%2520the%2520brain%2520using%2520positron%2520emission%2520tomography%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D484%26epage%3D489%26doi%3D10.1021%2Facschemneuro.5b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minamimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of sulfonamido-based [11C-Carbonyl]-carbamates and ureas for imaging monoacylglycerol lipase</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.7150/thno.15257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.7150%2Fthno.15257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27279908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Cis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1145-1159&author=L.+Wangauthor=W.+Moriauthor=R.+Chengauthor=J.+J.+Yuiauthor=A.+Hatoriauthor=L.+L.+Maauthor=Y.+D.+Zhangauthor=B.+H.+Rotsteinauthor=M.+Fujinagaauthor=Y.+Shimodaauthor=T.+Yamasakiauthor=L.+Xieauthor=Y.+Nagaiauthor=T.+Minamimotoauthor=M.+Higuchiauthor=N.+Vasdevauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=Synthesis+and+preclinical+evaluation+of+sulfonamido-based+%5B11C-Carbonyl%5D-carbamates+and+ureas+for+imaging+monoacylglycerol+lipase&doi=10.7150%2Fthno.15257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preclinical evaluation of sulfonamidobased [11C-carbonyl]-carbamates and ureas for imaging monoacylglycerol lipase</span></div><div class="casAuthors">Wang, Lu; Mori, Wakana; Cheng, Ran; Yui, Joji; Hatori, Akiko; Ma, Longle; Zhang, Yiding; Rotstein, Benjamin H.; Fujinaga, Masayuki; Shimoda, Yoko; Yamasaki, Tomoteru; Xie, Lin; Nagai, Yuji; Minamimoto, Takafumi; Higuchi, Makoto; Vasdev, Neil; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1145-1159</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a 33 kDa member of the serine hydrolase superfamily that preferentially degrades 2-arachidonoylglycerol (2-AG) to arachidonic acid in the endocannabinoid system.  Inhibition of MAGL is not only of interest for probing the cannabinoid pathway but also as a therapeutic and diagnostic target for neuroinflammation.  Limited attempts have been made to image MAGL in vivo and a suitable PET ligand for this target has yet to be identified and is urgently sought to guide small mol. drug development in this pathway.  Herein we synthesized and evaluated the physiochem. properties of an array of eleven sulfonamido-based carbamates and ureas with a series of terminal aryl moieties, linkers and leaving groups.  The most potent compds. were a novel MAGL inhibitor, N-((1-(1H-1,2,4-triazole-1-carbonyl)piperidin-4-yl) methyl)-4-chlorobenzenesulfonamide (TZPU; IC50 = 35.9 nM), and the known inhibitor 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(((4-chlorophenyl)sulfonamido) methyl)piperidine-1- carboxylate (SAR127303; IC50 = 39.3 nM), which were also shown to be selective for MAGL over fatty acid amide hydrolase (FAAH), and cannabinoid receptors (CB1 & CB2).  Both of these compds. were radiolabeled with carbon-11 via [11C]COCl2, followed by comprehensive ex vivo biodistribution and in vivo PET imaging studies in normal rats to det. their brain permeability, specificity, clearance and metab.  Whereas TZPU did not show adequate specificity to warrant further evaluation, [11C]SAR127303 was advanced for preliminary PET neuroimaging studies in nonhuman primate.  The tracer showed good brain permeability (ca. 1 SUV) and heterogeneous regional brain distribution which is consistent with the distribution of MAGL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5MOdhV6XvFbVg90H21EOLACvtfcHk0ljgfBmApMbRpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Cis78%253D&md5=eb8493b2b83af17721a22d03151b7ba2</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.7150%2Fthno.15257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.15257%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DYui%26aufirst%3DJ.%2BJ.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DL.%2BL.%26aulast%3DZhang%26aufirst%3DY.%2BD.%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DMinamimoto%26aufirst%3DT.%26aulast%3DHiguchi%26aufirst%3DM.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520sulfonamido-based%2520%255B11C-Carbonyl%255D-carbamates%2520and%2520ureas%2520for%2520imaging%2520monoacylglycerol%2520lipase%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D1145%26epage%3D1159%26doi%3D10.7150%2Fthno.15257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attili, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veghel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooms, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berben, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of [<sup>11</sup>C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejmech.2017.04.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28486208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVansro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=104-113&author=M.+Ahamedauthor=B.+Attiliauthor=D.+van+Veghelauthor=M.+Oomsauthor=P.+Berbenauthor=S.+Celenauthor=M.+Kooleauthor=L.+Declercqauthor=J.+R.+Savinainenauthor=J.+T.+Laitinenauthor=A.+Verbruggenauthor=G.+Bormans&title=Synthesis+and+preclinical+evaluation+of+%5B11C%5DMA-PB-1+for+in+vivo+imaging+of+brain+monoacylglycerol+lipase+%28MAGL%29&doi=10.1016%2Fj.ejmech.2017.04.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preclinical evaluation of [11C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL)</span></div><div class="casAuthors">Ahamed, Muneer; Attili, Bala; van Veghel, Daisy; Ooms, Maarten; Berben, Philippe; Celen, Sofie; Koole, Michel; Declercq, Lieven; Savinainen, Juha R.; Laitinen, Jarmo T.; Verbruggen, Alfons; Bormans, Guy</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-113</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Synthesis and preclin. evaluation of labeled [11C]MA-PB-1 (I) as an irreversible MAGL (monoacylglycerol lipase) inhibitor PET tracer is reported.  The in-vitro inhibitory activity, ex-vivo distribution, brain kinetics and specificity of compd. I binding were studied.  Ex-vivo biodistribution and microPET showed good brain uptake which could be blocked by pretreatment with both compd. I and a structurally non-related MAGL inhibitor MJN110 (compd. II).  These initial results suggested that compd. I is a suitable tracer for in-vivo imaging of MAGL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZZw-mML3QX7Vg90H21EOLACvtfcHk0liCzTJMn5kVig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVansro%253D&md5=8247caa5fc4f5d0bbee21e96c4dfbb24</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.066%26sid%3Dliteratum%253Aachs%26aulast%3DAhamed%26aufirst%3DM.%26aulast%3DAttili%26aufirst%3DB.%26aulast%3Dvan%2BVeghel%26aufirst%3DD.%26aulast%3DOoms%26aufirst%3DM.%26aulast%3DBerben%26aufirst%3DP.%26aulast%3DCelen%26aufirst%3DS.%26aulast%3DKoole%26aufirst%3DM.%26aulast%3DDeclercq%26aufirst%3DL.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DLaitinen%26aufirst%3DJ.%2BT.%26aulast%3DVerbruggen%26aufirst%3DA.%26aulast%3DBormans%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520%255B11C%255DMA-PB-1%2520for%2520in%2520vivo%2520imaging%2520of%2520brain%2520monoacylglycerol%2520lipase%2520%2528MAGL%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D104%26epage%3D113%26doi%3D10.1016%2Fj.ejmech.2017.04.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawrylik, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noell, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span> <span> </span><span class="NLM_article-title">Azetidine and piperidine carbamates as efficient, covalent inhibitors of monoacylglycerol lipase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9860</span>– <span class="NLM_lpage">9873</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01531</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01531" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9860-9873&author=C.+R.+Butlerauthor=E.+M.+Beckauthor=A.+Harrisauthor=Z.+Huangauthor=L.+A.+McAllisterauthor=C.+W.+Am+Endeauthor=K.+Fennellauthor=T.+L.+Foleyauthor=K.+Fonsecaauthor=S.+J.+Hawrylikauthor=D.+S.+Johnsonauthor=J.+D.+Knafelsauthor=S.+Menteauthor=G.+S.+Noellauthor=J.+Panditauthor=T.+B.+Phillipsauthor=J.+R.+Piroauthor=B.+N.+Rogersauthor=T.+A.+Samadauthor=J.+Wangauthor=S.+Wanauthor=M.+A.+Brodney&title=Azetidine+and+piperidine+carbamates+as+efficient%2C+covalent+inhibitors+of+monoacylglycerol+lipase&doi=10.1021%2Facs.jmedchem.7b01531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Azetidine and Piperidine Carbamates as Efficient, Covalent Inhibitors of Monoacylglycerol Lipase</span></div><div class="casAuthors">Butler, Christopher R.; Beck, Elizabeth M.; Harris, Anthony; Huang, Zhen; McAllister, Laura A.; am Ende, Christopher W.; Fennell, Kimberly; Foley, Timothy L.; Fonseca, Kari; Hawrylik, Steven J.; Johnson, Douglas S.; Knafels, John D.; Mente, Scot; Noell, G. Stephen; Pandit, Jayvardhan; Phillips, Tracy B.; Piro, Justin R.; Rogers, Bruce N.; Samad, Tarek A.; Wang, Jane; Wan, Shuangyi; Brodney, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9860-9873</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is the main enzyme responsible for degrdn. of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the CNS.  MAGL catalyzes the conversion of 2-AG to arachidonic acid (AA), a precursor to the proinflammatory eicosannoids such as prostaglandins.  Herein the authors describe highly efficient MAGL inhibitors, identified through a parallel medicinal chem. approach that highlighted the improved efficiency of azetidine and piperidine-derived carbamates.  The discovery and optimization of 3-substituted azetidine carbamate irreversible inhibitors of MAGL were aided by the generation of inhibitor-bound MAGL crystal structures.  Compd. 6 (1,1,1,3,3,3-hexafluoropropan-2-yl 3-(1-phenyl-1H-pyrazol-3-yl)azetidine-1-carboxylate), a highly efficient and selective MAGL inhibitor against recombinant enzyme and in a cellular context, was tested in vivo and shown to elevate central 2-AG levels at a 10 mg/kg dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoRIXhdu0BLrVg90H21EOLACvtfcHk0liCzTJMn5kVig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqurzO&md5=b89f7d44f611dd84cd49a8d240ac26b0</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01531%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMcAllister%26aufirst%3DL.%2BA.%26aulast%3DAm%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DFennell%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DT.%2BL.%26aulast%3DFonseca%26aufirst%3DK.%26aulast%3DHawrylik%26aufirst%3DS.%2BJ.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DNoell%26aufirst%3DG.%2BS.%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DT.%2BB.%26aulast%3DPiro%26aufirst%3DJ.%2BR.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DSamad%26aufirst%3DT.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DS.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26atitle%3DAzetidine%2520and%2520piperidine%2520carbamates%2520as%2520efficient%252C%2520covalent%2520inhibitors%2520of%2520monoacylglycerol%2520lipase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9860%26epage%3D9873%26doi%3D10.1021%2Facs.jmedchem.7b01531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhouayek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minamimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondrechen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of 11C-Labeled azetidinecarboxylates for imaging monoacylglycerol lipase by PET imaging studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2278</span>– <span class="NLM_lpage">2291</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01400</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01400" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlOmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2278-2291&author=R.+Chengauthor=W.+Moriauthor=L.+Maauthor=M.+Alhouayekauthor=A.+Hatoriauthor=Y.+Zhangauthor=D.+Ogasawaraauthor=G.+Yuanauthor=Z.+Chenauthor=X.+Zhangauthor=H.+Shiauthor=T.+Yamasakiauthor=L.+Xieauthor=K.+Kumataauthor=M.+Fujinagaauthor=Y.+Nagaiauthor=T.+Minamimotoauthor=M.+Svenssonauthor=L.+Wangauthor=Y.+Duauthor=M.+J.+Ondrechenauthor=N.+Vasdevauthor=B.+F.+Cravattauthor=C.+Fowlerauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=In+vitro+and+in+vivo+evaluation+of+11C-Labeled+azetidinecarboxylates+for+imaging+monoacylglycerol+lipase+by+PET+imaging+studies&doi=10.1021%2Facs.jmedchem.7b01400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and in Vivo Evaluation of 11C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies</span></div><div class="casAuthors">Cheng, Ran; Mori, Wakana; Ma, Longle; Alhouayek, Mireille; Hatori, Akiko; Zhang, Yiding; Ogasawara, Daisuke; Yuan, Gengyang; Chen, Zhen; Zhang, Xiaofei; Shi, Hang; Yamasaki, Tomoteru; Xie, Lin; Kumata, Katsushi; Fujinaga, Masayuki; Nagai, Yuji; Minamimoto, Takafumi; Svensson, Mona; Wang, Lu; Du, Yunfei; Ondrechen, Mary Jo; Vasdev, Neil; Cravatt, Benjamin F.; Fowler, Christopher; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2278-2291</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is the principle enzyme for metabolizing endogenous cannabinoid ligand 2-arachidonoyglycerol (2-AG).  Blockade of MAGL increases 2-AG levels, resulting in subsequent activation of the endocannabinoid system, and has emerged as a novel therapeutic strategy to treat drug addiction, inflammation, and neurodegenerative diseases.  Herein we report a new series of MAGL inhibitors, which were radiolabeled by site-specific labeling technologies, including 11C-carbonylation and spirocyclic iodonium ylide (SCIDY) radiofluorination.  The lead compd. [11C]10 (MAGL-0519) demonstrated high specific binding and selectivity in vitro and in vivo.  We also obsd. unexpected washout kinetics with these irreversible radiotracers, in which in vivo evidence for turnover of the covalent residue was unveiled between MAGL and azetidine carboxylates.  This work may lead to new directions for drug discovery and PET tracer development based on azetidine carboxylate inhibitor scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm2LL5zxwjx7Vg90H21EOLACvtfcHk0lj8NPH2kKqKwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlOmtb8%253D&md5=b2b4ddcfcccadac13be8d731127df7db</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01400%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DAlhouayek%26aufirst%3DM.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DMinamimoto%26aufirst%3DT.%26aulast%3DSvensson%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DOndrechen%26aufirst%3DM.%2BJ.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DFowler%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%252011C-Labeled%2520azetidinecarboxylates%2520for%2520imaging%2520monoacylglycerol%2520lipase%2520by%2520PET%2520imaging%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2278%26epage%3D2291%26doi%3D10.1021%2Facs.jmedchem.7b01400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafroth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of reversible and irreversible monoacylglycerol lipase positron emission tomography (PET) tracers using a ’tail switching’ strategy on a piperazinyl azetidine skeleton</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3336</span>– <span class="NLM_lpage">3353</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01778</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01778" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktV2mtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3336-3353&author=Z.+Chenauthor=W.+Moriauthor=X.+Dengauthor=R.+Chengauthor=D.+Ogasawaraauthor=G.+Zhangauthor=M.+A.+Schafrothauthor=K.+Dahlauthor=H.+Fuauthor=A.+Hatoriauthor=T.+Shaoauthor=Y.+Zhangauthor=T.+Yamasakiauthor=X.+Zhangauthor=J.+Rongauthor=Q.+Yuauthor=K.+Huauthor=M.+Fujinagaauthor=L.+Xieauthor=K.+Kumataauthor=Y.+Gouauthor=J.+Chenauthor=S.+Guauthor=L.+Baoauthor=L.+Wangauthor=T.+L.+Collierauthor=N.+Vasdevauthor=Y.+Shaoauthor=J.+A.+Maauthor=B.+F.+Cravattauthor=C.+Fowlerauthor=L.+Josephsonauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=Design%2C+synthesis+and+evaluation+of+reversible+and+irreversible+monoacylglycerol+lipase+positron+emission+tomography+%28PET%29+tracers+using+a+%E2%80%99tail+switching%E2%80%99+strategy+on+a+piperazinyl+azetidine+skeleton&doi=10.1021%2Facs.jmedchem.8b01778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a "Tail Switching" Strategy on a Piperazinyl Azetidine Skeleton</span></div><div class="casAuthors">Chen, Zhen; Mori, Wakana; Deng, Xiaoyun; Cheng, Ran; Ogasawara, Daisuke; Zhang, Genwei; Schafroth, Michael A.; Dahl, Kenneth; Fu, Hualong; Hatori, Akiko; Shao, Tuo; Zhang, Yiding; Yamasaki, Tomoteru; Zhang, Xiaofei; Rong, Jian; Yu, Qingzhen; Hu, Kuan; Fujinaga, Masayuki; Xie, Lin; Kumata, Katsushi; Gou, Yuancheng; Chen, Jingjin; Gu, Shuyin; Bao, Liang; Wang, Lu; Collier, Thomas Lee; Vasdev, Neil; Shao, Yihan; Ma, Jun-An; Cravatt, Benjamin F.; Fowler, Christopher; Josephson, Lee; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3336-3353</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a serine hydrolase that degrades 2-arachidonoylglycerol (2-AG) in the endocannabinoid system (eCB).  Selective inhibition of MAGL has emerged as a potential therapeutic approach for the treatment of diverse pathol. conditions, including chronic pain, inflammation, cancer, and neurodegeneration.  Herein, we disclose a novel array of reversible and irreversible MAGL inhibitors by means of "tail switching" on a piperazinyl azetidine scaffold.  We developed a lead irreversible-binding MAGL inhibitor 8 and reversible-binding compds. 17 and 37, which are amenable for radiolabeling with 11C or 18F. [11C]8 ([11C]MAGL-2-11) exhibited high brain uptake and excellent binding specificity in the brain toward MAGL.  Reversible radioligands [11C]17 ([11C]PAD) and [18F]37 ([18F]MAGL-4-11) also demonstrated excellent in vivo binding specificity toward MAGL in peripheral organs.  This work may pave the way for the development of MAGL-targeted positron emission tomog. tracers with tunability in reversible and irreversible binding mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq14JLjFrGKxrVg90H21EOLACvtfcHk0lj8NPH2kKqKwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktV2mtbs%253D&md5=261c3ea3d090e90c7f3c23701a0c9c34</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01778%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DSchafroth%26aufirst%3DM.%2BA.%26aulast%3DDahl%26aufirst%3DK.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRong%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DS.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DJ.%2BA.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DFowler%26aufirst%3DC.%26aulast%3DJosephson%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520reversible%2520and%2520irreversible%2520monoacylglycerol%2520lipase%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520tracers%2520using%2520a%2520%25E2%2580%2599tail%2520switching%25E2%2580%2599%2520strategy%2520on%2520a%2520piperazinyl%2520azetidine%2520skeleton%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3336%26epage%3D3353%26doi%3D10.1021%2Facs.jmedchem.8b01778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neidhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, G.</span></span> <span> </span><span class="NLM_article-title">“Scaffold-Hopping” by topological pharmacophore search: a contribution to virtual screening</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2894</span>– <span class="NLM_lpage">2896</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1521-3773(19991004)38:19<2894::AID-ANIE2894>3.0.CO;2-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2F%28SICI%291521-3773%2819991004%2938%3A19%3C2894%3A%3AAID-ANIE2894%3E3.0.CO%3B2-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK1MXmslKht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=2894-2896&author=G.+Schneiderauthor=W.+Neidhartauthor=T.+Gillerauthor=G.+Schmid&title=%E2%80%9CScaffold-Hopping%E2%80%9D+by+topological+pharmacophore+search%3A+a+contribution+to+virtual+screening&doi=10.1002%2F%28SICI%291521-3773%2819991004%2938%3A19%3C2894%3A%3AAID-ANIE2894%3E3.0.CO%3B2-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">"Scaffold-Hopping" by topological pharmacophore search: a contribution to virtual screening</span></div><div class="casAuthors">Schneider, Gisbert; Neidhart, Werner; Giller, Thomas; Schmid, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2894-2896</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">We present the successful application of a novel straightforward technique to "scaffold-hopping", i.e., identification of isofunctional mol. structures with significantly different mol. backbones.  The technique was applied to the prediction of novel cardiac T-type Ca2+ channel blocking agents using mibefradil as the seed structure.  The 12 highest-ranking mols. were tested using a cell culture assay for their ability to inhibit cellular Ca2+ influx.  One compd. (clopimozide) had an IC50 < 1 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgaa9cDF2whrVg90H21EOLACvtfcHk0lhB0dE7FqR1xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmslKht78%253D&md5=460b2116abc32e54ba9eb3b712333eb9</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-3773%2819991004%2938%3A19%3C2894%3A%3AAID-ANIE2894%3E3.0.CO%3B2-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-3773%252819991004%252938%253A19%253C2894%253A%253AAID-ANIE2894%253E3.0.CO%253B2-F%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DGiller%26aufirst%3DT.%26aulast%3DSchmid%26aufirst%3DG.%26atitle%3D%25E2%2580%259CScaffold-Hopping%25E2%2580%259D%2520by%2520topological%2520pharmacophore%2520search%253A%2520a%2520contribution%2520to%2520virtual%2520screening%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1999%26volume%3D38%26spage%3D2894%26epage%3D2896%26doi%3D10.1002%2F%28SICI%291521-3773%2819991004%2938%3A19%3C2894%3A%3AAID-ANIE2894%3E3.0.CO%3B2-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpfe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in scaffold hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1246</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01437</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSks7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1238-1246&author=Y.+Huauthor=D.+Stumpfeauthor=J.+Bajorath&title=Recent+advances+in+scaffold+hopping&doi=10.1021%2Facs.jmedchem.6b01437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Scaffold Hopping</span></div><div class="casAuthors">Hu, Ye; Stumpfe, Dagmar; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1238-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Scaffold hopping refers to the computer-aided search for active compds. contg. different core structures, which is a topic of high interest in medicinal chem.  Herein foundations and caveats of scaffold hopping approaches are discussed and recent methodol. developments analyzed.  Despite the conceptual prevalence of pharmacophore methods for scaffold hopping, a variety of computational approaches have been successfully applied.  In recent years, scaffold hopping calcns. are increasingly carried out at the level of scaffolds rather than compds., and scaffold queries increasingly from chem. structures.  In addn., relationships between compds., scaffolds, and biol. activities are beginning to be globally explored, beyond individual applications.  Going forward, computational scaffold hopping is thought to benefit from the consideration of new scaffold concepts and the development of methods capable of guiding search calcns. toward scaffolds that are likely to represent potent compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreklFOuNfjw7Vg90H21EOLACvtfcHk0lhB0dE7FqR1xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSks7%252FM&md5=a845ab13a7af0e397eedc94f7adcf870</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01437%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DStumpfe%26aufirst%3DD.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520in%2520scaffold%2520hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1238%26epage%3D1246%26doi%3D10.1021%2Facs.jmedchem.6b01437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary evaluation of a 11C-labeled piperidin-4-yl azetidine diamide for imaging monoacylglycerol lipase</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1004</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26966158" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=1004&author=L.+Wangauthor=M.+Fujinagaauthor=R.+Chengauthor=J.+Yuiauthor=Y.+Shimodaauthor=B.+Rotsteinauthor=Y.+Zhangauthor=N.+Vasdevauthor=M.+R.+Zhangauthor=S.+Liang&title=Synthesis+and+preliminary+evaluation+of+a+11C-labeled+piperidin-4-yl+azetidine+diamide+for+imaging+monoacylglycerol+lipase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DYui%26aufirst%3DJ.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DRotstein%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520preliminary%2520evaluation%2520of%2520a%252011C-labeled%2520piperidin-4-yl%2520azetidine%2520diamide%2520for%2520imaging%2520monoacylglycerol%2520lipase%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2016%26volume%3D57%26spage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and evaluation of a novel monoacylglycerol lipase radiotracer: 1,1,1,3,3,3-hexafluoropropan-2-yl-3-(1-benzyl-1H-pyrazol-3-yl)azetidine-1-[<sup>11</sup>C] carboxylate</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3568</span>– <span class="NLM_lpage">3573</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.06.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmc.2019.06.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31278005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSmsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=3568-3573&author=W.+Moriauthor=A.+Hatoriauthor=Y.+Zhangauthor=Y.+Kuriharaauthor=T.+Yamasakiauthor=L.+Xieauthor=K.+Kumataauthor=K.+Huauthor=M.+Fujinagaauthor=M.+R.+Zhang&title=Radiosynthesis+and+evaluation+of+a+novel+monoacylglycerol+lipase+radiotracer%3A+1%2C1%2C1%2C3%2C3%2C3-hexafluoropropan-2-yl-3-%281-benzyl-1H-pyrazol-3-yl%29azetidine-1-%5B11C%5D+carboxylate&doi=10.1016%2Fj.bmc.2019.06.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and evaluation of a novel monoacylglycerol lipase radiotracer: 1,1,1,3,3,3-hexafluoropropan-2-yl-3-(1-benzyl-1H-pyrazol-3-yl)azetidine-1-[11C]carboxylate</span></div><div class="casAuthors">Mori, Wakana; Hatori, Akiko; Zhang, Yiding; Kurihara, Yusuke; Yamasaki, Tomoteru; Xie, Lin; Kumata, Katsushi; Hu, Kuan; Fujinaga, Masayuki; Zhang, Ming-Rong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3568-3573</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) into arachidonic acid (AA) and glycerol in the brain.  Because 2-AG and AA are endogenous biol. active ligands in the brain, the inhibition of MAGL is an attractive therapeutic target for neurodegenerative diseases.  In this study, to visualize MAGL via positron emission tomog. (PET), we report a new carbon-11-labeled radiotracer, namely 1,1,1,3,3,3-hexafluoropropan-2-yl-3-(1-benzyl-1H-pyrazol-3-yl)azetidine-1-[11C]carboxylate ([11C]6).  Compd. 6 exhibited high in vitro binding affinity (IC50 = 0.41 nM) to MAGL in the brain with a suitable lipophilicity (cLogD = 3.29). [11C]6 was synthesized by reacting 1,1,1,3,3,3-hexafluoropropanol (7) with [11C]phosgene ([11C]COCl2), followed by a reaction with 3-(1-benzyl-1H-pyrazol-3-yl)azetidine hydrochloride (8), which resulted in a 15.0 ± 6.8% radiochem. yield (decay-cor., n = 7) based on [11C]CO2 and a 45 min synthesis time from the end of bombardment.  A biodistribution study in mice showed high uptake of radioactivity in MAGL-rich organs, including the lungs, heart, and kidneys.  More than 90% of the total radioactivity was irreversibly bound in the brain homogenate of rats 5 min and 30 min after the radiotracer injection.  PET summation images of rat brains showed high radioactivity in all brain regions.  Pretreatment with 6 or MAGL-selective inhibitor JW642 significantly reduced the uptake of radioactivity in the brain. [11C]6 is a promising PET tracer which offers in vivo specific binding and selectivity for MAGL in rodent brains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5t0r8GBm6l7Vg90H21EOLACvtfcHk0lhB0dE7FqR1xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSmsbbO&md5=5c6855f4a736513f1a37562f37bff574</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.06.037%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DW.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26atitle%3DRadiosynthesis%2520and%2520evaluation%2520of%2520a%2520novel%2520monoacylglycerol%2520lipase%2520radiotracer%253A%25201%252C1%252C1%252C3%252C3%252C3-hexafluoropropan-2-yl-3-%25281-benzyl-1H-pyrazol-3-yl%2529azetidine-1-%255B11C%255D%2520carboxylate%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D3568%26epage%3D3573%26doi%3D10.1016%2Fj.bmc.2019.06.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maresca, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildknegt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span> <span> </span><span class="NLM_article-title">Identification and development of an irreversible monoacylglycerol lipase (MAGL) positron emission tomography (PET) radioligand with high specificity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8532</span>– <span class="NLM_lpage">8543</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00847</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00847" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslSqsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8532-8543&author=L.+Zhangauthor=C.+R.+Butlerauthor=K.+P.+Marescaauthor=A.+Takanoauthor=S.+Nagauthor=Z.+Jiaauthor=R.+Arakawaauthor=J.+R.+Piroauthor=T.+Samadauthor=D.+L.+Smithauthor=D.+M.+Nasonauthor=S.+O%E2%80%99Neilauthor=L.+McAllisterauthor=K.+Schildknegtauthor=P.+Trapaauthor=T.+J.+McCarthyauthor=A.+Villalobosauthor=C.+Halldin&title=Identification+and+development+of+an+irreversible+monoacylglycerol+lipase+%28MAGL%29+positron+emission+tomography+%28PET%29+radioligand+with+high+specificity&doi=10.1021%2Facs.jmedchem.9b00847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Development of an Irreversible Monoacylglycerol Lipase (MAGL) Positron Emission Tomography (PET) Radioligand with High Specificity</span></div><div class="casAuthors">Zhang, Lei; Butler, Christopher R.; Maresca, Kevin P.; Takano, Akihiro; Nag, Sangram; Jia, Zhisheng; Arakawa, Ryosuke; Piro, Justin R.; Samad, Tarek; Smith, Deborah L.; Nason, Deane M.; O'Neil, Steven; McAllister, Laura; Schildknegt, Klaas; Trapa, Patrick; McCarthy, Timothy J.; Villalobos, Anabella; Halldin, Christer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8532-8543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL), a serine hydrolase extensively expressed throughout the brain, serves as a key gatekeeper regulating the tone of endocannabinoid signaling.  Preclinically, inhibition of MAGL is known to provide therapeutic benefits for a no. of neurol. disorders.  The availability of a MAGL-specific positron emission tomog. (PET) ligand would considerably facilitate the development and clin. characterization of MAGL inhibitors via noninvasive and quant. PET imaging.  Herein, we report the identification of the potent and selective irreversible MAGL inhibitor 7 (PF-06809247) as a suitable radioligand lead, which upon radiolabeling was found to exhibit a high level of MAGL specificity; this enabled cross-species measurement of MAGL brain expression (Bmax), assessment of in vivo binding in the rat, and nonhuman primate PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqln4bh3HqHSbVg90H21EOLACvtfcHk0linQui2F79d8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslSqsbfJ&md5=17513710756a393888768d92f327d172</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00847%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DMaresca%26aufirst%3DK.%2BP.%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DNag%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DZ.%26aulast%3DArakawa%26aufirst%3DR.%26aulast%3DPiro%26aufirst%3DJ.%2BR.%26aulast%3DSamad%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%26aulast%3DMcAllister%26aufirst%3DL.%26aulast%3DSchildknegt%26aufirst%3DK.%26aulast%3DTrapa%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DT.%2BJ.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DHalldin%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520development%2520of%2520an%2520irreversible%2520monoacylglycerol%2520lipase%2520%2528MAGL%2529%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520radioligand%2520with%2520high%2520specificity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8532%26epage%3D8543%26doi%3D10.1021%2Facs.jmedchem.9b00847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span>ClinicalTrials.gov.
Test re-test reliability of 11CPF-06809247 as a novel PET tacer. <a href="https://clinicaltrials.gov/ct2/show/NCT03100136" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03100136</a> (accessed Oct 8, 2010).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.%0ATest+re-test+reliability+of+11CPF-06809247+as+a+novel+PET+tacer.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03100136+%28accessed+Oct+8%2C+2010%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafroth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giffenig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papisov, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 18F-Labeled monoacylglycerol lipase inhibitors as novel positron emission tomography probes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8866</span>– <span class="NLM_lpage">8872</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00936</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00936" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKis7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8866-8872&author=Z.+Chenauthor=W.+Moriauthor=H.+Fuauthor=M.+A.+Schafrothauthor=A.+Hatoriauthor=T.+Shaoauthor=G.+Zhangauthor=R.+S.+Vanauthor=Y.+Zhangauthor=K.+Huauthor=M.+Fujinagaauthor=L.+Wangauthor=V.+Belovauthor=D.+Ogasawaraauthor=P.+Giffenigauthor=X.+Dengauthor=J.+Rongauthor=Q.+Yuauthor=X.+Zhangauthor=M.+I.+Papisovauthor=Y.+Shaoauthor=T.+L.+Collierauthor=J.+A.+Maauthor=B.+F.+Cravattauthor=L.+Josephsonauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=Design%2C+synthesis%2C+and+evaluation+of+18F-Labeled+monoacylglycerol+lipase+inhibitors+as+novel+positron+emission+tomography+probes&doi=10.1021%2Facs.jmedchem.9b00936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of 18F-Labeled Monoacylglycerol Lipase Inhibitors as Novel Positron Emission Tomography Probes</span></div><div class="casAuthors">Chen, Zhen; Mori, Wakana; Fu, Hualong; Schafroth, Michael A.; Hatori, Akiko; Shao, Tuo; Zhang, Genwei; Van, Richard S.; Zhang, Yiding; Hu, Kuan; Fujinaga, Masayuki; Wang, Lu; Belov, Vasily; Ogasawara, Daisuke; Giffenig, Pilar; Deng, Xiaoyun; Rong, Jian; Yu, Qingzhen; Zhang, Xiaofei; Papisov, Mikhail I.; Shao, Yihan; Collier, Thomas L.; Ma, Jun-An; Cravatt, Benjamin F.; Josephson, Lee; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8866-8872</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunction of monoacylglycerol lipase (MAGL) is assocd. with several psychopathol. disorders, including drug addiction and neurodegenerative diseases.  Herein we design, synthesize, and evaluate several irreversible fluorine-contg. MAGL inhibitors for positron emission tomog. (PET) ligand development.  Compd. 6 (identified from a therapeutic agent) was advanced for 18F-labeling via a novel spirocyclic iodonium ylide (SCIDY) strategy, which demonstrated high brain permeability and excellent specific binding.  This work supports further development of novel 18F-labeled MAGL PET probes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ9noubfh-w7Vg90H21EOLACvtfcHk0linQui2F79d8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKis7bF&md5=be7433643e89a96579a7be18198b5546</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00936%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DSchafroth%26aufirst%3DM.%2BA.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DVan%26aufirst%3DR.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBelov%26aufirst%3DV.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DGiffenig%26aufirst%3DP.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DRong%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPapisov%26aufirst%3DM.%2BI.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DMa%26aufirst%3DJ.%2BA.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DJosephson%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%252018F-Labeled%2520monoacylglycerol%2520lipase%2520inhibitors%2520as%2520novel%2520positron%2520emission%2520tomography%2520probes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8866%26epage%3D8872%26doi%3D10.1021%2Facs.jmedchem.9b00936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrogna, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uccello, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of trifluoromethyl glycol carbamates as potent and selective covalent monoacylglycerol lipase (MAGL) inhibitors for treatment of neuroinflammation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3008</span>– <span class="NLM_lpage">3026</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00070</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslKlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3008-3026&author=L.+A.+McAllisterauthor=C.+R.+Butlerauthor=S.+Menteauthor=S.+V.+O%E2%80%99Neilauthor=K.+R.+Fonsecaauthor=J.+R.+Piroauthor=J.+A.+Cianfrognaauthor=T.+L.+Foleyauthor=A.+M.+Gilbertauthor=A.+R.+Harrisauthor=C.+J.+Helalauthor=D.+S.+Johnsonauthor=J.+I.+Montgomeryauthor=D.+M.+Nasonauthor=S.+Noellauthor=J.+Panditauthor=B.+N.+Rogersauthor=T.+A.+Samadauthor=C.+L.+Shafferauthor=R.+G.+da+Silvaauthor=D.+P.+Uccelloauthor=D.+Webbauthor=M.+A.+Brodney&title=Discovery+of+trifluoromethyl+glycol+carbamates+as+potent+and+selective+covalent+monoacylglycerol+lipase+%28MAGL%29+inhibitors+for+treatment+of+neuroinflammation&doi=10.1021%2Facs.jmedchem.8b00070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation</span></div><div class="casAuthors">McAllister, Laura A.; Butler, Christopher R.; Mente, Scot; O'Neil, Steven V.; Fonseca, Kari R.; Piro, Justin R.; Cianfrogna, Julie A.; Foley, Timothy L.; Gilbert, Adam M.; Harris, Anthony R.; Helal, Christopher J.; Johnson, Douglas S.; Montgomery, Justin I.; Nason, Deane M.; Noell, Stephen; Pandit, Jayvardhan; Rogers, Bruce N.; Samad, Tarek A.; Shaffer, Christopher L.; da Silva, Rafael G.; Uccello, Daniel P.; Webb, Damien; Brodney, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3008-3026</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) inhibition provides a potential treatment approach to neuroinflammation through modulation of both the endocannabinoid pathway and arachidonoyl signaling in the central nervous system (CNS).  Herein we report the discovery of compd. I (PF-06795071), a potent and selective covalent MAGL inhibitor, featuring a novel trifluoromethyl glycol leaving group that confers significant physicochem. property improvements as compared with earlier inhibitor series with more lipophilic leaving groups.  The design strategy focused on identifying an optimized leaving group that delivers MAGL potency, serine hydrolase selectivity, and CNS exposure while simultaneously reducing log D, improving soly., and minimizing chem. lability.  Compd. I achieves excellent CNS exposure, extended 2-AG elevation effect in vivo, and decreased brain inflammatory markers in response to an inflammatory challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVEF-xXUaFF7Vg90H21EOLACvtfcHk0lgfg6Ah8E6eyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslKlurw%253D&md5=984babc4de306b698756e9c2a9fc5c8e</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00070%26sid%3Dliteratum%253Aachs%26aulast%3DMcAllister%26aufirst%3DL.%2BA.%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BV.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DPiro%26aufirst%3DJ.%2BR.%26aulast%3DCianfrogna%26aufirst%3DJ.%2BA.%26aulast%3DFoley%26aufirst%3DT.%2BL.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHarris%26aufirst%3DA.%2BR.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DMontgomery%26aufirst%3DJ.%2BI.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DNoell%26aufirst%3DS.%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DSamad%26aufirst%3DT.%2BA.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3Dda%2BSilva%26aufirst%3DR.%2BG.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26atitle%3DDiscovery%2520of%2520trifluoromethyl%2520glycol%2520carbamates%2520as%2520potent%2520and%2520selective%2520covalent%2520monoacylglycerol%2520lipase%2520%2528MAGL%2529%2520inhibitors%2520for%2520treatment%2520of%2520neuroinflammation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3008%26epage%3D3026%26doi%3D10.1021%2Facs.jmedchem.8b00070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic hypervalent iodine (III)-mediated radiofluorination of non-activated and hindered aromatics</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">4365</span>, <span class="refDoi"> DOI: 10.1038/ncomms5365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fncomms5365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25007318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4365&author=B.+H.+Rotsteinauthor=N.+A.+Stephensonauthor=N.+Vasdevauthor=S.+H.+Liang&title=Spirocyclic+hypervalent+iodine+%28III%29-mediated+radiofluorination+of+non-activated+and+hindered+aromatics&doi=10.1038%2Fncomms5365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics</span></div><div class="casAuthors">Rotstein, Benjamin H.; Stephenson, Nickeisha A.; Vasdev, Neil; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4365</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An effective soln. that relied on the chem. of spirocyclic hypervalent iodine(III) complexes, which served as precursors for rapid, one-step regioselective radiofluorination with [18F]fluoride was described.  This methodol. proved to be efficient for radiolabeling a diverse range of non-activated functionalized arenes and heteroarenes, including arene substrates bearing electron-donating groups, bulky ortho functionalities, benzylic substituents and meta-substituted electron-withdrawing groups.  Polyfunctional mols. and a range of previously elusive 18F-labeled building blocks, compds. and radiopharmaceuticals were synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk9O3Tg0Uxr7Vg90H21EOLACvtfcHk0lgfg6Ah8E6eyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVCiuro%253D&md5=4ae56df6f2c332f24beaece7097e77de</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1038%2Fncomms5365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms5365%26sid%3Dliteratum%253Aachs%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DStephenson%26aufirst%3DN.%2BA.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DSpirocyclic%2520hypervalent%2520iodine%2520%2528III%2529-mediated%2520radiofluorination%2520of%2520non-activated%2520and%2520hindered%2520aromatics%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D4365%26doi%3D10.1038%2Fncomms5365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Ortho-stabilized 18F-azido click agents and their application in PET imaging with single-stranded DNA aptamers</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">12777</span>– <span class="NLM_lpage">12781</span>, <span class="refDoi"> DOI: 10.1002/anie.201505927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fanie.201505927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVSju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=12777-12781&author=L.+Wangauthor=O.+Jacobsonauthor=D.+Avdicauthor=B.+H.+Rotsteinauthor=I.+D.+Weissauthor=L.+Collierauthor=X.+Chenauthor=N.+Vasdevauthor=S.+H.+Liang&title=Ortho-stabilized+18F-azido+click+agents+and+their+application+in+PET+imaging+with+single-stranded+DNA+aptamers&doi=10.1002%2Fanie.201505927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Ortho-Stabilized 18F-Azido Click Agents and their Application in PET Imaging with Single-Stranded DNA Aptamers</span></div><div class="casAuthors">Wang, Lu; Jacobson, Orit; Avdic, Din; Rotstein, Benjamin H.; Weiss, Ido D.; Collier, Lee; Chen, Xiaoyuan; Vasdev, Neil; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">12777-12781</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Azido 18F-arenes are important and versatile building blocks for the radiolabeling of biomols. via Huisgen cycloaddn. ("click chem.") for positron emission tomog. (PET).  However, routine access to such clickable agents is challenged by inefficient and/or poorly defined multistep radiochem. approaches.  A high-yielding direct radiofluorination for azido 18F-arenes was achieved through the development of an ortho-oxygen-stabilized iodonium deriv. (OID).  This OID strategy addresses an unmet need for a reliable azido 18F-arene clickable agent for bioconjugation reactions.  A ssDNA aptamer was radiolabeled with this agent and visualized in a xenograft mouse model of human colon cancer by PET, which demonstrates that this OID approach is a convenient and highly efficient way of labeling and tracking biomols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3SY-oFzg4xbVg90H21EOLACvtfcHk0lgfg6Ah8E6eyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVSju7jM&md5=005856216ed8a236a3a643d6792681ec</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1002%2Fanie.201505927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201505927%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DAvdic%26aufirst%3DD.%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DWeiss%26aufirst%3DI.%2BD.%26aulast%3DCollier%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DOrtho-stabilized%252018F-azido%2520click%2520agents%2520and%2520their%2520application%2520in%2520PET%2520imaging%2520with%2520single-stranded%2520DNA%2520aptamers%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D12777%26epage%3D12781%26doi%3D10.1002%2Fanie.201505927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patteson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(III) ylides</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">4407</span>– <span class="NLM_lpage">4417</span>, <span class="refDoi"> DOI: 10.1039/C6SC00197A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1039%2FC6SC00197A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27540460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xksl2nt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=4407-4417&author=B.+H.+Rotsteinauthor=L.+Wangauthor=R.+Y.+Liuauthor=J.+Pattesonauthor=E.+E.+Kwanauthor=N.+Vasdevauthor=S.+H.+Liang&title=Mechanistic+studies+and+radiofluorination+of+structurally+diverse+pharmaceuticals+with+spirocyclic+iodonium%28III%29+ylides&doi=10.1039%2FC6SC00197A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium</span></div><div class="casAuthors">Rotstein, Benjamin H.; Wang, Lu; Liu, Richard Y.; Patteson, Jon; Kwan, Eugene E.; Vasdev, Neil; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4407-4417</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Synthesis of non-activated electron-rich and sterically hindered 18F-arenes remains a major challenge due to limitations of existing radiofluorination methodologies.  The mechanistic investigations of spirocyclic iodonium(III) ylide precursors for arene radiofluorination, including their reactivity, selectivity and stability with no-carrier-added [18F]fluoride.  Benchmark calcns. at the G2[ECP] level indicated that pseudorotation and reductive elimination at iodine(III) can be modeled well by appropriately selected dispersion-cor. d. functional methods.  Modeling of the reaction pathways showed that fluoride-iodonium(III) adduct intermediates were strongly activated and highly regioselective for reductive elimination of the desired [18F]fluoroarenes (difference in barriers, ΔΔG‡ > 25 kcal mol-1).  The advantage of spirocyclic auxiliaries was further supported by NMR spectroscopy studies, which bolster evidence for underlying decompn. processes which can be overcome for radiofluorination of iodonium(III) precursors.  Using a novel adamantyl auxiliary, sterically hindered iodonium ylides were developed to enable highly efficient radiofluorination of electron-rich arenes, including fragments of pharmaceutically relevant nitrogen-contg. heterocycles and tertiary amines.  Furthermore, this methodol. was applied for the synthesis of the radiopharmaceuticals 6-[18F]fluoro-meta-tyrosine ([18F]FMT, 11 ± 1% isolated radiochem. yield, non-decay-cor. (RCY, n.d.c.), n = 3), and meta-[18F]fluorobenzylguanidine ([18F]mFBG, 14 ± 1% isolated RCY, n.d.c., n = 3) which cannot be directly radiolabeled using conventional nucleophilic arom. substitution with [18F]fluoride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWHGHDrUUxvLVg90H21EOLACvtfcHk0lj1cD2xA8Fcsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xksl2nt7c%253D&md5=2387e40f5ec7c24022aee848cc9e0436</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1039%2FC6SC00197A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6SC00197A%26sid%3Dliteratum%253Aachs%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DR.%2BY.%26aulast%3DPatteson%26aufirst%3DJ.%26aulast%3DKwan%26aufirst%3DE.%2BE.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DMechanistic%2520studies%2520and%2520radiofluorination%2520of%2520structurally%2520diverse%2520pharmaceuticals%2520with%2520spirocyclic%2520iodonium%2528III%2529%2520ylides%26jtitle%3DChem.%2520Sci.%26date%3D2016%26volume%3D7%26spage%3D4407%26epage%3D4417%26doi%3D10.1039%2FC6SC00197A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Chemistry for positron emission tomography: recent advances in 11C-, 18F-, 13N-, and 15O-labeling reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2580</span>– <span class="NLM_lpage">2605</span>, <span class="refDoi"> DOI: 10.1002/anie.201805501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fanie.201805501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=2580-2605&author=X.+Dengauthor=J.+Rongauthor=L.+Wangauthor=N.+Vasdevauthor=L.+Zhangauthor=L.+Josephsonauthor=S.+H.+Liang&title=Chemistry+for+positron+emission+tomography%3A+recent+advances+in+11C-%2C+18F-%2C+13N-%2C+and+15O-labeling+reactions&doi=10.1002%2Fanie.201805501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry for Positron Emission Tomography: Recent Advances in 11C-, 18F-, 13N-, and 15O-Labeling Reactions</span></div><div class="casAuthors">Deng, Xiaoyun; Rong, Jian; Wang, Lu; Vasdev, Neil; Zhang, Lei; Josephson, Lee; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2580-2605</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Positron emission tomog. (PET) is a mol. imaging technol. that provides quant. information about function and metab. in biol. processes in vivo for disease diagnosis and therapy assessment.  The broad application and rapid advances of PET has led to an increased demand for new radiochem. methods to synthesize highly specific mols. bearing positron-emitting radionuclides.  This Review provides an overview of commonly used labeling reactions through examples of clin. relevant PET tracers and highlights the most recent developments and breakthroughs over the past decade, with a focus on 11C, 18F, 13N, and 15O.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjYrPjeNgnYrVg90H21EOLACvtfcHk0lj1cD2xA8Fcsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSjsbo%253D&md5=d18cd38e57253fffae7844c93b13588f</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1002%2Fanie.201805501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201805501%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DRong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DJosephson%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DChemistry%2520for%2520positron%2520emission%2520tomography%253A%2520recent%2520advances%2520in%252011C-%252C%252018F-%252C%252013N-%252C%2520and%252015O-labeling%2520reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D2580%26epage%3D2605%26doi%3D10.1002%2Fanie.201805501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span> <span> </span><span class="NLM_article-title">A novel 18F-labeled MAG lipase biomarker for differentiating brown and white adipose tissue in the lipid network</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=262-262&author=Z.+Chenauthor=R.+Chengauthor=J.+Yangauthor=T.+Shaoauthor=N.+Vasdevauthor=C.+Ranauthor=M.-R.+Zhangauthor=S.+Liang&title=A+novel+18F-labeled+MAG+lipase+biomarker+for+differentiating+brown+and+white+adipose+tissue+in+the+lipid+network"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DT.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DRan%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.-R.%26aulast%3DLiang%26aufirst%3DS.%26atitle%3DA%2520novel%252018F-labeled%2520MAG%2520lipase%2520biomarker%2520for%2520differentiating%2520brown%2520and%2520white%2520adipose%2520tissue%2520in%2520the%2520lipid%2520network%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D262%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of (4 R)-1-{3-[2-(18F)Fluoro-4-methylpyridin-3-yl]phenyl}-4-[4-(1,3-thiazol-2-ylcarbo nyl)piperazin-1-yl]pyrrolidin-2-one ([<sup>18</sup>F]T-401) as a novel positron-emission tomography imaging agent for monoacylglycerol lipase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2362</span>– <span class="NLM_lpage">2375</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVSht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2362-2375&author=Y.+Hattoriauthor=K.+Aoyamaauthor=J.+Maedaauthor=N.+Arimuraauthor=Y.+Takahashiauthor=M.+Sasakiauthor=M.+Fujinagaauthor=C.+Sekiauthor=Y.+Nagaiauthor=K.+Kawamuraauthor=T.+Yamasakiauthor=M.+R.+Zhangauthor=M.+Higuchiauthor=T.+Koike&title=Design%2C+synthesis%2C+and+evaluation+of+%284+R%29-1-%7B3-%5B2-%2818F%29Fluoro-4-methylpyridin-3-yl%5Dphenyl%7D-4-%5B4-%281%2C3-thiazol-2-ylcarbo+nyl%29piperazin-1-yl%5Dpyrrolidin-2-one+%28%5B18F%5DT-401%29+as+a+novel+positron-emission+tomography+imaging+agent+for+monoacylglycerol+lipase&doi=10.1021%2Facs.jmedchem.8b01576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of (4R)-1-{3-[2-(18F)Fluoro-4-methylpyridin-3-yl]phenyl}-4-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]pyrrolidin-2-one ([18F]T-401) as a Novel Positron-Emission Tomography Imaging Agent for Monoacylglycerol Lipase</span></div><div class="casAuthors">Hattori, Yasushi; Aoyama, Kazunobu; Maeda, Jun; Arimura, Naoto; Takahashi, Yasuko; Sasaki, Masako; Fujinaga, Masayuki; Seki, Chie; Nagai, Yuji; Kawamura, Kazunori; Yamasaki, Tomoteru; Zhang, Ming-Rong; Higuchi, Makoto; Koike, Tatsuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2362-2375</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a cytosolic serine hydrolase involved in endocannabinoid and inflammatory signaling.  Positron-emission tomog. (PET) imaging of MAGL serves to validate target engagement of therapeutic MAGL inhibitors as well as to investigate MAGL levels under normal and disease conditions.  However, PET radioligands with reversible binding kinetics for MAGL, which allow quant. assessment of MAGL, are hitherto unavailable.  In this study, we designed and synthesized fluoro-contg. PET probes starting from a recently identified piperazinyl pyrrolidine-2-one deriv. with reversible binding to MAGL.  By tailoring the lipophilicity of the mol. to optimize nonspecific binding and blood-brain barrier permeability, we successfully identified two compds. that show high uptake to regions enriched with MAGL.  PET imaging of wild-type and MAGL-deficient mice as well as a macaque monkey indicated that [18F]I ((4R)-1-{3-[2-(18F)fluoro-4-methylpyridin-3-yl]phenyl}-4-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]pyrrolidin-2-one, [18F]T-401) specifically binds to MAGL with adequate reversibility, yielding a high contrast for MAGL within an appropriate imaging time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppgW6fA1E8WLVg90H21EOLACvtfcHk0lj1cD2xA8Fcsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVSht7k%253D&md5=4848fa8fce411e960b580b5bd007e0c9</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01576%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DY.%26aulast%3DAoyama%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DJ.%26aulast%3DArimura%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DM.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DC.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DHiguchi%26aufirst%3DM.%26aulast%3DKoike%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520%25284%2520R%2529-1-%257B3-%255B2-%252818F%2529Fluoro-4-methylpyridin-3-yl%255Dphenyl%257D-4-%255B4-%25281%252C3-thiazol-2-ylcarbo%2520nyl%2529piperazin-1-yl%255Dpyrrolidin-2-one%2520%2528%255B18F%255DT-401%2529%2520as%2520a%2520novel%2520positron-emission%2520tomography%2520imaging%2520agent%2520for%2520monoacylglycerol%2520lipase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2362%26epage%3D2375%26doi%3D10.1021%2Facs.jmedchem.8b01576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor 1 positive allosteric modulators for posttraumatic stress disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnpp.2017.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29192662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCrs7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=226-227&author=A.+Shekharauthor=G.+A.+Thakur&title=Cannabinoid+receptor+1+positive+allosteric+modulators+for+posttraumatic+stress+disorder&doi=10.1038%2Fnpp.2017.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid Receptor 1 Positive Allosteric Modulators for Posttraumatic Stress Disorder</span></div><div class="casAuthors">Shekhar, Anantha; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">226-227</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Post-traumatic stress disorder (PTSD) is a severe psychiatric disorder that develops in a subset of people following a traumatic event.  Exposure-based psychol. treatments and antidepressants are the current first-line treatments for PTSD symptoms.  However, many patients fail to receive effective treatments, drop out treatments, or are non-responsive to existing treatments (Watts et al, 2013), highlighting an urgent unmet need to develop novel therapeutics.  Part of the challenge in developing effective therapies has been the biol. heterogeneity in PTSD pathophysiol.  'Broad-spectrum' therapies such as antidepressants and standardized exposure therapies may not account for the biol. diversity of the underlying deficits in neurotransmitter mechanisms, stress resiliency, and learning deficits.  One of the novel targets that has emerged as being involved in PTSD with strong preclin. and human data is the endocannabinoid system.  The endocannabinoid system includes two principal cannabinoid receptors (CB1R and CB2R), their several endogenous ligands, including the two key ligands anandamide and 2- arachidonoylglycerol (2-AG), and enzymes responsible for endocannabinoid biosynthesis and inactivation.  Although there are some conflicting findings, perhaps due to differences in exptl. conditions, preclin. studies of fear disorder models generally support the concept that selective agonists of CB1R facilitate fear extinction.  Subjects with PTSD are reported to have significantly lower CB1R availability and reduced peripheral concn. of anandamide (Pietrzak et al, 2014; Neumeister et al, 2015) and appears to be assocd. with threat processing in trauma survivors (Pietrzak et al, 2014).  These data suggest that low anandamide levels and upregulation of endocannabinoid receptors in the amygdale-hippocampal-cortico-striatal circuitry could result in the enhanced reactivity to threat stimuli, and endogenous cannabinoid would ameliorate such responses (Neumeister et al, 2015).  Despite this strong mechanistic rationale, utilizing direct agonists of CB1R receptors has several disadvantages.  The CB1 receptors regulate many opposing functions in brain, esp. in the regulation of fear regulation circuitry and downregulation of receptors are seen after chronic exposure to agonists.  Agonists could also have adverse effects from off-target CB1 activation.  Therefore, alternative approaches to augment endocannabinoid signaling need to be explored.  One such promising approach is through inhibition of fatty acid amide hydrolase (FAAH) involved in endocannabinoid catabolism that would increase the availability of endogenously generated endocannabinoids (Gunduz-Cinar et al, 2013).  A second approach is to utilize pos. allosteric modulators (PAMs) that selectively increase the CB1R effects.  CB1R has allosteric sites spatially distinct from the orthosteric ligand-binding pocket, and engagement of CB1R by allosteric modulators induce a conformational change in the receptor that may be difficult to achieve with orthosteric ligands alone and thus one can 'fine-tune' the pharmacol. activity of the endogenous ligand.  Such compds. could offer not only enhanced CB1R selectivity, but also reduced receptor downregulation and inter-receptor promiscuity (Kulkarni et al, 2016).  One such compd. GAT211 increases CB1R effects, demonstrates good efficacy in rodent models of chronic pain without demonstrating acute tolerance, rewarding properties or dependence (Slivicki et al, 2017).  Our preliminary data show that GAT211 also enhances fear extinction in auditory cue-induced fear conditioning model and could potentially provide a novel approach to PTSD drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJLpQeI_DkbVg90H21EOLACvtfcHk0ljP8C7SiIRabw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCrs7bM&md5=bec736b4161aca902cec0be97020c0f1</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.230%26sid%3Dliteratum%253Aachs%26aulast%3DShekhar%26aufirst%3DA.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DCannabinoid%2520receptor%25201%2520positive%2520allosteric%2520modulators%2520for%2520posttraumatic%2520stress%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D226%26epage%3D227%26doi%3D10.1038%2Fnpp.2017.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span> <span> </span><span class="NLM_article-title">Structure of an allosteric modulator bound to the CB1 cannabinoid receptor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1205</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0387-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41589-019-0387-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31659318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCksLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1199-1205&author=Z.+Shaoauthor=W.+Yanauthor=K.+Chapmanauthor=K.+Rameshauthor=A.+J.+Ferrellauthor=J.+Yinauthor=X.+Wangauthor=Q.+Xuauthor=D.+M.+Rosenbaum&title=Structure+of+an+allosteric+modulator+bound+to+the+CB1+cannabinoid+receptor&doi=10.1038%2Fs41589-019-0387-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of an allosteric modulator bound to the CB1 cannabinoid receptor</span></div><div class="casAuthors">Shao, Zhenhua; Yan, Wei; Chapman, Karen; Ramesh, Karthik; Ferrell, Aaron J.; Yin, Jie; Wang, Xuehui; Xu, Qingping; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-1205</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The CB1 receptor mediates the central nervous system response to cannabinoids, and is a drug target for pain, anxiety and seizures.  CB1 also responds to allosteric modulators, which influence cannabinoid binding and efficacy.  To understand the mechanism of these compds., we solved the crystal structure of CB1 with the neg. allosteric modulator (NAM) ORG27569 and the agonist CP55940.  The structure reveals that the NAM binds to an extrahelical site within the inner leaflet of the membrane, which overlaps with a conserved site of cholesterol interaction in many G protein-coupled receptors (GPCRs).  The ternary structure with ORG27569 and CP55940 captures an intermediate state of the receptor, in which arom. residues at the base of the agonist-binding pocket adopt an inactive conformation despite the large contraction of the orthosteric pocket.  The structure illustrates a potential strategy for drug modulation of CB1 and other class A GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz52KMEDfkTbVg90H21EOLACvtfcHk0ljP8C7SiIRabw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCksLnM&md5=58150bc1805c874c5dce7ed13fcf7c68</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0387-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0387-2%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DRamesh%26aufirst%3DK.%26aulast%3DFerrell%26aufirst%3DA.%2BJ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26atitle%3DStructure%2520of%2520an%2520allosteric%2520modulator%2520bound%2520to%2520the%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D1199%26epage%3D1205%26doi%3D10.1038%2Fs41589-019-0387-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerksen, R. J.</span></span> <span> </span><span class="NLM_article-title">Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1080/07391102.2019.1567384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1080%2F07391102.2019.1567384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30652534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFygs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=32-47&author=P.+Pandeyauthor=K.+K.+Royauthor=R.+J.+Doerksen&title=Negative+allosteric+modulators+of+cannabinoid+receptor+2%3A+protein+modeling%2C+binding+site+identification+and+molecular+dynamics+simulations+in+the+presence+of+an+orthosteric+agonist&doi=10.1080%2F07391102.2019.1567384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist</span></div><div class="casAuthors">Pandey, Pankaj; Roy, Kuldeep K.; Doerksen, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Selective activation of the cannabinoid receptor subtype 2 (CB2) shows promise for treating pain, inflammation, multiple sclerosis, cancer, ischemic/reperfusion injury and osteoporosis.  Target selectivity and off-target side effects are two major limiting factors for orthosteric ligands, and therefore, the search for allosteric modulators (AMs) is a widely used drug discovery approach.  To date, only a limited no. of neg. CB2 AMs have been identified, possessing only micromolar activity at best, and the CB2 receptor's allosteric site(s) are not well characterized.  Herein, we used computational approaches including receptor modeling, site mapping, docking, mol. dynamics (MD) simulations and binding free energy calcns. to predict, characterize and validate allosteric sites within the complex of the CB2 receptor with bound orthosteric agonist CP55,940.  After docking of known neg. CB2 allosteric modulators (NAMs), dihydro-gambogic acid (DHGA) and trans-β-caryophyllene (TBC) (note that TBC also shows agonist activity), at the predicted allosteric sites, the best total complex with CB2, CP55,940 and NAM was embedded into a hydrated lipid bilayer and subjected to a 200 ns MD simulation.  The presence of an AM affected the CB2-CP55,940 complex, altering the relative positioning of the toggle switch residues and promoting a strong π-π interaction between Phe1173.36 and Trp2586.48.  Binding of either TBC or DHGA to a putative allosteric pocket directly adjacent to the orthosteric ligand reduced the binding free energy of CP55,940, which is consistent with the expected effect of a neg. AM.  The identified allosteric sites present immense scope for the discovery of novel classes of CB2 AMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkASmOl3-otbVg90H21EOLACvtfcHk0lik11Z9zMnLbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFygs78%253D&md5=a34d458fdc37179e86836bc5c1cd7afd</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1080%2F07391102.2019.1567384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2019.1567384%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DP.%26aulast%3DRoy%26aufirst%3DK.%2BK.%26aulast%3DDoerksen%26aufirst%3DR.%2BJ.%26atitle%3DNegative%2520allosteric%2520modulators%2520of%2520cannabinoid%2520receptor%25202%253A%2520protein%2520modeling%252C%2520binding%2520site%2520identification%2520and%2520molecular%2520dynamics%2520simulations%2520in%2520the%2520presence%2520of%2520an%2520orthosteric%2520agonist%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2020%26volume%3D38%26spage%3D32%26epage%3D47%26doi%3D10.1080%2F07391102.2019.1567384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4805</span>, <span class="refDoi"> DOI: 10.1111/bph.13250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fbph.13250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26218440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1CntL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=4790-4805&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=M.+E.+Kellyauthor=E.+M.+Denovan-Wright&title=Cannabidiol+is+a+negative+allosteric+modulator+of+the+cannabinoid+CB1+receptor&doi=10.1111%2Fbph.13250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor</span></div><div class="casAuthors">Laprairie, R. B.; Bagher, A. M.; Kelly, M. E. M.; Denovan-Wright, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4790-4805</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Cannabidiol has been reported to act as an antagonist at cannabinoid CB1 receptors.  We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through neg. allosteric modulation of CB1 receptors.  Exptl. Approach : Internalization of CB1 receptors, arrestin2 recruitment, and PLCβ3 and ERK1/2 phosphorylation, were quantified in HEK 293A cells heterologously expressing CB1 receptors and in the STHdhQ7/Q7 cell model of striatal neurons endogenously expressing CB1 receptors.  Cells were treated with 2-arachidonylglycerol or Δ9-tetrahydrocannabinol alone and in combination with different concns. of cannabidiol.  Key Results : Cannabidiol reduced the efficacy and potency of 2-arachidonylglycerol and Δ9-tetrahydrocannabinol on PLCβ3- and ERK1/2-dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdhQ7/Q7) expressing CB1 receptors.  By reducing arrestin2 recruitment to CB1 receptors, cannabidiol treatment prevented internalization of these receptors.  The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB1 receptor.  Conclusions and Implications : Cannabidiol behaved as a non-competitive neg. allosteric modulator of CB1 receptors.  Allosteric modulation, in conjunction with effects not mediated by CB1 receptors, may explain the in vivo effects of cannabidiol.  Allosteric modulators of CB1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects assocd. with orthosteric agonism or antagonism of these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCPkVL0nj1bLVg90H21EOLACvtfcHk0lik11Z9zMnLbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1CntL7P&md5=312ae749b793eb27dc8d50e21aba4fe8</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1111%2Fbph.13250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13250%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DCannabidiol%2520is%2520a%2520negative%2520allosteric%2520modulator%2520of%2520the%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D4790%26epage%3D4805%26doi%3D10.1111%2Fbph.13250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborrini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poetz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertsch, J.</span></span> <span> </span><span class="NLM_article-title">Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">36944</span>– <span class="NLM_lpage">36967</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.382481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1074%2Fjbc.M112.382481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22952224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=36944-36967&author=M.+Bauerauthor=A.+Chiccaauthor=M.+Tamborriniauthor=D.+Eisenauthor=R.+Lernerauthor=B.+Lutzauthor=O.+Poetzauthor=G.+Pluschkeauthor=J.+Gertsch&title=Identification+and+quantification+of+a+new+family+of+peptide+endocannabinoids+%28Pepcans%29+showing+negative+allosteric+modulation+at+CB1+receptors&doi=10.1074%2Fjbc.M112.382481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Quantification of a New Family of Peptide Endocannabinoids (Pepcans) Showing Negative Allosteric Modulation at CB1 Receptors</span></div><div class="casAuthors">Bauer, Mark; Chicca, Andrea; Tamborrini, Marco; Eisen, David; Lerner, Raissa; Lutz, Beat; Poetz, Oliver; Pluschke, Gerd; Gertsch, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">36944-36967</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The α-Hb-derived dodecapeptide RVD-hemopressin (RVDPVNFKLLSH) has been proposed to be an endogenous agonist for the cannabinoid receptor type 1 (CB1).  To study this peptide, we have raised mAbs against its C-terminal part.  Using an immunoaffinity mass spectrometry approach, a whole family of N-terminally extended peptides in addn. to RVD-Hpα were identified in rodent brain exts. and human and mouse plasma.  We designated these peptides Pepcan-12 (RVDPVNFKLLSH) to Pepcan-23 (SALSDLHAHKLRVDPVNFKLLSH), referring to peptide length.  The most abundant Pepcans found in the brain were tested for CB1 receptor binding.  In the classical radioligand displacement assay, Pepcan-12 was the most efficacious ligand but only partially displaced both [3H]CP 55,940 and [3H]WIN 55,212-2.  The data were fitted with the allosteric ternary complex model, revealing a cooperativity factor value α < 1, thus indicating a neg. allosteric modulation.  Dissocn. kinetic studies of [3H]CP 55,940 in the absence and presence of Pepcan-12 confirmed these results by showing increased dissocn. rate consts. induced by Pepcan-12.  A fluorescently labeled Pepcan-12 analog was synthesized to investigate the binding to CB1 receptors.  Competition binding studies revealed Ki values of several Pepcans in the nanomolar range.  Accordingly, using competitive ELISA, we found low nanomolar concns. of Pepcans in human plasma and ∼100 pmol/g in mouse brain.  Surprisingly, Pepcan-12 exhibited potent neg. allosteric modulation of the orthosteric agonist-induced cAMP accumulation, [35S]GTPγS binding, and CB1 receptor internalization.  Pepcans are the first endogenous allosteric modulators identified for CB1 receptors.  Given their abundance in the brain, Pepcans could play an important physiol. role in modulating endocannabinoid signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1hojsDy4as7Vg90H21EOLACvtfcHk0lik11Z9zMnLbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqsrfP&md5=02f7eab97175b4b0bd4bed69be655aa0</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.382481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.382481%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DM.%26aulast%3DChicca%26aufirst%3DA.%26aulast%3DTamborrini%26aufirst%3DM.%26aulast%3DEisen%26aufirst%3DD.%26aulast%3DLerner%26aufirst%3DR.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DPoetz%26aufirst%3DO.%26aulast%3DPluschke%26aufirst%3DG.%26aulast%3DGertsch%26aufirst%3DJ.%26atitle%3DIdentification%2520and%2520quantification%2520of%2520a%2520new%2520family%2520of%2520peptide%2520endocannabinoids%2520%2528Pepcans%2529%2520showing%2520negative%2520allosteric%2520modulation%2520at%2520CB1%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D36944%26epage%3D36967%26doi%3D10.1074%2Fjbc.M112.382481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pamplona, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes de Lima, O.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarinho, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotjak, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calixto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimarães, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. N.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">21134</span>– <span class="NLM_lpage">21139</span>, <span class="refDoi"> DOI: 10.1073/pnas.1202906109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.1202906109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23150578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1eksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=21134-21139&author=F.+A.+Pamplonaauthor=J.+Ferreiraauthor=O.+Menezes+de+Limaauthor=F.+S.+Duarteauthor=A.+F.+Bentoauthor=S.+Fornerauthor=J.+G.+Villarinhoauthor=L.+Bellocchioauthor=C.+T.+Wotjakauthor=R.+Lernerauthor=K.+Monoryauthor=B.+Lutzauthor=C.+Canettiauthor=I.+Matiasauthor=J.+B.+Calixtoauthor=G.+Marsicanoauthor=M.+Z.+Guimar%C3%A3esauthor=R.+N.+Takahashi&title=Anti-inflammatory+lipoxin+A4+is+an+endogenous+allosteric+enhancer+of+CB1+cannabinoid+receptor&doi=10.1073%2Fpnas.1202906109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor</span></div><div class="casAuthors">Pamplona, Fabricio A.; Ferreira, Juliano; Menezes de Lima, Octavio, Jr.; Duarte, Filipe Silveira; Bento, Allisson Freire; Forner, Stefania; Villarinho, Jardel G.; Bellocchio, Luigi; Wotjak, Carsten T.; Lerner, Raissa; Monory, Krisztina; Lutz, Beat; Canetti, Claudio; Matias, Isabelle; Calixto, Joao Batista; Marsicano, Giovanni; Guimaraes, Marilia Z. P.; Takahashi, Reinaldo N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">21134-21139, S21134/1-S21134/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Allosteric modulation of G-protein-coupled receptors represents a key goal of current pharmacol.  In particular, endogenous allosteric modulators might represent important targets of interventions aimed at maximizing therapeutic efficacy and reducing side effects of drugs.  The anti-inflammatory lipid lipoxin A4 is an endogenous allosteric enhancer of the CB1 cannabinoid receptor.  Lipoxin A4 was detected in brain tissues, did not compete for the orthosteric binding site of the CB1 receptor (vs. 3H-SR141716A), and did not alter endocannabinoid metab. (as opposed to URB597 and MAFP), but it enhanced affinity of anandamide at the CB1 receptor, thereby potentiating the effects of this endocannabinoid both in vitro and in vivo.  In addn., lipoxin A4 displayed a CB1 receptor-dependent protective effect against β-amyloid (1-40)-induced spatial memory impairment in mice.  The discovery of lipoxins as a class of endogenous allosteric modulators of CB1 receptors may foster the therapeutic exploitation of the endocannabinoid system, in particular for the treatment of neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtolBezEx077Vg90H21EOLACvtfcHk0liZErUltwlh8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1eksw%253D%253D&md5=594b68271d19309dcdc26f1c59738bdc</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1202906109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1202906109%26sid%3Dliteratum%253Aachs%26aulast%3DPamplona%26aufirst%3DF.%2BA.%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DMenezes%2Bde%2BLima%26aufirst%3DO.%26aulast%3DDuarte%26aufirst%3DF.%2BS.%26aulast%3DBento%26aufirst%3DA.%2BF.%26aulast%3DForner%26aufirst%3DS.%26aulast%3DVillarinho%26aufirst%3DJ.%2BG.%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DWotjak%26aufirst%3DC.%2BT.%26aulast%3DLerner%26aufirst%3DR.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DCanetti%26aufirst%3DC.%26aulast%3DMatias%26aufirst%3DI.%26aulast%3DCalixto%26aufirst%3DJ.%2BB.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DGuimar%25C3%25A3es%26aufirst%3DM.%2BZ.%26aulast%3DTakahashi%26aufirst%3DR.%2BN.%26atitle%3DAnti-inflammatory%2520lipoxin%2520A4%2520is%2520an%2520endogenous%2520allosteric%2520enhancer%2520of%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D21134%26epage%3D21139%26doi%3D10.1073%2Fpnas.1202906109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ignatowska-Jankowska, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damaj, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span> <span> </span><span class="NLM_article-title">A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2948</span>– <span class="NLM_lpage">2959</span>, <span class="refDoi"> DOI: 10.1038/npp.2015.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnpp.2015.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26052038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=2948-2959&author=B.+M.+Ignatowska-Jankowskaauthor=G.+L.+Baillieauthor=S.+Kinseyauthor=M.+Croweauthor=S.+Ghoshauthor=R.+A.+Owensauthor=I.+M.+Damajauthor=J.+Poklisauthor=J.+L.+Wileyauthor=M.+Zandaauthor=C.+Zanatoauthor=I.+R.+Greigauthor=A.+H.+Lichtmanauthor=R.+A.+Ross&title=A+cannabinoid+CB1+receptor-positive+allosteric+modulator+reduces+neuropathic+pain+in+the+mouse+with+no+psychoactive+effects&doi=10.1038%2Fnpp.2015.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects</span></div><div class="casAuthors">Ignatowska-Jankowska, Bogna M.; Baillie, Gemma L.; Kinsey, Steven; Crowe, Molly; Ghosh, Sudeshna; Owens, Robert A.; Damaj, Imad M.; Poklis, Justin; Wiley, Jenny L.; Zanda, Matteo; Zanato, Chiara; Greig, Iain R.; Lichtman, Aron H.; Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2948-2959</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The CB1 receptor represents a promising target for the treatment of several disorders including pain-related disease states.  However, therapeutic applications of Δ9-tetrahydrocannabinol and other CB1 orthosteric receptor agonists remain limited because of psychoactive side effects.  Pos. allosteric modulators (PAMs) offer an alternative approach to enhance CB1 receptor function for therapeutic gain with the promise of reduced side effects.  Here we describe the development of the novel synthetic CB1 PAM, 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011), which augments the in vitro and in vivo pharmacol. actions of the CB1 orthosteric agonists CP55,940 and N-arachidonoylethanolamine (AEA).  ZCZ011 potentiated binding of [3H]CP55,940 to the CB1 receptor as well as enhancing AEA-stimulated [35S]GTPγS binding in mouse brain membranes and β-arrestin recruitment and ERK phosphorylation in hCB1 cells.  In the whole animal, ZCZ011 is brain penetrant, increased the potency of these orthosteric agonists in mouse behavioral assays indicative of cannabimimetic activity, including antinociception, hypothermia, catalepsy, locomotor activity, and in the drug discrimination paradigm.  Administration of ZCZ011 alone was devoid of activity in these assays and did not produce a conditioned place preference or aversion, but elicited CB1 receptor-mediated antinociceptive effects in the chronic constriction nerve injury model of neuropathic pain and carrageenan model of inflammatory pain.  These data suggest that ZCZ011 acts as a CB1 PAM and provide the first proof of principle that CB1 PAMs offer a promising strategy to treat neuropathic and inflammatory pain with minimal or no cannabimimetic side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGrwc1SxmigLVg90H21EOLACvtfcHk0liZErUltwlh8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jI&md5=353f294dc5044468997e98fb49711abf</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.148%26sid%3Dliteratum%253Aachs%26aulast%3DIgnatowska-Jankowska%26aufirst%3DB.%2BM.%26aulast%3DBaillie%26aufirst%3DG.%2BL.%26aulast%3DKinsey%26aufirst%3DS.%26aulast%3DCrowe%26aufirst%3DM.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DOwens%26aufirst%3DR.%2BA.%26aulast%3DDamaj%26aufirst%3DI.%2BM.%26aulast%3DPoklis%26aufirst%3DJ.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DZanda%26aufirst%3DM.%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DGreig%26aufirst%3DI.%2BR.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DA%2520cannabinoid%2520CB1%2520receptor-positive%2520allosteric%2520modulator%2520reduces%2520neuropathic%2520pain%2520in%2520the%2520mouse%2520with%2520no%2520psychoactive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2015%26volume%3D40%26spage%3D2948%26epage%3D2959%26doi%3D10.1038%2Fnpp.2015.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khurana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, D. A.</span></span> <span> </span><span class="NLM_article-title">Modulation of CB1 cannabinoid receptor by allosteric ligands: pharmacology and therapeutic opportunities</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuropharm.2017.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28527758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVWhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=3-12&author=L.+Khuranaauthor=K.+Mackieauthor=D.+Piomelliauthor=D.+A.+Kendall&title=Modulation+of+CB1+cannabinoid+receptor+by+allosteric+ligands%3A+pharmacology+and+therapeutic+opportunities&doi=10.1016%2Fj.neuropharm.2017.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities</span></div><div class="casAuthors">Khurana, Leepakshi; Mackie, Ken; Piomelli, Daniele; Kendall, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-12</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cannabinoid pharmacol. has been intensely studied because of cannabis' pervasive medicinal and non-medicinal uses as well as for the therapeutic potential of cannabinoid-based drugs for the treatment of pain, anxiety, substance abuse, obesity, cancer and neurodegenerative disorders.  The identification of allosteric modulators of the cannabinoid receptor 1 (CB1) has given a new direction to the development of cannabinoid-based therapeutics due to the many advantages offered by targeting allosteric site(s).  Allosteric receptor modulators hold potential to develop subtype-specific and pathway-specific therapeutics.  Here we briefly discuss the first-generation of allosteric modulators of CB1 receptor, their structure-activity relationships, signaling pathways and the allosteric binding site(s) on the CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1NhrM0zr7WrVg90H21EOLACvtfcHk0liZErUltwlh8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVWhtbk%253D&md5=b89f30916f32ae196b0c234f9d4ed385</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DKhurana%26aufirst%3DL.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DKendall%26aufirst%3DD.%2BA.%26atitle%3DModulation%2520of%2520CB1%2520cannabinoid%2520receptor%2520by%2520allosteric%2520ligands%253A%2520pharmacology%2520and%2520therapeutic%2520opportunities%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D124%26spage%3D3%26epage%3D12%26doi%3D10.1016%2Fj.neuropharm.2017.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dainese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelucci, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufrusine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fezza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fabritiis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid hydrolase FAAH is an allosteric enzyme</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2292</span>, <span class="refDoi"> DOI: 10.1038/s41598-020-59120-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41598-020-59120-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32041998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVagtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=2292&author=E.+Daineseauthor=S.+Oddiauthor=M.+Simonettiauthor=A.+Sabatucciauthor=C.+B.+Angelucciauthor=A.+Balloneauthor=B.+Dufrusineauthor=F.+Fezzaauthor=G.+De+Fabritiisauthor=M.+Maccarrone&title=The+endocannabinoid+hydrolase+FAAH+is+an+allosteric+enzyme&doi=10.1038%2Fs41598-020-59120-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid hydrolase FAAH is an allosteric enzyme</span></div><div class="casAuthors">Dainese, Enrico; Oddi, Sergio; Simonetti, Monica; Sabatucci, Annalaura; Angelucci, Clotilde B.; Ballone, Alice; Dufrusine, Beatrice; Fezza, Filomena; De Fabritiis, Gianni; Maccarrone, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2292</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Fatty acid amide hydrolase (FAAH) is a membrane-bound homodimeric enzyme that in vivo controls content and biol. activity of N-arachidonoylethanolamine (AEA) and other relevant bioactive lipids termed endocannabinoids.  Parallel orientation of FAAH monomers likely allows both subunits to simultaneously recruit and cleave substrates.  Here, we show full inhibition of human and rat FAAH by means of enzyme inhibitors used at a homodimer:inhibitor stoichiometric ratio of 1:1, implying that occupation of only one of the two active sites of FAAH is enough to fully block catalysis.  Single W445Y substitution in rat FAAH displayed the same activity as the wild-type, but failed to show full inhibition at the homodimer:inhibitor 1:1 ratio.  Instead, F432A mutant exhibited reduced specific activity but was fully inhibited at the homodimer:inhibitor 1:1 ratio.  Kinetic anal. of AEA hydrolysis by rat FAAH and its F432A mutant demonstrated a Hill coeff. of ∼1.6, that instead was ∼1.0 in the W445Y mutant.  Of note, also human FAAH catalyzed an allosteric hydrolysis of AEA, showing a Hill coeff. of ∼1.9.  Taken together, this study demonstrates an unprecedented allosterism of FAAH, and represents a case of communication between two enzyme subunits seemingly controlled by a single amino acid (W445) at the dimer interface.  In the light of extensive attempts and subsequent failures over the last decade to develop effective drugs for human therapy, these findings pave the way to the rationale design of new mols. that, by acting as pos. or neg. heterotropic effectors of FAAH, may control more efficiently its activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp46eQPj0TvObVg90H21EOLACvtfcHk0lgbpHl_1g00SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVagtbw%253D&md5=328a4eb1c9832b343028943bc9141a8f</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1038%2Fs41598-020-59120-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-020-59120-1%26sid%3Dliteratum%253Aachs%26aulast%3DDainese%26aufirst%3DE.%26aulast%3DOddi%26aufirst%3DS.%26aulast%3DSimonetti%26aufirst%3DM.%26aulast%3DSabatucci%26aufirst%3DA.%26aulast%3DAngelucci%26aufirst%3DC.%2BB.%26aulast%3DBallone%26aufirst%3DA.%26aulast%3DDufrusine%26aufirst%3DB.%26aulast%3DFezza%26aufirst%3DF.%26aulast%3DDe%2BFabritiis%26aufirst%3DG.%26aulast%3DMaccarrone%26aufirst%3DM.%26atitle%3DThe%2520endocannabinoid%2520hydrolase%2520FAAH%2520is%2520an%2520allosteric%2520enzyme%26jtitle%3DSci.%2520Rep.%26date%3D2020%26volume%3D10%26spage%3D2292%26doi%3D10.1038%2Fs41598-020-59120-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, N.</span></span> <span> </span><span class="NLM_article-title">ABHD6: its place in endocannabinoid signaling and beyond</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2019.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.tips.2019.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30853109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Sis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=267-277&author=J.+K.+Caoauthor=J.+Kaplanauthor=N.+Stella&title=ABHD6%3A+its+place+in+endocannabinoid+signaling+and+beyond&doi=10.1016%2Fj.tips.2019.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">ABHD6: Its Place in Endocannabinoid Signaling and Beyond</span></div><div class="casAuthors">Cao, Jessica K.; Kaplan, Joshua; Stella, Nephi</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-277</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid (eCB) signaling system modulates neurotransmission and inflammation, among other physiol. functions.  Its newest member, α/β-hydrolase domain-contg. 6 (ABHD6), has emerged as a promising therapeutic target to treat several devastating diseases, including epilepsy.  Here, we review the mol. mechanisms that mediate and control eCB signaling and, within it, the specific role of ABHD6.  We also discuss how ABHD6 controls the abundance of addnl. lipids and the trafficking of ionotropic receptors to plasma membranes.  We finish with several unexplored questions regarding this novel enzyme.  Our current understanding of the mol. mechanism and biol. function of ABHD6 provides a strong foundation for the development of small-mol. therapeutics to treat devastating diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsu8ddxQw_fbVg90H21EOLACvtfcHk0lgbpHl_1g00SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Sis70%253D&md5=b7ed26bafde16f34f3274afd4898bb55</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%2BK.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DStella%26aufirst%3DN.%26atitle%3DABHD6%253A%2520its%2520place%2520in%2520endocannabinoid%2520signaling%2520and%2520beyond%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26spage%3D267%26epage%3D277%26doi%3D10.1016%2Fj.tips.2019.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manterola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal-Chico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Samartín, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Rodríguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Puertas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matute, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mato, S.</span></span> <span> </span><span class="NLM_article-title">Re-examining the potential of targeting ABHD6 in multiple sclerosis: efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.08.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuropharm.2018.08.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30171986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KktLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2018&pages=181-191&author=A.+Manterolaauthor=A.+Bernal-Chicoauthor=R.+Ciprianiauthor=A.+Ruizauthor=A.+P%C3%A9rez-Samart%C3%ADnauthor=M.+Moreno-Rodr%C3%ADguezauthor=K.-L.+Hsuauthor=B.+F.+Cravattauthor=J.+M.+Brownauthor=R.+Rodr%C3%ADguez-Puertasauthor=C.+Matuteauthor=S.+Mato&title=Re-examining+the+potential+of+targeting+ABHD6+in+multiple+sclerosis%3A+efficacy+of+systemic+and+peripherally+restricted+inhibitors+in+experimental+autoimmune+encephalomyelitis&doi=10.1016%2Fj.neuropharm.2018.08.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Manterola, Andrea; Bernal-Chico, Ana; Cipriani, Raffaela; Ruiz, Asier; Perez-Samartin, Alberto; Moreno-Rodriguez, Marta; Hsu, Ku-Lung; Cravatt, Benjamin F.; Brown, J. Mark; Rodriguez-Puertas, Rafael; Matute, Carlos; Mato, Susana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181-191</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">α/β-Hydrolase domain-contg. 6 (ABHD6) contributes to the hydrolysis of the major endocannabinoid 2-arachidonoylglycerol (2-AG) in the central nervous system (CNS) and in the periphery.  ABHD6 blockade has been proposed as novel strategy to treat multiple sclerosis (MS), based on the observation that the inhibitor WWL70 exerts protective anti-inflammatory effects in exptl. autoimmune encephalomyelitis (EAE).  According to recent data, WWL70 exhibits off-target anti-inflammatory activity in microglial cells and the potential of ABHD6 as drug target in MS remains controversial.  Here we further investigated the role of ABHD6 during autoimmune demyelination by comparing the efficacy of two novel inhibitors with different CNS permeability in vivo.  Preventive treatment with the systemically active inhibitor KT182 ameliorated the neurol. signs of EAE during the time-course of disease.  By contrast, administration of the peripherally restricted compd. KT203 was ineffective in attenuating EAE symptomatol.  Both inhibitors failed to improve corticospinal tract conduction latency and to attenuate inflammation at EAE recovery phase, despite being equally active at targeting brain ABHD6.  Chronic administration of KT182 was assocd. to a partial loss of brain CB1 receptor coupling ability, suggesting the engagement of CB1 receptor-mediated mechanisms during the EAE disease progression.  In cultured neurons, KT182 attenuated NMDA-stimulated excitotoxicity and mitochondrial calcium overload.  However, these protective effects were not attributable to ABHD6, as they were not mimicked by the alternative inhibitors KT203, KT195 and WWL70.  These results indicate that ABHD6 blockade exerts only modest therapeutic effects against autoimmune demyelination and call into question its utility as novel drug target in MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry8n8MXlD327Vg90H21EOLACvtfcHk0lgbpHl_1g00SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KktLfN&md5=8e56796aad16813180c8c0f2f78da317</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.08.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.08.038%26sid%3Dliteratum%253Aachs%26aulast%3DManterola%26aufirst%3DA.%26aulast%3DBernal-Chico%26aufirst%3DA.%26aulast%3DCipriani%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez-Samart%25C3%25ADn%26aufirst%3DA.%26aulast%3DMoreno-Rodr%25C3%25ADguez%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DK.-L.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DRodr%25C3%25ADguez-Puertas%26aufirst%3DR.%26aulast%3DMatute%26aufirst%3DC.%26aulast%3DMato%26aufirst%3DS.%26atitle%3DRe-examining%2520the%2520potential%2520of%2520targeting%2520ABHD6%2520in%2520multiple%2520sclerosis%253A%2520efficacy%2520of%2520systemic%2520and%2520peripherally%2520restricted%2520inhibitors%2520in%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D141%26spage%3D181%26epage%3D191%26doi%3D10.1016%2Fj.neuropharm.2018.08.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichu, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vartabedian, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benthuysen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulanovskaya, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulce, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teijaro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1099</span>– <span class="NLM_lpage">1108</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0155-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41589-018-0155-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30420694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1SgurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1099-1108&author=D.+Ogasawaraauthor=T.-A.+Ichuauthor=V.+F.+Vartabedianauthor=J.+Benthuysenauthor=H.+Jingauthor=A.+Reedauthor=O.+A.+Ulanovskayaauthor=J.+J.+Hulceauthor=A.+Robertsauthor=S.+Brownauthor=H.+Rosenauthor=J.+R.+Teijaroauthor=B.+F.+Cravatt&title=Selective+blockade+of+the+lyso-PS+lipase+ABHD12+stimulates+immune+responses+in+vivo&doi=10.1038%2Fs41589-018-0155-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo</span></div><div class="casAuthors">Ogasawara, Daisuke; Ichu, Taka-Aki; Vartabedian, Vincent F.; Benthuysen, Jacqueline; Jing, Hui; Reed, Alex; Ulanovskaya, Olesya A.; Hulce, Jonathan J.; Roberts, Amanda; Brown, Steven; Rosen, Hugh; Teijaro, John R.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1099-1108</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">ABHD12 metabolizes bioactive lysophospholipids, including lysophosphatidylserine (lyso-PS).  Deleterious mutations in human ABHD12 cause the neurol. disease PHARC, and ABHD12-/- mice display PHARC-like phenotypes, including hearing loss, along with elevated brain lyso-PS and features of stimulated innate immune cell function.  Here, we develop a selective and in vivo-active inhibitor of ABHD12 termed DO264 and show that this compd. elevates lyso-PS in mouse brain and primary human macrophages.  Unlike ABHD12-/- mice, adult mice treated with DO264 exhibited minimal perturbations in auditory function.  On the other hand, both DO264-treated and ABHD12-/- mice displayed heightened immunol. responses to lymphocytic choriomeningitis virus (LCMV) clone 13 infection that manifested as severe lung pathol. with elevated proinflammatory chemokines.  These results reveal similarities and differences in the phenotypic impact of pharmacol. vs. genetic blockade of ABHD12 and point to a key role for this enzyme in regulating immunostimulatory lipid pathways in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp__z7e6AC5arVg90H21EOLACvtfcHk0lhYprq_h8QDYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1SgurzM&md5=36064050300bdba18f0ef843284efa7b</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0155-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0155-8%26sid%3Dliteratum%253Aachs%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DIchu%26aufirst%3DT.-A.%26aulast%3DVartabedian%26aufirst%3DV.%2BF.%26aulast%3DBenthuysen%26aufirst%3DJ.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DA.%26aulast%3DUlanovskaya%26aufirst%3DO.%2BA.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DRoberts%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DTeijaro%26aufirst%3DJ.%2BR.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DSelective%2520blockade%2520of%2520the%2520lyso-PS%2520lipase%2520ABHD12%2520stimulates%2520immune%2520responses%2520in%2520vivo%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D1099%26epage%3D1108%26doi%3D10.1038%2Fs41589-018-0155-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span> <span> </span><span class="NLM_article-title">Diacylglycerol lipaseα (DAGLα) and DAGLβ cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1124/mol.113.085217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fmol.113.085217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23748223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=296-302&author=T.+Jainauthor=J.+Wager-Millerauthor=K.+Mackieauthor=A.+Straiker&title=Diacylglycerol+lipase%CE%B1+%28DAGL%CE%B1%29+and+DAGL%CE%B2+cooperatively+regulate+the+production+of+2-arachidonoyl+glycerol+in+autaptic+hippocampal+neurons&doi=10.1124%2Fmol.113.085217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Diacylglycerol lipaseα (DAGLα) and DAGLβ cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons</span></div><div class="casAuthors">Jain, Tarun; Wager-Miller, Jim; Mackie, Ken; Straiker, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-302</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cannabinoids are part of an endogenous signaling system consisting of cannabinoid receptors and endogenous cannabinoids as well as the enzymic machinery for their synthesis and degrdn.  Depolarization-induced suppression of excitation (DSE) is a form of cannabinoid CB1 receptor-mediated inhibition of synaptic transmission that involves the prodn. of the endogenous cannabinoid 2-arachidonoyl glycerol (2-AG).  Both diacylglycerol lipase α (DAGLα) and DAGLβ can produce 2-AG in vitro, but evidence from knockout animals argues strongly for a predominant, even exclusive, role for DAGLα in regulation of 2-AG-mediated synaptic plasticity.  What role, if any, might be played by DAGLβ remains largely unknown.  Cultured autaptic hippocampal neurons exhibit robust DSE.  With the ability to rapidly modulate expression of DAGLα and DAGLβ in these neurons with short hairpin RNA, they are well suited for a comparative study of the roles of each isoform in mediating DSE.  We find that RNA interference knockdown of DAGLα substantially reduces autaptic DSE, shifting the "depolarization-response curve" from an ED50 value of 1.7 s to 3.0 s.  Surprisingly, DAGLβ knockdown diminishes DSE as much or more (ED50 6.4 s), suggesting that DAGLβ is also responsible for a portion of 2-AG prodn. in autaptic neurons.  Similarly, the two DAGLs both contribute to the prodn. of 2-AG via group I metabotropic glutamate receptors.  Our results provide the first explicit evidence for a role of DAGLβ in modulating neurotransmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvnPTZAQNA-rVg90H21EOLACvtfcHk0lhYprq_h8QDYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsb7K&md5=c53f59e2025712b4e4333c1497bed9e6</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.085217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.085217%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DT.%26aulast%3DWager-Miller%26aufirst%3DJ.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DStraiker%26aufirst%3DA.%26atitle%3DDiacylglycerol%2520lipase%25CE%25B1%2520%2528DAGL%25CE%25B1%2529%2520and%2520DAGL%25CE%25B2%2520cooperatively%2520regulate%2520the%2520production%2520of%25202-arachidonoyl%2520glycerol%2520in%2520autaptic%2520hippocampal%2520neurons%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D296%26epage%3D302%26doi%3D10.1124%2Fmol.113.085217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adibekian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">999</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnchembio.1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23103940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOmt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=999-1007&author=K.+L.+Hsuauthor=K.+Tsuboiauthor=A.+Adibekianauthor=H.+Pughauthor=K.+Masudaauthor=B.+F.+Cravatt&title=DAGL%CE%B2+inhibition+perturbs+a+lipid+network+involved+in+macrophage+inflammatory+responses&doi=10.1038%2Fnchembio.1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses</span></div><div class="casAuthors">Hsu, Ku-Lung; Tsuboi, Katsunori; Adibekian, Alexander; Pugh, Holly; Masuda, Kim; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">999-1007</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The endocannabinoid 2-arachidonoylglycerol (2-AG) is biosynthesized by diacylglycerol lipases DAGLα and DAGLβ.  Chem. probes to perturb DAGLs are needed to characterize endocannabinoid function in biol. processes.  Here we report a series of 1,2,3-triazole urea inhibitors, along with paired neg.-control and activity-based probes, for the functional anal. of DAGLβ in living systems.  Optimized inhibitors showed high selectivity for DAGLβ over other serine hydrolases, including DAGLα (∼60-fold selectivity), and the limited off-targets, such as ABHD6, were also inhibited by the neg.-control probe.  Using these agents and Daglb-/- mice, we show that DAGLβ inactivation lowers 2-AG, as well as arachidonic acid and eicosanoids, in mouse peritoneal macrophages in a manner that is distinct and complementary to disruption of cytosolic phospholipase-A2.  We obsd. a corresponding redn. in lipopolysaccharide-induced tumor necrosis factor-α release.  These findings indicate that DAGLβ is a key metabolic hub within a lipid network that regulates proinflammatory responses in macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdo9sqnvKCvLVg90H21EOLACvtfcHk0lhYprq_h8QDYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOmt7zL&md5=c4ce8861f2a5d73701d1ccdb76481da1</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1105%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DK.%2BL.%26aulast%3DTsuboi%26aufirst%3DK.%26aulast%3DAdibekian%26aufirst%3DA.%26aulast%3DPugh%26aufirst%3DH.%26aulast%3DMasuda%26aufirst%3DK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DDAGL%25CE%25B2%2520inhibition%2520perturbs%2520a%2520lipid%2520network%2520involved%2520in%2520macrophage%2520inflammatory%2520responses%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D999%26epage%3D1007%26doi%3D10.1038%2Fnchembio.1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viader, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggelaar, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Dulk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A. M. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soethoudt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Wel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Alavez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span> <span> </span><span class="NLM_article-title">Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1073/pnas.1522364112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.1522364112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26668358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWjtLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=26-33&author=D.+Ogasawaraauthor=H.+Dengauthor=A.+Viaderauthor=M.+P.+Baggelaarauthor=A.+Bremanauthor=H.+den+Dulkauthor=A.+M.+C.+H.+van+den+Nieuwendijkauthor=M.+Soethoudtauthor=T.+van+der+Welauthor=J.+Zhouauthor=H.+S.+Overkleeftauthor=M.+Sanchez-Alavezauthor=S.+Moriauthor=W.+Nguyenauthor=B.+Contiauthor=X.+Liuauthor=Y.+Chenauthor=Q.-s.+Liuauthor=B.+F.+Cravattauthor=M.+van+der%0AStelt&title=Rapid+and+profound+rewiring+of+brain+lipid+signaling+networks+by+acute+diacylglycerol+lipase+inhibition&doi=10.1073%2Fpnas.1522364112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition</span></div><div class="casAuthors">Ogasawara, Daisuke; Deng, Hui; Viader, Andreu; Baggelaar, Marc P.; Breman, Arjen; Dulk, Hans den; van den Nieuwendijk, Adriann M. C. H.; Soethoudt, Marjolein; van der Wel, Tom; Zhou, Juan; Overkleeft, Herman S.; Sanchez-Alavez, Manuel; Mo, Simone; Nguyen, William; Conti, Bruno; Liu, Xiaojie; Chen, Yao; Liu, Qing-song; Cravatt, Benjamin F.; van der Stelt, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-33</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Diacylglycerol lipases (DAGLα and DAGLβ) convert diacylglycerol to the endocannabinoid 2-arachidonoylglycerol.  Our understanding of DAGL function has been hindered by a lack of chem. probes that can perturb these enzymes in vivo.  Here, we report a set of centrally active DAGL inhibitors and a structurally related control probe and their use, in combination with chem. proteomics and lipidomics, to det. the impact of acute DAGL blockade on brain lipid networks in mice.  Within 2 h, DAGL inhibition produced a striking reorganization of bioactive lipids, including elevations in DAGs and redns. in endocannabinoids and eicosanoids.  We also found that DAGLα is a short half-life protein, and the inactivation of DAGLs disrupts cannabinoid receptor-dependent synaptic plasticity and impairs neuroinflammatory responses, including lipopolysaccharide-induced anapyrexia.  These findings illuminate the highly interconnected and dynamic nature of lipid signaling pathways in the brain and the central role that DAGL enzymes play in regulating this network.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDxeIZyBqtsbVg90H21EOLACvtfcHk0ljy7H6byiE2Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWjtLvP&md5=8c597387f8f8a14539bc2582d42d2d7d</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1522364112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1522364112%26sid%3Dliteratum%253Aachs%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DViader%26aufirst%3DA.%26aulast%3DBaggelaar%26aufirst%3DM.%2BP.%26aulast%3DBreman%26aufirst%3DA.%26aulast%3Dden%2BDulk%26aufirst%3DH.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%2BC.%2BH.%26aulast%3DSoethoudt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BWel%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DSanchez-Alavez%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DW.%26aulast%3DConti%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.-s.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26atitle%3DRapid%2520and%2520profound%2520rewiring%2520of%2520brain%2520lipid%2520signaling%2520networks%2520by%2520acute%2520diacylglycerol%2520lipase%2520inhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D26%26epage%3D33%26doi%3D10.1073%2Fpnas.1522364112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunduz-Cinar, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantae, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paloczi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donvito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Esbroeck, A. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Gracht, A. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotsogianni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Wel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soethoudt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, A. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Hurk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hankemeier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buczynski, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1038/s41589-020-0528-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41589-020-0528-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32393901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVKhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=667-675&author=E.+D.+Mockauthor=M.+Mustafaauthor=O.+Gunduz-Cinarauthor=R.+Cinarauthor=G.+N.+Petrieauthor=V.+Kantaeauthor=X.+Diauthor=D.+Ogasawaraauthor=Z.+V.+Vargaauthor=J.+Palocziauthor=C.+Milianoauthor=G.+Donvitoauthor=A.+C.+M.+van+Esbroeckauthor=A.+M.+F.+van+der+Grachtauthor=I.+Kotsogianniauthor=J.+K.+Parkauthor=A.+Martellaauthor=T.+van+der%0AWelauthor=M.+Soethoudtauthor=M.+Jiangauthor=T.+J.+Wendelauthor=A.+P.+A.+Janssenauthor=A.+T.+Bakkerauthor=C.+M.+Donovanauthor=L.+I.+Castilloauthor=B.+I.+Floreaauthor=J.+Watauthor=H.+van+den+Hurkauthor=M.+Wittwerauthor=U.+Gretherauthor=A.+Holmesauthor=C.+A.+A.+van+Boeckelauthor=T.+Hankemeierauthor=B.+F.+Cravattauthor=M.+W.+Buczynskiauthor=M.+N.+Hillauthor=P.+Pacherauthor=A.+H.+Lichtmanauthor=M.+van+der%0AStelt&title=Discovery+of+a+NAPE-PLD+inhibitor+that+modulates+emotional+behavior+in+mice&doi=10.1038%2Fs41589-020-0528-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice</span></div><div class="casAuthors">Mock, Elliot D.; Mustafa, Mohammed; Gunduz-Cinar, Ozge; Cinar, Resat; Petrie, Gavin N.; Kantae, Vasudev; Di, Xinyu; Ogasawara, Daisuke; Varga, Zoltan V.; Paloczi, Janos; Miliano, Cristina; Donvito, Giulia; van Esbroeck, Annelot C. M.; van der Gracht, Anouk M. F.; Kotsogianni, Ioli; Park, Joshua K.; Martella, Andrea; van der Wel, Tom; Soethoudt, Marjolein; Jiang, Ming; Wendel, Tiemen J.; Janssen, Antonius P. A.; Bakker, Alexander T.; Donovan, Colleen M.; Castillo, Laura I.; Florea, Bogdan I.; Wat, Jesse; van den Hurk, Helma; Wittwer, Matthias; Grether, Uwe; Holmes, Andrew; van Boeckel, Constant A. A.; Hankemeier, Thomas; Cravatt, Benjamin F.; Buczynski, Matthew W.; Hill, Matthew N.; Pacher, Pal; Lichtman, Aron H.; van der Stelt, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-675</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: N-acylethanolamines (NAEs), which include the endocannabinoid anandamide, represent an important family of signaling lipids in the brain.  The lack of chem. probes that modulate NAE biosynthesis in living systems hamper the understanding of the biol. role of these lipids.  Using a high-throughput screen, chem. proteomics and targeted lipidomics, we report here the discovery and characterization of LEI-401 as a CNS-active N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) inhibitor.  LEI-401 reduced NAE levels in neuroblastoma cells and in the brain of freely moving mice, but not in NAPE-PLD KO cells and mice, resp.  LEI-401 activated the hypothalamus-pituitary-adrenal axis and impaired fear extinction, thereby emulating the effect of a cannabinoid CB1 receptor antagonist, which could be reversed by a fatty acid amide hydrolase inhibitor.  Our findings highlight the distinctive role of NAPE-PLD in NAE biosynthesis in the brain and suggest the presence of an endogenous NAE tone controlling emotional behavior. [graphic not available: see fulltext].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzC9MSWVmbH7Vg90H21EOLACvtfcHk0ljy7H6byiE2Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVKhs7g%253D&md5=093b78b3c98c31031915eea3bb596a18</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1038%2Fs41589-020-0528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-020-0528-7%26sid%3Dliteratum%253Aachs%26aulast%3DMock%26aufirst%3DE.%2BD.%26aulast%3DMustafa%26aufirst%3DM.%26aulast%3DGunduz-Cinar%26aufirst%3DO.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DPetrie%26aufirst%3DG.%2BN.%26aulast%3DKantae%26aufirst%3DV.%26aulast%3DDi%26aufirst%3DX.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DVarga%26aufirst%3DZ.%2BV.%26aulast%3DPaloczi%26aufirst%3DJ.%26aulast%3DMiliano%26aufirst%3DC.%26aulast%3DDonvito%26aufirst%3DG.%26aulast%3Dvan%2BEsbroeck%26aufirst%3DA.%2BC.%2BM.%26aulast%3Dvan%2Bder%2BGracht%26aufirst%3DA.%2BM.%2BF.%26aulast%3DKotsogianni%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DMartella%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BWel%26aufirst%3DT.%26aulast%3DSoethoudt%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DWendel%26aufirst%3DT.%2BJ.%26aulast%3DJanssen%26aufirst%3DA.%2BP.%2BA.%26aulast%3DBakker%26aufirst%3DA.%2BT.%26aulast%3DDonovan%26aufirst%3DC.%2BM.%26aulast%3DCastillo%26aufirst%3DL.%2BI.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DWat%26aufirst%3DJ.%26aulast%3Dvan%2Bden%2BHurk%26aufirst%3DH.%26aulast%3DWittwer%26aufirst%3DM.%26aulast%3DGrether%26aufirst%3DU.%26aulast%3DHolmes%26aufirst%3DA.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3DHankemeier%26aufirst%3DT.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBuczynski%26aufirst%3DM.%2BW.%26aulast%3DHill%26aufirst%3DM.%2BN.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520NAPE-PLD%2520inhibitor%2520that%2520modulates%2520emotional%2520behavior%2520in%2520mice%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D16%26spage%3D667%26epage%3D675%26doi%3D10.1038%2Fs41589-020-0528-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdullah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selley, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span> <span> </span><span class="NLM_article-title">Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fjpet.112.201426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23412396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlOgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2013&pages=492-501&author=S.+G.+Kinseyauthor=L.+E.+Wiseauthor=D.+Rameshauthor=R.+Abdullahauthor=D.+E.+Selleyauthor=B.+F.+Cravattauthor=A.+H.+Lichtman&title=Repeated+low-dose+administration+of+the+monoacylglycerol+lipase+inhibitor+JZL184+retains+cannabinoid+receptor+type+1-mediated+antinociceptive+and+gastroprotective+effects&doi=10.1124%2Fjpet.112.201426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects</span></div><div class="casAuthors">Kinsey, Steven G.; Wise, Laura E.; Ramesh, Divya; Abdullah, Rehab; Selley, Dana E.; Cravatt, Benjamin F.; Lichtman, Aron H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">492-501</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The monoacylglycerol lipase (MAGL) inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) produces antinociceptive and anti-inflammatory effects.  However, repeated administration of high-dose JZL184 (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacol. effects of cannabinoid receptor agonists, and cannabinoid receptor type 1 (CB1) downregulation and desensitization.  This functional CB1 receptor tolerance poses a hurdle in the development of MAGL inhibitors for therapeutic use.  Consequently, the present study tested whether repeated administration of low-dose JZL184 maintains its antinociceptive actions in the chronic constriction injury of the sciatic nerve neuropathic pain model and protective effects in a model of nonsteroidal anti-inflammatory drug-induced gastric hemorrhages.  Mice given daily injections of high-dose JZL184 (≥16 mg/kg) for 6 days displayed decreased CB1 receptor d. and function in the brain, as assessed in [3H]SR141716A binding and CP55,940 [(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol]-stimulated guanosine 5'-O-(3-[35S]thio)triphosphate binding assays, resp.  In contrast, normal CB1 receptor expression and function were maintained following repeated administration of low-dose JZL184 (≤8 mg/kg).  Likewise, the antinociceptive and gastroprotective effects of high-dose JZL184 underwent tolerance following repeated administration, but these effects were maintained following repeated low-dose JZL184 treatment.  Consistent with these observations, repeated high-dose JZL184, but not repeated low-dose JZL184, elicited cross-tolerance to the common pharmacol. effects of Δ9-tetrahydrocannabinol.  This same pattern of effects was found in a rimonabant [(5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide)]-pptd. withdrawal model of cannabinoid dependence.  Taken together, these results indicate that prolonged, partial MAGL inhibition maintains potentially beneficial antinociceptive and anti-inflammatory effects, without producing functional CB1 receptor tachyphylaxis/tolerance or cannabinoid dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZkkceF1Il2rVg90H21EOLACvtfcHk0lhbrRkHxmBZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlOgsL0%253D&md5=ea906c8140fa02a53729ff4fcbdcd8a8</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201426%26sid%3Dliteratum%253Aachs%26aulast%3DKinsey%26aufirst%3DS.%2BG.%26aulast%3DWise%26aufirst%3DL.%2BE.%26aulast%3DRamesh%26aufirst%3DD.%26aulast%3DAbdullah%26aufirst%3DR.%26aulast%3DSelley%26aufirst%3DD.%2BE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26atitle%3DRepeated%2520low-dose%2520administration%2520of%2520the%2520monoacylglycerol%2520lipase%2520inhibitor%2520JZL184%2520retains%2520cannabinoid%2520receptor%2520type%25201-mediated%2520antinociceptive%2520and%2520gastroprotective%2520effects%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D345%26spage%3D492%26epage%3D501%26doi%3D10.1124%2Fjpet.112.201426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Facile 18F labeling of non-activated arenes via a spirocyclic iodonium(III) ylide method and its application in the synthesis of the mGluR5 PET radiopharmaceutical [<sup>18</sup>F]FPEB</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1038/s41596-019-0149-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41596-019-0149-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30980032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12jsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1530-1545&author=S.+H.+Liangauthor=L.+Wangauthor=N.+A.+Stephensonauthor=B.+H.+Rotsteinauthor=N.+Vasdev&title=Facile+18F+labeling+of+non-activated+arenes+via+a+spirocyclic+iodonium%28III%29+ylide+method+and+its+application+in+the+synthesis+of+the+mGluR5+PET+radiopharmaceutical+%5B18F%5DFPEB&doi=10.1038%2Fs41596-019-0149-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Facile 18F labeling of non-activated arenes via a spirocyclic iodonium(III) ylide method and its application in the synthesis of the mGluR5 PET radiopharmaceutical [18F]FPEB</span></div><div class="casAuthors">Liang, Steven H.; Wang, Lu; Stephenson, Nickeisha A.; Rotstein, Benjamin H.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1530-1545</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Non-activated (electron-rich and/or sterically hindered) arenes are prevalent chem. scaffolds in pharmaceuticals and positron emission tomog. (PET) diagnostics.  Despite substantial efforts to develop a general method to introduce 18F into these moieties for mol. imaging by PET, there is an urgent and unmet need for novel radiofluorination strategies that result in sufficiently labeled tracers to enable human imaging.  Herein, we describe an efficient method that relies on spirocyclic iodonium ylide (SCIDY) precursors for one-step and regioselective radiofluorination, as well as proof-of-concept translation to the radiosynthesis of a clin. useful PET tracer, 3-[18F]fluoro-5-[(pyridin-3-yl)ethynyl] benzonitrile ([18F]FPEB).  The protocol begins with the prepn. of a SCIDY precursor for FPEB, followed by radiosynthesis of [18F]FPEB, by either manual operation or an automated synthesis module. [18F]FPEB can be obtained in quantities >7.4 GBq (200 mCi), ready for injection (20 ± 5%, non-decay cor.), and has excellent chem. and radiochem. purity (>98%) as well as high molar activity (666 ± 51.8 GBq/μmol; 18 ± 1.4 Ci/μmol).  The total time for the synthesis and purifn. of the corresponding labeling SCIDY precursor is 10 h.  The subsequent radionuclide prodn., exptl. setup, 18F labeling, and formulation of a product that is ready for injection require 2 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNst5tL0zqK7Vg90H21EOLACvtfcHk0lhbrRkHxmBZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12jsrg%253D&md5=16cb676c294708a7c7c5a801ae220d92</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1038%2Fs41596-019-0149-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41596-019-0149-3%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStephenson%26aufirst%3DN.%2BA.%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DFacile%252018F%2520labeling%2520of%2520non-activated%2520arenes%2520via%2520a%2520spirocyclic%2520iodonium%2528III%2529%2520ylide%2520method%2520and%2520its%2520application%2520in%2520the%2520synthesis%2520of%2520the%2520mGluR5%2520PET%2520radiopharmaceutical%2520%255B18F%255DFPEB%26jtitle%3DNat.%2520Protoc.%26date%3D2019%26volume%3D14%26spage%3D1530%26epage%3D1545%26doi%3D10.1038%2Fs41596-019-0149-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rodrigo  Teodoro</span>, <span class="hlFld-ContribAuthor ">Daniel  Gündel</span>, <span class="hlFld-ContribAuthor ">Winnie  Deuther-Conrad</span>, <span class="hlFld-ContribAuthor ">Lea  Ueberham</span>, <span class="hlFld-ContribAuthor ">Magali  Toussaint</span>, <span class="hlFld-ContribAuthor ">Guy  Bormans</span>, <span class="hlFld-ContribAuthor ">Peter  Brust</span>, <span class="hlFld-ContribAuthor ">Rareş-Petru  Moldovan</span>. </span><span class="cited-content_cbyCitation_article-title">Development of [18F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (15)
                                     , 8051. <a href="https://doi.org/10.3390/ijms22158051" title="DOI URL">https://doi.org/10.3390/ijms22158051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22158051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22158051%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDevelopment%252Bof%252B%25255B18F%25255DLU14%252Bfor%252BPET%252BImaging%252Bof%252BCannabinoid%252BReceptor%252BType%252B2%252Bin%252Bthe%252BBrain%26aulast%3DTeodoro%26aufirst%3DRodrigo%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D15%26spage%3D8051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keith A.  Kwan Cheung</span>, <span class="hlFld-ContribAuthor ">Murray D.  Mitchell</span>, <span class="hlFld-ContribAuthor ">Helen S.  Heussler</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabidiol and Neurodevelopmental Disorders in Children. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Psychiatry</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fpsyt.2021.643442" title="DOI URL">https://doi.org/10.3389/fpsyt.2021.643442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fpsyt.2021.643442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffpsyt.2021.643442%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Psychiatry%26atitle%3DCannabidiol%252Band%252BNeurodevelopmental%252BDisorders%252Bin%252BChildren%26aulast%3DKwan%2BCheung%26aufirst%3DKeith%2BA.%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Model for the ECS Signaling in the Nervous System</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative chemical structures for CB1R-specific PET tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative chemical structures for CB2R-specific PET tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Pharmacological Properties of FAAH and MALG Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative chemical structures for FAAH-specific PET tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/medium/jm0c01459_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representative chemical structures of MAGL-specific PET tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01459/20210107/images/large/jm0c01459_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01459&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38142" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38142" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 258 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, T. F.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid signaling as a synaptic circuit breaker in neurological disease</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1038/nm.f.1869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnm.f.1869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18776886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVyms7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=923-930&author=I.+Katonaauthor=T.+F.+Freund&title=Endocannabinoid+signaling+as+a+synaptic+circuit+breaker+in+neurological+disease&doi=10.1038%2Fnm.f.1869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid signaling as a synaptic circuit breaker in neurological disease</span></div><div class="casAuthors">Katona, Istvan; Freund, Tamas F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">923-930</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cannabis sativa is one of the oldest herbal plants in the history of medicine.  It was used in various therapeutic applications from pain to epilepsy, but its psychotropic effect has reduced its usage in recent medical practice.  However, renewed interest has been fueled by major discoveries revealing that cannabis-derived compds. act through a signaling pathway in the human body.  Here we review recent advances showing that endocannabinoid signaling is a key regulator of synaptic communication throughout the central nervous system.  Its underlying mol. architecture is highly conserved in synapses from the spinal cord to the neocortex, and as a neg. feed-back signal, it provides protection against excess presynaptic activity.  The endocannabinoid signaling machinery operates on demand in a synapse-specific manner; therefore, its modulation offers new therapeutic opportunities for the selective control of deleterious neuronal activity in several neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0yon-a5eEWbVg90H21EOLACvtfcHk0li6MGQUgsG2aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVyms7vM&md5=3e29744bd103a145e6be7ad48277ae6e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnm.f.1869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.f.1869%26sid%3Dliteratum%253Aachs%26aulast%3DKatona%26aufirst%3DI.%26aulast%3DFreund%26aufirst%3DT.%2BF.%26atitle%3DEndocannabinoid%2520signaling%2520as%2520a%2520synaptic%2520circuit%2520breaker%2520in%2520neurological%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D923%26epage%3D930%26doi%3D10.1038%2Fnm.f.1869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petrocellis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span> <span> </span><span class="NLM_article-title">From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1659</span>, <span class="refDoi"> DOI: 10.1152/physrev.00002.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1152%2Fphysrev.00002.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27630175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFGhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2016&pages=1593-1659&author=A.+Ligrestiauthor=L.+De+Petrocellisauthor=V.+Di+Marzo&title=From+phytocannabinoids+to+cannabinoid+receptors+and+endocannabinoids%3A+pleiotropic+physiological+and+pathological+roles+through+complex+pharmacology&doi=10.1152%2Fphysrev.00002.2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology</span></div><div class="casAuthors">Ligresti, Alessia; De Petrocellis, Luciano; Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1593-1659</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Apart from having been used and misused for at least four millennia for, among others, recreational and medicinal purposes, the cannabis plant and its most peculiar chem. components, the plant cannabinoids (phytocannabinoids), have the merit to have led humanity to discover one of the most intriguing and pleiotropic endogenous signaling systems, the endocannabinoid system (ECS).  This review article aims to describe and critically discuss, in the most comprehensive possible manner, the multifaceted aspects of 1) the pharmacol. and potential impact on mammalian physiol. of all major phytocannabinoids, and not only of the most famous one δ9-tetrahydrocannabinol, and 2) the adaptive prohomeostatic physiol., or maladaptive pathol., roles of the ECS in mammalian cells, tissues, and organs.  In doing so, we have respected the chronol. order of the milestones of the millennial route from medicinal/recreational cannabis to the ECS and beyond, as it is now clear that some of the early steps in this long path, which were originally neglected, are becoming important again.  The emerging picture is rather complex, but still supports the belief that more important discoveries on human physiol., and new therapies, might come in the future from new knowledge in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgrvObOREtBLVg90H21EOLACvtfcHk0ljwvz_1KtF9yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFGhsrw%253D&md5=47a9345b26cdcf8a8a4b73bf7a3744c6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00002.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00002.2016%26sid%3Dliteratum%253Aachs%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DDe%2BPetrocellis%26aufirst%3DL.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DFrom%2520phytocannabinoids%2520to%2520cannabinoid%2520receptors%2520and%2520endocannabinoids%253A%2520pleiotropic%2520physiological%2520and%2520pathological%2520roles%2520through%2520complex%2520pharmacology%26jtitle%3DPhysiol.%2520Rev.%26date%3D2016%26volume%3D96%26spage%3D1593%26epage%3D1659%26doi%3D10.1152%2Fphysrev.00002.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno-Shosaku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimotodani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, M.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoids and retrograde modulation of synaptic transmission</span>. <i>Neuroscientist</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1177/1073858410397377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1177%2F1073858410397377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21531987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslCmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=119-132&author=T.+Ohno-Shosakuauthor=A.+Tanimuraauthor=Y.+Hashimotodaniauthor=M.+Kano&title=Endocannabinoids+and+retrograde+modulation+of+synaptic+transmission&doi=10.1177%2F1073858410397377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoids and retrograde modulation of synaptic transmission</span></div><div class="casAuthors">Ohno-Shosaku, Takako; Tanimura, Asami; Hashimotodani, Yuki; Kano, Masanobu</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscientist</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-132</span>CODEN:
                <span class="NLM_cas:coden">NROSFJ</span>;
        ISSN:<span class="NLM_cas:issn">1073-8584</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Since the first reports of endocannabinoid-mediated retrograde signaling in 2001, great advances have been made toward understanding the mol. basis and functions of the endocannabinoid system.  Electrophysiol. studies have revealed that the endocannabinoid system is functional at various types of synapses throughout the brain.  Basic mechanisms have been clarified as to how endocannabinoids are produced and released from postsynaptic neurons and regulate neurotransmitter release through activating presynaptic cannabinoid CB1 receptors, although there remain unsolved questions and some discrepancies.  In addn. to this major function, recent studies suggest diverse functions of endocannabinoids, including control of other endocannabinoid-independent forms of synaptic plasticity, regulation of neuronal excitability, stimulation of glia-neuron interaction, and induction of CB1R-independent plasticity.  Using recently developed pharmacol. and genetic tools, behavioral studies have elucidated the roles of the endocannabinoid system in various aspects of neural functions.  In this review, we make a brief overview of mol. mechanisms underlying the endocannabinoid-mediated synaptic modulation and also summarize recent findings, which shed new light on a diversity of functional roles of endocannabinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlLctJDRHFp7Vg90H21EOLACvtfcHk0ljwvz_1KtF9yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslCmtrw%253D&md5=c5ac84fa4044ee03c08b2fd985644f5f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1177%2F1073858410397377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1073858410397377%26sid%3Dliteratum%253Aachs%26aulast%3DOhno-Shosaku%26aufirst%3DT.%26aulast%3DTanimura%26aufirst%3DA.%26aulast%3DHashimotodani%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DM.%26atitle%3DEndocannabinoids%2520and%2520retrograde%2520modulation%2520of%2520synaptic%2520transmission%26jtitle%3DNeuroscientist%26date%3D2012%26volume%3D18%26spage%3D119%26epage%3D132%26doi%3D10.1177%2F1073858410397377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uyama, T.</span></span> <span> </span><span class="NLM_article-title">Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">1874</span>– <span class="NLM_lpage">1894</span>, <span class="refDoi"> DOI: 10.1111/febs.12152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Ffebs.12152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23425575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFWgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=1874-1894&author=N.+Uedaauthor=K.+Tsuboiauthor=T.+Uyama&title=Metabolism+of+endocannabinoids+and+related+N-acylethanolamines%3A+canonical+and+alternative+pathways&doi=10.1111%2Ffebs.12152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of endocannabinoids and related N-acylethanolamines: Canonical and alternative pathways</span></div><div class="casAuthors">Ueda, Natsuo; Tsuboi, Kazuhito; Uyama, Toru</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1874-1894</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Endocannabinoids are endogenous ligands of the cannabinoid receptors CB1 and CB2.  Two arachidonic acid derivs., arachidonoylethanolamide (anandamide) and 2-arachidonoyl glycerol, are considered to be physiol. important endocannabinoids.  In the known metabolic pathway in mammals, anandamide and other bioactive N-acylethanolamines, such as palmitoylethanolamide and oleoylethanolamide, are biosynthesized from glycerophospholipids by a combination of Ca2+-dependent N-acyltransferase and N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D, and are degraded by fatty acid amide hydrolase.  However, recent studies have shown the involvement of other enzymes and pathways, which include the members of the tumor suppressor HRASLS family (the phospholipase A/acyltransferase family) functioning as Ca2+-independent N-acyltransferases, N-acyl-phosphatidylethanolamine-hydrolyzing phospholipaseD-independent multistep pathways via N-acylated lysophospholipid, and N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme that preferentially hydrolyzes palmitoylethanolamide.  Although their physiol. significance is poorly understood, these new enzymes/pathways may serve as novel targets for the development of therapeutic drugs.  For example, selective N-acylethanolamine-hydrolyzing acid amidase inhibitors are expected to be new anti-inflammatory and analgesic drugs.  In this minireview, we focus on advances in the understanding of these enzymes/pathways.  In addn., recent findings on 2-arachidonoyl glycerol metab. are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXGslrDcd7BrVg90H21EOLACvtfcHk0ljwvz_1KtF9yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFWgur4%253D&md5=8ad15d152019255551ab6e5bac9817d1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Ffebs.12152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.12152%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DN.%26aulast%3DTsuboi%26aufirst%3DK.%26aulast%3DUyama%26aufirst%3DT.%26atitle%3DMetabolism%2520of%2520endocannabinoids%2520and%2520related%2520N-acylethanolamines%253A%2520canonical%2520and%2520alternative%2520pathways%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D1874%26epage%3D1894%26doi%3D10.1111%2Ffebs.12152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensi, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathuria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Brain monoglyceride lipase participating in endocannabinoid enactivation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">10819</span>– <span class="NLM_lpage">10824</span>, <span class="refDoi"> DOI: 10.1073/pnas.152334899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.152334899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12136125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmt1ChtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=10819-10824&author=T.+P.+Dinhauthor=D.+Carpenterauthor=F.+M.+Leslieauthor=T.+F.+Freundauthor=I.+Katonaauthor=S.+L.+Sensiauthor=S.+Kathuriaauthor=D.+Piomelli&title=Brain+monoglyceride+lipase+participating+in+endocannabinoid+enactivation&doi=10.1073%2Fpnas.152334899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Brain monoglyceride lipase participating in endocannabinoid inactivation</span></div><div class="casAuthors">Dinh, T. P.; Carpenter, D.; Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">10819-10824</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The endogenous cannabinoids (endocannabinoids) are lipid mols. that may mediate retrograde signaling at central synapses and other forms of short-range neuronal communication.  The monoglyceride 2-arachidonoylglycerol (2-AG) meets several criteria of an endocannabinoid substance: (i) it activates cannabinoid receptors; (ii) it is produced by neurons in an activity-dependent manner; and (iii) it is rapidly eliminated.  2-AG inactivation is only partially understood, but it may occur by transport into cells and enzymic hydrolysis.  Here we tested the hypothesis that monoglyceride lipase (MGL), a serine hydrolase that converts monoglycerides to fatty acid and glycerol, participates in 2-AG inactivation.  We cloned MGL by homol. from a rat brain cDNA library.  Its cDNA sequence encoded for a 303-aa protein with a calcd. mol. wt. of 33,367 Da.  Northern blot and in situ hybridization analyses revealed that MGL mRNA is heterogeneously expressed in the rat brain, with highest levels in regions where CB1 cannabinoid receptors are also present (hippocampus, cortex, anterior thalamus, and cerebellum).  Immunohistochem. studies in the hippocampus showed that MGL distribution has striking laminar specificity, suggesting a presynaptic localization of the enzyme.  Adenovirus-mediated transfer of MGL cDNA into rat cortical neurons increased MGL expression and attenuated N-methyl-D-aspartate/carbachol-induced 2-AG accumulation in these cells.  No such effect was obsd. on the accumulation of anandamide, another endocannabinoid lipid.  The results suggest that hydrolysis by means of MGL is a primary mechanism for 2-AG inactivation in intact neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_r8g9sR9CB7Vg90H21EOLACvtfcHk0lgD7nrqlMAluQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmt1ChtLs%253D&md5=10f14e9625b33d9283d13fa8b9705478</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.152334899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.152334899%26sid%3Dliteratum%253Aachs%26aulast%3DDinh%26aufirst%3DT.%2BP.%26aulast%3DCarpenter%26aufirst%3DD.%26aulast%3DLeslie%26aufirst%3DF.%2BM.%26aulast%3DFreund%26aufirst%3DT.%2BF.%26aulast%3DKatona%26aufirst%3DI.%26aulast%3DSensi%26aufirst%3DS.%2BL.%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBrain%2520monoglyceride%2520lipase%2520participating%2520in%2520endocannabinoid%2520enactivation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D10819%26epage%3D10824%26doi%3D10.1073%2Fpnas.152334899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Marzo, V.</span></span> <span> </span><span class="NLM_article-title">New approaches and challenges to targeting the endocannabinoid system</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrd.2018.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30116049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFans73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=623-639&author=V.+Di%0AMarzo&title=New+approaches+and+challenges+to+targeting+the+endocannabinoid+system&doi=10.1038%2Fnrd.2018.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">New approaches and challenges to targeting the endocannabinoid system</span></div><div class="casAuthors">Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">623-639</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid signalling system was discovered because receptors in this system are the targets of compds. present in psychotropic prepns. of Cannabis sativa.  The search for new therapeutics that target endocannabinoid signalling is both challenging and potentially rewarding, as endocannabinoids are implicated in numerous physiol. and pathol. processes.  Hundreds of mediators chem. related to the endocannabinoids, often with similar metabolic pathways but different targets, have complicated the development of inhibitors of endocannabinoid metabolic enzymes but have also stimulated the rational design of multi-target drugs.  Meanwhile, drugs based on botanical cannabinoids have come to the clin. forefront, synthetic agonists designed to bind cannabinoid receptor 1 with very high affinity have become a societal threat and the gut microbiome has been found to signal in part through the endocannabinoid network.  The current development of drugs that alter endocannabinoid signalling and how this complex system could be pharmacol. manipulated in the future are described in this Opinion article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsITgIPYFrrVg90H21EOLACvtfcHk0lgD7nrqlMAluQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFans73O&md5=7a48b4e8a8c27a5da3e8ba0f80222a32</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.115%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DNew%2520approaches%2520and%2520challenges%2520to%2520targeting%2520the%2520endocannabinoid%2520system%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D623%26epage%3D639%26doi%3D10.1038%2Fnrd.2018.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saario, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, J.</span></span> <span> </span><span class="NLM_article-title">The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors</span>. <i>Acta Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1111/j.1748-1716.2011.02280.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1748-1716.2011.02280.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21418147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1eiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2012&pages=267-276&author=J.+Savinainenauthor=S.+Saarioauthor=J.+Laitinen&title=The+serine+hydrolases+MAGL%2C+ABHD6+and+ABHD12+as+guardians+of+2-arachidonoylglycerol+signalling+through+cannabinoid+receptors&doi=10.1111%2Fj.1748-1716.2011.02280.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors</span></div><div class="casAuthors">Savinainen, J. R.; Saario, S. M.; Laitinen, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Physiologica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-276</span>CODEN:
                <span class="NLM_cas:coden">APCHC4</span>;
        ISSN:<span class="NLM_cas:issn">1748-1708</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid 2-arachidonoylglycerol (2-AG) is a lipid mediator involved in various physiol. processes.  In response to neural activity, 2-AG is synthesized post-synaptically, then activates pre-synaptic cannabinoid CB1 receptors (CB1Rs) in a retrograde manner, resulting in transient and long-lasting redn. of neurotransmitter release.  The signalling competence of 2-AG is tightly regulated by the balanced action between "on demand" biosynthesis and degrdn.  We review recent research on monoacylglycerol lipase (MAGL), ABHD6 and ABHD12, three serine hydrolases that together account for approx. 99% of brain 2-AG hydrolase activity.  MAGL is responsible for approx. 85% of 2-AG hydrolysis and colocalizes with CB1R in axon terminals.  It is therefore ideally positioned to terminate 2-AG-CB1R signalling regardless of the source of this endocannabinoid.  Its acute pharmacol. inhibition leads to 2-AG accumulation and CB1R-mediated behavioral responses.  Chronic MAGL inactivation results in 2-AG overload, desensitization of CB1R signalling and behavioral tolerance.  ABHD6 accounts for approx. 4% of brain 2-AG hydrolase activity but in neurons it rivals MAGL in efficacy.  Neuronal ABHD6 resides post-synaptically, often juxtaposed with CB1Rs, and its acute inhibition leads to activity-dependent accumulation of 2-AG.  In cortical slices, selective ABHD6 blockade facilitates CB1R-dependent long-term synaptic depression.  ABHD6 is therefore positioned to guard intracellular pools of 2-AG at the site of generation.  ABHD12 is highly expressed in microglia and accounts for approx. 9% of total brain 2-AG hydrolysis.  Mutations in ABHD12 gene are causally linked to a neurodegenerative disease called PHARC.  Whether ABHD12 qualifies as a bona fide member to the endocannabinoid system remains to be established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIBgLJavyxUbVg90H21EOLACvtfcHk0lgD7nrqlMAluQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1eiuro%253D&md5=399f8c1e38ae5fd12886573245bec0ba</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1748-1716.2011.02280.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1748-1716.2011.02280.x%26sid%3Dliteratum%253Aachs%26aulast%3DSavinainen%26aufirst%3DJ.%26aulast%3DSaario%26aufirst%3DS.%26aulast%3DLaitinen%26aufirst%3DJ.%26atitle%3DThe%2520serine%2520hydrolases%2520MAGL%252C%2520ABHD6%2520and%2520ABHD12%2520as%2520guardians%2520of%25202-arachidonoylglycerol%2520signalling%2520through%2520cannabinoid%2520receptors%26jtitle%3DActa%2520Physiol.%26date%3D2012%26volume%3D204%26spage%3D267%26epage%3D276%26doi%3D10.1111%2Fj.1748-1716.2011.02280.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Torres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutando, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Torre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valjent, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaita, A.</span></span> <span> </span><span class="NLM_article-title">Monoacylglycerol lipase blockade impairs fine motor coordination and triggers cerebellar neuroinflammation through cyclooxygenase-2</span>. <i>Brain, Behav., Immun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/j.bbi.2019.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bbi.2019.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31251974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yrs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2019&pages=399-409&author=S.+Mart%C3%ADnez-Torresauthor=L.+Cutandoauthor=A.+Pastorauthor=A.+Katoauthor=K.+Sakimuraauthor=R.+de+la+Torreauthor=E.+Valjentauthor=R.+Maldonadoauthor=M.+Kanoauthor=A.+Ozaita&title=Monoacylglycerol+lipase+blockade+impairs+fine+motor+coordination+and+triggers+cerebellar+neuroinflammation+through+cyclooxygenase-2&doi=10.1016%2Fj.bbi.2019.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacylglycerol lipase blockade impairs fine motor coordination and triggers cerebellar neuroinflammation through cyclooxygenase-2</span></div><div class="casAuthors">Martinez-Torres, Sara; Cutando, Laura; Pastor, Antoni; Kato, Ako; Sakimura, Kenji; de la Torre, Rafael; Valjent, Emmanuel; Maldonado, Rafael; Kano, Masanobu; Ozaita, Andres</div><div class="citationInfo"><span class="NLM_cas:title">Brain, Behavior, and Immunity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">399-409</span>CODEN:
                <span class="NLM_cas:coden">BBIMEW</span>;
        ISSN:<span class="NLM_cas:issn">0889-1591</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is the main enzyme implicated in the degrdn. of the most abundant endocannabinoid in the brain, 2-arachidonoylglycerol (2-AG), producing arachidonic acid (AA) and glycerol.  MAGL pharmacol. inhibition with JZL184 or genetic deletion results in an exacerbated 2-AG signaling and reduced synthesis of prostaglandins (PGs), due to the reduced AA precursor levels.  We found that acute JZL184 administration, previously described to exert anti-inflammatory effects, and MAGL knockout (KO) mice display cerebellar, but not hippocampal, microglial reactivity, accompanied with increased expression of the mRNA levels of neuroinflammatory markers, such as cyclooxygenase-2 (COX-2).  Notably, this neuroinflammatory phenotype correlated with relevant motor coordination impairment in the beam-walking and the footprint tests.  Treatment with the COX-2 inhibitor NS398 during 5 days prevented the deficits in cerebellar function and the cerebellar microglia reactivity in MAGL KO, without affecting hippocampal reactivity.  Altogether, this study reveals the brain region-specific response to MAGL inhibition, with an important role of COX-2 in the cerebellar deficits assocd., which should be taken into account for the use of MAGL inhibitors as anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65TtmesmDJrVg90H21EOLACvtfcHk0lh4mm7RKJ1Drg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yrs7vK&md5=8fdf43cec6c49e3a6487dae16f9fc263</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2019.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2019.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez-Torres%26aufirst%3DS.%26aulast%3DCutando%26aufirst%3DL.%26aulast%3DPastor%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DA.%26aulast%3DSakimura%26aufirst%3DK.%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DR.%26aulast%3DValjent%26aufirst%3DE.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DKano%26aufirst%3DM.%26aulast%3DOzaita%26aufirst%3DA.%26atitle%3DMonoacylglycerol%2520lipase%2520blockade%2520impairs%2520fine%2520motor%2520coordination%2520and%2520triggers%2520cerebellar%2520neuroinflammation%2520through%2520cyclooxygenase-2%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2019%26volume%3D81%26spage%3D399%26epage%3D409%26doi%3D10.1016%2Fj.bbi.2019.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schelling, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campolongo, P.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system and post traumatic stress disorder (PTSD): from preclinical findings to innovative therapeutic approaches in clinical settings</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.phrs.2016.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27456243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=668-678&author=A.+Berardiauthor=G.+Schellingauthor=P.+Campolongo&title=The+endocannabinoid+system+and+post+traumatic+stress+disorder+%28PTSD%29%3A+from+preclinical+findings+to+innovative+therapeutic+approaches+in+clinical+settings&doi=10.1016%2Fj.phrs.2016.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings</span></div><div class="casAuthors">Berardi, Andrea; Schelling, Gustav; Campolongo, Patrizia</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">668-678</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Post-Traumatic Stress Disorder (PTSD) is a psychiatric chronic disease developing in individuals after the experience of an intense and life-threatening traumatic event.  The post-traumatic symptomatol. encompasses alterations in memory processes, mood, anxiety and arousal.  There is now consensus in considering the disease as an aberrant adaptation to traumatic stress.  Pharmacol. research, aimed at the discovery of new potential effective treatments, has lately directed its attention towards the "so-called" cognitive enhancers.  This class of substances, by modulating cognitive processes involved in the development and/or persistence of the post-traumatic symptomatol., could be of great help in improving the outcome of psychotherapies and patients' prognosis.  In this perspective, drugs acting on the endocannabinoid system are receiving great attention due to their dual ability to modulate memory processes on one hand, and to reduce anxiety and depression on the other.  The purpose of the present review is to offer a thorough overview of both animal and human studies investigating the effects of cannabinoids on memory processes.  First, we will briefly describe the characteristics of the endocannabinoid system and the most commonly used animal models of learning and memory.  Then, studies investigating cannabinoid modulatory influences on memory consolidation, retrieval and extinction will be sep. presented, and the potential benefits assocd. with each approach will be discussed.  In the final section, we will review literature data reporting beneficial effects of cannabinoid drugs in PTSD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb-PWPhgS1wLVg90H21EOLACvtfcHk0lh4mm7RKJ1Drg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygtrfL&md5=7fa5b94ff602c40853b26fcc197ac298</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DBerardi%26aufirst%3DA.%26aulast%3DSchelling%26aufirst%3DG.%26aulast%3DCampolongo%26aufirst%3DP.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520post%2520traumatic%2520stress%2520disorder%2520%2528PTSD%2529%253A%2520from%2520preclinical%2520findings%2520to%2520innovative%2520therapeutic%2520approaches%2520in%2520clinical%2520settings%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D668%26epage%3D678%26doi%3D10.1016%2Fj.phrs.2016.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, H. D.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid signaling in health and disease</span>. <i>Can. J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1139/cjpp-2016-0346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1139%2Fcjpp-2016-0346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28263083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsl2gtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2017&pages=311-327&author=Y.+Luauthor=H.+D.+Anderson&title=Cannabinoid+signaling+in+health+and+disease&doi=10.1139%2Fcjpp-2016-0346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid signaling in health and disease</span></div><div class="casAuthors">Lu, Yan; Anderson, Hope D.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-327</span>CODEN:
                <span class="NLM_cas:coden">CJPPA3</span>;
        ISSN:<span class="NLM_cas:issn">0008-4212</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">Cannabis sativa has long been used for medicinal purposes.  To improve safety and efficacy, compds. from C.sativa were purified or synthesized and named under an umbrella group as cannabinoids.  Currently, several cannabinoids may be prescribed in Canada for a variety of indications such as nausea and pain.  More recently, an increasing no. of reports suggest other salutary effects assocd. with endogenous cannabinoid signaling including cardioprotection.  The therapeutic potential of cannabinoids is therefore extended; however, evidence is limited and mechanisms remain unclear.  In addn., the use of cannabinoids clin. has been hindered due to pronounced psychoactive side effects.  This review provides an overview on the endocannabinoid system, including known physiol. roles, and conditions in which cannabinoid receptor signaling has been implicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsd9MesiR56LVg90H21EOLACvtfcHk0lh4mm7RKJ1Drg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsl2gtb8%253D&md5=e3e1c0f219bd9e0d44c0c063dd61626d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1139%2Fcjpp-2016-0346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fcjpp-2016-0346%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DAnderson%26aufirst%3DH.%2BD.%26atitle%3DCannabinoid%2520signaling%2520in%2520health%2520and%2520disease%26jtitle%3DCan.%2520J.%2520Physiol.%2520Pharmacol.%26date%3D2017%26volume%3D95%26spage%3D311%26epage%3D327%26doi%3D10.1139%2Fcjpp-2016-0346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulugol, A.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system as a potential therapeutic target for pain modulation</span>. <i>Balk. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.5152/balkanmedj.2014.13103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.5152%2Fbalkanmedj.2014.13103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25207181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=115-120&author=A.+Ulugol&title=The+endocannabinoid+system+as+a+potential+therapeutic+target+for+pain+modulation&doi=10.5152%2Fbalkanmedj.2014.13103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as a potential therapeutic target for pain modulation</span></div><div class="casAuthors">Ulugol, Ahmet</div><div class="citationInfo"><span class="NLM_cas:title">Balkan Medical Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-120, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">BMJAB7</span>;
        ISSN:<span class="NLM_cas:issn">2146-3131</span>.
    
            (<span class="NLM_cas:orgname">AVES</span>)
        </div><div class="casAbstract">A review.  Although cannabis has been used for pain management for millennia, very few approved cannabinoids are indicated for the treatment of pain and other medical symptoms.  Cannabinoid therapy re-gained attention only after the discovery of endocannabinoids and fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the enzymes playing a role in endocannabinoid metab.  Nowadays, research has focused on the inhibition of these degradative enzymes and the elevation of endocannabinoid tonus locally; special emphasis is given on multi-target analgesia compds., where one of the targets is the endocannabinoid degrading enzyme.  In this review, I provide an overview of the current understanding about the processes accounting for the biosynthesis, transport and metab. of endocannabinoids, and pharmacol. approaches and potential therapeutic applications in this area, regarding the use of drugs elevating endocannabinoid levels in pain conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_qeLQOWMa7Vg90H21EOLACvtfcHk0lhqt1r2IHWQ5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egtL3I&md5=b3401e563d92777405a1ef6c8569cb41</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.5152%2Fbalkanmedj.2014.13103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5152%252Fbalkanmedj.2014.13103%26sid%3Dliteratum%253Aachs%26aulast%3DUlugol%26aufirst%3DA.%26atitle%3DThe%2520endocannabinoid%2520system%2520as%2520a%2520potential%2520therapeutic%2520target%2520for%2520pain%2520modulation%26jtitle%3DBalk.%2520Med.%2520J.%26date%3D2014%26volume%3D31%26spage%3D115%26epage%3D120%26doi%3D10.5152%2Fbalkanmedj.2014.13103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bedse, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavecchia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, S.</span></span> <span> </span><span class="NLM_article-title">The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1136</span>, <span class="refDoi"> DOI: 10.3233/JAD-141635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3233%2FJAD-141635" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1115-1136&author=G.+Bedseauthor=A.+Romanoauthor=A.+M.+Lavecchiaauthor=T.+Cassanoauthor=S.+Gaetani&title=The+role+of+endocannabinoid+signaling+in+the+molecular+mechanisms+of+neurodegeneration+in+alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-141635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3233%2FJAD-141635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-141635%26sid%3Dliteratum%253Aachs%26aulast%3DBedse%26aufirst%3DG.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DLavecchia%26aufirst%3DA.%2BM.%26aulast%3DCassano%26aufirst%3DT.%26aulast%3DGaetani%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520endocannabinoid%2520signaling%2520in%2520the%2520molecular%2520mechanisms%2520of%2520neurodegeneration%2520in%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2014%26volume%3D43%26spage%3D1115%26epage%3D1136%26doi%3D10.3233%2FJAD-141635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhams, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neugebauer, V.</span></span> <span> </span><span class="NLM_article-title">The cannabinoid system and pain</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuropharm.2017.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28625720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGnsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=105-120&author=S.+G.+Woodhamsauthor=V.+Chapmanauthor=D.+P.+Finnauthor=A.+G.+Hohmannauthor=V.+Neugebauer&title=The+cannabinoid+system+and+pain&doi=10.1016%2Fj.neuropharm.2017.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The cannabinoid system and pain</span></div><div class="casAuthors">Woodhams, Stephen G.; Chapman, Victoria; Finn, David P.; Hohmann, Andrea G.; Neugebauer, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105-120</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic pain states are highly prevalent and yet poorly controlled by currently available analgesics, representing an enormous clin., societal, and economic burden.  Existing pain medications have significant limitations and adverse effects including tolerance, dependence, gastrointestinal dysfunction, cognitive impairment, and a narrow therapeutic window, making the search for novel analgesics ever more important.  In this article, we review the role of an important endogenous pain control system, the endocannabinoid (EC) system, in the sensory, emotional, and cognitive aspects of pain.  Herein, we briefly cover the discovery of the EC system and its role in pain processing pathways, before concg. on three areas of current major interest in EC pain research; 1.  Pharmacol. enhancement of endocannabinoid activity (via blockade of EC metab. or allosteric modulation of CB1receptors); 2.  The EC System and stress-induced modulation of pain; and 3.  The EC system & medial prefrontal cortex (mPFC) dysfunction in pain states.  While we focus predominantly on the preclin. data, we also include extensive discussion of recent clin. failures of endocannabinoid-related therapies, the future potential of these approaches, and important directions for future research on the EC system and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdKeLMGIq96bVg90H21EOLACvtfcHk0lhqt1r2IHWQ5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGnsbfO&md5=dbe8590a0cc4e110f80de7f2267347cf</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhams%26aufirst%3DS.%2BG.%26aulast%3DChapman%26aufirst%3DV.%26aulast%3DFinn%26aufirst%3DD.%2BP.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26aulast%3DNeugebauer%26aufirst%3DV.%26atitle%3DThe%2520cannabinoid%2520system%2520and%2520pain%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D124%26spage%3D105%26epage%3D120%26doi%3D10.1016%2Fj.neuropharm.2017.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toczek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinowska, B.</span></span> <span> </span><span class="NLM_article-title">Enhanced endocannabinoid tone as a potential target of pharmacotherapy</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2018.04.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.lfs.2018.04.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29729263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1Khsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2018&pages=20-45&author=M.+Toczekauthor=B.+Malinowska&title=Enhanced+endocannabinoid+tone+as+a+potential+target+of+pharmacotherapy&doi=10.1016%2Fj.lfs.2018.04.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced endocannabinoid tone as a potential target of pharmacotherapy</span></div><div class="casAuthors">Toczek, Marek; Malinowska, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-45</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system is up-regulated in numerous pathophysiol. states such as inflammatory, neurodegenerative, gastrointestinal, metabolic and cardiovascular diseases, pain, and cancer.  It has been suggested that this phenomenon primarily serves an autoprotective role in inhibiting disease progression and/or diminishing signs and symptoms.  Accordingly, enhancement of endogenous endocannabinoid tone by inhibition of endocannabinoid degrdn. represents a promising therapeutic approach for the treatment of many diseases.  Importantly, this allows for the avoidance of unwanted psychotropic side effects that accompany exogenously administered cannabinoids.  The effects of endocannabinoid metabolic pathway modulation are complex, as endocannabinoids can exert their actions directly or via numerous metabolites.  The two main strategies for blocking endocannabinoid degrdn. are inhibition of endocannabinoid-degrading enzymes and inhibition of endocannabinoid cellular uptake.  To date, the most investigated compds. are inhibitors of fatty acid amide hydrolase (FAAH), an enzyme that degrades the endocannabinoid anandamide.  However, application of FAAH inhibitors (and consequently other endocannabinoid degrdn. inhibitors) in medicine became questionable due to a lack of therapeutic efficacy in clin. trials and serious adverse effects evoked by one specific compd.  In this paper, we discuss multiple pathways of endocannabinoid metab., changes in endocannabinoid levels across numerous human diseases and corresponding exptl. models, pharmacol. strategies for enhancing endocannabinoid tone and potential therapeutic applications including multi-target drugs with addnl. targets outside of the endocannabinoid system (cyclooxygenase-2, cholinesterase, TRPV1, and PGF2α-EA receptors), and currently used medicines or medicinal herbs that addnl. enhance endocannabinoid levels.  Ultimately, further clin. and preclin. studies are warranted to develop medicines for enhancing endocannabinoid tone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHpA_mUdMumrVg90H21EOLACvtfcHk0lhqt1r2IHWQ5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1Khsbo%253D&md5=0cc869bf43372400169d7ab1f29d4227</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2018.04.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2018.04.054%26sid%3Dliteratum%253Aachs%26aulast%3DToczek%26aufirst%3DM.%26aulast%3DMalinowska%26aufirst%3DB.%26atitle%3DEnhanced%2520endocannabinoid%2520tone%2520as%2520a%2520potential%2520target%2520of%2520pharmacotherapy%26jtitle%3DLife%2520Sci.%26date%3D2018%26volume%3D204%26spage%3D20%26epage%3D45%26doi%3D10.1016%2Fj.lfs.2018.04.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tambaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives</span>. <i>Recent Pat. CNS Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.2174/157488912798842269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2174%2F157488912798842269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22280339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFSqt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=25-40&author=S.+Tambaroauthor=M.+Bortolato&title=Cannabinoid-related+agents+in+the+treatment+of+anxiety+disorders%3A+current+knowledge+and+future+perspectives&doi=10.2174%2F157488912798842269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives</span></div><div class="casAuthors">Tambaro, Simone; Bortolato, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on CNS Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>CODEN:
                <span class="NLM_cas:coden">RPCDC9</span>;
        ISSN:<span class="NLM_cas:issn">1574-8898</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Rich evidence has shown that cannabis products exert a broad gamut of effects on emotional regulation.  The main psychoactive ingredient of hemp, Δ9-tetrahydrocannabinol (THC), and its synthetic cannabinoid analogs have been reported to either attenuate or exacerbate anxiety and fear-related behaviors in humans and exptl. animals.  The heterogeneity of cannabis-induced psychol. outcomes reflects a complex network of mol. interactions between the key neurobiol. substrates of anxiety and fear and the endogenous cannabinoid system, mainly consisting of the arachidonic acid derivs. anandamide and 2-arachidonoylglycerol (2-AG) and two receptors, resp. termed CB1 and CB2.  The high degree of interindividual variability in the responses to cannabis is contributed by a wide spectrum of factors, including genetic and environmental determinants, as well as differences in the relative concns. of THC and other alkaloids (such as cannabidiol) within the plant itself.  The present article reviews the currently available knowledge on the herbal, synthetic and endogenous cannabinoids with respect to the modulation of anxiety responses, and high-lights the challenges that should be overcome to harness the therapeutic potential of some of these compds., all the while limiting the side effects assocd. with cannabis consumption.  In addn. the article presents some promising patents on cannabinoid-related agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp70n73araPC7Vg90H21EOLACvtfcHk0li4oC-aJziN2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFSqt78%253D&md5=b2e628adb3168a86ca29318cc899267f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F157488912798842269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488912798842269%26sid%3Dliteratum%253Aachs%26aulast%3DTambaro%26aufirst%3DS.%26aulast%3DBortolato%26aufirst%3DM.%26atitle%3DCannabinoid-related%2520agents%2520in%2520the%2520treatment%2520of%2520anxiety%2520disorders%253A%2520current%2520knowledge%2520and%2520future%2520perspectives%26jtitle%3DRecent%2520Pat.%2520CNS%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D25%26epage%3D40%26doi%3D10.2174%2F157488912798842269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3363</span>, <span class="refDoi"> DOI: 10.1098/rstb.2011.0381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1098%2Frstb.2011.0381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23108552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKgtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=3353-3363&author=R.+G.+Pertwee&title=Targeting+the+endocannabinoid+system+with+cannabinoid+receptor+agonists%3A+pharmacological+strategies+and+therapeutic+possibilities&doi=10.1098%2Frstb.2011.0381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities</span></div><div class="casAuthors">Pertwee, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1607</span>),
    <span class="NLM_cas:pages">3353-3363</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Human tissues express cannabinoid CB1 and CB2 receptors that can be activated by endogenously released 'endocannabinoids' or exogenously administered compds. in a manner that reduces the symptoms or opposes the underlying causes of several disorders in need of effective therapy.  Three medicines that activate cannabinoid CB1/CB2 receptors are now in the clinic: Cesamet (nabilone), Marinol (dronabinol; Δ9-tetrahydrocannabinol (Δ9-THC)) and Sativex (Δ9-THC with cannabidiol).  These can be prescribed for the amelioration of chemotherapy-induced nausea and vomiting (Cesamet and Marinol), stimulation of appetite (Marinol) and symptomatic relief of cancer pain and/or management of neuropathic pain and spasticity in adults with multiple sclerosis (Sativex).  This review mentions several possible addnl. therapeutic targets for cannabinoid receptor agonists.  These include other kinds of pain, epilepsy, anxiety, depression, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders.  It also describes potential strategies for improving the efficacy and/or benefit-to-risk ratio of these agonists in the clinic.  These are strategies that involve (i) targeting cannabinoid receptors located outside the blood-brain barrier, (ii) targeting cannabinoid receptors expressed by a particular tissue, (iii) targeting upregulated cannabinoid receptors, (iv) selectively targeting cannabinoid CB2 receptors, and/or (v) adjunctive 'multi-targeting'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Q3tFouTow7Vg90H21EOLACvtfcHk0li4oC-aJziN2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKgtL3L&md5=520dda552cdeb306560444cf7c5932f6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1098%2Frstb.2011.0381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2011.0381%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DTargeting%2520the%2520endocannabinoid%2520system%2520with%2520cannabinoid%2520receptor%2520agonists%253A%2520pharmacological%2520strategies%2520and%2520therapeutic%2520possibilities%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2012%26volume%3D367%26spage%3D3353%26epage%3D3363%26doi%3D10.1098%2Frstb.2011.0381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockings, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murnion, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, L.</span></span> <span> </span><span class="NLM_article-title">Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">1932</span>– <span class="NLM_lpage">1954</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000001293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1097%2Fj.pain.0000000000001293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29847469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslGnsrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2018&pages=1932-1954&author=E.+Stockingsauthor=G.+Campbellauthor=W.+D.+Hallauthor=S.+Nielsenauthor=D.+Zagicauthor=R.+Rahmanauthor=B.+Murnionauthor=M.+Farrellauthor=M.+Weierauthor=L.+Degenhardt&title=Cannabis+and+cannabinoids+for+the+treatment+of+people+with+chronic+noncancer+pain+conditions%3A+a+systematic+review+and+meta-analysis+of+controlled+and+observational+studies&doi=10.1097%2Fj.pain.0000000000001293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies</span></div><div class="casAuthors">Stockings, Emily; Campbell, Gabrielle; Hall, Wayne D.; Nielsen, Suzanne; Zagic, Dino; Rahman, Rakin; Murnion, Bridin; Farrell, Michael; Weier, Megan; Degenhardt, Louisa</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1932-1954</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines.  MEDLINE, Embase, PsycINFO, CENTRAL, and clinicaltrials.gov were searched in July 2017.  Analyses were conducted using Revman 5.3 and Stata 15.0.  A total of 91 publications contg. 104 studies were eligible (n = 9958 participants), including 47 randomised controlled trials (RCTs) and 57 observational studies.  Forty-eight studies examd. neuropathic pain, 7 studies examd. fibromyalgia, 1 rheumatoid arthritis, and 48 other CNCP (13 multiple sclerosis-related pain, 6 visceral pain, and 29 samples with mixed or undefined CNCP).  Across RCTs, pooled event rates (PERs) for 30% redn. in pain were 29.0% (cannabinoids) vs 25.9% (placebo); significant effect for cannabinoids was found; no. needed to treat to benefit was 24 (95% confidence interval [CI] 15-61); for 50% redn. in pain, PERs were 18.2% vs 14.4%; no significant difference was obsd.  Pooled change in pain intensity (standardised mean difference: -0.14, 95% CI -0.20 to -0.08) was equiv. to a 3 mm redn. on a 100 mm visual analog scale greater than placebo groups.  In RCTs, PERs for all-cause adverse events were 81.2% vs 66.2%; no. needed to treat to harm: 6 (95% CI 5-8).  There were no significant impacts on phys. or emotional functioning, and low-quality evidence of improved sleep and patient global impression of change.  Evidence for effectiveness of cannabinoids in CNCP is limited.  Effects suggest that no. needed to treat to benefit is high, and no. needed to treat to harm is low, with limited impact on other domains.  It seems unlikely that cannabinoids are highly effective medicines for CNCP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmM2l_gv8dtLVg90H21EOLACvtfcHk0li4oC-aJziN2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslGnsrvL&md5=b135acedade4757309f4edca9dfbda74</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000001293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000001293%26sid%3Dliteratum%253Aachs%26aulast%3DStockings%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DG.%26aulast%3DHall%26aufirst%3DW.%2BD.%26aulast%3DNielsen%26aufirst%3DS.%26aulast%3DZagic%26aufirst%3DD.%26aulast%3DRahman%26aufirst%3DR.%26aulast%3DMurnion%26aufirst%3DB.%26aulast%3DFarrell%26aufirst%3DM.%26aulast%3DWeier%26aufirst%3DM.%26aulast%3DDegenhardt%26aufirst%3DL.%26atitle%3DCannabis%2520and%2520cannabinoids%2520for%2520the%2520treatment%2520of%2520people%2520with%2520chronic%2520noncancer%2520pain%2520conditions%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520controlled%2520and%2520observational%2520studies%26jtitle%3DPain%26date%3D2018%26volume%3D159%26spage%3D1932%26epage%3D1954%26doi%3D10.1097%2Fj.pain.0000000000001293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">Translational PET imaging research</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2013.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nbd.2013.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24055214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FgtVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=32-38&author=R.+J.+Hargreavesauthor=E.+A.+Rabiner&title=Translational+PET+imaging+research&doi=10.1016%2Fj.nbd.2013.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Translational PET imaging research</span></div><div class="casAuthors">Hargreaves Richard J; Rabiner Eugenii A</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The goal of any early central nervous system (CNS) drug development program is always to test the mechanism and not the molecule in order to support additional research investments in late phase clinical trials.  Confirmation that drugs reach their targets using translational positron emission tomography (PET) imaging markers of engagement is central to successful clinical proof-of-concept testing and has become an important feature of most neuropsychiatric drug development programs.  CNS PET imaging can also play an important role in the clinical investigation of the neuropharmacological basis of psychiatric disease and the optimization of drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUu9pmPSXkA0g6wdEZmT2rfW6udTcc2eYKMJgURmsHx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FgtVGlsg%253D%253D&md5=84b76b18c4006d60f1b420ae0ebeb903</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2013.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2013.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DTranslational%2520PET%2520imaging%2520research%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2014%26volume%3D61%26spage%3D32%26epage%3D38%26doi%3D10.1016%2Fj.nbd.2013.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suridjan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">The application of positron emission tomography (PET) imaging in CNS drug development</span>. <i>Brain Imaging Behav.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1007/s11682-018-9967-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs11682-018-9967-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30259405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3czjtF2htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=354-365&author=I.+Suridjanauthor=R.+A.+Comleyauthor=E.+A.+Rabiner&title=The+application+of+positron+emission+tomography+%28PET%29+imaging+in+CNS+drug+development&doi=10.1007%2Fs11682-018-9967-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The application of positron emission tomography (PET) imaging in CNS drug development</span></div><div class="casAuthors">Suridjan Ivonne; Comley Robert A; Rabiner Eugenii A; Rabiner Eugenii A</div><div class="citationInfo"><span class="NLM_cas:title">Brain imaging and behavior</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-365</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As drug discovery and development in Neuroscience push beyond symptom management to disease modification, neuroimaging becomes a key area of translational research that enables measurements of the presence of drugs and downstream physiological consequences of drug action within the living brain.  As such, neuroimaging can be used to help optimize decision-making processes throughout the various phases of drug development.  Positron Emission Tomography (PET) is a functional imaging technique that allows the quantification and visualization of biochemical processes, by monitoring the time dependent distribution of molecules labelled with short-lived positron-emitting isotopes.  This review focuses on the application of PET to support CNS drug development, particularly in the early clinical phases, by allowing us to measure tissue exposure, target engagement, and pharmacological activity.  We will also discuss the application of PET imaging as tools to image the pathological hallmarks of disease and evaluate the potential disease-modifying effect of candidate drugs in slowing disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7fE6UVIccHDMsgLhIoICsfW6udTcc2eYKMJgURmsHx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czjtF2htA%253D%253D&md5=60ba9d81f4ee2f24c3767b5cf75ef3bc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs11682-018-9967-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11682-018-9967-0%26sid%3Dliteratum%253Aachs%26aulast%3DSuridjan%26aufirst%3DI.%26aulast%3DComley%26aufirst%3DR.%2BA.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DThe%2520application%2520of%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520imaging%2520in%2520CNS%2520drug%2520development%26jtitle%3DBrain%2520Imaging%2520Behav.%26date%3D2019%26volume%3D13%26spage%3D354%26epage%3D365%26doi%3D10.1007%2Fs11682-018-9967-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waaijer, S. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisses, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalving, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lub-de Hooge, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G. E.</span></span> <span> </span><span class="NLM_article-title">Molecular Imaging in cancer drug development</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.2967/jnumed.116.188045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.116.188045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29371402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWhurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=726-732&author=S.+J.+H.+Waaijerauthor=I.+C.+Kokauthor=B.+Eissesauthor=C.+P.+Schr%C3%B6derauthor=M.+Jalvingauthor=A.+H.+Brouwersauthor=M.+N.+Lub-de+Hoogeauthor=E.+G.+E.+de+Vries&title=Molecular+Imaging+in+cancer+drug+development&doi=10.2967%2Fjnumed.116.188045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular imaging in cancer drug development</span></div><div class="casAuthors">Waaijer, Stijn J. H.; Kok, Iris C.; Eisses, Bertha; Schroeder, Carolina P.; Jalving, Mathilde; Brouwers, Adrienne H.; Hooge, Marjolijn N. Lub-de; de Vries, Elisabeth G. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">726-732</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">A review.  Development of new oncol. drugs has increased since the improved understanding of cancer's complex biol.  The oncol. field has become the top therapeutic research area for new drugs.  However, only a limited no. of drugs entering clin. trials will be approved for use as the std. of care for cancer patients.  Mol. imaging is increasingly perceived as a tool to support go/no-go decisions early during drug development.  It encompasses a wide range of techniques that include radiolabeling a compd. of interest followed by visualization with SPECT or PET.  Radiolabeling can be performed using a variety of radionuclides, which are preferably matched to the compd. on the basis of size and half-life.  Imaging can provide information on drug behavior in vivo, whole-body drug target visualization, and heterogeneity in drug target expression.  This review focuses on current applications of mol. imaging in the development of small mols., antibodies, and antihormonal anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb8D8OZd-hCLVg90H21EOLACvtfcHk0liYYHHMpS8pcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWhurzN&md5=ebc90092c8f856d65d9b17d86dd65004</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.116.188045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.116.188045%26sid%3Dliteratum%253Aachs%26aulast%3DWaaijer%26aufirst%3DS.%2BJ.%2BH.%26aulast%3DKok%26aufirst%3DI.%2BC.%26aulast%3DEisses%26aufirst%3DB.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DC.%2BP.%26aulast%3DJalving%26aufirst%3DM.%26aulast%3DBrouwers%26aufirst%3DA.%2BH.%26aulast%3DLub-de%2BHooge%26aufirst%3DM.%2BN.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%2BE.%26atitle%3DMolecular%2520Imaging%2520in%2520cancer%2520drug%2520development%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D726%26epage%3D732%26doi%3D10.2967%2Fjnumed.116.188045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Gauthier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of PET radiopharmaceuticals at the academia-industry interface</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2017.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ddtec.2017.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29233263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC1MzgslClug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=19-26&author=V.+Bernard-Gauthierauthor=T.+L.+Collierauthor=S.+H.+Liangauthor=N.+Vasdev&title=Discovery+of+PET+radiopharmaceuticals+at+the+academia-industry+interface&doi=10.1016%2Fj.ddtec.2017.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PET radiopharmaceuticals at the academia-industry interface</span></div><div class="casAuthors">Bernard-Gauthier Vadim; Liang Steven H; Collier Thomas L; Vasdev Neil</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today. Technologies</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Project-specific collaborations between academia and pharmaceutical partners are a growing phenomenon within molecular imaging and in particular in the positron emission tomography (PET) radiopharmaceutical community.  This cultural shift can be attributed in part to decreased public funding in academia in conjunction with the increased reliance on outsourcing of chemistry, radiochemistry, pharmacology and molecular imaging studies by the pharmaceutical industry.  This account highlights some of our personal experiences working with industrial partners to develop new PET radiochemistry methodologies for drug discovery and neuro-PET research studies.  These symbiotic academic-industrial partnerships have not only led to novel radiotracers for new targets but also to the application of new carbon-11 and fluorine-18 labeling methodologies and technologies to label previously unprecedented compounds for in vivo evaluations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAVgLDs8Vgmsjl5L8hwNX0fW6udTcc2ebQQzSj3oLxgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzgslClug%253D%253D&md5=6bd1480c177f95675f332391d2118945</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2017.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2017.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Gauthier%26aufirst%3DV.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520PET%2520radiopharmaceuticals%2520at%2520the%2520academia-industry%2520interface%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2017%26volume%3D25%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.ddtec.2017.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevigny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span> <span> </span><span class="NLM_article-title">Optimizing central nervous system drug development using molecular imaging</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1002/cpt.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fcpt.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25869938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOms7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2015&pages=47-60&author=R.+J.+Hargreavesauthor=J.+Hoppinauthor=J.+Sevignyauthor=S.+Patelauthor=P.+Chiaoauthor=M.+Klimasauthor=A.+Verma&title=Optimizing+central+nervous+system+drug+development+using+molecular+imaging&doi=10.1002%2Fcpt.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing Central Nervous System Drug Development Using Molecular Imaging</span></div><div class="casAuthors">Hargreaves, R. J.; Hoppin, J.; Sevigny, J.; Patel, S.; Chiao, P.; Klimas, M.; Verma, A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Advances in multimodality fusion imaging technologies promise to accelerate the understanding of the systems biol. of disease and help in the development of new therapeutics.  The use of mol. imaging biomarkers has been proven to shorten cycle times for central nervous system (CNS) drug development and thereby increase the efficiency and return on investment from research.  Imaging biomarkers can be used to help select the mols., doses, and patients most likely to test therapeutic hypotheses by stopping those that have little chance of success and accelerating those with potential to achieve beneficial clin. outcomes.  CNS imaging biomarkers have the potential to drive new medical care practices for patients in the latent phases of progressive neurodegenerative disorders by enabling the detection, preventative treatment, and tracking of disease in a paradigm shift from today's approaches that have to see the overt symptoms of disease before treating it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA4Jc_IBQ4E7Vg90H21EOLACvtfcHk0lhb-nxgVnuAmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOms7fM&md5=90f5ace142f1c053385568e541c65a23</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fcpt.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.132%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26aulast%3DHoppin%26aufirst%3DJ.%26aulast%3DSevigny%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DChiao%26aufirst%3DP.%26aulast%3DKlimas%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DA.%26atitle%3DOptimizing%2520central%2520nervous%2520system%2520drug%2520development%2520using%2520molecular%2520imaging%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2015%26volume%3D98%26spage%3D47%26epage%3D60%26doi%3D10.1002%2Fcpt.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qijun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinghao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weijian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiaosong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhihua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhidong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span> <span> </span><span class="NLM_article-title">Positron emission tomography (PET) application in the phase 0 clinical trials in drug development</span>. <i>Pharmacy Today (Chinese)</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=99-105&author=H.+Luauthor=C.+Qijunauthor=W.+Luauthor=W.+Jinghaoauthor=Y.+Weijianauthor=W.+Xiaosongauthor=Z.+Zhihuaauthor=Z.+Zhidongauthor=X.+Hao&title=Positron+emission+tomography+%28PET%29+application+in+the+phase+0+clinical+trials+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DQijun%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DJinghao%26aufirst%3DW.%26aulast%3DWeijian%26aufirst%3DY.%26aulast%3DXiaosong%26aufirst%3DW.%26aulast%3DZhihua%26aufirst%3DZ.%26aulast%3DZhidong%26aufirst%3DZ.%26aulast%3DHao%26aufirst%3DX.%26atitle%3DPositron%2520emission%2520tomography%2520%2528PET%2529%2520application%2520in%2520the%2520phase%25200%2520clinical%2520trials%2520in%2520drug%2520development%26jtitle%3DPharmacy%2520Today%2520%2528Chinese%2529%26date%3D2020%26volume%3D30%26spage%3D99%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Guangdong
Province Pharmaceutical Association.</span> <span> </span><span class="NLM_article-title">Consensus on phase 0 clinical trial application for
positron radiopharmaceuticals</span>. <i>Pharmacy Today
(Chinese)</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">798</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=793-798&author=Guangdong%0AProvince+Pharmaceutical+Association.&title=Consensus+on+phase+0+clinical+trial+application+for%0Apositron+radiopharmaceuticals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DConsensus%2520on%2520phase%25200%2520clinical%2520trial%2520application%2520for%250Apositron%2520radiopharmaceuticals%26jtitle%3DPharmacy%2520Today%250A%2528Chinese%2529%26date%3D2020%26volume%3D30%26spage%3D793%26epage%3D798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wildt, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span> <span> </span><span class="NLM_article-title">Microdosing and other phase 0 clinical trials: facilitating translation in drug development</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1111/cts.12390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fcts.12390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26918865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC28jks1Giug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=74-88&author=T.+Burtauthor=K.+Yoshidaauthor=G.+Lappinauthor=L.+Vuongauthor=C.+Johnauthor=S.+N.+de+Wildtauthor=Y.+Sugiyamaauthor=M.+Rowland&title=Microdosing+and+other+phase+0+clinical+trials%3A+facilitating+translation+in+drug+development&doi=10.1111%2Fcts.12390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development</span></div><div class="casAuthors">Burt T; Yoshida K; John C; Yoshida K; Lappin G; Vuong L; Vuong L; de Wildt S N; Sugiyama Y; Rowland M; Rowland M</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">74-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A number of drivers and developments suggest that microdosing and other phase 0 applications will experience increased utilization in the near-to-medium future.  Increasing costs of drug development and ethical concerns about the risks of exposing humans and animals to novel chemical entities are important drivers in favor of these approaches, and can be expected only to increase in their relevance.  An increasing body of research supports the validity of extrapolation from the limited drug exposure of phase 0 approaches to the full, therapeutic exposure, with modeling and simulations capable of extrapolating even non-linear scenarios.  An increasing number of applications and design options demonstrate the versatility and flexibility these approaches offer to drug developers including the study of PK, bioavailability, DDI, and mechanistic PD effects.  PET microdosing allows study of target localization, PK and receptor binding and occupancy, while Intra-Target Microdosing (ITM) allows study of local therapeutic-level acute PD coupled with systemic microdose-level exposure.  Applications in vulnerable populations and extreme environments are attractive due to the unique risks of pharmacotherapy and increasing unmet healthcare needs.  All phase 0 approaches depend on the validity of extrapolation from the limited-exposure scenario to the full exposure of therapeutic intent, but in the final analysis the potential for controlled human data to reduce uncertainty about drug properties is bound to be a valuable addition to the drug development process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB4hk6rM5szw20zIbnCCI3fW6udTcc2ea3WfFtIqN-zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jks1Giug%253D%253D&md5=2852c3bb726cf87599926e6352f2eec0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fcts.12390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12390%26sid%3Dliteratum%253Aachs%26aulast%3DBurt%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DLappin%26aufirst%3DG.%26aulast%3DVuong%26aufirst%3DL.%26aulast%3DJohn%26aufirst%3DC.%26aulast%3Dde%2BWildt%26aufirst%3DS.%2BN.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DRowland%26aufirst%3DM.%26atitle%3DMicrodosing%2520and%2520other%2520phase%25200%2520clinical%2520trials%253A%2520facilitating%2520translation%2520in%2520drug%2520development%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2016%26volume%3D9%26spage%3D74%26epage%3D88%26doi%3D10.1111%2Fcts.12390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCartt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combes, R.</span></span> <span> </span><span class="NLM_article-title">Phase 0, including microdosing approaches: applying the three rs and increasing the efficiency of human drug development</span>. <i>ATLA, Altern. Lab. Anim.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1177/026119291804600603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1177%2F026119291804600603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30657329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3cjivVaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=335-346&author=T.+Burtauthor=L.+T.+Vuongauthor=E.+Bakerauthor=G.+C.+Youngauthor=A.+D.+McCarttauthor=M.+Bergstromauthor=Y.+Sugiyamaauthor=R.+Combes&title=Phase+0%2C+including+microdosing+approaches%3A+applying+the+three+rs+and+increasing+the+efficiency+of+human+drug+development&doi=10.1177%2F026119291804600603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development</span></div><div class="casAuthors">Burt Tal; Vuong Le Thuy; Baker Elizabeth; Young Graeme C; McCartt A Daniel; Bergstrom Mats; Sugiyama Yuichi; Combes Robert</div><div class="citationInfo"><span class="NLM_cas:title">Alternatives to laboratory animals : ATLA</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">335-346</span>
        ISSN:<span class="NLM_cas:issn">0261-1929</span>.
    </div><div class="casAbstract">Phase 0 approaches, including microdosing, involve the use of sub-therapeutic exposures to the tested drugs, thus enabling safer, more-relevant, quicker and cheaper first-in-human (FIH) testing.  These approaches also have considerable potential to limit the use of animals in human drug development.  Recent years have witnessed progress in applications, methodology, operations, and drug development culture.  Advances in applications saw an expansion in therapeutic areas, developmental scenarios and scientific objectives, in, for example, protein drug development and paediatric drug development.  In the operational area, the increased sensitivity of Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS), expansion of the utility of Positron Emission Tomography (PET) imaging, and the introduction of Cavity Ring-Down Spectroscopy (CRDS), have led to the increased accessibility and utility of Phase 0 approaches, while reducing costs and exposure to radioactivity.  PET has extended the application of microdosing, from its use as a predominant tool to record pharmacokinetics, to a method for recording target expression and target engagement, as well as cellular and tissue responses.  Advances in methodology include adaptive Phase 0/Phase 1 designs, cassette and cocktail microdosing, and Intra-Target Microdosing (ITM), as well as novel modelling opportunities and simulations.  Importantly, these methodologies increase the predictive power of extrapolation from microdose to therapeutic level exposures.  However, possibly the most challenging domain in which progress has been made, is the culture of drug development.  One of the main potential values of Phase 0 approaches is the opportunity to terminate development early, thus not only applying the principle of 'kill-early-kill-cheap' to enhance the efficiency of drug development, but also obviating the need for the full package of animal testing required for therapeutic level Phase 1 studies.  Finally, we list developmental scenarios that utilised Phase 0 approaches in novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9jWzpjX7CeTEC-75aqa5AfW6udTcc2ea3WfFtIqN-zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjivVaksg%253D%253D&md5=87e5688bfbd89c6315d2b6eb0cf6545a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F026119291804600603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F026119291804600603%26sid%3Dliteratum%253Aachs%26aulast%3DBurt%26aufirst%3DT.%26aulast%3DVuong%26aufirst%3DL.%2BT.%26aulast%3DBaker%26aufirst%3DE.%26aulast%3DYoung%26aufirst%3DG.%2BC.%26aulast%3DMcCartt%26aufirst%3DA.%2BD.%26aulast%3DBergstrom%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DCombes%26aufirst%3DR.%26atitle%3DPhase%25200%252C%2520including%2520microdosing%2520approaches%253A%2520applying%2520the%2520three%2520rs%2520and%2520increasing%2520the%2520efficiency%2520of%2520human%2520drug%2520development%26jtitle%3DATLA%252C%2520Altern.%2520Lab.%2520Anim.%26date%3D2018%26volume%3D46%26spage%3D335%26epage%3D346%26doi%3D10.1177%2F026119291804600603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varlow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Classics in neuroimaging: imaging the endocannabinoid pathway with PET</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.0c00305</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.0c00305" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtF2ksb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1855-1862&author=C.+Varlowauthor=I.+Boileauauthor=H.+Y.+Weyauthor=S.+H.+Liangauthor=N.+Vasdev&title=Classics+in+neuroimaging%3A+imaging+the+endocannabinoid+pathway+with+PET&doi=10.1021%2Facschemneuro.0c00305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Classics in Neuroimaging: Imaging the Endocannabinoid Pathway with PET</span></div><div class="casAuthors">Varlow, Cassis; Boileau, Isabelle; Wey, Hsiao-Ying; Liang, Steven H.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1855-1862</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Viewpoint aims to highlight positron emission tomog. (PET) research studies that have shaped our understanding of the endocannabinoid system (ECS) through radiopharmaceutical targeting of cannabinoid receptors 1 and 2 (CB1 and CB2), and the enzyme fatty acid amide hydrolase (FAAH), in several brain health illnesses including addiction, schizophrenia, eating disorders, and post-traumatic stress disorder.  Advances in radiochem., including 11C-carbonylation and radiofluorination of nonactivated arom. rings, are accelerating the translation of radiotracers with optimal kinetics, bringing us closer to clin. PET research studies to image the enzyme monoacylglycerol lipase (MAGL) and enabling the imaging of unexplored targets in the ECS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDv-Ls4H_44bVg90H21EOLACvtfcHk0ljTnA-L_kCUrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtF2ksb7N&md5=bb436524423c85a3b8c7fac6f69c357b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.0c00305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.0c00305%26sid%3Dliteratum%253Aachs%26aulast%3DVarlow%26aufirst%3DC.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DWey%26aufirst%3DH.%2BY.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DClassics%2520in%2520neuroimaging%253A%2520imaging%2520the%2520endocannabinoid%2520pathway%2520with%2520PET%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2020%26volume%3D11%26spage%3D1855%26epage%3D1862%26doi%3D10.1021%2Facschemneuro.0c00305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span> <span> </span><span class="NLM_article-title">In vivo imaging of the cannabinoid CB1 receptor with positron emission tomography</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1002/cpt.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fcpt.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25788235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFKrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=565-567&author=J.+Hirvonen&title=In+vivo+imaging+of+the+cannabinoid+CB1+receptor+with+positron+emission+tomography&doi=10.1002%2Fcpt.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo imaging of the cannabinoid CB1 receptor with positron emission tomography</span></div><div class="casAuthors">Hirvonen, J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-567</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Positron emission tomog. (PET) can visualize and quantify receptors and other targets in the living human brain, and recent progress in radioligand development has enabled measurement of cannabinoid type-1 (CB1) receptors.  Cannabinoid CB1 receptors have been implicated in multiple human diseases, such as obesity, mood disorders, and addiction.  First in vivo human studies have shown distinctive spatial and temporal alterations in cannabinoid CB1 receptor binding in addictive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBVyRtIVRdxLVg90H21EOLACvtfcHk0ljKl0kDlXO30w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFKrtr4%253D&md5=3c58f9046300d21011364a5255336d0b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcpt.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.116%26sid%3Dliteratum%253Aachs%26aulast%3DHirvonen%26aufirst%3DJ.%26atitle%3DIn%2520vivo%2520imaging%2520of%2520the%2520cannabinoid%2520CB1%2520receptor%2520with%2520positron%2520emission%2520tomography%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2015%26volume%3D97%26spage%3D565%26epage%3D567%26doi%3D10.1002%2Fcpt.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S.</span></span> <span> </span><span class="NLM_article-title">Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0035-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41401-018-0035-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29921889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOmsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=351-357&author=R.+Niauthor=L.+Muauthor=S.+Ametamey&title=Positron+emission+tomography+of+type+2+cannabinoid+receptors+for+detecting+inflammation+in+the+central+nervous+system&doi=10.1038%2Fs41401-018-0035-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system</span></div><div class="casAuthors">Ni, Ruiqing; Mu, Linjing; Ametamey, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-357</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cannabinoid receptor CB2 (CB2R) is upregulated on activated microglia and astrocytes in the brain under inflammatory conditions and plays important roles in many neurol. diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke.  The advent of positron emission tomog. (PET) using CB2R radiotracers has enabled the visualization of CB2R distribution in vivo in animal models of central nervous system inflammation, however translation to humans has been less successful.  Several novel CB2R radiotracers have been developed and evaluated to quantify microglial activation.  In this review, we summarize the recent preclin. and clin. imaging results of CB2R PET tracers and discuss the prospects of CB2R imaging using PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVQSh6Ru_9q7Vg90H21EOLACvtfcHk0ljKl0kDlXO30w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOmsrzF&md5=2244385624a23d12167e7ee37c187720</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0035-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0035-5%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DAmetamey%26aufirst%3DS.%26atitle%3DPositron%2520emission%2520tomography%2520of%2520type%25202%2520cannabinoid%2520receptors%2520for%2520detecting%2520inflammation%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D351%26epage%3D357%26doi%3D10.1038%2Fs41401-018-0035-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1002/jlcr.3579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjlcr.3579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29110331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=299-308&author=F.+Spinelliauthor=L.+Muauthor=S.+M.+Ametamey&title=Radioligands+for+positron+emission+tomography+imaging+of+cannabinoid+type+2+receptor&doi=10.1002%2Fjlcr.3579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor</span></div><div class="casAuthors">Spinelli, Francesco; Mu, Linjing; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-308</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  The cannabinoid type 2 (CB2) receptor is an immunomodulatory receptor mainly expressed in peripheral cells and organs of the immune system.  The expression level of CB2 in the central nervous system under physiol. conditions is negligible, however under neuroinflammatory conditions an upregulation of CB2 protein or mRNA mainly colocalized with activated microglial cells has been reported.  Consequently, CB2 agonists have been confirmed to play a role in neuroprotective and anti-inflammatory processes.  A suitable positron emission tomog. radioligand for imaging CB2 would provide an invaluable research tool to explore the role of CB2 receptor expression in inflammatory disorders.  In this review, we provide a summary of so far published CB2 radioligands as well as their in vitro and in vivo binding characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6zEMOTJW1t7Vg90H21EOLACvtfcHk0ljKl0kDlXO30w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kruw%253D%253D&md5=618a65ba969379132659149f2c4fa9bb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3579%26sid%3Dliteratum%253Aachs%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DRadioligands%2520for%2520positron%2520emission%2520tomography%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptor%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2018%26volume%3D61%26spage%3D299%26epage%3D308%26doi%3D10.1002%2Fjlcr.3579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plisson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O.</span></span> <span> </span><span class="NLM_article-title">Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1007/s00259-019-04488-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00259-019-04488-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31541283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWkur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2020&pages=451-489&author=S.+P.+McCluskeyauthor=C.+Plissonauthor=E.+A.+Rabinerauthor=O.+Howes&title=Advances+in+CNS+PET%3A+the+state-of-the-art+for+new+imaging+targets+for+pathophysiology+and+drug+development&doi=10.1007%2Fs00259-019-04488-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development</span></div><div class="casAuthors">McCluskey, Stuart P.; Plisson, Christophe; Rabiner, Eugenii A.; Howes, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">451-489</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Purpose: A limit on developing new treatments for a no. of central nervous system (CNS) disorders has been the inadequate understanding of the in vivo pathophysiol. underlying neurol. and psychiatric disorders and the lack of in vivo tools to det. brain penetrance, target engagement, and relevant mol. activity of novel drugs.  Mol. neuroimaging provides the tools to address this.  This article aims to provide a state-of-the-art review of new PET tracers for CNS targets, focusing on developments in the last 5 years for targets recently available for in-human imaging.  Methods: We provide an overview of the criteria used to evaluate PET tracers.  We then used the National Institute of Mental Health Research Priorities list to identify the key CNS targets.  We conducted a PubMed search (search period 1st of Jan. 2013 to 31st of Dec. 2018), which yielded 40 new PET tracers across 16 CNS targets which met our selectivity criteria.  For each tracer, we summarised the evidence of its properties and potential for use in studies of CNS pathophysiol. and drug evaluation, including its target selectivity and affinity, inter and intra-subject variability, and pharmacokinetic parameters.  We also consider its potential limitations and missing characterization data, but not specific applications in drug development.  Where multiple tracers were present for a target, we provide a comparison of their properties.  Results and conclusions: Our review shows that multiple new tracers have been developed for proteinopathy targets, particularly tau, as well as the purinoceptor P2X7, phosphodiesterase enzyme PDE10A, and synaptic vesicle glycoprotein 2A (SV2A), amongst others.  Some of the most promising of these include 18F-MK-6240 for tau imaging, 11C-UCB-J for imaging SV2A, 11C-CURB and 11C-MK-3168 for characterization of fatty acid amide hydrolase, 18F-FIMX for metabotropic glutamate receptor 1, and 18F-MNI-444 for imaging adenosine 2A.  Our review also identifies recurrent issues within the field.  Many of the tracers discussed lack in vivo blocking data, reducing confidence in selectivity.  Addnl., late-stage identification of substantial off-target sites for multiple tracers highlights incomplete pre-clin. characterization prior to translation, as well as human disease state studies carried out without confirmation of test-retest reproducibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY0u-7Ko8uWbVg90H21EOLACvtfcHk0ljX4p3vG-6tHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWkur%252FK&md5=277c998059c613ad478913f51eb81ae3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs00259-019-04488-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-019-04488-0%26sid%3Dliteratum%253Aachs%26aulast%3DMcCluskey%26aufirst%3DS.%2BP.%26aulast%3DPlisson%26aufirst%3DC.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26aulast%3DHowes%26aufirst%3DO.%26atitle%3DAdvances%2520in%2520CNS%2520PET%253A%2520the%2520state-of-the-art%2520for%2520new%2520imaging%2520targets%2520for%2520pathophysiology%2520and%2520drug%2520development%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2020%26volume%3D47%26spage%3D451%26epage%3D489%26doi%3D10.1007%2Fs00259-019-04488-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shahbazi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trant, J. F.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids and cannabinoid receptors: the story so far</span>. <i>iScience</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">101301</span>, <span class="refDoi"> DOI: 10.1016/j.isci.2020.101301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.isci.2020.101301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32629422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSisrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2020&pages=101301&author=F.+Shahbaziauthor=V.+Grandiauthor=A.+Banerjeeauthor=J.+F.+Trant&title=Cannabinoids+and+cannabinoid+receptors%3A+the+story+so+far&doi=10.1016%2Fj.isci.2020.101301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids and Cannabinoid Receptors: The Story so Far</span></div><div class="casAuthors">Shahbazi, Fred; Grandi, Victoria; Banerjee, Abhinandan; Trant, John F.</div><div class="citationInfo"><span class="NLM_cas:title">iScience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">101301</span>CODEN:
                <span class="NLM_cas:coden">ISCICE</span>;
        ISSN:<span class="NLM_cas:issn">2589-0042</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Like most modern mol. biol. and natural product chem., understanding cannabinoid pharmacol. centers around mol. interactions, in this case, between the cannabinoids and their putative targets, the G-protein coupled receptors (GPCRs) cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).  Understanding the complex structure and interplay between the partners in this mol. dance is required to understand the mechanism of action of synthetic, endogenous, and phytochem. cannabinoids.  This review, with 91 refs., surveys our understanding of the structural biol. of the cannabinoids and their target receptors including both a crit. comparison of the extant crystal structures and the computationally derived homol. models, as well as an in-depth discussion about the binding modes of the major cannabinoids.  The aim is to assist in situating structural biochemists, synthetic chemists, and mol. biologists who are new to the field of cannabis research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsxpectYVbRbVg90H21EOLACvtfcHk0ljX4p3vG-6tHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSisrjK&md5=20e40dcafb7fd6ed6f15ce9d09c119e4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.isci.2020.101301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.isci.2020.101301%26sid%3Dliteratum%253Aachs%26aulast%3DShahbazi%26aufirst%3DF.%26aulast%3DGrandi%26aufirst%3DV.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DTrant%26aufirst%3DJ.%2BF.%26atitle%3DCannabinoids%2520and%2520cannabinoid%2520receptors%253A%2520the%2520story%2520so%2520far%26jtitle%3DiScience%26date%3D2020%26volume%3D23%26spage%3D101301%26doi%3D10.1016%2Fj.isci.2020.101301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragunow, M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1016/S0306-4522(96)00428-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0306-4522%2896%2900428-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=9472392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK2sXhs1Gms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1997&pages=299-318&author=M.+Glassauthor=R.+Faullauthor=M.+Dragunow&title=Cannabinoid+receptors+in+the+human+brain%3A+a+detailed+anatomical+and+quantitative+autoradiographic+study+in+the+fetal%2C+neonatal+and+adult+human+brain&doi=10.1016%2FS0306-4522%2896%2900428-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain</span></div><div class="casAuthors">Glass, M.; Dragunow, M.; Faull, R. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-318</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The anatomical distribution and d. of cannabinoid receptors in the human brain was studied in one fetal (33 wk gestation), two neonatal (aged three to six \months) and eight adult (aged 21-81 yr) human cases using quant. receptor autoradiog. following in vitro labeling of sections with the synthetic cannabinoid agonist [3H]CP55,940.  Cannabinoid receptors were distributed in a heterogeneous fashion throughout the adult human brain and spinal cord.  The allocortex contained very high concns. of cannabinoid receptor binding sites in the dentate gyrus, Ammons's horn and subiculum of the hippocampal formation; high concns. of receptor were also present in the entorhinal cortex and amygdaloid complex.  Cannabinoid receptor binding sites were also present throughout all regions of the neocortex, where they showed a marked variation in d. between the primary, secondary and associational cortical regions: the greatest densities of receptors were present in the associational cortical regions of the frontal and limbic lobes, with moderate densities in the secondary sensory and motor cortical regions, and with the lowest densities of receptors in the primary sensory and motor cortical regions.  Relatively high concns. of cannabinoid receptors were consistently seen in cortical regions of the left (dominant) hemisphere, known to be assocd. with verbal language functions.  In all of the cortical regions, the pattern and d. of receptor labeling followed the neocortical laminar organization, with the greatest d. of receptors localized in two discrete bands-a clearly delineated narrow superficial band which coincided with lamina I and a deeper broader, conspicuous band of labeling which corresponded to laminae V and VI.  Labeling in the intervening cortical laminae (II-IV) showed lower densities, with a well delineated narrow band of label in the middle of laminae IV in the associational cortical regions.  The thalamus showed a distinctive heterogeneous distribution of cannabinoid receptors, with the highest concn. of receptors localized in the mediodorsal nucleus, anterior nuclear complex, and in the midline and intralaminar complex of nuclei, i.e. in thalamic nuclei which have connectional affiliations with the associational cortical areas.  The basal ganglia showed a distinctive heterogeneous pattern of receptor binding, with the very highest concns. in the globus pallidus internus, moderate concns. in the globus pallidus externus and ventral pallidum, and moderately low levels of binding throughout the striatal complex.  In the midbrain, some of the highest levels of cannabinoid receptor binding sites in the human brain were present in the substantia nigra pars reticulata, with very low levels of labeling in all other midbrain areas.  The highest densities of cannabinoid receptor binding in the hindbrain were localized in the mol. layer of the cerebellar cortex and the dorsal motor nucleus of the vagus, with moderate densities of receptors in the nucleus of the solitary tract.  The spinal cord showed very low levels of receptor binding.  Studies on the distribution of cannabinoid receptors in the fetal and neonatal human brain showed similar patterns of receptor distribution to that obsd. in the adult human brain, except that the d. of receptor binding was generally markedly higher, esp. in the basal ganglia and substantia nigra.  The pattern of cannabinoid receptor labeling in the striatum showed a striking patchy pattern of organization which was esp. conspicuous in the fetal brain.  These results show that cannabinoid receptor binding sites in the human brain are localized mainly in: forebrain areas assocd. with higher cognitive functions; forebrain, midbrain and hindbrain areas assocd. with the control of movement; and in hindbrain areas assocd. with the control of motor and sensory functions of the autonomic nervous system.  The possible role of these receptors is discussed with respect to the known behavioral and psychomotor effects of cannabinoids in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphwrS-2VBdCLVg90H21EOLACvtfcHk0ljX4p3vG-6tHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhs1Gms7w%253D&md5=998c8c209c7d0a72d745be7f3946e2b9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2896%2900428-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252896%252900428-9%26sid%3Dliteratum%253Aachs%26aulast%3DGlass%26aufirst%3DM.%26aulast%3DFaull%26aufirst%3DR.%26aulast%3DDragunow%26aufirst%3DM.%26atitle%3DCannabinoid%2520receptors%2520in%2520the%2520human%2520brain%253A%2520a%2520detailed%2520anatomical%2520and%2520quantitative%2520autoradiographic%2520study%2520in%2520the%2520fetal%252C%2520neonatal%2520and%2520adult%2520human%2520brain%26jtitle%3DNeuroscience%26date%3D1997%26volume%3D77%26spage%3D299%26epage%3D318%26doi%3D10.1016%2FS0306-4522%2896%2900428-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herkenham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynn, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melvin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor localization in brain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1932</span>– <span class="NLM_lpage">1936</span>, <span class="refDoi"> DOI: 10.1073/pnas.87.5.1932</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.87.5.1932" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=2308954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFWktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=1932-1936&author=M.+Herkenhamauthor=A.+B.+Lynnauthor=M.+D.+Littleauthor=M.+R.+Johnsonauthor=L.+S.+Melvinauthor=B.+R.+De+Costaauthor=K.+C.+Rice&title=Cannabinoid+receptor+localization+in+brain&doi=10.1073%2Fpnas.87.5.1932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor localization in brain</span></div><div class="casAuthors">Herkenham, Miles; Lynn, Allison B.; Little, Mark D.; Johnson, M. Ross; Melvin, Lawrence S.; De Costa, Brian R.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1932-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">[3H]CP 55,940, a radiolabeled synthetic cannabinoid, which is 10-100 times more potent in vivo than Δ9-tetrahydrocannabinol, was used to characterize and localize a specific cannabinoid receptor in brain sections.  The potencies of a series of natural and synthetic cannabinoids as competitors of [3H]CP 55,940 binding correlated closely with their relative potencies in several biol. assays, suggesting that the receptor characterized in this in vitro assay is the same receptor that mediates behavioral and pharmacol. effects of cannabinoids, including human subjective experience.  Autoradiog. of cannabinoid receptors in brain sections from several mammalian species, including man, reveals a unique and conserved distribution; binding is most dense in outflow nuclei of the basal ganglia (the substantia nigra pars reticulata and globus pallidus) and in the hippocampus and cerebellum.  Generally high densities in forebrain and cerebellum implicate roles for cannabinoids in cognition and movement.  Sparse densities in lower brainstem areas controlling cardiovascular and respiratory functions may explain why high doses of Δ9-tetrahydrocannabinol are not lethal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFR443WjQM47Vg90H21EOLACvtfcHk0liX2Z9lznBgpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFWktLs%253D&md5=59c7c3cebae57b8563f4c04af7aca7ef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.5.1932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.5.1932%26sid%3Dliteratum%253Aachs%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DLynn%26aufirst%3DA.%2BB.%26aulast%3DLittle%26aufirst%3DM.%2BD.%26aulast%3DJohnson%26aufirst%3DM.%2BR.%26aulast%3DMelvin%26aufirst%3DL.%2BS.%26aulast%3DDe%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DCannabinoid%2520receptor%2520localization%2520in%2520brain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26spage%3D1932%26epage%3D1936%26doi%3D10.1073%2Fpnas.87.5.1932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptors: where they are and what they do</span>. <i>J. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2826.2008.01671.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1365-2826.2008.01671.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18426493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsl2itbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=10-14&author=K.+Mackie&title=Cannabinoid+receptors%3A+where+they+are+and+what+they+do&doi=10.1111%2Fj.1365-2826.2008.01671.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors: where they are and what they do</span></div><div class="casAuthors">Mackie, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">10-14</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system consists of the endogenous cannabinoids (endocannabinoids), cannabinoid receptors and the enzymes that synthesize and degrade endocannabinoids.  Many of the effects of cannabinoids and endocannabinoids are mediated by two G protein-coupled receptors (GPCRs), CB1 and CB2, although addnl. receptors may be involved.  CB1 receptors are present in very high levels in several brain regions and in lower amts. in a more wide-spread fashion.  These receptors mediate many of the psychoactive effects of cannabinoids.  CB2 receptors have a more restricted distribution, being found in a no. of immune cells and in a few neurons.  Both CB1 and CB2 couple primarily to inhibitory G proteins and are subject to the same pharmacol. influences as other GPCRs.  Thus, partial agonism, functional selectivity and inverse agonism all play important roles in detg. the cellular response to specific cannabinoid receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE3tJevcn32LVg90H21EOLACvtfcHk0liX2Z9lznBgpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsl2itbs%253D&md5=e87a4821e2475ef50f57f26507c2dc7f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2008.01671.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2008.01671.x%26sid%3Dliteratum%253Aachs%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DCannabinoid%2520receptors%253A%2520where%2520they%2520are%2520and%2520what%2520they%2520do%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2008%26volume%3D20%26spage%3D10%26epage%3D14%26doi%3D10.1111%2Fj.1365-2826.2008.01671.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bab, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bíró, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konje, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, A.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid signaling at the periphery: 50 years after THC</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.tips.2015.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25796370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFehur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=277-296&author=M.+Maccarroneauthor=I.+Babauthor=T.+B%C3%ADr%C3%B3author=G.+A.+Cabralauthor=S.+K.+Deyauthor=V.+Di+Marzoauthor=J.+C.+Konjeauthor=G.+Kunosauthor=R.+Mechoulamauthor=P.+Pacherauthor=K.+A.+Sharkeyauthor=A.+Zimmer&title=Endocannabinoid+signaling+at+the+periphery%3A+50+years+after+THC&doi=10.1016%2Fj.tips.2015.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid signaling at the periphery: 50 years after THC</span></div><div class="casAuthors">Maccarrone, Mauro; Bab, Itai; Biro, Tamas; Cabral, Guy A.; Dey, Sudhansu K.; Di Marzo, Vincenzo; Konje, Justin C.; Kunos, George; Mechoulam, Raphael; Pacher, Pal; Sharkey, Keith A.; Zimmer, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">277-296</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In 1964, the psychoactive ingredient of Cannabis sativa, Δ9-tetrahydrocannabinol (THC), was isolated.  Nearly 30 years later the endogenous counterparts of THC, collectively termed endocannabinoids (eCBs), were discovered: N-arachidonoylethanolamine (anandamide) (AEA) in 1992 and 2-arachidonoylglycerol (2-AG) in 1995.  Since then, considerable research has shed light on the impact of eCBs on human health and disease, identifying an ensemble of proteins that bind, synthesize, and degrade them and that together form the eCB system (ECS). eCBs control basic biol. processes including cell choice between survival and death and progenitor/stem cell proliferation and differentiation.  Unsurprisingly, in the past two decades eCBs have been recognized as key mediators of several aspects of human pathophysiol. and thus have emerged to be among the most widespread and versatile signaling mols. ever discovered.  Here some of the pioneers of this research field review the state of the art of crit. eCB functions in peripheral organs.  Our community effort is aimed at establishing consensus views on the relevance of the peripheral ECS for human health and disease pathogenesis, as well as highlighting emerging challenges and therapeutic hopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliBLJSeUEKLVg90H21EOLACvtfcHk0lgsXklymLUEtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFehur4%253D&md5=a06cc2d98beb8bd8e42336b5c9c7a278</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DMaccarrone%26aufirst%3DM.%26aulast%3DBab%26aufirst%3DI.%26aulast%3DB%25C3%25ADr%25C3%25B3%26aufirst%3DT.%26aulast%3DCabral%26aufirst%3DG.%2BA.%26aulast%3DDey%26aufirst%3DS.%2BK.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DKonje%26aufirst%3DJ.%2BC.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26aulast%3DZimmer%26aufirst%3DA.%26atitle%3DEndocannabinoid%2520signaling%2520at%2520the%2520periphery%253A%252050%2520years%2520after%2520THC%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D277%26epage%3D296%26doi%3D10.1016%2Fj.tips.2015.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, K. A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids and the gut: new developments and emerging concepts</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.pharmthera.2009.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20117132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1Kgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=21-38&author=A.+A.+Izzoauthor=K.+A.+Sharkey&title=Cannabinoids+and+the+gut%3A+new+developments+and+emerging+concepts&doi=10.1016%2Fj.pharmthera.2009.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids and the gut: New developments and emerging concepts</span></div><div class="casAuthors">Izzo, Angelo A.; Sharkey, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-38</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric infections and inflammatory conditions to disorders of motility, emesis and abdominal pain.  The mechanistic basis of these treatments emerged after the discovery of Δ9-tetrahydrocannabinol as the major constituent of Cannabis.  Further progress was made when the receptors for Δ9-tetrahydrocannabinol were identified as part of an endocannabinoid system, that consists of specific cannabinoid receptors, endogenous ligands and their biosynthetic and degradative enzymes.  Anatomical, physiol. and pharmacol. studies have shown that the endocannabinoid system is widely distributed throughout the gut, with regional variation and organ-specific actions.  It is involved in the regulation of food intake, nausea and emesis, gastric secretion and gastroprotection, GI motility, ion transport, visceral sensation, intestinal inflammation and cell proliferation in the gut.  Cellular targets have been defined that include the enteric nervous system, epithelial and immune cells.  Mol. targets of the endocannabinoid system include, in addn. to the cannabinoid receptors, transient receptor potential vanilloid 1 receptors, peroxisome proliferator-activated receptor alpha receptors and the orphan G-protein coupled receptors, GPR55 and GPR119.  Pharmacol. agents that act on these targets have been shown in preclin. models to have therapeutic potential.  Here, we discuss cannabinoid receptors and their localization in the gut, the proteins involved in endocannabinoid synthesis and degrdn. and the presence of endocannabinoids in the gut in health and disease.  We focus on the pharmacol. actions of cannabinoids in relation to GI disorders, highlighting recent data on genetic mutations in the endocannabinoid system in GI disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSuvBS54QzJbVg90H21EOLACvtfcHk0lgsXklymLUEtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1Kgs7g%253D&md5=97a1de4d71ab7c738bf84c85e7c37764</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DIzzo%26aufirst%3DA.%2BA.%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26atitle%3DCannabinoids%2520and%2520the%2520gut%253A%2520new%2520developments%2520and%2520emerging%2520concepts%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D126%26spage%3D21%26epage%3D38%26doi%3D10.1016%2Fj.pharmthera.2009.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montecucco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span> <span> </span><span class="NLM_article-title">At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2012.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.tips.2012.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22503477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFCkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=331-340&author=F.+Montecuccoauthor=V.+Di+Marzo&title=At+the+heart+of+the+matter%3A+the+endocannabinoid+system+in+cardiovascular+function+and+dysfunction&doi=10.1016%2Fj.tips.2012.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction</span></div><div class="casAuthors">Montecucco, Fabrizio; Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">331-340</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Starting from the well-documented effects of marijuana smoking on heart rate and blood pressure, the cardiovascular effects of Δ9-tetrahydrocannabinol (THC, the main psychotropic ingredient of Cannabis) and endocannabinoids [THC endogenous counterparts that activate cannabinoid receptor type 1 (CB1) and 2 (CB2)] have been thoroughly investigated.  These studies were mostly aimed at establishing the mol. bases of the hypotensive actions of THC, endocannabinoids and related mols., but also evaluated their therapeutic potential in cardiac injury protection, metabolic cardiovascular risk factors and atherosclerotic plaque vulnerability.  The results of these investigations, reviewed here, also served to highlight some of the most peculiar aspects of endocannabinoid signaling, such as redundancy in endocannabinoid targets and the often dualistic role of CB1 and CB2 receptors during pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojs2zPa3fwB7Vg90H21EOLACvtfcHk0lhDKLjtNue7Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFCkt7o%253D&md5=e3301962ac762719220b2366e96a7854</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DMontecucco%26aufirst%3DF.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DAt%2520the%2520heart%2520of%2520the%2520matter%253A%2520the%2520endocannabinoid%2520system%2520in%2520cardiovascular%2520function%2520and%2520dysfunction%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D331%26epage%3D340%26doi%3D10.1016%2Fj.tips.2012.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2017.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrcardio.2017.130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28905873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2isLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=151-166&author=P.+Pacherauthor=S.+Steffensauthor=G.+Hask%C3%B3author=T.+H.+Schindlerauthor=G.+Kunos&title=Cardiovascular+effects+of+marijuana+and+synthetic+cannabinoids%3A+the+good%2C+the+bad%2C+and+the+ugly&doi=10.1038%2Fnrcardio.2017.130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly</span></div><div class="casAuthors">Pacher, Pal; Steffens, Sabine; Hasko, Gyorgy; Schindler, Thomas H.; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dysregulation of the endogenous lipid mediators endocannabinoids and their G-protein-coupled cannabinoid receptors 1 and 2 (CB1R and CB2R) has been implicated in a variety of cardiovascular pathologies.  Activation of CB1R facilitates the development of cardiometabolic disease, whereas activation of CB2R (expressed primarily in immune cells) exerts anti-inflammatory effects.  The psychoactive constituent of marijuana, Δ9-tetrahydrocannabinol (THC), is an agonist of both CB1R and CB2R, and exerts its psychoactive and adverse cardiovascular effects through the activation of CB1R in the central nervous and cardiovascular systems.  The past decade has seen a nearly tenfold increase in the THC content of marijuana as well as the increased availability of highly potent synthetic cannabinoids for recreational use.  These changes have been accompanied by the emergence of serious adverse cardiovascular events, including myocardial infarction, cardiomyopathy, arrhythmias, stroke, and cardiac arrest.  In this Review, we summarize the role of the endocannabinoid system in cardiovascular disease, and critically discuss the cardiovascular consequences of marijuana and synthetic cannabinoid use.  With the legalization of marijuana for medicinal purposes and/or recreational use in many countries, physicians should be alert to the possibility that the use of marijuana or its potent synthetic analogs might be the underlying cause of severe cardiovascular events and pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoctXDjzQtJ-bVg90H21EOLACvtfcHk0lhDKLjtNue7Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2isLnN&md5=9f1ce4c6c3173e5c9c4dc19a307c99d0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2017.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2017.130%26sid%3Dliteratum%253Aachs%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSteffens%26aufirst%3DS.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26aulast%3DSchindler%26aufirst%3DT.%2BH.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DCardiovascular%2520effects%2520of%2520marijuana%2520and%2520synthetic%2520cannabinoids%253A%2520the%2520good%252C%2520the%2520bad%252C%2520and%2520the%2520ugly%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2018%26volume%3D15%26spage%3D151%26epage%3D166%26doi%3D10.1038%2Fnrcardio.2017.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembovler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrosino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casap, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shteyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yirmiya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shohami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bab, I.</span></span> <span> </span><span class="NLM_article-title">The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1096/fj.06-7957com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1096%2Ffj.06-7957com" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17704191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=285-294&author=J.+Tamauthor=V.+Trembovlerauthor=V.+Di+Marzoauthor=S.+Petrosinoauthor=G.+Leoauthor=A.+Alexandrovichauthor=E.+Regevauthor=N.+Casapauthor=A.+Shteyerauthor=C.+Ledentauthor=M.+Karsakauthor=A.+Zimmerauthor=R.+Mechoulamauthor=R.+Yirmiyaauthor=E.+Shohamiauthor=I.+Bab&title=The+cannabinoid+CB1+receptor+regulates+bone+formation+by+modulating+adrenergic+signaling&doi=10.1096%2Ffj.06-7957com"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling</span></div><div class="casAuthors">Tam, Joseph; Trembovler, Victoria; Di Marzo, Vincenzo; Petrosino, Stefania; Leo, Gabriella; Alexandrovich, Alex; Regev, Eran; Casap, Nardy; Shteyer, Arie; Ledent, Catherine; Karsak, Meliha; Zimmer, Andreas; Mechoulam, Raphael; Yirmiya, Raz; Shohami, Esther; Bab, Itai</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">285-294, 10.1096/fj.06-7957com</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">We have recently reported that in bone the cannabinoid CB1 receptor is present in sympathetic terminals.  Here we show that traumatic brain injury (TBI), which in humans enhances peripheral osteogenesis and fracture healing, acutely stimulates bone formation in a distant skeletal site.  At this site we demonstrate (i) a high level of the main endocannabinoid, 2-arachidonoylglycerol (2-AG), and expression of diacylglycerol lipases, enzymes essential for 2-AG synthesis; (ii) that the TBI-induced increase in bone formation is preceded by elevation of the 2-AG and a decrease in norepinephrine (NE) levels.  The TBI stimulation of bone formation was absent in CB1-null mice.  In wild-type animals it could be mimicked, including the suppression of NE levels, by 2-AG administration.  The TBI- and 2-AG-induced stimulation of osteogenesis was restrained by the β-adrenergic receptor agonist isoproterenol.  NE from sympathetic terminals is known to tonically inhibit bone formation by activating osteoblastic β2-adrenergic receptors.  The present findings further demonstrate that the sympathetic control of bone formation is regulated through 2-AG activation of prejunctional CB1.  Elevation of bone 2-AG apparently suppresses NE release from bone sympathetic terminals, thus alleviating the inhibition of bone formation.  The involvement of osteoblastic CB2 signaling in this process is minimal, if any.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHBWEs2cC3IrVg90H21EOLACvtfcHk0lhDKLjtNue7Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslWmsw%253D%253D&md5=18848f3beebb92be4b7a354ba8d4ea4f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1096%2Ffj.06-7957com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.06-7957com%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DTrembovler%26aufirst%3DV.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DPetrosino%26aufirst%3DS.%26aulast%3DLeo%26aufirst%3DG.%26aulast%3DAlexandrovich%26aufirst%3DA.%26aulast%3DRegev%26aufirst%3DE.%26aulast%3DCasap%26aufirst%3DN.%26aulast%3DShteyer%26aufirst%3DA.%26aulast%3DLedent%26aufirst%3DC.%26aulast%3DKarsak%26aufirst%3DM.%26aulast%3DZimmer%26aufirst%3DA.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DYirmiya%26aufirst%3DR.%26aulast%3DShohami%26aufirst%3DE.%26aulast%3DBab%26aufirst%3DI.%26atitle%3DThe%2520cannabinoid%2520CB1%2520receptor%2520regulates%2520bone%2520formation%2520by%2520modulating%2520adrenergic%2520signaling%26jtitle%3DFASEB%2520J.%26date%3D2008%26volume%3D22%26spage%3D285%26epage%3D294%26doi%3D10.1096%2Ffj.06-7957com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Shaar, M.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of a peripheral receptor for cannabinoids</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1038/365061a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2F365061a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=7689702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=1993&pages=61-65&author=S.+Munroauthor=K.+L.+Thomasauthor=M.+Abu-Shaar&title=Molecular+characterization+of+a+peripheral+receptor+for+cannabinoids&doi=10.1038%2F365061a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of a peripheral receptor for cannabinoids</span></div><div class="casAuthors">Munro, Sean; Thomas, Kerrie L.; Abu-Shaar, Muna</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">6441</span>),
    <span class="NLM_cas:pages">61-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The major active ingredient of marijuana, Δ9-tetrahydrocannabinol (Δ-THC), has been used as a psychoactive agent for thousands of years.  Marijuana, and Δ9-THC, also exert a wide range of other effects including analgesia, anti-inflammation, immunosuppression, anticonvulsion, alleviation of intraocular pressure in glaucoma, and attenuation of vomiting.  The clin. application of cannabinoids has, however, been limited by their psychoactive effects, and this has led to interest in the biochem. bases of their action.  Progress stemmed initially from the synthesis of potent derivs. of Δ9-THC4,5, and more recently from the cloning of a gene encoding a G-protein-coupled receptor for cannabinoids.  This receptor is expressed in the brain but not in the periphery, except for a low level in testes.  It has been proposed that the nonpsychoactive effects of cannabinoids are either mediated centrally or through direct interaction with other, non-receptor proteins.  Here the authors report the cloning of a receptor for cannabinoids that is not expressed in the brain but rather in macrophages in the marginal zone of spleen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHsq4vy1XH17Vg90H21EOLACvtfcHk0lhkwXewKUPrYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D&md5=476435b57bd0f24483e2f24b813cc32f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2F365061a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F365061a0%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DK.%2BL.%26aulast%3DAbu-Shaar%26aufirst%3DM.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520peripheral%2520receptor%2520for%2520cannabinoids%26jtitle%3DNature%26date%3D1993%26volume%3D365%26spage%3D61%26epage%3D65%26doi%3D10.1038%2F365061a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casellas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devane, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herkenham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">International union of pharmacology. XXVII. classification of cannabinoid receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1124/pr.54.2.161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlettauthor=F.+Barthauthor=T.+I.+Bonnerauthor=G.+Cabralauthor=P.+Casellasauthor=W.+A.+Devaneauthor=C.+C.+Felderauthor=M.+Herkenhamauthor=K.+Mackieauthor=B.+R.+Martinauthor=R.+Mechoulamauthor=R.+G.+Pertwee&title=International+union+of+pharmacology.+XXVII.+classification+of+cannabinoid+receptors&doi=10.1124%2Fpr.54.2.161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0lhkwXewKUPrYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DDevane%26aufirst%3DW.%2BA.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XXVII.%2520classification%2520of%2520cannabinoid%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202%26doi%3D10.1124%2Fpr.54.2.161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Sickle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingsley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouihate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, J. S.</span></span> <span> </span><span class="NLM_article-title">Identification and functional characterization of brainstem cannabinoid CB2 receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1126/science.1115740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1126%2Fscience.1115740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16224028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2hurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2005&pages=329-332&author=M.+D.+Van%0ASickleauthor=M.+Duncanauthor=P.+J.+Kingsleyauthor=A.+Mouihateauthor=P.+Urbaniauthor=K.+Mackieauthor=N.+Stellaauthor=A.+Makriyannisauthor=D.+Piomelliauthor=J.+S.+Davison&title=Identification+and+functional+characterization+of+brainstem+cannabinoid+CB2+receptors&doi=10.1126%2Fscience.1115740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and functional characterization of brainstem cannabinoid CB2 receptors</span></div><div class="casAuthors">Van Sickle, Marja D.; Duncan, Marnie; Kingsley, Philip J.; Mouihate, Abdeslam; Urbani, Paolo; Mackie, Ken; Stella, Nephi; Makriyannis, Alexandros; Piomelli, Daniele; Davison, Joseph S.; Marnett, Lawrence J.; Di Marzo, Vincenzo; Pittman, Quentin J.; Patel, Kamala D.; Sharkey, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">5746</span>),
    <span class="NLM_cas:pages">329-332</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The presence and function of CB2 receptors in central nervous system (CNS) neurons are controversial.  The authors report the expression of CB2 receptor mRNA and protein localization on brainstem neurons.  These functional CB2 receptors in the brainstem were activated by a CB2 receptor agonist, 2-arachidonoylglycerol, and by elevated endogenous levels of endocannabinoids, which also act at CB1 receptors.  CB2 receptors represent an alternative site of action of endocannabinoids that opens the possibility of nonpsychotropic therapeutic interventions using enhanced endocannabinoid levels in localized brain areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriWgg6LDIT0bVg90H21EOLACvtfcHk0lhkwXewKUPrYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2hurvL&md5=ab457ab0bd1b8e30ea927a1e61366323</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscience.1115740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1115740%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BSickle%26aufirst%3DM.%2BD.%26aulast%3DDuncan%26aufirst%3DM.%26aulast%3DKingsley%26aufirst%3DP.%2BJ.%26aulast%3DMouihate%26aufirst%3DA.%26aulast%3DUrbani%26aufirst%3DP.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DStella%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DDavison%26aufirst%3DJ.%2BS.%26atitle%3DIdentification%2520and%2520functional%2520characterization%2520of%2520brainstem%2520cannabinoid%2520CB2%2520receptors%26jtitle%3DScience%26date%3D2005%26volume%3D310%26spage%3D329%26epage%3D332%26doi%3D10.1126%2Fscience.1115740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human cannabinoid receptor CB1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2016.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27768894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=750-762&author=T.+Huaauthor=K.+Vemuriauthor=M.+Puauthor=L.+Quauthor=G.+W.+Hanauthor=Y.+Wuauthor=S.+Zhaoauthor=W.+Shuiauthor=S.+Liauthor=A.+Kordeauthor=R.+B.+Laprairieauthor=E.+L.+Stahlauthor=J.+H.+Hoauthor=N.+Zvonokauthor=H.+Zhouauthor=I.+Kufarevaauthor=B.+Wuauthor=Q.+Zhaoauthor=M.+A.+Hansonauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.+J.+Liu&title=Crystal+structure+of+the+human+cannabinoid+receptor+CB1&doi=10.1016%2Fj.cell.2016.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB1</span></div><div class="casAuthors">Hua, Tian; Vemuri, Kiran; Pu, Mengchen; Qu, Lu; Han, Gye Won; Wu, Yiran; Zhao, Suwen; Shui, Wenqing; Li, Shanshan; Korde, Anisha; Laprairie, Robert B.; Stahl, Edward L.; Ho, Jo-Hao; Zvonok, Nikolai; Zhou, Han; Kufareva, Irina; Wu, Beili; Zhao, Qiang; Hanson, Michael A.; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-762.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) is the principal target of Δ9-tetrahydrocannabinol (THC), a psychoactive chem. from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use.  CB1 is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders.  Here, the authors present the 2.8 Å crystal structure of human CB1 in complex with AM6538, a stabilizing antagonist, synthesized and characterized for this structural study.  The structure of the CB1-AM6538 complex reveals key features of the receptor and crit. interactions for antagonist binding.  In combination with functional studies and mol. modeling, the structure provides insight into the binding mode of naturally occurring CB1 ligands, such as THC, and synthetic cannabinoids.  This enhances the understanding of the mol. basis for the physiol. functions of CB1 and provides new opportunities for the design of next-generation CB1-targeting pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAuMgAfmO22bVg90H21EOLACvtfcHk0ljcwQiKovxduQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI&md5=f4862c31391550ee2b83ef198c9c7b17</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DShui%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKorde%26aufirst%3DA.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DHo%26aufirst%3DJ.%2BH.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB1%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D750%26epage%3D762%26doi%3D10.1016%2Fj.cell.2016.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human cannabinoid receptor CB2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2018.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30639103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=459-467&author=X.+Liauthor=T.+Huaauthor=K.+Vemuriauthor=J.+H.+Hoauthor=Y.+Wuauthor=L.+Wuauthor=P.+Popovauthor=O.+Benchamaauthor=N.+Zvonokauthor=K.+Lockeauthor=L.+Quauthor=G.+W.+Hanauthor=M.+R.+Iyerauthor=R.+Cinarauthor=N.+J.+Coffeyauthor=J.+Wangauthor=M.+Wuauthor=V.+Katritchauthor=S.+Zhaoauthor=G.+Kunosauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.+J.+Liu&title=Crystal+structure+of+the+human+cannabinoid+receptor+CB2&doi=10.1016%2Fj.cell.2018.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB2</span></div><div class="casAuthors">Li, Xiaoting; Hua, Tian; Vemuri, Kiran; Ho, Jo-Hao; Wu, Yiran; Wu, Lijie; Popov, Petr; Benchama, Othman; Zvonok, Nikolai; Locke, K'ara; Qu, Lu; Han, Gye Won; Iyer, Malliga R.; Cinar, Resat; Coffey, Nathan J.; Wang, Jingjing; Wu, Meng; Katritch, Vsevolod; Zhao, Suwen; Kunos, George; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-467.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cannabinoid receptor CB2 is predominately expressed in the immune system, and selective modulation of CB2 without the psychoactivity of CB1 has therapeutic potential in inflammatory, fibrotic, and neurodegenerative diseases.  Here, we report the crystal structure of human CB2 in complex with a rationally designed antagonist, AM10257, at 2.8 Å resoln.  The CB2-AM10257 structure reveals a distinctly different binding pose compared with CB1.  However, the extracellular portion of the antagonist-bound CB2 shares a high degree of conformational similarity with the agonist-bound CB1, which led to the discovery of AM10257's unexpected opposing functional profile of CB2 antagonism vs. CB1 agonism.  Further structural anal. using mutagenesis studies and mol. docking revealed the mol. basis of their function and selectivity for CB2 and CB1.  Addnl. analyses of our designed antagonist and agonist pairs provide important insight into the activation mechanism of CB2.  The present findings should facilitate rational drug design toward precise modulation of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFwNUEO0q03LVg90H21EOLACvtfcHk0ljcwQiKovxduQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFKktw%253D%253D&md5=90ee72a6dc13b74b84fb6799c3aa0471</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DJ.%2BH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DBenchama%26aufirst%3DO.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DLocke%26aufirst%3DK.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DCoffey%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB2%26jtitle%3DCell%26date%3D2019%26volume%3D176%26spage%3D459%26epage%3D467%26doi%3D10.1016%2Fj.cell.2018.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliopoulos-Tsoutsouvas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikas, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span> <span> </span><span class="NLM_article-title">Activation and signaling mechanism revealed by cannabinoid receptor-G(i) complex structures</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2020.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32004463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFeqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=655-665&author=T.+Huaauthor=X.+Liauthor=L.+Wuauthor=C.+Iliopoulos-Tsoutsouvasauthor=Y.+Wangauthor=M.+Wuauthor=L.+Shenauthor=C.+A.+Johnstonauthor=S.+P.+Nikasauthor=F.+Songauthor=X.+Songauthor=S.+Yuanauthor=Q.+Sunauthor=Y.+Wuauthor=S.+Jiangauthor=T.+W.+Grimauthor=O.+Benchamaauthor=E.+L.+Stahlauthor=N.+Zvonokauthor=S.+Zhaoauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=Z.+J.+Liu&title=Activation+and+signaling+mechanism+revealed+by+cannabinoid+receptor-G%28i%29+complex+structures&doi=10.1016%2Fj.cell.2020.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures</span></div><div class="casAuthors">Hua, Tian; Li, Xiaoting; Wu, Lijie; Iliopoulos-Tsoutsouvas, Christos; Wang, Yuxia; Wu, Meng; Shen, Ling; Johnston, Christina A.; Nikas, Spyros P.; Song, Feng; Song, Xiyong; Yuan, Shuguang; Sun, Qianqian; Wu, Yiran; Jiang, Shan; Grim, Travis W.; Benchama, Othman; Stahl, Edward L.; Zvonok, Nikolai; Zhao, Suwen; Bohn, Laura M.; Makriyannis, Alexandros; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-665.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human endocannabinoid systems modulate multiple physiol. processes mainly through the activation of cannabinoid receptors CB1 and CB2.  Their high sequence similarity, low agonist selectivity, and lack of activation and G protein-coupling knowledge have hindered the development of therapeutic applications.  Importantly, missing structural information has significantly held back the development of promising CB2-selective agonist drugs for treating inflammatory and neuropathic pain without the psychoactivity of CB1.  Here, we report the cryoelectron microscopy structures of synthetic cannabinoid-bound CB2 and CB1 in complex with Gi, as well as agonist-bound CB2 crystal structure.  Of important scientific and therapeutic benefit, our results reveal a diverse activation and signaling mechanism, the structural basis of CB2-selective agonists design, and the unexpected interaction of cholesterol with CB1, suggestive of its endogenous allosteric modulating role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgy9tDrt9HArVg90H21EOLACvtfcHk0ljcwQiKovxduQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFeqtbc%253D&md5=b9d4dd05094f3bae76b315a41a11c21b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DIliopoulos-Tsoutsouvas%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DJohnston%26aufirst%3DC.%2BA.%26aulast%3DNikas%26aufirst%3DS.%2BP.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DBenchama%26aufirst%3DO.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3DActivation%2520and%2520signaling%2520mechanism%2520revealed%2520by%2520cannabinoid%2520receptor-G%2528i%2529%2520complex%2520structures%26jtitle%3DCell%26date%3D2020%26volume%3D180%26spage%3D655%26epage%3D665%26doi%3D10.1016%2Fj.cell.2020.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">The molecular logic of endocannabinoid signalling</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1038/nrn1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrn1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=14595399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=873-884&author=D.+Piomelli&title=The+molecular+logic+of+endocannabinoid+signalling&doi=10.1038%2Fnrn1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular logic of endocannabinoid signalling</span></div><div class="casAuthors">Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">873-884</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The endocannabinoids are a family of lipid messengers that engage the cell surface receptors that are targeted by Δ9-tetrahydrocannabinol, the active principle in marijuana (Cannabis).  They are made on demand through cleavage of membrane precursors and are involved in various short-range signaling processes.  In the brain, they combine with CB1 cannabinoid receptors on axon terminals to regulate ion channel activity and neurotransmitter release.  Their ability to modulate synaptic efficacy has a wide range of functional consequences and provides unique therapeutic possibilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUrtdaKTjDoLVg90H21EOLACvtfcHk0lif6pUkQBPItg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOktrY%253D&md5=d4af135f5309e6551bdb1f8ade45b565</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrn1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1247%26sid%3Dliteratum%253Aachs%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DThe%2520molecular%2520logic%2520of%2520endocannabinoid%2520signalling%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2003%26volume%3D4%26spage%3D873%26epage%3D884%26doi%3D10.1038%2Fnrn1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eggan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, D. A.</span></span> <span> </span><span class="NLM_article-title">Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">772</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.65.7.772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1001%2Farchpsyc.65.7.772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18606950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD1cvjs1CqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=772-784&author=S.+M.+Egganauthor=T.+Hashimotoauthor=D.+A.+Lewis&title=Reduced+cortical+cannabinoid+1+receptor+messenger+RNA+and+protein+expression+in+schizophrenia&doi=10.1001%2Farchpsyc.65.7.772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia</span></div><div class="casAuthors">Eggan Stephen M; Hashimoto Takanori; Lewis David A</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">772-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Cannabis use is associated with both impaired cognitive functions, including working memory, and an increased risk of schizophrenia.  Schizophrenia is characterized by impairments in working memory that are associated with reduced gamma-aminobutyric acid (GABA) neurotransmission in the dorsolateral prefrontal cortex.  The cannabinoid 1 receptor (CB1R) is highly expressed in the dorsolateral prefrontal cortex, is contained in the axon terminals of a subpopulation of perisomatic-targeting GABA neurons, and, when activated, suppresses the release of GABA.  OBJECTIVE:  To determine the potential relationship between CB1R signaling and altered GABA neurotransmission in schizophrenia by evaluating CB1R messenger RNA (mRNA) and protein expression in the dorsolateral prefrontal cortex.  DESIGN:  In situ hybridization and immunocytochemistry techniques were used to examine the cortical levels of CB1R mRNA and protein, respectively.  SETTING:  Brain specimens were obtained from autopsies conducted at the Allegheny County Medical Examiner's Office, Pittsburgh, Pennsylvania.  PARTICIPANTS:  Postmortem brain specimens from 23 pairs of subjects with schizophrenia and age-, sex-, and postmortem interval-matched comparison subjects, as well as brain specimens from 18 macaque monkeys with long-term exposure to haloperidol, olanzapine, or placebo.  MAIN OUTCOME MEASURES:  Optical density measures of CB1R mRNA expression and protein levels and correlations with previously reported glutamic acid decarboxylase 67 and cholecystokinin mRNA measures.  RESULTS:  Levels of CB1R mRNA were significantly lower by 14.8% in the subjects with schizophrenia.  Similarly, CB1R protein levels, assessed by radioimmunocytochemistry and standard immunocytochemistry, were significantly decreased by 11.6% and 13.9%, respectively.  Group differences in CB1R mRNA levels were significantly correlated with those in glutamic acid decarboxylase 67 and cholecystokinin mRNA levels.  Expression of CB1R mRNA was not changed in antipsychotic-exposed monkeys, and neither CB1R mRNA levels nor protein levels were affected by potential confounding factors in the subjects with schizophrenia.  CONCLUSIONS:  This combination of findings suggests the testable hypothesis that reduced CB1R mRNA and protein levels in schizophrenia represent a compensatory mechanism to increase GABA transmission from perisomatic-targeting cholecystokinin interneurons with impaired GABA synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX7QVJCUq_ngHqQV89nF-2fW6udTcc2eaqNPYrV_gM_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvjs1CqtA%253D%253D&md5=847a7b6301f8194010fbb7db075e7a24</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.65.7.772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.65.7.772%26sid%3Dliteratum%253Aachs%26aulast%3DEggan%26aufirst%3DS.%2BM.%26aulast%3DHashimoto%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DD.%2BA.%26atitle%3DReduced%2520cortical%2520cannabinoid%25201%2520receptor%2520messenger%2520RNA%2520and%2520protein%2520expression%2520in%2520schizophrenia%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2008%26volume%3D65%26spage%3D772%26epage%3D784%26doi%3D10.1001%2Farchpsyc.65.7.772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gazzerro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notarnicola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misciagna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span> <span> </span><span class="NLM_article-title">Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population</span>. <i>Int. J. Obes.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1038/sj.ijo.0803510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fsj.ijo.0803510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlslCqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2007&pages=908-912&author=P.+Gazzerroauthor=M.+Carusoauthor=M.+Notarnicolaauthor=G.+Misciagnaauthor=V.+Guerraauthor=C.+Laezzaauthor=M.+Bifulco&title=Association+between+cannabinoid+type-1+receptor+polymorphism+and+body+mass+index+in+a+southern+Italian+population&doi=10.1038%2Fsj.ijo.0803510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population</span></div><div class="casAuthors">Gazzerro, P.; Caruso, M. G.; Notarnicola, M.; Misciagna, G.; Guerra, V.; Laezza, C.; Bifulco, M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">908-912</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Endocannabinoids control food intake via both central and peripheral mechanisms, and cannabinoid type-1 receptor (CB1) modulates lipogenesis in primary adipocyte cell cultures and in animal models of obesity.  We aimed to evaluate, at the population level, the frequency of a genetic polymorphism of CB1 and to study its correlation with body mass index.  Healthy subjects from a population survey carried out in southern Italy examd. in 1992-1993 and older than 65 years (n = 419, M = 237, F = 182) were divided into quintiles by body mass index (BMI).  Two hundred and ten subjects were randomly sampled from the first, third and fifth quintile of BMI (BMI, resp.: 16.2-23.8 = normal, 26.7-28.4 = overweight, 31.6-49.7 = obese) to reach a total of 70 per quintile.  Their serum and white cells from the biol. bank were used to measure the genotype and the blood variables for the study.  Anthropometric parameters, blood pressure, serum glucose and lipid levels were measured with std. methods; genotyping for the CB1 1359G/A polymorphism was performed using multiplex PCR.  Statistical methods included χ2 for trend, binomial and multinomial multiple logistic regression to model BMI on the genotype, controlling for potential confounders.  We found a clear trend of increasing relative frequency of the CB1 wild-type genotype with the increase of BMI (P = 0.03) and, using a multiple logistic regression model, wild-type genotype, female gender, age, glycemia and triglycerides were directly assocd. with both overweight (third quintile of BMI) and obesity (fifth quintile of BMI).  Although performed in a limited no. of subjects, our results show that the presence of the CB1 polymorphic allele was significantly assocd. with a lower BMI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa4x_YKKxHP7Vg90H21EOLACvtfcHk0lif6pUkQBPItg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlslCqs78%253D&md5=f4bda104c88560d24b08b5e15ce91aba</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fsj.ijo.0803510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ijo.0803510%26sid%3Dliteratum%253Aachs%26aulast%3DGazzerro%26aufirst%3DP.%26aulast%3DCaruso%26aufirst%3DM.%26aulast%3DNotarnicola%26aufirst%3DM.%26aulast%3DMisciagna%26aufirst%3DG.%26aulast%3DGuerra%26aufirst%3DV.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DBifulco%26aufirst%3DM.%26atitle%3DAssociation%2520between%2520cannabinoid%2520type-1%2520receptor%2520polymorphism%2520and%2520body%2520mass%2520index%2520in%2520a%2520southern%2520Italian%2520population%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2007%26volume%3D31%26spage%3D908%26epage%3D912%26doi%3D10.1038%2Fsj.ijo.0803510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubler, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalla, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagotto, U.</span></span> <span> </span><span class="NLM_article-title">Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1574</span>– <span class="NLM_lpage">1581</span>, <span class="refDoi"> DOI: 10.1210/en.2005-1649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1210%2Fen.2005-1649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17194743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjvVOhtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2007&pages=1574-1581&author=D.+Cotaauthor=M.-A.+Steinerauthor=G.+Marsicanoauthor=C.+Cervinoauthor=J.+P.+Hermanauthor=Y.+Grublerauthor=J.+Stallaauthor=R.+Pasqualiauthor=B.+Lutzauthor=G.+K.+Stallaauthor=U.+Pagotto&title=Requirement+of+cannabinoid+receptor+type+1+for+the+basal+modulation+of+hypothalamic-pituitary-adrenal+axis+function&doi=10.1210%2Fen.2005-1649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function</span></div><div class="casAuthors">Cota, Daniela; Steiner, Michel-Alexander; Marsicano, Giovanni; Cervino, Cristina; Herman, James P.; Gruebler, Yvonne; Stalla, Johanna; Pasquali, Renato; Lutz, Beat; Stalla, Guenter K.; Pagotto, Uberto</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1574-1581</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The endocannabinoid system affects the neuroendocrine regulation of hormone secretion, including the activity of the hypothalamus-pituitary-adrenal (HPA) axis.  However, the mechanisms by which endocannabinoids regulate HPA axis function have remained unclear.  Here we demonstrate that mice lacking cannabinoid receptor type 1 (CB1-/-) display a significant dysregulation of the HPA axis.  Although circadian HPA axis responsiveness is preserved, CB1-/- mice are characterized by an enhanced circadian drive on the HPA axis, resulting in elevated plasma corticosterone concns. at the onset of the dark as compared with wild-type (CB1+/+) littermates.  Moreover, CB1-/--derived pituitary cells respond with a significantly higher ACTH secretion to CRH and forskolin challenges as compared with pituitary cells derived from CB1+/+ mice.  Both CBL-/- and CB1+/+ mice properly respond to a high-dose dexamethasone test, but response to low-dose dexamethasone is influenced by genotype.  In addn., CB1-/- mice show increased CRH mRNA levels in the paraventricular nucleus of the hypothalamus but not in other extrahypothalamic areas, such as the amygdala and piriform cortex, in which CB1 and CRH mRNA have been colocalized.  Finally, CB1-/- mice have selective glucocorticoid receptor mRNA down-regulation in the CA1 region of the hippocampus but not in the dentate gyrus or paraventricular nucleus.  Conversely, mineralocorticoid receptor mRNA expression levels were found unchanged in these brain areas.  In conclusion, our findings indicate that CB1 deficiency enhances the circadian HPA axis activity peak and leads to central impairment of glucocorticoid feedback, thus further outlining the essential role of the endocannabinoid system in the modulation of neuroendocrine functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXUtiTQEiXILVg90H21EOLACvtfcHk0lgPpQcwMzQxzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjvVOhtr4%253D&md5=450b95cdc96f3897b1ccda5f76234896</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1210%2Fen.2005-1649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2005-1649%26sid%3Dliteratum%253Aachs%26aulast%3DCota%26aufirst%3DD.%26aulast%3DSteiner%26aufirst%3DM.-A.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DCervino%26aufirst%3DC.%26aulast%3DHerman%26aufirst%3DJ.%2BP.%26aulast%3DGrubler%26aufirst%3DY.%26aulast%3DStalla%26aufirst%3DJ.%26aulast%3DPasquali%26aufirst%3DR.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DStalla%26aufirst%3DG.%2BK.%26aulast%3DPagotto%26aufirst%3DU.%26atitle%3DRequirement%2520of%2520cannabinoid%2520receptor%2520type%25201%2520for%2520the%2520basal%2520modulation%2520of%2520hypothalamic-pituitary-adrenal%2520axis%2520function%26jtitle%3DEndocrinology%26date%3D2007%26volume%3D148%26spage%3D1574%26epage%3D1581%26doi%3D10.1210%2Fen.2005-1649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puighermanal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busquets-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaita, A.</span></span> <span> </span><span class="NLM_article-title">Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">3254</span>– <span class="NLM_lpage">3263</span>, <span class="refDoi"> DOI: 10.1098/rstb.2011.0384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1098%2Frstb.2011.0384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23108544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKgtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=3254-3263&author=E.+Puighermanalauthor=A.+Busquets-Garciaauthor=R.+Maldonadoauthor=A.+Ozaita&title=Cellular+and+intracellular+mechanisms+involved+in+the+cognitive+impairment+of+cannabinoids&doi=10.1098%2Frstb.2011.0384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids</span></div><div class="casAuthors">Puighermanal, Emma; Busquets-Garcia, Arnau; Maldonado, Rafael; Ozaita, Andres</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1607</span>),
    <span class="NLM_cas:pages">3254-3263</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Exogenous cannabinoids, such as delta9-tetrahydrocannabinol (THC), as well as the modulation of endogenous cannabinoids, affect cognitive function through the activation of cannabinoid receptors.  Indeed, these compds. modulate a no. of signalling pathways critically implicated in the deleterious effect of cannabinoids on learning and memory.  Thus, the involvement of the mammalian target of rapamycin pathway and extracellular signal-regulated kinases, together with their consequent regulation of cellular processes such as protein translation, play a crit. role in the amnesic-like effects of cannabinoids.  In this study, we summarize the cellular and mol. mechanisms reported in the modulation of cognitive function by the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDaAZkvCfWcrVg90H21EOLACvtfcHk0lgPpQcwMzQxzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKgtLzF&md5=2e29a221700879d7f07d33a2b38bb916</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1098%2Frstb.2011.0384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2011.0384%26sid%3Dliteratum%253Aachs%26aulast%3DPuighermanal%26aufirst%3DE.%26aulast%3DBusquets-Garcia%26aufirst%3DA.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DOzaita%26aufirst%3DA.%26atitle%3DCellular%2520and%2520intracellular%2520mechanisms%2520involved%2520in%2520the%2520cognitive%2520impairment%2520of%2520cannabinoids%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2012%26volume%3D367%26spage%3D3254%26epage%3D3263%26doi%3D10.1098%2Frstb.2011.0384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, Y. L.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid signalling in reward and addiction</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1038/nrn4004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrn4004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26373473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWls7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=579-594&author=L.+H.+Parsonsauthor=Y.+L.+Hurd&title=Endocannabinoid+signalling+in+reward+and+addiction&doi=10.1038%2Fnrn4004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid signaling in reward and addiction</span></div><div class="casAuthors">Parsons, Loren H.; Hurd, Yasmin L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">579-594</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Brain endocannabinoid (eCB) signaling influences the motivation for natural rewards (such as palatable food, sexual activity and social interaction) and modulates the rewarding effects of addictive drugs.  Pathol. forms of natural and drug-induced reward are assocd. with dysregulated eCB signaling that may derive from pre-existing genetic factors or from prolonged drug exposure.  Impaired eCB signaling contributes to dysregulated synaptic plasticity, increased stress responsivity, neg. emotional states and cravings that propel addiction.  Understanding the contributions of eCB disruptions to behavioral and physiol. traits provides insight into the eCB influence on addiction vulnerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2s5P4XZrYGbVg90H21EOLACvtfcHk0lgPpQcwMzQxzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWls7%252FF&md5=0a7180790eba188007435ec107c6a2a9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrn4004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn4004%26sid%3Dliteratum%253Aachs%26aulast%3DParsons%26aufirst%3DL.%2BH.%26aulast%3DHurd%26aufirst%3DY.%2BL.%26atitle%3DEndocannabinoid%2520signalling%2520in%2520reward%2520and%2520addiction%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2015%26volume%3D16%26spage%3D579%26epage%3D594%26doi%3D10.1038%2Fnrn4004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaulme, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calandra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neliat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caput, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breliere, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Fur, G.</span></span> <span> </span><span class="NLM_article-title">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(94)00773-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2F0014-5793%2894%2900773-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=8070571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1994&pages=240-244&author=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=M.+Heaulmeauthor=D.+Shireauthor=B.+Calandraauthor=C.+Congyauthor=S.+Martinezauthor=J.+Maruaniauthor=G.+Neliatauthor=D.+Caputauthor=P.+Ferraraauthor=P.+Soubrieauthor=J.+C.+Breliereauthor=G.+Le+Fur&title=SR141716A%2C+a+potent+and+selective+antagonist+of+the+brain+cannabinoid+receptor&doi=10.1016%2F0014-5793%2894%2900773-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span></div><div class="casAuthors">Rinaldi-Carmona, Murielle; Barth, Francis; Heaulme, Michel; Shire, David; Calandra, Bernard; Congy, Christian; Martinez, Serge; Maruani, Jeanne; Neliat, Gervais; et al.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">240-4</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor.  This compd. displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor.  In vitro, SR141716A antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes.  After i.p. or oral administration, SR141716A antagonizes classical pharmacol. and behavioral effects of cannabinoid receptor agonists.  This compd. should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLJ59LaZb2cbVg90H21EOLACvtfcHk0lj9heSLt90loA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D&md5=1eebdfec28d2dde64729cddb859aa6c8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2900773-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252900773-X%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DHeaulme%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DCalandra%26aufirst%3DB.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DMaruani%26aufirst%3DJ.%26aulast%3DNeliat%26aufirst%3DG.%26aulast%3DCaput%26aufirst%3DD.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DBreliere%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BFur%26aufirst%3DG.%26atitle%3DSR141716A%252C%2520a%2520potent%2520and%2520selective%2520antagonist%2520of%2520the%2520brain%2520cannabinoid%2520receptor%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D350%26spage%3D240%26epage%3D244%26doi%3D10.1016%2F0014-5793%2894%2900773-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sam, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghatei, M. A.</span></span> <span> </span><span class="NLM_article-title">Rimonabant: from RIO to ban</span>. <i>J. Obes.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">432607</span>, <span class="refDoi"> DOI: 10.1155/2011/432607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1155%2F2011%2F432607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21773005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnps1SnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=432607&author=A.+H.+Samauthor=V.+Salemauthor=M.+A.+Ghatei&title=Rimonabant%3A+from+RIO+to+ban&doi=10.1155%2F2011%2F432607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant: From RIO to Ban</span></div><div class="casAuthors">Sam Amir H; Salem Victoria; Ghatei Mohammad A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of obesity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">432607</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century.  The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome.  However, the drug was quickly withdrawn due to the emergence of significant side effects-notably severe mood disorders.  This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgmzv1LvwoEZSWdIdmEou5fW6udTcc2eahxs8aahu6Grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnps1SnsQ%253D%253D&md5=03967572404bd633a2298bd1a62baff1</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1155%2F2011%2F432607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F432607%26sid%3Dliteratum%253Aachs%26aulast%3DSam%26aufirst%3DA.%2BH.%26aulast%3DSalem%26aufirst%3DV.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26atitle%3DRimonabant%253A%2520from%2520RIO%2520to%2520ban%26jtitle%3DJ.%2520Obes.%26date%3D2011%26volume%3D2011%26spage%3D432607%26doi%3D10.1155%2F2011%2F432607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beal, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yangco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plasse, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, K. V.</span></span> <span> </span><span class="NLM_article-title">Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS</span>. <i>J. Pain Symptom Manage.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/0885-3924(94)00117-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2F0885-3924%2894%2900117-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=7730690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADyaK2M3kvVWluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1995&pages=89-97&author=J.+E.+Bealauthor=R.+Olsonauthor=L.+Laubensteinauthor=J.+O.+Moralesauthor=P.+Bellmanauthor=B.+Yangcoauthor=L.+Lefkowitzauthor=T.+F.+Plasseauthor=K.+V.+Shepard&title=Dronabinol+as+a+treatment+for+anorexia+associated+with+weight+loss+in+patients+with+AIDS&doi=10.1016%2F0885-3924%2894%2900117-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS</span></div><div class="casAuthors">Beal J E; Olson R; Laubenstein L; Morales J O; Bellman P; Yangco B; Lefkowitz L; Plasse T F; Shepard K V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pain and symptom management</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-97</span>
        ISSN:<span class="NLM_cas:issn">0885-3924</span>.
    </div><div class="casAbstract">The effects of dronabinol on appetite and weight were evaluated in 139 patients with AIDS-related anorexia and > or = 2.3 kg weight loss in a multi-institutional study.  Patients were randomized to receive 2.5 mg dronabinol twice daily or placebo.  Patients rated appetite, mood, and nausea by using a 100-mm visual analogue scale 3 days weekly.  Efficacy was evaluable in 88 patients.  Dronabinol was associated with increased appetite above baseline (38% vs 8% for placebo, P = 0.015), improvement in mood (10% vs -2%, P = 0.06), and decreased nausea (20% vs 7%; P = 0.05).  Weight was stable in dronabinol patients, while placebo recipients had a mean loss of 0.4 kg (P = 0.14).  Of the dronabinol patients, 22% gained > or = 2 kg, compared with 10.5% of placebo recipients (P = 0.11).  Side effects were mostly mild to moderate in severity (euphoria, dizziness, thinking abnormalities); there was no difference in discontinued therapy between dronabinol (8.3%) and placebo (4.5%) recipients.  Dronabinol was found to be safe and effective for anorexia associated with weight loss in patients with AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1ELU2l20LmzdblLE_E9PWfW6udTcc2eahxs8aahu6Grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3kvVWluw%253D%253D&md5=d1fa3546d61c4151d74607a321db1fc8</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2F0885-3924%2894%2900117-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0885-3924%252894%252900117-4%26sid%3Dliteratum%253Aachs%26aulast%3DBeal%26aufirst%3DJ.%2BE.%26aulast%3DOlson%26aufirst%3DR.%26aulast%3DLaubenstein%26aufirst%3DL.%26aulast%3DMorales%26aufirst%3DJ.%2BO.%26aulast%3DBellman%26aufirst%3DP.%26aulast%3DYangco%26aufirst%3DB.%26aulast%3DLefkowitz%26aufirst%3DL.%26aulast%3DPlasse%26aufirst%3DT.%2BF.%26aulast%3DShepard%26aufirst%3DK.%2BV.%26atitle%3DDronabinol%2520as%2520a%2520treatment%2520for%2520anorexia%2520associated%2520with%2520weight%2520loss%2520in%2520patients%2520with%2520AIDS%26jtitle%3DJ.%2520Pain%2520Symptom%2520Manage.%26date%3D1995%26volume%3D10%26spage%3D89%26epage%3D97%26doi%3D10.1016%2F0885-3924%2894%2900117-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badowski, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanful, P. K.</span></span> <span> </span><span class="NLM_article-title">Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S126849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2147%2FTCRM.S126849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29670357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKlu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=643-651&author=M.+E.+Badowskiauthor=P.+K.+Yanful&title=Dronabinol+oral+solution+in+the+management+of+anorexia+and+weight+loss+in+AIDS+and+cancer&doi=10.2147%2FTCRM.S126849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer</span></div><div class="casAuthors">Badowski, Melissa E.; Yanful, Paa Kwesi</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">643-651</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The true incidence of anorexia secondary to human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and cancer is not well classified owing to the fact that there is a lack of standardized definitions and recent clin. data in these settings.  Dronabinol, or Δ-9-tetrahydrocannabinol, is a synthetic mol. that closely mimics the action of Cannabis sativa L., a naturally occurring compd. activated in the central nervous system by cannabinoid receptors.  Dronabinol exerts its effects by directly acting on the vomiting and appetite control centers in the brain, which in turn increases appetite and prevents vomiting.  In the USA, dronabinol is currently available in two dosage formulations - oral capsule and oral soln.  While the oral capsule was initially approved by the US Food and Drug Administration in 1985, the recent approval of the oral soln. in 2016 presents an "easy-to-swallow" alternative for patients using or intending to use dronabinol.  Dronabinol is indicated in adult patients with HIV/AIDS for the treatment of anorexia and wt. loss.  However, there is no approved indication in the setting of cancer-related anorexia and wt. loss.  This review aims at presenting available data on the use of oral dronabinol in the management of anorexia and wt. loss in HIV/AIDS and cancer, as well as characterizing and highlighting the pharmaco-therapeutic considerations of the newest formulation of dronabinol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9hcSlGt-jtbVg90H21EOLACvtfcHk0lhLpJPVN1E_pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKlu77J&md5=aebbe7ff76bcc9f93490727b707d6a3a</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S126849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S126849%26sid%3Dliteratum%253Aachs%26aulast%3DBadowski%26aufirst%3DM.%2BE.%26aulast%3DYanful%26aufirst%3DP.%2BK.%26atitle%3DDronabinol%2520oral%2520solution%2520in%2520the%2520management%2520of%2520anorexia%2520and%2520weight%2520loss%2520in%2520AIDS%2520and%2520cancer%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2018%26volume%3D14%26spage%3D643%26epage%3D651%26doi%3D10.2147%2FTCRM.S126849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pergolizzi, J. V.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeQuang, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampogna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, R. B.</span></span> <span> </span><span class="NLM_article-title">Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1007/s00280-017-3257-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00280-017-3257-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28235999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVGnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2017&pages=467-477&author=J.+V.+Pergolizziauthor=R.+Taylorauthor=J.+A.+LeQuangauthor=G.+Zampognaauthor=R.+B.+Raffa&title=Concise+review+of+the+management+of+iatrogenic+emesis+using+cannabinoids%3A+emphasis+on+nabilone+for+chemotherapy-induced+nausea+and+vomiting&doi=10.1007%2Fs00280-017-3257-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Pergolizzi, Joseph V., Jr.; Taylor, Robert; Le Quang, Jo Ann; Zampogna, Gianpietro; Raffa, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">467-477</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Chemotherapy-induced nausea and vomiting (CINV) is a prevalent, distressing, and burdensome side effect of cancer chemotherapy.  It is estd. to affect the majority of patients receiving certain anti-cancer drug regimens and can be treatment-limiting, even for life-saving medications.  Despite seemingly numerous options, such as antimuscarinic anticholinergics, antihistamines, 5-HT3 receptor antagonists, dopamine receptor antagonists, and neurokinin-1 receptor antagonists, preventative therapies are often inadequately effective, particularly for "delayed CINV"-leaving an important unmet clin. need.  Cannabinoid receptor agonists, by virtue of their unique mechanism of action and efficacy and safety data reported in clin. trials, appear to offer a useful addnl. option.  The mechanistic value of cannabinoids has been well known for many years, but these agents may have been underutilized in the past because of the notoriety and legal status of marijuana.  While botanical marijuana contains nearly 500 components, including the psychoactive tetrahydrocannabinol (THC), nabilone is an established, single-entity synthetic cannabinoid receptor agonist that has become the focus of renewed interest.  We review the basic pharmacol. and clin. trial data of nabilone for use in prophylaxis and treatment of CINV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOLNktdc8JTrVg90H21EOLACvtfcHk0lhLpJPVN1E_pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVGnt70%253D&md5=d23853821db49c80c62166d8787b7beb</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs00280-017-3257-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-017-3257-1%26sid%3Dliteratum%253Aachs%26aulast%3DPergolizzi%26aufirst%3DJ.%2BV.%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DLeQuang%26aufirst%3DJ.%2BA.%26aulast%3DZampogna%26aufirst%3DG.%26aulast%3DRaffa%26aufirst%3DR.%2BB.%26atitle%3DConcise%2520review%2520of%2520the%2520management%2520of%2520iatrogenic%2520emesis%2520using%2520cannabinoids%253A%2520emphasis%2520on%2520nabilone%2520for%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2017%26volume%3D79%26spage%3D467%26epage%3D477%26doi%3D10.1007%2Fs00280-017-3257-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novotna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mares, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratcliffe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapletalova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzilli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cefaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelmasiak, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis</span>. <i>Eur. J. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1111/j.1468-1331.2010.03328.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1468-1331.2010.03328.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21362108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC3MfltlehsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1122-1131&author=A.+Novotnaauthor=J.+Maresauthor=S.+Ratcliffeauthor=I.+Novakovaauthor=M.+Vachovaauthor=O.+Zapletalovaauthor=C.+Gasperiniauthor=C.+Pozzilliauthor=L.+Cefaroauthor=G.+Comiauthor=P.+Rossiauthor=Z.+Amblerauthor=Z.+Stelmasiakauthor=A.+Erdmannauthor=X.+Montalbanauthor=A.+Klimekauthor=P.+Davies&title=A+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel-group%2C+enriched-design+study+of+nabiximols*+%28Sativex%29%2C+as+add-on+therapy%2C+in+subjects+with+refractory+spasticity+caused+by+multiple+sclerosis&doi=10.1111%2Fj.1468-1331.2010.03328.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis</span></div><div class="casAuthors">Novotna A; Mares J; Ratcliffe S; Novakova I; Vachova M; Zapletalova O; Gasperini C; Pozzilli C; Cefaro L; Comi G; Rossi P; Ambler Z; Stelmasiak Z; Erdmann A; Montalban X; Klimek A; Davies P</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1122-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:    Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition.  We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design.  METHODS:    A 19-week follow-up, multicentre, double-blind, randomized, placebo-controlled, parallel-group study in subjects with multiple sclerosis spasticity not fully relieved with current antispasticity therapy.  Subjects were treated with nabiximols, as add-on therapy, in a single-blind manner for 4weeks, after which those achieving an improvement in spasticity of ≥20% progressed to a 12-week randomized, placebo-controlled phase.  RESULTS:    Of the 572 subjects enrolled, 272 achieved a ≥20% improvement after 4weeks of single-blind treatment, and 241 were randomized.  The primary end-point was the difference between treatments in the mean spasticity Numeric Rating Scale (NRS) in the randomized, controlled phase of the study.  Intention-to-treat (ITT) analysis showed a highly significant difference in favour of nabiximols (P=0.0002).  Secondary end-points of responder analysis, Spasm Frequency Score, Sleep Disturbance NRS Patient, Carer and Clinician Global Impression of Change were all significant in favour of nabiximols.  CONCLUSIONS:    The enriched study design provides a method of determining the efficacy and safety of nabiximols in a way that more closely reflects proposed clinical practice, by limiting exposure to those patients who are likely to benefit from it.  Hence, the difference between active and placebo should be a reflection of efficacy and safety in the population intended for treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWbubnBKIFBK-9TkgmBqTqfW6udTcc2ebTkjL0ACrIerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfltlehsA%253D%253D&md5=c9b0a9c9f24acfed4b383390f77dd9cd</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1331.2010.03328.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1331.2010.03328.x%26sid%3Dliteratum%253Aachs%26aulast%3DNovotna%26aufirst%3DA.%26aulast%3DMares%26aufirst%3DJ.%26aulast%3DRatcliffe%26aufirst%3DS.%26aulast%3DNovakova%26aufirst%3DI.%26aulast%3DVachova%26aufirst%3DM.%26aulast%3DZapletalova%26aufirst%3DO.%26aulast%3DGasperini%26aufirst%3DC.%26aulast%3DPozzilli%26aufirst%3DC.%26aulast%3DCefaro%26aufirst%3DL.%26aulast%3DComi%26aufirst%3DG.%26aulast%3DRossi%26aufirst%3DP.%26aulast%3DAmbler%26aufirst%3DZ.%26aulast%3DStelmasiak%26aufirst%3DZ.%26aulast%3DErdmann%26aufirst%3DA.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DKlimek%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DP.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel-group%252C%2520enriched-design%2520study%2520of%2520nabiximols%252A%2520%2528Sativex%2529%252C%2520as%2520add-on%2520therapy%252C%2520in%2520subjects%2520with%2520refractory%2520spasticity%2520caused%2520by%2520multiple%2520sclerosis%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2011%26volume%3D18%26spage%3D1122%26epage%3D1131%26doi%3D10.1111%2Fj.1468-1331.2010.03328.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devinsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verducci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filloux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szaflarski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzer, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wechsler, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, D.</span></span> <span> </span><span class="NLM_article-title">Open-label use of highly purified CBD (Epidiolex) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes</span>. <i>Epilepsy Behav.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/j.yebeh.2018.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.yebeh.2018.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30006259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FotVSqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2018&pages=131-137&author=O.+Devinskyauthor=C.+Verducciauthor=E.+A.+Thieleauthor=L.+C.+Lauxauthor=A.+D.+Patelauthor=F.+Fillouxauthor=J.+P.+Szaflarskiauthor=A.+Wilfongauthor=G.+D.+Clarkauthor=Y.+D.+Parkauthor=L.+E.+Seltzerauthor=E.+M.+Bebinauthor=R.+Flaminiauthor=R.+T.+Wechslerauthor=D.+Friedman&title=Open-label+use+of+highly+purified+CBD+%28Epidiolex%29+in+patients+with+CDKL5+deficiency+disorder+and+Aicardi%2C+Dup15q%2C+and+Doose+syndromes&doi=10.1016%2Fj.yebeh.2018.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes</span></div><div class="casAuthors">Devinsky Orrin; Verducci Chloe; Friedman Daniel; Thiele Elizabeth A; Laux Linda C; Patel Anup D; Filloux Francis; Szaflarski Jerzy P; Wilfong Angus; Clark Gary D; Park Yong D; Seltzer Laurie E; Bebin E Martina; Flamini Robert; Wechsler Robert T</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy & behavior : E&B</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">131-137</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  We studied our collective open-label, compassionate use experience in using cannabidiol (CBD) to treat epilepsy in patients with CDKL5 deficiency disorder and Aicardi, Doose, and Dup15q syndromes.  METHODS:  We included patients aged 1-30 years with severe childhood-onset epilepsy who received CBD for ≥10 weeks as part of multiple investigator-initiated expanded access or state access programs for a compassionate prospective interventional study: CDKL5 deficiency disorder (n = 20), Aicardi syndrome (n = 19), Dup15q syndrome (n = 8), and Doose syndrome (n = 8).  These patients were treated at 11 institutions from January 2014 to December 2016.  RESULTS:  The percent change in median convulsive seizure frequency for all patients taking CBD in the efficacy group decreased from baseline [n = 46] to week 12 (51.4% [n = 35], interquartile range (IQR): 9-85%) and week 48 (59.1% [n = 27], IQR: 14-86%).  There was a significant difference between the percent changes in monthly convulsive seizure frequency during baseline and week 12, χ(2)(2) = 22.9, p = 0.00001, with no difference in seizure percent change between weeks 12 and 48.  Of the 55 patients in the safety group, 15 (27%) withdrew from extended observation by week 144: 4 due to adverse effects, 9 due to lack of efficacy, 1 withdrew consent, and 1 was lost to follow-up.  SIGNIFICANCE:  This open-label drug trial provides class III evidence for the long-term safety and efficacy of CBD administration in patients with treatment-resistant epilepsy (TRE) associated with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.  Adjuvant therapy with CBD showed similar safety and efficacy for these four syndromes as reported in a diverse population of TRE etiologies.  This study extended analysis of the prior report from 12 weeks to 48 weeks of efficacy data and suggested that placebo-controlled randomized trials should be conducted to formally assess the safety and efficacy of CBD in these epileptic encephalopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAJZ0hazDFZrFU0A1HOshhfW6udTcc2eZKre4Sdtloz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FotVSqsA%253D%253D&md5=65776f247230dd73a7696bce00f9f034</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.yebeh.2018.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yebeh.2018.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DDevinsky%26aufirst%3DO.%26aulast%3DVerducci%26aufirst%3DC.%26aulast%3DThiele%26aufirst%3DE.%2BA.%26aulast%3DLaux%26aufirst%3DL.%2BC.%26aulast%3DPatel%26aufirst%3DA.%2BD.%26aulast%3DFilloux%26aufirst%3DF.%26aulast%3DSzaflarski%26aufirst%3DJ.%2BP.%26aulast%3DWilfong%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%2BD.%26aulast%3DPark%26aufirst%3DY.%2BD.%26aulast%3DSeltzer%26aufirst%3DL.%2BE.%26aulast%3DBebin%26aufirst%3DE.%2BM.%26aulast%3DFlamini%26aufirst%3DR.%26aulast%3DWechsler%26aufirst%3DR.%2BT.%26aulast%3DFriedman%26aufirst%3DD.%26atitle%3DOpen-label%2520use%2520of%2520highly%2520purified%2520CBD%2520%2528Epidiolex%2529%2520in%2520patients%2520with%2520CDKL5%2520deficiency%2520disorder%2520and%2520Aicardi%252C%2520Dup15q%252C%2520and%2520Doose%2520syndromes%26jtitle%3DEpilepsy%2520Behav.%26date%3D2018%26volume%3D86%26spage%3D131%26epage%3D137%26doi%3D10.1016%2Fj.yebeh.2018.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span>Artelo
BIOSCIENCES. <a href="http://artelobio.com/pipeline" class="extLink">http://artelobio.com/pipeline</a> (accessed Oct 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Artelo%0ABIOSCIENCES.+http%3A%2F%2Fartelobio.com%2Fpipeline+%28accessed+Oct+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span>CORBUS
Pharmaceuticals. <a href="https://www.corbuspharma.com/our-science/crb-4001" class="extLink">https://www.corbuspharma.com/our-science/crb-4001</a> (accessed Oct 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CORBUS%0APharmaceuticals.+https%3A%2F%2Fwww.corbuspharma.com%2Four-science%2Fcrb-4001+%28accessed+Oct+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kale, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zmarowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparrow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorospe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorvat, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terse, P. S.</span></span> <span> </span><span class="NLM_article-title">Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">104483</span>, <span class="refDoi"> DOI: 10.1016/j.yrtph.2019.104483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.yrtph.2019.104483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31580887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCktrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2019&pages=104483&author=V.+P.+Kaleauthor=S.+Gibbsauthor=J.+A.+Taylorauthor=A.+Zmarowskiauthor=J.+Novakauthor=K.+Pattonauthor=B.+Sparrowauthor=J.+Gorospeauthor=S.+Anandauthor=R.+Cinarauthor=G.+Kunosauthor=R.+J.+Chorvatauthor=P.+S.+Terse&title=Preclinical+toxicity+evaluation+of+JD5037%2C+a+peripherally+restricted+CB1+receptor+inverse+agonist%2C+in+rats+and+dogs+for+treatment+of+nonalcoholic+steatohepatitis&doi=10.1016%2Fj.yrtph.2019.104483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis</span></div><div class="casAuthors">Kale, Vijay Pralhad; Gibbs, Seth; Taylor, John A.; Zmarowski, Amy; Novak, Joseph; Patton, Kristin; Sparrow, Barney; Gorospe, Jenni; Anand, Satheesh; Cinar, Resat; Kunos, George; Chorvat, Robert J.; Terse, Pramod S.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104483</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">JD5037 is a novel peripherally restricted CB1 receptor (CB1R) inverse agonist being developed for the treatment of visceral obesity and its metabolic complications, including nonalcoholic fatty liver disease and dyslipidemia.  JD5037 was administered by oral gavage at 10, 40, and 150 mg/kg/day dose levels for up to 34 days to Sprague Dawley rats, and at 5, 20, and 75 mg/kg/day dose levels for 28 consecutive days to Beagle dogs.  In rats, higher incidences of stereotypic behaviors were obsd. in 10 mg/kg females and 40 mg/kg males, and slower responses for reflex and sensory tests were obsd. only in males at 10 and 40 mg/kg during neurobehavioral testing.  Sporadic minimal incidences of decreased activity (males) and seizures (both sexes) were obsd. in rats during daily clin. observations, without any clear dose-relationship.  Male dogs at 75 mg/kg during treatment period, but not recovery period, had an increased incidence of gut assocd. lymphoid tissue hyperplasia and inflammation in the intestine.  In both species, highest dose resulted in lower AUCs indicative of non-linear kinetics.  Free access to food increased the plasma AUC∞ by ∼4.5-fold at 20 mg/kg in dogs, suggesting presence of food may help in systemic absorption of JD5037 in dogs.  Based on the study results, 150 mg/kg/day in rats, and 20 and 75 mg/kg/day doses in male and female dogs, resp., were detd. to be the no-obsd.-adverse-effect-levels (NOAELs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtyXBEwV_5Z7Vg90H21EOLACvtfcHk0lgoU5llc2wAUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCktrjM&md5=680bce0e87639dc009d7bdd541b42e88</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2019.104483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2019.104483%26sid%3Dliteratum%253Aachs%26aulast%3DKale%26aufirst%3DV.%2BP.%26aulast%3DGibbs%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DJ.%2BA.%26aulast%3DZmarowski%26aufirst%3DA.%26aulast%3DNovak%26aufirst%3DJ.%26aulast%3DPatton%26aufirst%3DK.%26aulast%3DSparrow%26aufirst%3DB.%26aulast%3DGorospe%26aufirst%3DJ.%26aulast%3DAnand%26aufirst%3DS.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DTerse%26aufirst%3DP.%2BS.%26atitle%3DPreclinical%2520toxicity%2520evaluation%2520of%2520JD5037%252C%2520a%2520peripherally%2520restricted%2520CB1%2520receptor%2520inverse%2520agonist%252C%2520in%2520rats%2520and%2520dogs%2520for%2520treatment%2520of%2520nonalcoholic%2520steatohepatitis%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2019%26volume%3D109%26spage%3D104483%26doi%3D10.1016%2Fj.yrtph.2019.104483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maresz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponomarev, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittel, B. N.</span></span> <span> </span><span class="NLM_article-title">Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2005.03380.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1471-4159.2005.03380.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16086683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFegu7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2005&pages=437-445&author=K.+Mareszauthor=E.+J.+Carrierauthor=E.+D.+Ponomarevauthor=C.+J.+Hillardauthor=B.+N.+Dittel&title=Modulation+of+the+cannabinoid+CB2+receptor+in+microglial+cells+in+response+to+inflammatory+stimuli&doi=10.1111%2Fj.1471-4159.2005.03380.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli</span></div><div class="casAuthors">Maresz, Katarzyna; Carrier, Erica J.; Ponomarev, Eugene D.; Hillard, Cecilia J.; Dittel, Bonnie N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">437-445</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The cannabinoid system is known to be important in neuronal regulation, but is also capable of modulating immune function.  Although the CNS resident microglial cells have been shown to express the CB2 subtype of cannabinoid receptor during non-immune-mediated pathol. conditions, little is known about the expression of the cannabinoid system during immune-mediated CNS pathol.  To examine this question, the authors measured CB2 receptor mRNA expression in the CNS of mice with exptl. autoimmune encephalomyelitis (EAE) and, by real-time PCR, found a 100-fold increase in CB2 receptor mRNA expression during EAE onset.  The authors next detd. whether microglial cells specifically express the CB2 receptor during EAE, and found that activated microglial cells expressed 10-fold more CB2 receptor than microglia in the resting state.  To det. the signals required for the up-regulation of the CB2 receptor, the authors cultured microglial cells with combinations of γ-interferon (IFN-γ) and granulocyte) macrophage-colony stimulating factor (GM-CSF), which both promote microglial cell activation and are expressed in the CNS during EAE, and found that they synergized, resulting in an eight to 10-fold increase in the CB2 receptor.  The authors found no difference in the amt. of the CB2 receptor ligand, 2-arachidonylglycerol (2-AG), in the spinal cord during EAE.  These data demonstrate that microglial cell activation is accompanied by CB2 receptor up-regulation, suggesting that this receptor plays an important role in microglial cell function in the CNS during autoimmune-induced inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9PXl5k5Q8SbVg90H21EOLACvtfcHk0lgoU5llc2wAUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFegu7jM&md5=a7c0e744aa03f3769eddc96c6dfc81dc</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2005.03380.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2005.03380.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaresz%26aufirst%3DK.%26aulast%3DCarrier%26aufirst%3DE.%2BJ.%26aulast%3DPonomarev%26aufirst%3DE.%2BD.%26aulast%3DHillard%26aufirst%3DC.%2BJ.%26aulast%3DDittel%26aufirst%3DB.%2BN.%26atitle%3DModulation%2520of%2520the%2520cannabinoid%2520CB2%2520receptor%2520in%2520microglial%2520cells%2520in%2520response%2520to%2520inflammatory%2520stimuli%26jtitle%3DJ.%2520Neurochem.%26date%3D2005%26volume%3D95%26spage%3D437%26epage%3D445%26doi%3D10.1111%2Fj.1471-4159.2005.03380.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano-Cabral, F.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptors in microglia of the central nervous system: immune functional relevance</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1192</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1189/jlb.0405216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1189%2Fjlb.0405216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16204639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtleksL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2005&pages=1192-1197&author=G.+Cabralauthor=F.+Marciano-Cabral&title=Cannabinoid+receptors+in+microglia+of+the+central+nervous+system%3A+immune+functional+relevance&doi=10.1189%2Fjlb.0405216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors in microglia of the central nervous system: Immune functional relevance</span></div><div class="casAuthors">Cabral, G. A.; Marciano-Cabral, F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1192-1197</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Microglia, resident macrophages of the brain, function as immune effector and accessory cells.  Paradoxically, they not only play a role in host defense and tissue repair but also have been implicated in a variety of neuropathol. processes.  Microglia, in addn. to exhibiting phenotypic markers for macrophages, express CB1 and CB2 cannabinoid receptors.  Recent studies suggest the existence of a third, yet-to-be cloned, non-CB1, non-CB2 cannabinoid receptor.  These receptors appear to be functionally relevant within defined windows of microglial activation state and have been implicated as linked to cannabinoid modulation of chemokine and cytokine expression.  The recognition that microglia express cannabinoid receptors and that their activation results in modulation of select cellular activities suggests that they may be amenable to therapeutic manipulation for ablating untoward inflammatory responses in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXknErGXGXdLVg90H21EOLACvtfcHk0libHnO3E9iy9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtleksL3L&md5=c856712600eb54f8d8a1482626fb6c7c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0405216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0405216%26sid%3Dliteratum%253Aachs%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DMarciano-Cabral%26aufirst%3DF.%26atitle%3DCannabinoid%2520receptors%2520in%2520microglia%2520of%2520the%2520central%2520nervous%2520system%253A%2520immune%2520functional%2520relevance%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2005%26volume%3D78%26spage%3D1192%26epage%3D1197%26doi%3D10.1189%2Fjlb.0405216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolon, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 receptors in human brain inflammation</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fsj.bjp.0707505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17934510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFCktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=277-285&author=C.+Benitoauthor=R.+M.+Tolonauthor=M.+R.+Pazosauthor=E.+Nunezauthor=A.+I.+Castilloauthor=J.+Romero&title=Cannabinoid+CB2+receptors+in+human+brain+inflammation&doi=10.1038%2Fsj.bjp.0707505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors in human brain inflammation</span></div><div class="casAuthors">Benito, C.; Tolon, R. M.; Pazos, M. R.; Nunez, E.; Castillo, A. I.; Romero, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-285</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The presence of functional cannabinoid CB2 receptors in the CNS has provoked considerable controversy over the past few years.  Formerly considered as an exclusively peripheral receptor, it is now accepted that it is also present in limited amts. and distinct locations in the brain of several animal species, including humans.  Furthermore, the inducible nature of these receptors under neuroinflammatory conditions, in contrast to CB1, makes them attractive targets for the development of novel therapeutic approaches.  In fact, the undesired psychoactive effects caused by CB1 activation have largely limited the clin. use of cannabinoid-related compds. that act on these receptors.  In this review some recent findings on the antiinflammatory properties of CB2 receptors are presented, as well as new perspectives that have been obtained based on studies of human postmortem brain samples.  In addn., various working hypotheses are also proposed and discussed.  British Journal of Pharmacol. (2008) 153, 277-285; doi:10.1038/sj.bjp.0707505; published online 15 Oct. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy1sC3kUak-7Vg90H21EOLACvtfcHk0libHnO3E9iy9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFCktg%253D%253D&md5=acc7f2244e1db16d66e5953eadecb381</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707505%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DC.%26aulast%3DTolon%26aufirst%3DR.%2BM.%26aulast%3DPazos%26aufirst%3DM.%2BR.%26aulast%3DNunez%26aufirst%3DE.%26aulast%3DCastillo%26aufirst%3DA.%2BI.%26aulast%3DRomero%26aufirst%3DJ.%26atitle%3DCannabinoid%2520CB2%2520receptors%2520in%2520human%2520brain%2520inflammation%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D277%26epage%3D285%26doi%3D10.1038%2Fsj.bjp.0707505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchet, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laviolette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamand, N.</span></span> <span> </span><span class="NLM_article-title">The CB2 receptor and its role as a regulator of inflammation</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4449</span>– <span class="NLM_lpage">4470</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2300-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00018-016-2300-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27402121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCrtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=4449-4470&author=C.+Turcotteauthor=M.+R.+Blanchetauthor=M.+Lavioletteauthor=N.+Flamand&title=The+CB2+receptor+and+its+role+as+a+regulator+of+inflammation&doi=10.1007%2Fs00018-016-2300-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The CB2 receptor and its role as a regulator of inflammation</span></div><div class="casAuthors">Turcotte, Caroline; Blanchet, Marie-Renee; Laviolette, Michel; Flamand, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4449-4470</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">The CB2 receptor is the peripheral receptor for cannabinoids.  It is mainly expressed in immune tissues, highlighting the possibility that the endocannabinoid system has an immunomodulatory role.  In this respect, the CB2 receptor was shown to modulate immune cell functions, both in cellulo and in animal models of inflammatory diseases.  In this regard, numerous studies have reported that mice lacking the CB2 receptor have an exacerbated inflammatory phenotype.  This suggests that therapeutic strategies aiming at modulating CB2 signaling could be promising for the treatment of various inflammatory conditions.  Herein, we review the pharmacol. of the CB2 receptor, its expression pattern, and the signaling pathways induced by its activation.  We next examine the regulation of immune cell functions by the CB2 receptor and the evidence obtained from primary human cells, immortalized cell lines, and animal models of inflammation.  Finally, we discuss the possible therapies targeting the CB2 receptor and the questions that remain to be addressed to det. whether this receptor could be a potential target to treat inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa70FJsUK5IbVg90H21EOLACvtfcHk0libHnO3E9iy9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCrtLrN&md5=572eaca44428863b1c69dde0bca87662</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2300-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2300-4%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DC.%26aulast%3DBlanchet%26aufirst%3DM.%2BR.%26aulast%3DLaviolette%26aufirst%3DM.%26aulast%3DFlamand%26aufirst%3DN.%26atitle%3DThe%2520CB2%2520receptor%2520and%2520its%2520role%2520as%2520a%2520regulator%2520of%2520inflammation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D4449%26epage%3D4470%26doi%3D10.1007%2Fs00018-016-2300-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capparelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span> <span> </span><span class="NLM_article-title">Perspectives of cannabinoid type 2 receptor (CB2R) ligands in neurodegenerative disorders: structure-affinity relationship (SAfiR) and structure-activity relationship (SAR) studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9913</span>– <span class="NLM_lpage">9931</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9913-9931&author=F.+Spinelliauthor=E.+Capparelliauthor=C.+Abateauthor=N.+A.+Colabufoauthor=M.+Contino&title=Perspectives+of+cannabinoid+type+2+receptor+%28CB2R%29+ligands+in+neurodegenerative+disorders%3A+structure-affinity+relationship+%28SAfiR%29+and+structure-activity+relationship+%28SAR%29+studies&doi=10.1021%2Facs.jmedchem.7b00155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Spinelli, Francesco; Capparelli, Elena; Abate, Carmen; Colabufo, Nicola A.; Contino, Marialessandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9913-9931</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Up-regulation of CB2R on activated microglial cells, the first step in neurodegeneration, has been widely demonstrated, and this finding makes the receptor a promising target in the early diagnosis and treatment of several neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and multiple sclerosis (MS).  The development of CB2R PET ligands could help demonstrate the neurodegenerative pathogenesis, thus providing useful tools for characterizing the role of neuroinflammation in the progression of these disorders.  CB2R agonists and inverse agonists have emerged as neuroprotective agents and CB2R agonists have entered several clin. trials.  CB2R ligands have therefore received great attention and different mol. scaffolds have been selected to target CB2R subtypes.  This perspective is focused on structure-activity relationship (SAR) and structure-affinity relationship (SAfiR) studies performed on different scaffolds with the aim to identify the mol. features useful for the design of both therapeutic and diagnostic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy3g8MJz6QjbVg90H21EOLACvtfcHk0liMd1yFwxEvkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisbY%253D&md5=e4dfd58a0cb94a9d00203a8f32de43f8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00155%26sid%3Dliteratum%253Aachs%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DCapparelli%26aufirst%3DE.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DContino%26aufirst%3DM.%26atitle%3DPerspectives%2520of%2520cannabinoid%2520type%25202%2520receptor%2520%2528CB2R%2529%2520ligands%2520in%2520neurodegenerative%2520disorders%253A%2520structure-affinity%2520relationship%2520%2528SAfiR%2529%2520and%2520structure-activity%2520relationship%2520%2528SAR%2529%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9913%26epage%3D9931%26doi%3D10.1021%2Facs.jmedchem.7b00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T.</span></span> <span> </span><span class="NLM_article-title">Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid receptor ligands</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.2174/09298673113206660296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2174%2F09298673113206660296" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=187-203&author=T.+Nevalainen&title=Recent+development+of+CB2+selective+and+peripheral+CB1%2FCB2+cannabinoid+receptor+ligands&doi=10.2174%2F09298673113206660296"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2174%2F09298673113206660296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113206660296%26sid%3Dliteratum%253Aachs%26aulast%3DNevalainen%26aufirst%3DT.%26atitle%3DRecent%2520development%2520of%2520CB2%2520selective%2520and%2520peripheral%2520CB1%252FCB2%2520cannabinoid%2520receptor%2520ligands%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D187%26epage%3D203%26doi%3D10.2174%2F09298673113206660296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. Q.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the human cannabinoid receptor CB2-Gi signaling complex</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2020.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32004460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFequr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=645-654&author=C.+Xingauthor=Y.+Zhuangauthor=T.+H.+Xuauthor=Z.+Fengauthor=X.+E.+Zhouauthor=M.+Chenauthor=L.+Wangauthor=X.+Mengauthor=Y.+Xueauthor=J.+Wangauthor=H.+Liuauthor=T.+F.+McGuireauthor=G.+Zhaoauthor=K.+Melcherauthor=C.+Zhangauthor=H.+E.+Xuauthor=X.+Q.+Xie&title=Cryo-EM+structure+of+the+human+cannabinoid+receptor+CB2-Gi+signaling+complex&doi=10.1016%2Fj.cell.2020.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex</span></div><div class="casAuthors">Xing, Changrui; Zhuang, Youwen; Xu, Ting-Hai; Feng, Zhiwei; Zhou, X. Edward; Chen, Maozi; Wang, Lei; Meng, Xing; Xue, Ying; Wang, Junmei; Liu, Heng; McGuire, Terence Francis; Zhao, Gongpu; Melcher, Karsten; Zhang, Cheng; Xu, H. Eric; Xie, Xiang-Qun</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">645-654.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drugs selectively targeting CB2 hold promise for treating neurodegenerative disorders, inflammation, and pain while avoiding psychotropic side effects mediated by CB1.  The mechanisms underlying CB2 activation and signaling are poorly understood but crit. for drug design.  Here we report the cryo-EM structure of the human CB2-Gi signaling complex bound to the agonist WIN 55,212-2.  The 3D structure reveals the binding mode of WIN 55,212-2 and structural determinants for distinguishing CB2 agonists from antagonists, which are supported by a pair of rationally designed agonist and antagonist.  Further structural analyses with computational docking results uncover the differences between CB2 and CB1 in receptor activation, ligand recognition, and Gi coupling.  These findings are expected to facilitate rational structure-based discovery of drugs targeting the cannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxe6yMtfE8RbVg90H21EOLACvtfcHk0liMd1yFwxEvkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFequr8%253D&md5=2c54b7bd90e2f9b33b141adb36e57688</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DC.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DT.%2BH.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DX.%2BE.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMcGuire%26aufirst%3DT.%2BF.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DH.%2BE.%26aulast%3DXie%26aufirst%3DX.%2BQ.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB2-Gi%2520signaling%2520complex%26jtitle%3DCell%26date%3D2020%26volume%3D180%26spage%3D645%26epage%3D654%26doi%3D10.1016%2Fj.cell.2020.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span>ARENA
Pharmaceuticals. <a href="https://www.arenapharm.com/pipeline/apd371/#" class="extLink">https://www.arenapharm.com/pipeline/apd371/#</a> (accessed Oct 8, 2010).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ARENA%0APharmaceuticals.+https%3A%2F%2Fwww.arenapharm.com%2Fpipeline%2Fapd371%2F%23+%28accessed+Oct+8%2C+2010%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musachio, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of [<sup>18</sup>F]SR144385: A selective radioligand for positron emission tomographic studies of brain cannabinoid receptors</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1099-1344(199906)42:6<589::AID-JLCR219>3.0.CO;2-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2F%28SICI%291099-1344%28199906%2942%3A6%3C589%3A%3AAID-JLCR219%3E3.0.CO%3B2-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK1MXjvVKitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=589-596&author=W.+B.+Mathewsauthor=H.+T.+Ravertauthor=J.+L.+Musachioauthor=R.+A.+Frankauthor=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=R.+F.+Dannals&title=Synthesis+of+%5B18F%5DSR144385%3A+A+selective+radioligand+for+positron+emission+tomographic+studies+of+brain+cannabinoid+receptors&doi=10.1002%2F%28SICI%291099-1344%28199906%2942%3A6%3C589%3A%3AAID-JLCR219%3E3.0.CO%3B2-B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of [18F] SR144385: a selective radioligand for positron emission tomographic studies of brain cannabinoid receptors</span></div><div class="casAuthors">Mathews, William B.; Ravert, Hayden T.; Musachio, John L.; Frank, Richard A.; Rinaldi-Carmona, Murielle; Barth, Francis; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds & Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">589-596</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A cannabinoid receptor antagonist, SR144385, has been labeled with fluorine-18.  [18F] SR144385 was synthesized in a multi-step reaction in which fluorine-18 was introduced by nucleophilic halogen displacement on a bromo precursor.  The fluorine-18 labeled intermediate was deprotected and coupled with 1-aminopiperidine to give [18F] SR144385.  The time for radiosynthesis, HPLC purifn., and formulation was 2 h from end-of-bombardment.  [18F] SR144385 of high radiochem. purity was obtained at end-of-synthesis with an av. (n = 11) specific radioactivity of 1852 mCi/μmol and an av. isolated, non-decay cor. radiochem. yield of 4% from potassium [18F] fluoride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrenpEX6Zf6C7Vg90H21EOLACvtfcHk0lhFW73EFybknQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvVKitro%253D&md5=cbf9d68fe17657cbd2b13dba4245ce92</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291099-1344%28199906%2942%3A6%3C589%3A%3AAID-JLCR219%3E3.0.CO%3B2-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291099-1344%2528199906%252942%253A6%253C589%253A%253AAID-JLCR219%253E3.0.CO%253B2-B%26sid%3Dliteratum%253Aachs%26aulast%3DMathews%26aufirst%3DW.%2BB.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DMusachio%26aufirst%3DJ.%2BL.%26aulast%3DFrank%26aufirst%3DR.%2BA.%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520of%2520%255B18F%255DSR144385%253A%2520A%2520selective%2520radioligand%2520for%2520positron%2520emission%2520tomographic%2520studies%2520of%2520brain%2520cannabinoid%2520receptors%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D1999%26volume%3D42%26spage%3D589%26epage%3D596%26doi%3D10.1002%2F%28SICI%291099-1344%28199906%2942%3A6%3C589%3A%3AAID-JLCR219%3E3.0.CO%3B2-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">Biodistribution of [<sup>18</sup>F] SR144385 and [<sup>18</sup>F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1016/S0969-8051(00)00152-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0969-8051%2800%2900152-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=11150708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVWltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=757-762&author=W.+B.+Mathewsauthor=U.+Scheffelauthor=P.+Finleyauthor=H.+T.+Ravertauthor=R.+A.+Frankauthor=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=R.+F.+Dannals&title=Biodistribution+of+%5B18F%5D+SR144385+and+%5B18F%5D+SR147963%3A+selective+radioligands+for+positron+emission+tomographic+studies+of+brain+cannabinoid+receptors&doi=10.1016%2FS0969-8051%2800%2900152-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors</span></div><div class="casAuthors">Mathews, W. B.; Scheffel, U.; Finley, P.; Ravert, H. T.; Frank, R. A.; Rinaldi-Carmona, M.; Barth, F.; Dannals, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">757-762</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">[18F]SR144385 and [18F]SR147963 were synthesized in a multistep reaction in which fluorine-18 was introduced by nucleophilic halogen displacement on a bromo precursor.  The fluorine-18-labeled intermediate was deprotected and coupled with the appropriate alkyl amine to give the final products.  Both radioligands had appropriate regional brain distribution for cannabinoid receptors with a target to nontarget ratio of 1.7 for [18F] SR147963 and 2.5 for [18F] SR144385 at 60 and 90 min postinjection, resp.  The uptake of both tracers was blocked with a 1 mg/kg dose of SR141716A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpar4_s-xCqsrVg90H21EOLACvtfcHk0lhFW73EFybknQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVWltA%253D%253D&md5=74b77f6263aa1d057034a00153033434</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0969-8051%2800%2900152-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-8051%252800%252900152-9%26sid%3Dliteratum%253Aachs%26aulast%3DMathews%26aufirst%3DW.%2BB.%26aulast%3DScheffel%26aufirst%3DU.%26aulast%3DFinley%26aufirst%3DP.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DFrank%26aufirst%3DR.%2BA.%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DBiodistribution%2520of%2520%255B18F%255D%2520SR144385%2520and%2520%255B18F%255D%2520SR147963%253A%2520selective%2520radioligands%2520for%2520positron%2520emission%2520tomographic%2520studies%2520of%2520brain%2520cannabinoid%2520receptors%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2000%26volume%3D27%26spage%3D757%26epage%3D762%26doi%3D10.1016%2FS0969-8051%2800%2900152-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauseo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellames, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">Carbon-11 labeled radioligands for imaging brain cannabinoid receptors</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/S0969-8051(02)00308-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0969-8051%2802%2900308-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12234592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVeisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2002&pages=671-677&author=W.+B.+Mathewsauthor=U.+Scheffelauthor=P.+A.+Rauseoauthor=H.+T.+Ravertauthor=R.+A.+Frankauthor=G.+J.+Ellamesauthor=J.+M.+Herbertauthor=F.+Barthauthor=M.+Rinaldi-Carmonaauthor=R.+F.+Dannals&title=Carbon-11+labeled+radioligands+for+imaging+brain+cannabinoid+receptors&doi=10.1016%2FS0969-8051%2802%2900308-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Carbon-11 labeled radioligands for imaging brain cannabinoid receptors</span></div><div class="casAuthors">Mathews, William B.; Scheffel, Ursula; Rauseo, Paige A.; Ravert, Hayden T.; Frank, Richard A.; Ellames, George J.; Herbert, John M.; Barth, Francis; Rinaldi-Carmona, Murielle; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Two radioligands, [11C] SR149080 and its morpholino analog [11C] SR149568, were synthesized by reaction of the resp. phenolic precursors with [11C] Me iodide.  Both radioligands had appropriate regional brain distribution for cannabinoid receptors in mice with peak target to non-target ratios of 2.2 for [11C] SR149080 and 1.6 for [11C] SR149568 at 90 and 30 min post-injection resp.  The uptake of both tracers was blocked with a 1 mg/kg dose of SR141716A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJHhYCFQ1OybVg90H21EOLACvtfcHk0lhFW73EFybknQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVeisL8%253D&md5=975e6cd40f1731fa39fad1ebd2ddc428</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0969-8051%2802%2900308-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-8051%252802%252900308-6%26sid%3Dliteratum%253Aachs%26aulast%3DMathews%26aufirst%3DW.%2BB.%26aulast%3DScheffel%26aufirst%3DU.%26aulast%3DRauseo%26aufirst%3DP.%2BA.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DFrank%26aufirst%3DR.%2BA.%26aulast%3DEllames%26aufirst%3DG.%2BJ.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DCarbon-11%2520labeled%2520radioligands%2520for%2520imaging%2520brain%2520cannabinoid%2520receptors%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2002%26volume%3D29%26spage%3D671%26epage%3D677%26doi%3D10.1016%2FS0969-8051%2802%2900308-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 1-(2,4-dichlorophenyl)-4-cyano-5-(4-11C-methoxyphenyl)-N-(piperidin-1-y l)-1H-pyrazole-3-carboxamide (11C-JHU75528) and 1-(2bromophenyl)-4-cyano-5-(4- 11C methoxyphenyl)-N-(piperidin-1-yl)-1H -pyrazole-3-carboxamide ( 11C JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1002/jlcr.1125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjlcr.1125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12hu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1021-1036&author=H.+Fanauthor=H.+T.+Ravertauthor=D.+P.+Holtauthor=R.+F.+Dannalsauthor=A.+G.+Horti&title=Synthesis+of+1-%282%2C4-dichlorophenyl%29-4-cyano-5-%284-11C-methoxyphenyl%29-N-%28piperidin-1-y+l%29-1H-pyrazole-3-carboxamide+%2811C-JHU75528%29+and+1-%282bromophenyl%29-4-cyano-5-%284-+11C+methoxyphenyl%29-N-%28piperidin-1-yl%29-1H+-pyrazole-3-carboxamide+%28+11C+JHU75575%29+as+potential+radioligands+for+PET+imaging+of+cerebral+cannabinoid+receptor&doi=10.1002%2Fjlcr.1125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 1-(2,4-dichlorophenyl)-4-cyano-5-(4-[11C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([11C]JHU75528) and 1-(2-bromophenyl)-4-cyano-5-(4-[11C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([11C]JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor</span></div><div class="casAuthors">Fan, Hong; Ravert, Hayden T.; Holt, Daniel P.; Dannals, Robert F.; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1021-1036</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Two novel ligands for cerebral cannabinoid receptor (CB1), 1-(2,4-dichlorophenyl)-4-cyano-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (JHU75528) and 1-(2-bromophenyl)-4-cyano-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (JHU75575) have been synthesized.  Both JHU75528 and JHU75575 display a combination of higher binding affinity and lower lipophilicity than those of Rimonabant (SR141716), a high affinity CB1 selective antagonist, and AM281, the only available ligand for emission tomog. imaging of CB1 in human subjects.  Radiolabeled [11C]JHU75528 and [11C]JHU75575 were prepd. by reaction of [11C]methyl iodide with nor-Me precursors.  The av. radiochem. yield, specific radioactivity, and radiochem. purity of [11C]JHU75528 were 16%, 235 GBq/μmol (6360 mCi/μmol), and 99%, resp.; those of [11C]JHU75575 were 8%, 196 GBq/μmol (5308 mCi/μmol), and 99%, resp.  Both ligands hold promise as PET radioligands for imaging CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP3er6g9CD-bVg90H21EOLACvtfcHk0ljU-fY9_Wr5JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12hu7zO&md5=d012863379858aa0eaa2e074ef4a0407</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.1125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.1125%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DH.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DHolt%26aufirst%3DD.%2BP.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DSynthesis%2520of%25201-%25282%252C4-dichlorophenyl%2529-4-cyano-5-%25284-11C-methoxyphenyl%2529-N-%2528piperidin-1-y%2520l%2529-1H-pyrazole-3-carboxamide%2520%252811C-JHU75528%2529%2520and%25201-%25282bromophenyl%2529-4-cyano-5-%25284-%252011C%2520methoxyphenyl%2529-N-%2528piperidin-1-yl%2529-1H%2520-pyrazole-3-carboxamide%2520%2528%252011C%2520JHU75575%2529%2520as%2520potential%2520radioligands%2520for%2520PET%2520imaging%2520of%2520cerebral%2520cannabinoid%2520receptor%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2006%26volume%3D49%26spage%3D1021%26epage%3D1036%26doi%3D10.1002%2Fjlcr.1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotsikorou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CBI): Development of ligands with optimized lipophilicity and binding affinity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.03.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejmech.2008.03.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18511157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlWjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=593-608&author=H.+Fanauthor=E.+Kotsikorouauthor=A.+F.+Hoffmanauthor=H.+T.+Ravertauthor=D.+Holtauthor=D.+P.+Hurstauthor=C.+R.+Lupicaauthor=P.+H.+Reggioauthor=R.+F.+Dannalsauthor=A.+G.+Horti&title=Analogs+of+JHU75528%2C+a+PET+ligand+for+imaging+of+cerebral+cannabinoid+receptors+%28CBI%29%3A+Development+of+ligands+with+optimized+lipophilicity+and+binding+affinity&doi=10.1016%2Fj.ejmech.2008.03.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): Development of ligands with optimized lipophilicity and binding affinity</span></div><div class="casAuthors">Fan, Hong; Kotsikorou, Evangelia; Hoffman, Alexander F.; Ravert, Hayden T.; Holt, Daniel; Hurst, Dow P.; Lupica, Carl R.; Reggio, Patricia H.; Dannals, Robert F.; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">593-608</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Cyano analogs of Rimonabant with high binding affinity for the cerebral cannabinoid receptor (CB1) and with optimized lipophilicity have been synthesized as potential positron emission tomog. (PET) ligands.  The best ligands of the series are optimal targets for the future radiolabeling with PET isotopes and in vivo evaluation as radioligands with enhanced properties for PET imaging of CB1 receptors in human subjects.  Extracellular electrophysiol. recordings in rodent brain slices demonstrated that JHU75528, 4, the lead compd. of the new series, has functional CB antagonist properties that are consistent with its structural relationship to Rimonabant.  Mol. modeling anal. revealed an important role of the binding of the cyano group with the CB1 binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOiNlgowGkprVg90H21EOLACvtfcHk0ljU-fY9_Wr5JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlWjs74%253D&md5=556955be52dd2f5d1ba57fbbee84bce9</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.03.040%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DH.%26aulast%3DKotsikorou%26aufirst%3DE.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DHolt%26aufirst%3DD.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DAnalogs%2520of%2520JHU75528%252C%2520a%2520PET%2520ligand%2520for%2520imaging%2520of%2520cerebral%2520cannabinoid%2520receptors%2520%2528CBI%2529%253A%2520Development%2520of%2520ligands%2520with%2520optimized%2520lipophilicity%2520and%2520binding%2520affinity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D593%26epage%3D608%26doi%3D10.1016%2Fj.ejmech.2008.03.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1696</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17015906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKjtrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=1689-1696&author=A.+G.+Hortiauthor=H.+Fanauthor=H.+Kuwabaraauthor=J.+Hiltonauthor=H.+T.+Ravertauthor=D.+P.+Holtauthor=M.+Alexanderauthor=A.+Kumarauthor=A.+Rahmimauthor=U.+Scheffelauthor=D.+F.+Wongauthor=R.+F.+Dannals&title=11C-JHU75528%3A+a+radiotracer+for+PET+imaging+of+CB1+cannabinoid+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors</span></div><div class="casAuthors">Horti, Andrew G.; Fan, Hong; Kuwabara, Hiroto; Hilton, John; Ravert, Hayden T.; Holt, Daniel P.; Alexander, Mohab; Kumar, Anil; Rahmim, Arman; Scheffel, Ursula; Wong, Dean F.; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1689-1696</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">The development of the radioligands for PET imaging of the cerebral cannabinoid receptor (CB1) is of great importance for studying its role in neuropsychiatric disorders, obesity, and drug dependence.  None of the currently available radioligands for CB1 are suitable for quant. PET, primarily because of their insufficient binding potential (BP) in brain or low penetration through the blood-brain barrier (BBB).  The goal of this study was to evaluate 11C-JHU75528, an analog of the selective CB1 antagonist rimonabant, in vivo as a potential CB1 radioligand for PET.  Methods: The brain regional distribution and pharmacol. of 11C-JHU75528 have been evaluated in vivo in mice (dissection) and baboons (PET).  Results: 11C-JHU75528 readily entered the mouse and baboon brain and specifically and selectively labeled cerebral CB1 receptors.  The ratio of striatum to brain stem in mice and the binding potential (BP) in the baboon putamen were 3.4 and 1.3-1.5, resp.  The specific binding of 11C-JHU75528 in vivo was blocked by preinjection of nonlabeled JHU75528.  Administration of rimonabant (1 mg/kg, i.v.) also blocked the specific binding of 11C-JHU75528 binding in the mouse and baboon brain, whereas various central non-cannabinoid drugs did not significantly reduce the 11C-JHU75528 binding in the mouse brain.  11C-JHU75528 formed several hydrophilic metabolites, but only a minute fraction of metabolic radioactivity penetrated the BBB.  Conclusion: 11C-JHU75528 holds promise as a radiotracer with suitable imaging properties for quantification of CB1 receptors in the human brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKZkkvcJ8HULVg90H21EOLACvtfcHk0ljU-fY9_Wr5JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKjtrbK&md5=3edbf9ef5616ae6c5927cefe7b69448f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorti%26aufirst%3DA.%2BG.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DHilton%26aufirst%3DJ.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DHolt%26aufirst%3DD.%2BP.%26aulast%3DAlexander%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DRahmim%26aufirst%3DA.%26aulast%3DScheffel%26aufirst%3DU.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3D11C-JHU75528%253A%2520a%2520radiotracer%2520for%2520PET%2520imaging%2520of%2520CB1%2520cannabinoid%2520receptors%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D1689%26epage%3D1696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascella, N.</span></span> <span> </span><span class="NLM_article-title">PET Imaging of cannabinoid CB1 type receptors in healthy humans and patients with schizophrenia using [<sup>11</sup>C]OMAR</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">T51</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2008.04.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2008.04.225" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=T51&author=D.+F.+Wongauthor=H.+Kuwabaraauthor=A.+Hortiauthor=A.+Kumarauthor=J.+Brasicauthor=W.+Yeauthor=M.+Alexanderauthor=V.+Raymontauthor=J.+Galeckiauthor=M.+Charlotteauthor=N.+Cascella&title=PET+Imaging+of+cannabinoid+CB1+type+receptors+in+healthy+humans+and+patients+with+schizophrenia+using+%5B11C%5DOMAR&doi=10.1016%2Fj.neuroimage.2008.04.225"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2008.04.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2008.04.225%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DHorti%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DBrasic%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DAlexander%26aufirst%3DM.%26aulast%3DRaymont%26aufirst%3DV.%26aulast%3DGalecki%26aufirst%3DJ.%26aulast%3DCharlotte%26aufirst%3DM.%26aulast%3DCascella%26aufirst%3DN.%26atitle%3DPET%2520Imaging%2520of%2520cannabinoid%2520CB1%2520type%2520receptors%2520in%2520healthy%2520humans%2520and%2520patients%2520with%2520schizophrenia%2520using%2520%255B11C%255DOMAR%26jtitle%3DNeuroImage%26date%3D2008%26volume%3D41%26spage%3DT51%26doi%3D10.1016%2Fj.neuroimage.2008.04.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guevara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grachev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascella, N.</span></span> <span> </span><span class="NLM_article-title">Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [<sup>11</sup>C]OMAR</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1513</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2010.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2010.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20406692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVGnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=1505-1513&author=D.+F.+Wongauthor=H.+Kuwabaraauthor=A.+G.+Hortiauthor=V.+Raymontauthor=J.+Brasicauthor=M.+Guevaraauthor=W.+Yeauthor=R.+F.+Dannalsauthor=H.+T.+Ravertauthor=A.+Nandiauthor=A.+Rahmimauthor=J.+E.+Mingauthor=I.+Grachevauthor=C.+Royauthor=N.+Cascella&title=Quantification+of+cerebral+cannabinoid+receptors+subtype+1+%28CB1%29+in+healthy+subjects+and+schizophrenia+by+the+novel+PET+radioligand+%5B11C%5DOMAR&doi=10.1016%2Fj.neuroimage.2010.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR</span></div><div class="casAuthors">Wong, Dean F.; Kuwabara, Hiroto; Horti, Andrew G.; Raymont, Vanessa; Brasic, James; Guevara, Maria; Ye, Weiguo; Dannals, Robert F.; Ravert, Hayden T.; Nandi, Ayon; Rahmim, Arman; Ming, Jeffrey E.; Grachev, Igor; Roy, Christine; Cascella, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1505-1513</span>CODEN:
                <span class="NLM_cas:coden">NEIMEF</span>;
        ISSN:<span class="NLM_cas:issn">1053-8119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Several studies have examd. the link between the cannabinoid CB1 receptor and several neuropsychiatric illnesses, including schizophrenia.  As such, there is a need for in vivo imaging tracers so that the relationship between CB1 and schizophrenia (SZ) can be further studied.  In this paper, we present our first human studies in both healthy control patients and patients with schizophrenia using the novel PET tracer, [11C]OMAR (JHU75528), we have shown its utility as a tracer for imaging human CB1 receptors and to investigate normal aging and the differences in the cannabinoid system of healthy controls vs. patients with schizophrenia.  A total of ten healthy controls and nine patients with schizophrenia were included and studied with high specific activity [11C]OMAR.  The CB1 binding (expressed as the distribution vol.; VT) was highest in the globus pallidus and the cortex in both controls and patients with schizophrenia.  Controls showed a correlation with the known distribution of CB1 and decline of [11C]OMAR binding with age, most significantly in the globus pallidus.  Overall, we obsd. elevated mean binding in patients with schizophrenia across all regions studied, and this increase was statistically significant in the pons (p < 0.05), by the Students t-test.  When we ran a regression of the control subjects VT values with age and then compared the patient data to 95% prediction limits of the linear regression, three patients fell completely outside for the globus pallidus, and in all other regions there were at least 1-3 patients outside of the prediction intervals.  There was no statistically significant correlations between PET measures and the individual Brief Psychiatry Rating Score (BPRS) subscores (r = 0.49), but there was a significant correlation between VT and the ratio of the BPRS psychosis to withdrawal score in the frontal lobe (r = 0.60), and middle and posterior cingulate regions (r = 0.71 and r = 0.79 resp.).  In conclusion, we found that [11C]OMAR can image human CB1 receptors in normal aging and schizophrenia.  In addn., our initial data in subjects with schizophrenia seem to suggest an assocn. of elevated binding specific brain regions and symptoms of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOEH2Wkw4jW7Vg90H21EOLACvtfcHk0ligfkJxx1fD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVGnt70%253D&md5=6f7bf8d2410075a00b7f7f1969106823</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2010.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2010.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26aulast%3DRaymont%26aufirst%3DV.%26aulast%3DBrasic%26aufirst%3DJ.%26aulast%3DGuevara%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DNandi%26aufirst%3DA.%26aulast%3DRahmim%26aufirst%3DA.%26aulast%3DMing%26aufirst%3DJ.%2BE.%26aulast%3DGrachev%26aufirst%3DI.%26aulast%3DRoy%26aufirst%3DC.%26aulast%3DCascella%26aufirst%3DN.%26atitle%3DQuantification%2520of%2520cerebral%2520cannabinoid%2520receptors%2520subtype%25201%2520%2528CB1%2529%2520in%2520healthy%2520subjects%2520and%2520schizophrenia%2520by%2520the%2520novel%2520PET%2520radioligand%2520%255B11C%255DOMAR%26jtitle%3DNeuroImage%26date%3D2010%26volume%3D52%26spage%3D1505%26epage%3D1513%26doi%3D10.1016%2Fj.neuroimage.2010.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Briones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurnauer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planeta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skosnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaree, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, D. C.</span></span> <span> </span><span class="NLM_article-title">Reduced brain cannabinoid receptor availability in schizophrenia</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1005</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2015.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.biopsych.2015.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26432420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2hu7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=997-1005&author=M.+Ranganathanauthor=J.+Cortes-Brionesauthor=R.+Radhakrishnanauthor=H.+Thurnauerauthor=B.+Planetaauthor=P.+Skosnikauthor=H.+Gaoauthor=D.+Labareeauthor=A.+Neumeisterauthor=B.+Pittmanauthor=T.+Surtiauthor=Y.+Huangauthor=R.+E.+Carsonauthor=D.+C.+D%E2%80%99Souza&title=Reduced+brain+cannabinoid+receptor+availability+in+schizophrenia&doi=10.1016%2Fj.biopsych.2015.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced Brain Cannabinoid Receptor Availability In Schizophrenia</span></div><div class="casAuthors">Ranganathan, Mohini; Cortes-Briones, Jose; Radhakrishnan, Rajiv; Thurnauer, Halle; Planeta, Beata; Skosnik, Patrick; Gao, Hong; Labaree, David; Neumeister, Alexander; Pittman, Brian; Surti, Toral; Huang, Yiyun; Carson, Richard E.; D'Souza, Deepak Cyril</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">997-1005</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BACKGROUND: Several lines of evidence suggest the presence of abnormalities in the endocannabinoid (eCB) system in schizophrenia (SCZ).  However, there are limited in vivo measures of the eCB system in SCZ.  METHODS: Twenty five male SCZ subjects (SCZs) (18 antipsychotic treated and 7 antipsychotic free) were compared with 18 age-matched male healthy control subjects (HCs).  Subjects underwent one positron emission tomog. scan each with the cannabinoid receptor-1 (CB1R) selective radiotracer [11C]OMAR on the high resoln. research tomog. scanner.  Regional vol. of distribution (VT) values were detd. using kinetic modeling of positron emission tomog. data as a measure of CB1R availability.  Group differences in mean composite [11C]OMAR VT values were compared between SCZs and HCs.  Exploratory comparisons of CB1R availability within 15 brain regions were also conducted.  All analyses were covaried for age and body mass index.  RESULTS: SCZs showed significantly (p = .02) lower composite [11C]OMAR VT relative to HCs (∼12% difference, effect size d = .73). [11C]OMAR VT was significantly (all ps < .05) lower in SCZs in the amygdala, caudate, posterior cingulate cortex, hippocampus, hypothalamus, and insula.  Composite [11]OMAR VT was HCs > antipsychotic treated SZCs > antipsychotic free SZCs.  Furthermore, composite [11C]OMAR VT was greater in HCs than SCZ smokers (n = 11) and SCZ nonsmokers (n = 14).  CONCLUSIONS: CB1R availability is lower in male SCZ subjects compared with HCs.  Furthermore, antipsychotics and tobacco use may increase CB1R availability in this population.  The findings of the study provide further evidence supporting the hypothesis that alterations in the eCB system might contribute to the pathophysiol. of SCZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBZyqsE12WArVg90H21EOLACvtfcHk0ligfkJxx1fD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2hu7vE&md5=820e1afd3acd95bac1b0470a061e26bd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2015.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2015.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DCortes-Briones%26aufirst%3DJ.%26aulast%3DRadhakrishnan%26aufirst%3DR.%26aulast%3DThurnauer%26aufirst%3DH.%26aulast%3DPlaneta%26aufirst%3DB.%26aulast%3DSkosnik%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DLabaree%26aufirst%3DD.%26aulast%3DNeumeister%26aufirst%3DA.%26aulast%3DPittman%26aufirst%3DB.%26aulast%3DSurti%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26atitle%3DReduced%2520brain%2520cannabinoid%2520receptor%2520availability%2520in%2520schizophrenia%26jtitle%3DBiol.%2520Psychiatry%26date%3D2016%26volume%3D79%26spage%3D997%26epage%3D1005%26doi%3D10.1016%2Fj.biopsych.2015.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hungund, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szakall, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavarajappa, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadasz, C.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2003.01576.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1046%2Fj.1471-4159.2003.01576.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12562514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1amsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2003&pages=698-704&author=B.+L.+Hungundauthor=I.+Szakallauthor=A.+Adamauthor=B.+S.+Basavarajappaauthor=C.+Vadasz&title=Cannabinoid+CB1+receptor+knockout+mice+exhibit+markedly+reduced+voluntary+alcohol+consumption+and+lack+alcohol-induced+dopamine+release+in+the+nucleus+accumbens&doi=10.1046%2Fj.1471-4159.2003.01576.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens</span></div><div class="casAuthors">Hungund, Basalingappa L.; Szakall, Istvan; Adam, Agota; Basavarajappa, Balapal S.; Vadasz, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">698-704</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The mechanisms underlying predisposition to alc. abuse and alcoholism are poorly understood.  In this study, we evaluated the role of cannabinoid (CB1) receptors in (i) voluntary alc. consumption, and (ii) acute alc.-induced dopamine (DA) release in the nucleus accumbens, using mice that lack the CB1 receptor gene (CB1-/-).  CB1-/- mice exhibited dramatically reduced voluntary alc. consumption, and completely lacked alc.-induced DA release in the nucleus accumbens, as compared to wild-type mice.  The gender difference, with female mice consuming significantly more alc. than wild-type male mice, was obsd. in wild-type mice, whereas this gender difference was nonexistent in CB1 mutant male and female mice.  There was also a significant gender difference, with the wild-type, heterozygous, and mutant females consuming significantly more liq. and food than wild-type, heterozygous and mutant males.  However, the total vol. of fluid consumption and food intake did not differ between wild-type, heterozygous, and mutant mice.  These results strongly suggest that the CB1 receptor system plays an important role in regulating the pos. reinforcing properties of alc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc8YMoO8pzH7Vg90H21EOLACvtfcHk0lgtzf7oDStk0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1amsbo%253D&md5=f33e9f29974662aafbc7460ecfc22980</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2003.01576.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2003.01576.x%26sid%3Dliteratum%253Aachs%26aulast%3DHungund%26aufirst%3DB.%2BL.%26aulast%3DSzakall%26aufirst%3DI.%26aulast%3DAdam%26aufirst%3DA.%26aulast%3DBasavarajappa%26aufirst%3DB.%2BS.%26aulast%3DVadasz%26aufirst%3DC.%26atitle%3DCannabinoid%2520CB1%2520receptor%2520knockout%2520mice%2520exhibit%2520markedly%2520reduced%2520voluntary%2520alcohol%2520consumption%2520and%2520lack%2520alcohol-induced%2520dopamine%2520release%2520in%2520the%2520nucleus%2520accumbens%26jtitle%3DJ.%2520Neurochem.%26date%3D2003%26volume%3D84%26spage%3D698%26epage%3D704%26doi%3D10.1046%2Fj.1471-4159.2003.01576.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basavarajappa, B. S.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid system and alcohol abuse disorders</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1162</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1007/978-3-030-21737-2_6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2F978-3-030-21737-2_6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31332736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVGrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1162&publication_year=2019&pages=89-127&author=B.+S.+Basavarajappa&title=Endocannabinoid+system+and+alcohol+abuse+disorders&doi=10.1007%2F978-3-030-21737-2_6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid System and Alcohol Abuse Disorders</span></div><div class="casAuthors">Basavarajappa, Balapal S.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1162</span>
        (<span class="NLM_cas:issue">Recent Advances in Cannabinoid Physiology and Pathology</span>),
    <span class="NLM_cas:pages">89-127</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Δ9 -tetrahydrocannabinol (Δ9 -THC), the primary active component in Cannabis sativa prepns. such as hashish and marijuana, signals by binding to cell surface receptors.  Two types of receptors have been cloned and characterized as cannabinoid (CB) receptors.  CB1 receptors (CB1R) are ubiquitously present in the central nervous system (CNS) and are present in both inhibitory interneurons and excitatory neurons at the presynaptic terminal.  CB2 receptors (CB2R) are demonstrated in microglial cells, astrocytes, and several neuron subpopulations and are present in both pre- and postsynaptic terminals.  The majority of studies on these receptors have been conducted in the past two and half decades after the identification of the mol. constituents of the endocannabinoid (eCB) system that started with the characterization of CB1R.  Subsequently, the seminal discovery was made, which suggested that alc. (ethanol) alters the eCB system, thus establishing the contribution of the eCB system in the motivation to consume ethanol.  Several preclin. studies have provided evidence that CB1R significantly contributes to the motivational and reinforcing properties of ethanol and that the chronic consumption of ethanol alters eCB transmitters and CB1R expression in the brain nuclei assocd. with addiction pathways.  Addnl., recent seminal studies have further established the role of the eCB system in the development of ethanol-induced developmental disorders, such as fetal alc. spectrum disorders (FASD).  These results are augmented by in vitro and ex vivo studies, showing that acute and chronic treatment with ethanol produces physiol. relevant alterations in the function of the eCB system during development and in the adult stage.  This chapter provides a current and comprehensive review of the literature concerning the role of the eCB system in alc. abuse disorders (AUD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1JfwQRXQR2LVg90H21EOLACvtfcHk0lgtzf7oDStk0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVGrsLo%253D&md5=9166c5636e0dfaa614a9ae07e27348a2</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-21737-2_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-030-21737-2_6%26sid%3Dliteratum%253Aachs%26aulast%3DBasavarajappa%26aufirst%3DB.%2BS.%26atitle%3DEndocannabinoid%2520system%2520and%2520alcohol%2520abuse%2520disorders%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2019%26volume%3D1162%26spage%3D89%26epage%3D127%26doi%3D10.1007%2F978-3-030-21737-2_6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Femenia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Gutierrez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzanares, J.</span></span> <span> </span><span class="NLM_article-title">CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats</span>. <i>Alcohol.: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1111/j.1530-0277.2009.01074.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1530-0277.2009.01074.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19860799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVyrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=131-141&author=T.+Femeniaauthor=M.+S.+Garcia-Gutierrezauthor=J.+Manzanares&title=CB1+receptor+blockade+decreases+ethanol+intake+and+associated+neurochemical+changes+in+fawn-hooded+rats&doi=10.1111%2Fj.1530-0277.2009.01074.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats</span></div><div class="casAuthors">Femenia, Teresa; Garcia-Gutierrez, Maria S.; Manzanares, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical & Experimental Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-141</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: This study was undertaken to identify the neurochem. changes underlying the attenuation of voluntary ethanol intake induced by the cannabinoid CB1 receptor antagonist AM251 in fawn-hooded rats.  Methods: Rats were exposed to the 2-bottle-choice paradigm (ethanol 10% vol./vol. or water) for 15 days.  After this period, rats received AM251 (3 to 6 mg/kg, i.p.) or vehicle.  Results: Voluntary ethanol intake decreased (30%) with the administration of incremental dosages of AM251 (3 mg/kg, 5 days and 6 mg/kg, 5 days) in rats with acquired high preferring ethanol consumption (> 3.5 g of ethanol/kg/d).  Ethanol intake significantly decreased proopiomelanocortin expression in the arcuate nucleus (38.31%) and μ-opioid-DAMGO-stimulated [35S]-GTPγ binding in the caudate-putamen (40%), nucleus accumbens core (AccC) (32.87%), and shell (AccS) (34.21%).  Moreover, ethanol intake increased tyrosine hydroxylase (TH) gene expression in the substantia nigra (24%) and ventral tegmental area (23%) and corticotrophin-releasing gene expression in the paraventricular hypothalamic nucleus (41.6%).  The redn. of ethanol intake induced by AM251 was assocd. with blockade or significant redn. of the changes produced by ethanol in the expression of these genes in key regions related to drug dependence.  Interestingly, treatment with AM251 reduced (20%) TH gene expression in rats drinking only water.  In this respect, the action of AM251 in reducing TH gene expression may not be specific.  Conclusion: Taken together, these results revealed that blockade of cannabinoid CB1 receptors (CB1r) decreased voluntary ethanol intake in ethanol-habituated rats by normalizing the neurochem. alterations induced by ethanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoePE2DgCm0jLVg90H21EOLACvtfcHk0lhWGkvjMB3aig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVyrtL0%253D&md5=e2a94f2d7702dccd914b1c2cce6b47ad</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2009.01074.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2009.01074.x%26sid%3Dliteratum%253Aachs%26aulast%3DFemenia%26aufirst%3DT.%26aulast%3DGarcia-Gutierrez%26aufirst%3DM.%2BS.%26aulast%3DManzanares%26aufirst%3DJ.%26atitle%3DCB1%2520receptor%2520blockade%2520decreases%2520ethanol%2520intake%2520and%2520associated%2520neurochemical%2520changes%2520in%2520fawn-hooded%2520rats%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2010%26volume%3D34%26spage%3D131%26epage%3D141%26doi%3D10.1111%2Fj.1530-0277.2009.01074.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normandin, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galatzer-Levy, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potenza, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span> <span> </span><span class="NLM_article-title">Positron emission tomography shows elevated cannabinoid CB 1 receptor binding in men with alcohol dependence</span>. <i>Alcohol.: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2104</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1111/j.1530-0277.2012.01815.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1530-0277.2012.01815.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22551199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=2104-2109&author=A.+Neumeisterauthor=M.+D.+Normandinauthor=J.+W.+Murroughauthor=S.+Henryauthor=C.+R.+Baileyauthor=D.+A.+Luckenbaughauthor=K.+Tuitauthor=M.-Q.+Zhengauthor=I.+R.+Galatzer-Levyauthor=R.+Sinhaauthor=R.+E.+Carsonauthor=M.+N.+Potenzaauthor=Y.+Huang&title=Positron+emission+tomography+shows+elevated+cannabinoid+CB+1+receptor+binding+in+men+with+alcohol+dependence&doi=10.1111%2Fj.1530-0277.2012.01815.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence</span></div><div class="casAuthors">Neumeister, Alexander; Normandin, Marc D.; Murrough, James W.; Henry, Shannan; Bailey, Christopher R.; Luckenbaugh, David A.; Tuit, Keri; Zheng, Ming-Qiang; Galatzer-Levy, Isaac R.; Sinha, Rajita; Carson, Richard E.; Potenza, Marc N.; Huang, Yiyun</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical & Experimental Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2104-2109</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Several lines of evidence link cannabinoid (CB) type 1 (CB1) receptor-mediated endogenous CB (eCB) signaling to the etiol. of alc. dependence (AD).  However, to date, only peripheral measures of eCB function have been collected in living humans with AD and no human in vivo data on the potentially crit. role of the brain CB1 receptor in AD have been published.  This is an important gap in the literature, because recent therapeutic developments suggest that these receptors could be targeted for the treatment for AD.  Methods: Medication-free participants were scanned during early abstinence 4 wk after their last drink.  Using positron emission tomog. (PET) with a high-resoln. research tomograph and the CB1 receptor selective radiotracer [11C]OMAR, we detd. [11C]OMAR vol. of distribution (VT) values, a measure of CB1 receptor d., in a priori selected brain regions in men with AD (n = 8, age 37.4 ± 7.9 years; 5 smokers) and healthy control (HC) men (n = 8, age 32.5 ± 6.9 years; all nonsmokers).  PET images reconstructed using the MOLAR algorithm with hardware motion correction were rigidly aligned to the subject-specific magnetic resonance (MR) image, which in turn was warped to an MR template.  Time-activity curves (TACs) were extd. from the dynamic PET data using a priori selected regions of interest delineated in the MR template space.  Results: In AD relative to HC, [11C]OMAR VT values were elevated by approx. 20% (p = 0.023) in a circuit, including the amygdala, hippocampus, putamen, insula, anterior and posterior cingulate cortices, and orbitofrontal cortex.  Age, body mass index, or smoking status did not influence the outcome.  Conclusions: These findings agree with preclin. evidence and provide the first, albeit still preliminary in vivo evidence suggesting a role for brain CB1 receptors in AD.  The current study design does not answer the important question of whether elevated CB1 receptors are a preexisting vulnerability factor for AD or whether elevations develop as a consequence of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIlr91KkxuGrVg90H21EOLACvtfcHk0lh2OMcQk82qtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCjtbk%253D&md5=dd5ac94acc4060ffea6578362adf96d2</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2012.01815.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2012.01815.x%26sid%3Dliteratum%253Aachs%26aulast%3DNeumeister%26aufirst%3DA.%26aulast%3DNormandin%26aufirst%3DM.%2BD.%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DHenry%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DC.%2BR.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DTuit%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DM.-Q.%26aulast%3DGalatzer-Levy%26aufirst%3DI.%2BR.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DPotenza%26aufirst%3DM.%2BN.%26aulast%3DHuang%26aufirst%3DY.%26atitle%3DPositron%2520emission%2520tomography%2520shows%2520elevated%2520cannabinoid%2520CB%25201%2520receptor%2520binding%2520in%2520men%2520with%2520alcohol%2520dependence%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D2104%26epage%3D2109%26doi%3D10.1111%2Fj.1530-0277.2012.01815.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valenta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T. H.</span></span> <span> </span><span class="NLM_article-title">Feasibility evaluation of myocardial cannabinoid type 1 receptor imaging in obesity: a translational approach</span>. <i>JACC Cardiovasc. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1016/j.jcmg.2017.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.jcmg.2017.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29413441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvos1aqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=320-332&author=I.+Valentaauthor=Z.+V.+Vargaauthor=H.+Valentineauthor=R.+Cinarauthor=A.+Hortiauthor=W.+B.+Mathewsauthor=R.+F.+Dannalsauthor=K.+Steeleauthor=G.+Kunosauthor=R.+L.+Wahlauthor=M.+G.+Pomperauthor=D.+F.+Wongauthor=P.+Pacherauthor=T.+H.+Schindler&title=Feasibility+evaluation+of+myocardial+cannabinoid+type+1+receptor+imaging+in+obesity%3A+a+translational+approach&doi=10.1016%2Fj.jcmg.2017.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach</span></div><div class="casAuthors">Valenta Ines; Valentine Heather; Horti Andrew; Mathews William B; Dannals Robert F; Pomper Martin G; Wong Dean F; Varga Zoltan V; Cinar Resat; Kunos George; Steele Kimberley; Wahl Richard L; Pacher Pal; Schindler Thomas H</div><div class="citationInfo"><span class="NLM_cas:title">JACC. Cardiovascular imaging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2 Pt 2</span>),
    <span class="NLM_cas:pages">320-332</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The aim of this study was to evaluate the feasibility of targeted imaging of myocardial cannabinoid type 1 receptor (CB1-R) and its potential up-regulation in obese mice with translation to humans using [(11)C]-OMAR and positron emission tomography (PET)/computed tomography (CT).  BACKGROUND:  Activation of myocardial CB1-R by endocannabinoids has been implicated in cardiac dysfunction in diabetic mice.  Obesity may lead to an up-regulation of myocardial CB1-R, potentially providing a mechanistic link between obesity and the initiation and/or progression of cardiomyopathy.  METHODS:  Binding specificity of [(11)C]-OMAR to CB1-R was investigated by blocking studies with rimonabant in mice.  The heart was harvested from each mouse, and its radioactivity was determined by γ-counter.  Furthermore, [(11)C]-OMAR dynamic micro-PET/CT was carried out in obese and normal-weight mice.  Ex vivo validation was performed by droplet digital polymerase chain reaction (absolute quantification) and RNAscope Technology (an in situ ribonucleic acid analysis platform).  Subsequently, myocardial CB1-R expression was probed noninvasively with intravenous injection of CB1-R ligand [(11)C]-OMAR and PET/CT in humans with advanced obesity and normal-weight human control subjects, respectively.  RESULTS:  Rimonabant significantly blocked OMAR uptake in the heart muscle compared with vehicle, signifying specific binding of OMAR to the CB1-R in the myocardium.  The myocardial OMAR retention quantified by micro-PET/CT in mice was significantly higher in obese compared with normal-weight mice.  Absolute quantification of CB1-R gene expression with droplet digital polymerase chain reaction and in situ hybridization confirmed CB1-R up-regulation in all major myocardial cell types (e.g., cardiomyocytes, endothelium, vascular smooth muscle cells, and fibroblasts) of obese mice.  Obese mice also had elevated myocardial levels of endocannabinoids anandamide and 2-arachidonoylglycerol compared with lean mice.  Translation to humans revealed higher myocardial OMAR retention in advanced obesity compared with normal-weight subjects.  CONCLUSIONS:  Noninvasive imaging of cardiac CB1-R expression in obesity is feasible applying [(11)C]-OMAR and PET/CT.  These results may provide a rationale for further clinical testing of CB1-R-targeted molecular imaging in cardiometabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjuViowtDkaX6HPRus0rAafW6udTcc2ebnrjoROtGVDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvos1aqtw%253D%253D&md5=0613321cb418452cbb16c8bb38e15207</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmg.2017.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmg.2017.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DValenta%26aufirst%3DI.%26aulast%3DVarga%26aufirst%3DZ.%2BV.%26aulast%3DValentine%26aufirst%3DH.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DHorti%26aufirst%3DA.%26aulast%3DMathews%26aufirst%3DW.%2BB.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DSteele%26aufirst%3DK.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DWahl%26aufirst%3DR.%2BL.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%2BH.%26atitle%3DFeasibility%2520evaluation%2520of%2520myocardial%2520cannabinoid%2520type%25201%2520receptor%2520imaging%2520in%2520obesity%253A%2520a%2520translational%2520approach%26jtitle%3DJACC%2520Cardiovasc.%2520Imaging%26date%3D2018%26volume%3D11%26spage%3D320%26epage%3D332%26doi%3D10.1016%2Fj.jcmg.2017.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valenta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilsizian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T. H.</span></span> <span> </span><span class="NLM_article-title">Novel myocardial PET/CT receptor imaging and potential therapeutic targets</span>. <i>Curr. Cardiol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">55</span>, <span class="refDoi"> DOI: 10.1007/s11886-019-1148-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs11886-019-1148-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31104205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ntlSisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=55&author=I.+Valentaauthor=P.+Pacherauthor=V.+Dilsizianauthor=T.+H.+Schindler&title=Novel+myocardial+PET%2FCT+receptor+imaging+and+potential+therapeutic+targets&doi=10.1007%2Fs11886-019-1148-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Myocardial PET/CT Receptor Imaging and Potential Therapeutic Targets</span></div><div class="casAuthors">Valenta Ines; Schindler Thomas H; Pacher Pal; Dilsizian Vasken</div><div class="citationInfo"><span class="NLM_cas:title">Current cardiology reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF THE REVIEW:  Activation of myocardial cannabinoid type 1 receptors (CB1-R) and/or angiotensin II type 1 receptors (AT1-R) likely plays an important mechanistic role in determining the left-ventricular remodeling process in systolic heart failure.  We provide an overview on novel radiotracer probes and positron emission tomography (PET)/computed tomography (CT) imaging to noninvasively probe the expression of myocardial CB1-R and/or AT1-R.  RECENT FINDINGS:  Recent translational investigations have demonstrated the feasibility of (11)C-OMAR or (11)C-KR31173 and PET/CT to image and quantify myocardial CB1-R and/or AT1-R expression, respectively.  There is an increasing understanding of the mechanisms of activated myocardial CB1-R and/or AT1-R to influence the left-ventricular remodeling process in systolic heart failure in different disease entities.  The review summarizes contributions of PET to image myocardial CB1-R and AT1-R expression that may have the potential to serve as a target to tailor preventive medical care in the individual patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2g3e0fpt8hb7NkxioyDXTfW6udTcc2ebnrjoROtGVDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ntlSisw%253D%253D&md5=577fd6635ffba5422de3845412c3ffd5</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2Fs11886-019-1148-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11886-019-1148-2%26sid%3Dliteratum%253Aachs%26aulast%3DValenta%26aufirst%3DI.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DDilsizian%26aufirst%3DV.%26aulast%3DSchindler%26aufirst%3DT.%2BH.%26atitle%3DNovel%2520myocardial%2520PET%252FCT%2520receptor%2520imaging%2520and%2520potential%2520therapeutic%2520targets%26jtitle%3DCurr.%2520Cardiol.%2520Rep.%26date%3D2019%26volume%3D21%26spage%3D55%26doi%3D10.1007%2Fs11886-019-1148-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fish, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajjar, R. J.</span></span> <span> </span><span class="NLM_article-title">Myocardial cannabinoid receptor imaging in obesity</span>. <i>JACC Cardiovasc. imaging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1016/j.jcmg.2017.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.jcmg.2017.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29413442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvos1aqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=333-335&author=K.+M.+Fishauthor=R.+J.+Hajjar&title=Myocardial+cannabinoid+receptor+imaging+in+obesity&doi=10.1016%2Fj.jcmg.2017.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Myocardial Cannabinoid Receptor Imaging in Obesity</span></div><div class="casAuthors">Fish Kenneth M; Hajjar Roger J</div><div class="citationInfo"><span class="NLM_cas:title">JACC. Cardiovascular imaging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2 Pt 2</span>),
    <span class="NLM_cas:pages">333-335</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjuViowtDkaQwxfk_AGB-EfW6udTcc2eYkX63rvpx8Ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvos1aqtA%253D%253D&md5=9db693742957a67c8ed8099e3370938e</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmg.2017.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmg.2017.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DFish%26aufirst%3DK.%2BM.%26aulast%3DHajjar%26aufirst%3DR.%2BJ.%26atitle%3DMyocardial%2520cannabinoid%2520receptor%2520imaging%2520in%2520obesity%26jtitle%3DJACC%2520Cardiovasc.%2520imaging%26date%3D2018%26volume%3D11%26spage%3D333%26epage%3D335%26doi%3D10.1016%2Fj.jcmg.2017.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. C.</span></span> <span> </span><span class="NLM_article-title">The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/S1056-8719(02)00166-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS1056-8719%2802%2900166-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12481843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslKhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=61-71&author=H.+C.+Cheng&title=The+power+issue%3A+determination+of+KB+or+Ki+from+IC50.+A+closer+look+at+the+Cheng-Prusoff+equation%2C+the+Schild+plot+and+related+power+equations&doi=10.1016%2FS1056-8719%2802%2900166-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations</span></div><div class="casAuthors">Cheng, Hsien C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-71</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Introduction: The Cheng-Prusoff equation (1973) is often applied to the detn. of equil. dissocn. const. (KB) of a competitive receptor antagonist when the IC50 value is available.  The purpose of this study is to illustrate that the slope function (K) of an agonist concn.-response curve is crit. to the detn. of KB values.  Methods: The article describes new equations, which incorporate the slope function, consequently yielding more accurate estn. of KB values for antagonists, and tests them using simulated data.  The value of KB was calcd. according to the following new power equation: KB=IC50/(1+AK/KP)=IC50/[1+(A/EC50)K], where IC50 is the concn. of the antagonist producing 50% inhibition, A is the concn. of the agonist against which the IC50 is being detd. and KP is the apparent equil. dissocn. const. of the agonist.  Results: The new equation is the same as the Cheng-Prusoff equation when the slope function K is exactly unity.  Application of the equation avoids errors inherent in the use of the Cheng-Prusoff equation when the slope function of the agonist concn.-response curve deviates from unity.  The new equation was applicable to slope functions less than, equal to or greater than unity.  All inhibition curves have a neg. slope function of 1, indicating that there is only one single receptor population even though different slope functions of agonist concn.-response curves are involved.  The importance of the power function in the Schild plot is illustrated by using the equation: log (xK-1)=log B-log KB, where x is the concn. ratio and B is the concn. of the antagonist.  Discussion: This investigation illustrates the application of six power equations for accurate estn. of KB values covering situations with different slope functions of the agonist concn.-response curves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWVFwIc5R1grVg90H21EOLACvtfcHk0ljRgw_xTXnneg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslKhtr8%253D&md5=ac48f20214a292284c03533088118d7f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2802%2900166-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252802%252900166-1%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%2BC.%26atitle%3DThe%2520power%2520issue%253A%2520determination%2520of%2520KB%2520or%2520Ki%2520from%2520IC50.%2520A%2520closer%2520look%2520at%2520the%2520Cheng-Prusoff%2520equation%252C%2520the%2520Schild%2520plot%2520and%2520related%2520power%2520equations%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2001%26volume%3D46%26spage%3D61%26epage%3D71%26doi%3D10.1016%2FS1056-8719%2802%2900166-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesterfield, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladding, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">The PET radioligand [<sup>11</sup>C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1301402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fsj.npp.1301402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17392732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=259-269&author=F.+Yasunoauthor=A.+K.+Brownauthor=S.+S.+Zoghbiauthor=J.+H.+Krushinskiauthor=E.+Chernetauthor=J.+Tauscherauthor=J.+M.+Schausauthor=L.+A.+Phebusauthor=A.+K.+Chesterfieldauthor=C.+C.+Felderauthor=R.+L.+Gladdingauthor=J.+Hongauthor=C.+Halldinauthor=V.+W.+Pikeauthor=R.+B.+Innis&title=The+PET+radioligand+%5B11C%5DMePPEP+binds+reversibly+and+with+high+specific+signal+to+cannabinoid+CB1+receptors+in+nonhuman+primate+brain&doi=10.1038%2Fsj.npp.1301402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain</span></div><div class="casAuthors">Yasuno, Fumihiko; Brown, Amira K.; Zoghbi, Sami S.; Krushinski, Joseph H.; Chernet, Eyassu; Tauscher, Johannes; Schaus, John M.; Phebus, Lee A.; Chesterfield, Amy K.; Felder, Christian C.; Gladding, Robert L.; Hong, Jinsoo; Halldin, Christer; Pike, Victor W.; Innis, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-269</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The cannabinoid CB1 receptor is one of the most abundant G protein-coupled receptors in the brain and is a promising target of therapeutic drug development.  Success of drug development for neuropsychiatric indications is significantly enhanced with the ability to directly measure spatial and temporal binding of compds. to receptors in central compartments.  We assessed the utility of a new positron emission tomog. (PET) radioligand to image CB1 receptors in monkey brain. [11C]MePPEP ((3R,5R)-5-(3-methoxy-phenyl)-3-((R)-1-phenyl-ethylamino)-1-(4-trifluoromethyl-phenyl)-pyrrolidin-2-one) has high CB1 affinity (Kb = 0.574 ± 0.207 nM) but also moderately high lipophilicity (measured LogD7.4 = 4.8).  After i.v. injection of [11C]MePPEP, brain activity reached high levels of almost 600% standardized uptake value (SUV) within 10-20 min.  The regional uptake was consistent with the distribution of CB1 receptors, with high radioactivity in striatum and cerebellum and low in thalamus and pons.  Injection of pharmacol. doses of CB1-selective agents confirmed that the tracer doses of [11C]MePPEP reversibly labeled CB1 receptors.  Preblockade or displacement with two CB1 selective agents (ISPB; (4-(3-cyclopentyl-indole-1-sulfonyl)-N-(tetrahydro-pyran-4-ylmethyl)-benzamide) and rimonabant) showed that the majority (>89%) of brain uptake in regions with high receptor densities was specific and reversibly bound to CB1 receptors in the high binding regions. [11C]MePPEP was rapidly removed from arterial plasma.  Regional brain uptake could be quantified as distribution vol. relative to the concn. of parent radiotracer in plasma.  The P-glycoprotein (P-gp) inhibitor DCPQ ((R)-4-[(1a,6,10b)-1,1-dichloro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-[(5-quinolinyloxy)methyl]-1-piperazineethanol) did not significantly increase brain uptake of [11C]MePPEP, suggesting it is not a substrate for this efflux transporter at the blood-brain barrier. [11C]MePPEP is a radioligand with high brain uptake, high specific signal to CB1 receptors, and adequately fast washout from brain that allows quantification with 11C (half-life=20 min).  These promising results in monkey justify studying this radioligand in human subjects.  Neuropsychopharmacol. (2008) 33, 259-269; doi:10.1038/sj.npp.1301402; published online 28 March 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7SzUHk8qx9rVg90H21EOLACvtfcHk0ljRgw_xTXnneg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSktrrI&md5=bbad5e8f87edbec604c0e5e38ef91568</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301402%26sid%3Dliteratum%253Aachs%26aulast%3DYasuno%26aufirst%3DF.%26aulast%3DBrown%26aufirst%3DA.%2BK.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DChernet%26aufirst%3DE.%26aulast%3DTauscher%26aufirst%3DJ.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DPhebus%26aufirst%3DL.%2BA.%26aulast%3DChesterfield%26aufirst%3DA.%2BK.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DGladding%26aufirst%3DR.%2BL.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DThe%2520PET%2520radioligand%2520%255B11C%255DMePPEP%2520binds%2520reversibly%2520and%2520with%2520high%2520specific%2520signal%2520to%2520cannabinoid%2520CB1%2520receptors%2520in%2520nonhuman%2520primate%2520brain%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D259%26epage%3D269%26doi%3D10.1038%2Fsj.npp.1301402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesterfield, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5833</span>– <span class="NLM_lpage">5842</span>, <span class="refDoi"> DOI: 10.1021/jm800416m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800416m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVChsL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5833-5842&author=S.+R.+Donohueauthor=J.+H.+Krushinskiauthor=V.+W.+Pikeauthor=E.+Chernetauthor=L.+Phebusauthor=A.+K.+Chesterfieldauthor=C.+C.+Felderauthor=C.+Halldinauthor=J.+M.+Schaus&title=Synthesis%2C+ex+vivo+evaluation%2C+and+radiolabeling+of+potent+1%2C5-diphenylpyrrolidin-2-one+cannabinoid+subtype-1+receptor+ligands+as+candidates+for+in+vivo+imaging&doi=10.1021%2Fjm800416m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Ex Vivo Evaluation, and Radiolabeling of Potent 1,5-Diphenylpyrrolidin-2-one Cannabinoid Subtype-1 Receptor Ligands as Candidates for In Vivo Imaging</span></div><div class="casAuthors">Donohue, Sean R.; Krushinski, Joseph H.; Pike, Victor W.; Chernet, Eyassu; Phebus, Lee; Chesterfield, Amy K.; Felder, Christian C.; Halldin, Christer; Schaus, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5833-5842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have reported that [methyl-11C] (3R,5R)-5-(3-methoxyphenyl)-3-[(R)-1-phenylethylamino]-1-(4-trifluoromethylphenyl)pyrrolidin-2-one (I, R = OC11H3) binds with high selectivity to cannabinoid type-1 (CB1) receptors in monkey brain in vivo.  We now describe the synthesis of I (R = OCH3) and four analogs, namely, the 4-fluorophenyl, 3-fluoromethoxy, 3-fluoromethoxy-d2, and 3-fluoroethoxy analogs, and report their activity in an ex vivo model designed to identify compds. suitable for use as positron emission tomog. (PET) ligands.  These ligands exhibited high, selective potency at CB1 receptors in vitro (Kb < 1 nM).  Each ligand (30 μg/kg, iv) was injected into rats under baseline and pretreatment conditions and quantified at later times in frontal cortex ex vivo with liq. chromatog.-mass spectrometry (LC-MS) detection.  Maximal ligand uptakes were high (22.6-48.0 ng/g).  Under pretreatment, maximal brain uptakes were greatly reduced (6.5-17.3 ng/g).  Since each ligand readily entered brain and bound with high selectivity to CB1 receptors, we then established and here describe methods for producing I (R = OC11H3) as well as other [11C]- and [18F]-labeled ligands in adequate activities for evaluation as candidate PET radioligands in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBPuzDtuODnLVg90H21EOLACvtfcHk0lgqVShrnLhnQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVChsL3E&md5=f25e5b4f2a9bf02aa5967f3a1b852510</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm800416m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800416m%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DChernet%26aufirst%3DE.%26aulast%3DPhebus%26aufirst%3DL.%26aulast%3DChesterfield%26aufirst%3DA.%2BK.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26atitle%3DSynthesis%252C%2520ex%2520vivo%2520evaluation%252C%2520and%2520radiolabeling%2520of%2520potent%25201%252C5-diphenylpyrrolidin-2-one%2520cannabinoid%2520subtype-1%2520receptor%2520ligands%2520as%2520candidates%2520for%2520in%2520vivo%2520imaging%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5833%26epage%3D5842%26doi%3D10.1021%2Fjm800416m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladding, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using 18F-labeled inverse agonist radioligands</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.2967/jnumed.109.067074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.109.067074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20008988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=112-120&author=G.+E.+Terryauthor=J.+Hirvonenauthor=J.+S.+Liowauthor=S.+S.+Zoghbiauthor=R.+Gladdingauthor=J.+T.+Tauscherauthor=J.+M.+Schausauthor=L.+Phebusauthor=C.+C.+Felderauthor=C.+L.+Morseauthor=S.+R.+Donohueauthor=V.+W.+Pikeauthor=C.+Halldinauthor=R.+B.+Innis&title=Imaging+and+quantitation+of+cannabinoid+CB1+receptors+in+human+and+monkey+brains+using+18F-labeled+inverse+agonist+radioligands&doi=10.2967%2Fjnumed.109.067074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using 18F-labeled inverse agonist radioligands</span></div><div class="casAuthors">Terry, Garth E.; Hirvonen, Jussi; Liow, Jeih-San; Zoghbi, Sami S.; Gladding, Robert; Tauscher, Johannes T.; Schaus, John M.; Phebus, Lee; Felder, Christian C.; Morse, Cheryl L.; Donohue, Sean R.; Pike, Victor W.; Halldin, Christer; Innis, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-120</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">We recently demonstrated that 11C-MePPEP, a PET ligand for CB1 receptors, has such high uptake in the human brain that it can be imaged for 210 min and that receptor d. can be quantified as distribution vol. (VT) using the gold std. of compartmental modeling.  However, 11C-MePPEP had relatively poor retest and intersubject variabilities, which were likely caused by errors in the measurements of radioligand in plasma at low concns. by 120 min.  We sought to find an analog of 11C-MePPEP that would provide more accurate plasma measurements.  We evaluated several promising analogs in the monkey brain and chose the 18F-di-deutero fluoromethoxy analog (18F-FMPEP-d2) to evaluate further in the human brain.  Methods: 11C-FMePPEP, 18F-FEPEP, 18F-FMPEP, and 18F-FMPEP-d2 were studied in 5 monkeys with 10 PET scans.  We calcd. VT using compartmental modeling with serial measurements of unchanged parent radioligand in arterial plasma and radioactivity in the brain.  Nonspecific binding was detd. by administering a receptor-satg. dose of rimonabant, an inverse agonist at the CB1 receptor.  Nine healthy human subjects participated in 17 PET scans using 18F-FMPEP-d2, with 8 subjects having 2 PET scans to assess retest variability.  To identify sources of error, we compared intersubject and retest variability of brain uptake, arterial plasma measurements, and VT.  Results: 18F-FMPEP-d2 had high uptake in the monkey brain, with greater than 80% specific binding, and yielded less radioactivity uptake in bone than did 18F-FMPEP.  High brain uptake with 18F-FMPEP-d2 was also obsd. in humans, in whom VT was well identified within approx. 60 min.  Retest variability of plasma measurements was good (16%); consequently, VT had a good retest variability (14%), intersubject variability (26%), and intraclass correlation coeff. (0.89).  VT increased after 120 min, suggesting an accumulation of radiometabolites in the brain.  Radioactivity accumulated in the skull throughout the entire scan but was thought to be an insignificant source of data contamination.  Conclusion: Studies in monkeys facilitated our development and selection of 18F-FMPEP-d2, com- pared with 18F-FMPEP, as a radioligand demonstrating high brain uptake, high percentage of specific binding, and reduced uptake in bone.  Retest anal. in human subjects showed that 18F-FMPEP-d2 has greater precision and accuracy than 11C-MePPEP, allowing smaller sample sizes to detect a significant difference between groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEIsZPKGaLO7Vg90H21EOLACvtfcHk0lgqVShrnLhnQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCrsbs%253D&md5=148e9549eef03cd8e45f739656b13414</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.109.067074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.109.067074%26sid%3Dliteratum%253Aachs%26aulast%3DTerry%26aufirst%3DG.%2BE.%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DLiow%26aufirst%3DJ.%2BS.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DGladding%26aufirst%3DR.%26aulast%3DTauscher%26aufirst%3DJ.%2BT.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DPhebus%26aufirst%3DL.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DMorse%26aufirst%3DC.%2BL.%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DImaging%2520and%2520quantitation%2520of%2520cannabinoid%2520CB1%2520receptors%2520in%2520human%2520and%2520monkey%2520brains%2520using%252018F-labeled%2520inverse%2520agonist%2520radioligands%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2010%26volume%3D51%26spage%3D112%26epage%3D120%26doi%3D10.2967%2Fjnumed.109.067074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farris, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2009.06.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2009.06.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19573609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD1MrntVylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=362-370&author=G.+E.+Terryauthor=J.+S.+Liowauthor=S.+S.+Zoghbiauthor=J.+Hirvonenauthor=A.+G.+Farrisauthor=A.+Lernerauthor=J.+T.+Tauscherauthor=J.+M.+Schausauthor=L.+Phebusauthor=C.+C.+Felderauthor=C.+L.+Morseauthor=J.+S.+Hongauthor=V.+W.+Pikeauthor=C.+Halldinauthor=R.+B.+Innis&title=Quantitation+of+cannabinoid+CB1+receptors+in+healthy+human+brain+using+positron+emission+tomography+and+an+inverse+agonist+radioligand&doi=10.1016%2Fj.neuroimage.2009.06.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand</span></div><div class="casAuthors">Terry Garth E; Liow Jeih-San; Zoghbi Sami S; Hirvonen Jussi; Farris Amanda G; Lerner Alicja; Tauscher Johannes T; Schaus John M; Phebus Lee; Felder Christian C; Morse Cheryl L; Hong Jinsoo S; Pike Victor W; Halldin Christer; Innis Robert B</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">362-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">[11C]MePPEP is a high affinity, CB1 receptor-selective, inverse agonist that has been studied in rodents and monkeys.  We examined the ability of [11C]MePPEP to quantify CB1 receptors in human brain as distribution volume calculated with the "gold standard" method of compartmental modeling and compared results with the simple measure of brain uptake.  A total of 17 healthy subjects participated in 26 positron emission tomography (PET) scans, with 8 having two PET scans to assess retest variability.  After injection of [11C]MePPEP, brain uptake of radioactivity was high (e.g., 3.6 SUV in putamen at approximately 60 min) and washed out very slowly.  A two-tissue compartment model yielded values of distribution volume (which is proportional to receptor density) that were both well identified (SE 5%) and stable between 60 and 210 min.  The simple measure of brain uptake (average concentration of radioactivity between 40 and 80 min) had good retest variability ( approximately 8%) and moderate intersubject variability (16%, coefficient of variation).  In contrast, distribution volume had two-fold greater retest variability ( approximately 15%) and, thus, less precision.  In addition, distribution volume had three-fold greater intersubject variability ( approximately 52%).  The decreased precision of distribution volume compared to brain uptake was likely due to the slow washout of radioactivity from brain and to noise in measurements of the low concentrations of [11C]MePPEP in plasma.  These results suggest that brain uptake can be used for within subject studies (e.g., to measure receptor occupancy by medications) but that distribution volume remains the gold standard for accurate measurements between groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh0yJMiTh8SMuCWE5mhx1RfW6udTcc2eYX-hGGmkauqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrntVylsQ%253D%253D&md5=2270ceaed417a38df15bdff660ca95bb</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2009.06.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2009.06.059%26sid%3Dliteratum%253Aachs%26aulast%3DTerry%26aufirst%3DG.%2BE.%26aulast%3DLiow%26aufirst%3DJ.%2BS.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DFarris%26aufirst%3DA.%2BG.%26aulast%3DLerner%26aufirst%3DA.%26aulast%3DTauscher%26aufirst%3DJ.%2BT.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DPhebus%26aufirst%3DL.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DMorse%26aufirst%3DC.%2BL.%26aulast%3DHong%26aufirst%3DJ.%2BS.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DQuantitation%2520of%2520cannabinoid%2520CB1%2520receptors%2520in%2520healthy%2520human%2520brain%2520using%2520positron%2520emission%2520tomography%2520and%2520an%2520inverse%2520agonist%2520radioligand%26jtitle%3DNeuroImage%26date%3D2009%26volume%3D48%26spage%3D362%26epage%3D370%26doi%3D10.1016%2Fj.neuroimage.2009.06.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharyya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egerton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riano Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brammer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkheimer, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, P.</span></span> <span> </span><span class="NLM_article-title">Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15025</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-14203-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41598-017-14203-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29101333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC1M7nsFygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=15025&author=S.+Bhattacharyyaauthor=A.+Egertonauthor=E.+Kimauthor=L.+Rossoauthor=D.+Riano+Barrosauthor=A.+Hammersauthor=M.+Brammerauthor=F.+E.+Turkheimerauthor=O.+D.+Howesauthor=P.+McGuire&title=Acute+induction+of+anxiety+in+humans+by+delta-9-tetrahydrocannabinol+related+to+amygdalar+cannabinoid-1+%28CB1%29+receptors&doi=10.1038%2Fs41598-017-14203-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors</span></div><div class="casAuthors">Bhattacharyya Sagnik; Egerton Alice; Howes Oliver D; McGuire Philip; Kim Euitae; Rosso Lula; Howes Oliver D; Riano Barros Daniela; Hammers Alexander; Brammer Michael; Turkheimer Federico E</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15025</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Use of Cannabis, the most widely used illicit drug worldwide, is associated with acute anxiety, and anxiety disorders following regular use.  The precise neural and receptor basis of these effects have not been tested in man.  Employing a combination of functional MRI (fMRI) and positron emission tomography (PET), we investigated whether the effects of delta-9-tetrahydrocannabinol (delta-9-THC), the main psychoactive ingredient of cannabis, on anxiety and on amygdala response while processing fearful stimuli were related to local availability of its main central molecular target, cannabinoid-1 (CB1) receptors in man.  Fourteen healthy males were studied with fMRI twice, one month apart, following an oral dose of either delta-9-THC (10 mg) or placebo, while they performed a fear-processing task.  Baseline availability of the CB1 receptor was studied using PET with [(11)C]MePPEP, a CB1 inverse agonist radioligand.  Relative to the placebo condition, delta-9-THC induced anxiety and modulated right amygdala activation while processing fear.  Both these effects were positively correlated with CB1 receptor availability in the right amygdala.  These results suggest that the acute effects of cannabis on anxiety in males are mediated by the modulation of amygdalar function by delta-9-THC and the extent of these effects are related to local availability of CB1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWW6OSv3swrOkdrW1FkXG-fW6udTcc2eYX-hGGmkauqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7nsFygtA%253D%253D&md5=97db42b3e015b7298cfc7910e80c54d3</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-14203-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-14203-4%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharyya%26aufirst%3DS.%26aulast%3DEgerton%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DRosso%26aufirst%3DL.%26aulast%3DRiano%2BBarros%26aufirst%3DD.%26aulast%3DHammers%26aufirst%3DA.%26aulast%3DBrammer%26aufirst%3DM.%26aulast%3DTurkheimer%26aufirst%3DF.%2BE.%26aulast%3DHowes%26aufirst%3DO.%2BD.%26aulast%3DMcGuire%26aufirst%3DP.%26atitle%3DAcute%2520induction%2520of%2520anxiety%2520in%2520humans%2520by%2520delta-9-tetrahydrocannabinol%2520related%2520to%2520amygdalar%2520cannabinoid-1%2520%2528CB1%2529%2520receptors%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D15025%26doi%3D10.1038%2Fs41598-017-14203-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">Approaches to quantify radioligands that wash out slowly from target organs</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1007/s00259-010-1426-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00259-010-1426-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20358196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC3c3lvVOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=917-919&author=J.+Hirvonenauthor=G.+E.+Terryauthor=C.+Halldinauthor=V.+W.+Pikeauthor=R.+B.+Innis&title=Approaches+to+quantify+radioligands+that+wash+out+slowly+from+target+organs&doi=10.1007%2Fs00259-010-1426-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to quantify radioligands that wash out slowly from target organs</span></div><div class="casAuthors">Hirvonen Jussi; Terry Garth E; Halldin Christer; Pike Victor W; Innis Robert B</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">917-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTps0oEc91oVb5oR8RchjrrfW6udTcc2eYX-hGGmkauqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3lvVOlug%253D%253D&md5=8165e589d3b290a23db51533b562ff1a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs00259-010-1426-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-010-1426-0%26sid%3Dliteratum%253Aachs%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DTerry%26aufirst%3DG.%2BE.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DApproaches%2520to%2520quantify%2520radioligands%2520that%2520wash%2520out%2520slowly%2520from%2520target%2520organs%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2010%26volume%3D37%26spage%3D917%26epage%3D919%26doi%3D10.1007%2Fs00259-010-1426-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R.</span></span> <span> </span><span class="NLM_article-title">Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1038/mp.2011.82</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fmp.2011.82" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21747398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1Sktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=642-649&author=J.+Hirvonenauthor=R.+Goodwinauthor=C.-T.+Liauthor=G.+Terryauthor=S.+Zoghbiauthor=C.+Morseauthor=V.+Pikeauthor=N.+Volkowauthor=M.+Huestisauthor=R.+Innis&title=Reversible+and+regionally+selective+downregulation+of+brain+cannabinoid+CB+1+receptors+in+chronic+daily+cannabis+smokers&doi=10.1038%2Fmp.2011.82"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers</span></div><div class="casAuthors">Hirvonen, J.; Goodwin, R. S.; Li, C.-T.; Terry, G. E.; Zoghbi, S. S.; Morse, C.; Pike, V. W.; Volkow, N. D.; Huestis, M. A.; Innis, R. B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">642-649</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic cannabis (marijuana, hashish) smoking can result in dependence.  Rodent studies show reversible downregulation of brain cannabinoid CB1 (cannabinoid receptor type 1) receptors after chronic exposure to cannabis.  However, whether downregulation occurs in humans who chronically smoke cannabis is unknown.  Here we show, using positron emission tomog. imaging, reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in human subjects who chronically smoke cannabis.  Downregulation correlated with years of cannabis smoking and was selective to cortical brain regions.  After ∼4 wk of continuously monitored abstinence from cannabis on a secure research unit, CB1 receptor d. returned to normal levels.  This is the first direct demonstration of cortical cannabinoid CB1 receptor downregulation as a neuroadaptation that may promote cannabis dependence in human brain.  Mol. Psychiatry (2012) 17, 642-649; doi:10.1038/mp.2011.82; published online 12 July 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSq7vDYUA3N7Vg90H21EOLACvtfcHk0livSDM8egSuTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1Sktrc%253D&md5=81dbbb04565fdd12aad5646c9dcc2cae</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fmp.2011.82&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2011.82%26sid%3Dliteratum%253Aachs%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DGoodwin%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DC.-T.%26aulast%3DTerry%26aufirst%3DG.%26aulast%3DZoghbi%26aufirst%3DS.%26aulast%3DMorse%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%26aulast%3DVolkow%26aufirst%3DN.%26aulast%3DHuestis%26aufirst%3DM.%26aulast%3DInnis%26aufirst%3DR.%26atitle%3DReversible%2520and%2520regionally%2520selective%2520downregulation%2520of%2520brain%2520cannabinoid%2520CB%25201%2520receptors%2520in%2520chronic%2520daily%2520cannabis%2520smokers%26jtitle%3DMol.%2520Psychiatry%26date%3D2012%26volume%3D17%26spage%3D642%26epage%3D649%26doi%3D10.1038%2Fmp.2011.82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti-Fregonara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umhau, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rallis-Frutos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyoo, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, M.</span></span> <span> </span><span class="NLM_article-title">Reduced cannabinoid CB 1 receptor binding in alcohol dependence measured with positron emission tomography</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1038/mp.2012.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fmp.2012.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22776901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1SlsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=916-921&author=J.+Hirvonenauthor=P.+Zanotti-Fregonaraauthor=J.+C.+Umhauauthor=D.+T.+Georgeauthor=D.+Rallis-Frutosauthor=C.+H.+Lyooauthor=C.-T.+Liauthor=C.+S.+Hinesauthor=H.+Sunauthor=G.+E.+Terryauthor=C.+Morseauthor=S.+S.+Zoghbiauthor=V.+W.+Pikeauthor=R.+B.+Innisauthor=M.+Heilig&title=Reduced+cannabinoid+CB+1+receptor+binding+in+alcohol+dependence+measured+with+positron+emission+tomography&doi=10.1038%2Fmp.2012.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography</span></div><div class="casAuthors">Hirvonen, J.; Zanotti-Fregonara, P.; Umhau, J. C.; George, D. T.; Rallis-Frutos, D.; Lyoo, C. H.; Li, C.-T.; Hines, C. S.; Sun, H.; Terry, G. E.; Morse, C.; Zoghbi, S. S.; Pike, V. W.; Innis, R. B.; Heilig, M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">916-921</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Brain cannabinoid CB1 receptors contribute to alc.-related behaviors in exptl. animals, but their potential role in humans with alc. dependence is poorly understood.  We measured CB1 receptors in alc. dependent patients in early and protracted abstinence, and in comparison with control subjects without alc. use disorders, using positron emission tomog. and [18F]FMPEP-d2, a radioligand for CB1 receptors.  We scanned 18 male in-patients with alc. dependence twice, within 3-7 days of admission from ongoing drinking, and after 2-4 wk of supervised abstinence.  Imaging data were compared with those from 19 age-matched healthy male control subjects.  Data were also analyzed for potential influence of a common functional variation (rs2023239) in the CB1 receptor gene (CNR1) that may moderate CB1 receptor d.  On the first scan, CB1 receptor binding was 20-30% lower in patients with alc. dependence than in control subjects in all brain regions and was neg. correlated with years of alc. abuse.  After 2-4 wk of abstinence, CB1 receptor binding remained similarly reduced in these patients.  Irresp. of the diagnostic status, C allele carriers at rs2023239 had higher CB1 receptor binding compared with non-carriers.  Alc. dependence is assocd. with a widespread redn. of cannabinoid CB1 receptor binding in the human brain and this redn. persists at least 2-4 wk into abstinence.  The correlation of reduced binding with years of alc. abuse suggests an involvement of CB1 receptors in alc. dependence in humans.  Mol. Psychiatry (2013) 18, 916-921; doi:10.1038/mp.2012.100; published online 10 July 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC5CLHcqpwmLVg90H21EOLACvtfcHk0livSDM8egSuTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1SlsbjE&md5=90de4a2b558c2f6d65833a6cebd14258</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fmp.2012.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2012.100%26sid%3Dliteratum%253Aachs%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DZanotti-Fregonara%26aufirst%3DP.%26aulast%3DUmhau%26aufirst%3DJ.%2BC.%26aulast%3DGeorge%26aufirst%3DD.%2BT.%26aulast%3DRallis-Frutos%26aufirst%3DD.%26aulast%3DLyoo%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DC.-T.%26aulast%3DHines%26aufirst%3DC.%2BS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DTerry%26aufirst%3DG.%2BE.%26aulast%3DMorse%26aufirst%3DC.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DHeilig%26aufirst%3DM.%26atitle%3DReduced%2520cannabinoid%2520CB%25201%2520receptor%2520binding%2520in%2520alcohol%2520dependence%2520measured%2520with%2520positron%2520emission%2520tomography%26jtitle%3DMol.%2520Psychiatry%26date%3D2013%26volume%3D18%26spage%3D916%26epage%3D921%26doi%3D10.1038%2Fmp.2012.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borgan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurikainen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaparanta-Solin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahoun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogdaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salokangas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karukivi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Forti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkheimer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hietala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O.</span></span> <span> </span><span class="NLM_article-title">In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis</span>. <i>JAMA Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1074</span>– <span class="NLM_lpage">1084</span>, <span class="refDoi"> DOI: 10.1001/jamapsychiatry.2019.1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1001%2Fjamapsychiatry.2019.1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31268519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BB3Mzjs1Khuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2019&pages=1074-1084&author=F.+Borganauthor=H.+Laurikainenauthor=M.+Veroneseauthor=T.+R.+Marquesauthor=M.+Haaparanta-Solinauthor=O.+Solinauthor=T.+Dahounauthor=M.+Rogdakiauthor=R.+K.+Salokangasauthor=M.+Karukiviauthor=M.+Di+Fortiauthor=F.+Turkheimerauthor=J.+Hietalaauthor=O.+Howes&title=In+vivo+availability+of+cannabinoid+1+receptor+levels+in+patients+with+first-episode+psychosis&doi=10.1001%2Fjamapsychiatry.2019.1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis</span></div><div class="casAuthors">Borgan Faith; Marques Tiago Reis; Di Forti Marta; Howes Oliver; Borgan Faith; Marques Tiago Reis; Dahoun Tarik; Rogdaki Maria; Howes Oliver; Laurikainen Heikki; Haaparanta-Solin Merja; Solin Olof; Hietala Jarmo; Laurikainen Heikki; Salokangas Raimo Kr; Hietala Jarmo; Veronese Mattia; Turkheimer Federico; Dahoun Tarik; Howes Oliver; Dahoun Tarik; Karukivi Max</div><div class="citationInfo"><span class="NLM_cas:title">JAMA psychiatry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1074-1084</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis.  However, whether CB1R levels are altered in the early stages of psychosis and whether they are linked to cognitive function or symptom severity remain unknown.  Objective:  To investigate CB1R availability in first-episode psychosis (FEP) without the confounds of illness chronicity or the use of illicit substances or antipsychotics.  Design, Setting, and Participants:  This cross-sectional, case-control study of 2 independent samples included participants receiving psychiatric early intervention services at 2 independent centers in Turku, Finland (study 1) and London, United Kingdom (study 2).  Study 1 consisted of 18 volunteers, including 7 patients with affective or nonaffective psychoses taking antipsychotic medication and 11 matched controls; study 2, 40 volunteers, including 20 antipsychotic-naive or antipsychotic-free patients with schizophrenia or schizoaffective disorder and 20 matched controls.  Data were collected from January 5, 2015, through September 26, 2018, and analyzed from June 20, 2016, through February 12, 2019.  Main Outcomes and Measures:  The availability of CB1R was indexed using the distribution volume (VT, in milliliters per cubic centimeter) of 2 CB1R-selective positron emission tomography radiotracers: fluoride 18-labeled FMPEP-d2 (study 1) and carbon 11-labeled MePPEP (study 2).  Cognitive function was measured using the Wechsler Digit Symbol Coding Test.  Symptom severity was measured using the Brief Psychiatric Rating Scale for study 1 and the Positive and Negative Syndrome Scale for study 2.  Results:  A total of 58 male individuals were included in the analyses (mean [SD] age of controls, 27.16 [5.93] years; mean [SD] age of patients, 26.96 [4.55] years).  In study 1, 7 male patients with FEP (mean [SD] age, 26.80 [5.40] years) were compared with 11 matched controls (mean [SD] age, 27.18 [5.86] years); in study 2, 20 male patients with FEP (mean [SD] age, 27.00 [5.06] years) were compared with 20 matched controls (mean [SD] age, 27.15 [6.12] years).  In study 1, a significant main effect of group on [18F]FMPEP-d2 VT was found in the anterior cingulate cortex (ACC) (t16 = -4.48; P < .001; Hedges g = 1.2), hippocampus (t16 = -2.98; P = .006; Hedges g = 1.4), striatum (t16 = -4.08; P = .001; Hedges g = 1.9), and thalamus (t16 = -4.67; P < .001; Hedges g = 1.4).  In study 2, a significant main effect of group on [11C]MePPEP VT was found in the ACC (Hedges g = 0.8), hippocampus (Hedges g = 0.5), striatum (Hedges g = 0.4), and thalamus (Hedges g = 0.7).  In patients, [11C]MePPEP VT in the ACC was positively associated with cognitive functioning (R = 0.60; P = .01), and [11C]MePPEP VT in the hippocampus was inversely associated with Positive and Negative Syndrome Scale total symptom severity (R = -0.50; P = .02).  Conclusions and Relevance:  The availability of CB1R was lower in antipsychotic-treated and untreated cohorts relative to matched controls.  Exploratory analyses indicated that greater reductions in CB1R levels were associated with greater symptom severity and poorer cognitive functioning in male patients.  These findings suggest that CB1R may be a potential target for the treatment of psychotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsgVim5oaKgUQ0lWbKiCflfW6udTcc2eaerPfXegR6FLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mzjs1Khuw%253D%253D&md5=765b732632f557ca57db9573b9d11343</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2019.1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2019.1427%26sid%3Dliteratum%253Aachs%26aulast%3DBorgan%26aufirst%3DF.%26aulast%3DLaurikainen%26aufirst%3DH.%26aulast%3DVeronese%26aufirst%3DM.%26aulast%3DMarques%26aufirst%3DT.%2BR.%26aulast%3DHaaparanta-Solin%26aufirst%3DM.%26aulast%3DSolin%26aufirst%3DO.%26aulast%3DDahoun%26aufirst%3DT.%26aulast%3DRogdaki%26aufirst%3DM.%26aulast%3DSalokangas%26aufirst%3DR.%2BK.%26aulast%3DKarukivi%26aufirst%3DM.%26aulast%3DDi%2BForti%26aufirst%3DM.%26aulast%3DTurkheimer%26aufirst%3DF.%26aulast%3DHietala%26aufirst%3DJ.%26aulast%3DHowes%26aufirst%3DO.%26atitle%3DIn%2520vivo%2520availability%2520of%2520cannabinoid%25201%2520receptor%2520levels%2520in%2520patients%2520with%2520first-episode%2520psychosis%26jtitle%3DJAMA%2520Psychiatry%26date%3D2019%26volume%3D76%26spage%3D1074%26epage%3D1084%26doi%3D10.1001%2Fjamapsychiatry.2019.1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuominen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsback, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaparanta-Solin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hietala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuutila, P.</span></span> <span> </span><span class="NLM_article-title">The cannabinoid receptor-1 is an imaging biomarker of brown adipose tissue</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1941</span>, <span class="refDoi"> DOI: 10.2967/jnumed.115.156422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.115.156422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26359260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XntV2htL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=1937-1941&author=O.+Erikssonauthor=K.+Mikkolaauthor=D.+Espesauthor=L.+Tuominenauthor=K.+Virtanenauthor=S.+Forsbackauthor=M.+Haaparanta-Solinauthor=J.+Hietalaauthor=O.+Solinauthor=P.+Nuutila&title=The+cannabinoid+receptor-1+is+an+imaging+biomarker+of+brown+adipose+tissue&doi=10.2967%2Fjnumed.115.156422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The cannabinoid receptor-1 is an imaging biomarker of brown adipose tissue</span></div><div class="casAuthors">Eriksson, Olof; Mikkola, Kirsi; Espes, Daniel; Tuominen, Lauri; Virtanen, Kirsi; Forsback, Sarita; Haaparanta-Solin, Merja; Hietala, Jarmo; Solin, Olof; Nuutila, Pirjo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1937-1941</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Recently, the existence of significant deposits of brown adipose tissue (BAT) in human adults was confirmed.  Its role in the human metab. is unknown but could be substantial.  Inhibition of the cannabinoid receptor-1 (CB1) by the antagonist rimonabant (SR141716) has been assocd. with activation of BAT thermogenesis and wt. loss in mice and rats.  The role of peripheral and central CB1 in the activation of BAT merits further investigation.  Here we developed a technique for quantifying CB1 in BAT by PET.  Sections of rat BAT and s.c. white adipose tissue (WAT) were stained for CB1 and uncoupling protein-1 by immunofluorescent staining.  Binding of the radiolabeled CB1 antagonist (3R,5R)-5-(3-(18F-fluoromethoxy)phenyl)-3-(((R)-1-phenylethyl)amino)-1-(4-(trifluoromethyl)-phenyl)pyrrolidin-2-one (18F-FMPEP-d2) to BAT in vivo and in vitro was assessed in rats by PET.  We found that CB1 was colocalized with uncoupling protein-1 in BAT, but neither protein was found in WAT.  Binding of the radiotracer to BAT sections (but not WAT) in vitro was high and displaceable by pretreatment with rimonabant.  Deposits of BAT in rats had significant binding of 18F-FMPEP-d2 in vivo, indicating high CB1 d.  WAT deposits were neg. for 18F-FMPEP-d2, consistent with the immunofluorescent staining and in vitro results.  Conclusion:18F-FMPEP-d2 PET can quantify CB1 d. noninvasively in vivo in rats.  CB1 is therefore a promising surrogate imaging biomarker for assessing the presence of BAT deposits as well as for elucidating the mechanism of CB1 antagonist-mediated wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOYHvJSreG5LVg90H21EOLACvtfcHk0lgrDNbX79h4gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntV2htL0%253D&md5=2d88732d8a0fedcde52560f88b76f66e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.115.156422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.115.156422%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DO.%26aulast%3DMikkola%26aufirst%3DK.%26aulast%3DEspes%26aufirst%3DD.%26aulast%3DTuominen%26aufirst%3DL.%26aulast%3DVirtanen%26aufirst%3DK.%26aulast%3DForsback%26aufirst%3DS.%26aulast%3DHaaparanta-Solin%26aufirst%3DM.%26aulast%3DHietala%26aufirst%3DJ.%26aulast%3DSolin%26aufirst%3DO.%26aulast%3DNuutila%26aufirst%3DP.%26atitle%3DThe%2520cannabinoid%2520receptor-1%2520is%2520an%2520imaging%2520biomarker%2520of%2520brown%2520adipose%2520tissue%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26spage%3D1937%26epage%3D1941%26doi%3D10.2967%2Fjnumed.115.156422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahesmaa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikonen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskensalo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teuho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taittonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahdenpohja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">U Din, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaparanta-Solin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuutila, P.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid type 1 receptors are upregulated during acute activation of brown adipose tissue</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1226</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.2337/db17-1366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2337%2Fdb17-1366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29650773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktleqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2018&pages=1226-1236&author=M.+Lahesmaaauthor=O.+Erikssonauthor=T.+Gnadauthor=V.+Oikonenauthor=M.+Bucciauthor=J.+Hirvonenauthor=K.+Koskensaloauthor=J.+Teuhoauthor=T.+Niemiauthor=M.+Taittonenauthor=S.+Lahdenpohjaauthor=M.+U+Dinauthor=M.+Haaparanta-Solinauthor=A.+Pfeiferauthor=K.+A.+Virtanenauthor=P.+Nuutila&title=Cannabinoid+type+1+receptors+are+upregulated+during+acute+activation+of+brown+adipose+tissue&doi=10.2337%2Fdb17-1366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid Type 1 Receptors Are Upregulated During Acute Activation of Brown Adipose Tissue</span></div><div class="casAuthors">Lahesmaa, Minna; Eriksson, Olof; Gnad, Thorsten; Oikonen, Vesa; Bucci, Marco; Hirvonen, Jussi; Koskensalo, Kalle; Teuho, Jarmo; Niemi, Tarja; Taittonen, Markku; Lahdenpohja, Salla; Din, Mueez U.; Haaparanta-Solin, Merja; Pfeifer, Alexander; Virtanen, Kirsi A.; Nuutila, Pirjo</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1226-1236</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Activating brown adipose tissue (BAT) could provide a potential approach for the treatment of obesity and metabolic disease in humans.  Obesity is assocd. with upregulation of the endocannabinoid system, and blocking the cannabinoid type 1 receptor (CB1R) has been shown to cause wt. loss and to decrease cardiometabolic risk factors.  These effects may be mediated partly via increased BAT metab., since there is evidence that CB1R antagonism activates BAT in rodents.  To investigate the significance of CB1R in BAT function, we quantified the d. of CB1R in human and rodent BAT using the positron emission tomog. radioligand [18F]FMPEP-d2 and measured BAT activation in parallel with the glucose analog [18F]-fluorodeoxyglucose.  Activation by cold exposure markedly increased CB1R d. and glucose uptake in the BAT of lean men.  Similarly, β3-receptor agonism increased CB1R d. in the BAT of rats.  In contrast, overweight men with reduced BAT activity exhibited decreased CB1R in BAT, reflecting impaired endocannabinoid regulation.  Image-guided biopsies confirmed CB1R mRNA expression in human BAT.  Furthermore, CB1R blockade increased glucose uptake and lipolysis of brown adipocytes.  Our results highlight that CB1Rs are significant for human BAT activity, and the CB1Rs provide a novel therapeutic target for BAT activation in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrld9meZDX3-7Vg90H21EOLACvtfcHk0lgrDNbX79h4gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktleqsLc%253D&md5=a0c46b08748f0e0aa391b47502ab3988</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2337%2Fdb17-1366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb17-1366%26sid%3Dliteratum%253Aachs%26aulast%3DLahesmaa%26aufirst%3DM.%26aulast%3DEriksson%26aufirst%3DO.%26aulast%3DGnad%26aufirst%3DT.%26aulast%3DOikonen%26aufirst%3DV.%26aulast%3DBucci%26aufirst%3DM.%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DKoskensalo%26aufirst%3DK.%26aulast%3DTeuho%26aufirst%3DJ.%26aulast%3DNiemi%26aufirst%3DT.%26aulast%3DTaittonen%26aufirst%3DM.%26aulast%3DLahdenpohja%26aufirst%3DS.%26aulast%3DU%2BDin%26aufirst%3DM.%26aulast%3DHaaparanta-Solin%26aufirst%3DM.%26aulast%3DPfeifer%26aufirst%3DA.%26aulast%3DVirtanen%26aufirst%3DK.%2BA.%26aulast%3DNuutila%26aufirst%3DP.%26atitle%3DCannabinoid%2520type%25201%2520receptors%2520are%2520upregulated%2520during%2520acute%2520activation%2520of%2520brown%2520adipose%2520tissue%26jtitle%3DDiabetes%26date%3D2018%26volume%3D67%26spage%3D1226%26epage%3D1236%26doi%3D10.2337%2Fdb17-1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burns, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanabria-Bohorquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamill, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lepeleire, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoch, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagmann, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesdiener, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Hoon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortelmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span> <span> </span><span class="NLM_article-title">[<sup>18</sup>F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">9800</span>– <span class="NLM_lpage">9805</span>, <span class="refDoi"> DOI: 10.1073/pnas.0703472104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.0703472104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=17535893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFSmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=9800-9805&author=H.+D.+Burnsauthor=K.+Van+Laereauthor=S.+Sanabria-Bohorquezauthor=T.+G.+Hamillauthor=G.+Bormansauthor=W.+S.+Engauthor=R.+Gibsonauthor=C.+Ryanauthor=B.+Connollyauthor=S.+Patelauthor=S.+Krauseauthor=A.+Vankoauthor=A.+Van+Heckenauthor=P.+Dupontauthor=I.+De+Lepeleireauthor=P.+Rothenbergauthor=S.+A.+Stochauthor=J.+Coteauthor=W.+K.+Hagmannauthor=J.+P.+Jewellauthor=L.+S.+Linauthor=P.+Liuauthor=M.+T.+Gouletauthor=K.+Gottesdienerauthor=J.+A.+Wagnerauthor=J.+de+Hoonauthor=L.+Mortelmansauthor=T.+M.+Fongauthor=R.+J.+Hargreaves&title=%5B18F%5DMK-9470%2C+a+positron+emission+tomography+%28PET%29+tracer+for+in+vivo+human+PET+brain+imaging+of+the+cannabinoid-1+receptor&doi=10.1073%2Fpnas.0703472104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor</span></div><div class="casAuthors">Burns, H. Donald; Van Laere, Koen; Sanabria-Bohorquez, Sandra; Hamill, Terence G.; Bormans, Guy; Eng, Wai-Si; Gibson, Ray; Ryan, Christine; Connolly, Brett; Patel, Shil; Krause, Stephen; Vanko, Amy; Van Hecken, Anne; Dupont, Patrick; De Lepeleire, Inge; Rothenberg, Paul; Stoch, S. Aubrey; Cote, Josee; Hagmann, William K.; Jewell, James P.; Lin, Linus S.; Liu, Ping; Goulet, Mark T.; Gottesdiener, Keith; Wagner, John A.; de Hoon, Jan; Mortelmans, Luc; Fong, Tung M.; Hargreaves, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9800-9805</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">[18F]MK-9470 is a selective, high-affinity, inverse agonist (human IC50, 0.7 nM) for the cannabinoid CB1 receptor (CB1R) that has been developed for use in human brain imaging.  Autoradiog. studies in rhesus monkey brain showed that [18F]MK-9470 binding is aligned with the reported distribution of CB1 receptors with high specific binding in the cerebral cortex, cerebellum, caudate/putamen, globus pallidus, substantia nigra, and hippocampus.  Positron emission tomog. (PET) imaging studies in rhesus monkeys showed high brain uptake and a distribution pattern generally consistent with that seen in the autoradiog. studies.  Uptake was blocked by pretreatment with a potent CB1 inverse agonist, MK-0364.  The ratio of total to nonspecific binding in putamen was 4-5:1, indicative of a strong specific signal that was confirmed to be reversible via displacement studies with MK-0364.  Baseline PET imaging studies in human research subject demonstrated behavior of [18F]MK-9470 very similar to that seen in monkeys, with very good test-retest variability (7%).  Proof of concept studies in healthy young male human subjects showed that MK-0364, given orally, produced a dose-related redn. in [18F]MK-9470 binding reflecting CB1R receptor occupancy by the drug.  Thus, [18F]MK-9470 has the potential to be a valuable, noninvasive research tool for the in vivo study of CB1R biol. and pharmacol. in a variety of neuropsychiatric disorders in humans.  In addn., it allows demonstration of target engagement and noninvasive dose-occupancy studies to aid in dose selection for clin. trials of CB1R inverse agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8neFicpfiT7Vg90H21EOLACvtfcHk0lgCXQseILJDKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFSmsLc%253D&md5=d8bca5f5cbbc743319c3df462dc8972c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0703472104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0703472104%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DH.%2BD.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DSanabria-Bohorquez%26aufirst%3DS.%26aulast%3DHamill%26aufirst%3DT.%2BG.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DEng%26aufirst%3DW.%2BS.%26aulast%3DGibson%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DC.%26aulast%3DConnolly%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DKrause%26aufirst%3DS.%26aulast%3DVanko%26aufirst%3DA.%26aulast%3DVan%2BHecken%26aufirst%3DA.%26aulast%3DDupont%26aufirst%3DP.%26aulast%3DDe%2BLepeleire%26aufirst%3DI.%26aulast%3DRothenberg%26aufirst%3DP.%26aulast%3DStoch%26aufirst%3DS.%2BA.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DLin%26aufirst%3DL.%2BS.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DGoulet%26aufirst%3DM.%2BT.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BHoon%26aufirst%3DJ.%26aulast%3DMortelmans%26aufirst%3DL.%26aulast%3DFong%26aufirst%3DT.%2BM.%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26atitle%3D%255B18F%255DMK-9470%252C%2520a%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520tracer%2520for%2520in%2520vivo%2520human%2520PET%2520brain%2520imaging%2520of%2520the%2520cannabinoid-1%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D9800%26epage%3D9805%26doi%3D10.1073%2Fpnas.0703472104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kent, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=6104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADyaL3c3gvFKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1980&pages=14-23&author=R.+S.+Kentauthor=A.+De+Leanauthor=R.+J.+Lefkowitz&title=A+quantitative+analysis+of+beta-adrenergic+receptor+interactions%3A+resolution+of+high+and+low+affinity+states+of+the+receptor+by+computer+modeling+of+ligand+binding+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data</span></div><div class="casAuthors">Kent R S; De Lean A; Lefkowitz R J</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-23</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvtQ56tMYqkK69lAbTj9rGfW6udTcc2eY58XOvBZO89bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3c3gvFKqtQ%253D%253D&md5=70f9116fd24d17e34229d48137cafa4e</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKent%26aufirst%3DR.%2BS.%26aulast%3DDe%2BLean%26aufirst%3DA.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520beta-adrenergic%2520receptor%2520interactions%253A%2520resolution%2520of%2520high%2520and%2520low%2520affinity%2520states%2520of%2520the%2520receptor%2520by%2520computer%2520modeling%2520of%2520ligand%2520binding%2520data%26jtitle%3DMol.%2520Pharmacol.%26date%3D1980%26volume%3D17%26spage%3D14%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortelmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Hoon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span> <span> </span><span class="NLM_article-title">Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [<sup>18</sup>F]MK-9470 PET</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1533</span>– <span class="NLM_lpage">1541</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2007.10.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2007.10.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18077184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FovFSqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2008&pages=1533-1541&author=K.+Van+Laereauthor=K.+Goffinauthor=C.+Casteelsauthor=P.+Dupontauthor=L.+Mortelmansauthor=J.+de+Hoonauthor=G.+Bormans&title=Gender-dependent+increases+with+healthy+aging+of+the+human+cerebral+cannabinoid-type+1+receptor+binding+using+%5B18F%5DMK-9470+PET&doi=10.1016%2Fj.neuroimage.2007.10.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET</span></div><div class="casAuthors">Van Laere Koen; Goffin Karolien; Casteels Cindy; Dupont Patrick; Mortelmans Luc; de Hoon Jan; Bormans Guy</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1533-41</span>
        ISSN:<span class="NLM_cas:issn">1053-8119</span>.
    </div><div class="casAbstract">The endocannabinoid system (ECS) is implicated as a regulator of homeostasis of several cerebral functions and is a novel target for drug treatment of neuropyschiatric disorders.  So far, the cerebral cannabinoid-type 1 receptor (CB1R) has only been studied using in vitro, animal model, electrophysiological and post-mortem data.  We have used positron emission tomography (PET) using a high-affinity, subtype-selective radioligand, [(18)F]MK-9470, to assess the in vivo cerebral CB1R distribution and its variation with healthy aging and gender.  Fifty healthy volunteers (25 M/25 F, 18-69 years) underwent [(18)F]MK-9470 PET.  Parametric [(18)F]MK-9470 binding maps were constructed, corrected for partial volume effects and analyzed using statistical parametric mapping in a combined categorical (gender) and covariate (age) design.  We found that [(18)F]MK-9470 binding to CB1R increased with aging but only in women (p(FWE)<0.05, corrected for multiple comparisons); this was most pronounced in the basal ganglia, lateral temporal cortex and limbic system, especially in the hippocampus.  Men showed higher [(18)F]MK-9470 binding then women (p<0.001, uncorrected), in clusters of the limbic system and cortico-striato-thalamic-cortical circuit.  Region-dependent and gender-related upregulation of [(18)F]MK-9470 binding with aging is in line with ex vivo findings in rodent studies and may be associated with a changing homeostatic capacity or compensation mechanisms in the ECS that is modulated by sex hormones.  In vivo PET of the CB1R will likely improve our understanding of the ECS in several neurological and psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRkebs6x3EJPcsfMJQC1ZdfW6udTcc2eY58XOvBZO89bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FovFSqtQ%253D%253D&md5=6c7b114e4cbfe1da00d79d74de5d39c2</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2007.10.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2007.10.053%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DGoffin%26aufirst%3DK.%26aulast%3DCasteels%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DP.%26aulast%3DMortelmans%26aufirst%3DL.%26aulast%3Dde%2BHoon%26aufirst%3DJ.%26aulast%3DBormans%26aufirst%3DG.%26atitle%3DGender-dependent%2520increases%2520with%2520healthy%2520aging%2520of%2520the%2520human%2520cerebral%2520cannabinoid-type%25201%2520receptor%2520binding%2520using%2520%255B18F%255DMK-9470%2520PET%26jtitle%3DNeuroImage%26date%3D2008%26volume%3D39%26spage%3D1533%26epage%3D1541%26doi%3D10.1016%2Fj.neuroimage.2007.10.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gérard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2011.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.biopsych.2011.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21718968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GntrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=777-784&author=N.+G%C3%A9rardauthor=G.+Pietersauthor=K.+Goffinauthor=G.+Bormansauthor=K.+Van+Laere&title=Brain+type+1+cannabinoid+receptor+availability+in+patients+with+anorexia+and+bulimia+nervosa&doi=10.1016%2Fj.biopsych.2011.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Type 1 Cannabinoid Receptor Availability in Patients with Anorexia and Bulimia Nervosa</span></div><div class="casAuthors">Gerard, Nathalie; Pieters, Guido; Goffin, Karolien; Bormans, Guy; Van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">777-784</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The endocannabinoid system is a possible target in the treatment of eating disorders.  We used positron emission tomog. to investigate the type 1 cannabinoid receptor (CB1R) in bulimic and anorectic patients.  We investigated 16 female bulimia nervosa patients (BN) (age = 23.8 ± 7.1 years) and 14 female anorexia nervosa patients (AN) (age = 20.5 ± 3.6 years) using the selective CB1R ligand [18F]MK-9470.  The control group consisted of 19 age-matched women (age = 25.2 ± 8.5 years).  Statistical parametric mapping (p family-wise error < .05) and vol.-of-interest analyses of CB1R availability were performed.  Global CB1R availability was significantly increased in cortical and subcortical brain areas in AN patients compared with healthy control subjects (+24.5%, p = .0003).  Regionally, CB1R availability was increased in the insula in both AN and BN patients (p = .01 and p = .0004) and the inferior frontal and temporal cortex in AN patients only (p = .02).  Global CB1R upregulation in AN patients is a possible long-term compensatory mechanism to an underactive endocannabinoid system in anorectic conditions.  There is a similarity in CB1R dysregulation both in AN and BN in the insular cortex, which is involved in the integration of interoceptive information, gustatory information, reward, and emotion processing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAhT1tF1-SpbVg90H21EOLACvtfcHk0liHFBJ_DPNe8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GntrnJ&md5=2d48bfa7bea48333e632d83c5c2a477e</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2011.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2011.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25A9rard%26aufirst%3DN.%26aulast%3DPieters%26aufirst%3DG.%26aulast%3DGoffin%26aufirst%3DK.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DBrain%2520type%25201%2520cannabinoid%2520receptor%2520availability%2520in%2520patients%2520with%2520anorexia%2520and%2520bulimia%2520nervosa%26jtitle%3DBiol.%2520Psychiatry%26date%3D2011%26volume%3D70%26spage%3D777%26epage%3D784%26doi%3D10.1016%2Fj.biopsych.2011.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van der Schueren, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gérard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Hoon, J. N.</span></span> <span> </span><span class="NLM_article-title">Interictal type 1 cannabinoid receptor binding is increased in female migraine patients</span>. <i>Headache</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1111/j.1526-4610.2011.02030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1526-4610.2011.02030.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22077199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC383pvVyntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=433-440&author=B.+J.+Van+der+Schuerenauthor=K.+Van+Laereauthor=N.+G%C3%A9rardauthor=G.+Bormansauthor=J.+N.+De+Hoon&title=Interictal+type+1+cannabinoid+receptor+binding+is+increased+in+female+migraine+patients&doi=10.1111%2Fj.1526-4610.2011.02030.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Interictal type 1 cannabinoid receptor binding is increased in female migraine patients</span></div><div class="casAuthors">Van der Schueren Bart J; Van Laere Koen; Gerard Nathalie; Bormans Guy; De Hoon Jan N</div><div class="citationInfo"><span class="NLM_cas:title">Headache</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">433-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To compare binding of the type 1 cannabinoid receptor (CB1R) between migraine patients and healthy volunteers.  BACKGROUND:  It has been suggested that endocannabinoid deficiency may play a role in the pathophysiology of migraine.  Nonetheless, biochemical studies substantiating this idea remain scarce and are faced with methodological shortcomings partly because of the difficulty to perform measurements of endocannabinoids within the central nervous system itself.  METHODS:  An observational cross-sectional study was conducted in 20 female migraine patients and 18 healthy women matched for age and body mass index.  Positron emission tomography acquisition was performed 90 minutes after intravenous injection of the radioligand [(18)F]MK-9470 to assess binding of [(18)F]MK-9470 to CB1R.  RESULTS:  Binding of CB1 R was globally increased in migraine patients vs healthy controls (average gray matter difference +16%; P = .009, 2-sample 2-sided Student's t-test).  There were no correlations between CB1R binding and any predefined migraine characteristics.  Increases in CB1R binding were most pronounced in the anterior cingulate, mesial temporal, prefrontal, and superior frontal cortices.  CONCLUSION:  The increased interictal CB1R binding, especially in brain regions that exert top-down influences to modulate pain, supports the idea that endocannibinoid deficiency is present in female patients suffering from episodic migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLXDtqzqQ_X0kUaC_kzhvyfW6udTcc2eZ3BwFxRMUotLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383pvVyntA%253D%253D&md5=b063478758937ca9eb0bd7d43dd3dc60</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1526-4610.2011.02030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1526-4610.2011.02030.x%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BSchueren%26aufirst%3DB.%2BJ.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DG%25C3%25A9rard%26aufirst%3DN.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DDe%2BHoon%26aufirst%3DJ.%2BN.%26atitle%3DInterictal%2520type%25201%2520cannabinoid%2520receptor%2520binding%2520is%2520increased%2520in%2520female%2520migraine%2520patients%26jtitle%3DHeadache%26date%3D2012%26volume%3D52%26spage%3D433%26epage%3D440%26doi%3D10.1111%2Fj.1526-4610.2011.02030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Paesschen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.1093/brain/awq385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1093%2Fbrain%2Fawq385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21303859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC3Mvgt12gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2011&pages=1033-1040&author=K.+Goffinauthor=W.+Van+Paesschenauthor=K.+Van+Laere&title=In+vivo+activation+of+endocannabinoid+system+in+temporal+lobe+epilepsy+with+hippocampal+sclerosis&doi=10.1093%2Fbrain%2Fawq385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis</span></div><div class="casAuthors">Goffin Karolien; Van Paesschen Wim; Van Laere Koen</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">Pt 4</span>),
    <span class="NLM_cas:pages">1033-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The endocannabinoid system modulates neuronal excitability, protects neurons against hyperexcitability and is involved in epileptogenesis in animal models of mesial temporal lobe epilepsy with hippocampal sclerosis.  We performed in vivo positron emission tomography imaging of the type 1 cannabinoid receptor in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.  Twelve patients with refractory mesial temporal lobe epilepsy due to hippocampal sclerosis received a [(18)F]MK-9470 scan to assess type 1 cannabinoid receptor availability in vivo.  Parametric modified standard uptake values were used as quantitative measure of type 1 cannabinoid receptor availability and images were spatially normalized to standard space.  Voxel-based analysis was performed comparing patients with hippocampal sclerosis to controls and correlations between type 1 cannabinoid receptor status and seizure characteristics were done using volumes of interest.  Type 1 cannabinoid receptor positron emission tomography was co-registered with subtraction ictal single photon emission computed tomography co-registered to magnetic resonance imaging of a complex partial seizure (n = 9).  An increased type 1 cannabinoid receptor availability in the ipsilateral temporal lobe was observed, which correlated negatively with the latency since last seizure before scanning and positively to the number of seizures in the month before scanning.  A decreased type 1 cannabinoid receptor availability was present in the superior insular cortex, ipsilateral more than contralateral.  The ipsilateral insular region displayed a mild ictal hyperperfusion in the transition zone of subtraction ictal single photon emission computed tomography co-registered to magnetic resonance imaging temporal lobe hyperperfusion-frontal lobe hypoperfusion during complex partial seizures.  Type 1 cannabinoid receptor availability showed opposite changes in different brain regions that are involved during complex partial seizures in refractory mesial temporal lobe epilepsy with hippocampal sclerosis.  The increase in type 1 cannabinoid receptor availability at the seizure onset zone might be a protective mechanism of neurons against hyperexcitability and seizure activity, or contribute to the process of epileptogenesis, or both.  The decreased type 1 cannabinoid receptor availability in the insula may play a role in surround inhibition and prevention of seizure propagation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMoXID3BH1GEbxh97K6Vt6fW6udTcc2eZ3BwFxRMUotLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mvgt12gsw%253D%253D&md5=862b151f793157cdb1017597a293c379</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawq385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawq385%26sid%3Dliteratum%253Aachs%26aulast%3DGoffin%26aufirst%3DK.%26aulast%3DVan%2BPaesschen%26aufirst%3DW.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DIn%2520vivo%2520activation%2520of%2520endocannabinoid%2520system%2520in%2520temporal%2520lobe%2520epilepsy%2520with%2520hippocampal%2520sclerosis%26jtitle%3DBrain%26date%3D2011%26volume%3D134%26spage%3D1033%26epage%3D1040%26doi%3D10.1093%2Fbrain%2Fawq385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Vliet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbulcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Behavioral symptoms in premanifest huntington disease correlate with reduced frontal CB1R levels</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.2967/jnumed.118.210393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.118.210393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29934407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOmu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=115-121&author=J.+Ceccariniauthor=R.+Ahmadauthor=L.+Van+de+Vlietauthor=C.+Casteelsauthor=M.+Vandenbulckeauthor=W.+Vandenbergheauthor=K.+Van+Laere&title=Behavioral+symptoms+in+premanifest+huntington+disease+correlate+with+reduced+frontal+CB1R+levels&doi=10.2967%2Fjnumed.118.210393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral symptoms in premanifest huntington disease correlate with reduced frontal CB1R levels</span></div><div class="casAuthors">Ceccarini, Jenny; Ahmad, Rawaha; Van de Vliet, Laura; Casteels, Cindy; Vandenbulcke, Mathieu; Vandenberghe, Wim; Van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-121</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Many Huntington disease (HD) mutation carriers already have cognitive and psychiatric symptoms in the premanifest (premotor) phase of the disease (pre-HD), but the mol. underpinnings of these symptoms are not well understood.  Previous work has shown reduced availability of the cerebral type 1 cannabinoid receptor (CB1R) in manifest HD.  Here, we investigated whether CB1R binding is related to cognitive and psychiatric symptoms in pre-HD mutation carriers.  Methods: CB1R binding was measured with 18F-MK-9470 (N-[(2S,3S)-3-(3-cyanophenyl)-4-(4-ethoxyphenyl)butan-2-yl]-2-methyl-2-(5-methylpyridin-2-yl)oxypropanamide) PET in 15 pre-HD subjects (8 men, 7 women; age, 39.3 ± 9.9 y), 15 gene-neg. controls from HD families (9 men, 6 women; age, 37.0 ± 10.6 y), and 12 community controls (6 men and 6 women; age, 39.9 ± 15.1 y).  All subjects also underwent extensive assessment of motor and cognitive function, as well as a behavioral test battery including the Problem Behavior Assessment for HD (PBA-HD), and MRI.  Parametric binding images of 18F-MK-9470 were cor. for partial-vol. effect.  Results: There was no difference in CB1R binding, gray matter vol., cognitive function, or psychiatric scores between gene-neg. controls from HD families and community controls, which were therefore pooled to one control group.  Compared with controls, pre-HD subjects showed striatal atrophy, a decrease in CB1R binding in the prefrontal cortex, and higher PBA-HD scores on depression, apathy, and irritability (range, P = 0.01-0.005).  The PBA-HD scores inversely correlated with CB1R binding in prefrontal regions and cingulate cortex in pre-HD (range: r = -0.64 to -0.72; P = 0.01-0.008).  Conclusion: The assocn. between behavioral symptoms and reduced prefrontal CB1R levels may provide new insight into the mol. basis of neuropsychiatric symptoms in pre-HD and suggest new therapeutic avenues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL33qq-XJBJbVg90H21EOLACvtfcHk0ljw-hjSuQ-SDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOmu7bM&md5=98f9c4984ecfeda0cf9e67c10c0579b7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.210393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.210393%26sid%3Dliteratum%253Aachs%26aulast%3DCeccarini%26aufirst%3DJ.%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DVan%2Bde%2BVliet%26aufirst%3DL.%26aulast%3DCasteels%26aufirst%3DC.%26aulast%3DVandenbulcke%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DW.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DBehavioral%2520symptoms%2520in%2520premanifest%2520huntington%2520disease%2520correlate%2520with%2520reduced%2520frontal%2520CB1R%2520levels%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D115%26epage%3D121%26doi%3D10.2967%2Fjnumed.118.210393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteels, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabbé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Vliet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaute, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbulcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson’s disease</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2348</span>– <span class="NLM_lpage">2357</span>, <span class="refDoi"> DOI: 10.1007/s00259-019-04445-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00259-019-04445-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31342135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVCht7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2019&pages=2348-2357&author=J.+Ceccariniauthor=C.+Casteelsauthor=R.+Ahmadauthor=M.+Crabb%C3%A9author=L.+Van+de+Vlietauthor=H.+Vanhauteauthor=M.+Vandenbulckeauthor=W.+Vandenbergheauthor=K.+Van+Laere&title=Regional+changes+in+the+type+1+cannabinoid+receptor+are+associated+with+cognitive+dysfunction+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs00259-019-04445-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease</span></div><div class="casAuthors">Ceccarini, Jenny; Casteels, Cindy; Ahmad, Rawaha; Crabbe, Melissa; Van de Vliet, Laura; Vanhaute, Heleen; Vandenbulcke, Mathieu; Vandenberghe, Wim; Van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2348-2357</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The endocannabinoid system plays a regulatory role in a no. of physiol. functions, including motor control but also mood, emotion, and cognition.  A no. of preclin. studies in Parkinson's disease (PD) models demonstrated that modulating the type 1 cannabinoid receptor (CB1R) may improve motor symptoms and components of cognitive processing.  However, the relation between CB1R, cognitive decline and behavioral symptoms has not been investigated in PD patients so far.  The aim of this study was to examine whether CB1R availability is assocd. with measures of cognitive and behavioral function in PD patients.  Methods: Thirty-eight PD patients and ten age- and gender-matched controls underwent a [18F]MK-9470 PET scan to assess CB1R availability, as well as volumetric MR imaging.  Neuropsychol. symptoms were evaluated using an extensive cognitive and behavioral battery covering the five cognitive domains, depression, anxiety, apathy, and psychiatric complications, and were correlated to CB1R availability using vowel-wise regression anal. (P < 0.05, cor. for family-wise error).  Results: PD patients with poorer performance in episodic memory, executive functioning, speed and mental flexibility (range P 0.003-0.03) showed lower CB1R availability in predominantly the midcingulate cortex and middle to superior frontal gyrus (Tpeak-level > 4.0).  Also, PD patients with more severe visuospatial dysfunction showed decreased CB1R availability in the precuneus, midcingulate, supplementary motor cortex, inferior orbitofrontal gyrus and thalamus (Tpeak-level = 5.5).  These correlations were not related to cortical gray matter atrophy.  No relationship was found between CB1R availability and mood or behavioral symptom scores.  Conclusions: Decreased CB1R availability in the prefrontal and midcingulate cortex in PD patients is strongly correlated with disturbances in executive functioning, episodic memory, and visuospatial functioning.  Further investigation of regional CB1R expression in groups of PD patients with mild cognitive impairment or dementia is warranted in order to further investigate the role of CB1R expression in different levels of cognitive impairment in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0x0S4EDHDR7Vg90H21EOLACvtfcHk0ljw-hjSuQ-SDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVCht7bL&md5=c8153c6b49172901b13fbff26460a461</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs00259-019-04445-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-019-04445-x%26sid%3Dliteratum%253Aachs%26aulast%3DCeccarini%26aufirst%3DJ.%26aulast%3DCasteels%26aufirst%3DC.%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DCrabb%25C3%25A9%26aufirst%3DM.%26aulast%3DVan%2Bde%2BVliet%26aufirst%3DL.%26aulast%3DVanhaute%26aufirst%3DH.%26aulast%3DVandenbulcke%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DW.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DRegional%2520changes%2520in%2520the%2520type%25201%2520cannabinoid%2520receptor%2520are%2520associated%2520with%2520cognitive%2520dysfunction%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2019%26volume%3D46%26spage%3D2348%26epage%3D2357%26doi%3D10.1007%2Fs00259-019-04445-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span> <span> </span><span class="NLM_article-title">End of the line for cannabinoid receptor 1 as an anti-obesity target?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1038/nrd2775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnrd2775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19043439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVenurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=961-962&author=D.+Jones&title=End+of+the+line+for+cannabinoid+receptor+1+as+an+anti-obesity+target%3F&doi=10.1038%2Fnrd2775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">End of the line for cannabinoid receptor 1 as an anti-obesity target?</span></div><div class="casAuthors">Jones, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">961-962</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A wave of terminations of development programs for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters.  Nevertheless, lessons learned might help salvage something for future such approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnUVPwDEhXwrVg90H21EOLACvtfcHk0lit-amatM6UfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVenurbO&md5=e9f31da702da5a058d2ece7ab08be3c0</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnrd2775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2775%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DD.%26atitle%3DEnd%2520of%2520the%2520line%2520for%2520cannabinoid%2520receptor%25201%2520as%2520an%2520anti-obesity%2520target%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D961%26epage%3D962%26doi%3D10.1038%2Fnrd2775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnema, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vivo evaluation of a new PET radioligand for imaging the cannabinoid type-1 (CB1) receptors</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">T50</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2006.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2006.04.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=T50&author=S.+Donohueauthor=C.+Halldinauthor=S.+Finnemaauthor=B.+Gulyasauthor=V.+Pike&title=Synthesis+and+in+vivo+evaluation+of+a+new+PET+radioligand+for+imaging+the+cannabinoid+type-1+%28CB1%29+receptors&doi=10.1016%2Fj.neuroimage.2006.04.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2006.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2006.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DS.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DFinnema%26aufirst%3DS.%26aulast%3DGulyas%26aufirst%3DB.%26aulast%3DPike%26aufirst%3DV.%26atitle%3DSynthesis%2520and%2520in%2520vivo%2520evaluation%2520of%2520a%2520new%2520PET%2520radioligand%2520for%2520imaging%2520the%2520cannabinoid%2520type-1%2520%2528CB1%2529%2520receptors%26jtitle%3DNeuroImage%26date%3D2006%26volume%3D31%26spage%3DT50%26doi%3D10.1016%2Fj.neuroimage.2006.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsujikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenko, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladding, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of 11C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2013.09.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2013.09.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24076222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWju7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2014&pages=733-741&author=T.+Tsujikawaauthor=S.+S.+Zoghbiauthor=J.+Hongauthor=S.+R.+Donohueauthor=K.+J.+Jenkoauthor=R.+L.+Gladdingauthor=C.+Halldinauthor=V.+W.+Pikeauthor=R.+B.+Innisauthor=M.+Fujita&title=In+vitro+and+in+vivo+evaluation+of+11C-SD5024%2C+a+novel+PET+radioligand+for+human+brain+imaging+of+cannabinoid+CB1+receptors&doi=10.1016%2Fj.neuroimage.2013.09.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo evaluation of 11C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors</span></div><div class="casAuthors">Tsujikawa, Tetsuya; Zoghbi, Sami S.; Hong, Jinsoo; Donohue, Sean R.; Jenko, Kimberly J.; Gladding, Robert L.; Halldin, Christer; Pike, Victor W.; Innis, Robert B.; Fujita, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">733-741</span>CODEN:
                <span class="NLM_cas:coden">NEIMEF</span>;
        ISSN:<span class="NLM_cas:issn">1053-8119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We recently developed a novel cannabinoid subtype-1 (CB1) receptor radioligand 11C-SD5024 for brain imaging.  This study aimed to evaluate 11C-SD5024 both in vitro and in vivo and compare it with the other CB1 receptor ligands previously used in humans, i.e., 11C-MePPEP, 11C-OMAR, 18F-MK-9470, and 18F-FMPEP-d2.  In vitro expts. were performed to measure dissocn. const. (Ki) in the human brain and to measure the lipophilicity of the five CB1 receptor ligands listed above.  In vivo specific binding in monkeys was measured by comparing total distribution vol. (VT) at baseline and after full receptor blockade.  The kinetics of 11C-SD5024 in humans were evaluated in seven healthy subjects with compartmental modeling.  SD5024 showed Ki = 0.47 nM, which was at an intermediate level among the five CB1 receptor ligands.  Lipophilicity (LogD7.4) was 3.79, which is appropriate for brain imaging.  Monkey scans showed high proportion of specific binding: ∼ 80̂ of VT.  In humans, 11C-SD5024 showed peak brain uptake of 1.5-3 standardized uptake value, which was slightly higher than that of 11C-OMAR and 18F-MK-9470.  One-compartment model showed good fitting, consistent with the vast majority of brain uptake being specific binding found in the monkey.  Regional VT values were consistent with known distribution of CB1 receptors.  VT calcd. from 80 and 120 min of scan data was strongly correlated (R2 = 0.97), indicating that 80 min provided adequate information for quantitation and that the influence of radiometabolites was low.  Intersubject variability for VT of 11C-SD5024 was 22̂, which was low among the five radioligands and indicated precise measurement.  In conclusion, 11C-SD5024 has appropriate affinity and lipophilicity, high specific binding, moderate brain uptake, and provides good precision to measure the binding.  The results suggest that 11C-SD5024 is slightly better than or equiv. to 11C-OMAR and that both are suitable for clin. studies, esp. those that involve two scans in one day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSuJxTjY4PkLVg90H21EOLACvtfcHk0lit-amatM6UfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWju7fJ&md5=b4427668202331ff0a1357cb0ecf09b3</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2013.09.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2013.09.043%26sid%3Dliteratum%253Aachs%26aulast%3DTsujikawa%26aufirst%3DT.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DJenko%26aufirst%3DK.%2BJ.%26aulast%3DGladding%26aufirst%3DR.%2BL.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DFujita%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%252011C-SD5024%252C%2520a%2520novel%2520PET%2520radioligand%2520for%2520human%2520brain%2520imaging%2520of%2520cannabinoid%2520CB1%2520receptors%26jtitle%3DNeuroImage%26date%3D2014%26volume%3D84%26spage%3D733%26epage%3D741%26doi%3D10.1016%2Fj.neuroimage.2013.09.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hjorth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jucaite, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahlby Hamren, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstrom, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farde, L.</span></span> <span> </span><span class="NLM_article-title">A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuropharm.2015.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25791528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVSku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=519-530&author=S.+Hjorthauthor=C.+Karlssonauthor=A.+Jucaiteauthor=K.+Varnasauthor=U.+Wahlby+Hamrenauthor=P.+Johnstromauthor=B.+Gulyasauthor=S.+R.+Donohueauthor=V.+W.+Pikeauthor=C.+Halldinauthor=L.+Farde&title=A+PET+study+comparing+receptor+occupancy+by+five+selective+cannabinoid+1+receptor+antagonists+in+non-human+primates&doi=10.1016%2Fj.neuropharm.2015.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates</span></div><div class="casAuthors">Hjorth, Stephan; Karlsson, Cecilia; Jucaite, Aurelija; Varnaes, Katarina; Waehlby Hamren, Ulrika; Johnstroem, Peter; Gulyas, Balazs; Donohue, Sean R.; Pike, Victor W.; Halldin, Christer; Farde, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519-530</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is a medical need for safe and efficacious anti-obesity drugs with acceptable side effect profiles.  To mitigate the challenge posed by translating target interaction across species and balancing beneficial vs. adverse effects, a positron emission tomog. (PET) approach could help guide clin. dose optimization.  Thus, as part of a compd. differentiation effort, three novel selective CB1 receptor (CB1R) antagonists, developed by AstraZeneca (AZ) for the treatment of obesity, were compared with two clin. tested ref. compds., rimonabant and taranabant, with regard to receptor occupancy relative to dose and exposure.  A total of 42 PET measurements were performed in 6 non-human primates using the novel CB1R antagonist radioligand [11C]SD5024.  The AZ CB1R antagonists bound in a saturable manner to brain CB1R with in vivo affinities similar to that of rimonabant and taranabant, compds. with proven wt. loss efficacy in clin. trials.  Interestingly, it was found that exposures corresponding to those needed for optimal clin. efficacy of rimonabant and taranabant resulted in a CB1R occupancy typically around ∼20-30%, thus much lower than what would be expected for classical G-protein coupled receptor (GPCR) antagonists in other therapeutic contexts.  These findings are also discussed in relation to emerging literature on the potential usefulness of 'neutral' vs. 'classical' CB1R (inverse agonist) antagonists.  The study addnl. highlighted the usefulness of the radioligand [11C]SD5024 as a specific tracer for CB1R in the primate brain, though an arterial input function would ideally be required in future studies to further assure accurate quant. anal. of specific binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsy3zXkro_77Vg90H21EOLACvtfcHk0lg8XbzP7Alwvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVSku7k%253D&md5=8c81c21f73e6b3cdd988b23d160fe576</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DHjorth%26aufirst%3DS.%26aulast%3DKarlsson%26aufirst%3DC.%26aulast%3DJucaite%26aufirst%3DA.%26aulast%3DVarnas%26aufirst%3DK.%26aulast%3DWahlby%2BHamren%26aufirst%3DU.%26aulast%3DJohnstrom%26aufirst%3DP.%26aulast%3DGulyas%26aufirst%3DB.%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DFarde%26aufirst%3DL.%26atitle%3DA%2520PET%2520study%2520comparing%2520receptor%2520occupancy%2520by%2520five%2520selective%2520cannabinoid%25201%2520receptor%2520antagonists%2520in%2520non-human%2520primates%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D101%26spage%3D519%26epage%3D530%26doi%3D10.1016%2Fj.neuropharm.2015.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjorth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapham, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span> <span> </span><span class="NLM_article-title">Binding properties of antagonists to cannabinoid receptors in intact cells</span>. <i>Fundam. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1111/j.1472-8206.2010.00843.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1472-8206.2010.00843.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20608998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=200-210&author=M.+Wennerbergauthor=L.+Chengauthor=S.+Hjorthauthor=J.+C.+Claphamauthor=A.+Balendranauthor=G.+Vauquelin&title=Binding+properties+of+antagonists+to+cannabinoid+receptors+in+intact+cells&doi=10.1111%2Fj.1472-8206.2010.00843.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Binding properties of antagonists to Cannabinoid receptors in intact cells</span></div><div class="casAuthors">Wennerberg, Marie; Cheng, Leifeng; Hjorth, Stephan; Clapham, John C.; Balendran, Anudharan; Vauquelin, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-210</span>CODEN:
                <span class="NLM_cas:coden">FCPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">0767-3981</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The implication of the cannabinoid receptor 1 (CB1 receptor) in several pathophysiol. states has sparked the development of selective antagonists.  Here we compare binding of the antagonists [3H]-AZ12491187, [3H]-taranabant and [3H]-rimonabant to intact human embryonic kidney cells stably expressing recombinant human CB1 receptors (CB1r cells).  Unlabeled ligands decreased the total binding of the three radioligands with closely the same order of potency: i.e. AZ12288553 ∼ AZ12491187 ∼ taranabant > rimonabant.  Nondisplaceable (i.e. nonspecific) binding to the CB1R cells was the same as total binding to the wells contg. untransfected cells and it was more pronounced for [3H]-AZ12491187 and [3H]-rimonabant than for [3H]-taranabant.  [3H]-Rimonabant and (to a lesser extent) [3H]-AZ12491187 were also prone to bind nonspecifically to the walls of the wells.  Compared to the other radioligands, [3H]-rimonabant displayed lower potency for the CB1 receptors in satn. binding studies and faster assocn. and dissocn. in kinetic expts.  When dissocd., the three radioligands also showed prominent rebinding to the cells in medium only.  This could be relieved by the presence of excess of unlabeled ligand and of bovine serum albumin (BSA) but a combination thereof was most efficient.  The long "residence time" of AZ12491187 at the CB1 receptor (because of slow dissocn. and prominent rebinding) and its pronounced incorporation into the membranes of the cells could contribute to long-lasting in vivo CB1 receptor blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7r6I6kbyu17Vg90H21EOLACvtfcHk0lg8XbzP7Alwvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOqs7w%253D&md5=a110cb216c5f73757e9de57e7ceef0a9</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fj.1472-8206.2010.00843.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1472-8206.2010.00843.x%26sid%3Dliteratum%253Aachs%26aulast%3DWennerberg%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DHjorth%26aufirst%3DS.%26aulast%3DClapham%26aufirst%3DJ.%2BC.%26aulast%3DBalendran%26aufirst%3DA.%26aulast%3DVauquelin%26aufirst%3DG.%26atitle%3DBinding%2520properties%2520of%2520antagonists%2520to%2520cannabinoid%2520receptors%2520in%2520intact%2520cells%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D25%26spage%3D200%26epage%3D210%26doi%3D10.1111%2Fj.1472-8206.2010.00843.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnema, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyás, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span> <span> </span><span class="NLM_article-title">Discovery and labeling of a homochiral high affinity 3,4-diarylpyrazoline as a candidate radioligand for in vivo imaging of cannabinoid type-1 receptors</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">T90</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2008.04.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2008.04.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=T90&author=S.+R.+Donohueauthor=S.+J.+Finnemaauthor=P.+Truongauthor=J.+Anderssonauthor=B.+Guly%C3%A1sauthor=V.+W.+Pikeauthor=C.+Halldin&title=Discovery+and+labeling+of+a+homochiral+high+affinity+3%2C4-diarylpyrazoline+as+a+candidate+radioligand+for+in+vivo+imaging+of+cannabinoid+type-1+receptors&doi=10.1016%2Fj.neuroimage.2008.04.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2008.04.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2008.04.059%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DFinnema%26aufirst%3DS.%2BJ.%26aulast%3DTruong%26aufirst%3DP.%26aulast%3DAndersson%26aufirst%3DJ.%26aulast%3DGuly%25C3%25A1s%26aufirst%3DB.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520labeling%2520of%2520a%2520homochiral%2520high%2520affinity%25203%252C4-diarylpyrazoline%2520as%2520a%2520candidate%2520radioligand%2520for%2520in%2520vivo%2520imaging%2520of%2520cannabinoid%2520type-1%2520receptors%26jtitle%3DNeuroImage%26date%3D2008%26volume%3D41%26spage%3DT90%26doi%3D10.1016%2Fj.neuroimage.2008.04.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willis, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlova, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chefer, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaupel, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5813</span>– <span class="NLM_lpage">5822</span>, <span class="refDoi"> DOI: 10.1021/jm0502743</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0502743" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVertbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5813-5822&author=P.+G.+Willisauthor=O.+A.+Pavlovaauthor=S.+I.+Cheferauthor=D.+B.+Vaupelauthor=A.+G.+Mukhinauthor=A.+G.+Horti&title=Synthesis+and+structure-activity+relationship+of+a+novel+series+of+aminoalkylindoles+with+potential+for+imaging+the+neuronal+cannabinoid+receptor+by+positron+emission+tomography&doi=10.1021%2Fjm0502743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationship of a Novel Series of Aminoalkylindoles with Potential for Imaging the Neuronal Cannabinoid Receptor by Positron Emission Tomography</span></div><div class="casAuthors">Willis, Peter G.; Pavlova, Olga A.; Chefer, Svetlana I.; Vaupel, D. Bruce; Mukhin, Alexey G.; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5813-5822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of CB1 ligands I (R = 4-Me-1-naphthyl, 2-IC6H4, 1-naphthylamino, etc.) with high binding affinity (Ki = 0.7-100 nM) and moderate lipophilicity (cLogD7.4) in the range of 2.1-4.5 has been synthesized.  A structure-activity relationship study demonstrated that for the studied set of aminoalkylindoles, the mol. dipole of the ground state conformation within the series was inversely related to the affinity.  The racemic ligand with highest affinity (0.7 nM), I (R = 4-fluoro-1-naphthyl), was radiolabeled with 18F.  This radioligand specifically labeled CB1 receptors in mouse brain and accumulated in regions of high vs. low CB1 receptor d. in a ratio of 1.6.  The displaceable radioactivity of one enantiomer in the brains of mice detd. in a pretreatment study using the CB1 antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) was nearly double that of the racemate for the same detn.; therefore, the active enantiomer is a candidate for PET studies in animals.  A pretreatment study for the other enantiomer found no displaceable radioactivity in the same group of mice; this result suggested the enantiomer was inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSeOt9IGNWf7Vg90H21EOLACvtfcHk0lg8XbzP7Alwvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVertbs%253D&md5=02a724ee78558e62f9c3176231c9670c</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm0502743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0502743%26sid%3Dliteratum%253Aachs%26aulast%3DWillis%26aufirst%3DP.%2BG.%26aulast%3DPavlova%26aufirst%3DO.%2BA.%26aulast%3DChefer%26aufirst%3DS.%2BI.%26aulast%3DVaupel%26aufirst%3DD.%2BB.%26aulast%3DMukhin%26aufirst%3DA.%2BG.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%2520a%2520novel%2520series%2520of%2520aminoalkylindoles%2520with%2520potential%2520for%2520imaging%2520the%2520neuronal%2520cannabinoid%2520receptor%2520by%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5813%26epage%3D5822%26doi%3D10.1021%2Fjm0502743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhawan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinfeleye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruneus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimaio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gifford, A. N.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[<sup>125</sup>/<sup>131</sup>I] AM2233</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1002/syn.20277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fsyn.20277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16715483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFChu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=93-101&author=J.+Dhawanauthor=H.+Dengauthor=S.+J.+Gatleyauthor=A.+Makriyannisauthor=T.+Akinfeleyeauthor=M.+Bruneusauthor=A.+A.+Dimaioauthor=A.+N.+Gifford&title=Evaluation+of+the+in+vivo+receptor+occupancy+for+the+behavioral+effects+of+cannabinoids+using+a+radiolabeled+cannabinoid+receptor+agonist%2C+R-%5B125%2F131I%5D+AM2233&doi=10.1002%2Fsyn.20277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233</span></div><div class="casAuthors">Dhawan, Jasbeer; Deng, Hongfeng; Gatley, S. John; Makriyannis, Alexandros; Akinfeleye, Tolulope; Bruneus, Magalie; Dimaio, Alexis A.; Gifford, Andrew N.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-101</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">G-protein coupled receptors exist in both high and low agonist affinity conformations, with tracer levels of agonist radioligands preferentially binding to the former.  The goal of the present study was to characterize the in vivo binding of the amino-alkyindole-based, CB1 receptor agonist, R-[125/131I]AM2233 ((2-[125/131I]iodo-phenyl)-[1-(1-methyl-piperidin-2-yl-methyl)-1H-indol-3-yl]-methanone), and to use this radiotracer to selectively measure the receptor occupancy by the related CB1 receptor agonist, WIN55212-2, to the agonist-preferring affinity state of the receptor.  In mouse locomotor assays, both WIN55212-2 and AM2233 (racemic) produced an ∼60% redn. in activity at 1 mg/kg, (i.v.) and completely inhibited activity at 3 mg/kg, confirming their agonist nature.  In ex vivo autoradiog., preferential uptake of R-[131I]AM2233 was apparent in CB1 receptor-rich areas, including globus pallidus, substantia nigra, striatum, cerebellum, and hippocampus.  Overall brain uptake of R-[131I]AM2233 was 1.3% injected activity/g at 5 min in mice.  Coinjection of 3 mg/kg (i.v.) SR141716A, a CB1 receptor antagonist, with R-[125I]AM2233 inhibited the radiotracer binding almost to nonspecific levels in the striatum, globus pallidus, and substantia nigra, although residual binding to a non-CB1 receptor remained in the hippocampus.  In contrast to the effect of SR141716A, coinjection of 10 mg/kg (i.v.) WIN55212-2, a high dose that produced an immediate and profound immobility and catalepsy in the mice, reduced CB1 receptor-specific binding of R-[125I]AM2233 in CB1 receptor-rich areas by only 21-43%.  These observations suggest that the behavioral effects of CB1 receptor agonists are manifested with a relatively small fraction of the agonist-preferring affinity state of the receptor occupied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriXfFfDmY9PLVg90H21EOLACvtfcHk0lj_4PlG6ugjhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFChu74%253D&md5=f1f9670cec72b23ee2676989e081e28d</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20277%26sid%3Dliteratum%253Aachs%26aulast%3DDhawan%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DGatley%26aufirst%3DS.%2BJ.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DAkinfeleye%26aufirst%3DT.%26aulast%3DBruneus%26aufirst%3DM.%26aulast%3DDimaio%26aufirst%3DA.%2BA.%26aulast%3DGifford%26aufirst%3DA.%2BN.%26atitle%3DEvaluation%2520of%2520the%2520in%2520vivo%2520receptor%2520occupancy%2520for%2520the%2520behavioral%2520effects%2520of%2520cannabinoids%2520using%2520a%2520radiolabeled%2520cannabinoid%2520receptor%2520agonist%252C%2520R-%255B125%252F131I%255D%2520AM2233%26jtitle%3DSynapse%26date%3D2006%26volume%3D60%26spage%3D93%26epage%3D101%26doi%3D10.1002%2Fsyn.20277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. B.</span>; <span class="NLM_string-name">Amegadzie, K. M.</span>; <span class="NLM_string-name">Gardiner, G. S.</span>; <span class="NLM_string-name">Hitchcock, A.</span>; <span class="NLM_string-name">Hoogestraat, W. J.</span></span> <span> </span><span class="NLM_article-title">CB1 Modulator Compounds</span>. Patent <span class="NLM_patent">WO2005/066126A1</span>, Jul 21, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+B.+Allen&author=K.+M.+Amegadzie&author=G.+S.+Gardiner&author=A.+Hitchcock&author=W.+J.+Hoogestraat&title=CB1+Modulator+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BB.%26atitle%3DCB1%2520Modulator%2520Compounds%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phebus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardinier, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruley, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span> <span> </span><span class="NLM_article-title">Radiolabeling of a high potency cannabinoid subtype-1 receptor ligand, N-(4-fluoro-benzyl)-4-(3-(piperidin-1-yl)-indole-1-sulfonyl)benzamide (PipISB), with carbon-11 or fluorine-18</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1002/jlcr.1491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjlcr.1491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVKgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=146-152&author=S.+R.+Donohueauthor=C.+Halldinauthor=M.+Schouauthor=J.+Hongauthor=L.+Phebusauthor=E.+Chernetauthor=S.+A.+Hitchcockauthor=K.+M.+Gardinierauthor=K.+M.+Ruleyauthor=J.+H.+Krushinskiauthor=J.+Schausauthor=V.+W.+Pike&title=Radiolabeling+of+a+high+potency+cannabinoid+subtype-1+receptor+ligand%2C+N-%284-fluoro-benzyl%29-4-%283-%28piperidin-1-yl%29-indole-1-sulfonyl%29benzamide+%28PipISB%29%2C+with+carbon-11+or+fluorine-18&doi=10.1002%2Fjlcr.1491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Radiolabeling of a high potency cannabinoid subtype-1 receptor ligand, N-(4-fluoro-benzyl)-4-(3-(piperidin-1-yl)-indole-1-sulfonyl)benzamide (PipISB), with carbon-11 or fluorine-18</span></div><div class="casAuthors">Donohue, Sean R.; Halldin, Christer; Schou, Magnus; Hong, Jinsoo; Phebus, Lee; Chernet, Eyassu; Hitchcock, Stephen A.; Gardinier, Kevin M.; Ruley, Kevin M.; Krushinski, Joseph H.; Schaus, John; Pike, Victor W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">146-152</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">PipISB [N-(4-fluorobenzyl)-4-(3-(piperidin-1-yl)indole-1-sulfonyl)benzamide, I] was identified as a selective high potency CB1 receptor ligand.  Here we describe the labeling of I with positron-emitters to provide candidate radioligands for imaging brain CB1 receptors with positron emission tomog. (PET).  The radiolabeling of I was achieved by two methods, method A with carbon-11 and method B with fluorine-18.  In method A, [11C]I was prepd. in one step from [11C]carbon monoxide, itself prepd. from cyclotron-produced [11C]carbon dioxide.  In method B, [18F]I was prepd. from cyclotron-produced [18F]fluoride ion in a two-stage, four-step synthesis with [18F]4-fluorobenzyl bromide as a labeling agent.  The radiosynthesis time for method A was 44 min; decay-cor. radiochem. yields (RCYs) from [11C]carbon monoxide ranged from 3.1 to 11.6% and specific radioactivities ranged from 21 to 67 GBq/μmol.  The radiosynthesis time for method B was 115 min; RCYs from [18F]fluoride ion ranged from 1.5 to 5.6% and specific radioactivities ranged from 200 to 348 GBq/μmol.  With these methods, [11C]I and [18F]I may be prepd. with adequate activity and quality for future evaluation as PET radioligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHbhAoO0U7qrVg90H21EOLACvtfcHk0lj_4PlG6ugjhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVKgtrY%253D&md5=7c46eed40e9ff3fff9412da9af01581f</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.1491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.1491%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DSchou%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DPhebus%26aufirst%3DL.%26aulast%3DChernet%26aufirst%3DE.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DGardinier%26aufirst%3DK.%2BM.%26aulast%3DRuley%26aufirst%3DK.%2BM.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DSchaus%26aufirst%3DJ.%26aulast%3DPike%26aufirst%3DV.%2BW.%26atitle%3DRadiolabeling%2520of%2520a%2520high%2520potency%2520cannabinoid%2520subtype-1%2520receptor%2520ligand%252C%2520N-%25284-fluoro-benzyl%2529-4-%25283-%2528piperidin-1-yl%2529-indole-1-sulfonyl%2529benzamide%2520%2528PipISB%2529%252C%2520with%2520carbon-11%2520or%2520fluorine-18%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2008%26volume%3D51%26spage%3D146%26epage%3D152%26doi%3D10.1002%2Fjlcr.1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnema, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of [<sup>11</sup>C]PipISB and [<sup>18</sup>F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1002/syn.20578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fsyn.20578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18925657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD1cnpsVamtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2009&pages=22-30&author=S.+J.+Finnemaauthor=S.+R.+Donohueauthor=S.+S.+Zoghbiauthor=A.+K.+Brownauthor=B.+Gulyasauthor=R.+B.+Innisauthor=C.+Halldinauthor=V.+W.+Pike&title=Evaluation+of+%5B11C%5DPipISB+and+%5B18F%5DPipISB+in+monkey+as+candidate+radioligands+for+imaging+brain+cannabinoid+type-1+receptors+in+vivo&doi=10.1002%2Fsyn.20578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo</span></div><div class="casAuthors">Finnema Sjoerd J; Donohue Sean R; Zoghbi Sami S; Brown Amira K; Gulyas Balazs; Innis Robert B; Halldin Christer; Pike Victor W</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">N-(4-Fluorobenzyl)-4-[3-(piperidin-1-yl)indole-1-sulfonyl]benzamide] (PipISB, 3) is a selective and high-potency cannabinoid subtype-1 (CB1) receptor inverse agonist.  We have previously reported radiosyntheses of [11C]3 and [18F]3.  Here, we aimed to evaluate the uptake and CB(1) receptor-specific binding of each radioligand in monkey brain in vivo with positron emission tomography (PET). [11C]3 or [18F]3 was injected intravenously into rhesus or cynomolgus monkey, respectively, and examined with PET at baseline or after pretreatment with a receptor-saturating dose of CB1 receptor-selective ligand (3 for [11C]3 or 8 for [18F]3).  In one PET experiment, the dose of 3 was administered at 100 min after [11C]3.  Relative plasma concentrations of radioligand and radiometabolites were concurrently measured in baseline experiments with high-performance liquid chromatography.  Brain radioactivity uptake was highest in striatum and cerebellum, and it reached 170-270% standardized uptake value (SUV) at 120 min after injection of [11C]3 and 180% SUV at 240 min after injection of [18F]3.  Radioactivity was well retained in all CB1 receptor-rich regions.  No reference region could be identified for nonspecifically bound radioligand.  Under CB1 receptor pretreatment and displacement conditions, initial brain uptakes of radioactivity were similar to those at baseline.  Regional brain radioactivity concentrations then became homogeneous and diminished to between 70 and 80% SUV at 120 min after injection of [11C]3 and to 25% SUV at 240 min after injection of [18F]3. [18F]3 was not defluorinated but was metabolized to less lipophilic radiometabolites, as was [11C]3.  Hence, [11C]3 and [18F]3 showed high CB1 receptor-specific binding in monkey brain in vivo and merit further investigation as prospective PET radioligands in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlf8GQ8ajv6s-crCu0nI_sfW6udTcc2eZceCRtmOvUHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnpsVamtQ%253D%253D&md5=6988fe4d33bc473e3c06163c92a64149</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20578%26sid%3Dliteratum%253Aachs%26aulast%3DFinnema%26aufirst%3DS.%2BJ.%26aulast%3DDonohue%26aufirst%3DS.%2BR.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DBrown%26aufirst%3DA.%2BK.%26aulast%3DGulyas%26aufirst%3DB.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DPike%26aufirst%3DV.%2BW.%26atitle%3DEvaluation%2520of%2520%255B11C%255DPipISB%2520and%2520%255B18F%255DPipISB%2520in%2520monkey%2520as%2520candidate%2520radioligands%2520for%2520imaging%2520brain%2520cannabinoid%2520type-1%2520receptors%2520in%2520vivo%26jtitle%3DSynapse%26date%3D2009%26volume%3D63%26spage%3D22%26epage%3D30%26doi%3D10.1002%2Fsyn.20578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">German, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmour, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure–activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl) pyridin-2-yl] phenyl} urea (PSNCBAM-1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7758</span>– <span class="NLM_lpage">7769</span>, <span class="refDoi"> DOI: 10.1021/jm501042u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501042u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCnu7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7758-7769&author=N.+Germanauthor=A.+M.+Deckerauthor=B.+P.+Gilmourauthor=E.+A.+Gayauthor=J.+L.+Wileyauthor=B.+F.+Thomasauthor=Y.+Zhang&title=Diarylureas+as+allosteric+modulators+of+the+cannabinoid+CB1+receptor%3A+structure%E2%80%93activity+relationship+studies+on+1-%284-chlorophenyl%29-3-%7B3-%5B6-%28pyrrolidin-1-yl%29+pyridin-2-yl%5D+phenyl%7D+urea+%28PSNCBAM-1%29&doi=10.1021%2Fjm501042u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylureas as Allosteric Modulators of the Cannabinoid CB1 Receptor: Structure-Activity Relationship Studies on 1-(4-Chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)</span></div><div class="casAuthors">German, Nadezhda; Decker, Ann M.; Gilmour, Brian P.; Gay, Elaine A.; Wiley, Jenny L.; Thomas, Brian F.; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7758-7769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent discovery of allosteric modulators of the CB1 receptor including PSNCBAM-1 (4) has generated significant interest in CB1 receptor allosteric modulation.  Here in the first SAR study on 4, we have designed and synthesized a series of analogs focusing on modifications at two positions.  Pharmacol. evaluation in calcium mobilization and binding assays revealed the importance of alkyl substitution at the 2-aminopyridine moiety and electron deficient arom. groups at the 4-chlorophenyl position for activity at the CB1 receptor, resulting in several analogs with comparable potency to 4.  These compds. increased the specific binding of [3H]CP55,940, in agreement with previous reports.  Importantly, 4 and two analogs dose-dependently reduced the Emax of the agonist curve in the CB1 calcium mobilization assays, confirming their neg. allosteric modulator characteristics.  Given the side effects assocd. with CB1 receptor orthosteric antagonists, neg. allosteric modulators provide an alternative approach to modulate the pharmacol. important CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKoWK33ooy7Vg90H21EOLACvtfcHk0lhk-1hBofoF0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCnu7bE&md5=c7cfd8bd55b25d5861768a10496cca70</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm501042u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501042u%26sid%3Dliteratum%253Aachs%26aulast%3DGerman%26aufirst%3DN.%26aulast%3DDecker%26aufirst%3DA.%2BM.%26aulast%3DGilmour%26aufirst%3DB.%2BP.%26aulast%3DGay%26aufirst%3DE.%2BA.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiarylureas%2520as%2520allosteric%2520modulators%2520of%2520the%2520cannabinoid%2520CB1%2520receptor%253A%2520structure%25E2%2580%2593activity%2520relationship%2520studies%2520on%25201-%25284-chlorophenyl%2529-3-%257B3-%255B6-%2528pyrrolidin-1-yl%2529%2520pyridin-2-yl%255D%2520phenyl%257D%2520urea%2520%2528PSNCBAM-1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7758%26epage%3D7769%26doi%3D10.1021%2Fjm501042u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakizaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and evaluation of new PET ligands for peripheral cannabinoid receptor type 1 imaging</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4114</span>– <span class="NLM_lpage">4117</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.07.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmcl.2017.07.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28757061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GktbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4114-4117&author=T.+Yamasakiauthor=M.+Fujinagaauthor=Y.+Shimodaauthor=W.+Moriauthor=Y.+Zhangauthor=H.+Wakizakaauthor=M.+Ogawaauthor=M.+R.+Zhang&title=Radiosynthesis+and+evaluation+of+new+PET+ligands+for+peripheral+cannabinoid+receptor+type+1+imaging&doi=10.1016%2Fj.bmcl.2017.07.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and evaluation of new PET ligands for peripheral cannabinoid receptor type 1 imaging</span></div><div class="casAuthors">Yamasaki, Tomoteru; Fujinaga, Masayuki; Shimoda, Yoko; Mori, Wakana; Zhang, Yiding; Wakizaka, Hidekatsu; Ogawa, Masanao; Zhang, Ming-Rong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4114-4117</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of radiolabeled compds. I (X = Cl, Y = (CH3)2N; X = CN, Y = pyrrolidin-1-yl) using [11C]COCl2 and an evaluation of their potential as PET ligands for CB1 imaging using in vitro and in vivo techniques were reported.  Compds. I were successfully synthesized in two steps using [11C]COCl2.  The radiochem. yields of I were 17 ± 8% and 20 ± 9% (decay-cor. to the end of bombardment, based on [11C]CO2).  The specific activities of I were 42 ± 36 and 37 ± 13 GBq/μmol, resp.  The results of an in vitro binding assay using brown adipose tissue (BAT) homogenate showed that the binding affinity of 1-(4-Chloro-phenyl)-3-[3-(6-dimethylamino-pyridin-2-yl)-phenyl]-urea for CB1 (KD = 15.3 μM) was much higher than that of 1-(4-cyano-phenyl)-3-[3-(6-pyrrolidin-1-yl-pyridin-2-yl)-phenyl]-urea (KD = 26.0 μM).  PET studies with I (X = Cl; Y = (CH3)2N) showed a high uptake of radioactivity in BAT, which decreased in animals pretreated with AM281 (a selective antagonist for CB1).  In conclusion, I (X = Cl; Y = (CH3)2N) may be a useful PET ligand for imaging peripheral CB1 in BAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZyVetOisQH7Vg90H21EOLACvtfcHk0lhk-1hBofoF0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GktbnO&md5=2821e74fe07f3addb84bcbe8645c21f6</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.07.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.07.040%26sid%3Dliteratum%253Aachs%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWakizaka%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26atitle%3DRadiosynthesis%2520and%2520evaluation%2520of%2520new%2520PET%2520ligands%2520for%2520peripheral%2520cannabinoid%2520receptor%2520type%25201%2520imaging%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4114%26epage%3D4117%26doi%3D10.1016%2Fj.bmcl.2017.07.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelagalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marwick, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Angelo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinaci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardingham, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanda, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2096</span>, <span class="refDoi"> DOI: 10.1039/C6OB02796B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1039%2FC6OB02796B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28210722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1Whs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=2086-2096&author=C.+Zanatoauthor=A.+Pelagalliauthor=K.+F.+Marwickauthor=M.+Pirasauthor=S.+Dall%E2%80%99Angeloauthor=A.+Spinaciauthor=R.+G.+Pertweeauthor=D.+J.+Wyllieauthor=G.+E.+Hardinghamauthor=M.+Zanda&title=Synthesis%2C+radio-synthesis+and+in+vitro+evaluation+of+terminally+fluorinated+derivatives+of+HU-210+and+HU-211+as+novel+candidate+PET+tracers&doi=10.1039%2FC6OB02796B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers</span></div><div class="casAuthors">Zanato, Chiara; Pelagalli, Alessia; Marwick, Katie F. M.; Piras, Monica; Dall'Angelo, Sergio; Spinaci, Andrea; Pertwee, Roger G.; Wyllie, David J. A.; Hardingham, Giles E.; Zanda, Matteo</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2086-2096</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We report the synthesis of terminally fluorinated HU-210 and HU-211 analogs (HU-210F and HU-211F, resp.) and their biol. evaluation as ligands of cannabinoid receptors (CB1 and CB2) and N-Me D-aspartate receptor (NMDAR). [18F]-labeled HU-210F was radiosynthesised from the bromo-substituted precursor.  In vitro assays showed that both HU-210F and HU-211F retain the potent pharmacol. profile of HU-210 and HU-211, suggesting that [18F]-radiolabeled HU-210F and HU-211F could have potential as PET tracers for in vivo imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfDBpn2w-O2LVg90H21EOLACvtfcHk0ljELush7vxo_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1Whs70%253D&md5=fa689a4c76b4d8fc6b057d373e2efb09</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1039%2FC6OB02796B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB02796B%26sid%3Dliteratum%253Aachs%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DPelagalli%26aufirst%3DA.%26aulast%3DMarwick%26aufirst%3DK.%2BF.%26aulast%3DPiras%26aufirst%3DM.%26aulast%3DDall%25E2%2580%2599Angelo%26aufirst%3DS.%26aulast%3DSpinaci%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DWyllie%26aufirst%3DD.%2BJ.%26aulast%3DHardingham%26aufirst%3DG.%2BE.%26aulast%3DZanda%26aufirst%3DM.%26atitle%3DSynthesis%252C%2520radio-synthesis%2520and%2520in%2520vitro%2520evaluation%2520of%2520terminally%2520fluorinated%2520derivatives%2520of%2520HU-210%2520and%2520HU-211%2520as%2520novel%2520candidate%2520PET%2520tracers%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2017%26volume%3D15%26spage%3D2086%26epage%3D2096%26doi%3D10.1039%2FC6OB02796B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K. S.</span></span> <span> </span><span class="NLM_article-title">Fluorine-18 isotope labeling for positron emission tomography imaging. Direct evidence for DBPR211 as a peripherally restricted CB1 inverse agonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.11.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmc.2018.11.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30528163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnu7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=216-223&author=C.+P.+Changauthor=H.+L.+Huangauthor=J.+K.+Huangauthor=M.+S.+Hungauthor=C.+H.+Wuauthor=J.+S.+Songauthor=C.+J.+Leeauthor=C.+S.+Yuauthor=K.+S.+Shia&title=Fluorine-18+isotope+labeling+for+positron+emission+tomography+imaging.+Direct+evidence+for+DBPR211+as+a+peripherally+restricted+CB1+inverse+agonist&doi=10.1016%2Fj.bmc.2018.11.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine-18 isotope labeling for positron emission tomography imaging. Direct evidence for DBPR211 as a peripherally restricted CB1 inverse agonist</span></div><div class="casAuthors">Chang, Chun-Ping; Huang, Ho-Lien; Huang, Jing-Kai; Hung, Ming-Shiu; Wu, Chien-Huang; Song, Jen-Shin; Lee, Chia-Jui; Yu, Chung-Shan; Shia, Kak-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">216-223</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The [18F] isotope-labeled CB1 inverse agonist 3 was elaborated and synthesized for positron emission tomog. scanning studies.  After immediate purifn. and calibration with its unlabeled counterpart, compd. 3 was i.v. injected in mice and revealed that its distribution percentage in brain over 90-min scans among five region of interests, including brain, liver, heart, thigh muscle and kidney was lower than 1%, thus providing direct evidence to justify itself as a peripherally restricted CB1 antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY2-c_Wr1LNLVg90H21EOLACvtfcHk0ljELush7vxo_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnu7fE&md5=13a1edf2520bc1731960217b22282d8d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.11.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.11.043%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%2BP.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DHuang%26aufirst%3DJ.%2BK.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DC.%2BJ.%26aulast%3DYu%26aufirst%3DC.%2BS.%26aulast%3DShia%26aufirst%3DK.%2BS.%26atitle%3DFluorine-18%2520isotope%2520labeling%2520for%2520positron%2520emission%2520tomography%2520imaging.%2520Direct%2520evidence%2520for%2520DBPR211%2520as%2520a%2520peripherally%2520restricted%2520CB1%2520inverse%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D216%26epage%3D223%26doi%3D10.1016%2Fj.bmc.2018.11.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Cueto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ruiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagerovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span> <span> </span><span class="NLM_article-title">Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">406</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3389%2Ffnins.2016.00406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27679556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC2svktlSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=406&author=G.+Navarroauthor=P.+Moralesauthor=C.+Rodriguez-Cuetoauthor=J.+Fernandez-Ruizauthor=N.+Jagerovicauthor=R.+Franco&title=Targeting+cannabinoid+CB2+receptors+in+the+central+nervous+system.+Medicinal+chemistry+approaches+with+focus+on+neurodegenerative+disorders&doi=10.3389%2Ffnins.2016.00406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders</span></div><div class="casAuthors">Navarro Gemma; Franco Rafael; Morales Paula; Rodriguez-Cueto Carmen; Fernandez-Ruiz Javier; Jagerovic Nadine</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">406</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Endocannabinoids activate two types of specific G-protein-coupled receptors (GPCRs), namely cannabinoid CB1 and CB2.  Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 receptors appear as promising drugs to combat CNS diseases (Parkinson's disease, Huntington's chorea, cerebellar ataxia, amyotrohic lateral sclerosis).  Differential localization of CB2 receptors in neural cell types and upregulation in neuroinflammation are keys to understand the therapeutic potential in inter alia diseases that imply progressive neurodegeneration.  Medicinal chemistry approaches are now engaged to develop imaging tools to map receptors in the living human brain, to develop more efficacious agonists, and to investigate the possibility to develop allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3wLImrF0SGijiVMCqkKxVfW6udTcc2eao8QSLQwea9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svktlSitg%253D%253D&md5=5301fd9e4c3411b77a0cc9809389aee8</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00406%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DRodriguez-Cueto%26aufirst%3DC.%26aulast%3DFernandez-Ruiz%26aufirst%3DJ.%26aulast%3DJagerovic%26aufirst%3DN.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DTargeting%2520cannabinoid%2520CB2%2520receptors%2520in%2520the%2520central%2520nervous%2520system.%2520Medicinal%2520chemistry%2520approaches%2520with%2520focus%2520on%2520neurodegenerative%2520disorders%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D406%26doi%3D10.3389%2Ffnins.2016.00406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. J.</span></span> <span> </span><span class="NLM_article-title">Role of neuroinflammation in neurodegenerative diseases (Review)</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3391</span>– <span class="NLM_lpage">3396</span>, <span class="refDoi"> DOI: 10.3892/mmr.2016.4948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3892%2Fmmr.2016.4948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26935478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12rsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=3391-3396&author=W.+W.+Chenauthor=X.+Zhangauthor=W.+J.+Huang&title=Role+of+neuroinflammation+in+neurodegenerative+diseases+%28Review%29&doi=10.3892%2Fmmr.2016.4948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Role of neuroinflammation in neurodegenerative diseases (Review)</span></div><div class="casAuthors">Chen, Wei-Wei; Zhang, Xia; Huang, Wen-Juan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3391-3396</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Neurodegeneration is a phenomenon that occurs in the central nervous system through the hallmarks assocg. the loss of neuronal structure and function.  Neurodegeneration is obsd. after viral insult and mostly in various so-called 'neurodegenerative diseases', generally obsd. in the elderly, such as Alzheimer's disease, multiple sclerosis, Parkinson's disease and amyotrophic lateral sclerosis that neg. affect mental and phys. functioning.  Causative agents of neurodegeneration have yet to be identified.  However, recent data have identified the inflammatory process as being closely linked with multiple neurodegenerative pathways, which are assocd. with depression, a consequence of neurodegenerative disease.  Accordingly, pro-inflammatory cytokines are important in the pathophysiol. of depression and dementia.  These data suggest that the role of neuroinflammation in neurodegeneration must be fully elucidated, since pro-inflammatory agents, which are the causative effects of neuroinflammation, occur widely, particularly in the elderly in whom inflammatory mechanisms are linked to the pathogenesis of functional and mental impairments.  In this review, we investigated the role played by the inflammatory process in neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp398nJGS8HIrVg90H21EOLACvtfcHk0lhOfTMhafIkcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12rsL7E&md5=36d22b27436bea74776a33a373108e9d</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2016.4948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2016.4948%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%2BW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26atitle%3DRole%2520of%2520neuroinflammation%2520in%2520neurodegenerative%2520diseases%2520%2528Review%2529%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2016%26volume%3D13%26spage%3D3391%26epage%3D3396%26doi%3D10.3892%2Fmmr.2016.4948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raitio, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vepsäläinen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2022</span>– <span class="NLM_lpage">2027</span>, <span class="refDoi"> DOI: 10.1021/jm050879z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050879z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2022-2027&author=K.+H.+Raitioauthor=J.+R.+Savinainenauthor=J.+Veps%C3%A4l%C3%A4inenauthor=J.+T.+Laitinenauthor=A.+Posoauthor=T.+J%C3%A4rvinenauthor=T.+Nevalainen&title=Synthesis+and+SAR+studies+of+2-oxoquinoline+derivatives+as+CB2+receptor+inverse+agonists&doi=10.1021%2Fjm050879z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR Studies of 2-Oxoquinoline Derivatives as CB2 Receptor Inverse Agonists</span></div><div class="casAuthors">Raitio, Katri H.; Savinainen, Juha R.; Vepsaelaeinen, Jouko; Laitinen, Jarmo T.; Poso, Antti; Jaervinen, Tomi; Nevalainen, Tapio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2022-2027</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The highly CB2 selective cannabinoid receptor inverse agonist, N-benzo[1,3]dioxol-5-ylmethyl 7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide I (R = 1,3-benzodioxolan-5-ylmethyl) (JTE-907), served as the lead compd. for investigating the structure-activity relationships of its analogs and in the search for more potent and effective CB2 receptor inverse agonists.  A series of amides I [R = PhCH2, Ph(CH2)3, 4-O2NC6H4CH2CH2, 2-(3-indolyl)ethyl, etc.] was synthesized, and the CB2 receptor activities of the compds. were detd. by a [35S]GTPγS-binding assay using membranes of CHO cells stably transfected with the human CB2 receptor.  As a result, all the compds. were defined as full CB2 receptor inverse agonists, and addnl., except for I [R = 3,4-(HO)2C6H3(CH2)n; n = 1, 2], they were found to be equally potent as SR144528.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrzdBz_5pRFrVg90H21EOLACvtfcHk0lhOfTMhafIkcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Grur8%253D&md5=e9a4a044d6ed3f8fbb2c2eb2f2623e2b</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fjm050879z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050879z%26sid%3Dliteratum%253Aachs%26aulast%3DRaitio%26aufirst%3DK.%2BH.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DVeps%25C3%25A4l%25C3%25A4inen%26aufirst%3DJ.%26aulast%3DLaitinen%26aufirst%3DJ.%2BT.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DT.%26aulast%3DNevalainen%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520SAR%2520studies%2520of%25202-oxoquinoline%2520derivatives%2520as%2520CB2%2520receptor%2520inverse%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2022%26epage%3D2027%26doi%3D10.1021%2Fjm050879z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houbrechts, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2009.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2009.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19423014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslWitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=455-465&author=N.+Evensauthor=G.+G.+Muccioliauthor=N.+Houbrechtsauthor=D.+M.+Lambertauthor=A.+M.+Verbruggenauthor=K.+Van+Laereauthor=G.+M.+Bormans&title=Synthesis+and+biological+evaluation+of+carbon-11-+and+fluorine-18-labeled+2-oxoquinoline+derivatives+for+type+2+cannabinoid+receptor+positron+emission+tomography+imaging&doi=10.1016%2Fj.nucmedbio.2009.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging</span></div><div class="casAuthors">Evens, Nele; Muccioli, Giulio G.; Houbrechts, Nele; Lambert, Didier M.; Verbruggen, Alfons M.; Van Laere, Koen; Bormans, Guy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">455-465</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: The type 2 cannabinoid (CB2) receptor is part of the endocannabinoid system and has been suggested as a mediator of several central and peripheral inflammatory processes.  Imaging of the CB2 receptor has been unsuccessful so far.  We synthesized and evaluated a carbon-11- and a fluorine-18-labeled 2-oxoquinoline deriv. as new PET tracers with high specificity and affinity for the CB2 receptor.  Methods: Two 2-oxoquinoline derivs. were synthesized and radiolabeled with either carbon-11 or fluorine-18.  Their affinity and selectivity for the human CB2 receptor were detd.  Biol. evaluation was done by biodistribution, radiometabolite and autoradiog. studies in mice.  Results: In vitro studies showed that both compds. are high affinity CB2-specific inverse agonists.  Biodistribution study of the tracers in mice showed a high in vivo initial brain uptake and fast brain washout, in accordance with the low CB2 receptor expression levels in normal brain.  A persistently high in vivo binding to the spleen was obsd., which was inhibited by pretreatment with two structurally unrelated CB2 selective inverse agonists.  In vitro autoradiog. studies with the radioligands confirmed CB2-specific binding to the mouse spleen.  Conclusion: We synthesized two novel CB2 receptor PET tracers that show high affinity/selectivity for CB2 receptors.  Both tracers show favorable characteristics as radioligands for central and peripheral in vivo visualization of the CB2 receptor and are promising candidates for primate and human CB2 PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvj-Yo-xj7b7Vg90H21EOLACvtfcHk0lhOfTMhafIkcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslWitr4%253D&md5=215490676fd3fc7a7f96a22d0a67daf8</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2009.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2009.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DEvens%26aufirst%3DN.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DHoubrechts%26aufirst%3DN.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26aulast%3DVerbruggen%26aufirst%3DA.%2BM.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DBormans%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520carbon-11-%2520and%2520fluorine-18-labeled%25202-oxoquinoline%2520derivatives%2520for%2520type%25202%2520cannabinoid%2520receptor%2520positron%2520emission%2520tomography%2520imaging%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2009%26volume%3D36%26spage%3D455%26epage%3D465%26doi%3D10.1016%2Fj.nucmedbio.2009.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeputte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coolen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekelandt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G. M.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of [<sup>11</sup>C]NE40, a type 2 cannabinoid receptor PET tracer</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2011.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22154685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Oqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=389-399&author=N.+Evensauthor=C.+Vandeputteauthor=C.+Coolenauthor=P.+Janssenauthor=R.+Sciotauthor=V.+Baekelandtauthor=A.+M.+Verbruggenauthor=Z.+Debyserauthor=K.+Van+Laereauthor=G.+M.+Bormans&title=Preclinical+evaluation+of+%5B11C%5DNE40%2C+a+type+2+cannabinoid+receptor+PET+tracer&doi=10.1016%2Fj.nucmedbio.2011.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer</span></div><div class="casAuthors">Evens, Nele; Vandeputte, Caroline; Coolen, Charlotte; Janssen, Peter; Sciot, Raf; Baekelandt, Veerle; Verbruggen, Alfons M.; Debyser, Zeger; Van Laere, Koen; Bormans, Guy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-399</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Up-regulation of the type 2 cannabinoid receptor (CB2R) has been reported in (neuro)inflammatory diseases.  In this study, we report the preclin. evaluation of [11C]NE40 as positron emission tomog. (PET) radioligand for visualization of the CB2R.  The selectivity of NE40 for CB2R and its toxicity and mutagenicity were detd.  [11C]NE40 was evaluated by biodistribution and autoradiog. studies in normal rats and a microPET study in normal mice, rats and a rhesus monkey.  Specific in vivo binding of [11C]NE40 to human CB2R (hCB2R) was studied in a rat model with hCB2R overexpression.[11C]NE40 shows specific CB2R binding in the spleen and blood of normal rats and high brain uptake in rhesus monkey.  [11C]NE40 showed specific and reversible binding to hCB2R in vivo in a rat model with local hCB2R overexpression.  [11C]NE40 shows favorable characteristics as radioligand for in vivo visualization of the CB2R and is a promising candidate for hCB2R PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJz5-qNs-FbVg90H21EOLACvtfcHk0ljWXxFonBkc3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Oqu7k%253D&md5=be1c9b2ff6196d6f7cbe5f4ab02150bb</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DEvens%26aufirst%3DN.%26aulast%3DVandeputte%26aufirst%3DC.%26aulast%3DCoolen%26aufirst%3DC.%26aulast%3DJanssen%26aufirst%3DP.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DBaekelandt%26aufirst%3DV.%26aulast%3DVerbruggen%26aufirst%3DA.%2BM.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DBormans%26aufirst%3DG.%2BM.%26atitle%3DPreclinical%2520evaluation%2520of%2520%255B11C%255DNE40%252C%2520a%2520type%25202%2520cannabinoid%2520receptor%2520PET%2520tracer%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2012%26volume%3D39%26spage%3D389%26epage%3D399%26doi%3D10.1016%2Fj.nucmedbio.2011.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postnov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versijpt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbulcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">2219</span>– <span class="NLM_lpage">2227</span>, <span class="refDoi"> DOI: 10.1007/s00259-016-3457-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs00259-016-3457-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27488857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlansbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=2219-2227&author=R.+Ahmadauthor=A.+Postnovauthor=G.+Bormansauthor=J.+Versijptauthor=M.+Vandenbulckeauthor=K.+Van+Laere&title=Decreased+in+vivo+availability+of+the+cannabinoid+type+2+receptor+in+Alzheimer%E2%80%99s+disease&doi=10.1007%2Fs00259-016-3457-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease</span></div><div class="casAuthors">Ahmad, Rawaha; Postnov, Andrey; Bormans, Guy; Versijpt, Jan; Vandenbulcke, Mathieu; Van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2219-2227</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The cannabinoid type 2 receptor (CB2R) is expressed by immune cells such as monocytes and macrophages.  In the brain, CB2R is primarily found on microglia.  CB2R upregulation has been reported in animal models of Alzheimer's disease, with a preferential localization near amyloid beta (Aβ) plaques, and in patients post mortem.  We performed in vivo brain imaging and kinetic modeling of the CB2R tracer [11C]NE40 in healthy controls (HC) and in patients with Alzheimer's disease (AD) to investigate whether higher CB2R availability regionally colocalized to Aβ deposits is present in vivo.  Methods: Dynamic 90-min [11C]NE40 PET scans were performed in eight HC and nine AD patients with full kinetic modeling using arterial sampling and metabolite correction and partial vol. correction.  All AD patients received a static [11C]PIB scan 40 min after injection.  In four HC, a retest scan with [11C]NE40 PET was performed within 9 wk to investigate test-retest characteristics.  Results: [11C]NE40 was metabolized quickly leading to 50 % of intact tracer 20 min after injection and 20 % at 90 min.  A two-tissue kinetic model fitted most of the time-activity curves best; both binding potential (BPND) and distribution vol. (VT) parameters could be used.  Brain uptake was generally low with an av. K1 value of 0.07 mL/min/mL tissue.  VT and BPND were in the range of 0.7 - 1.8 and 0.6 - 1.6, resp.  Test values in HC were about 30 % for VT and BPND.  AD patients showed overall significantly lower CB2R binding.  No relationship was found between regional or global amyloid load and CB2R availability.  Conclusion: Kinetic modeling of [11C]NE40 is possible with a two-tissue reversible model.  In contrast to preclin. and post-mortem data, [11C]NE40 PET shows lower CB2R availability in vivo in AD patients, with no relationship to Aβ plaques.  A possible explanation for these findings is that [11C]NE40 binds to CB2R with lower affinity and/or selectivity than to CB1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8dZ0AOY_CYrVg90H21EOLACvtfcHk0ljWXxFonBkc3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlansbvI&md5=206d502f265b83e15c0f032499b08eb6</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3457-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3457-7%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DPostnov%26aufirst%3DA.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DVersijpt%26aufirst%3DJ.%26aulast%3DVandenbulcke%26aufirst%3DM.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26atitle%3DDecreased%2520in%2520vivo%2520availability%2520of%2520the%2520cannabinoid%2520type%25202%2520receptor%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2016%26volume%3D43%26spage%3D2219%26epage%3D2227%26doi%3D10.1007%2Fs00259-016-3457-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herde, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.01.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejmech.2015.01.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25599952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFGmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=554-564&author=R.+Slavikauthor=A.+M.+Herdeauthor=D.+Bieriauthor=M.+Weberauthor=R.+Schibliauthor=S.+D.+Kramerauthor=S.+M.+Ametameyauthor=L.+Mu&title=Synthesis%2C+radiolabeling+and+evaluation+of+novel+4-oxo-quinoline+derivatives+as+PET+tracers+for+imaging+cannabinoid+type+2+receptor&doi=10.1016%2Fj.ejmech.2015.01.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor</span></div><div class="casAuthors">Slavik, Roger; Herde, Adrienne Muller; Bieri, Daniel; Weber, Markus; Schibli, Roger; Kramer, Stefanie D.; Ametamey, Simon M.; Mu, Linjing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">554-564</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Our goal is to develop a highly specific and selective PET brain tracer for imaging CB2 expression in patients with neuroinflammatory diseases.  Based on our previous findings on a carbon-11 labeled 4-oxo-quinoline structure, designated KD2, further structural optimizations were performed, which led to the discovery of N-(1-adamantyl)-1-(2-ethoxyethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxamide of formula I (RS-016).  Compared to KD2, RS-016 exhibits a higher binding affinity towards CB2 (Ki = 0.7 nM) with a selectivity over CB1 of > 10,000 and lower lipophilicity (logD = 2.78). [11C]RS-016 was obtained in ≥ 99 % radiochem. purity and up to 850 GBq/μmol specific radioactivity at the end of synthesis.  In vitro autoradiog. on rodent spleen tissue showed high specific binding to CB2. [11C]RS-016 was stable in vitro in rodent and human plasma over 40 min, whereas 47 % intact compd. was found in vivo in rat blood plasma 20 min post injection (p.i.).  High specific binding to CB2 was obsd. in murine spleen tissues and postmortem ALS patient spinal cord tissues in vitro autoradiog., ex vivo biodistribution data confirmed the high and specific uptake of [11C]RS-016 in spleen region in rats.  In vivo specificity of [11C]RS-016 could also be shown in brain by PET imaging using a murine neuroinflammation model, which has higher CB2 receptor expression level in the brain induced by lipopolysaccharide (LPS) application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3_cA3WYogLVg90H21EOLACvtfcHk0ljWXxFonBkc3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFGmsQ%253D%253D&md5=9416c5ac46b4a73ab18ca7b8580eacb9</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.01.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.01.028%26sid%3Dliteratum%253Aachs%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DHerde%26aufirst%3DA.%2BM.%26aulast%3DBieri%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26aulast%3DMu%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520radiolabeling%2520and%2520evaluation%2520of%2520novel%25204-oxo-quinoline%2520derivatives%2520as%2520PET%2520tracers%2520for%2520imaging%2520cannabinoid%2520type%25202%2520receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D554%26epage%3D564%26doi%3D10.1016%2Fj.ejmech.2015.01.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drandarov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cermak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1111/jnc.12354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fjnc.12354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23795580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSqu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2013&pages=616-624&author=L.+Muauthor=D.+Bieriauthor=R.+Slavikauthor=K.+Drandarovauthor=A.+Mullerauthor=S.+Cermakauthor=M.+Weberauthor=R.+Schibliauthor=S.+D.+Kramerauthor=S.+M.+Ametamey&title=Radiolabeling+and+in+vitro+%2Fin+vivo+evaluation+of+N-%281-adamantyl%29-8-methoxy-4-oxo-1-phenyl-1%2C4-dihydroquinoline-3-carboxamide+as+a+PET+probe+for+imaging+cannabinoid+type+2+receptor&doi=10.1111%2Fjnc.12354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor</span></div><div class="casAuthors">Mu, Linjing; Bieri, Daniel; Slavik, Roger; Drandarov, Konstantin; Mueller, Adrienne; Cermak, Stjepko; Weber, Markus; Schibli, Roger; Kraemer, Stefanie D.; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">5&6</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The cannabinoid type 2 (CB2) receptor plays an important role in neuroinflammatory and neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease and is therefore a very promising target for therapeutic approaches as well as for imaging.  Based on the literature, we identified one 4-oxoquinoline deriv. (designated KD2) as the lead structure.  It was synthesized, radiolabeled and evaluated as a potential imaging tracer for CB2. [11C]KD2 was obtained in 99% radiochem. purity.  Moderate blood-brain barrier (BBB) passage was predicted for KD2 from an in vitro transport assay with P-glycoprotein-transfected Madin Darby canine kidney cells.  No efflux of KD2 by P-glycoprotein was detected.  In vitro autoradiog. of rat and mouse spleen slices demonstrated that [11C]KD2 exhibits high specific binding towards CB2.  High spleen uptake of [11C]KD2 was obsd. in dynamic positron emission tomog. (PET) studies with Wistar rats and its specificity was confirmed by displacement study with a selective CB2 agonist, GW405833.  A pilot autoradiog. study with post-mortem spinal cord slices from amyotrophic lateral sclerosis (ALS) patients with [11C]KD2 suggested the presence of CB2 receptors under disease conditions.  Specificity of [11C]KD2 binding could also be demonstrated on these human tissues.  In conclusion, [11C]KD2 shows good in vitro and in vivo properties as a potential PET tracer for CB2.  The cannabinoid type 2 receptor (CB2) plays an important role in neuroinflammatory and neuro-degenerative diseases. [11C]KD2, a new CB2 radioligand, exhibits selectivity towards CB2 receptor in vitro and in vivo in rat.  A pilot autoradiog. study with spinal cord slices from amyotrophic lateral sclerosis patients with [11C]KD2 suggested the presence of CB2 under disease conditions (Figure).  Selective CB2 agonist, GW405833.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5nK7DhzHrErVg90H21EOLACvtfcHk0lj3fSiaI5Xysg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSqu7zN&md5=863e2ab5064c38648f1618a9a2424410</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12354%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DL.%26aulast%3DBieri%26aufirst%3DD.%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DDrandarov%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DA.%26aulast%3DCermak%26aufirst%3DS.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DRadiolabeling%2520and%2520in%2520vitro%2520%252Fin%2520vivo%2520evaluation%2520of%2520N-%25281-adamantyl%2529-8-methoxy-4-oxo-1-phenyl-1%252C4-dihydroquinoline-3-carboxamide%2520as%2520a%2520PET%2520probe%2520for%2520imaging%2520cannabinoid%2520type%25202%2520receptor%26jtitle%3DJ.%2520Neurochem.%26date%3D2013%26volume%3D126%26spage%3D616%26epage%3D624%26doi%3D10.1111%2Fjnc.12354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meletta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rancic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller
Herde, A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [<sup>11</sup>C]RS-016 targeting CB2 in atherosclerosis</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2017.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2017.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28104528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=31-43&author=R.+Melettaauthor=R.+Slavikauthor=L.+Muauthor=Z.+Rancicauthor=N.+Borelauthor=R.+Schibliauthor=S.+M.+Ametameyauthor=S.+D.+Kramerauthor=A.+Muller%0AHerde&title=Cannabinoid+receptor+type+2+%28CB2%29+as+one+of+the+candidate+genes+in+human+carotid+plaque+imaging%3A+Evaluation+of+the+novel+radiotracer+%5B11C%5DRS-016+targeting+CB2+in+atherosclerosis&doi=10.1016%2Fj.nucmedbio.2017.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evalu1ation of the novel radiotracer [11C]RS-016 targeting CB2 in atherosclerosis</span></div><div class="casAuthors">Meletta, Romana; Slavik, Roger; Mu, Linjing; Rancic, Zoran; Borel, Nicole; Schibli, Roger; Ametamey, Simon M.; Kramer, Stefanie D.; Muller Herde, Adrienne</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-43</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Endarterectomized human atherosclerotic plaques are a valuable basis for gene expression studies to disclose novel imaging biomarkers and therapeutic targets, such as the cannabinoid receptor type 2 (CB2).  In this work, CB2 is expressed on activated immune cells, which are abundant in inflamed plaques.  We evaluated the CB2-specific radiotracer [11C]RS-016 for imaging vascular inflammation in human and mouse atherosclerotic lesions.  Methods: The differential gene expression of microscopically classified human carotid plaques was evaluated using quant. polymerase chain reaction.  In addn., CB2 expression levels in human plaques were investigated by in vitro autoradiog.  As an appropriate animal model we used apolipoprotein E knockout mice (ApoE KO) with shear stress-induced atherosclerosis to evaluate CB2 levels in vivo.  Positron emission tomog. (PET) was performed with both the CB2 radioligand [11C]RS-016 and the metabolic radiotracer [18F]fluorodeoxyglucose ([18F]FDG) at various time points.  Retrospectively, carotids were dissected for histopathol. and gene expression anal.  Results: We identified 28 human genes differentially expressed in atherosclerotic plaques compared to normal arteries of which 12 were upregulated preferentially in vulnerable plaques.  The latter group included members of matrix metalloproteinase family and the T-lymphocyte activation antigens CD80 and CD86.  CB2 was upregulated by 2-fold in human atherosclerotic plaques correlating with CD68 expression levels.  Specific in vitro binding of [11C]RS-016 was predominantly obsd. to plaques.  In vivo PET imaging of ApoE KO mice revealed accumulation of [11C]RS-016 and [18F]FDG in atherosclerotic plaques.  Development of advanced plaques with elevated CB2 and CD68 levels were found in vitro in ApoE KO mice resembling human vulnerable plaques.  Conclusion: We identified human genes assocd. with plaque vulnerability, which potentially could serve as novel imaging or therapeutic targets.  The CB2-specific radiotracer [11C]RS-016 detected human plaques by in vitro autoradiog. and accumulated in vivo in plaques of ApoE KO mice, however not exclusively in vulnerable plaques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMl-qV7Q_iMLVg90H21EOLACvtfcHk0lj3fSiaI5Xysg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ahs70%253D&md5=5b905f400a54ca39e4a0bda213987fdb</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2017.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2017.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DMeletta%26aufirst%3DR.%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DRancic%26aufirst%3DZ.%26aulast%3DBorel%26aufirst%3DN.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DMuller%2BHerde%26aufirst%3DA.%26atitle%3DCannabinoid%2520receptor%2520type%25202%2520%2528CB2%2529%2520as%2520one%2520of%2520the%2520candidate%2520genes%2520in%2520human%2520carotid%2520plaque%2520imaging%253A%2520Evaluation%2520of%2520the%2520novel%2520radiotracer%2520%255B11C%255DRS-016%2520targeting%2520CB2%2520in%2520atherosclerosis%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2017%26volume%3D47%26spage%3D31%26epage%3D43%26doi%3D10.1016%2Fj.nucmedbio.2017.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller Herde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1111/jnc.13716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fjnc.13716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27385045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gqt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=874-886&author=R.+Slavikauthor=A.+Muller+Herdeauthor=A.+Haiderauthor=S.+D.+Kramerauthor=M.+Weberauthor=R.+Schibliauthor=S.+M.+Ametameyauthor=L.+Mu&title=Discovery+of+a+fluorinated+4-oxo-quinoline+derivative+as+a+potential+positron+emission+tomography+radiotracer+for+imaging+cannabinoid+receptor+type+2&doi=10.1111%2Fjnc.13716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2</span></div><div class="casAuthors">Slavik, Roger; Mueller Herde, Adrienne; Haider, Ahmed; Kraemer, Stefanie D.; Weber, Markus; Schibli, Roger; Ametamey, Simon M.; Mu, Linjing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-886</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The cannabinoid receptor type 2 (CB2) is part of the endocannabinoid system and has gained growing attention in recent years because of its important role in neuroinflammatory/neurodegenerative diseases.  Recently, we reported on a carbon-11 labeled 4-oxo-quinoline deriv., designated RS-016, as a promising radiotracer for imaging CB2 using PET.  In this study, three novel fluorinated analogs of RS-016 were designed, synthesized, and pharmacol. evaluated.  The results of our efforts led to the identification of N-(1-adamantyl)-1-(2-(2-fluoroethoxy)ethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxamide (RS-126) as the most potent candidate for evaluation as a CB2 PET ligand. [18F]RS-126 was obtained in ≥ 99% radiochem. purity with an av. specific radioactivity of 98 GBq/μmol at the end of the radiosynthesis. [18F]RS-126 showed a logD7.4 value of 1.99 and is stable in vitro in rat and human plasma over 120 min, whereas 55% intact parent compd. was found in vivo in rat blood plasma at 10 min post injection.  In vitro autoradiog. studies with CB2-pos. rat spleen tissue revealed high and blockable binding which was confirmed in in vivo displacement expts. with rats by dynamic PET imaging.  Ex vivo biodistribution studies confirmed accumulation of [18F]RS-126 in rat spleen with a specificity of 79% under blocking conditions.  The moderate elevated CB2 levels in LPS-treated mice brain did not permit the detection of CB2 by [18F]RS-126 using PET imaging.  In summary, [18F]RS-126 demonstrated high specificity toward CB2 receptor in vitro and in vivo and is a promising radioligand for imaging CB2 receptor expression.  Cannabinoid receptor type 2 (CB2) is an interesting target for PET imaging.  Specific binding of [18F]RS-126 in CB2-pos. spleen tissue (white arrow head) was confirmed in in vivo displacement expts. with rats.  Time activity curve of [18F]RS-126 in the spleen after the addn. of GW405833 (CB2 specific ligand, green) demonstrates faster radiotracer elimination (blue) compared to the tracer only (red).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6l7D--J1F7Vg90H21EOLACvtfcHk0lj3fSiaI5Xysg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gqt7rK&md5=2b51bf80bdb7a8743f315b3442e4166a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13716%26sid%3Dliteratum%253Aachs%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DMuller%2BHerde%26aufirst%3DA.%26aulast%3DHaider%26aufirst%3DA.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26aulast%3DMu%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520fluorinated%25204-oxo-quinoline%2520derivative%2520as%2520a%2520potential%2520positron%2520emission%2520tomography%2520radiotracer%2520for%2520imaging%2520cannabinoid%2520receptor%2520type%25202%26jtitle%3DJ.%2520Neurochem.%26date%3D2016%26volume%3D138%26spage%3D874%26epage%3D886%26doi%3D10.1111%2Fjnc.13716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herde, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margelisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejmech.2017.12.097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29353725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=746-759&author=A.+Haiderauthor=F.+Spinelliauthor=A.+M.+Herdeauthor=B.+Muauthor=C.+Kellerauthor=M.+Margelischauthor=M.+Weberauthor=R.+Schibliauthor=L.+Muauthor=S.+M.+Ametamey&title=Evaluation+of+4-oxo-quinoline-based+CB2+PET+radioligands+in+R6%2F2+chorea+huntington+mouse+model+and+human+ALS+spinal+cord+tissue&doi=10.1016%2Fj.ejmech.2017.12.097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue</span></div><div class="casAuthors">Haider, Ahmed; Spinelli, Francesco; Herde, Adrienne Muller; Mu, Boshuai; Keller, Claudia; Margelisch, Markus; Weber, Markus; Schibli, Roger; Mu, Linjing; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">746-759</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The cannabinoid receptor 2 (CB2) has been implicated in a series of neurodegenerative disorders and has emerged as an interesting biol. target for therapeutic as well as diagnostic purposes.  In the present work, we describe an improved radiosynthetic approach to obtain the previously reported CB2-specific PET radioligand [18F]RS-126 in higher radiochem. yields and molar activities.  Addnl., the study revealed that prolongation of the [18F]RS-126 fluoroalkyl side chain ultimately leads to an improved stability towards mouse liver enzymes but is accompanied by a redn. in selectivity over the cannabinoid receptor 1 (CB1).  Huntington-related phenotypic changes as well as striatal D2R downregulation were confirmed for the transgenic R6/2 mouse model.  CB2 upregulation in R6/2 Chorea Huntington mice was obsd. in hippocampus, cortex, striatum and cerebellum by qPCR, however, these results could not be confirmed at the protein level by PET imaging.  Furthermore, we evaluated the utility of the newly developed [11C]RS-028, a potent [18F]RS-126 deriv. with increased polarity and high selectivity over CB1 in post-mortem human ALS spinal cord and control tissue.  Applying in vitro autoradiog., the translational relevance of CB2 imaging was demonstrated by the specific binding of [11C]RS-028 to post-mortem human ALS spinal cord tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplQbODli8237Vg90H21EOLACvtfcHk0liY9W_JCIUwEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOhsL0%253D&md5=12d0514c79a7a3e45b1aa751971af494</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.097%26sid%3Dliteratum%253Aachs%26aulast%3DHaider%26aufirst%3DA.%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DHerde%26aufirst%3DA.%2BM.%26aulast%3DMu%26aufirst%3DB.%26aulast%3DKeller%26aufirst%3DC.%26aulast%3DMargelisch%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DEvaluation%2520of%25204-oxo-quinoline-based%2520CB2%2520PET%2520radioligands%2520in%2520R6%252F2%2520chorea%2520huntington%2520mouse%2520model%2520and%2520human%2520ALS%2520spinal%2520cord%2520tissue%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D145%26spage%3D746%26epage%3D759%26doi%3D10.1016%2Fj.ejmech.2017.12.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller Herde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingerle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4266</span>– <span class="NLM_lpage">4277</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00283</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00283" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVSntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4266-4277&author=R.+Slavikauthor=U.+Gretherauthor=A.+Muller+Herdeauthor=L.+Gobbiauthor=J.+Fingerleauthor=C.+Ullmerauthor=S.+D.+Kramerauthor=R.+Schibliauthor=L.+Muauthor=S.+M.+Ametamey&title=Discovery+of+a+high+affinity+and+selective+pyridine+analog+as+a+potential+positron+emission+tomography+imaging+agent+for+cannabinoid+type+2+receptor&doi=10.1021%2Facs.jmedchem.5b00283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a High Affinity and Selective Pyridine Analog as a Potential Positron Emission Tomography Imaging Agent for Cannabinoid Type 2 Receptor</span></div><div class="casAuthors">Slavik, Roger; Grether, Uwe; Muller Herde, Adrienne; Gobbi, Luca; Fingerle, Jurgen; Ullmer, Christoph; Kramer, Stefanie D.; Schibli, Roger; Mu, Linjing; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4266-4277</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of our efforts to develop CB2 PET imaging agents, we investigated 2,5,6-substituted pyridines as a novel class of potential CB2 PET ligands.  A total of 21 novel compds. were designed, synthesized, and evaluated for their potency and binding properties toward human and rodent CB1 and CB2.  The most promising ligand 6a was radiolabeled with carbon-11 to yield 16 ([11C]RSR-056).  Specific binding of 16 to CB2-pos. spleen tissue of rats and mice was demonstrated by in vitro autogadiog. and verified in vivo in PET and biodistribution expts.  Furthermore, 16 was evaluated in a lipopolysaccharid (LPS) induced murine model of neuroinflammation.  Brain radioactivity was strikingly higher in the LPS-treated mice than the control mice.  Compd. 16 is a promising radiotracer for imaging CB2 in rodents.  It might serve as a tool for the investigation of CB2 receptor expression levels in healthy tissues and different neuroinflammatory disorders in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWUcSCaQyFerVg90H21EOLACvtfcHk0liY9W_JCIUwEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVSntr8%253D&md5=ed007d65ae82025274ddc73ec0668220</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00283%26sid%3Dliteratum%253Aachs%26aulast%3DSlavik%26aufirst%3DR.%26aulast%3DGrether%26aufirst%3DU.%26aulast%3DMuller%2BHerde%26aufirst%3DA.%26aulast%3DGobbi%26aufirst%3DL.%26aulast%3DFingerle%26aufirst%3DJ.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%2520a%2520high%2520affinity%2520and%2520selective%2520pyridine%2520analog%2520as%2520a%2520potential%2520positron%2520emission%2520tomography%2520imaging%2520agent%2520for%2520cannabinoid%2520type%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4266%26epage%3D4277%26doi%3D10.1021%2Facs.jmedchem.5b00283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xaio, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niehoff, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, J. E.</span></span> <span> </span><span class="NLM_article-title">Effect of LPS on the permeability of the blood-brain barrier to insulin</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>896</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/S0006-8993(00)03247-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0006-8993%2800%2903247-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=11277970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitF2rsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=896&publication_year=2001&pages=36-42&author=H.+Xaioauthor=W.+A.+Banksauthor=M.+L.+Niehoffauthor=J.+E.+Morley&title=Effect+of+LPS+on+the+permeability+of+the+blood-brain+barrier+to+insulin&doi=10.1016%2FS0006-8993%2800%2903247-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of LPS on the permeability of the blood-brain barrier to insulin</span></div><div class="casAuthors">Xaio, H.; Banks, W. A.; Niehoff, M. L.; Morley, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">896</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">36-42</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Insulin has emerged as an important neuropeptide.  Central actions of insulin appear to oppose those in the periphery.  Insulin is transported across the blood-brain barrier (BBB) by a saturable transport system.  The permeability of the BBB to insulin is altered by various events, but no studies exist that have examd. the permeability of the BBB to insulin during infection or inflammation, states which can induce peripheral insulin resistance.  The authors looked at the effects of lipopolysaccharide (LPS), a bacterial endotoxin and a powerful cytokine releaser, on the permeability of the BBB to human insulin in CD-1 mice.  I.p. injections of LPS significantly increased the uptake by the brain of 131I-insulin and disrupted the BBB to 125I-albumin.  After subtraction of the brain/serum ratio for 125I-albumin, brain/serum ratios for insulin were increased: 10.38±0.70 μL/g (LPS) vs. 3.62±0.27 μL/g (no LPS), P<0.0001, showing that LPS increased the uptake of insulin independent of BBB disruption.  This increase in insulin uptake was due to enhanced saturable transport.  Pretreatment with indomethacin 10 min before LPS injections enhanced BBB disruption, but not insulin transport.  Pretreatment with the nitric oxide (NO) synthase inhibitor aminoguanidine had no effect on insulin or albumin uptake, but pretreatment with NG-nitro-L-arginine Me ester (L-NAME) enhanced insulin transport, but not BBB disruption.  Thus, LPS increases the saturable transport of insulin across the BBB independent of disruption and prostaglandins with potentiation by NO inhibition.  Such increased transport could potentiate the central effects of insulin and so contribute to the peripheral insulin resistance seen with infection and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodWLkGN_YapLVg90H21EOLACvtfcHk0liY9W_JCIUwEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitF2rsbo%253D&md5=c22da3654f329faf70cab547681fe3b7</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2800%2903247-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252800%252903247-9%26sid%3Dliteratum%253Aachs%26aulast%3DXaio%26aufirst%3DH.%26aulast%3DBanks%26aufirst%3DW.%2BA.%26aulast%3DNiehoff%26aufirst%3DM.%2BL.%26aulast%3DMorley%26aufirst%3DJ.%2BE.%26atitle%3DEffect%2520of%2520LPS%2520on%2520the%2520permeability%2520of%2520the%2520blood-brain%2520barrier%2520to%2520insulin%26jtitle%3DBrain%2520Res.%26date%3D2001%26volume%3D896%26spage%3D36%26epage%3D42%26doi%3D10.1016%2FS0006-8993%2800%2903247-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartelmus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingerle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knuesel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herde, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies of pyridine-based ligands and identification of a fluorinated derivative for positron emission tomography imaging of cannabinoid type 2 receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">11165</span>– <span class="NLM_lpage">11181</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01280</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01280" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SnsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11165-11181&author=A.+Haiderauthor=J.+Kretzauthor=L.+Gobbiauthor=H.+Ahmedauthor=K.+Atzauthor=M.+Burklerauthor=C.+Bartelmusauthor=J.+Fingerleauthor=W.+Gubaauthor=C.+Ullmerauthor=M.+Honerauthor=I.+Knueselauthor=M.+Weberauthor=A.+Brinkauthor=A.+M.+Herdeauthor=C.+Kellerauthor=R.+Schibliauthor=L.+Muauthor=U.+Gretherauthor=S.+M.+Ametamey&title=Structure-activity+relationship+studies+of+pyridine-based+ligands+and+identification+of+a+fluorinated+derivative+for+positron+emission+tomography+imaging+of+cannabinoid+type+2+receptors&doi=10.1021%2Facs.jmedchem.9b01280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors</span></div><div class="casAuthors">Haider, Ahmed; Kretz, Julian; Gobbi, Luca; Ahmed, Hazem; Atz, Kenneth; Burkler, Markus; Bartelmus, Christian; Fingerle, Jurgen; Guba, Wolfgang; Ullmer, Christoph; Honer, Michael; Knuesel, Irene; Weber, Markus; Brink, Andreas; Herde, Adrienne Muller; Keller, Claudia; Schibli, Roger; Mu, Linjing; Grether, Uwe; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11165-11181</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cannabinoid type 2 (CB2) receptor has emerged as a valuable target for therapy and imaging of immune-mediated pathologies.  With the aim to find a suitable radiofluorinated analog of the previously reported CB2 positron emission tomog. (PET) radioligand [11C]RSR-056, 38 fluorinated derivs. were synthesized and tested by in vitro binding assays.  With a Ki (hCB2) of 6 nM and a selectivity factor of nearly 700 over cannabinoid type 1 receptors, target compd. 3 exhibited optimal in vitro properties and was selected for evaluation as a PET radioligand. [18F]3 was obtained in an av. radiochem. yield of 11 ± 4% and molar activities between 33 and 114 GBq/μmol.  Specific binding of [18F]3 to CB2 was demonstrated by in vitro autoradiog. and in vivo PET expts. using the CB2 ligand GW-405 833.  Metabolite anal. revealed only intact [18F]3 in the rat brain. [18F]3 detected CB2 upregulation in human amyotrophic lateral sclerosis spinal cord tissue and may thus become a candidate for diagnostic use in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-5mBBCTvMY7Vg90H21EOLACvtfcHk0ljK_ZnznkhScw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SnsbzP&md5=2635e2a8659b53485ddcbabcf26afd18</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01280%26sid%3Dliteratum%253Aachs%26aulast%3DHaider%26aufirst%3DA.%26aulast%3DKretz%26aufirst%3DJ.%26aulast%3DGobbi%26aufirst%3DL.%26aulast%3DAhmed%26aufirst%3DH.%26aulast%3DAtz%26aufirst%3DK.%26aulast%3DBurkler%26aufirst%3DM.%26aulast%3DBartelmus%26aufirst%3DC.%26aulast%3DFingerle%26aufirst%3DJ.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DHoner%26aufirst%3DM.%26aulast%3DKnuesel%26aufirst%3DI.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DBrink%26aufirst%3DA.%26aulast%3DHerde%26aufirst%3DA.%2BM.%26aulast%3DKeller%26aufirst%3DC.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DGrether%26aufirst%3DU.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520pyridine-based%2520ligands%2520and%2520identification%2520of%2520a%2520fluorinated%2520derivative%2520for%2520positron%2520emission%2520tomography%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D11165%26epage%3D11181%26doi%3D10.1021%2Facs.jmedchem.9b01280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartelmus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knuesel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herde, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical development of a 2,5,6-trisubstituted fluorinated pyridine derivative as a radioligand for the positron emission tomography imaging of cannabinoid type 2 receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10287</span>– <span class="NLM_lpage">10306</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00778</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00778" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFOju7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10287-10306&author=A.+Haiderauthor=L.+C.+Gobbiauthor=J.+Kretzauthor=C.+Ullmerauthor=A.+Brinkauthor=M.+Honerauthor=T.+J.+Wolteringauthor=D.+Muriauthor=H.+Idingauthor=M.+B%C3%BCrklerauthor=M.+Binderauthor=C.+Bartelmusauthor=I.+Knueselauthor=P.+Pacherauthor=A.+M.+Herdeauthor=F.+Spinelliauthor=H.+Ahmedauthor=K.+Atzauthor=C.+Kellerauthor=M.+Weberauthor=R.+Schibliauthor=L.+Muauthor=U.+Gretherauthor=S.+M.+Ametamey&title=Identification+and+preclinical+development+of+a+2%2C5%2C6-trisubstituted+fluorinated+pyridine+derivative+as+a+radioligand+for+the+positron+emission+tomography+imaging+of+cannabinoid+type+2+receptors&doi=10.1021%2Facs.jmedchem.0c00778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors</span></div><div class="casAuthors">Haider, Ahmed; Gobbi, Luca; Kretz, Julian; Ullmer, Christoph; Brink, Andreas; Honer, Michael; Woltering, Thomas J.; Muri, Dieter; Iding, Hans; Burkler, Markus; Binder, Martin; Bartelmus, Christian; Knuesel, Irene; Pacher, Pal; Herde, Adrienne Muller; Spinelli, Francesco; Ahmed, Hazem; Atz, Kenneth; Keller, Claudia; Weber, Markus; Schibli, Roger; Mu, Linjing; Grether, Uwe; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10287-10306</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clin. routine.  In this work, we synthesized 15 fluorinated pyridine derivs. and tested their binding affinities toward CB2 and CB1.  With a sub-nanomolar affinity (Ki for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an av. radiochem. yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochem. purity > 99%). [18F]RoSMA-18-d6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiog., ex vivo biodistribution, and positron emission tomog. (PET).  Further, [18F]RoSMA-18-d6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues.  Overall, these results suggest that [18F]RoSMA-18-d6 is a promising CB2 PET radioligand for clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7gtOgThXrm7Vg90H21EOLACvtfcHk0ljK_ZnznkhScw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFOju7rI&md5=52c2fc5eb0b41922de8cd959ba99dd4c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00778%26sid%3Dliteratum%253Aachs%26aulast%3DHaider%26aufirst%3DA.%26aulast%3DGobbi%26aufirst%3DL.%2BC.%26aulast%3DKretz%26aufirst%3DJ.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DBrink%26aufirst%3DA.%26aulast%3DHoner%26aufirst%3DM.%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DMuri%26aufirst%3DD.%26aulast%3DIding%26aufirst%3DH.%26aulast%3DB%25C3%25BCrkler%26aufirst%3DM.%26aulast%3DBinder%26aufirst%3DM.%26aulast%3DBartelmus%26aufirst%3DC.%26aulast%3DKnuesel%26aufirst%3DI.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DHerde%26aufirst%3DA.%2BM.%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DAhmed%26aufirst%3DH.%26aulast%3DAtz%26aufirst%3DK.%26aulast%3DKeller%26aufirst%3DC.%26aulast%3DWeber%26aufirst%3DM.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMu%26aufirst%3DL.%26aulast%3DGrether%26aufirst%3DU.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DIdentification%2520and%2520preclinical%2520development%2520of%2520a%25202%252C5%252C6-trisubstituted%2520fluorinated%2520pyridine%2520derivative%2520as%2520a%2520radioligand%2520for%2520the%2520positron%2520emission%2520tomography%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10287%26epage%3D10306%26doi%3D10.1021%2Facs.jmedchem.0c00778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savonenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biodistribution of [<sup>11</sup>C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5202</span>– <span class="NLM_lpage">5207</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.05.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmc.2010.05.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20554448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslagurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5202-5207&author=A.+G.+Hortiauthor=Y.+Gaoauthor=H.+T.+Ravertauthor=P.+Finleyauthor=H.+Valentineauthor=D.+F.+Wongauthor=C.+J.+Endresauthor=A.+V.+Savonenkoauthor=R.+F.+Dannals&title=Synthesis+and+biodistribution+of+%5B11C%5DA-836339%2C+a+new+potential+radioligand+for+PET+imaging+of+cannabinoid+type+2+receptors+%28CB2%29&doi=10.1016%2Fj.bmc.2010.05.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2)</span></div><div class="casAuthors">Horti, Andrew G.; Gao, Yongjun; Ravert, Hayden T.; Finley, Paige; Valentine, Heather; Wong, Dean F.; Endres, Christopher J.; Savonenko, Alena V.; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5202-5207</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, A-836339 [2,2,3,3-tetramethylcyclopropanecarboxylic acid [3-(2-methoxyethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]amide] (1) was reported to be a selective CB2 agonist with high binding affinity.  Here we describe the radiosynthesis of [11C]A-836339 ([11C]1) via its desmethyl precursor as a candidate radioligand for imaging CB2 receptors with positron-emission tomog. (PET).  Whole body and the regional brain distribution of [11C]1 in control CD1 mice demonstrated that this radioligand exhibits specific uptake in the CB2-rich spleen and little specific in vivo binding in the control mouse brain.  However, [11C]1 shows specific cerebral uptake in the lipopolysaccharide (LPS)-induced mouse model of neuroinflammation and in the brain areas with Aβ amyloid plaque deposition in a mouse model of Alzheimer's disease (APPswe/PS1dE9 mice).  These data establish a proof of principle that CB2 receptors binding in the neuroinflammation and related disorders can be measured in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrriR2pw_HawbVg90H21EOLACvtfcHk0lhiwSXWpmkc0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslagurc%253D&md5=1baba739bf8db92d34ac41f16906482c</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.058%26sid%3Dliteratum%253Aachs%26aulast%3DHorti%26aufirst%3DA.%2BG.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DFinley%26aufirst%3DP.%26aulast%3DValentine%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DEndres%26aufirst%3DC.%2BJ.%26aulast%3DSavonenko%26aufirst%3DA.%2BV.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520and%2520biodistribution%2520of%2520%255B11C%255DA-836339%252C%2520a%2520new%2520potential%2520radioligand%2520for%2520PET%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptors%2520%2528CB2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D5202%26epage%3D5207%26doi%3D10.1016%2Fj.bmc.2010.05.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moldovan, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teodoro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Development of a high-affinity PET radioligand for imaging cannabinoid subtype 2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7840</span>– <span class="NLM_lpage">7855</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00554</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00554" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSms7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7840-7855&author=R.+P.+Moldovanauthor=R.+Teodoroauthor=Y.+Gaoauthor=W.+Deuther-Conradauthor=M.+Kranzauthor=Y.+Wangauthor=H.+Kuwabaraauthor=M.+Nakanoauthor=H.+Valentineauthor=S.+Fischerauthor=M.+G.+Pomperauthor=D.+F.+Wongauthor=R.+F.+Dannalsauthor=P.+Brustauthor=A.+G.+Horti&title=Development+of+a+high-affinity+PET+radioligand+for+imaging+cannabinoid+subtype+2+receptor&doi=10.1021%2Facs.jmedchem.6b00554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor</span></div><div class="casAuthors">Moldovan, Rares-Petru; Teodoro, Rodrigo; Gao, Yongjun; Deuther-Conrad, Winnie; Kranz, Mathias; Wang, Yuchuan; Kuwabara, Hiroto; Nakano, Masayoshi; Valentine, Heather; Fischer, Steffen; Pomper, Martin G.; Wong, Dean F.; Dannals, Robert F.; Brust, Peter; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7840-7855</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cannabinoid receptors type 2 (CB2) represent a target with increasing importance for neuroimaging due to its upregulation under various pathol. conditions.  Encouraged by preliminary results obtained with [11C](Z)-N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl-cyclopropanecarboxamide ([11C]A-836339, [11C]1) in a mouse model of acute neuroinflammation (induced by lipopolysaccharide, LPS), we designed a library of fluorinated analogs aiming for an [18F]-labeled radiotracer with improved CB2 binding affinity and selectivity.  Compd. (Z)-N-(3-(4-fluorobutyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl-cyclopropanecarboxamide (29) was selected as the ligand with the highest CB2 affinity (Ki = 0.39 nM) and selectivity over those of CB1 (factor of 1000). [18F]29 was prepd. starting from the bromo precursor (53).  Specific binding was shown in vitro, whereas fast metab. was obsd. in vivo in CD-1 mice.  Animal PET revealed a brain uptake comparable to that of [11C]1.  In the LPS-treated mice, a 20-30% higher uptake in brain was found in comparison to that in nontreated mice (n = 3, P < 0.05).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGoJDH-P8D8bVg90H21EOLACvtfcHk0lhiwSXWpmkc0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSms7jM&md5=3fc2fc09c2f83aa7cd50458060e0128c</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00554%26sid%3Dliteratum%253Aachs%26aulast%3DMoldovan%26aufirst%3DR.%2BP.%26aulast%3DTeodoro%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DValentine%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DDevelopment%2520of%2520a%2520high-affinity%2520PET%2520radioligand%2520for%2520imaging%2520cannabinoid%2520subtype%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7840%26epage%3D7855%26doi%3D10.1021%2Facs.jmedchem.6b00554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savonenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnikova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pletnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncoso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horti, A. G.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 receptors in a mouse model of abeta amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0129618</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0129618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1371%2Fjournal.pone.0129618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26086915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWntLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0129618&author=A.+V.+Savonenkoauthor=T.+Melnikovaauthor=Y.+Wangauthor=H.+Ravertauthor=Y.+Gaoauthor=J.+Koppelauthor=D.+Leeauthor=O.+Pletnikovaauthor=E.+Choauthor=N.+Sayyidaauthor=A.+Hiattauthor=J.+Troncosoauthor=P.+Daviesauthor=R.+F.+Dannalsauthor=M.+G.+Pomperauthor=A.+G.+Horti&title=Cannabinoid+CB2+receptors+in+a+mouse+model+of+abeta+amyloidosis%3A+immunohistochemical+analysis+and+suitability+as+a+PET+biomarker+of+neuroinflammation&doi=10.1371%2Fjournal.pone.0129618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation</span></div><div class="casAuthors">Savonenko, Alena V.; Melnikova, Tatiana; Wang, Yuchuan; Ravert, Hayden; Gao, Yongjun; Koppel, Jeremy; Lee, Deidre; Pletnikova, Olga; Cho, Eugenia; Sayyida, Nuzhat; Hiatt, Andrew; Troncoso, Juan; Davies, Peter; Dannals, Robert F.; Pomper, Martin G.; Horti, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0129618/1-e0129618/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In Alzheimer's disease (AD), one of the early responses to Aβ amyloidosis is recruitment of microglia to areas of new plaque.  Microglial receptors such as cannabinoid receptor 2 (CB2) might be a suitable target for development of PET radiotracers that could serve as imaging biomarkers of Aβ-induced neuroinflammation.  Mouse models of amyloidosis (J20APPswe/ind and APPswe/PS1ΔE9) were used to investigate the cellular distribution of CB2 receptors.  Specificity of CB2 antibody (H60) was confirmed using J20APPswe/ind mice lacking CB2 receptors.  APPswe/PS1ΔE9 mice were used in small animal PET with a CB2-targeting radiotracer, [11C]A836339.  These studies revealed increased binding of [11C]A836339 in amyloid-bearing mice.  Specificity of the PET signal was confirmed in a blockade study with a specific CB2 antagonist, AM630.  Confocal microscopy revealed that CB2-receptor immunoreactivity was assocd. with astroglial (GFAP) and, predominantly, microglial (CD68) markers.  CB2 receptors were obsd., in particular, in microglial processes forming engulfment synapses with Aβ plaques.  In contrast to glial cells, neuron (NeuN)-derived CB2 signal was equal between amyloid-bearing and control mice.  The pattern of neuronal CB2 staining in amyloid-bearing mice was similar to that in human cases of AD.  The data collected in this study indicate that Aβ amyloidosis without concomitant tau pathol. is sufficient to activate CB2 receptors that are suitable as an imaging biomarker of neuroinflammation.  The main source of enhanced CB2 PET binding in amyloid-bearing mice is increased CB2 immunoreactivity in activated microglia.  The presence of CB2 immunoreactivity in neurons does not likely contribute to the enhanced CB2 PET signal in amyloid-bearing mice due to a lack of significant neuronal loss in this model.  However, significant loss of neurons as seen at late stages of AD might decrease the CB2 PET signal due to loss of neuronally-derived CB2.  Thus this study in mouse models of AD indicates that a CB2-specific radiotracer can be used as a biomarker of neuroinflammation in the early preclin. stages of AD, when no significant neuronal loss has yet developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAhB68J9FaFLVg90H21EOLACvtfcHk0lhiwSXWpmkc0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWntLjP&md5=45755102bb41c0682c473a71082079b7</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0129618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0129618%26sid%3Dliteratum%253Aachs%26aulast%3DSavonenko%26aufirst%3DA.%2BV.%26aulast%3DMelnikova%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRavert%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DKoppel%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DPletnikova%26aufirst%3DO.%26aulast%3DCho%26aufirst%3DE.%26aulast%3DSayyida%26aufirst%3DN.%26aulast%3DHiatt%26aufirst%3DA.%26aulast%3DTroncoso%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DHorti%26aufirst%3DA.%2BG.%26atitle%3DCannabinoid%2520CB2%2520receptors%2520in%2520a%2520mouse%2520model%2520of%2520abeta%2520amyloidosis%253A%2520immunohistochemical%2520analysis%2520and%2520suitability%2520as%2520a%2520PET%2520biomarker%2520of%2520neuroinflammation%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0129618%26doi%3D10.1371%2Fjournal.pone.0129618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pottier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Vallejo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisgard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkeler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span> <span> </span><span class="NLM_article-title">PET imaging of cannabinoid type 2 receptors with [<sup>11</sup>C]A-836339 did not evidence changes following neuroinflammation in rats</span>. <i>J. Cereb. Blood Flow Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1177/0271678X16685105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1177%2F0271678X16685105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28079433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1163-1178&author=G.+Pottierauthor=V.+Gomez-Vallejoauthor=D.+Padroauthor=R.+Boisgardauthor=F.+Dolleauthor=J.+Llopauthor=A.+Winkelerauthor=A.+Martin&title=PET+imaging+of+cannabinoid+type+2+receptors+with+%5B11C%5DA-836339+did+not+evidence+changes+following+neuroinflammation+in+rats&doi=10.1177%2F0271678X16685105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging of cannabinoid type 2 receptors with [11C]A-836339 did not evidence changes following neuroinflammation in rats</span></div><div class="casAuthors">Pottier, Geraldine; Gomez-Vallejo, Vanessa; Padro, Daniel; Boisgard, Raphael; Dolle, Frederic; Llop, Jordi; Winkeler, Alexandra; Martin, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1163-1178</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Cannabinoid type 2 receptors (CB2R) have emerged as promising targets for the diagnosis and therapy of brain pathologies.  However, no suitable radiotracers for accurate CB2R mapping have been found to date, limiting the investigation of the CB2 receptor expression using positron emission tomog. (PET) imaging.  In this work, we report the evaluation of the in vivo expression of CB2R with [11C]A-836339 PET after cerebral ischemia and in two rat models of neuroinflammation, first by intrastriatal LPS and then by AMPA injection.  PET images and in vitro autoradiog. showed a lack of specific [11C]A-836339 uptake in these animal models demonstrating the limitation of this radiotracer to image CB2 receptor under neuroinflammatory conditions.  Further, using immunohistochem., the CB2 receptor displayed a modest expression increase after cerebral ischemia, LPS and AMPA models.  Finally, [18F]DPA-714-PET and immunohistochem. demonstrated decreased neuroinflammation by a selective CB2R agonist, JWH133.  Taken together, these findings suggest that [11C]A-836339 is not a suitable radiotracer to monitor in vivo CB2R expression by using PET imaging.  Future studies will have to investigate alternative radiotracers that could provide an accurate binding to CB2 receptors following brain inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjVLRGvLaxgLVg90H21EOLACvtfcHk0lhY6r9LA4eXZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKns7k%253D&md5=2a64e3b77030906c9cbdc02c42bda307</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1177%2F0271678X16685105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0271678X16685105%26sid%3Dliteratum%253Aachs%26aulast%3DPottier%26aufirst%3DG.%26aulast%3DGomez-Vallejo%26aufirst%3DV.%26aulast%3DPadro%26aufirst%3DD.%26aulast%3DBoisgard%26aufirst%3DR.%26aulast%3DDolle%26aufirst%3DF.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DWinkeler%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DA.%26atitle%3DPET%2520imaging%2520of%2520cannabinoid%2520type%25202%2520receptors%2520with%2520%255B11C%255DA-836339%2520did%2520not%2520evidence%2520changes%2520following%2520neuroinflammation%2520in%2520rats%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2017%26volume%3D37%26spage%3D1163%26epage%3D1178%26doi%3D10.1177%2F0271678X16685105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hortala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oustric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oury-Donat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avenet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barret, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamagnan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmcl.2013.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24291040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOhs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=283-287&author=L.+Hortalaauthor=J.+Arnaudauthor=P.+Rouxauthor=D.+Oustricauthor=L.+Bouluauthor=F.+Oury-Donatauthor=P.+Avenetauthor=T.+Rooneyauthor=D.+Alagilleauthor=O.+Barretauthor=G.+Tamagnanauthor=F.+Barth&title=Synthesis+and+preliminary+evaluation+of+a+new+fluorine-18+labelled+triazine+derivative+for+PET+imaging+of+cannabinoid+CB2+receptor&doi=10.1016%2Fj.bmcl.2013.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor</span></div><div class="casAuthors">Hortala, Laurent; Arnaud, Joelle; Roux, Pascale; Oustric, Didier; Boulu, Laurent; Oury-Donat, Florence; Avenet, Patrick; Rooney, Thomas; Alagille, David; Barret, Olivier; Tamagnan, Gilles; Barth, Francis</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-287</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cannabinoid CB2 PET tracers are considered as a promising alternative to PBR/TSPO tracers for the in-vivo imaging of neuroinflammation.  We describe here the synthesis and characterization of compd. I, a new potent and brain penetrating CB2 ligand based on an original triazine template.  The PET tracer [18F]-dideutero-I (II) was prepd. in a three steps radiosynthesis, and demonstrated significant uptake in rhesus macaque and baboon brain with a max. SUV of about 0.7-0.9 g/mL, followed by a moderate washout over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOttCEg3j-SLVg90H21EOLACvtfcHk0lhY6r9LA4eXZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOhs7zM&md5=280f4f22351c8468b1147c9dac62d766</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DHortala%26aufirst%3DL.%26aulast%3DArnaud%26aufirst%3DJ.%26aulast%3DRoux%26aufirst%3DP.%26aulast%3DOustric%26aufirst%3DD.%26aulast%3DBoulu%26aufirst%3DL.%26aulast%3DOury-Donat%26aufirst%3DF.%26aulast%3DAvenet%26aufirst%3DP.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DAlagille%26aufirst%3DD.%26aulast%3DBarret%26aufirst%3DO.%26aulast%3DTamagnan%26aufirst%3DG.%26aulast%3DBarth%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520preliminary%2520evaluation%2520of%2520a%2520new%2520fluorine-18%2520labelled%2520triazine%2520derivative%2520for%2520PET%2520imaging%2520of%2520cannabinoid%2520CB2%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D283%26epage%3D287%26doi%3D10.1016%2Fj.bmcl.2013.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yrjola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarparanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Airaksinen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hytti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauppinen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasonen-Seppanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adinolfi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keinanen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2014.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejps.2014.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25447744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCnt7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=85-96&author=S.+Yrjolaauthor=M.+Sarparantaauthor=A.+J.+Airaksinenauthor=M.+Hyttiauthor=A.+Kauppinenauthor=S.+Pasonen-Seppanenauthor=B.+Adinolfiauthor=P.+Nieriauthor=C.+Maneraauthor=O.+Keinanenauthor=A.+Posoauthor=T.+J.+Nevalainenauthor=T.+Parkkari&title=Synthesis%2C+in+vitro+and+in+vivo+evaluation+of+1%2C3%2C5-triazines+as+cannabinoid+CB2+receptor+agonists&doi=10.1016%2Fj.ejps.2014.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists</span></div><div class="casAuthors">Yrjola, Sari; Sarparanta, Mirkka; Airaksinen, Anu J.; Hytti, Maria; Kauppinen, Anu; Pasonen-Seppanen, Sanna; Adinolfi, Barbara; Nieri, Paola; Manera, Clementina; Keinanen, Outi; Poso, Antti; Nevalainen, Tapio J.; Parkkari, Teija</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-96</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cannabinoid receptors type 2 (CBR2) are attractive therapeutic targets of the endocannabinoid signaling system (ECS) as they are not displaying the undesired psychotropic and cardiovascular side-effects seen with cannabinoid receptor type 1 (CB1R) agonists.  In continuation of our previous work on 2,4,6-trisubstituted 1,3,5-triazines as potent CB2 agonists, we synthesized an addnl. series of more polar analogs (1-10), which were found to possess high CB2R agonist activity with enhanced water soly.  The most potent compd. in the series was N-(adamantan-1-yl)-4-ethoxy-6-(4-(2-fluoroethyl)piperazin-1-yl)-1,3,5-triazin-2-amine (9) with EC50 value of 0.60 nM.  To further evaluate the biol. effects of the compds., the selected compds. were tested in vitro against four different cell lines.  A human retinal pigment epithelial cell line (ARPE-19) was used to evaluate the cytotoxicity of the compds. whereas an androgen-sensitive human prostate adenocarcinoma cell line (LNCaP), a Jurkat leukemia cell line and a C8161 melanoma cell line were used to assess the antiproliferative activity of the compds.  The most interesting results were obtained for N-(adamantan-1-yl)-4-ethoxy-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (6), which induced cell viability decrease in prostate and leukemia cell lines, and diminished proliferation of C8161 melanoma cells.  The results could be reversed in leukemia cells with the selective CB2R antagonist AM630, whereas in prostate cells the AM630 induced a significant cell viability decrease with a mechanism probably unlinked to CB2 cannabinoid receptor.  The antiproliferative effect of 6 on the melanoma cells seemed not to be mediated via the CB1R or CB2R.  No cytotoxicity was detected against ARPE-19 cell line at concns. of 1 and 10 μM for compd. 6.  However, at 30 μM concn. the compd. 6 decreased the cell viability.  Finally, in order to est. in vivo behavior of these compds., 18F labeled PET ligand, N-cyclopentyl-4-ethoxy-6-(4-(2-fluoro-18-ethyl)piperazin-1-yl)-1,3,5-triazin-2-amine ([18F]5), was synthesized and its biodistribution was detd. in healthy male Sprague-Dawley rats.  As a result, the tracer showed a rapid (<15 min) elimination in urine accompanied by a slower excretion via the hepatobiliary route.  In conclusion, we further demonstrated that 1,3,5-triazine scaffold serves as a suitable template for the design of highly potent CB2R agonists with reasonable water soly. properties.  The compds. may be useful when studying the role of the endocannabinoid system in different diseases.  The triazine scaffold is also a promising candidate for the development of new CB2R PET ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_1aEvtEgaW7Vg90H21EOLACvtfcHk0lhY6r9LA4eXZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCnt7bL&md5=8153b8fd95235ae3541e6bf209eef499</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2014.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2014.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DYrjola%26aufirst%3DS.%26aulast%3DSarparanta%26aufirst%3DM.%26aulast%3DAiraksinen%26aufirst%3DA.%2BJ.%26aulast%3DHytti%26aufirst%3DM.%26aulast%3DKauppinen%26aufirst%3DA.%26aulast%3DPasonen-Seppanen%26aufirst%3DS.%26aulast%3DAdinolfi%26aufirst%3DB.%26aulast%3DNieri%26aufirst%3DP.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DKeinanen%26aufirst%3DO.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DNevalainen%26aufirst%3DT.%2BJ.%26aulast%3DParkkari%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%25201%252C3%252C5-triazines%2520as%2520cannabinoid%2520CB2%2520receptor%2520agonists%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D67%26spage%3D85%26epage%3D96%26doi%3D10.1016%2Fj.ejps.2014.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veghel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Laere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biodistribution and in vitro evaluation of brain permeable high affinity type 2 cannabinoid receptor agonists [<sup>11</sup>C]MA2 and [<sup>18</sup>F]MA3</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">431</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3389%2Ffnins.2016.00431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27713686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BC2svnvFKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=431&author=M.+Ahamedauthor=D.+van+Veghelauthor=C.+Ullmerauthor=K.+Van+Laereauthor=A.+Verbruggenauthor=G.+M.+Bormans&title=Synthesis%2C+biodistribution+and+in+vitro+evaluation+of+brain+permeable+high+affinity+type+2+cannabinoid+receptor+agonists+%5B11C%5DMA2+and+%5B18F%5DMA3&doi=10.3389%2Ffnins.2016.00431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [(11)C]MA2 and [(18)F]MA3</span></div><div class="casAuthors">Ahamed Muneer; van Veghel Daisy; Verbruggen Alfons; Bormans Guy M; Ullmer Christoph; Van Laere Koen</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">431</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">The type 2 cannabinoid receptor (CB2) is a member of the endocannabinoid system and is known for its important role in (neuro)inflammation.  A PET-imaging agent that allows in vivo visualization of CB2 expression may thus allow quantification of neuroinflammation.  In this paper, we report the synthesis, radiosynthesis, biodistribution and in vitro evaluation of a carbon-11 ([(11)C]MA2) and a fluorine-18 ([(18)F]MA3) labeled analog of a highly potent N-arylamide oxadiazole CB2 agonist (EC50 = 0.015 nM).  MA2 and MA3 behaved as potent CB2 agonist (EC50: 3 nM and 0.1 nM, respectively) and their in vitro binding affinity for hCB2 was found to be 87 nM and 0.8 nM, respectively.  Also MA3 (substituted with a fluoro ethyl group) was found to have higher binding affinity and EC50 values when compared to the originally reported trifluoromethyl analog 12. [(11)C]MA2 and [(18)F]MA3 were successfully synthesized with good radiochemical yield, high radiochemical purity and high specific activity.  In mice, both tracers were efficiently cleared from blood and all major organs by the hepatobiliary pathway and importantly these compounds showed high brain uptake.  In conclusion, [(11)C]MA2 and [(18)F]MA3 are shown to be high potent CB2 agonists with good brain uptake, these favorable characteristics makes them potential PET probes for in vivo imaging of brain CB2 receptors.  However, in view of its higher affinity and selectivity, further detailed evaluation of MA3 as a PET tracer for CB2 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREdksh7qntkZNiNltV31zlfW6udTcc2eaN7G6X37Yoh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnvFKktg%253D%253D&md5=3240509303d6d5aa35daa26c7e8a59fb</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00431%26sid%3Dliteratum%253Aachs%26aulast%3DAhamed%26aufirst%3DM.%26aulast%3Dvan%2BVeghel%26aufirst%3DD.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DVan%2BLaere%26aufirst%3DK.%26aulast%3DVerbruggen%26aufirst%3DA.%26aulast%3DBormans%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%252C%2520biodistribution%2520and%2520in%2520vitro%2520evaluation%2520of%2520brain%2520permeable%2520high%2520affinity%2520type%25202%2520cannabinoid%2520receptor%2520agonists%2520%255B11C%255DMA2%2520and%2520%255B18F%255DMA3%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D431%26doi%3D10.3389%2Ffnins.2016.00431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Attili, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haute, C. V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanduffel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of [<sup>18</sup>F]MA3: a CB2 receptor agonist radiotracer for PET</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1491</span>, <span class="refDoi"> DOI: 10.1111/bph.14564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fbph.14564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30588600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVyru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=1481-1491&author=B.+Attiliauthor=S.+Celenauthor=M.+Ahamedauthor=M.+Kooleauthor=C.+V.+D.+Hauteauthor=W.+Vanduffelauthor=G.+Bormans&title=Preclinical+evaluation+of+%5B18F%5DMA3%3A+a+CB2+receptor+agonist+radiotracer+for+PET&doi=10.1111%2Fbph.14564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of [18F]MA3: a CB2 receptor agonist radiotracer for PET</span></div><div class="casAuthors">Attili, Bala; Celen, Sofie; Ahamed, Muneer; Koole, Michel; Van Den Haute, Chris; Vanduffel, Wim; Bormans, Guy</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1481-1491</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Non-invasive in vivo imaging of cannabinoid CB2 receptors using PET is pursued to study neuroinflammation.  The purpose of this study is to evaluate the in vivo binding specificity of [18F]MA3, a CB2 receptor agonist, in a rat model with local overexpression of human (h) CB2 receptors.  [18F]MA3 was produced with good radiochem. yield and radiochem. purity.  The radiotracer was evaluated in rats with local overexpression of hCB2 receptors and in a healthy non-human primate using PET.  Ex vivo autoradiog. demonstrated CB2-specific binding of [18F]MA3 in rat hCB2 receptor vector injected striatum.  Further clin. evaluation of [18F]MA3 in patients with neuroinflammation is warranted.  Evaluation of [18F]MA3 in a rat model with local overexpression of hCB2 receptors showed CB2 receptor-specific and reversible tracer binding.  [18F]MA3 showed good brain uptake and subsequent washout in a healthy non-human primate, but no specific binding was obsd.  This study identified the utility of mutated inactive vector model for evaluation of CB2 receptor agonist PET tracers.  [18F]MA3 PET scans in the non-human primate showed good uptake and fast washout from brain, but no CB2 receptor-specific binding was obsd.  Binding in hCB2 receptor vector-injected striatum was blocked with a structurally non-related CB2 receptor inverse agonist, and a displacement study confirmed the reversibility of tracer binding.  In a PET study, increased tracer binding in the hCB2 receptor vector-injected striatum compared to the contralateral control vector-injected striatum was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnC8Wt9qbYfrVg90H21EOLACvtfcHk0liP3ZvaLekpcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVyru74%253D&md5=8f8224cb59149a1a5df55a6424682438</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fbph.14564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14564%26sid%3Dliteratum%253Aachs%26aulast%3DAttili%26aufirst%3DB.%26aulast%3DCelen%26aufirst%3DS.%26aulast%3DAhamed%26aufirst%3DM.%26aulast%3DKoole%26aufirst%3DM.%26aulast%3DHaute%26aufirst%3DC.%2BV.%2BD.%26aulast%3DVanduffel%26aufirst%3DW.%26aulast%3DBormans%26aufirst%3DG.%26atitle%3DPreclinical%2520evaluation%2520of%2520%255B18F%255DMA3%253A%2520a%2520CB2%2520receptor%2520agonist%2520radiotracer%2520for%2520PET%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3D1481%26epage%3D1491%26doi%3D10.1111%2Fbph.14564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stasiulewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Znajdek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudzień, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawiński, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowska, A. J. I.</span></span> <span> </span><span class="NLM_article-title">A guide to targeting the endocannabinoid system in drug design</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2778</span>, <span class="refDoi"> DOI: 10.3390/ijms21082778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.3390%2Fijms21082778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVCnt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=2778&author=A.+Stasiulewiczauthor=K.+Znajdekauthor=M.+Grudzie%C5%84author=T.+Pawi%C5%84skiauthor=A.+J.+I.+Sulkowska&title=A+guide+to+targeting+the+endocannabinoid+system+in+drug+design&doi=10.3390%2Fijms21082778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">A guide to targeting the endocannabinoid system in drug design</span></div><div class="casAuthors">Stasiulewicz, Adam; Znajdek, Katarzyna; Grudzien, Monika; Pawinski, Tomasz; Sulkowska, Joanna I.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2778</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  He endocannabinoid system (ECS) is one of the most crucial systems in the human organism, exhibiting multi-purpose regulatory character.  It is engaged in a vast array of physiol. processes, including nociception, mood regulation, cognitive functions, neurogenesis and neuroprotection, appetite, lipid metab., as well as cell growth and proliferation.  Thus, ECS proteins, including cannabinoid receptors and their endogenous ligands' synthesizing and degrading enzymes, are promising therapeutic targets.  Their modulation has been employed in or extensively studied as a treatment of multiple diseases.  However, due to a complex nature of ECS and its crosstalk with other biol. systems, the development of novel drugs turned out to be a challenging task.  In this , we summarize potential therapeutic applications for ECS-targeting drugs, esp. focusing on promising synthetic compds. and preclin. studies.  We put emphasis on modulation of specific proteins of ECS in different pathophysiol. areas.  In addn., we stress possible difficulties and risks and highlight proposed solns.  By presenting this , we point out information pivotal in the spotlight of ECS-targeting drug design, as well as provide an overview of the current state of knowledge on ECS-related pharmacodynamics and show possible directions for needed research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKa6x7jgTR7rVg90H21EOLACvtfcHk0liP3ZvaLekpcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVCnt7jN&md5=ac09145f2e89c1b7e703f523e38ca497</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3390%2Fijms21082778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21082778%26sid%3Dliteratum%253Aachs%26aulast%3DStasiulewicz%26aufirst%3DA.%26aulast%3DZnajdek%26aufirst%3DK.%26aulast%3DGrudzie%25C5%2584%26aufirst%3DM.%26aulast%3DPawi%25C5%2584ski%26aufirst%3DT.%26aulast%3DSulkowska%26aufirst%3DA.%2BJ.%2BI.%26atitle%3DA%2520guide%2520to%2520targeting%2520the%2520endocannabinoid%2520system%2520in%2520drug%2520design%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D2778%26doi%3D10.3390%2Fijms21082778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gulyas, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracey, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, T. F.</span></span> <span> </span><span class="NLM_article-title">Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2004.03428.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1460-9568.2004.03428.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15233753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A280%3ADC%252BD2czjt1Gntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=441-458&author=A.+I.+Gulyasauthor=B.+F.+Cravattauthor=M.+H.+Braceyauthor=T.+P.+Dinhauthor=D.+Piomelliauthor=F.+Bosciaauthor=T.+F.+Freund&title=Segregation+of+two+endocannabinoid-hydrolyzing+enzymes+into+pre-+and+postsynaptic+compartments+in+the+rat+hippocampus%2C+cerebellum+and+amygdala&doi=10.1111%2Fj.1460-9568.2004.03428.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala</span></div><div class="casAuthors">Gulyas A I; Cravatt B F; Bracey M H; Dinh T P; Piomelli D; Boscia F; Freund T F</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-58</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) catalyse the hydrolysis of the endocannabinoids anandamide and 2-arachidonoyl glycerol.  We investigated their ultrastructural distribution in brain areas where the localization and effects of cannabinoid receptor activation are known.  In the hippocampus, FAAH was present in somata and dendrites of principal cells, but not in interneurons.  It was located mostly on the membrane surface of intracellular organelles known to store Ca(2+) (e.g. mitochondria, smooth endoplasmic reticulum), less frequently on the somatic or dendritic plasma membrane.  MGL immunoreactivity was found in axon terminals of granule cells, CA3 pyramidal cells and some interneurons.  In the cerebellum, Purkinje cells and their dendrites are intensively immunoreactive for FAAH, together with a sparse axon plexus at the border of the Purkinje cell/granule cell layers.  Immunostaining for MGL was complementary, the axons in the molecular layer were intensively labelled leaving the Purkinje cell dendrites blank.  FAAH distribution in the amygdala was similar to that of the CB(1) cannabinoid receptor: evident signal in neuronal somata and proximal dendrites in the basolateral nucleus, and hardly any labelling in the central nucleus.  MGL staining was restricted to axons in the neuropil, with similar relative signal intensities seen for FAAH in different nuclei.  Thus, FAAH is primarily a postsynaptic enzyme, whereas MGL is presynaptic.  FAAH is associated with membranes of cytoplasmic organelles.  The differential compartmentalization of the two enzymes suggests that anandamide and 2-AG signalling may subserve functional roles that are spatially segregated at least at the stage of metabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTW_4mkeOzg3z0O18WR3iAofW6udTcc2eaNIy0vba4f1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czjt1Gntg%253D%253D&md5=8c77b186a775f898e85cda664263d81b</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2004.03428.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2004.03428.x%26sid%3Dliteratum%253Aachs%26aulast%3DGulyas%26aufirst%3DA.%2BI.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBracey%26aufirst%3DM.%2BH.%26aulast%3DDinh%26aufirst%3DT.%2BP.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DBoscia%26aufirst%3DF.%26aulast%3DFreund%26aufirst%3DT.%2BF.%26atitle%3DSegregation%2520of%2520two%2520endocannabinoid-hydrolyzing%2520enzymes%2520into%2520pre-%2520and%2520postsynaptic%2520compartments%2520in%2520the%2520rat%2520hippocampus%252C%2520cerebellum%2520and%2520amygdala%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2004%26volume%3D20%26spage%3D441%26epage%3D458%26doi%3D10.1111%2Fj.1460-9568.2004.03428.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Structure and function of fatty acid amide hydrolase</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.74.082803.133450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1146%2Fannurev.biochem.74.082803.133450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15952893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVensL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2005&pages=411-432&author=M.+K.+McKinneyauthor=B.+F.+Cravatt&title=Structure+and+function+of+fatty+acid+amide+hydrolase&doi=10.1146%2Fannurev.biochem.74.082803.133450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of fatty acid amide hydrolase</span></div><div class="casAuthors">McKinney, Michele K.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">411-432</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Fatty acid amide hydrolase (FAAH) is a mammalian integral membrane enzyme that degrades the fatty acid amide family of endogenous signaling lipids, which includes the endogenous cannabinoid, anandamide, and the sleep-inducing substance, oleamide.  FAAH belongs to a large and diverse class of enzymes referred to as the amidase signature (AS) family.  Investigations into the structure and function of FAAH, in combination with complementary studies of other AS enzymes, have engendered provocative mol. models to explain how this enzyme integrates into cell membranes and terminates fatty acid amide signaling in vivo.  These studies, as well as their biol. and therapeutic implications, are the subject of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprO7TpUTr6n7Vg90H21EOLACvtfcHk0ljDffe3Gt1phQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVensL4%253D&md5=d28b43f14feb6894d48e907064087867</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.74.082803.133450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.74.082803.133450%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinney%26aufirst%3DM.%2BK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStructure%2520and%2520function%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2005%26volume%3D74%26spage%3D411%26epage%3D432%26doi%3D10.1146%2Fannurev.biochem.74.082803.133450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of monoacylglycerol lipase inhibitors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2012.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.lfs.2012.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23142242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKqsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2013&pages=492-497&author=M.+M.+Mulvihillauthor=D.+K.+Nomura&title=Therapeutic+potential+of+monoacylglycerol+lipase+inhibitors&doi=10.1016%2Fj.lfs.2012.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of monoacylglycerol lipase inhibitors</span></div><div class="casAuthors">Mulvihill, Melinda M.; Nomura, Daniel K.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">492-497</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Marijuana and aspirin have been used for millennia to treat a wide range of maladies including pain and inflammation.  Both cannabinoids, like marijuana, that exert anti-inflammatory action through stimulating cannabinoid receptors, and cyclooxygenase (COX) inhibitors, like aspirin, that suppress pro-inflammatory eicosanoid prodn. have shown beneficial outcomes in mouse models of neurodegenerative diseases and cancer.  Both cannabinoids and COX inhibitors, however, have untoward effects that discourage their chronic usage, including cognitive deficits and gastrointestinal toxicity, resp.  Recent studies have uncovered that the serine hydrolase monoacylglycerol lipase (MAGL) links the endocannabinoid and eicosanoid systems together through hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG) to provide the major arachidonic acid (AA) precursor pools for pro-inflammatory eicosanoid synthesis in specific tissues.  Studies in recent years have shown that MAGL inhibitors elicit anti-nociceptive, anxiolytic, and anti-emetic responses and attenuate pptd. withdrawal symptoms in addiction paradigms through enhancing endocannabinoid signaling.  MAGL inhibitors have also been shown to exert anti-inflammatory action in the brain and protect against neurodegeneration through lowering eicosanoid prodn.  In cancer, MAGL inhibitors have been shown to have anti-cancer properties not only through modulating the endocannabinoid-eicosanoid network, but also by controlling fatty acid release for the synthesis of protumorigenic signaling lipids.  Thus, MAGL serves as a crit. node in simultaneously coordinating multiple lipid signaling pathways in both physiol. and disease contexts.  This review will discuss the diverse (patho)physiol. roles of MAGL and the therapeutic potential of MAGL inhibitors in treating a vast array of complex human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpojyVx1YSerrVg90H21EOLACvtfcHk0ljDffe3Gt1phQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKqsL7O&md5=cb44625201730a7849701df80fadb708</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DMulvihill%26aufirst%3DM.%2BM.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26atitle%3DTherapeutic%2520potential%2520of%2520monoacylglycerol%2520lipase%2520inhibitors%26jtitle%3DLife%2520Sci.%26date%3D2013%26volume%3D92%26spage%3D492%26epage%3D497%26doi%3D10.1016%2Fj.lfs.2012.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleu-Chavain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of fatty acid amide hydrolase, monoacylglycerol lipase, and N-acylethanolamine acid amidase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00538</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00538" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWjsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4-46&author=W.+Tuoauthor=N.+Leleu-Chavainauthor=J.+Spencerauthor=S.+Sansookauthor=R.+Milletauthor=P.+Chavatte&title=Therapeutic+potential+of+fatty+acid+amide+hydrolase%2C+monoacylglycerol+lipase%2C+and+N-acylethanolamine+acid+amidase+inhibitors&doi=10.1021%2Facs.jmedchem.6b00538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors</span></div><div class="casAuthors">Tuo, Wei; Leleu-Chavain, Natascha; Spencer, John; Sansook, Supojjanee; Millet, Regis; Chavatte, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-46</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Fatty acid ethanolamides (FAEs) and endocannabinoids (ECs) have been shown to alleviate pain and inflammation, regulate motility and appetite, and produce anti-cancer, anxiolytic, and neuroprotective efficacies via cannabinoid receptor type 1 (CB1) or type 2 (CB2), or via peroxisome proliferator-activated receptor α (PPAR-α) stimulation.  FAEs and ECs are synthesized by a series of endogenous enzymes, including N-acylphosphatidylethanolamine-phospholipase D (NAPE-PLD), diacylglycerol lipase (DAGL), or phospholipase C (PLC), and their metab. is mediated by several metabolic enzymes, including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL), N-acylethanolamine acid amidase (NAAA), or cyclooxygenase-2 (COX-2).  Over the last decades, increasing the concn. of FAEs and ECs through the inhibition of degrading enzymes has been considered to be a viable therapeutic approach to enhance their anti-nociceptive and anti-inflammatory effects, as well as protecting the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoamrYPCqYEIbVg90H21EOLACvtfcHk0lifBThAo3Zkqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWjsLzI&md5=dd509179171644767726a67cb42dd074</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00538%26sid%3Dliteratum%253Aachs%26aulast%3DTuo%26aufirst%3DW.%26aulast%3DLeleu-Chavain%26aufirst%3DN.%26aulast%3DSpencer%26aufirst%3DJ.%26aulast%3DSansook%26aufirst%3DS.%26aulast%3DMillet%26aufirst%3DR.%26aulast%3DChavatte%26aufirst%3DP.%26atitle%3DTherapeutic%2520potential%2520of%2520fatty%2520acid%2520amide%2520hydrolase%252C%2520monoacylglycerol%2520lipase%252C%2520and%2520N-acylethanolamine%2520acid%2520amidase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4%26epage%3D46%26doi%3D10.1021%2Facs.jmedchem.6b00538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.chembiol.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18096503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1347-1356&author=J.+L.+Blankmanauthor=G.+M.+Simonauthor=B.+F.+Cravatt&title=A+comprehensive+profile+of+brain+enzymes+that+hydrolyze+the+endocannabinoid+2-arachidonoylglycerol&doi=10.1016%2Fj.chembiol.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol</span></div><div class="casAuthors">Blankman, Jacqueline L.; Simon, Gabriel M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Endogenous ligands for cannabinoid receptors ("endocannabinoids") include the lipid transmitters anandamide and 2-arachidonoylglycerol (2-AG).  Endocannabinoids modulate a diverse set of physiol. processes and are tightly regulated by enzymic biosynthesis and degrdn.  Termination of anandamide signaling by fatty acid amide hydrolase (FAAH) is well characterized, but less is known about the inactivation of 2-AG, which can be hydrolyzed by multiple enzymes in vitro, including FAAH and monoacylglycerol lipase (MAGL).  Here, we have taken a functional proteomic approach to comprehensively map 2-AG hydrolases in the mouse brain.  Our data reveal that ∼85% of brain 2-AG hydrolase activity can be ascribed to MAGL, and that the remaining 15% is mostly catalyzed by two uncharacterized enzymes, ABHD6 and ABHD12.  Interestingly, MAGL, ABHD6, and ABHD12 display distinct subcellular distributions, suggesting that they may control different pools of 2-AG in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF_Kmd_7v5urVg90H21EOLACvtfcHk0lifBThAo3Zkqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE&md5=78c6355a3909bff3cbae25989ab6a956</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DSimon%26aufirst%3DG.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520comprehensive%2520profile%2520of%2520brain%2520enzymes%2520that%2520hydrolyze%2520the%2520endocannabinoid%25202-arachidonoylglycerol%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D1347%26epage%3D1356%26doi%3D10.1016%2Fj.chembiol.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">The metabolic serine hydrolases and their functions in mammalian physiology and disease</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">6022</span>– <span class="NLM_lpage">6063</span>, <span class="refDoi"> DOI: 10.1021/cr200075y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200075y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFagtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=6022-6063&author=J.+Z.+Longauthor=B.+F.+Cravatt&title=The+metabolic+serine+hydrolases+and+their+functions+in+mammalian+physiology+and+disease&doi=10.1021%2Fcr200075y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic serine hydrolases and their functions in mammalian physiology and disease</span></div><div class="casAuthors">Long, Jonathan Z.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6022-6063</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Serine hydrolases (SHs) consist of >200 enzymes in humans which are characterized by the presence of an active site Ser residue that is used for the hydrolysis of substrates.  The membership of this enzyme class is nearly equally split between serine proteases (trypsin/chymotrypsin/subtilisin enzymes) and "metabolic" SHs that cleave ester, amide, or thioester bonds in small mols., peptides, or proteins.  The focus of this review is on the metabolic SHs.  Here, the authors attempt to provide a comprehensive summary that captures the state of knowledge about metabolic SHs in their entirety, including those enzymes that remain mostly or completely uncharacterized.  Particular emphasis is placed on relating the biochem. and enzymol. of individual SHs to the physiol. substrates and products they regulate in living systems, and how SHs, through the regulation of specific metabolic pathways impact health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5UaSiI-yXi7Vg90H21EOLACvtfcHk0lifBThAo3Zkqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFagtb8%253D&md5=c978f77bd911d5877df4ba97fc09e4b3</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fcr200075y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200075y%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DThe%2520metabolic%2520serine%2520hydrolases%2520and%2520their%2520functions%2520in%2520mammalian%2520physiology%2520and%2520disease%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26spage%3D6022%26epage%3D6063%26doi%3D10.1021%2Fcr200075y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2004.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.pain.2004.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15157693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1SltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2004&pages=319-327&author=A.+H.+Lichtmanauthor=C.+C.+Sheltonauthor=T.+Advaniauthor=B.+F.+Cravatt&title=Mice+lacking+fatty+acid+amide+hydrolase+exhibit+a+cannabinoid+receptor-mediated+phenotypic+hypoalgesia&doi=10.1016%2Fj.pain.2004.01.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia</span></div><div class="casAuthors">Lichtman, Aron H.; Shelton, Christopher C.; Advani, Tushar; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-327</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Although the N-arachidonoyl ethanolamine (anandamide) binds to cannabinoid receptors and has been implicated in the suppression of pain, its rapid catabolism in vivo by fatty acid amide hydrolase (FAAH) has presented a challenge in investigating the physiol. functions of this endogenous cannabinoid.  In order to test whether anandamide and other non-cannabinoid fatty amides modulate nociception, we compared FAAH (+/+) and (-/-) mice in the tail immersion, hot plate, and formalin tests, as well as for thermal hyperalgesia in the carrageenan and the chronic constriction injury (CCI) models.  FAAH (-/-) mice exhibited a CB1 receptor-mediated phenotypic hypoalgesia in thermal nociceptive tests.  These mice also exhibited CB1 receptor-mediated hypoalgesia in both phases of the formalin test accompanied with a phenotypic anti-edema effect, which was not blocked by either CB1 or CB2 antagonists.  Addnl., FAAH (-/-) mice displayed thermal anti-hyperalgesic and anti-inflammatory effects in the carrageenan model that were mediated, in part, by CB2, but not CB1 receptors.  In contrast, no genotype differences in pain behavior were evident following CCI, which was instead found to obliterate the phenotypic hypoalgesia displayed by FAAH (-/-) mice in the tail immersion and hot plate tests, suggesting that nerve injury may promote adaptive changes in these animals.  Collectively, these findings demonstrate a cannabinoid receptor-mediated analgesic phenotype in FAAH (-/-) mice.  In more general terms, these findings suggest that selective inhibitors of FAAH might represent a viable pharmacol. approach for the clin. treatment of pain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotqtNiSPx6jbVg90H21EOLACvtfcHk0ljXdJ7DcqBJAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1SltL4%253D&md5=522ddc54fa86e8b181f751bbbb7903c3</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2004.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2004.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DShelton%26aufirst%3DC.%2BC.%26aulast%3DAdvani%26aufirst%3DT.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DMice%2520lacking%2520fatty%2520acid%2520amide%2520hydrolase%2520exhibit%2520a%2520cannabinoid%2520receptor-mediated%2520phenotypic%2520hypoalgesia%26jtitle%3DPain%26date%3D2004%26volume%3D109%26spage%3D319%26epage%3D327%26doi%3D10.1016%2Fj.pain.2004.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambico, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campolongo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgese, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debonnel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duranti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarzia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trezza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">18620</span>– <span class="NLM_lpage">18625</span>, <span class="refDoi"> DOI: 10.1073/pnas.0509591102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.0509591102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16352709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1yq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=18620-18625&author=G.+Gobbiauthor=F.+R.+Bambicoauthor=R.+Mangieriauthor=M.+Bortolatoauthor=P.+Campolongoauthor=M.+Solinasauthor=T.+Cassanoauthor=M.+G.+Morgeseauthor=G.+Debonnelauthor=A.+Durantiauthor=A.+Tontiniauthor=G.+Tarziaauthor=M.+Morauthor=V.+Trezzaauthor=S.+R.+Goldbergauthor=V.+Cuomoauthor=D.+Piomelli&title=Antidepressant-like+activity+and+modulation+of+brain+monoaminergic+transmission+by+blockade+of+anandamide+hydrolysis&doi=10.1073%2Fpnas.0509591102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis</span></div><div class="casAuthors">Gobbi, G.; Bambico, F. R.; Mangieri, R.; Bortolato, M.; Campolongo, P.; Solinas, M.; Cassano, T.; Morgese, M. G.; Debonnel, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Mor, M.; Trezza, V.; Goldberg, S. R.; Cuomo, V.; Piomelli, D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">18620-18625</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Although anecdotal reports suggest that cannabis may be used to alleviate symptoms of depression, the psychotropic effects and abuse liability of this drug prevent its therapeutic application.  The active constituent of cannabis, Δ9-tetrahydrocannabinol, acts by binding to brain CB1 cannabinoid receptors, but an alternative approach might be to develop agents that amplify the actions of endogenous cannabinoids by blocking their deactivation.  Here, we show that URB597, a selective inhibitor of the enzyme fatty-acid amide hydrolase, which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide, exerts potent antidepressant-like effects in the mouse tail-suspension test and the rat forced-swim test.  Moreover, URB597 increases firing activity of serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in the nucleus locus ceruleus.  These actions are prevented by the CB1 antagonist rimonabant, are accompanied by increased brain anandamide levels, and are maintained upon repeated URB597 administration.  Unlike direct CB1 agonists, URB597 does not exert rewarding effects in the conditioned place preference test or produce generalization to the discriminative effects of Δ9-tetrahydrocannabinol in rats.  The findings support a role for anandamide in mood regulation and point to fatty-acid amide hydrolase as a previously uncharacterized target for antidepressant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVtAcOEAiXh7Vg90H21EOLACvtfcHk0ljXdJ7DcqBJAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1yq&md5=92475dd0b18fa1d1a3351cc3bf2f4a67</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0509591102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0509591102%26sid%3Dliteratum%253Aachs%26aulast%3DGobbi%26aufirst%3DG.%26aulast%3DBambico%26aufirst%3DF.%2BR.%26aulast%3DMangieri%26aufirst%3DR.%26aulast%3DBortolato%26aufirst%3DM.%26aulast%3DCampolongo%26aufirst%3DP.%26aulast%3DSolinas%26aufirst%3DM.%26aulast%3DCassano%26aufirst%3DT.%26aulast%3DMorgese%26aufirst%3DM.%2BG.%26aulast%3DDebonnel%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTrezza%26aufirst%3DV.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26aulast%3DCuomo%26aufirst%3DV.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DAntidepressant-like%2520activity%2520and%2520modulation%2520of%2520brain%2520monoaminergic%2520transmission%2520by%2520blockade%2520of%2520anandamide%2520hydrolysis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D18620%26epage%3D18625%26doi%3D10.1073%2Fpnas.0509591102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scalvini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span> <span> </span><span class="NLM_article-title">Monoglyceride lipase: Structure and inhibitors</span>. <i>Chem. Phys. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.chemphyslip.2015.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.chemphyslip.2015.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26216043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWgtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2016&pages=13-24&author=L.+Scalviniauthor=D.+Piomelliauthor=M.+Mor&title=Monoglyceride+lipase%3A+Structure+and+inhibitors&doi=10.1016%2Fj.chemphyslip.2015.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Monoglyceride lipase: Structure and inhibitors</span></div><div class="casAuthors">Scalvini, Laura; Piomelli, Daniele; Mor, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry and Physics of Lipids</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-24</span>CODEN:
                <span class="NLM_cas:coden">CPLIA4</span>;
        ISSN:<span class="NLM_cas:issn">0009-3084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Monoglyceride lipase (MGL), the main enzyme responsible for the hydrolytic deactivation of the endocannabinoid 2-arachidonoyl-sn-glycerol (2-AG), is an intracellular serine hydrolase that plays crit. roles in many physiol. and pathol. processes, such as pain, inflammation, neuroprotection and cancer.  The crystal structures of MGL that are currently available provide valuable information about how this enzyme might function and interact with site-directed small-mol. inhibitors.  On the other hand, its conformational equil. and the contribution of regulatory cysteine residues present within the substrate-binding pocket or on protein surface remain open issues.  Several classes of MGL inhibitors have been developed, from early reversible ones, such as URB602 and pristimerin, to carbamoylating agents that react with the catalytic serine, such as JZL184 and more recent O-hexafluoroisopropyl carbamates.  Other inhibitors that modulate MGL activity by interacting with conserved regulatory cysteines act through mechanisms that deserve to be more thoroughly investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo87N6IaURGmLVg90H21EOLACvtfcHk0ljXdJ7DcqBJAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWgtrfJ&md5=2caf6260d15d85af413b2235f1d46450</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.chemphyslip.2015.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemphyslip.2015.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DScalvini%26aufirst%3DL.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DMonoglyceride%2520lipase%253A%2520Structure%2520and%2520inhibitors%26jtitle%3DChem.%2520Phys.%2520Lipids%26date%3D2016%26volume%3D197%26spage%3D13%26epage%3D24%26doi%3D10.1016%2Fj.chemphyslip.2015.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcondes, M. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1126/science.1209200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1126%2Fscience.1209200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22021672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVagtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=809-813&author=D.+K.+Nomuraauthor=B.+E.+Morrisonauthor=J.+L.+Blankmanauthor=J.+Z.+Longauthor=S.+G.+Kinseyauthor=M.+C.+G.+Marcondesauthor=A.+M.+Wardauthor=Y.+K.+Hahnauthor=A.+H.+Lichtmanauthor=B.+Contiauthor=B.+F.+Cravatt&title=Endocannabinoid+Hydrolysis+Generates+Brain+Prostaglandins+That+Promote+Neuroinflammation&doi=10.1126%2Fscience.1209200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation</span></div><div class="casAuthors">Nomura, Daniel K.; Morrison, Bradley E.; Blankman, Jacqueline L.; Long, Jonathan Z.; Kinsey, Steven G.; Marcondes, Maria Cecilia G.; Ward, Anna M.; Hahn, Yun Kyung; Lichtman, Aron H.; Conti, Bruno; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6057</span>),
    <span class="NLM_cas:pages">809-813</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Phospholipase A2(PLA2) enzymes are considered the primary source of arachidonic acid for cyclooxygenase (COX)-mediated biosynthesis of prostaglandins.  Here, we show that a distinct pathway exists in brain, where monoacyl-glycerol lipase (MAGL) hydrolyzes the endocannabinoid 2-arachidonoylglycerol to generate a major arachidonate precursor pool for neuroinflammatory prostaglandins.  MAGL-disrupted animals show neuroprotection in a parkinsonian mouse model.  These animals are spared the hemorrhaging caused by COX inhibitors in the gut, where prostaglandins are instead regulated by cytosolic PLA2.  These findings identify MAGL as a distinct metabolic node that couples endocannabinoid to prostaglandin signaling networks in the nervous system and suggest that inhibition of this enzyme may be a new and potentially safer way to suppress the proinflammatory cascades that underlie neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPRRB-JEf2GrVg90H21EOLACvtfcHk0ljXdJ7DcqBJAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVagtrnJ&md5=17967f2d83876f57e4bc901df2e7dc68</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1126%2Fscience.1209200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1209200%26sid%3Dliteratum%253Aachs%26aulast%3DNomura%26aufirst%3DD.%2BK.%26aulast%3DMorrison%26aufirst%3DB.%2BE.%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DKinsey%26aufirst%3DS.%2BG.%26aulast%3DMarcondes%26aufirst%3DM.%2BC.%2BG.%26aulast%3DWard%26aufirst%3DA.%2BM.%26aulast%3DHahn%26aufirst%3DY.%2BK.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DConti%26aufirst%3DB.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DEndocannabinoid%2520Hydrolysis%2520Generates%2520Brain%2520Prostaglandins%2520That%2520Promote%2520Neuroinflammation%26jtitle%3DScience%26date%3D2011%26volume%3D334%26spage%3D809%26epage%3D813%26doi%3D10.1126%2Fscience.1209200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Ordonez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fontecha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Gutierrez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Rodriguez, M. L.</span></span> <span> </span><span class="NLM_article-title">Monoacylglycerol lipase (MAGL) as a promising therapeutic target</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.07.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bcp.2018.07.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30059673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVersL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=18-32&author=A.+Gil-Ordonezauthor=M.+Martin-Fontechaauthor=S.+Ortega-Gutierrezauthor=M.+L.+Lopez-Rodriguez&title=Monoacylglycerol+lipase+%28MAGL%29+as+a+promising+therapeutic+target&doi=10.1016%2Fj.bcp.2018.07.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacylglycerol lipase (MAGL) as a promising therapeutic target</span></div><div class="casAuthors">Gil-Ordonez, Ana; Martin-Fontecha, Mar; Ortega-Gutierrez, Silvia; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-32</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Monoacylglycerol lipase (MAGL) has been characterized as the main enzyme responsible for the inactivation of the most abundant brain endocannabinoid, 2-arachidonoylglycerol (2-AG).  Besides this role, MAGL has progressively acquired a growing importance as an integrative metabolic hub that controls not only the in vivo levels of 2-AG but also of other monoacylglycerides and, indirectly, the levels of free fatty acids derived from their hydrolysis as well as other lipids with pro-inflammatory or pro-tumorigenic effects, coming from the further metab. of fatty acids.  All these functions have only started to be elucidated in the last years due to the progress made in the knowledge of the structure of MAGL and in the development of genetic and chem. tools.  In this review the authors report the advances made in the field with a special focus on the last decade and how MAGL has become a promising therapeutic target for the treatment of several diseases that currently lack appropriate therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIoQ1x3SqqRrVg90H21EOLACvtfcHk0lj0Yj0P9WylkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVersL3L&md5=476dd950e4e1f221b0744dc0f7ede64f</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.07.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.07.036%26sid%3Dliteratum%253Aachs%26aulast%3DGil-Ordonez%26aufirst%3DA.%26aulast%3DMartin-Fontecha%26aufirst%3DM.%26aulast%3DOrtega-Gutierrez%26aufirst%3DS.%26aulast%3DLopez-Rodriguez%26aufirst%3DM.%2BL.%26atitle%3DMonoacylglycerol%2520lipase%2520%2528MAGL%2529%2520as%2520a%2520promising%2520therapeutic%2520target%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D157%26spage%3D18%26epage%3D32%26doi%3D10.1016%2Fj.bcp.2018.07.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habib, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chokr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro-Parenti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lettéron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouillet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Faouder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotersztajn, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2018-316137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1136%2Fgutjnl-2018-316137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30301768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFOns7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2019&pages=522-532&author=A.+Habibauthor=D.+Chokrauthor=J.+Wanauthor=P.+Hegdeauthor=M.+Mabireauthor=M.+Siebertauthor=L.+Ribeiro-Parentiauthor=M.+Le+Gallauthor=P.+Lett%C3%A9ronauthor=N.+Pilardauthor=A.+Mansouriauthor=A.+Brouilletauthor=M.+Tardelliauthor=E.+Weissauthor=P.+Le+Faouderauthor=H.+Guillouauthor=B.+F.+Cravattauthor=R.+Moreauauthor=M.+Traunerauthor=S.+Lotersztajn&title=Inhibition+of+monoacylglycerol+lipase%2C+an+anti-inflammatory+and+antifibrogenic+strategy+in+the+liver&doi=10.1136%2Fgutjnl-2018-316137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of monoacylglycerol lipase, an antiinflammatory and antifibrogenic strategy in the liver</span></div><div class="casAuthors">Habib, Aa; Chokr, Dina; Wan, JingHong; Hegde, Pushpa; Mabire, Morgane; Siebert, Matthieu; Ribeiro-Parenti, Lara; Gall, Maude Le; Letteron, Philippe; Pilard, Nathalie; Mansouri, Abdellah; Brouillet, Arthur; Tardelli, Matteo; Weiss, Emmanuel; Faouder, Pauline Le; Guillou, Herve; Cravatt, Benjamin F.; Moreau, Richard; Trauner, Michael; Lotersztajn, Sophie</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">522-532</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective Sustained inflammation originating from macrophages is a driving force of fibrosis progression and resoln.  Monoacylglycerol lipase (MAGL ) is the rate-limiting enzyme in the degrdn. of monoacylglycerols.  It is a proinflammatory enzyme that metabolises 2-arachidonoylglycerol, an endocannabinoid receptor ligand, into arachidonic acid.  Here, we investigated the impact of MAGL on inflammation and fibrosis during chronic liver injury.  Design C 57BL/6J mice and mice with global invalidation of MAGL (MAGL -/-), or myeloid-specific deletion of either MAGL (MAGL Mye-/-), ATG 5 (ATG Mye-/-) or CB2 (CB2Mye-/-), were used.  Fibrosis was induced by repeated carbon tetrachloride (CCl4) injections or bile duct ligation (BDL).  Studies were performed on peritoneal or bone marrow-derived macrophages and Kupffer cells.  Results MAGL -/- or MAGL Mye-/- mice exposed to CCl4 or subjected to BDL were more resistant to inflammation and fibrosis than wild-type counterparts.  Therapeutic intervention with MJN110, an MAGL inhibitor, reduced hepatic macrophage no. and inflammatory gene expression and slowed down fibrosis progression.  MAGL inhibitors also accelerated fibrosis regression and increased Ly-6Clow macrophage no.  Antifibrogenic effects exclusively relied on MAGL inhibition in macrophages, since MJN110 treatment of MAGL Mye-/- BDL mice did not further decrease liver fibrosis.  Cultured macrophages exposed to MJN110 or from MAGL Mye-/- mice displayed reduced cytokine secretion.  These effects were independent of the cannabinoid receptor 2, as they were preserved in CB2Mye-/- mice.  They relied on macrophage autophagy, since anti-inflammatory and antifibrogenic effects of MJN110 were lost in ATG 5Mye-/- BDL mice, and were assocd. with increased autophagic flux and autophagosome biosynthesis in macrophages when MAGL was pharmacol. or genetically inhibited.  Conclusion MAGL is an immunometabolic target in the liver.  MAGL inhibitors may show promising antifibrogenic effects during chronic liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHtyJlRmcarVg90H21EOLACvtfcHk0lj0Yj0P9WylkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFOns7jI&md5=bfa2ac283139753566804e4e2237ea3b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2018-316137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2018-316137%26sid%3Dliteratum%253Aachs%26aulast%3DHabib%26aufirst%3DA.%26aulast%3DChokr%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DHegde%26aufirst%3DP.%26aulast%3DMabire%26aufirst%3DM.%26aulast%3DSiebert%26aufirst%3DM.%26aulast%3DRibeiro-Parenti%26aufirst%3DL.%26aulast%3DLe%2BGall%26aufirst%3DM.%26aulast%3DLett%25C3%25A9ron%26aufirst%3DP.%26aulast%3DPilard%26aufirst%3DN.%26aulast%3DMansouri%26aufirst%3DA.%26aulast%3DBrouillet%26aufirst%3DA.%26aulast%3DTardelli%26aufirst%3DM.%26aulast%3DWeiss%26aufirst%3DE.%26aulast%3DLe%2BFaouder%26aufirst%3DP.%26aulast%3DGuillou%26aufirst%3DH.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DMoreau%26aufirst%3DR.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DLotersztajn%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520monoacylglycerol%2520lipase%252C%2520an%2520anti-inflammatory%2520and%2520antifibrogenic%2520strategy%2520in%2520the%2520liver%26jtitle%3DGut%26date%3D2019%26volume%3D68%26spage%3D522%26epage%3D532%26doi%3D10.1136%2Fgutjnl-2018-316137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dipasquale, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Righetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, V.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs</span>. <i>Int. Rev. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/S0074-7742(09)85005-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2FS0074-7742%2809%2985005-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19607961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Wis7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=57-72&author=S.+Gaetaniauthor=P.+Dipasqualeauthor=A.+Romanoauthor=L.+Righettiauthor=T.+Cassanoauthor=D.+Piomelliauthor=V.+Cuomo&title=The+endocannabinoid+system+as+a+target+for+novel+anxiolytic+and+antidepressant+drugs&doi=10.1016%2FS0074-7742%2809%2985005-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs</span></div><div class="casAuthors">Gaetani, Silvana; Dipasquale, Pasqua; Romano, Adele; Righetti, Laura; Cassano, Tommaso; Piomelli, Daniele; Cuomo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">Advances in Neuropharmacology</span>),
    <span class="NLM_cas:pages">57-72</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Observational studies in humans suggest that exposure to marijuana and other cannabis-derived drugs produces a wide range of subjective effects on mood tone and emotionality.  These observations have their counterpart in animal studies, showing that cannabinoid agonists strongly affect emotional reactivity in directions that vary depending on dose and context.  Based on these evidence, the activation of central CB1 receptor has emerged as potential target for the development of antianxiety and antidepressant therapies.  However, the variable effects of exogenous cannabinoid agonists have gradually shifted the interest to the alternative approach of amplifying the effects of endogenous cannabinoids (EC), namely anandamide (AEA) and 2-arachidonoylglycerol (2-AG), by preventing their deactivation.  The enzyme fatty acid amide hydrolase (FAAH) has been the target of intense research efforts aimed at developing potent and selective inhibitors that might prolong AEA actions in vivo.  Among the inhibitors developed, the compd. URB597 was found to potently inhibit FAAH activity in vivo and cause brain AEA levels to increase.  Interestingly, the enhanced AEA tone produced by URB597 does not result in the behavioral effects typical of a direct-acting cannabinoid agonist.  Though URB597 does not elicit a full-fledged cannabinoid profile of behavioral responses, it does elicit marked anxiolytic-like and antidepressant-like effects in rats and mice.  Such effects involve the downstream activation of CB1 receptors, since they are attenuated by the CB1 antagonist SR141716 (rimonabant).  Parallel to FAAH inhibition, similar results can also be obsd. by pharmacol. blocking the AEA transport system, which is responsible of the intracellular uptake of AEA from the synaptic cleft.  The reason why FAAH inhibition approach produces a smaller set of cannabimimetic effects might depend on the mechanism of EC synthesis and release upon neuronal activation and on the target selectivity of the drug.  The mechanism of EC release is commonly referred to as "on request", since they are not synthesized and stored in synaptic vesicles, such as classical neurotransmitters, but are synthesized from membrane precursors and immediately released in the synaptic cleft following neuronal activation.  The neural stimulation in specific brain areas, for example, those involved in the regulation of mood tone and/or emotional reactivity, would result in an increased EC tone in these same areas, but not necessarily in others.  Therefore, inhibition of AEA metab. activity could amplify CB1 activation mainly where AEA release is higher.  Furthermore, the inhibition of FAAH causes an accumulation of AEA but not 2-AG, which, being 200-fold more abundant than AEA in the brain, might differently modulate CB1-mediated behavioral responses.  The evidence outlined above supports the hypothesis that the EC system plays an important role in anxiety and mood disorders and suggests that modulation of FAAH activity might be a pharmacol. target for novel anxiolytic and antidepressant therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoikIKJ9JJfGLVg90H21EOLACvtfcHk0lhUVfiAUajtRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Wis7rL&md5=159980712c246a32cd127e61a98df686</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2FS0074-7742%2809%2985005-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0074-7742%252809%252985005-8%26sid%3Dliteratum%253Aachs%26aulast%3DGaetani%26aufirst%3DS.%26aulast%3DDipasquale%26aufirst%3DP.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DRighetti%26aufirst%3DL.%26aulast%3DCassano%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCuomo%26aufirst%3DV.%26atitle%3DThe%2520endocannabinoid%2520system%2520as%2520a%2520target%2520for%2520novel%2520anxiolytic%2520and%2520antidepressant%2520drugs%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D2009%26volume%3D85%26spage%3D57%26epage%3D72%26doi%3D10.1016%2FS0074-7742%2809%2985005-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerr, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, T. A.</span></span> <span> </span><span class="NLM_article-title">A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer’s disease</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2012.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.celrep.2012.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22813736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOrsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=617-623&author=J.+R.+Piroauthor=D.+I.+Benjaminauthor=J.+M.+Duerrauthor=Y.+Piauthor=C.+Gonzalesauthor=K.+M.+Woodauthor=J.+W.+Schwartzauthor=D.+K.+Nomuraauthor=T.+A.+Samad&title=A+dysregulated+endocannabinoid-eicosanoid+network+supports+pathogenesis+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.celrep.2012.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Piro, Justin R.; Benjamin, Daniel I.; Duerr, James M.; Pi, YeQing; Gonzales, Cathleen; Wood, Kathleen M.; Schwartz, Joel W.; Nomura, Daniel K.; Samad, Tarek A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">617-623</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although inflammation in the brain is meant as a defense mechanism against neurotoxic stimuli, increasing evidence suggests that uncontrolled, chronic, and persistent inflammation contributes to neurodegeneration.  Most neurodegenerative diseases have now been assocd. with chronic inflammation, including Alzheimer's disease (AD).  Whether anti-inflammatory approaches can be used to treat AD, however, is a major unanswered question.  We recently demonstrated that monoacylglycerol lipase (MAGL) hydrolyzes endocannabinoids to generate the primary arachidonic acid pool for neuroinflammatory prostaglandins.  In this study, we show that genetic inactivation of MAGL attenuates neuroinflammation and lowers amyloid β levels and plaques in an AD mouse model.  We also find that pharmacol. blockade of MAGL recapitulates the cytokine-lowering effects through reduced prostaglandin prodn., rather than enhanced endocannabinoid signaling.  Our findings thus reveal a role of MAGL in modulating neuroinflammation and amyloidosis in AD etiol. and put forth MAGL inhibitors as a potential next-generation strategy for combating AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhEmpHXwNVC7Vg90H21EOLACvtfcHk0lhUVfiAUajtRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOrsrvM&md5=a84bec802e0b547d6e06052f39d1db0f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2012.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2012.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DPiro%26aufirst%3DJ.%2BR.%26aulast%3DBenjamin%26aufirst%3DD.%2BI.%26aulast%3DDuerr%26aufirst%3DJ.%2BM.%26aulast%3DPi%26aufirst%3DY.%26aulast%3DGonzales%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DK.%2BM.%26aulast%3DSchwartz%26aufirst%3DJ.%2BW.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26aulast%3DSamad%26aufirst%3DT.%2BA.%26atitle%3DA%2520dysregulated%2520endocannabinoid-eicosanoid%2520network%2520supports%2520pathogenesis%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCell%2520Rep.%26date%3D2012%26volume%3D1%26spage%3D617%26epage%3D623%26doi%3D10.1016%2Fj.celrep.2012.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Monoacylglycerol lipase is a therapeutic target for Alzheimer’s disease</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1339</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2012.09.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.celrep.2012.09.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23122958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWns77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1329-1339&author=R.+Chenauthor=J.+Zhangauthor=Y.+Wuauthor=D.+Wangauthor=G.+Fengauthor=Y.+P.+Tangauthor=Z.+Tengauthor=C.+Chen&title=Monoacylglycerol+lipase+is+a+therapeutic+target+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.celrep.2012.09.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease</span></div><div class="casAuthors">Chen, Rongqing; Zhang, Jian; Wu, Yan; Wang, Dongqing; Feng, Guoping; Tang, Ya-Ping; Teng, Zhaoqian; Chen, Chu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1329-1339</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common cause of dementia among older people.  There are no effective medications currently available to prevent and treat AD and halt disease progression.  Monoacylglycerol lipase (MAGL) is the primary enzyme metabolizing the endocannabinoid 2-arachidonoylglycerol in the brain.  We show here that inactivation of MAGL robustly suppressed prodn. and accumulation of β-amyloid (Aβ) assocd. with reduced expression of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) in a mouse model of AD.  MAGL inhibition also prevented neuroinflammation, decreased neurodegeneration, maintained integrity of hippocampal synaptic structure and function, and improved long-term synaptic plasticity, spatial learning, and memory in AD animals.  Although the mol. mechanisms underlying the beneficial effects produced by MAGL inhibition remain to be detd., our results suggest that MAGL, which regulates endocannabinoid and prostaglandin signaling, contributes to pathogenesis and neuropathol. of AD, and thus is a promising therapeutic target for the prevention and treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq66o3D4dpA5bVg90H21EOLACvtfcHk0lhUVfiAUajtRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWns77I&md5=ed129dd8f6b0222062777cb113060ad0</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2012.09.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2012.09.030%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DY.%2BP.%26aulast%3DTeng%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DMonoacylglycerol%2520lipase%2520is%2520a%2520therapeutic%2520target%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCell%2520Rep.%26date%3D2012%26volume%3D2%26spage%3D1329%26epage%3D1339%26doi%3D10.1016%2Fj.celrep.2012.09.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habib, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okorokov, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bras, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Drimmelen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houlden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. J.</span></span> <span> </span><span class="NLM_article-title">Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">e249</span>– <span class="NLM_lpage">e253</span>, <span class="refDoi"> DOI: 10.1016/j.bja.2019.02.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bja.2019.02.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30929760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2019&pages=e249-e253&author=A.+M.+Habibauthor=A.+L.+Okorokovauthor=M.+N.+Hillauthor=J.+T.+Brasauthor=M.+C.+Leeauthor=S.+Liauthor=S.+J.+Gossageauthor=M.+van+Drimmelenauthor=M.+Morenaauthor=H.+Houldenauthor=J.+D.+Ramirezauthor=D.+L.+H.+Bennettauthor=D.+Srivastavaauthor=J.+J.+Cox&title=Microdeletion+in+a+FAAH+pseudogene+identified+in+a+patient+with+high+anandamide+concentrations+and+pain+insensitivity&doi=10.1016%2Fj.bja.2019.02.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrationsand pain insensitivity</span></div><div class="casAuthors">Habib, Abdella M.; Okorokov, Andrei L.; Hill, Matthew N.; Bras, Jose T.; Lee, Man-Cheung; Li, Shengnan; Gossage, Samuel J.; van Drimmelen, Marie; Morena, Maria; Houlden, Henry; Ramirez, Juan D.; Bennett, David L. H.; Srivastava, Devjit; Cox, James J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e249-e253</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">1471-6771</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The study of rare families with inherited pain insensitivity can identify new human-validated analgesic drug targets.  Here, a 66-yr-old female presented with nil requirement for postoperative analgesia after a normally painful orthopaedic hand surgery (trapeziectomy).  Further investigations revealed a lifelong history of painless injuries, such as frequent cuts and burns, which were obsd. to heal quickly.  We report the causative mutations for this new pain insensitivity disorder: the co-inheritance of (i) a microdeletion in dorsal root ganglia and brain-expressed pseudogene, FAAH-OUT, which we cloned from the fatty-acid amide hydrolase (FAAH) chromosomal region; and (ii) a common functional single-nucleotide polymorphism in FAAH conferring reduced expression and activity.  Circulating concns. of anandamide and related fatty-acid amides (palmitoylethanolamide and oleoylethanolamine) that are all normally degraded by FAAH were significantly elevated in peripheral blood compared with normal control carriers of the hypomorphic single-nucleotide polymorphism.  The genetic findings and elevated circulating fatty-acid amides are consistent with a phenotype resulting from enhanced endocannabinoid signaling and a loss of function of FAAH.  Our results highlight previously unknown complexity at the FAAH genomic locus involving the expression of FAAH-OUT, a novel pseudogene and long non-coding RNA.  These data suggest new routes to develop FAAH-based analgesia by targeting of FAAH-OUT, which could significantly improve the treatment of postoperative pain and potentially chronic pain and anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXNQj7AwBRvLVg90H21EOLACvtfcHk0linvluZd9HL8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlOhtbs%253D&md5=a64125a64e7ce5733bdc3962ff34eb53</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bja.2019.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bja.2019.02.019%26sid%3Dliteratum%253Aachs%26aulast%3DHabib%26aufirst%3DA.%2BM.%26aulast%3DOkorokov%26aufirst%3DA.%2BL.%26aulast%3DHill%26aufirst%3DM.%2BN.%26aulast%3DBras%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGossage%26aufirst%3DS.%2BJ.%26aulast%3Dvan%2BDrimmelen%26aufirst%3DM.%26aulast%3DMorena%26aufirst%3DM.%26aulast%3DHoulden%26aufirst%3DH.%26aulast%3DRamirez%26aufirst%3DJ.%2BD.%26aulast%3DBennett%26aufirst%3DD.%2BL.%2BH.%26aulast%3DSrivastava%26aufirst%3DD.%26aulast%3DCox%26aufirst%3DJ.%2BJ.%26atitle%3DMicrodeletion%2520in%2520a%2520FAAH%2520pseudogene%2520identified%2520in%2520a%2520patient%2520with%2520high%2520anandamide%2520concentrations%2520and%2520pain%2520insensitivity%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2019%26volume%3D123%26spage%3De249%26epage%3De253%26doi%3D10.1016%2Fj.bja.2019.02.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo Verme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astarita, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calignano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1124/mol.104.006353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fmol.104.006353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15465922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt12ksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=15-19&author=J.+Lo+Vermeauthor=J.+Fuauthor=G.+Astaritaauthor=G.+La+Ranaauthor=R.+Russoauthor=A.+Calignanoauthor=D.+Piomelli&title=The+nuclear+receptor+peroxisome+proliferator-activated+receptor-alpha+mediates+the+anti-inflammatory+actions+of+palmitoylethanolamide&doi=10.1124%2Fmol.104.006353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide</span></div><div class="casAuthors">Lo Verme, Jesse; Fu, Jin; Astarita, Giuseppe; La Rana, Giovanna; Russo, Roberto; Calignano, Antonio; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-19</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Palmitoylethanolamide (PEA), the naturally occurring amide of palmitic acid and ethanolamine, reduces pain and inflammation through an as-yet-uncharacterized mechanism.  Here, we identify the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) as the mol. target responsible for the anti-inflammatory properties of PEA.  PEA selectively activates PPAR-α in vitro with an EC50 value of 3.1±0.4 μM and induces the expression of PPAR-α mRNA when applied topically to mouse skin.  In two animal models, carrageenan-induced paw edema and phorbol ester-induced ear edema, PEA attenuates inflammation in wild-type mice but has no effect in mice deficient in PPAR-α.  The natural PPAR-α agonist oleoylethanolamide (OEA) and the synthetic PPAR-α agonists GW7647 and Wy-14643 mimic these effects in a PPAR-α-dependent manner.  These findings indicate that PPAR-α mediates the anti-inflammatory effects of PEA and suggest that this fatty-acid ethanolamide may serve, like its analog OEA, as an endogenous ligand of PPAR-α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw2rfZ_7rANLVg90H21EOLACvtfcHk0linvluZd9HL8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt12ksA%253D%253D&md5=c6c20156b93828c507ecbdee107c7061</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1124%2Fmol.104.006353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.104.006353%26sid%3Dliteratum%253Aachs%26aulast%3DLo%2BVerme%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DAstarita%26aufirst%3DG.%26aulast%3DLa%2BRana%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DR.%26aulast%3DCalignano%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DThe%2520nuclear%2520receptor%2520peroxisome%2520proliferator-activated%2520receptor-alpha%2520mediates%2520the%2520anti-inflammatory%2520actions%2520of%2520palmitoylethanolamide%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D15%26epage%3D19%26doi%3D10.1124%2Fmol.104.006353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoover, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.11.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.cell.2009.11.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20079333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=49-61&author=D.+K.+Nomuraauthor=J.+Z.+Longauthor=S.+Niessenauthor=H.+S.+Hooverauthor=S.-W.+Ngauthor=B.+F.+Cravatt&title=Monoacylglycerol+lipase+regulates+a+fatty+acid+network+that+promotes+cancer+pathogenesis&doi=10.1016%2Fj.cell.2009.11.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis</span></div><div class="casAuthors">Nomura, Daniel K.; Long, Jonathan Z.; Niessen, Sherry; Hoover, Heather S.; Ng, Shu-Wing; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-61</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tumor cells display progressive changes in metab. that correlate with malignancy, including development of a lipogenic phenotype.  How stored fats are liberated and remodeled to support cancer pathogenesis, however, remains unknown.  Here, we show that the enzyme monoacylglycerol lipase (MAGL) is highly expressed in aggressive human cancer cells and primary tumors, where it regulates a fatty acid network enriched in oncogenic signaling lipids that promotes migration, invasion, survival, and in vivo tumor growth.  Overexpression of MAGL in nonaggressive cancer cells recapitulates this fatty acid network and increases their pathogenicity-phenotypes that are reversed by an MAGL inhibitor.  Impairments in MAGL-dependent tumor growth are rescued by a high-fat diet, indicating that exogenous sources of fatty acids can contribute to malignancy in cancers lacking MAGL activity.  Together, these findings reveal how cancer cells can co-opt a lipolytic enzyme to translate their lipogenic state into an array of protumorigenic signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJjx-809DEL7Vg90H21EOLACvtfcHk0linvluZd9HL8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWiurw%253D&md5=2eccd811b2e806e79215cc00c72b7d6a</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.11.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.11.027%26sid%3Dliteratum%253Aachs%26aulast%3DNomura%26aufirst%3DD.%2BK.%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DHoover%26aufirst%3DH.%2BS.%26aulast%3DNg%26aufirst%3DS.-W.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DMonoacylglycerol%2520lipase%2520regulates%2520a%2520fatty%2520acid%2520network%2520that%2520promotes%2520cancer%2520pathogenesis%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D49%26epage%3D61%26doi%3D10.1016%2Fj.cell.2009.11.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morbidelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aviello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imperatore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capasso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piscitelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, A. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.phrs.2017.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28193521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlyqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2017&pages=227-236&author=E.+Paganoauthor=F.+Borrelliauthor=P.+Orlandoauthor=B.+Romanoauthor=M.+Montiauthor=L.+Morbidelliauthor=G.+Avielloauthor=R.+Imperatoreauthor=R.+Capassoauthor=F.+Piscitelliauthor=L.+Buonoauthor=V.+Di+Marzoauthor=A.+A.+Izzo&title=Pharmacological+inhibition+of+MAGL+attenuates+experimental+colon+carcinogenesis&doi=10.1016%2Fj.phrs.2017.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis</span></div><div class="casAuthors">Pagano, Ester; Borrelli, Francesca; Orlando, Pierangelo; Romano, Barbara; Monti, Martina; Morbidelli, Lucia; Aviello, Gabriella; Imperatore, Roberta; Capasso, Raffaele; Piscitelli, Fabiana; Buono, Lorena; Di Marzo, Vincenzo; Izzo, Angelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">227-236</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Colorectal cancer (CRC) is a major health problem in Western countries.  The endocannabinoid 2-arachidonoyl-glycerol (2-AG) exerts antiproliferative actions in a no. of tumoral cell lines, including CRC cells.  Monoacylglycerol lipase (MAGL), a serine hydrolase that inactivates 2-AG, is highly expressed in aggressive human cancer cells.  Here, we investigated the role of MAGL in exptl. colon carcinogenesis.  The role of MAGL was assessed in vivo by using the xenograft and the azoxymethane models of colon carcinogenesis; MAGL expression was evaluated by RT-PCR and immunohistochem.; 2-AG levels were measured by liq. chromatog. mass spectrometry; angiogenesis was evaluated in tumor tissues [by microvessel counting and by investigating the expression of vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) proteins] as well as in human umbilical vein endothelial cells (HUVEC); cyclin D1 was evaluated by RT-PCR.  MAGL and 2-AG were strongly expressed in tumor tissues.  The MAGL inhibitor URB602 reduced xenograft tumor vol., this effect being assocd. to down-regulation of VEGF and FGF-2, redn. in the no. of vessels and down-regulation of cyclin D1.  In HUVEC, URB602 exerted a direct antiangiogenic effect by inhibiting FGF-2 induced proliferation and migration, and by modulating pro/anti-angiogenic agents.  In expts. aiming at investigating the role of MAGL in chemoprevention, URB602 attenuated azoxymethane-induced preneoplastic lesions, polyps and tumors.  MAGL, possibly through modulation of angiogenesis, plays a pivotal role in exptl. colon carcinogenesis.  Pharmacol. inhibition of MAGL could represent an innovative therapeutic approach to reduce colorectal tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXVAd5-AN_rVg90H21EOLACvtfcHk0liNZU7vdvkdag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlyqsL0%253D&md5=24855bcf178b5093b8310525358d11a7</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DE.%26aulast%3DBorrelli%26aufirst%3DF.%26aulast%3DOrlando%26aufirst%3DP.%26aulast%3DRomano%26aufirst%3DB.%26aulast%3DMonti%26aufirst%3DM.%26aulast%3DMorbidelli%26aufirst%3DL.%26aulast%3DAviello%26aufirst%3DG.%26aulast%3DImperatore%26aufirst%3DR.%26aulast%3DCapasso%26aufirst%3DR.%26aulast%3DPiscitelli%26aufirst%3DF.%26aulast%3DBuono%26aufirst%3DL.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DIzzo%26aufirst%3DA.%2BA.%26atitle%3DPharmacological%2520inhibition%2520of%2520MAGL%2520attenuates%2520experimental%2520colon%2520carcinogenesis%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D119%26spage%3D227%26epage%3D236%26doi%3D10.1016%2Fj.phrs.2017.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisogno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span> <span> </span><span class="NLM_article-title">Latest advances in the discovery of fatty acid amide hydrolase inhibitors</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.780021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1517%2F17460441.2013.780021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23488865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFWrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=509-522&author=T.+Bisognoauthor=M.+Maccarrone&title=Latest+advances+in+the+discovery+of+fatty+acid+amide+hydrolase+inhibitors&doi=10.1517%2F17460441.2013.780021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Latest advances in the discovery of fatty acid amide hydrolase inhibitors</span></div><div class="casAuthors">Bisogno, Tiziana; Maccarrone, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">509-522</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Fatty acid amide hydrolase (FAAH) is the major catabolic enzyme of the endocannabinoid N-arachidonoylethanolamine (anandamide) that, with different degrees of efficiency, also hydrolyzes other endogenous fatty acid ethanolamides.  FAAH is increasingly being considered a relevant therapeutic target, esp. in models of inflammatory pain.  The opportunity to selectively increase the endocannabinoid tone only in those tissues where such an enhancement can be beneficial might result in a therapeutic benefit with more limited side effects, compared to the use of direct agonists of anandamide-binding receptors.  Thus the research for selective FAAH inhibitors has become a hot topic in current drug discovery.  Areas covered: This review highlights the advances in the development of different compds. belonging to different chem. families that have been proposed as FAAH inhibitors.  Several classes of inhibitors have been reported so far, and they may be classified into two major classes: reversible and irreversible compds.  These inhibitors are reviewed herein with an emphasis on their potency and selectivity.  Expert opinion: In recent years, tremendous efforts have been made to develop the FAAH inhibitors, and consequently many novel chem. templates have been discovered.  It is still a major challenge to identify the first inhibitor of FAAH suitable for clin. exploitation that satisfies the requirements of potency, selectivity vs. proteins related to anandamide activity as well as other potential off-targets, reversibility vs. irreversibility, and efficacy toward rat vs. human FAAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaENSbBN0bAbVg90H21EOLACvtfcHk0liNZU7vdvkdag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFWrt7o%253D&md5=bb68fa44724b72d5e1b35e2e7b0c7b0c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.780021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.780021%26sid%3Dliteratum%253Aachs%26aulast%3DBisogno%26aufirst%3DT.%26aulast%3DMaccarrone%26aufirst%3DM.%26atitle%3DLatest%2520advances%2520in%2520the%2520discovery%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D509%26epage%3D522%26doi%3D10.1517%2F17460441.2013.780021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burston, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosburg, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavon, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selley, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1038/nchembio.129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnchembio.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19029917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWgsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=37-44&author=J.+Z.+Longauthor=W.+Liauthor=L.+Bookerauthor=J.+J.+Burstonauthor=S.+G.+Kinseyauthor=J.+E.+Schlosburgauthor=F.+J.+Pavonauthor=A.+M.+Serranoauthor=D.+E.+Selleyauthor=L.+H.+Parsonsauthor=A.+H.+Lichtmanauthor=B.+F.+Cravatt&title=Selective+blockade+of+2-arachidonoylglycerol+hydrolysis+produces+cannabinoid+behavioral+effects&doi=10.1038%2Fnchembio.129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects</span></div><div class="casAuthors">Long, Jonathan Z.; Li, Weiwei; Booker, Lamont; Burston, James J.; Kinsey, Steven G.; Schlosburg, Joel E.; Pavon, Franciso J.; Serrano, Antonia M.; Selley, Dana E.; Parsons, Loren H.; Lichtman, Aron H.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-44</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">2-Arachidonoylglycerol (2-AG) and anandamide are endocannabinoids that activate the cannabinoid receptors CB1 and CB2.  Endocannabinoid signaling is terminated by enzymic hydrolysis, a process that for anandamide is mediated by fatty acid amide hydrolase (FAAH), and for 2-AG is thought to involve monoacylglycerol lipase (MAGL).  FAAH inhibitors produce a select subset of the behavioral effects obsd. with CB1 agonists, which suggests a functional segregation of endocannabinoid signaling pathways in vivo.  Testing this hypothesis, however, requires specific tools to independently block anandamide and 2-AG metab.  Here, we report a potent and selective inhibitor of MAGL called JZL184 that, upon administration to mice, raises brain 2-AG by eight-fold without altering anandamide.  JZL184-treated mice exhibited a broad array of CB1-dependent behavioral effects, including analgesia, hypothermia and hypomotility.  These data indicate that 2-AG endogenously modulates several behavioral processes classically assocd. with the pharmacol. of cannabinoids and point to overlapping and unique functions for 2-AG and anandamide in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY1sK0ulYFK7Vg90H21EOLACvtfcHk0liNZU7vdvkdag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWgsr3F&md5=1ffee44019b0e52db5da38fe30a6e4d0</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.129%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DBooker%26aufirst%3DL.%26aulast%3DBurston%26aufirst%3DJ.%2BJ.%26aulast%3DKinsey%26aufirst%3DS.%2BG.%26aulast%3DSchlosburg%26aufirst%3DJ.%2BE.%26aulast%3DPavon%26aufirst%3DF.%2BJ.%26aulast%3DSerrano%26aufirst%3DA.%2BM.%26aulast%3DSelley%26aufirst%3DD.%2BE.%26aulast%3DParsons%26aufirst%3DL.%2BH.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DSelective%2520blockade%2520of%25202-arachidonoylglycerol%2520hydrolysis%2520produces%2520cannabinoid%2520behavioral%2520effects%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D37%26epage%3D44%26doi%3D10.1038%2Fnchembio.129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohnz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span> <span> </span><span class="NLM_article-title">Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">6859</span>– <span class="NLM_lpage">6869</span>, <span class="refDoi"> DOI: 10.1039/C4CS00047A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1039%2FC4CS00047A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24676249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2mtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=6859-6869&author=R.+A.+Kohnzauthor=D.+K.+Nomura&title=Chemical+approaches+to+therapeutically+target+the+metabolism+and+signaling+of+the+endocannabinoid+2-AG+and+eicosanoids&doi=10.1039%2FC4CS00047A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids</span></div><div class="casAuthors">Kohnz, Rebecca A.; Nomura, Daniel K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6859-6869</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system, most popularly known as the target of the psychoactive component of marijuana, Δ9-tetrahydrocannabinol (THC), is a signaling network that modulates a diverse range of physiol. processes including nociception, behavior, cognitive function, appetite, metab., motor control, memory formation, and inflammation.  While THC and its derivs. have garnered notoriety in the eyes of the public, the endocannabinoid system consists of two endogenous signaling lipids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anandamide), which activate cannabinoid receptors CB1 and CB2 in the nervous system and peripheral tissues.  This review will focus on the recent efforts to chem. manipulate 2-AG signaling through the development of inhibitors of the 2-AG-synthesizing enzyme diacylglycerol lipase (DAGL) or the 2-AG-degrading enzyme monoacylglycerol lipase (MAGL), and assessing the therapeutic potential of DAGL and MAGL inhibitors in pain, inflammation, degenerative diseases, tissue injury, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo061VrnQ7sP7Vg90H21EOLACvtfcHk0ljGvhzOBQ6HJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2mtrjM&md5=930d2e70ae5741c872c870860b61d5a7</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1039%2FC4CS00047A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CS00047A%26sid%3Dliteratum%253Aachs%26aulast%3DKohnz%26aufirst%3DR.%2BA.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26atitle%3DChemical%2520approaches%2520to%2520therapeutically%2520target%2520the%2520metabolism%2520and%2520signaling%2520of%2520the%2520endocannabinoid%25202-AG%2520and%2520eicosanoids%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2014%26volume%3D43%26spage%3D6859%26epage%3D6869%26doi%3D10.1039%2FC4CS00047A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huggins, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span> <span> </span><span class="NLM_article-title">An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">1837</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2012.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.pain.2012.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22727500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKnurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2012&pages=1837-1846&author=J.+P.+Hugginsauthor=T.+S.+Smartauthor=S.+Langmanauthor=L.+Taylorauthor=T.+Young&title=An+efficient+randomised%2C+placebo-controlled+clinical+trial+with+the+irreversible+fatty+acid+amide+hydrolase-1+inhibitor+PF-04457845%2C+which+modulates+endocannabinoids+but+fails+to+induce+effective+analgesia+in+patients+with+pain+due+to+osteoarthritis+of+the+knee&doi=10.1016%2Fj.pain.2012.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee</span></div><div class="casAuthors">Huggins, John P.; Smart, Trevor S.; Langman, Stephen; Taylor, Louise; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1837-1846</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A randomised, placebo-controlled clin. trial with PF-04457845, a novel irreversible fatty acid amide hydrolase-1 inhibitor, increases endocannabinoids, but does not induce analgesia in patients with osteoarthritis.  The effect of PF-04457845, a potent and selective fatty acid amide hydrolase-1 (FAAH1) inhibitor, on pain due to osteoarthritis of the knee was investigated in a randomised placebo and active-controlled clin. trial.  The trial involved 2 periods (sepd. by a 2-wk washout) consisting of a 1-wk wash-in phase followed by 2 wk double-blind treatment.  Patients received single-blind placebo throughout the wash-in and washout periods.  Patients were randomised to receive either 4 mg q.d.  PF-04457845 followed by placebo (or vice versa), or 500 mg b.i.d. naproxen followed by placebo (or vice versa).  The primary end point was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score.  The trial had predefined decision rules based on likelihood that PF-04457845 was better or worse than the std. of care (considered to be a 1.8 redn. in WOMAC pain score compared to placebo).  A total of 74 patients were randomised to 1 of 4 treatment sequences.  The mean differences (80% confidence intervals) from placebo in WOMAC pain score were 0.04 (-0.63 to 0.71) for PF-04457845 and -1.13 (-1.79 to -0.47) for naproxen, indicating that while naproxen seemed efficacious, PF-04457845 was not differentiated from placebo.  The study was stopped at the interim anal. for futility.  PF-04457845 decreased FAAH activity by >96% and substantially increased 4 endogenous substrates (fatty acid amides).  PF-04457845 was well tolerated in osteoarthritis patients, and there was no evidence of cannabinoid-type adverse events.  The lack of analgesic effect of FAAH1 inhibition in humans is in contrast to data from animal models.  This apparent disconnect between species needs further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbHcORiYgJbVg90H21EOLACvtfcHk0ljGvhzOBQ6HJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKnurrF&md5=2b63f10426d6cacef059d972a5a825c1</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2012.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2012.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DHuggins%26aufirst%3DJ.%2BP.%26aulast%3DSmart%26aufirst%3DT.%2BS.%26aulast%3DLangman%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DAn%2520efficient%2520randomised%252C%2520placebo-controlled%2520clinical%2520trial%2520with%2520the%2520irreversible%2520fatty%2520acid%2520amide%2520hydrolase-1%2520inhibitor%2520PF-04457845%252C%2520which%2520modulates%2520endocannabinoids%2520but%2520fails%2520to%2520induce%2520effective%2520analgesia%2520in%2520patients%2520with%2520pain%2520due%2520to%2520osteoarthritis%2520of%2520the%2520knee%26jtitle%3DPain%26date%3D2012%26volume%3D153%26spage%3D1837%26epage%3D1846%26doi%3D10.1016%2Fj.pain.2012.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pawsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, S.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability and pharmacokinetics of FAAH inhibitor V158866: a double-blind, randomised, placebo-controlled phase I study in healthy volunteers</span>. <i>Drugs R&amp;D</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1007/s40268-016-0127-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs40268-016-0127-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26987975" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=181-191&author=S.+Pawseyauthor=M.+Woodauthor=H.+Browneauthor=K.+Donaldsonauthor=M.+Christieauthor=S.+Warrington&title=Safety%2C+tolerability+and+pharmacokinetics+of+FAAH+inhibitor+V158866%3A+a+double-blind%2C+randomised%2C+placebo-controlled+phase+I+study+in+healthy+volunteers&doi=10.1007%2Fs40268-016-0127-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1007%2Fs40268-016-0127-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40268-016-0127-y%26sid%3Dliteratum%253Aachs%26aulast%3DPawsey%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DBrowne%26aufirst%3DH.%26aulast%3DDonaldson%26aufirst%3DK.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DWarrington%26aufirst%3DS.%26atitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520FAAH%2520inhibitor%2520V158866%253A%2520a%2520double-blind%252C%2520randomised%252C%2520placebo-controlled%2520phase%2520I%2520study%2520in%2520healthy%2520volunteers%26jtitle%3DDrugs%2520R%2526amp%253BD%26date%3D2016%26volume%3D16%26spage%3D181%26epage%3D191%26doi%3D10.1007%2Fs40268-016-0127-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postnov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Hoon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hecken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Boer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannikos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Ark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Laere, K.</span></span> <span> </span><span class="NLM_article-title">Fatty acid amide hydrolase inhibition by JNJ-42165279: a multiple-ascending dose and a positron emission tomography study in healthy volunteers</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1111/cts.12548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fcts.12548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29575526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12mt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=397-404&author=A.+Postnovauthor=M.+E.+Schmidtauthor=D.+J.+Pembertonauthor=J.+de+Hoonauthor=A.+van+Heckenauthor=M.+van+den+Boerauthor=P.+Zannikosauthor=P.+van+der+Arkauthor=J.+A.+Palmerauthor=S.+Rassnickauthor=S.+Celenauthor=G.+Bormansauthor=K.+van+Laere&title=Fatty+acid+amide+hydrolase+inhibition+by+JNJ-42165279%3A+a+multiple-ascending+dose+and+a+positron+emission+tomography+study+in+healthy+volunteers&doi=10.1111%2Fcts.12548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers</span></div><div class="casAuthors">Postnov, Andrey; Schmidt, Mark E.; Pemberton, Darrel J.; de Hoon, Jan; van Hecken, Anne; van den Boer, Maarten; Zannikos, Peter; van der Ark, Peter; Palmer, James A.; Rassnick, Stef; Celen, Sofie; Bormans, Guy; van Laere, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-404</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Inhibition of fatty acid amide hydrolase (FAAH) potentiates endocannabinoid activity and is hypothesized to have therapeutic potential for mood and anxiety disorders and pain.  The clin. profile of JNJ-42165279, an oral selective FAAH inhibitor, was assessed by investigating the pharmacokinetics, pharmacodynamics, safety, and binding to FAAH in the brain of healthy human volunteers.  Concns. of JNJ-42165279 (plasma, cerebrospinal fluid (CSF), urine) and fatty acid amides (FAA; plasma, CSF), and FAAH activity in leukocytes was detd. in a phase I multiple ascending dose study.  A positron emission tomog. study with the FAAH tracer [11C]MK3168 was conducted to det. brain FAAH occupancy after single and multiple doses of JNJ-42165279.  JNJ-42165279 administration resulted in an increase in plasma and CSF FAA.  Significant blocking of brain FAAH binding of [11C]MK3168 was obsd. after pretreatment with JNJ-42165279.  JNJ-42165279 produces potent central and peripheral FAAH inhibition.  Satn. of brain FAAH occupancy occurred with doses ≥10 mg of JNJ-42165279.  No safety concerns were identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7z52Pfhrl_LVg90H21EOLACvtfcHk0ljGvhzOBQ6HJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12mt73M&md5=2b389cf4f21d8ffdbf13b66e4ff18571</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fcts.12548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12548%26sid%3Dliteratum%253Aachs%26aulast%3DPostnov%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DM.%2BE.%26aulast%3DPemberton%26aufirst%3DD.%2BJ.%26aulast%3Dde%2BHoon%26aufirst%3DJ.%26aulast%3Dvan%2BHecken%26aufirst%3DA.%26aulast%3Dvan%2Bden%2BBoer%26aufirst%3DM.%26aulast%3DZannikos%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BArk%26aufirst%3DP.%26aulast%3DPalmer%26aufirst%3DJ.%2BA.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DCelen%26aufirst%3DS.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3Dvan%2BLaere%26aufirst%3DK.%26atitle%3DFatty%2520acid%2520amide%2520hydrolase%2520inhibition%2520by%2520JNJ-42165279%253A%2520a%2520multiple-ascending%2520dose%2520and%2520a%2520positron%2520emission%2520tomography%2520study%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2018%26volume%3D11%26spage%3D397%26epage%3D404%26doi%3D10.1111%2Fcts.12548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerbrat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillatre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronziere, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carsin-Nicol, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvrit, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tulzo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edan, G.</span></span> <span> </span><span class="NLM_article-title">Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1717</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1604221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1056%2FNEJMoa1604221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27806235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1717-1725&author=A.+Kerbratauthor=J.+C.+Ferreauthor=P.+Fillatreauthor=T.+Ronziereauthor=S.+Vannierauthor=B.+Carsin-Nicolauthor=S.+Lavoueauthor=M.+Verinauthor=J.+Y.+Gauvritauthor=Y.+Le+Tulzoauthor=G.+Edan&title=Acute+neurologic+disorder+from+an+inhibitor+of+fatty+acid+amide+hydrolase&doi=10.1056%2FNEJMoa1604221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase</span></div><div class="casAuthors">Kerbrat, Anne; Ferre, Jean-Christophe; Fillatre, Pierre; Ronziere, Thomas; Vannier, Stephane; Carsin-Nicol, Beatrice; Lavoue, Sylvain; Verin, Marc; Gauvrit, Jean-Yves; Le Tulzo, Yves; Edan, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1717-1725</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND A decrease in fatty acid amide hydrolase (FAAH) activity increases the levels of endogenous analogs of cannabinoids, or endocannabinoids.  FAAH inhibitors have shown analgesic and antiinflammatory activity in animal models, and some have been tested in phase 1 and 2 studies.  In a phase 1 study, BIA 10-2474, an orally administered reversible FAAH inhibitor, was given to healthy volunteers to assess safety.  METHODS Single doses (0.25 to 100 mg) and repeated oral doses (2.5 to 20 mg for 10 days) of BIA 10-2474 had been administered to 84 healthy volunteers in sequential cohorts; no severe adverse events had been reported.  Another cohort of participants was then assigned to placebo (2 participants) or 50 mg of BIA 10-2474 per day (6 participants).  This report focuses on neurol. adverse events in participants in this final cohort.  A total of 4 of the 6 participants who received active treatment consented to have their clin. and radiol. data included in this report.  RESULTS An acute and rapidly progressive neurol. syndrome developed in three of the four participants starting on the fifth day of drug administration.  The main clin. features were headache, a cerebellar syndrome, memory impairment, and altered consciousness.  Magnetic resonance imaging showed bilateral and sym. cerebral lesions, including microhemorrhages and hyperintensities on fluid-attenuated inversion recovery and diffusion-weighted imaging sequences predominantly involving the pons and hippocampi.  One patient became brain dead; the condition of two patients subsequently improved, but one patient had residual memory impairment, and the other patient had a residual cerebellar syndrome.  One patient remained asymptomatic.  CONCLUSIONS An unanticipated severe neurol. disorder occurred after ingestion of BIA 10-2474 at the highest dose level used in a phase 1 trial.  The underlying mechanism of this toxic cerebral syndrome remains unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGSymlUTX16LVg90H21EOLACvtfcHk0lhnBf9Q2GzhUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrbJ&md5=55be96221464c92030a1a90b46e4afff</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1604221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1604221%26sid%3Dliteratum%253Aachs%26aulast%3DKerbrat%26aufirst%3DA.%26aulast%3DFerre%26aufirst%3DJ.%2BC.%26aulast%3DFillatre%26aufirst%3DP.%26aulast%3DRonziere%26aufirst%3DT.%26aulast%3DVannier%26aufirst%3DS.%26aulast%3DCarsin-Nicol%26aufirst%3DB.%26aulast%3DLavoue%26aufirst%3DS.%26aulast%3DVerin%26aufirst%3DM.%26aulast%3DGauvrit%26aufirst%3DJ.%2BY.%26aulast%3DLe%2BTulzo%26aufirst%3DY.%26aulast%3DEdan%26aufirst%3DG.%26atitle%3DAcute%2520neurologic%2520disorder%2520from%2520an%2520inhibitor%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D1717%26epage%3D1725%26doi%3D10.1056%2FNEJMoa1604221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fazio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscuolo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barboni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fezza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span> <span> </span><span class="NLM_article-title">Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold?</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1080/17460441.2020.1751118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1080%2F17460441.2020.1751118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32292082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVGhtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=765-778&author=D.+Fazioauthor=E.+Criscuoloauthor=A.+Piccoliauthor=B.+Barboniauthor=F.+Fezzaauthor=M.+Maccarrone&title=Advances+in+the+discovery+of+fatty+acid+amide+hydrolase+inhibitors%3A+what+does+the+future+hold%3F&doi=10.1080%2F17460441.2020.1751118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold</span></div><div class="casAuthors">Fazio, Domenico; Criscuolo, Emanuele; Piccoli, Alessandra; Barboni, Barbara; Fezza, Filomena; Maccarrone, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">765-778</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Fatty acid amide hydrolase (FAAH) is a membrane-bound enzyme, that inactivates endogenous signaling lipids of the fatty acid amide family, including the endocannabinoid anandamide (N-arachidonoylethanolamine, AEA).  The latter compd. has been shown to regulate a no. of important pathophysiol. conditions in humans, like feeding, obesity, immune response, reproductive events, motor coordination, and neurol. disorders.  Hence, direct manipulation of the endocannabinoid tone is thought to have therapeutic potential.  A new opportunity to develop effective drugs may arise from multi-target directed ligand (MTDL) strategies, which brings the concept that a single compd. can recognize different targets involved in the cascade of pathophysiol. events.  This review reports the latest advances in the development of new single targeted and dual-targeted FAAH inhibitors over the past 5 years.  In recent years, several FAAH inhibitors have been synthesized and investigated, yet to date none of them has reached the market as a systemic drug.  Due to the diligence of inherent redundancy and robustness in many biol. networks and pathways, multitarget inhibitors present a new prospect in the pharmaceutical industry for treatment of complex diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZjorYOeiGbrVg90H21EOLACvtfcHk0lhnBf9Q2GzhUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVGhtLg%253D&md5=6bd1fe56ef4bf88286312b78e1ea2f46</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1080%2F17460441.2020.1751118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2020.1751118%26sid%3Dliteratum%253Aachs%26aulast%3DFazio%26aufirst%3DD.%26aulast%3DCriscuolo%26aufirst%3DE.%26aulast%3DPiccoli%26aufirst%3DA.%26aulast%3DBarboni%26aufirst%3DB.%26aulast%3DFezza%26aufirst%3DF.%26aulast%3DMaccarrone%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%253A%2520what%2520does%2520the%2520future%2520hold%253F%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2020%26volume%3D15%26spage%3D765%26epage%3D778%26doi%3D10.1080%2F17460441.2020.1751118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaway, E.</span></span> <span> </span><span class="NLM_article-title">Scientists in the dark after fatal french clinical trial</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>529</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nature.2016.19189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnature.2016.19189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26791697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=263-264&author=D.+Butlerauthor=E.+Callaway&title=Scientists+in+the+dark+after+fatal+french+clinical+trial&doi=10.1038%2Fnature.2016.19189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Scientists in the dark after French clinical trial proves fatal</span></div><div class="casAuthors">Butler, Declan; Callaway, Ewen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">263-264</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Knowledge about the drug's structure would help researchers understand what happened.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxsp23F3gJiLVg90H21EOLACvtfcHk0lhnBf9Q2GzhUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oju7s%253D&md5=0fd9e8d7117ea49fc8593bdedc7cb95d</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fnature.2016.19189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature.2016.19189%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DD.%26aulast%3DCallaway%26aufirst%3DE.%26atitle%3DScientists%2520in%2520the%2520dark%2520after%2520fatal%2520french%2520clinical%2520trial%26jtitle%3DNature%26date%3D2016%26volume%3D529%26spage%3D263%26epage%3D264%26doi%3D10.1038%2Fnature.2016.19189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beliaev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loureiro, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, long-acting, and CNS-active inhibitor (BIA 10-2474) of fatty acid amide hydrolase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fcmdc.201800393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30113139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Ort73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2177-2188&author=L.+E.+Kissauthor=A.+Beliaevauthor=H.+S.+Ferreiraauthor=C.+P.+Rosaauthor=M.+J.+Bonifacioauthor=A.+I.+Loureiroauthor=N.+M.+Piresauthor=P.+N.+Palmaauthor=P.+Soares-da-Silva&title=Discovery+of+a+potent%2C+long-acting%2C+and+CNS-active+inhibitor+%28BIA+10-2474%29+of+fatty+acid+amide+hydrolase&doi=10.1002%2Fcmdc.201800393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase</span></div><div class="casAuthors">Kiss, Laszlo E.; Beliaev, Alexandre; Ferreira, Humberto S.; Rosa, Carla P.; Bonifacio, Maria Joao; Loureiro, Ana I.; Pires, Nuno M.; Palma, P. Nuno; Soares-da-Silva, Patricio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2177-2188</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) can be targeted for the treatment of pain assocd. with various medical conditions.  Herein we report the design and synthesis of a novel series of heterocyclic-N-carboxamide FAAH inhibitors that have a good alignment of potency, metabolic stability and selectivity for FAAH over monoacylglycerol lipase (MAGL) and carboxylesterases (CEs).  Lead optimization efforts carried out with benzotriazolyl- and imidazolyl-N-carboxamide series led to the discovery of clin. candidate 8 l (3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide; BIA 10-2474) as a potent and long-acting inhibitor of FAAH.  However, during a Phase I clin. trial with compd. 8l, unexpected and unpredictable serious neurol. adverse events occurred, affecting five healthy volunteers, including the death of one subject.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy1XH_cx1SxLVg90H21EOLACvtfcHk0lj7MaWAwd32AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Ort73J&md5=5cf530290c058e85e6fc7ced59770b9e</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800393%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DL.%2BE.%26aulast%3DBeliaev%26aufirst%3DA.%26aulast%3DFerreira%26aufirst%3DH.%2BS.%26aulast%3DRosa%26aufirst%3DC.%2BP.%26aulast%3DBonifacio%26aufirst%3DM.%2BJ.%26aulast%3DLoureiro%26aufirst%3DA.%2BI.%26aulast%3DPires%26aufirst%3DN.%2BM.%26aulast%3DPalma%26aufirst%3DP.%2BN.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520long-acting%252C%2520and%2520CNS-active%2520inhibitor%2520%2528BIA%252010-2474%2529%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D2177%26epage%3D2188%26doi%3D10.1002%2Fcmdc.201800393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaikin, P.</span></span> <span> </span><span class="NLM_article-title">The Bial 10-2474 Phase 1 Study-a drug development perspective and recommendations for future first-in-human trials</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1002/jcph.889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjcph.889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28387940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=690-703&author=P.+Chaikin&title=The+Bial+10-2474+Phase+1+Study-a+drug+development+perspective+and+recommendations+for+future+first-in-human+trials&doi=10.1002%2Fjcph.889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The Bial 10-2474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials</span></div><div class="casAuthors">Chaikin, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">690-703</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BIA 10-2474 (a fatty acid amide hydrolase inhibitor) was evaluated in a first-in-human phase 1 study in normal volunteers to assess safety/tolerability, pharmacokinetics, pharmacodynamics, and food effect.  The dose-escalation process consisted of a single-ascending-dose phase (SAD) and multiple-ascending-dose phase (MAD).  Prospective detn. of the starting dose and maximal escalated dose was consistent with the usual clin. pharmacol. principles for extrapolation of preclin. toxicol. data to human equiv. doses.  After only 5-6 days of multiple-dose administration of 50 mg daily in the MAD phase, several subjects became quite ill with central nervous system symptoms.  One subject progressed to brain death within several days of symptom onset.  Magnetic resonance imaging scans demonstrated signal abnormalities consistent with microbleeds affecting the hippocampus and pons, suggestive of possible cytotoxic or vasogenic edema compatible with a toxic/metabolic process.  There were no findings at lower MAD doses or during the SAD phase.  The toxicol. program carried out in 4 preclin. species (mouse, rat, dog, and monkey) did not demonstrate significant neurotoxicity.  The probable mechanism of neurol. toxicity demonstrated in humans at the 50-mg daily dose was inhibition of off-target cerebral receptors or through another mechanism.  Addnl. recommendations have been proposed for future first-in-human studies to maximize subject safety.  However, one must also accept the basic premise that, in general, first-in-human phase 1 studies are remarkably safe, and these rare events are not 100% avoidable during the drug development process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpTSyCaZuUtrVg90H21EOLACvtfcHk0lj7MaWAwd32AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7k%253D&md5=bdfe25f40f07efff9c9545fb9387282e</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2Fjcph.889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.889%26sid%3Dliteratum%253Aachs%26aulast%3DChaikin%26aufirst%3DP.%26atitle%3DThe%2520Bial%252010-2474%2520Phase%25201%2520Study-a%2520drug%2520development%2520perspective%2520and%2520recommendations%2520for%2520future%2520first-in-human%2520trials%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D57%26spage%3D690%26epage%3D703%26doi%3D10.1002%2Fjcph.889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A.</span></span> <span> </span><span class="NLM_article-title">Enzymology: Tracking off-targets</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">817</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnchembio.2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28853735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyisbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=817&author=A.+Farrell&title=Enzymology%3A+Tracking+off-targets&doi=10.1038%2Fnchembio.2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymology Tracking off-targets</span></div><div class="casAuthors">Farrell, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">817</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMdaf2xoivrVg90H21EOLACvtfcHk0lj7MaWAwd32AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyisbrO&md5=e00dea87da5f91cbea497d80372cd917</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2445%26sid%3Dliteratum%253Aachs%26aulast%3DFarrell%26aufirst%3DA.%26atitle%3DEnzymology%253A%2520Tracking%2520off-targets%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D817%26doi%3D10.1038%2Fnchembio.2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seneviratne, U. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cognetta, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">am
Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Global portrait of protein targets of metabolites of the neurotoxic compound BIA 10–2474</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b01097</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b01097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2it7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=192-197&author=Z.+Huangauthor=D.+Ogasawaraauthor=U.+I.+Seneviratneauthor=A.+B.+Cognettaauthor=C.+W.+am%0AEndeauthor=D.+M.+Nasonauthor=K.+Laphamauthor=J.+Litchfieldauthor=D.+S.+Johnsonauthor=B.+F.+Cravatt&title=Global+portrait+of+protein+targets+of+metabolites+of+the+neurotoxic+compound+BIA+10%E2%80%932474&doi=10.1021%2Facschembio.8b01097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Global Portrait of Protein Targets of Metabolites of the Neurotoxic Compound BIA 10-2474</span></div><div class="casAuthors">Huang, Zhen; Ogasawara, Daisuke; Seneviratne, Uthpala I.; Cognetta, Armand B., III; am Ende, Christopher W.; Nason, Deane M.; Lapham, Kimberly; Litchfield, John; Johnson, Douglas S.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">192-197</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin. investigation of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 resulted in serious adverse neurol. events.  Structurally unrelated FAAH inhibitors tested in humans have not presented safety concerns, suggesting that BIA 10-2474 has off-target activities.  A recent activity-based protein profiling (ABPP) study revealed that BIA 10-2474 and one of its major metabolites inhibit multiple members of the serine hydrolase class to which FAAH belongs.  Here, we extend these studies by performing a proteome-wide anal. of covalent targets of BIA 10-2474 metabolites.  Using alkynylated probes for click chem.-ABPP in human cells, we show that des-methylated metabolites of BIA 10-2474 covalently modify the conserved catalytic cysteine in aldehyde dehydrogenases, including ALDH2, which has been implicated in protecting the brain from oxidative stress-related damage.  These findings indicate that BIA 10-2474 and its metabolites have the potential to inhibit multiple mechanistically distinct enzyme classes involved in nervous system function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4x2mj4V6zUrVg90H21EOLACvtfcHk0ljPLNUt0i16iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2it7g%253D&md5=2760f9d1be5460939bf323135ae4b1a7</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b01097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b01097%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DSeneviratne%26aufirst%3DU.%2BI.%26aulast%3DCognetta%26aufirst%3DA.%2BB.%26aulast%3Dam%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DLitchfield%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DGlobal%2520portrait%2520of%2520protein%2520targets%2520of%2520metabolites%2520of%2520the%2520neurotoxic%2520compound%2520BIA%252010%25E2%2580%25932474%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D192%26epage%3D197%26doi%3D10.1021%2Facschembio.8b01097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadagopan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Becelaere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2009.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.chembiol.2009.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19389627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVCms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=411-420&author=K.+Ahnauthor=D.+S.+Johnsonauthor=M.+Mileniauthor=D.+Beidlerauthor=J.+Z.+Longauthor=M.+K.+McKinneyauthor=E.+Weerapanaauthor=N.+Sadagopanauthor=M.+Liimattaauthor=S.+E.+Smithauthor=S.+Lazerwithauthor=C.+Stiffauthor=S.+Kamtekarauthor=K.+Bhattacharyaauthor=Y.+Zhangauthor=S.+Swaneyauthor=K.+Van+Becelaereauthor=R.+C.+Stevensauthor=B.+F.+Cravatt&title=Discovery+and+characterization+of+a+highly+selective+FAAH+inhibitor+that+reduces+inflammatory+pain&doi=10.1016%2Fj.chembiol.2009.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain</span></div><div class="casAuthors">Ahn, Kay; Johnson, Douglas S.; Mileni, Mauro; Beidler, David; Long, Jonathan Z.; McKinney, Michele K.; Weerapana, Eranthie; Sadagopan, Nalini; Liimatta, Marya; Smith, Sarah E.; Lazerwith, Scott; Stiff, Cory; Kamtekar, Satwik; Bhattacharya, Keshab; Zhang, Yanhua; Swaney, Stephen; Van Becelaere, Keri; Stevens, Raymond C.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-420</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Endocannabinoids are lipid signaling mols. that regulate a wide range of mammalian behaviors, including pain, inflammation, and cognitive/emotional state.  The endocannabinoid anandamide is principally degraded by the integral membrane enzyme fatty acid amide hydrolase (FAAH), and there is currently much interest in developing FAAH inhibitors to augment endocannabinoid signaling in vivo.  Here, we report the discovery and detailed characterization of a highly efficacious and selective FAAH inhibitor, PF-3845.  Mechanistic and structural studies confirm that PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile.  PF-3845 selectively inhibits FAAH in vivo, as detd. by activity-based protein profiling; raises brain anandamide levels for up to 24 h; and produces significant cannabinoid receptor-dependent redns. in inflammatory pain.  These data thus designate PF-3845 as a valuable pharmacol. tool for in vivo characterization of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWANdntofbhbVg90H21EOLACvtfcHk0ljPLNUt0i16iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVCms7w%253D&md5=c418dbdf626109415af7001db5a7cb93</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2009.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2009.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DMileni%26aufirst%3DM.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DMcKinney%26aufirst%3DM.%2BK.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DSadagopan%26aufirst%3DN.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DLazerwith%26aufirst%3DS.%26aulast%3DStiff%26aufirst%3DC.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DBhattacharya%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSwaney%26aufirst%3DS.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520highly%2520selective%2520FAAH%2520inhibitor%2520that%2520reduces%2520inflammatory%2520pain%26jtitle%3DChem.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D411%26epage%3D420%26doi%3D10.1016%2Fj.chembiol.2009.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarzia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duranti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasse, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaghan, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putman, D.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2006.00021.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fj.1527-3458.2006.00021.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=16834756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD28Xos1yksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=21-38&author=D.+Piomelliauthor=G.+Tarziaauthor=A.+Durantiauthor=A.+Tontiniauthor=M.+Morauthor=T.+R.+Comptonauthor=O.+Dasseauthor=E.+P.+Monaghanauthor=J.+A.+Parrottauthor=D.+Putman&title=Pharmacological+profile+of+the+selective+FAAH+inhibitor+KDS-4103+%28URB597%29&doi=10.1111%2Fj.1527-3458.2006.00021.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)</span></div><div class="casAuthors">Piomelli, Daniele; Tarzia, Giorgio; Duranti, Andrea; Tontini, Andrea; Mor, Marco; Compton, Timothy R.; Dasse, Olivier; Monaghan, Edward P.; Parrott, Jeff A.; Putman, David</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-38</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  In the present article, we review the pharmacol. properties of KDS-4103 (URB597), a highly potent and selective inhibitor of the enzyme fatty-acid amide hydrolase (FAAH), which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide.  In vitro, KDS-4103 inhibits FAAH activity with median inhibitory concns. (IC50) of 5 nM in rat brain membranes and 3 nM in human liver microsomes.  In vivo, KDS-4103 inhibits rat brain FAAH activity after i.p. administration with a median ID (ID50) of 0.15 mg/kg.  The compd. does not significantly interact with other cannabinoid-related targets, including cannabinoid receptors and anandamide transport, or with a broad panel of receptors, ion channels, transporters and enzymes.  By i.p. administration to rats and mice KDS-4103 elicits significant, anxiolytic-like, anti-depressant-like and analgesic effects, which are prevented by treatment with CB1 receptor antagonists.  By contrast, at doses that significantly inhibit FAAH activity and substantially raise brain anandamide levels, KDS-4103 does not evoke classical cannabinoid-like effects (e.g., catalepsy, hypothermia, hyperphagia), does not cause place preference, and does not produce generalization to the discriminative effects of the active ingredient of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC).  These findings suggest that KDS-4103 acts by enhancing the tonic actions of anandamide on a subset of CB1 receptors, which may normally be engaged in controlling emotions and pain.  KDS-4103 is orally available in rats and cynomolgus monkeys.  Sub-chronic repeated dose studies (1500 mg/kg, per os) in these two species have not demonstrated systemic toxicity.  Likewise, no toxicity was noted in bacterial cytotoxicity tests in vitro and in the Ames test.  Furthermore, no deficits were obsd. in rats on the rotarod test after acute i.p. treatment with KDS-4103 at doses up to 5 mg/kg or in a functional observation battery after oral doses up to 1500 mg/kg.  The results suggest that KDS-4103 will offer a novel approach with a favorable therapeutic window for the treatment of anxiety, depression and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yDW3FkE5dbVg90H21EOLACvtfcHk0ljPLNUt0i16iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xos1yksL0%253D&md5=3acddbfe31c13facb4d46fa35e8e4582</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2006.00021.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2006.00021.x%26sid%3Dliteratum%253Aachs%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DCompton%26aufirst%3DT.%2BR.%26aulast%3DDasse%26aufirst%3DO.%26aulast%3DMonaghan%26aufirst%3DE.%2BP.%26aulast%3DParrott%26aufirst%3DJ.%2BA.%26aulast%3DPutman%26aufirst%3DD.%26atitle%3DPharmacological%2520profile%2520of%2520the%2520selective%2520FAAH%2520inhibitor%2520KDS-4103%2520%2528URB597%2529%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2006%26volume%3D12%26spage%3D21%26epage%3D38%26doi%3D10.1111%2Fj.1527-3458.2006.00021.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">13019</span>– <span class="NLM_lpage">13030</span>, <span class="refDoi"> DOI: 10.1021/bi701378g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi701378g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyiurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=13019-13030&author=K.+Ahnauthor=D.+S.+Johnsonauthor=L.+R.+Fitzgeraldauthor=M.+Liimattaauthor=A.+Arendseauthor=T.+Stevensonauthor=E.+T.+Lundauthor=R.+A.+Nugentauthor=T.+K.+Nomanbhoyauthor=J.+P.+Alexanderauthor=B.+F.+Cravatt&title=Novel+mechanistic+class+of+fatty+acid+amide+hydrolase+inhibitors+with+remarkable+selectivity&doi=10.1021%2Fbi701378g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity</span></div><div class="casAuthors">Ahn, Kyunghye; Johnson, Douglas S.; Fitzgerald, Laura R.; Liimatta, Marya; Arendse, Andrea; Stevenson, Tracy; Lund, Eric. T.; Nugent, Richard A.; Nomanbhoy, Tyzoon K.; Alexander, Jessica P.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">13019-13030</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide.  Genetic or pharmacol. inactivation of FAAH leads to analgesic, anti-inflammatory, anxiolytic, and antidepressant phenotypes in rodents without showing the undesirable side effects obsd. with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for treatment of pain, inflammation, and other central nervous system disorders.  However, the FAAH inhibitors reported to date lack drug-like pharmacokinetic properties and/or selectivity.  Herein the authors describe piperidine/piperazine ureas represented by N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide (PF-750) and N-phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide (PF-622) as a novel mechanistic class of FAAH inhibitors.  PF-750 and PF-622 show higher in vitro potencies than previously established classes of FAAH inhibitors.  Rather unexpectedly based on the high chem. stability of the urea functional group, PF-750 and PF-622 were found to inhibit FAAH in a time-dependent manner by covalently modifying the enzyme's active site serine nucleophile.  Activity-based proteomic profiling revealed that PF-750 and PF-622 were completely selective for FAAH relative to other mammalian serine hydrolases.  The authors hypothesize that this remarkable specificity derives, at least in part, from FAAH's special ability to function as a C(O)-N bond hydrolase, which distinguishes it from the vast majority of metabolic serine hydrolases in mammals that are restricted to hydrolyzing esters and/or thioesters.  The piperidine/piperazine urea may thus represent a privileged chem. scaffold for the synthesis of FAAH inhibitors that display an unprecedented combination of potency and selectivity for use as potential analgesic and anxiolytic/antidepressant agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NGZiH1DJ-rVg90H21EOLACvtfcHk0ljGwXctaFdcpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyiurjM&md5=eb6f7945ff233b6fc0fea6b8677ecc87</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fbi701378g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi701378g%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DFitzgerald%26aufirst%3DL.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DArendse%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DT.%26aulast%3DLund%26aufirst%3DE.%2BT.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DAlexander%26aufirst%3DJ.%2BP.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DNovel%2520mechanistic%2520class%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%2520with%2520remarkable%2520selectivity%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D13019%26epage%3D13030%26doi%3D10.1021%2Fbi701378g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kathuria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duranti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarzia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calignano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giustino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tattoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Modulation of anxiety through blockade of anandamide hydrolysis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1038/nm803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnm803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=12461523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivF2l" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=76-81&author=S.+Kathuriaauthor=S.+Gaetaniauthor=D.+Fegleyauthor=F.+Valinoauthor=A.+Durantiauthor=A.+Tontiniauthor=M.+Morauthor=G.+Tarziaauthor=G.+La+Ranaauthor=A.+Calignanoauthor=A.+Giustinoauthor=M.+Tattoliauthor=M.+Palmeryauthor=V.+Cuomoauthor=D.+Piomelli&title=Modulation+of+anxiety+through+blockade+of+anandamide+hydrolysis&doi=10.1038%2Fnm803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of anxiety through blockade of anandamide hydrolysis</span></div><div class="casAuthors">Kathuria, Satish; Gaetani, Silvana; Fegley, Darren; Valino, Fernando; Duranti, Andrea; Tontini, Andrea; Mor, Marco; Tarzia, Giorgio; La Rana, Giovanna; Calignano, Antonio; Giustino, Arcangela; Tattoli, Maria; Palmery, Maura; Cuomo, Vincenzo; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-81</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion.  But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists.  An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation.  Here, the authors describe a class of potent, selective, and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degrdn. of the endogenous cannabinoid anandamide.  Like clin. used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations.  These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade.  Apparently, anandamide participates in the modulation of emotional states and fatty acid amide hydrolase inhibition is an innovative approach to anti-anxiety therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbjKypjqxPcrVg90H21EOLACvtfcHk0ljGwXctaFdcpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivF2l&md5=350c8a5af97b6ea4e41e9f0c821231e4</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fnm803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm803%26sid%3Dliteratum%253Aachs%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DGaetani%26aufirst%3DS.%26aulast%3DFegley%26aufirst%3DD.%26aulast%3DValino%26aufirst%3DF.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DLa%2BRana%26aufirst%3DG.%26aulast%3DCalignano%26aufirst%3DA.%26aulast%3DGiustino%26aufirst%3DA.%26aulast%3DTattoli%26aufirst%3DM.%26aulast%3DPalmery%26aufirst%3DM.%26aulast%3DCuomo%26aufirst%3DV.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DModulation%2520of%2520anxiety%2520through%2520blockade%2520of%2520anandamide%2520hydrolysis%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D76%26epage%3D81%26doi%3D10.1038%2Fnm803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyffels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapanda, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span> <span> </span><span class="NLM_article-title">PET imaging of fatty acid amide hydrolase in the brain: synthesis and biological evaluation of an 11C-labelled URB597 analogue</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2010.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2010.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=20610171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVyjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=665-675&author=L.+Wyffelsauthor=G.+G.+Muccioliauthor=C.+N.+Kapandaauthor=G.+Labarauthor=S.+De+Bruyneauthor=F.+De+Vosauthor=D.+M.+Lambert&title=PET+imaging+of+fatty+acid+amide+hydrolase+in+the+brain%3A+synthesis+and+biological+evaluation+of+an+11C-labelled+URB597+analogue&doi=10.1016%2Fj.nucmedbio.2010.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging of fatty acid amide hydrolase in the brain: synthesis and biological evaluation of an 11C-labelled URB597 analogue</span></div><div class="casAuthors">Wyffels, Leonie; Muccioli, Giulio G.; Kapanda, Coco N.; Labar, Geoffray; De Bruyne, Sylvie; De Vos, Filip; Lambert, Didier M.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">665-675</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Fatty acid amide hydrolase (FAAH) is part of the endocannabinoid system (ECS) and has been linked to the etiol. of several neurol. and neuropsychiatric disorders.  So far no useful PET or SPECT tracer for in vivo visualisation of FAAH has been reported.  We synthesized and evaluated a carbon-11-labeled URB597 analog, biphenyl-3-yl [11C]-4-methoxyphenylcarbamate or [11C]-1, as potential FAAH imaging agent.  Methods: The inhibitory activity of 1 was detd. in vitro using recombinant FAAH.  Radiosynthesis of [11C]-1 was performed by methylation using [11C]-CH3I, followed by HPLC purifn.  Biol. evaluation was done by biodistribution studies in wild-type and FAAH knock-out mice, and by ex vivo and in vivo metabolite anal.  The influence of URB597 pretreatment on the metabolisation profile was assessed.  Results: [11C]-1 was obtained in good yields and high radiochem. purity.  Biodistribution studies revealed high brain uptake in wild-type and FAAH knock-out mice, but no retention of radioactivity could be demonstrated.  Metabolite anal. and URB597 pretreatment confirmed the non-FAAH-mediated metabolisation of [11C]-1.  The inhibition mechanism was detd. to be reversible.  In addn., the inhibition of URB597 appeared slowly reversible.  Conclusions: Although [11C]-1 inhibits FAAH in vitro and displays high brain uptake, the inhibition mechanism seems to deviate from the proposed carbamylation mechanism.  Consequently, it does not covalently bind to FAAH and will not be useful for mapping the enzyme in vivo.  However, it represents a potential starting point for the development of in vivo FAAH imaging tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDMBRSTBX257Vg90H21EOLACvtfcHk0lgA4ccRNWu01A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVyjsr0%253D&md5=c6d32ca4c9175799140aae2382759fbe</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2010.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2010.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DWyffels%26aufirst%3DL.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DKapanda%26aufirst%3DC.%2BN.%26aulast%3DLabar%26aufirst%3DG.%26aulast%3DDe%2BBruyne%26aufirst%3DS.%26aulast%3DDe%2BVos%26aufirst%3DF.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26atitle%3DPET%2520imaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520the%2520brain%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520an%252011C-labelled%2520URB597%2520analogue%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2010%26volume%3D37%26spage%3D665%26epage%3D675%26doi%3D10.1016%2Fj.nucmedbio.2010.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clapper, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duranti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarzia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1513</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fcmdc.200900210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19637155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKgtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1505-1513&author=J.+R.+Clapperauthor=F.+Vacondioauthor=A.+R.+Kingauthor=A.+Durantiauthor=A.+Tontiniauthor=C.+Silvaauthor=S.+Sanchiniauthor=G.+Tarziaauthor=M.+Morauthor=D.+Piomelli&title=A+second+generation+of+carbamate-based+fatty+acid+amide+hydrolase+inhibitors+with+improved+activity+in+vivo&doi=10.1002%2Fcmdc.200900210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">A Second Generation of Carbamate-Based Fatty Acid Amide Hydrolase Inhibitors with Improved Activity in vivo</span></div><div class="casAuthors">Clapper, Jason R.; Vacondio, Federica; King, Alvin R.; Duranti, Andrea; Tontini, Andrea; Silva, Claudia; Sanchini, Silvano; Tarzia, Giorgio; Mor, Marco; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1505-1513</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The fatty acid ethanolamides are a class of signaling lipids that include agonists at cannabinoid and α type peroxisome proliferator-activated receptors (PPARα).  In the brain, these compds. are primarily hydrolyzed by the intracellular serine enzyme fatty acid amide hydrolase (FAAH).  O-aryl carbamate FAAH inhibitors such as URB597 are being evaluated clin. for the treatment of pain and anxiety, but interactions with carboxylesterases in liver might limit their usefulness.  Here we explore two strategies aimed at overcoming this limitation.  Lipophilic N-terminal substitutions, which enhance FAAH recognition, yield potent inhibitors but render such compds. susceptible to attack by broad-spectrum hydrolases and inactive in vivo.  By contrast, polar electron-donating O-aryl substituents, which decrease carbamate reactivity, yield compds., such as URB694, that are highly potent FAAH inhibitors in vivo and less reactive with off-target carboxylesterases.  The results suggest that an approach balancing inhibitor reactivity with target recognition produces FAAH inhibitors that display significantly improved drug-likeness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLif0z6dIbyLVg90H21EOLACvtfcHk0lgA4ccRNWu01A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKgtLnE&md5=fc73dbc173384549dfa0f319abb76479</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900210%26sid%3Dliteratum%253Aachs%26aulast%3DClapper%26aufirst%3DJ.%2BR.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DKing%26aufirst%3DA.%2BR.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DSanchini%26aufirst%3DS.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DA%2520second%2520generation%2520of%2520carbamate-based%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%2520with%2520improved%2520activity%2520in%2520vivo%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1505%26epage%3D1513%26doi%3D10.1002%2Fcmdc.200900210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">[<sup>11</sup>C]-URB694 for FAAH PET imaging: A novel radiotracer for a new target</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">S24</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2010.04.208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2010.04.208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=S24&author=A.+A.+Wilsonauthor=A.+Garciaauthor=S.+Houleauthor=N.+Vasdev&title=%5B11C%5D-URB694+for+FAAH+PET+imaging%3A+A+novel+radiotracer+for+a+new+target&doi=10.1016%2Fj.neuroimage.2010.04.208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2010.04.208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2010.04.208%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3D%255B11C%255D-URB694%2520for%2520FAAH%2520PET%2520imaging%253A%2520A%2520novel%2520radiotracer%2520for%2520a%2520new%2520target%26jtitle%3DNeuroImage%26date%3D2010%26volume%3D52%26spage%3DS24%26doi%3D10.1016%2Fj.neuroimage.2010.04.208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">[<sup>11</sup>C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2010.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2010.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21315280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFGqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=247-253&author=A.+A.+Wilsonauthor=A.+Garciaauthor=J.+Parkesauthor=S.+Houleauthor=J.+Tongauthor=N.+Vasdev&title=%5B11C%5DCURB%3A+Evaluation+of+a+novel+radiotracer+for+imaging+fatty+acid+amide+hydrolase+by+positron+emission+tomography&doi=10.1016%2Fj.nucmedbio.2010.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">[11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography</span></div><div class="casAuthors">Wilson, Alan A.; Garcia, Armando; Parkes, Jun; Houle, Sylvain; Tong, Junchao; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">247-253</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Fatty acid amide hydrolase (FAAH) is the enzyme responsible for metabolizing the endogenous cannabinoid, anandamide, and thus represents an important target for mol. imaging.  To date, no radiotracer has been shown to be useful for imaging of FAAH using either positron emission tomog. (PET) or single photon emission computed tomog. (SPECT).  We here det. the suitability of a novel carbon-11-labeled inhibitor of FAAH via ex vivo biodistribution studies in rat brain in conjunction with pharmacol. challenges.  Methods: A potent irreversible inhibitor of FAAH, URB694, radiolabeled with carbon-11 in the carbonyl position ([11C]CURB), was administered to male rats via tail-vein injection.  Rats were sacrificed at various time points postinjection, and tissue samples were dissected, counted and weighed.  Specific binding to FAAH was investigated by pretreatment of animals with URB694 or URB597.  For metab. and mechanism of binding studies, whole brains were excised post-radiotracer injection, homogenized and extd. exhaustively with 80% aq. acetonitrile to det. the time course and fraction of radioactivity that was irreversibly bound to brain parenchyma.  Results: Upon i.v. injection into rats, [11C]CURB showed high brain uptake [std. uptake value (SUV) of 1.6-2.4 at 5 min] with little washout over time, which is characteristic of irreversible binding.  Highest uptake of radioactivity was seen in the cortex, intermediate in the cerebellum and lowest in the hypothalamus, reflecting the reported distribution of FAAH.  Brain uptake of radioactivity was decreased in a dose-dependent manner by pretreatment with increasing amts. of URB694, demonstrating that binding was saturable.  Pretreatment with the well-characterized FAAH inhibitor, URB597, reduced binding in all brain regions by 70-80%.  Homogenised brain extn. expts. demonstrated unequivocally that [11C]CURB was irreversibly bound to FAAH.  Conclusions: The title radiotracer demonstrates favorable properties such as good brain uptake, regional heterogeneity and specificity of binding based on ex vivo biodistribution studies in conscious rat brain.  [11C]CURB represents a highly promising radiotracer for the imaging of FAAH using PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0P7jO28_d8rVg90H21EOLACvtfcHk0lgA4ccRNWu01A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFGqtbc%253D&md5=b48b9f107ddd4580b3629b7fb3d8bab0</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2010.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2010.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3D%255B11C%255DCURB%253A%2520Evaluation%2520of%2520a%2520novel%2520radiotracer%2520for%2520imaging%2520fatty%2520acid%2520amide%2520hydrolase%2520by%2520positron%2520emission%2520tomography%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2011%26volume%3D38%26spage%3D247%26epage%3D253%26doi%3D10.1016%2Fj.nucmedbio.2010.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobaugh, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span> <span> </span><span class="NLM_article-title">Mapping human brain fatty acid amide hydrolase activity with PET</span>. <i>J. Cereb. Blood Flow Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1038/jcbfm.2012.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fjcbfm.2012.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23211960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVKkur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=407-414&author=P.+M.+Rusjanauthor=A.+A.+Wilsonauthor=R.+Mizrahiauthor=I.+Boileauauthor=S.+E.+Chavezauthor=N.+J.+Lobaughauthor=S.+J.+Kishauthor=S.+Houleauthor=J.+Tong&title=Mapping+human+brain+fatty+acid+amide+hydrolase+activity+with+PET&doi=10.1038%2Fjcbfm.2012.180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping human brain fatty acid amide hydrolase activity with PET</span></div><div class="casAuthors">Rusjan, Pablo M.; Wilson, Alan A.; Mizrahi, Romina; Boileau, Isabelle; Chavez, Sofia E.; Lobaugh, Nancy J.; Kish, Stephen J.; Houle, Sylvain; Tong, Junchao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Endocannabinoid tone has recently been implicated in a no. of prevalent neuropsychiatric conditions. [11C]CURB is the first available positron emission tomog. (PET) radiotracer for imaging fatty acid amide hydrolase (FAAH), the enzyme which metabolizes the prominent endocannabinoid anandamide.  Here, we sought to det. the most suitable kinetic modeling approach for quantifying [11C]CURB that binds selectively to FAAH.  Six healthy volunteers were scanned with arterial blood sampling for 90 min.  Kinetic parameters were estd. regionally using a one-tissue compartment model (TCM), a 2-TCM with and without irreversible trapping, and an irreversible 3-TCM.  The 2-TCM with irreversible trapping provided the best identifiability of PET outcome measures among the approaches studied (coeff. of variation (COV) of the net influx const. Ki and the composite parameter λk3 (λ=K1/k2) <5%, and COV(k3)<10%).  Reducing scan time to 60 min did not compromise the identifiability of rate consts.  Arterial spin labeling measures of regional cerebral blood flow were only slightly correlated with Ki, but not with k3 or λk3.  Our data suggest that λk3 is sensitive to changes in FAAH activity, therefore, optimal for PET quantification of FAAH activities with [11C]CURB.  Simulations showed that [11C]CURB binding in healthy subjects is far from a flow-limited uptake.  Journal of Cerebral Blood Flow & Metab. (2013) 33, 407-414; doi:10.1038/jcbfm.2012.180; published online 5 Dec. 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcOoWAfJlbbrVg90H21EOLACvtfcHk0lgTxKlwKjs1IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVKkur8%253D&md5=7e7a12397411c12c9e14e2ce96c93214</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fjcbfm.2012.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjcbfm.2012.180%26sid%3Dliteratum%253Aachs%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DMizrahi%26aufirst%3DR.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DChavez%26aufirst%3DS.%2BE.%26aulast%3DLobaugh%26aufirst%3DN.%2BJ.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DJ.%26atitle%3DMapping%2520human%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%2520activity%2520with%2520PET%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2013%26volume%3D33%26spage%3D407%26epage%3D414%26doi%3D10.1038%2Fjcbfm.2012.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakizaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nengaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span> <span> </span><span class="NLM_article-title">First demonstration of in vivo mapping for regional brain monoacylglycerol lipase using PET with [<sup>11</sup>C]SAR127303</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2018.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuroimage.2018.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29738910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1Knt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2018&pages=313-320&author=T.+Yamasakiauthor=W.+Moriauthor=Y.+Zhangauthor=A.+Hatoriauthor=M.+Fujinagaauthor=H.+Wakizakaauthor=Y.+Kuriharaauthor=L.+Wangauthor=N.+Nengakiauthor=T.+Ohyaauthor=S.+H.+Liangauthor=M.+R.+Zhang&title=First+demonstration+of+in+vivo+mapping+for+regional+brain+monoacylglycerol+lipase+using+PET+with+%5B11C%5DSAR127303&doi=10.1016%2Fj.neuroimage.2018.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">First demonstration of in vivo mapping for regional brain monoacylglycerol lipase using PET with [11C]SAR127303</span></div><div class="casAuthors">Yamasaki, Tomoteru; Mori, Wakana; Zhang, Yiding; Hatori, Akiko; Fujinaga, Masayuki; Wakizaka, Hidekatsu; Kurihara, Yusuke; Wang, Lu; Nengaki, Nobuki; Ohya, Tomoyuki; Liang, Steven H.; Zhang, Ming-Rong</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">313-320</span>CODEN:
                <span class="NLM_cas:coden">NEIMEF</span>;
        ISSN:<span class="NLM_cas:issn">1053-8119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a main regulator of the endocannabinoid system within the central nervous system (CNS).  Recently, [11C]SAR127303 was developed as a promising radioligand for MAGL imaging.  In this study, we aimed to quantify regional MAGL concns. in the rat brain using positron emission tomog. (PET) with [11C]SAR127303.  An irreversible two-tissue compartment model (2-TCMi, k4 = 0) anal. was conducted to est. quant. parameters (k3, K2-TCMii, and λk3).  These parameters were successfully obtained with high identifiability (<10 %COV) for the following regions ranked in order from highest to lowest: cingulate cortex > striatum > hippocampus > thalamus > cerebellum > hypothalamus ≈ pons.  In vitro autoradiographs using [11C]SAR127303 showed a heterogeneous distribution of radioactivity, as seen in the PET images.  The K2-TCMii and λk3 values correlated relatively highly with in vitro binding (r > 0.4, P < 0.005).  The K2-TCMii values showed high correlation and low underestimation (<10%) compared with the slope of a Patlak plot anal. with linear regression (KPatlaki).  In conclusion, we successfully estd. regional net uptake value of [11C]SAR127303 reflecting MAGL concns. in rat brain regions for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_WJ7neZ6JbVg90H21EOLACvtfcHk0lgTxKlwKjs1IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1Knt7o%253D&md5=6bb95add4389d8d2e607b6fc4373511f</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2018.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2018.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DWakizaka%26aufirst%3DH.%26aulast%3DKurihara%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNengaki%26aufirst%3DN.%26aulast%3DOhya%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26atitle%3DFirst%2520demonstration%2520of%2520in%2520vivo%2520mapping%2520for%2520regional%2520brain%2520monoacylglycerol%2520lipase%2520using%2520PET%2520with%2520%255B11C%255DSAR127303%26jtitle%3DNeuroImage%26date%3D2018%26volume%3D176%26spage%3D313%26epage%3D320%26doi%3D10.1016%2Fj.neuroimage.2018.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Silva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span> <span> </span><span class="NLM_article-title">Fatty acid amide hydrolase is lower in young cannabis users</span>. <i>Addict. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">e12872</span>, <span class="refDoi"> DOI: 10.1111/adb.12872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fadb.12872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31960544" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2021&pages=e12872&author=M.+R.+Jacobsonauthor=J.+J.+Wattsauthor=T.+Da+Silvaauthor=R.+F.+Tyndaleauthor=P.+M.+Rusjanauthor=S.+Houleauthor=A.+A.+Wilsonauthor=R.+A.+Rossauthor=I.+Boileauauthor=R.+Mizrahi&title=Fatty+acid+amide+hydrolase+is+lower+in+young+cannabis+users&doi=10.1111%2Fadb.12872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1111%2Fadb.12872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fadb.12872%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DM.%2BR.%26aulast%3DWatts%26aufirst%3DJ.%2BJ.%26aulast%3DDa%2BSilva%26aufirst%3DT.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DMizrahi%26aufirst%3DR.%26atitle%3DFatty%2520acid%2520amide%2520hydrolase%2520is%2520lower%2520in%2520young%2520cannabis%2520users%26jtitle%3DAddict.%2520Biol.%26date%3D2021%26volume%3D26%26spage%3De12872%26doi%3D10.1111%2Fadb.12872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payer, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span> <span> </span><span class="NLM_article-title">Fatty acid amide hydrolase binding in brain of cannabis users: imaging with the novel radiotracer [<sup>11</sup>C]CURB</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2016.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.biopsych.2016.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27345297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2gt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2016&pages=691-701&author=I.+Boileauauthor=E.+Mansouriauthor=B.+Williamsauthor=B.+Le+Follauthor=P.+Rusjanauthor=R.+Mizrahiauthor=R.+F.+Tyndaleauthor=M.+A.+Huestisauthor=D.+E.+Payerauthor=A.+A.+Wilsonauthor=S.+Houleauthor=S.+J.+Kishauthor=J.+Tong&title=Fatty+acid+amide+hydrolase+binding+in+brain+of+cannabis+users%3A+imaging+with+the+novel+radiotracer+%5B11C%5DCURB&doi=10.1016%2Fj.biopsych.2016.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB</span></div><div class="casAuthors">Boileau, Isabelle; Mansouri, Esmaeil; Williams, Belinda; Le Foll, Bernard; Rusjan, Pablo; Mizrahi, Romina; Tyndale, Rachel F.; Huestis, Marilyn A.; Payer, Doris E.; Wilson, Alan A.; Houle, Sylvain; Kish, Stephen J.; Tong, Junchao</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">691-701</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">One of the major mechanisms for terminating the actions of the endocannabinoid anandamide is hydrolysis by fatty acid amide hydrolase (FAAH), and inhibitors of the enzyme were suggested as potential treatment for human cannabis dependence.  However, the status of brain FAAH in cannabis use disorder is unknown.  Brain FAAH binding was measured with positron emission tomog. and [11C]CURB in 22 healthy control subjects and ten chronic cannabis users during early abstinence.  The FAAH genetic polymorphism (rs324420) and blood, urine, and hair levels of cannabinoids and metabolites were detd.  In cannabis users, FAAH binding was significantly lower by 14%-20% across the brain regions examd. than in matched control subjects (overall Cohen's d = 0.96).  Lower binding was neg. correlated with cannabinoid concns. in blood and urine and was assocd. with higher trait impulsiveness.  Lower FAAH binding levels in the brain may be a consequence of chronic and recent cannabis exposure and could contribute to cannabis withdrawal.  This effect should be considered in the development of novel treatment strategies for cannabis use disorder that target FAAH and endocannabinoids.  Further studies are needed to examine possible changes in FAAH binding during prolonged cannabis abstinence and whether lower FAAH binding predates drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph9pP9zUMIDrVg90H21EOLACvtfcHk0lg64g8UX15WCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2gt77N&md5=e7d5eb1531e5e5e43d1b157e33a8a0ea</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2016.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2016.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DMansouri%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DRusjan%26aufirst%3DP.%26aulast%3DMizrahi%26aufirst%3DR.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DHuestis%26aufirst%3DM.%2BA.%26aulast%3DPayer%26aufirst%3DD.%2BE.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DTong%26aufirst%3DJ.%26atitle%3DFatty%2520acid%2520amide%2520hydrolase%2520binding%2520in%2520brain%2520of%2520cannabis%2520users%253A%2520imaging%2520with%2520the%2520novel%2520radiotracer%2520%255B11C%255DCURB%26jtitle%3DBiol.%2520Psychiatry%26date%3D2016%26volume%3D80%26spage%3D691%26epage%3D701%26doi%3D10.1016%2Fj.biopsych.2016.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazinet, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagzdins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendershot, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span> <span> </span><span class="NLM_article-title">Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [<sup>11</sup>C] CURB</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1296</span>, <span class="refDoi"> DOI: 10.1038/s41386-020-0606-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41386-020-0606-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31910433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFOitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2020&pages=1289-1296&author=L.+M.+Bestauthor=B.+Williamsauthor=B.+Le+Follauthor=E.+Mansouriauthor=R.+P.+Bazinetauthor=L.+Linauthor=V.+De+Lucaauthor=D.+Lagzdinsauthor=P.+Rusjanauthor=R.+F.+Tyndaleauthor=A.+A.+Wilsonauthor=C.+S.+Hendershotauthor=M.+Heiligauthor=S.+Houleauthor=J.+Tongauthor=S.+J.+Kishauthor=I.+Boileau&title=Lower+brain+fatty+acid+amide+hydrolase+in+treatment-seeking+patients+with+alcohol+use+disorder%3A+a+positron+emission+tomography+study+with+%5B11C%5D+CURB&doi=10.1038%2Fs41386-020-0606-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB</span></div><div class="casAuthors">Best, Laura M.; Williams, Belinda; Le Foll, Bernard; Mansouri, Esmaeil; Bazinet, Richard P.; Lin, Lin; De Luca, Vincenzo; Lagzdins, Dina; Rusjan, Pablo; Tyndale, Rachel F.; Wilson, Alan A.; Hendershot, Christian S.; Heilig, Markus; Houle, Sylvain; Tong, Junchao; Kish, Stephen J.; Boileau, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1289-1296</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The endocannabinoid enzyme, fatty acid amide hydrolase (FAAH), has been proposed as a therapeutic target for alc. use disorder (AUD) and co-morbid psychiatric illnesses.  Investigating this target in the living human brain and its relationship to clin. outcome is a crit. step of informed drug development.  Our objective was to establish whether brain FAAH levels are low in individuals with AUD and related to drinking behavior.  In this pilot study, treatment-seeking patients with AUD completed two PET scans with the FAAH radiotracer [C-11]CURB after 3-7 days (n = 14) and 2-4 wk (n = 9) of monitored abstinence.  Healthy controls (n = 25) completed one scan.  FAAH genetic polymorphism (rs324420) and blood concns. of anandamide and other N-acylethanolamines metabolized by FAAH were detd. and AUD symptoms assessed.  In AUD, brain FAAH levels were globally lower than controls during early abstinence (F(1,36) = 5.447; p = 0.025) and FAAH substrates (anandamide, oleoylethanolamide, and N-docosahexaenoylethanolamide) were significantly elevated (30-67%).  No significant differences in FAAH or FAAH substrates were noted after 2-4 wk abstinence.  FAAH levels neg. correlated with drinks per wk (r = -0.57, p = 0.032) and plasma concns. of the three FAAH substrates (r > 0.57; p < 0.04).  Our findings suggest that early abstinence from alc. in AUD is assocd. with transiently low brain FAAH levels, which are inversely related to heavier alc. use and elevated plasma levels of FAAH substrates.  Whether low FAAH is an adaptive beneficial response to chronic alc. is unknown.  Therapeutic strategies focusing on FAAH inhibition should consider the possibility that low FAAH during early abstinence may be related to drinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5EKo2n_EFSbVg90H21EOLACvtfcHk0lg64g8UX15WCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFOitQ%253D%253D&md5=b0023050192aa9005471fd6d2f4a59de</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1038%2Fs41386-020-0606-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-020-0606-2%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DL.%2BM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DMansouri%26aufirst%3DE.%26aulast%3DBazinet%26aufirst%3DR.%2BP.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DDe%2BLuca%26aufirst%3DV.%26aulast%3DLagzdins%26aufirst%3DD.%26aulast%3DRusjan%26aufirst%3DP.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DHendershot%26aufirst%3DC.%2BS.%26aulast%3DHeilig%26aufirst%3DM.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DBoileau%26aufirst%3DI.%26atitle%3DLower%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520treatment-seeking%2520patients%2520with%2520alcohol%2520use%2520disorder%253A%2520a%2520positron%2520emission%2520tomography%2520study%2520with%2520%255B11C%255D%2520CURB%26jtitle%3DNeuropsychopharmacology%26date%3D2020%26volume%3D45%26spage%3D1289%26epage%3D1296%26doi%3D10.1038%2Fs41386-020-0606-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span> <span> </span><span class="NLM_article-title">Imaging brain fatty acid amide hydrolase in untreated patients with psychosis</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2020.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.biopsych.2020.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32387132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVegu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2020&pages=727-735&author=J.+J.+Wattsauthor=M.+R.+Jacobsonauthor=N.+Lalangauthor=I.+Boileauauthor=R.+F.+Tyndaleauthor=M.+Kiangauthor=R.+A.+Rossauthor=S.+Houleauthor=A.+A.+Wilsonauthor=P.+Rusjanauthor=R.+Mizrahi&title=Imaging+brain+fatty+acid+amide+hydrolase+in+untreated+patients+with+psychosis&doi=10.1016%2Fj.biopsych.2020.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis</span></div><div class="casAuthors">Watts, Jeremy J.; Jacobson, Maya R.; Lalang, Nittha; Boileau, Isabelle; Tyndale, Rachel F.; Kiang, Michael; Ross, Ruth A.; Houle, Sylvain; Wilson, Alan A.; Rusjan, Pablo; Mizrahi, Romina</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The brain's endocannabinoid system, the primary target of cannabis, has been implicated in psychosis.  The endocannabinoid anandamide is elevated in cerebrospinal fluid of patients with schizophrenia.  Fatty acid amide hydrolase (FAAH) controls brain anandamide levels; however, it is unknown if FAAH is altered in vivo in psychosis or related to pos. psychotic symptoms.  Twenty-seven patients with schizophrenia spectrum disorders and 36 healthy control subjects completed high-resoln. positron emission tomog. scans with the novel FAAH radioligand [11C]CURB and structural magnetic resonance imaging.  Data were analyzed using the validated irreversible 2-tissue compartment model with a metabolite-cor. arterial input function.  FAAH did not differ significantly between patients with psychotic disorders and healthy control subjects (F1,62.85 = 0.48, p = .49).  In contrast, lower FAAH predicted greater pos. psychotic symptom severity, with the strongest effect obsd. for the pos. symptom dimension, which includes suspiciousness, delusions, unusual thought content, and hallucinations (F1,26.69 = 12.42, p = .002; Cohen's f = 0.42, large effect).  Shorter duration of illness (F1,26.95 = 13.78, p = .001; Cohen's f = 0.39, medium to large effect) and duration of untreated psychosis predicted lower FAAH (F1,26.95 = 6.03, p = .021, Cohen's f = 0.27, medium effect).  These results were not explained by past cannabis exposure or current intake of antipsychotic medications.  FAAH exhibited marked differences across brain regions (F7,112.62 = 175.85, p < 1 x 10-56; Cohen's f > 1).  Overall, FAAH was higher in female subjects than in male subjects (F1,62.84 = 10.05, p = .002; Cohen's f = 0.37).  This first study of brain FAAH in psychosis indicates that FAAH may represent a biomarker of disease state of potential utility for clin. studies targeting psychotic symptoms or as a novel target for interventions to treat psychotic symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBQj1xFOipMbVg90H21EOLACvtfcHk0lg64g8UX15WCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVegu78%253D&md5=8826853f4031720264855e31be2f538a</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2020.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2020.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DWatts%26aufirst%3DJ.%2BJ.%26aulast%3DJacobson%26aufirst%3DM.%2BR.%26aulast%3DLalang%26aufirst%3DN.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DKiang%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DRusjan%26aufirst%3DP.%26aulast%3DMizrahi%26aufirst%3DR.%26atitle%3DImaging%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520untreated%2520patients%2520with%2520psychosis%26jtitle%3DBiol.%2520Psychiatry%26date%3D2020%26volume%3D88%26spage%3D727%26epage%3D735%26doi%3D10.1016%2Fj.biopsych.2020.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span> <span> </span><span class="NLM_article-title">Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [<sup>11</sup>C]CURB positron emission tomography study</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1834</span>– <span class="NLM_lpage">1841</span>, <span class="refDoi"> DOI: 10.1038/s41386-020-0731-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41386-020-0731-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32521537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Kgsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2020&pages=1834-1841&author=N.+J.+Kollaauthor=R.+Mizrahiauthor=K.+Karasauthor=C.+Wangauthor=R.+M.+Bagbyauthor=S.+McMainauthor=A.+I.+Simpsonauthor=P.+M.+Rusjanauthor=R.+Tyndaleauthor=S.+Houleauthor=I.+Boileau&title=Elevated+fatty+acid+amide+hydrolase+in+the+prefrontal+cortex+of+borderline+personality+disorder%3A+a+%5B11C%5DCURB+positron+emission+tomography+study&doi=10.1038%2Fs41386-020-0731-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study</span></div><div class="casAuthors">Kolla, N. J.; Mizrahi, R.; Karas, K.; Wang, C.; Bagby, R. M.; McMain, S.; Simpson, A. I.; Rusjan, P. M.; Tyndale, R.; Houle, S.; Boileau, I.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1834-1841</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Amygdala-prefrontal cortex (PFC) functional impairments have been linked to emotion dysregulation and aggression in borderline personality disorder (BPD).  Fatty acid amide hydrolase (FAAH), the major catabolic enzyme for the endocannabinoid anandamide, has been proposed as a key regulator of the amygdala-PFC circuit that subserves emotion regulation.  We tested the hypothesis that FAAH levels measured with [11C]CURB positron emission tomog. in amygdala and PFC would be elevated in BPD and would relate to hostility and aggression.  Twenty BPD patients and 20 healthy controls underwent FAAH genotyping (rs324420) and scanning with [11C]CURB.  BPD patients were medication-free and were not experiencing a current major depressive episode.  Regional differences in [11C]CURB binding were assessed using multivariate anal. of covariance with PFC and amygdala [11C]CURB binding as dependent variables, diagnosis as a fixed factor, and sex and genotype as covariates. [11C]CURB binding was marginally elevated across the PFC and amygdala in BPD (p = 0.08).  In a priori selected PFC, but not amygdala, [11C]CURB binding was significantly higher in BPD (11.0%, p = 0.035 vs. 10.6%, p = 0.29).  PFC and amygdala [11C]CURB binding was pos. correlated with measures of hostility in BPD (r > 0.4; p < 0.04).  This study is the first to provide preliminary evidence of elevated PFC FAAH binding in any psychiatric condition.  Findings are consistent with the model that lower endocannabinoid tone could perturb PFC circuitry that regulates emotion and aggression.  Replication of these findings could encourage testing of FAAH inhibitors as innovative treatments for BPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAO_EHMBKUwLVg90H21EOLACvtfcHk0lixgvEk5vAD4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Kgsb3O&md5=27ce60a98633a51d985c17d796edc6cf</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1038%2Fs41386-020-0731-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-020-0731-y%26sid%3Dliteratum%253Aachs%26aulast%3DKolla%26aufirst%3DN.%2BJ.%26aulast%3DMizrahi%26aufirst%3DR.%26aulast%3DKaras%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DBagby%26aufirst%3DR.%2BM.%26aulast%3DMcMain%26aufirst%3DS.%26aulast%3DSimpson%26aufirst%3DA.%2BI.%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DTyndale%26aufirst%3DR.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DBoileau%26aufirst%3DI.%26atitle%3DElevated%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520the%2520prefrontal%2520cortex%2520of%2520borderline%2520personality%2520disorder%253A%2520a%2520%255B11C%255DCURB%2520positron%2520emission%2520tomography%2520study%26jtitle%3DNeuropsychopharmacology%26date%3D2020%26volume%3D45%26spage%3D1834%26epage%3D1841%26doi%3D10.1038%2Fs41386-020-0731-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and evaluation of [11C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1021/jm301492y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301492y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2mu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=201-209&author=A.+A.+Wilsonauthor=J.+W.+Hicksauthor=O.+Sadovskiauthor=J.+Parkesauthor=J.+Tongauthor=S.+Houleauthor=C.+J.+Fowlerauthor=N.+Vasdev&title=Radiosynthesis+and+evaluation+of+%5B11C-carbonyl%5D-labeled+carbamates+as+fatty+acid+amide+hydrolase+radiotracers+for+positron+emission+tomography&doi=10.1021%2Fjm301492y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and Evaluation of [11C-Carbonyl]-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography</span></div><div class="casAuthors">Wilson, Alan A.; Hicks, Justin W.; Sadovski, Oleg; Parkes, Jun; Tong, Junchao; Houle, Sylvain; Fowler, Christopher J.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-209</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) plays a key role in regulating the tone of the endocannabinoid system.  Radiotracers are required to image and quantify FAAH activity in vivo.  A series of potent FAAH inhibitors encompassing two classes of N-alkyl-O-arylcarbamates were synthesized and eight of them were radiolabeled with carbon-11.  The [11C-carbonyl]-radiotracers were evaluated in vitro and ex vivo in rats as potential FAAH imaging agents for positron emission tomog. (PET).  Both sets of [11C]O-arylcarbamates showed good to excellent brain penetration and an appropriate regional distribution.  Pre-treatments with a FAAH inhibitor demonstrated that 80-95% of brain uptake of radioactivity constituted binding of the radiotracers to FAAH.  Brain extn. measurements showed that binding to FAAH was irreversible and kinetically different for the two classes of carbamates.  These promising results are discussed in terms of the requirements of a suitable radiotracer for the in vivo imaging of FAAH using PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXOvMBW9txTbVg90H21EOLACvtfcHk0lixgvEk5vAD4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2mu73M&md5=94d72f4c0c436168dc2192b2d2989cff</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Fjm301492y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301492y%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DHicks%26aufirst%3DJ.%2BW.%26aulast%3DSadovski%26aufirst%3DO.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DFowler%26aufirst%3DC.%2BJ.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DRadiosynthesis%2520and%2520evaluation%2520of%2520%255B11C-carbonyl%255D-labeled%2520carbamates%2520as%2520fatty%2520acid%2520amide%2520hydrolase%2520radiotracers%2520for%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D201%26epage%3D209%26doi%3D10.1021%2Fjm301492y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, A.</span>; <span class="NLM_string-name">Munagata, R.</span>; <span class="NLM_string-name">Kawano, N.</span>; <span class="NLM_string-name">Samizu, K.</span>; <span class="NLM_string-name">Oka, H.</span>; <span class="NLM_string-name">Ishii, T.</span></span> <span> </span><span class="NLM_article-title">Azole Compound</span>. U.S. Patent, <span class="NLM_patent">US8,207,199B2</span>, Jun 26, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Aoki&author=R.+Munagata&author=N.+Kawano&author=K.+Samizu&author=H.+Oka&author=T.+Ishii&title=Azole+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DA.%26atitle%3DAzole%2520Compound%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span> <span> </span><span class="NLM_article-title">Development of [<sup>11</sup>C]MFTC for PET imaging of fatty acid amide hydrolase in rat and monkey brains</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1021/cn500269g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500269g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=339-346&author=K.+Kumataauthor=J.+Yuiauthor=A.+Hatoriauthor=J.+Maedaauthor=L.+Xieauthor=M.+Ogawaauthor=T.+Yamasakiauthor=Y.+Nagaiauthor=Y.+Shimodaauthor=M.+Fujinagaauthor=K.+Kawamuraauthor=M.+R.+Zhang&title=Development+of+%5B11C%5DMFTC+for+PET+imaging+of+fatty+acid+amide+hydrolase+in+rat+and+monkey+brains&doi=10.1021%2Fcn500269g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Development of [11C]MFTC for PET Imaging of Fatty Acid Amide Hydrolase in Rat and Monkey Brains</span></div><div class="casAuthors">Kumata, Katsushi; Yui, Joji; Hatori, Akiko; Maeda, Jun; Xie, Lin; Ogawa, Masanao; Yamasaki, Tomoteru; Nagai, Yuji; Shimoda, Yoko; Fujinaga, Masayuki; Kawamura, Kazunori; Zhang, Ming-Rong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-346</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We developed 2-methylpyridin-3-yl-4-(5-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl)piperidine-1-[11C]carboxylate ([11C]MFTC) as a promising PET tracer for in vivo imaging of fatty acid amide hydrolase (FAAH) in rat and monkey brains. [11C]MFTC was synthesized by reacting 3-hydroxy-2-methylpyridine (2) with [11C]phosgene ([11C]COCl2), followed by reacting with 4-(5-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl)piperidine (3), with a 20 ± 4.6% radiochem. yield (decay-cor., n = 30) based on [11C]CO2 and 40 min synthesis time from the end of bombardment.  A biodistribution study in mice showed high uptake of radioactivity in FAAH-rich organs, including the lung, liver, and kidneys.  Positron emission tomog. (PET) summation images of rat brains showed high radioactivity in the frontal cortex, cerebellum, and hippocampus, which was consistent with the regional distribution pattern of FAAH in rodent brain.  Pretreatment with MFTC or FAAH-selective URB597 significantly reduced the uptake in the brain.  PET imaging of monkey brain showed relatively high uptake in the whole brain, particularly in the occipital cortex, which was also inhibited by treatment with MFTC or URB597.  More than 96% of the total radioactivity was irreversible in the brain homogenate of rats 5 min after the radiotracer injection.  The specific in vivo FAAH binding indicates that [11C]MFTC is a promising PET tracer for visualizing FAAH in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsICjWUI9PtbVg90H21EOLACvtfcHk0lixgvEk5vAD4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsb7K&md5=59ea077964694b652c32790f82be982a</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Fcn500269g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500269g%26sid%3Dliteratum%253Aachs%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DYui%26aufirst%3DJ.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26atitle%3DDevelopment%2520of%2520%255B11C%255DMFTC%2520for%2520PET%2520imaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520in%2520rat%2520and%2520monkey%2520brains%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D339%26epage%3D346%26doi%3D10.1021%2Fcn500269g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobrega, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span> <span> </span><span class="NLM_article-title">Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4351</span>– <span class="NLM_lpage">4357</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.04.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmc.2013.04.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23712084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=4351-4357&author=O.+Sadovskiauthor=J.+W.+Hicksauthor=J.+Parkesauthor=R.+Raymondauthor=J.+Nobregaauthor=S.+Houleauthor=M.+Ciprianoauthor=C.+J.+Fowlerauthor=N.+Vasdevauthor=A.+A.+Wilson&title=Development+and+characterization+of+a+promising+fluorine-18+labelled+radiopharmaceutical+for+in+vivo+imaging+of+fatty+acid+amide+hydrolase&doi=10.1016%2Fj.bmc.2013.04.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase</span></div><div class="casAuthors">Sadovski, Oleg; Hicks, Justin W.; Parkes, Jun; Raymond, Roger; Nobrega, Jose; Houle, Sylvain; Cipriano, Mariateresa; Fowler, Christopher J.; Vasdev, Neil; Wilson, Alan A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4351-4357</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH), the enzyme responsible for terminating signaling by the endocannabinoid anandamide, plays an important role in the endocannabinoid system, and FAAH inhibitors are attractive drugs for pain, addiction, and neurol. disorders.  The synthesis, radiosynthesis, and evaluation, in vitro and ex vivo in rat, of an 18F-radiotracer designed to image FAAH using positron emission tomog. (PET) is described.  Fluorine-18 labeled 3-(4,5-dihydrooxazol-2-yl)phenyl (5-fluoropentyl)carbamate, [18F]5, was synthesized at high specific activity in a one-pot three step reaction using a com. module with a radiochem. yield of 17-22% (from [18F]fluoride).  In vitro assay using rat brain homogenates showed that 5 inhibited FAAH in a time-dependent manner, with an IC50 value of 0.82 nM after a preincubation of 60 min.  Ex vivo biodistribution studies and ex vivo autoradiog. in rat brain demonstrated that [18F]5 had high brain penetration with std. uptake values of up to 4.6 and had a regional distribution which correlated with reported regional FAAH enzyme activity.  Specificity of binding to FAAH with [18F]5 was high (>90%) as demonstrated by pharmacol. challenges with potent and selective FAAH inhibitors and was irreversible as demonstrated by radioactivity measurements on homogenized brain tissue exts  We infer from these results that [18F]5 is a highly promising candidate radiotracer with which to image FAAH in human subjects using PET and clin. studies are proceeding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Us6Ifw6o_7Vg90H21EOLACvtfcHk0lj3cIP4cklW-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGmurk%253D&md5=367e67c5863b85854eeeebe2b02ee8d0</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.04.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.04.077%26sid%3Dliteratum%253Aachs%26aulast%3DSadovski%26aufirst%3DO.%26aulast%3DHicks%26aufirst%3DJ.%2BW.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DRaymond%26aufirst%3DR.%26aulast%3DNobrega%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DCipriano%26aufirst%3DM.%26aulast%3DFowler%26aufirst%3DC.%2BJ.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520a%2520promising%2520fluorine-18%2520labelled%2520radiopharmaceutical%2520for%2520in%2520vivo%2520imaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D4351%26epage%3D4357%26doi%3D10.1016%2Fj.bmc.2013.04.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoup, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">PET imaging of fatty acid amide hydrolase with [<sup>18</sup>F]DOPP in nonhuman primates</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3832</span>– <span class="NLM_lpage">3838</span>, <span class="refDoi"> DOI: 10.1021/mp500316h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500316h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=3832-3838&author=B.+H.+Rotsteinauthor=H.+Y.+Weyauthor=T.+M.+Shoupauthor=A.+A.+Wilsonauthor=S.+H.+Liangauthor=J.+M.+Hookerauthor=N.+Vasdev&title=PET+imaging+of+fatty+acid+amide+hydrolase+with+%5B18F%5DDOPP+in+nonhuman+primates&doi=10.1021%2Fmp500316h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">PET Imaging of Fatty Acid Amide Hydrolase with [18F]DOPP in Nonhuman Primates</span></div><div class="casAuthors">Rotstein, Benjamin H.; Wey, Hsiao-Ying; Shoup, Timothy M.; Wilson, Alan A.; Liang, Steven H.; Hooker, Jacob M.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3832-3838</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) regulates endocannabinoid signaling. [11C]CURB, an irreversibly binding FAAH inhibitor, has been developed for clin. research imaging with PET.  However, no fluorine-18 labeled radiotracer for FAAH has yet advanced to human studies. [18F]DOPP ([18F]3-(4,5-dihydrooxazol-2-yl)phenyl (5-fluoropentyl)carbamate) has been identified as a promising 18F-labeled analog based on rodent studies.  The goal of this work is to evaluate [18F]DOPP in nonhuman primates to support its clin. translation.  High specific activity [18F]DOPP (5-6 Ci·μmol-1) was administered i.v. (iv) to three baboons (2M/1F, 3-4 years old).  The distribution and pharmacokinetics were quantified following a 2 h dynamic imaging session using a simultaneous PET/MR scanner.  Pretreatment with the FAAH-selective inhibitor, URB597, was carried out at 200 or 300 μg/kg iv, 10 min prior to [18F]DOPP administration.  Rapid arterial blood sampling for the first 3 min was followed by interval sampling with metabolite anal. to provide a parent radiotracer plasma input function that indicated ∼95% baseline metab. at 60 min and a reduced rate of metab. after pretreatment with URB597.  Regional distribution data were analyzed with 1-, 2-, and 3-tissue compartment models (TCMs), with and without irreversible trapping since [18F]DOPP covalently links to the active site of FAAH.  Consistent with previous findings for [11C]CURB, the 2TCM with irreversible binding was found to provide the best fit for modeling the data in all regions.  The composite parameter λk3 was therefore used to evaluate whole brain (WB) and regional binding of [18F]DOPP.  Pretreatment studies showed inhibition of λk3 across all brain regions (WB baseline: 0.112 mL/cm3/min; 300 μg/kg URB597: 0.058 mL/cm3/min), suggesting that [18F]DOPP binding is specific for FAAH, consistent with previous rodent data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfComo4JWN7Vg90H21EOLACvtfcHk0lj3cIP4cklW-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtLvP&md5=026a7a53140bb381593d760d9cf67cc6</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fmp500316h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500316h%26sid%3Dliteratum%253Aachs%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DWey%26aufirst%3DH.%2BY.%26aulast%3DShoup%26aufirst%3DT.%2BM.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DPET%2520imaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520with%2520%255B18F%255DDOPP%2520in%2520nonhuman%2520primates%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D3832%26epage%3D3838%26doi%3D10.1021%2Fmp500316h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobrega, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of fatty acid amide hydrolase by BIA 10–2474 in rat brain</span>. <i>J. Cereb. Blood Flow Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3635</span>– <span class="NLM_lpage">3639</span>, <span class="refDoi"> DOI: 10.1177/0271678X16668890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1177%2F0271678X16668890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27650910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=3635-3639&author=J.+Tongauthor=R.+Mizrahiauthor=S.+Houleauthor=S.+J.+Kishauthor=I.+Boileauauthor=J.+Nobregaauthor=P.+M.+Rusjanauthor=A.+A.+Wilson&title=Inhibition+of+fatty+acid+amide+hydrolase+by+BIA+10%E2%80%932474+in+rat+brain&doi=10.1177%2F0271678X16668890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain</span></div><div class="casAuthors">Tong, Junchao; Mizrahi, Romina; Houle, Sylvain; Kish, Stephen J.; Boileau, Isabelle; Nobrega, Jose; Rusjan, Pablo M.; Wilson, Alan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3635-3639</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">In a recent clin. trial, the drug BIA 10-2474, a putative fatty acid amide hydrolase(FAAH) inhibitor, was responsible for severe adverse events (SAEs), including one death.  To date, there has been little reliable information divulged about the potency of BIA 10-2474 at FAAH in the central nervous system.  We synthesized BIA 10-2474 and detd. its ability to inhibit FAAH ex vivo in rat brain using a FAAH selective radiotracer.  BIA 10-2474 proved to be a potent FAAH inhibitor with IC50s of 50-70 μg/kg (i.p.) in various brain regions.  This information may be useful for detg. the cause of the SAEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX6sYwd9zuH7Vg90H21EOLACvtfcHk0lj3cIP4cklW-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKnu70%253D&md5=c0e494b3f946e6d22626462f9e6dd333</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1177%2F0271678X16668890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0271678X16668890%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DMizrahi%26aufirst%3DR.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DNobrega%26aufirst%3DJ.%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26atitle%3DInhibition%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520by%2520BIA%252010%25E2%2580%25932474%2520in%2520rat%2520brain%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2017%26volume%3D37%26spage%3D3635%26epage%3D3639%26doi%3D10.1177%2F0271678X16668890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoup, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonab, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of [<sup>18</sup>F]FCHC for neuroimaging of fatty acid amide hydrolase</span>. <i>Mol. Imaging. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1007/s11307-014-0789-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2Fs11307-014-0789-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25273322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Smur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=257-263&author=T.+M.+Shoupauthor=A.+A.+Bonabauthor=A.+A.+Wilsonauthor=N.+Vasdev&title=Synthesis+and+preclinical+evaluation+of+%5B18F%5DFCHC+for+neuroimaging+of+fatty+acid+amide+hydrolase&doi=10.1007%2Fs11307-014-0789-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Preclinical Evaluation of [18F]FCHC for Neuroimaging of Fatty Acid Amide Hydrolase</span></div><div class="casAuthors">Shoup, Timothy M.; Bonab, Ali A.; Wilson, Alan A.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging and Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-263</span>CODEN:
                <span class="NLM_cas:coden">MIBOCZ</span>;
        ISSN:<span class="NLM_cas:issn">1860-2002</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The synthesis of a new fluorine-18-labeled FAAH inhibitor, trans-3-(4,5-dihydrooxazol-2-yl)phenyl-4-[18F]fluorocyclohexylcarbamate ([18F]FCHC), and its evaluation in rat brain were described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKabTPxYtktbVg90H21EOLACvtfcHk0lhQ1aACjSeAIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Smur%252FL&md5=34ee9685d43115416e309c4be8687595</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1007%2Fs11307-014-0789-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-014-0789-1%26sid%3Dliteratum%253Aachs%26aulast%3DShoup%26aufirst%3DT.%2BM.%26aulast%3DBonab%26aufirst%3DA.%2BA.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520%255B18F%255DFCHC%2520for%2520neuroimaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DMol.%2520Imaging.%2520Biol.%26date%3D2015%26volume%3D17%26spage%3D257%26epage%3D263%26doi%3D10.1007%2Fs11307-014-0789-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesten, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadagopan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattachar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesten, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1021/ml100190t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100190t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVaisrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=91-96&author=D.+S.+Johnsonauthor=C.+Stiffauthor=S.+E.+Lazerwithauthor=S.+R.+Kestenauthor=L.+K.+Fayauthor=M.+Morrisauthor=D.+Beidlerauthor=M.+B.+Liimattaauthor=S.+E.+Smithauthor=D.+T.+Dudleyauthor=N.+Sadagopanauthor=S.+N.+Bhattacharauthor=S.+J.+Kestenauthor=T.+K.+Nomanbhoyauthor=B.+F.+Cravattauthor=K.+Ahn&title=Discovery+of+PF-04457845%3A+a+highly+potent%2C+orally+bioavailable%2C+and+selective+urea+FAAH+inhibitor&doi=10.1021%2Fml100190t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor</span></div><div class="casAuthors">Johnson, Douglas S.; Stiff, Cory; Lazerwith, Scott E.; Kesten, Suzanne R.; Fay, Lorraine K.; Morris, Mark; Beidler, David; Liimatta, Marya B.; Smith, Sarah E.; Dudley, David T.; Sadagopan, Nalini; Bhattachar, Shobha N.; Kesten, Stephen J.; Nomanbhoy, Tyzoon K.; Cravatt, Benjamin F.; Ahn, Kay</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-96</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide.  Genetic or pharmacol. inactivation of FAAH leads to analgesic and anti-inflammatory phenotypes in rodents without showing the undesirable side effects obsd. with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for the treatment of inflammatory pain and other nervous system disorders.  Herein, the discovery and characterization of a highly efficacious and selective FAAH inhibitor PF-04457845, N-(3-pyridazinyl)-4-(3-[5-trifluoromethyl-2-pyridinyloxy]benzylidene)piperidine-1-carboxamide (I), are reported.  This compd. inhibited FAAH by a covalent, irreversible mechanism involving carbamylation of the active-site serine nucleophile of FAAH with high in vitro potency (kinact/Ki and IC50 values of 40300 M-1 s-1 and 7.2 nM, resp., for human FAAH).  The compd. I had exquisite selectivity for FAAH relative to other members of the serine hydrolase superfamily as demonstrated by competitive activity-based protein profiling.  Oral administration of I at 0.1 mg/kg results in efficacy comparable to that of naproxen at 10 mg/kg in a rat model of inflammatory pain.  Compd. I is being evaluated in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoINP05KK-SNLVg90H21EOLACvtfcHk0lhQ1aACjSeAIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVaisrfO&md5=c7ba2900e3abeda46f885d23bf1f76b8</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fml100190t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100190t%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DStiff%26aufirst%3DC.%26aulast%3DLazerwith%26aufirst%3DS.%2BE.%26aulast%3DKesten%26aufirst%3DS.%2BR.%26aulast%3DFay%26aufirst%3DL.%2BK.%26aulast%3DMorris%26aufirst%3DM.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DLiimatta%26aufirst%3DM.%2BB.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DSadagopan%26aufirst%3DN.%26aulast%3DBhattachar%26aufirst%3DS.%2BN.%26aulast%3DKesten%26aufirst%3DS.%2BJ.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DAhn%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520PF-04457845%253A%2520a%2520highly%2520potent%252C%2520orally%2520bioavailable%252C%2520and%2520selective%2520urea%2520FAAH%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D91%26epage%3D96%26doi%3D10.1021%2Fml100190t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadagopan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Becelaere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattachar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.180257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fjpet.111.180257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=21505060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=114-124&author=K.+Ahnauthor=S.+E.+Smithauthor=M.+B.+Liimattaauthor=D.+Beidlerauthor=N.+Sadagopanauthor=D.+T.+Dudleyauthor=T.+Youngauthor=P.+Wrenauthor=Y.+Zhangauthor=S.+Swaneyauthor=K.+Van+Becelaereauthor=J.+L.+Blankmanauthor=D.+K.+Nomuraauthor=S.+N.+Bhattacharauthor=C.+Stiffauthor=T.+K.+Nomanbhoyauthor=E.+Weerapanaauthor=D.+S.+Johnsonauthor=B.+F.+Cravatt&title=Mechanistic+and+pharmacological+characterization+of+PF-04457845%3A+a+highly+potent+and+selective+fatty+acid+amide+hydrolase+inhibitor+that+reduces+inflammatory+and+noninflammatory+pain&doi=10.1124%2Fjpet.111.180257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain</span></div><div class="casAuthors">Ahn, Kay; Smith, Sarah E.; Liimatta, Marya B.; Beidler, David; Sadagopan, Nalini; Dudley, David T.; Young, Tim; Wren, Paul; Zhang, Yanhua; Swaney, Steven; Van Becelaere, Keri; Blankman, Jacqueline L.; Nomura, Daniel K.; Bhattachar, Shobha N.; Stiff, Cory; Nomanbhoy, Tyzoon K.; Weerapana, Eranthie; Johnson, Douglas S.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-124</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The endogenous cannabinoid (endocannabinoid) anandamide is principally degraded by the integral membrane enzyme fatty acid amide hydrolase (FAAH).  Pharmacol. blockade of FAAH has emerged as a potentially attractive strategy for augmenting endocannabinoid signaling and retaining the beneficial effects of cannabinoid receptor activation, while avoiding the undesirable side effects, such as wt. gain and impairments in cognition and motor control, obsd. with direct cannabinoid receptor 1 agonists.  Here, we report the detailed mechanistic and pharmacol. characterization of N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide (PF-04457845), a highly efficacious and selective FAAH inhibitor.  Mechanistic studies confirm that PF-04457845 is a time-dependent, covalent FAAH inhibitor that carbamylates FAAH's catalytic serine nucleophile.  PF-04457845 inhibits human FAAH with high potency (kinact/Ki = 40,300 M-1s-1; IC50 = 7.2 nM) and is exquisitely selective in vivo as detd. by activity-based protein profiling.  Oral administration of PF-04457845 produced potent antinociceptive effects in both inflammatory [complete Freund's adjuvant (CFA)] and noninflammatory (monosodium iodoacetate) pain models in rats, with a min. ED of 0.1 mg/kg (CFA model).  PF-04457845 displayed a long duration of action as a single oral administration at 1 mg/kg showed in vivo efficacy for 24 h with a concomitant near-complete inhibition of FAAH activity and maximal sustained elevation of anandamide in brain.  Significantly, PF-04457845-treated mice at 10 mg/kg elicited no effect in motility, catalepsy, and body temp.  Based on its exceptional selectivity and in vivo efficacy, combined with long duration of action and optimal pharmacokinetic properties, PF-04457845 is a clin. candidate for the treatment of pain and other nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd5BIw55W3OrVg90H21EOLACvtfcHk0lhQ1aACjSeAIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiurY%253D&md5=b32df795c9df175bd6403fdd5672eae2</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.180257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.180257%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DLiimatta%26aufirst%3DM.%2BB.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DSadagopan%26aufirst%3DN.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DYoung%26aufirst%3DT.%26aulast%3DWren%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSwaney%26aufirst%3DS.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26aulast%3DBhattachar%26aufirst%3DS.%2BN.%26aulast%3DStiff%26aufirst%3DC.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DMechanistic%2520and%2520pharmacological%2520characterization%2520of%2520PF-04457845%253A%2520a%2520highly%2520potent%2520and%2520selective%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitor%2520that%2520reduces%2520inflammatory%2520and%2520noninflammatory%2520pain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D114%26epage%3D124%26doi%3D10.1124%2Fjpet.111.180257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">11CO2 fixation: a renaissance in PET radiochemistry</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5621</span>– <span class="NLM_lpage">5629</span>, <span class="refDoi"> DOI: 10.1039/c3cc42236d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1039%2Fc3cc42236d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23673726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVemsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=5621-5629&author=B.+H.+Rotsteinauthor=S.+H.+Liangauthor=J.+P.+Hollandauthor=T.+L.+Collierauthor=J.+M.+Hookerauthor=A.+A.+Wilsonauthor=N.+Vasdev&title=11CO2+fixation%3A+a+renaissance+in+PET+radiochemistry&doi=10.1039%2Fc3cc42236d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">11CO2 fixation: a renaissance in PET radiochemistry</span></div><div class="casAuthors">Rotstein, Benjamin H.; Liang, Steven H.; Holland, Jason P.; Collier, Thomas Lee; Hooker, Jacob M.; Wilson, Alan A.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">5621-5629</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Carbon-11 labeled carbon dioxide is the cyclotron-generated feedstock reagent for most positron emission tomog. (PET) tracers using this radionuclide.  Most carbon-11 labels, however, are installed using deriv. reagents generated from [11C]CO2.  In recent years, [11C]CO2 has seen a revival in applications for the direct incorporation of carbon-11 into functional groups such as ureas, carbamates, oxazolidinones, carboxylic acids, esters, and amides.  This review summarizes classical [11C]CO2 fixation strategies using organometallic reagents and then focuses on newly developed methods that employ strong org. bases to reversibly capture [11C]CO2 into soln., thereby enabling highly functionalized labeled compds. to be prepd.  Labeled compds. and radiopharmaceuticals that have been translated to the clinic are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxQyYB25RBbbVg90H21EOLACvtfcHk0likrzDtpoee9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVemsbo%253D&md5=555cd1c94c0e870cf268ff5db0578c0c</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1039%2Fc3cc42236d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc42236d%26sid%3Dliteratum%253Aachs%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DHolland%26aufirst%3DJ.%2BP.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3D11CO2%2520fixation%253A%2520a%2520renaissance%2520in%2520PET%2520radiochemistry%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26spage%3D5621%26epage%3D5629%26doi%3D10.1039%2Fc3cc42236d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2013.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2013.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23731552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslWmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=740-746&author=J.+W.+Hicksauthor=J.+Parkesauthor=O.+Sadovskiauthor=J.+Tongauthor=S.+Houleauthor=N.+Vasdevauthor=A.+A.+Wilson&title=Synthesis+and+preclinical+evaluation+of+%5B11C-carbonyl%5DPF-04457845+for+neuroimaging+of+fatty+acid+amide+hydrolase&doi=10.1016%2Fj.nucmedbio.2013.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase</span></div><div class="casAuthors">Hicks, Justin W.; Parkes, Jun; Sadovski, Oleg; Tong, Junchao; Houle, Sylvain; Vasdev, Neil; Wilson, Alan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">740-746</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) has a significant role in regulating endocannabinoid signaling in the central nervous system.  As such, FAAH inhibitors are being actively sought for pain, addiction, and other indications.  This has led to the recent pursuit of positron emission tomog. (PET) radiotracers targeting FAAH.  We report herein the prepn. and preclin. evaluation of [11C-carbonyl]PF-04457845, an isotopologue of the potent irreversible FAAH inhibitor.  PF-04457845 was radiolabeled at the carbonyl position via automated [11C]CO2-fixation.  Ex vivo brain biodistribution of [11C-carbonyl]PF-04457845 was carried out in conscious rats.  Specificity was detd. by pre-administration of PF-04457845 or URB597 prior to [11C-carbonyl]PF-04457845.  In a sep. expt., rats injected with the title radiotracer had whole brains excised, homogenized and extd. to examine irreversible binding to brain parenchyma.  The title compd. was prepd. in 5 ± 1% (n = 4) isolated radiochem. yield based on starting [11C]CO2 (decay uncorrected) within 25 min from end-of-bombardment in > 98% radiochem. purity and a specific activity of 73.5 ± 8.2 GBq/μmol at end-of-synthesis.  Uptake of [11C-carbonyl]PF-04457845 into the rat brain was high (range of 1.2-4.4 SUV), heterogeneous, and in accordance with reported FAAH distribution.  Saturable binding was demonstrated by a dose-dependent redn. in brain radioactivity uptake following pre-treatment with PF-04457845.  Pre-treatment with the prototypical FAAH inhibitor, URB597, reduced the brain radiotracer uptake in all regions by 71-81%, demonstrating specificity for FAAH.  The binding of [11C-carbonyl]PF-04457845 to FAAH at 40 min post injection was irreversible as 98% of the radioactivity in the brain could not be extd.  [11C-carbonyl]PF-04457845 was rapidly synthesized via an automated radiosynthesis.  Ex vivo biodistribution studies in conscious rodents demonstrate that [11C PF-04457845 is a promising candidate radiotracer for imaging FAAH in the brain with PET.  These results coupled with the known pharmacol. and toxicol. of PF-04457845 should facilitate clin. translation of this radiotracer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3VVfFVnooC7Vg90H21EOLACvtfcHk0likrzDtpoee9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslWmt7o%253D&md5=17ff0759bc57b31cd49887f5e30b3afa</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2013.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2013.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DJ.%2BW.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DSadovski%26aufirst%3DO.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520%255B11C-carbonyl%255DPF-04457845%2520for%2520neuroimaging%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2013%26volume%3D40%26spage%3D740%26epage%3D746%26doi%3D10.1016%2Fj.nucmedbio.2013.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skaddan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zasadny, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuszpit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niphakis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">The synthesis and in vivo evaluation of [<sup>18</sup>F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH)</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1058</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2012.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2012.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22571907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslynu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=1058-1067&author=M.+B.+Skaddanauthor=L.+Zhangauthor=D.+S.+Johnsonauthor=A.+Zhuauthor=K.+R.+Zasadnyauthor=R.+V.+Coelhoauthor=K.+Kuszpitauthor=G.+Currierauthor=K.+H.+Fanauthor=E.+M.+Beckauthor=L.+Chenauthor=S.+E.+Drozdaauthor=G.+Balanauthor=M.+Niphakisauthor=B.+F.+Cravattauthor=K.+Ahnauthor=T.+Bocanauthor=A.+Villalobos&title=The+synthesis+and+in+vivo+evaluation+of+%5B18F%5DPF-9811%3A+a+novel+PET+ligand+for+imaging+brain+fatty+acid+amide+hydrolase+%28FAAH%29&doi=10.1016%2Fj.nucmedbio.2012.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH)</span></div><div class="casAuthors">Skaddan, Marc B.; Zhang, Lei; Johnson, Douglas S.; Zhu, Aijun; Zasadny, Kenneth R.; Coelho, Richard V.; Kuszpit, Kyle; Currier, Gwen; Fan, Kuo-Hsien; Beck, Elizabeth M.; Chen, Laigao; Drozda, Susan E.; Balan, Gayatri; Niphakis, Micah; Cravatt, Benjamin F.; Ahn, Kay; Bocan, Thomas; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1058-1067</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) is responsible for the enzymic degrdn. of the fatty acid amide family of signaling lipids, including the endogenous cannabinoid (endocannabinoid) anandamide.  The involvement of the endocannabinoid system in pain and other nervous system disorders has made FAAH an attractive target for drug development.  Companion mol. imaging probes are needed, however, to assess FAAH inhibition in the nervous system in vivo.  We report here the synthesis and in vivo evaluation of [18F]PF-9811, a novel PET ligand for non-invasive imaging of FAAH in the brain.The potency and selectivity of unlabeled PF-9811 were detd. by activity-based protein profiling (ABPP) both in vitro and in vivo. [18F]PF-9811 was synthesized in a 3-step, one-pot reaction sequence, followed by HPLC purifn.  Biol. evaluation was performed by biodistribution and dynamic PET imaging studies in male rats.  The specificity of [18F]PF-9811 uptake was evaluated by pre-administration of PF-04457845, a potent and selective FAAH inhibitor, 1 h prior to radiotracer injection.Biodistribution studies show good uptake (SUV ~ 0.8 at 90 min) of [18F]PF-9811 in rat brain, with significant redn. of the radiotracer in all brain regions (37%-73% at 90 min) in blocking expts.  Dynamic PET imaging expts. in rat confirmed the heterogeneous uptake of [18F]PF-9811 in brain regions with high FAAH enzymic activity, as well as statistically significant redns. in signal following pre-administration of the blocking compd. PF-04457845.[18F]PF-9811 is a promising PET imaging agent for FAAH.  Biodistribution and PET imaging expts. show that the tracer has good uptake in brain, regional heterogeneity, and specific binding as detd. by blocking expts. with the highly potent and selective FAAH inhibitor, PF-04457845.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd02lQkPZjcLVg90H21EOLACvtfcHk0likrzDtpoee9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslynu7o%253D&md5=fe073d3c7b88670e8bef5ceb2412c0e3</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2012.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2012.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DSkaddan%26aufirst%3DM.%2BB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DZhu%26aufirst%3DA.%26aulast%3DZasadny%26aufirst%3DK.%2BR.%26aulast%3DCoelho%26aufirst%3DR.%2BV.%26aulast%3DKuszpit%26aufirst%3DK.%26aulast%3DCurrier%26aufirst%3DG.%26aulast%3DFan%26aufirst%3DK.%2BH.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DBalan%26aufirst%3DG.%26aulast%3DNiphakis%26aufirst%3DM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DBocan%26aufirst%3DT.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DThe%2520synthesis%2520and%2520in%2520vivo%2520evaluation%2520of%2520%255B18F%255DPF-9811%253A%2520a%2520novel%2520PET%2520ligand%2520for%2520imaging%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2012%26volume%3D39%26spage%3D1058%26epage%3D1067%26doi%3D10.1016%2Fj.nucmedbio.2012.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Design and prototype of an automated “in-loop” [<sup>11</sup>C] CO2-fixation apparatus</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">330</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=330-330&author=K.+Dahlauthor=T.+Collierauthor=X.+Zhangauthor=S.+Liangauthor=N.+Vasdev&title=Design+and+prototype+of+an+automated+%E2%80%9Cin-loop%E2%80%9D+%5B11C%5D+CO2-fixation+apparatus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DK.%26aulast%3DCollier%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DDesign%2520and%2520prototype%2520of%2520an%2520automated%2520%25E2%2580%259Cin-loop%25E2%2580%259D%2520%255B11C%255D%2520CO2-fixation%2520apparatus%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D330%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">“In-loop” [<sup>11</sup>C]CO2 fixation: Prototype and proof of concept</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1002/jlcr.3528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fjlcr.3528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28600835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wlt7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=252-262&author=K.+Dahlauthor=T.+L.+Collierauthor=R.+Chengauthor=X.+Zhangauthor=O.+Sadovskiauthor=S.+H.+Liangauthor=N.+Vasdev&title=%E2%80%9CIn-loop%E2%80%9D+%5B11C%5DCO2+fixation%3A+Prototype+and+proof+of+concept&doi=10.1002%2Fjlcr.3528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">"In-loop" [11C]CO2 fixation: Prototype and proof of concept</span></div><div class="casAuthors">Dahl, Kenneth; Collier, Thomas L.; Cheng, Ran; Zhang, Xiaofei; Sadovski, Oleg; Liang, Steven H.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">252-262</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The development of an app. that takes advantage of "in-loop" technologies to facilitate robust and reproducible syntheses of 11C-carbonyl-based radiotracers by [11C]CO2-fixation was reported.  The "in-loop" [11C]CO2-fixation method was simple, efficient and proceeded smoothly at ambient pressure and temp.  The model 11C-carbonyl-labeled carbamates as well as sym. and unsym. ureas based on their widespread use in radiotracer design and clin. research interests was selected for proof of concept.  Utility of this method was demonstrated by the synthesis of a reversible radiopharmaceutical for monoamine oxidase B, [11C]SL25.1188 and 2 novel fatty acid amide hydrolase inhibitors.  These radiotracers were isolated and formulated (>3.5 GBq; 100 mCi) with radiochem. purities (>99%) and molar radioactivity (≥80 GBq/μmol; ≥2162 mCi/μmol).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8EB1T6TBx8rVg90H21EOLACvtfcHk0lj1soQ6wyyuiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wlt7jP&md5=c37196764c5f7f8a103e34c5b7f0b6f5</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3528%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DK.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSadovski%26aufirst%3DO.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3D%25E2%2580%259CIn-loop%25E2%2580%259D%2520%255B11C%255DCO2%2520fixation%253A%2520Prototype%2520and%2520proof%2520of%2520concept%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2018%26volume%3D61%26spage%3D252%26epage%3D262%26doi%3D10.1002%2Fjlcr.3528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">The assay of enzyme activity by positron emission tomography</span>. <i>Neuromethods</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1007/7657_2012_53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1007%2F7657_2012_53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2012&pages=111-135&author=P.+Cummingauthor=N.+Vasdev&title=The+assay+of+enzyme+activity+by+positron+emission+tomography&doi=10.1007%2F7657_2012_53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">The Assay of Enzyme Activity by Positron Emission Tomography</span></div><div class="casAuthors">Cumming, Paul; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Neuromethods</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">Molecular Imaging in the Clinical Neurosciences</span>),
    <span class="NLM_cas:pages">111-135</span>CODEN:
                <span class="NLM_cas:coden">NUROE8</span>;
        ISSN:<span class="NLM_cas:issn">0893-2336</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  In a relatively small no. of instances, the activity in brain of specific enzymes can be measured with positron emission tomog. (PET) using radioactive enzyme substrates in conjunction with compartmental modeling.  Thus, the trapping of [11C]-labeled amino acids in brain protein was an early application of PET, which found particular use in the detection of brain tumors.  The most successful PET agent remains the glucose analog [18F]-fluoro-deoxyglucose (FDG), which is trapped in brain as FDG-phosphate, at a rate detd. by the local activity of the hexokinase enzyme.  The integrity of nigrostriatal dopamine innervations can be assessed with the DOPA decarboxylase tracer [18F]-fluoro-L-DOPA (FDOPA), whereas the rate of serotonin synthesis has been measured in PET studies with α-[14C]-methyl-L-tryptophan.  Monoamine oxidase, uniquely, can be assessed in PET studies with suicide substrates such as L-[11C]-deprenyl, where the rate of trapping in living tissue is a function of the local catalytic activity of MAO-B.  However, the abundance of MAO-A is most conveniently assessed with [11C]-harmine and other competitor ligands, which bind reversibly to the enzyme. [11C]-PMP and a no. of other substrates for acetylcholine esterase have been developed, based on the prodn. in situ of a nondiffusible hydrolysis product.  The activity of P-glycoprotein in the blood-brain barrier can be assessed only indirectly, by virtue of increased influx to brain of labeled substrates, following administration of P-glycoprotein inhibitors.  Positron-emitting inhibitors of phosphodiesterase enzymes have been described, which should herald the eventual development of a much wider array of tracers targeting signal transduction pathways.  Cell proliferation can be detected with [11C]-thymidine and synthetic nucleosides.  Very recently, it has become possible to measure the abundance in brain of aromatase, which catalyzes the synthesis of estrogen.  In general, the net influx of an enzyme substrate from blood to brain is calcd. by linear graphical anal., whereas individual steps in the non-uptake process can be estd. by compartmental anal.  When trapping of a PET tracer is catalyzed by the enzymic step, the magnitude of the corresponding rate const. (k 3; min-1) ranges from the lowest useful limit of 0.01 min-1 (α-[14C]-methyl-L-tryptophan) to >0.1 min-1 (L-[11C]-deprenyl, [11C]PMP).  Quantification is problematic at the lower end of this range due to low specific signal and also at the high end due to blood flow limiting effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKjqO1aeEBwLVg90H21EOLACvtfcHk0lj1soQ6wyyuiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWqu7g%253D&md5=2c863f2fadcb96d8354c71bce128085e</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1007%2F7657_2012_53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7657_2012_53%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DP.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DThe%2520assay%2520of%2520enzyme%2520activity%2520by%2520positron%2520emission%2520tomography%26jtitle%3DNeuromethods%26date%3D2012%26volume%3D71%26spage%3D111%26epage%3D135%26doi%3D10.1007%2F7657_2012_53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span> <span> </span><span class="NLM_article-title">PET radiotracers: crossing the blood-brain barrier and surviving metabolism</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2009.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.tips.2009.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=19616318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1KgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=431-440&author=V.+W.+Pike&title=PET+radiotracers%3A+crossing+the+blood-brain+barrier+and+surviving+metabolism&doi=10.1016%2Fj.tips.2009.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">PET radiotracers: crossing the blood-brain barrier and surviving metabolism</span></div><div class="casAuthors">Pike, Victor W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">431-440</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Radiotracers for imaging protein targets in the living human brain with positron emission tomog. (PET) are increasingly useful in clin. research and in drug development.  Such radiotracers must fulfill many criteria, among which an ability to enter brain adequately and reversibly without contamination by troublesome radiometabolites is desirable for accurate measurement of the d. of a target protein (e.g. neuroreceptor, transporter, enzyme or plaque).  Candidate radiotracers can fail as a result of poor passive brain entry, rejection from brain by efflux transporters or undesirable metab.  These issues are reviewed.  Emerging PET radiotracers for measuring efflux transporter function and new strategies for ameliorating radiotracer metab. are discussed.  A growing understanding of the mol. features affecting the brain penetration, metab. and efflux transporter sensitivity of prospective radiotracers should ultimately lead to their more rational and efficient design, and also to their greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6ftMCpkOSmrVg90H21EOLACvtfcHk0lj1soQ6wyyuiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1KgsLg%253D&md5=97704995fecd968baf1e0892bf70324e</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DV.%2BW.%26atitle%3DPET%2520radiotracers%253A%2520crossing%2520the%2520blood-brain%2520barrier%2520and%2520surviving%2520metabolism%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D431%26epage%3D440%26doi%3D10.1016%2Fj.tips.2009.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamill, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellureficio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanabria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajdu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochnowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebetski, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holahan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posavec, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riffel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-3168: a PET tracer for imaging brain fatty acid amide hydrolase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1021/ml4000996</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000996" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ylu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=509-513&author=P.+Liuauthor=T.+G.+Hamillauthor=M.+Chiodaauthor=H.+Chobanianauthor=S.+Fungauthor=Y.+Guoauthor=L.+Changauthor=R.+Bakshiauthor=Q.+Hongauthor=J.+Dellureficioauthor=L.+S.+Linauthor=C.+Abbadieauthor=J.+Alexanderauthor=H.+Jinauthor=S.+Mandalaauthor=L.+L.+Shiaoauthor=W.+Liauthor=S.+Sanabriaauthor=D.+Williamsauthor=Z.+Zengauthor=R.+Hajduauthor=N.+Jochnowitzauthor=M.+Rosenbachauthor=B.+Karanamauthor=M.+Madeiraauthor=G.+Salituroauthor=J.+Powellauthor=L.+Xuauthor=J.+L.+Terebetskiauthor=J.+F.+Leoneauthor=P.+Millerauthor=J.+Cookauthor=M.+Holahanauthor=A.+Joshiauthor=S.+O%E2%80%99Malleyauthor=M.+Purcellauthor=D.+Posavecauthor=T.+B.+Chenauthor=K.+Riffelauthor=M.+Williamsauthor=R.+Hargreavesauthor=K.+A.+Sullivanauthor=R.+P.+Nargundauthor=R.+J.+DeVita&title=Discovery+of+MK-3168%3A+a+PET+tracer+for+imaging+brain+fatty+acid+amide+hydrolase&doi=10.1021%2Fml4000996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase</span></div><div class="casAuthors">Liu, Ping; Hamill, Terence G.; Chioda, Marc; Chobanian, Harry; Fung, Selena; Guo, Yan; Chang, Linda; Bakshi, Raman; Hong, Qingmei; Dellureficio, James; Lin, Linus S.; Abbadie, Catherine; Alexander, Jessica; Jin, Hong; Mandala, Suzanne; Shiao, Lin-Lin; Li, Wenping; Sanabria, Sandra; Williams, David; Zeng, Zhizhen; Hajdu, Richard; Jochnowitz, Nina; Rosenbach, Mark; Karanam, Bindhu; Madeira, Maria; Salituro, Gino; Powell, Joyce; Xu, Ling; Terebetski, Jenna L.; Leone, Joseph F.; Miller, Patricia; Cook, Jacquelynn; Holahan, Marie; Joshi, Aniket; O'Malley, Stacey; Purcell, Mona; Posavec, Diane; Chen, Tsing-Bau; Riffel, Kerry; Williams, Mangay; Hargreaves, Richard; Sullivan, Kathleen A.; Nargund, Ravi P.; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">509-513</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery of a fatty acid amide hydrolase (FAAH) positron emission tomog. (PET) tracer.  Starting from a pyrazole lead, medicinal chem. efforts directed toward reducing lipophilicity led to the synthesis of a series of imidazole analogs.  Compd. 6 was chosen for further profiling due to its appropriate phys. chem. properties and excellent FAAH inhibition potency across species. [11C]-6 (MK-3168) exhibited good brain uptake and FAAH-specific signal in rhesus monkeys and is a suitable PET tracer for imaging FAAH in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ7TcIehUa5rVg90H21EOLACvtfcHk0lh-FCKPHh2F2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ylu7Y%253D&md5=a5ec9a3750ed61f576732b8dfd541026</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Fml4000996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000996%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DHamill%26aufirst%3DT.%2BG.%26aulast%3DChioda%26aufirst%3DM.%26aulast%3DChobanian%26aufirst%3DH.%26aulast%3DFung%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DBakshi%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DQ.%26aulast%3DDellureficio%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%2BS.%26aulast%3DAbbadie%26aufirst%3DC.%26aulast%3DAlexander%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DShiao%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSanabria%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DKaranam%26aufirst%3DB.%26aulast%3DMadeira%26aufirst%3DM.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DTerebetski%26aufirst%3DJ.%2BL.%26aulast%3DLeone%26aufirst%3DJ.%2BF.%26aulast%3DMiller%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DHolahan%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DS.%26aulast%3DPurcell%26aufirst%3DM.%26aulast%3DPosavec%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DRiffel%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DSullivan%26aufirst%3DK.%2BA.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-3168%253A%2520a%2520PET%2520tracer%2520for%2520imaging%2520brain%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D509%26epage%3D513%26doi%3D10.1021%2Fml4000996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanabria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holahan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laere, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamill, T.</span></span> <span> </span><span class="NLM_article-title">Translational studies with [<sup>11</sup>C]MK-3168, a PET tracer for fatty acid amide hydrolase (FAAH)</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">S1</span>),  <span class="NLM_fpage">397</span>, <span class="refDoi"> DOI: 10.2967/jnumed.111.090340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.2967%2Fjnumed.111.090340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=397&issue=S1&author=A.+Joshiauthor=W.+Liauthor=S.+Sanabriaauthor=M.+Holahanauthor=M.+Purcellauthor=R.+Declercqauthor=M.+Depreauthor=G.+Bormansauthor=K.+V.+Laereauthor=T.+Hamill&title=Translational+studies+with+%5B11C%5DMK-3168%2C+a+PET+tracer+for+fatty+acid+amide+hydrolase+%28FAAH%29&doi=10.2967%2Fjnumed.111.090340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.111.090340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.111.090340%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSanabria%26aufirst%3DS.%26aulast%3DHolahan%26aufirst%3DM.%26aulast%3DPurcell%26aufirst%3DM.%26aulast%3DDeclercq%26aufirst%3DR.%26aulast%3DDepre%26aufirst%3DM.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DLaere%26aufirst%3DK.%2BV.%26aulast%3DHamill%26aufirst%3DT.%26atitle%3DTranslational%2520studies%2520with%2520%255B11C%255DMK-3168%252C%2520a%2520PET%2520tracer%2520for%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2012%26volume%3D53%26issue%3DS1%26spage%3D397%26doi%3D10.2967%2Fjnumed.111.090340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postnov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecken, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannikos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoon, J. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laere, K. V.</span></span> <span> </span><span class="NLM_article-title">Kinetic modeling of fatty acid amide hydrolase (FAAH) enzyme occupancy after JNJ42165279 inhibition based on 11CMK3168 PET imaging of human brain</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">S3</span>),  <span class="NLM_fpage">362</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=362&issue=S3&author=A.+Postnovauthor=M.+Schmidtauthor=J.+Pensonauthor=A.+V.+Heckenauthor=P.+Zannikosauthor=D.+Pembertonauthor=J.+Palmerauthor=J.+d.+Hoonauthor=G.+Bormansauthor=K.+V.+Laere&title=Kinetic+modeling+of+fatty+acid+amide+hydrolase+%28FAAH%29+enzyme+occupancy+after+JNJ42165279+inhibition+based+on+11CMK3168+PET+imaging+of+human+brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPostnov%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DM.%26aulast%3DPenson%26aufirst%3DJ.%26aulast%3DHecken%26aufirst%3DA.%2BV.%26aulast%3DZannikos%26aufirst%3DP.%26aulast%3DPemberton%26aufirst%3DD.%26aulast%3DPalmer%26aufirst%3DJ.%26aulast%3DHoon%26aufirst%3DJ.%2Bd.%26aulast%3DBormans%26aufirst%3DG.%26aulast%3DLaere%26aufirst%3DK.%2BV.%26atitle%3DKinetic%2520modeling%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%2520enzyme%2520occupancy%2520after%2520JNJ42165279%2520inhibition%2520based%2520on%252011CMK3168%2520PET%2520imaging%2520of%2520human%2520brain%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26issue%3DS3%26spage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mileni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfunkle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">10497</span>– <span class="NLM_lpage">10506</span>, <span class="refDoi"> DOI: 10.1021/ja902694n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja902694n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot1Gnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=10497-10506&author=M.+Mileniauthor=J.+Garfunkleauthor=J.+K.+DeMartinoauthor=B.+F.+Cravattauthor=D.+L.+Bogerauthor=R.+C.+Stevens&title=Binding+and+inactivation+mechanism+of+a+humanized+fatty+acid+amide+hydrolase+by+alpha-ketoheterocycle+inhibitors+revealed+from+cocrystal+structures&doi=10.1021%2Fja902694n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Binding and Inactivation Mechanism of a Humanized Fatty Acid Amide Hydrolase by α-Ketoheterocycle Inhibitors Revealed from Cocrystal Structures</span></div><div class="casAuthors">Mileni, Mauro; Garfunkle, Joie; DeMartino, Jessica K.; Cravatt, Benjamin F.; Boger, Dale L.; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">10497-10506</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cocrystal x-ray structures of two isomeric α-ketooxazole inhibitors (1 (OL-135) and 2) bound to fatty acid amide hydrolase (FAAH), a key enzymic regulator of endocannabinoid signaling, are disclosed.  The active site catalytic Ser241 is covalently bound to the inhibitors' electrophilic carbonyl groups, providing the first structures of FAAH bound to an inhibitor as a deprotonated hemiketal mimicking the enzymic tetrahedral intermediate.  The work also offers a detailed view of the oxyanion hole and an exceptional "in-action" depiction of the unusual Ser-Ser-Lys catalytic triad.  These structures capture the first picture of inhibitors that span the active site into the cytosolic port providing new insights that help to explain FAAH's interaction with substrate leaving groups and their role in modulating inhibitor potency and selectivity.  The role for the activating central heterocycle is clearly defined and distinguished from that obsd. in prior applications with serine proteases, reconciling the large electronic effect of attached substituents found unique to this class of inhibitors with FAAH.  Addnl. striking active site flexibility is seen upon binding of the inhibitors, providing insights into the existence of a now well-defined membrane access channel with the disappearance of a spatially independent portion of the acyl chain-binding pocket.  Finally, comparison of the structures of OL-135 (1) and its isomer 2 indicates that they bind identically to FAAH, albeit with reversed orientations of the central activating heterocycle, revealing that the terminal 2-pyridyl substituent and the acyl chain Ph group provide key anchoring interactions and confirming the distinguishing role of the activating oxazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0VYXvkQBlWLVg90H21EOLACvtfcHk0lh-FCKPHh2F2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot1Gnurc%253D&md5=7acaa93a726e1d8fac4816aee62927e4</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1021%2Fja902694n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja902694n%26sid%3Dliteratum%253Aachs%26aulast%3DMileni%26aufirst%3DM.%26aulast%3DGarfunkle%26aufirst%3DJ.%26aulast%3DDeMartino%26aufirst%3DJ.%2BK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBoger%26aufirst%3DD.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DBinding%2520and%2520inactivation%2520mechanism%2520of%2520a%2520humanized%2520fatty%2520acid%2520amide%2520hydrolase%2520by%2520alpha-ketoheterocycle%2520inhibitors%2520revealed%2520from%2520cocrystal%2520structures%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D10497%26epage%3D10506%26doi%3D10.1021%2Fja902694n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otrubova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boger, D. L.</span></span> <span> </span><span class="NLM_article-title">α-Ketoheterocycle-based inhibitors of fatty acid amide hydrolase (FAAH)</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1021/cn2001206</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn2001206" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ChtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=340-348&author=K.+Otrubovaauthor=D.+L.+Boger&title=%CE%B1-Ketoheterocycle-based+inhibitors+of+fatty+acid+amide+hydrolase+%28FAAH%29&doi=10.1021%2Fcn2001206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">α-Ketoheterocycle-Based Inhibitors of Fatty Acid Amide Hydrolase (FAAH)</span></div><div class="casAuthors">Otrubova, Katerina; Boger, Dale L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">340-348</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A summary of the initial discovery and characterization of the enzyme fatty acid amide hydrolase (FAAH), and the subsequent advancement of an important class of competitive, reversible, potent, and selective inhibitors is presented.  Initially explored using substrate-inspired inhibitors bearing electrophilic carbonyls, the examn. of α-ketoheterocyle-based inhibitors of FAAH with the benefit of a unique activity-based protein-profiling (ABPP)-based proteome-wide selectivity assay, a powerful in vivo biomarker-based in vivo screen, and subsequent retrospective x-ray cocrystal structures with the enzyme, is summarized.  These efforts defined the impact of the central activating heterocycle and its key substituents, provided key simplifications in the C2 acyl side chain and clear interpretations for the unique role and subsequent optimization of the central activating heterocycle, and established the basis for the recent further conformational constraints in the C2 acyl side chain, providing potent, long-acting, orally active FAAH inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4v_VJgMuMirVg90H21EOLACvtfcHk0lgHIxM9ZSe3vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ChtL3E&md5=e44d87e37c2f21bb7e7400bb1bc1f674</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1021%2Fcn2001206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn2001206%26sid%3Dliteratum%253Aachs%26aulast%3DOtrubova%26aufirst%3DK.%26aulast%3DBoger%26aufirst%3DD.%2BL.%26atitle%3D%25CE%25B1-Ketoheterocycle-based%2520inhibitors%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D340%26epage%3D348%26doi%3D10.1021%2Fcn2001206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardouin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayl, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boger, D. L.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3359</span>– <span class="NLM_lpage">3368</span>, <span class="refDoi"> DOI: 10.1021/jm061414r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061414r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Kru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3359-3368&author=C.+Hardouinauthor=M.+J.+Kelsoauthor=F.+A.+Romeroauthor=T.+J.+Raylauthor=D.+Leungauthor=I.+Hwangauthor=B.+F.+Cravattauthor=D.+L.+Boger&title=Structure-activity+relationships+of+alpha-ketooxazole+inhibitors+of+fatty+acid+amide+hydrolase&doi=10.1021%2Fjm061414r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase</span></div><div class="casAuthors">Hardouin, Christophe; Kelso, Michael J.; Romero, F. Anthony; Rayl, Thomas J.; Leung, Donmienne; Hwang, Inkyu; Cravatt, Benjamin F.; Boger, Dale L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3359-3368</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A systematic study of the structure-activity relationships of 2b (OL-135), a potent inhibitor of fatty acid amide hydrolase (FAAH), is detailed targeting the C2 acyl side chain.  A series of aryl replacements or substituents for the terminal Ph group provided effective inhibitors (e.g., 5c, aryl = 1-naphthyl, Ki = 2.6 nM), with 5hh (aryl = 3-ClPh, Ki = 900 pM) being 5-fold more potent than 2b.  Conformationally restricted C2 side chains were examd., and many provided exceptionally potent inhibitors, of which 11j (ethylbiphenyl side chain) was established to be a 750 pM inhibitor.  A systematic series of heteroatoms (O, NMe, S), electron-withdrawing groups (SO, SO2), and amides positioned within and hydroxyl substitutions on the linking side chain were investigated, which typically led to a loss in potency.  The most tolerant positions provided effective inhibitors (12p, 6-position S, Ki = 3 nM, or 13d, 2-position OH, Ki = 8 nM) comparable in potency to 2b.  Proteome-wide screening of selected inhibitors from the systematic series of >100 candidates prepd. revealed that they are selective for FAAH over all other mammalian serine proteases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFr5ELUCrPurVg90H21EOLACvtfcHk0lgHIxM9ZSe3vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Kru70%253D&md5=6f64cd49c935c5aeaea5d0ba0d776bea</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Fjm061414r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061414r%26sid%3Dliteratum%253Aachs%26aulast%3DHardouin%26aufirst%3DC.%26aulast%3DKelso%26aufirst%3DM.%2BJ.%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DRayl%26aufirst%3DT.%2BJ.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DHwang%26aufirst%3DI.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBoger%26aufirst%3DD.%2BL.%26atitle%3DStructure-activity%2520relationships%2520of%2520alpha-ketooxazole%2520inhibitors%2520of%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3359%26epage%3D3368%26doi%3D10.1021%2Fjm061414r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary PET imaging studies of a FAAH radiotracer ([<sup>11</sup>C]MPPO) based on alpha-ketoheterocyclic scaffold</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWltL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=109-118&author=L.+Wangauthor=J.+Yuiauthor=Q.+Wangauthor=Y.+Zhangauthor=W.+Moriauthor=Y.+Shimodaauthor=M.+Fujinagaauthor=K.+Kumataauthor=T.+Yamasakiauthor=A.+Hatoriauthor=B.+H.+Rotsteinauthor=T.+L.+Collierauthor=C.+Ranauthor=N.+Vasdevauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=Synthesis+and+preliminary+PET+imaging+studies+of+a+FAAH+radiotracer+%28%5B11C%5DMPPO%29+based+on+alpha-ketoheterocyclic+scaffold&doi=10.1021%2Facschemneuro.5b00248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Preliminary PET Imaging Studies of a FAAH Radiotracer ([11C]MPPO) Based on α-Ketoheterocyclic Scaffold</span></div><div class="casAuthors">Wang, Lu; Yui, Joji; Wang, Qifan; Zhang, Yiding; Mori, Wakana; Shimoda, Yoko; Fujinaga, Masayuki; Kumata, Katsushi; Yamasaki, Tomoteru; Hatori, Akiko; Rotstein, Benjamin H.; Collier, Thomas Lee; Ran, Chongzhao; Vasdev, Neil; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-118</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) is one of the principle enzymes for metabolizing endogenous cannabinoid neurotransmitters such as anandamide, and thus regulates endocannabinoid (eCB) signaling.  Selective pharmacol. blockade of FAAH has emerged as a potential therapy to discern the endogenous functions of anandamide-mediated eCB pathways in anxiety, pain, and addiction.  Quantification of FAAH in the living brain by positron emission tomog. (PET) would help our understanding of the endocannabinoid system in these conditions.  While most FAAH radiotracers operate by an irreversible ("suicide") binding mechanism, a FAAH tracer with reversibility would facilitate quant. anal.  We have identified and radiolabeled a reversible FAAH inhibitor, 7-(2-[11C]methoxyphenyl)-1-(5-(pyridin-2-yl)oxazol-2-yl)heptan-1-one ([11C]MPPO) in 13% radiochem. yield (nondecay cor.) with >99% radiochem. purity and 2 Ci/μmol (74 GBq/μmol) specific activity.  The tracer showed moderate brain uptake (0.8 SUV) with heterogeneous brain distribution.  However, blocking studies with a potent FAAH inhibitor URB597 demonstrated a low to modest specificity to the target.  Measurement of lipophilicity, metabolite, and efflux pathway anal. were also performed to study the pharmacokinetic profile of [11C]MPPO.  In all, we reported an efficient radiolabeling and preliminary evaluation of the first-in-class FAAH inhibitor [11C]MPPO with α-ketoheterocyclic scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpinihkxqhUKbVg90H21EOLACvtfcHk0lgHIxM9ZSe3vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWltL%252FP&md5=7fbd39323c54b80e222012094df4bce6</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00248%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYui%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DRan%26aufirst%3DC.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DSynthesis%2520and%2520preliminary%2520PET%2520imaging%2520studies%2520of%2520a%2520FAAH%2520radiotracer%2520%2528%255B11C%255DMPPO%2529%2520based%2520on%2520alpha-ketoheterocyclic%2520scaffold%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D109%26epage%3D118%26doi%3D10.1021%2Facschemneuro.5b00248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127513</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmcl.2020.127513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32860981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127513&author=Z.+Chenauthor=L.+Houauthor=J.+Ganauthor=Q.+Caiauthor=W.+Yeauthor=J.+Chenauthor=Z.+Tanauthor=C.+Zhengauthor=G.+Liauthor=H.+Xuauthor=C.+J.+Fowlerauthor=S.+H.+Liangauthor=L.+Wang&title=Synthesis+and+preliminary+evaluation+of+a+novel+positron+emission+tomography+%28PET%29+ligand+for+imaging+fatty+acid+amide+hydrolase+%28FAAH%29&doi=10.1016%2Fj.bmcl.2020.127513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH)</span></div><div class="casAuthors">Chen, Zhen; Hou, Lu; Gan, Jiefeng; Cai, Qijun; Ye, Weijian; Chen, Jiahui; Tan, Zhiqiang; Zheng, Chao; Li, Guocong; Xu, Hao; Fowler, Christopher J.; Liang, Steven H.; Wang, Lu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">127513</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fatty acid amide hydrolase (FAAH) exerts its main function in the catabolism of the endogenous chem. messenger anandamide (AEA), thus modulating the endocannabinoid (eCB) pathway.  Inhibition of FAAH may serve as an effective strategy to relieve anxiety and possibly other central nervous system (CNS)-related disorders.  Positron emission tomog. (PET) would facilitate us to better understand the relationship between FAAH in certain disease conditions, and accelerate clin. translation of FAAH inhibitors by providing in vivo quant. information.  So far, most PET tracers show irreversible binding patterns with FAAH, which would result in complicated quant. processes.  Herein, we have identified a new FAAH inhibitor (1-((1-methyl-1H-indol-2-yl)methyl)piperidin-4-yl)(oxazol-2-yl)methanone (8) which inhibits the hydrolysis of AEA in the brain with high potency (IC50 value 11 nM at a substrate concn. of 0.5 μM), and without showing time-dependency.  The PET tracer [11C]8 (also called [11C]FAAH-1906) was successfully radiolabeled with [11C]MeI in 17 ± 6% decay-cor. radiochem. yield (n = 7) with >74.0 GBq/μmol (2 Ci/μmol) molar activity and >99% radiochem. purity.  Ex vivo biodistribution and blocking studies of [11C]8 in normal mice were also conducted, indicating good brain penetration, high brain target selectivity, and modest to excellent target selectivity in peripheral tissues.  Thus, [11C]8 is a potentially useful PET ligand with enzyme inhibitory and target binding properties consistent with a reversible mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo5IaDQQ8S_rVg90H21EOLACvtfcHk0lgFylOgE6TVHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsLrL&md5=95147be5650ba431674b3477e9be54f6</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127513%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DL.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DFowler%26aufirst%3DC.%2BJ.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520preliminary%2520evaluation%2520of%2520a%2520novel%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520ligand%2520for%2520imaging%2520fatty%2520acid%2520amide%2520hydrolase%2520%2528FAAH%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127513%26doi%3D10.1016%2Fj.bmcl.2020.127513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saario, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, R.</span></span> <span> </span><span class="NLM_article-title">Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1381</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2003.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bcp.2003.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=15013854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVyhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2004&pages=1381-1387&author=S.+M.+Saarioauthor=J.+R.+Savinainenauthor=J.+T.+Laitinenauthor=T.+Jarvinenauthor=R.+Niemi&title=Monoglyceride+lipase-like+enzymatic+activity+is+responsible+for+hydrolysis+of+2-arachidonoylglycerol+in+rat+cerebellar+membranes&doi=10.1016%2Fj.bcp.2003.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes</span></div><div class="casAuthors">Saario, Susanna M.; Savinainen, Juha R.; Laitinen, Jarmo T.; Jarvinen, Tomi; Niemi, Riku</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1381-1387</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">2-Arachidonoylglycerol (2-AG) is an endogenous cannabinoid that binds to CB1 and CB2 cannabinoid receptors, inducing cannabimimetic effects.  However, the cannabimimetic effects of 2-AG are weak in vivo due to its rapid enzymic hydrolysis.  The enzymic hydrolysis of 2-AG has been proposed to mainly occur by monoglyceride lipase (monoacylglycerol lipase).  Fatty acid amide hydrolase (FAAH), the enzyme responsible for the hydrolysis of N-arachidonoylethanolamide (AEA), is also able to hydrolyze 2-AG.  In the present study, we investigated the hydrolysis of endocannabinoids in rat cerebellar membranes and obsd. that enzymic activity towards 2-AG was 50-fold higher than that towards AEA.  Furthermore, various inhibitors for 2-AG hydrolase activity were studied in rat cerebellar membranes.  2-AG hydrolysis was inhibited by Me arachidonylfluorophosphonate, hexadecylsulfonyl fluoride and phenylmethylsulfonyl fluoride with ic50 values of 2.2 nM, 241 nM and 155 μM, resp.  Potent FAAH inhibitors, such as OL-53 and URB597, did not inhibit the hydrolysis of 2-AG, suggesting that 2-AG is inactivated in rat cerebellar membranes by an enzyme distinct of FAAH.  The observation that the hydrolysis of 1(3)-AG and 2-AG occurred at equal rates supports the role of MGL in 2-AG inactivation.  This enzyme assay provides a useful method for future inhibition studies of 2-AG degrading enzyme(s) in brain membrane prepn. having considerably higher MGL-like activity when compared to FAAH activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi3kULx0FFRbVg90H21EOLACvtfcHk0lgFylOgE6TVHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVyhsLw%253D&md5=28b09b3dd9d8a19dc48196b737291fce</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2003.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2003.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DSaario%26aufirst%3DS.%2BM.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DLaitinen%26aufirst%3DJ.%2BT.%26aulast%3DJarvinen%26aufirst%3DT.%26aulast%3DNiemi%26aufirst%3DR.%26atitle%3DMonoglyceride%2520lipase-like%2520enzymatic%2520activity%2520is%2520responsible%2520for%2520hydrolysis%2520of%25202-arachidonoylglycerol%2520in%2520rat%2520cerebellar%2520membranes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D67%26spage%3D1381%26epage%3D1387%26doi%3D10.1016%2Fj.bcp.2003.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.chembiol.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=18096503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1347-1356&author=J.+L.+Blankmanauthor=G.+M.+Simonauthor=B.+F.+Cravatt&title=A+comprehensive+profile+of+brain+enzymes+that+hydrolyze+the+endocannabinoid+2-arachidonoylglycerol&doi=10.1016%2Fj.chembiol.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol</span></div><div class="casAuthors">Blankman, Jacqueline L.; Simon, Gabriel M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Endogenous ligands for cannabinoid receptors ("endocannabinoids") include the lipid transmitters anandamide and 2-arachidonoylglycerol (2-AG).  Endocannabinoids modulate a diverse set of physiol. processes and are tightly regulated by enzymic biosynthesis and degrdn.  Termination of anandamide signaling by fatty acid amide hydrolase (FAAH) is well characterized, but less is known about the inactivation of 2-AG, which can be hydrolyzed by multiple enzymes in vitro, including FAAH and monoacylglycerol lipase (MAGL).  Here, we have taken a functional proteomic approach to comprehensively map 2-AG hydrolases in the mouse brain.  Our data reveal that ∼85% of brain 2-AG hydrolase activity can be ascribed to MAGL, and that the remaining 15% is mostly catalyzed by two uncharacterized enzymes, ABHD6 and ABHD12.  Interestingly, MAGL, ABHD6, and ABHD12 display distinct subcellular distributions, suggesting that they may control different pools of 2-AG in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF_Kmd_7v5urVg90H21EOLACvtfcHk0lgFylOgE6TVHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE&md5=78c6355a3909bff3cbae25989ab6a956</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DSimon%26aufirst%3DG.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520comprehensive%2520profile%2520of%2520brain%2520enzymes%2520that%2520hydrolyze%2520the%2520endocannabinoid%25202-arachidonoylglycerol%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D1347%26epage%3D1356%26doi%3D10.1016%2Fj.chembiol.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and ex vivo evaluation of [11C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2014.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.nucmedbio.2014.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=24969632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFentb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=688-694&author=J.+W.+Hicksauthor=J.+Parkesauthor=J.+Tongauthor=S.+Houleauthor=N.+Vasdevauthor=A.+A.+Wilson&title=Radiosynthesis+and+ex+vivo+evaluation+of+%5B11C-carbonyl%5Dcarbamate-+and+urea-based+monoacylglycerol+lipase+inhibitors&doi=10.1016%2Fj.nucmedbio.2014.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and ex vivo evaluation of [11C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors</span></div><div class="casAuthors">Hicks, Justin W.; Parkes, Jun; Tong, Junchao; Houle, Sylvain; Vasdev, Neil; Wilson, Alan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">688-694</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) are the two primary enzymes that regulate the tone of endocannabinoid signaling.  Although new PET radiotracers have been discovered for imaging FAAH in vivo, no such radiotracer exists for imaging MAGL.  Here we report the radiosynthesis of five candidate MAGL radiotracers and their ex vivo evaluations in mice and rats.Candidate carbamate and urea MAGL inhibitors were radiolabeled at the carbonyl position by [11C]CO2 fixation.  Radiotracers were administered (tail-vein injection) to rodents and brain uptake of radioactivity measured at early and late time points ex vivo.  Specificity of uptake was explored by pretreatment with unlabeled inhibitors (2 mg/kg, i.p.) 30 min prior to radiotracer administration.All five candidate MAGL radiotracers were prepd. in high specific activity (> 65 GBq/μmol) and radiochem. purity (> 98%).  Moderate brain uptake (0.2-0.8 SUV) was obsd. for each candidate while pretreatment did not reduce uptake for four of the five tested.  For two candidates ([11C]12 and [11C]14), high retention of radioactivity was obsd. in the blood (ca. 10 and 4 SUV at 40 min) which was blocked by pretreatment with unlabeled inhibitors.  The most promising candidate, [11C]18, demonstrated moderate brain uptake (ca. 0.8 SUV) which showed circa 50% blockade by pretreatment with unlabeled 18.One putative and four reported potent and selective MAGL inhibitors have been radiolabeled via [11C]CO2 fixation as radiotracers for this enzyme.  Despite the promising in vitro pharmacol. profile, none of the five candidate radiotracers exhibited in vivo behavior suitable for PET neuroimaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi4CWj3XLZqrVg90H21EOLACvtfcHk0lij6Lw2bHZ7IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFentb3M&md5=dcedea3b995995c96c88e7fa130378fa</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2014.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2014.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DJ.%2BW.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26atitle%3DRadiosynthesis%2520and%2520ex%2520vivo%2520evaluation%2520of%2520%255B11C-carbonyl%255Dcarbamate-%2520and%2520urea-based%2520monoacylglycerol%2520lipase%2520inhibitors%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2014%26volume%3D41%26spage%3D688%26epage%3D694%26doi%3D10.1016%2Fj.nucmedbio.2014.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griebel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeske, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Even, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Grancha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstykh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederschain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergis, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avenet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escoubet, J.</span></span> <span> </span><span class="NLM_article-title">Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">7642</span>, <span class="refDoi"> DOI: 10.1038/srep07642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fsrep07642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25560837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGgurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=7642&author=G.+Griebelauthor=P.+Pichatauthor=S.+Beeskeauthor=T.+Leroyauthor=N.+Redonauthor=A.+Jacquetauthor=D.+Franconauthor=L.+Bertauthor=L.+Evenauthor=M.+Lopez-Granchaauthor=T.+Tolstykhauthor=F.+Sunauthor=Q.+Yuauthor=S.+Brittainauthor=H.+Arltauthor=T.+Heauthor=B.+Zhangauthor=D.+Wiederschainauthor=T.+Bertrandauthor=J.+Houtmannauthor=A.+Rakauthor=F.+Valleeauthor=N.+Michotauthor=F.+Augeauthor=V.+Menetauthor=O.+E.+Bergisauthor=P.+Georgeauthor=P.+Avenetauthor=V.+Mikolauthor=M.+Didierauthor=J.+Escoubet&title=Selective+blockade+of+the+hydrolysis+of+the+endocannabinoid+2-arachidonoylglycerol+impairs+learning+and+memory+performance+while+producing+antinociceptive+activity+in+rodents&doi=10.1038%2Fsrep07642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents</span></div><div class="casAuthors">Griebel, Guy; Pichat, Philippe; Beeske, Sandra; Leroy, Thibaud; Redon, Nicolas; Jacquet, Agnes; Francon, Dominique; Bert, Lionel; Even, Luc; Lopez-Grancha, Mati; Tolstykh, Tatiana; Sun, Fangxian; Yu, Qunyan; Brittain, Scott; Arlt, Heike; He, Timothy; Zhang, Bailin; Wiederschain, Dmitri; Bertrand, Thomas; Houtmann, Jacques; Rak, Alexey; Vallee, Francois; Michot, Nadine; Auge, Franck; Menet, Veronique; Bergis, Olivier E.; George, Pascal; Avenet, Patrick; Mikol, Vincent; Didier, Michel; Escoubet, Johanna</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7642</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) represents a primary degrdn. enzyme of the endogenous cannabinoid (eCB), 2-arachidonoyglycerol (2-AG).  This study reports a potent covalent MAGL inhibitor, SAR127303.  The compd. behaves as a selective and competitive inhibitor of mouse and human MAGL, which potently elevates hippocampal levels of 2-AG in mice.  In vivo, SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain.  In addn., the drug alters learning performance in several assays related to episodic, working and spatial memory.  Moreover, long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus, two hallmarks of memory function, are both decreased by SAR127303.  Although inactive in acute seizure tests, repeated administration of SAR127303 delays the acquisition and decreases kindled seizures in mice, indicating that the drug slows down epileptogenesis, a finding deserving further investigation to evaluate the potential of MAGL inhibitors as antiepileptics.  However, the observation that 2-AG hydrolysis blockade alters learning and memory performance, suggests that such drugs may have limited value as therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiPpgk18M26bVg90H21EOLACvtfcHk0lij6Lw2bHZ7IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGgurrL&md5=4160ed016b730ea80abb5c093e66a284</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1038%2Fsrep07642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep07642%26sid%3Dliteratum%253Aachs%26aulast%3DGriebel%26aufirst%3DG.%26aulast%3DPichat%26aufirst%3DP.%26aulast%3DBeeske%26aufirst%3DS.%26aulast%3DLeroy%26aufirst%3DT.%26aulast%3DRedon%26aufirst%3DN.%26aulast%3DJacquet%26aufirst%3DA.%26aulast%3DFrancon%26aufirst%3DD.%26aulast%3DBert%26aufirst%3DL.%26aulast%3DEven%26aufirst%3DL.%26aulast%3DLopez-Grancha%26aufirst%3DM.%26aulast%3DTolstykh%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DBrittain%26aufirst%3DS.%26aulast%3DArlt%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWiederschain%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DHoutmann%26aufirst%3DJ.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DVallee%26aufirst%3DF.%26aulast%3DMichot%26aufirst%3DN.%26aulast%3DAuge%26aufirst%3DF.%26aulast%3DMenet%26aufirst%3DV.%26aulast%3DBergis%26aufirst%3DO.%2BE.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DAvenet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DDidier%26aufirst%3DM.%26aulast%3DEscoubet%26aufirst%3DJ.%26atitle%3DSelective%2520blockade%2520of%2520the%2520hydrolysis%2520of%2520the%2520endocannabinoid%25202-arachidonoylglycerol%2520impairs%2520learning%2520and%2520memory%2520performance%2520while%2520producing%2520antinociceptive%2520activity%2520in%2520rodents%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D7642%26doi%3D10.1038%2Fsrep07642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Placzek, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de
Bittner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">A novel radiotracer for imaging monoacylglycerol lipase in the brain using positron emission tomography</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=484-489&author=C.+Wangauthor=M.+S.+Placzekauthor=G.+C.+Van+de%0ABittnerauthor=F.+A.+Schroederauthor=J.+M.+Hooker&title=A+novel+radiotracer+for+imaging+monoacylglycerol+lipase+in+the+brain+using+positron+emission+tomography&doi=10.1021%2Facschemneuro.5b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Radiotracer for Imaging Monoacylglycerol Lipase in the Brain Using Positron Emission Tomography</span></div><div class="casAuthors">Wang, Changning; Placzek, Michael S.; Van de Bittner, Genevieve C.; Schroeder, Frederick A.; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">484-489</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a serine hydrolase that hydrolyzes monoacylglycerols to glycerol and fatty acid and plays an important role in neuroinflammation.  MAGL inhibitors are a class of mols. with therapeutic potential for human diseases of the central nervous system (CNS), in areas such as pain and inflammation, immunol. disorders, and neurol. and psychiatric conditions.  Development of a noninvasive imaging probe would elucidate the distribution and functional roles of MAGL in the brain and accelerate medical research and drug discovery in this domain.  Herein, we describe the synthesis and pilot rodent imaging of a novel MAGL imaging agent, [11C]SAR127303.  Our imaging results demonstrate the high specificity, good selectivity, and appropriate kinetics and distribution of [11C]SAR127303, validating its utility for imaging MAGL in the brain.  Our findings support the translational potential for human CNS MAGL imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwFMlYYqhfbVg90H21EOLACvtfcHk0lij6Lw2bHZ7IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7nP&md5=0cc854816045539b5ccb7b5d7819372b</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00293%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPlaczek%26aufirst%3DM.%2BS.%26aulast%3DVan%2Bde%2BBittner%26aufirst%3DG.%2BC.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DA%2520novel%2520radiotracer%2520for%2520imaging%2520monoacylglycerol%2520lipase%2520in%2520the%2520brain%2520using%2520positron%2520emission%2520tomography%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D484%26epage%3D489%26doi%3D10.1021%2Facschemneuro.5b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minamimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of sulfonamido-based [11C-Carbonyl]-carbamates and ureas for imaging monoacylglycerol lipase</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.7150/thno.15257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.7150%2Fthno.15257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27279908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Cis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1145-1159&author=L.+Wangauthor=W.+Moriauthor=R.+Chengauthor=J.+J.+Yuiauthor=A.+Hatoriauthor=L.+L.+Maauthor=Y.+D.+Zhangauthor=B.+H.+Rotsteinauthor=M.+Fujinagaauthor=Y.+Shimodaauthor=T.+Yamasakiauthor=L.+Xieauthor=Y.+Nagaiauthor=T.+Minamimotoauthor=M.+Higuchiauthor=N.+Vasdevauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=Synthesis+and+preclinical+evaluation+of+sulfonamido-based+%5B11C-Carbonyl%5D-carbamates+and+ureas+for+imaging+monoacylglycerol+lipase&doi=10.7150%2Fthno.15257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preclinical evaluation of sulfonamidobased [11C-carbonyl]-carbamates and ureas for imaging monoacylglycerol lipase</span></div><div class="casAuthors">Wang, Lu; Mori, Wakana; Cheng, Ran; Yui, Joji; Hatori, Akiko; Ma, Longle; Zhang, Yiding; Rotstein, Benjamin H.; Fujinaga, Masayuki; Shimoda, Yoko; Yamasaki, Tomoteru; Xie, Lin; Nagai, Yuji; Minamimoto, Takafumi; Higuchi, Makoto; Vasdev, Neil; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1145-1159</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a 33 kDa member of the serine hydrolase superfamily that preferentially degrades 2-arachidonoylglycerol (2-AG) to arachidonic acid in the endocannabinoid system.  Inhibition of MAGL is not only of interest for probing the cannabinoid pathway but also as a therapeutic and diagnostic target for neuroinflammation.  Limited attempts have been made to image MAGL in vivo and a suitable PET ligand for this target has yet to be identified and is urgently sought to guide small mol. drug development in this pathway.  Herein we synthesized and evaluated the physiochem. properties of an array of eleven sulfonamido-based carbamates and ureas with a series of terminal aryl moieties, linkers and leaving groups.  The most potent compds. were a novel MAGL inhibitor, N-((1-(1H-1,2,4-triazole-1-carbonyl)piperidin-4-yl) methyl)-4-chlorobenzenesulfonamide (TZPU; IC50 = 35.9 nM), and the known inhibitor 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(((4-chlorophenyl)sulfonamido) methyl)piperidine-1- carboxylate (SAR127303; IC50 = 39.3 nM), which were also shown to be selective for MAGL over fatty acid amide hydrolase (FAAH), and cannabinoid receptors (CB1 & CB2).  Both of these compds. were radiolabeled with carbon-11 via [11C]COCl2, followed by comprehensive ex vivo biodistribution and in vivo PET imaging studies in normal rats to det. their brain permeability, specificity, clearance and metab.  Whereas TZPU did not show adequate specificity to warrant further evaluation, [11C]SAR127303 was advanced for preliminary PET neuroimaging studies in nonhuman primate.  The tracer showed good brain permeability (ca. 1 SUV) and heterogeneous regional brain distribution which is consistent with the distribution of MAGL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5MOdhV6XvFbVg90H21EOLACvtfcHk0liWTEJDc2FZxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Cis78%253D&md5=eb8493b2b83af17721a22d03151b7ba2</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.7150%2Fthno.15257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.15257%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DYui%26aufirst%3DJ.%2BJ.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DL.%2BL.%26aulast%3DZhang%26aufirst%3DY.%2BD.%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DMinamimoto%26aufirst%3DT.%26aulast%3DHiguchi%26aufirst%3DM.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520sulfonamido-based%2520%255B11C-Carbonyl%255D-carbamates%2520and%2520ureas%2520for%2520imaging%2520monoacylglycerol%2520lipase%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D1145%26epage%3D1159%26doi%3D10.7150%2Fthno.15257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attili, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veghel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooms, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berben, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bormans, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of [<sup>11</sup>C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.ejmech.2017.04.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28486208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVansro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=104-113&author=M.+Ahamedauthor=B.+Attiliauthor=D.+van+Veghelauthor=M.+Oomsauthor=P.+Berbenauthor=S.+Celenauthor=M.+Kooleauthor=L.+Declercqauthor=J.+R.+Savinainenauthor=J.+T.+Laitinenauthor=A.+Verbruggenauthor=G.+Bormans&title=Synthesis+and+preclinical+evaluation+of+%5B11C%5DMA-PB-1+for+in+vivo+imaging+of+brain+monoacylglycerol+lipase+%28MAGL%29&doi=10.1016%2Fj.ejmech.2017.04.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preclinical evaluation of [11C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL)</span></div><div class="casAuthors">Ahamed, Muneer; Attili, Bala; van Veghel, Daisy; Ooms, Maarten; Berben, Philippe; Celen, Sofie; Koole, Michel; Declercq, Lieven; Savinainen, Juha R.; Laitinen, Jarmo T.; Verbruggen, Alfons; Bormans, Guy</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-113</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Synthesis and preclin. evaluation of labeled [11C]MA-PB-1 (I) as an irreversible MAGL (monoacylglycerol lipase) inhibitor PET tracer is reported.  The in-vitro inhibitory activity, ex-vivo distribution, brain kinetics and specificity of compd. I binding were studied.  Ex-vivo biodistribution and microPET showed good brain uptake which could be blocked by pretreatment with both compd. I and a structurally non-related MAGL inhibitor MJN110 (compd. II).  These initial results suggested that compd. I is a suitable tracer for in-vivo imaging of MAGL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZZw-mML3QX7Vg90H21EOLACvtfcHk0liWTEJDc2FZxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVansro%253D&md5=8247caa5fc4f5d0bbee21e96c4dfbb24</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.066%26sid%3Dliteratum%253Aachs%26aulast%3DAhamed%26aufirst%3DM.%26aulast%3DAttili%26aufirst%3DB.%26aulast%3Dvan%2BVeghel%26aufirst%3DD.%26aulast%3DOoms%26aufirst%3DM.%26aulast%3DBerben%26aufirst%3DP.%26aulast%3DCelen%26aufirst%3DS.%26aulast%3DKoole%26aufirst%3DM.%26aulast%3DDeclercq%26aufirst%3DL.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DLaitinen%26aufirst%3DJ.%2BT.%26aulast%3DVerbruggen%26aufirst%3DA.%26aulast%3DBormans%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520%255B11C%255DMA-PB-1%2520for%2520in%2520vivo%2520imaging%2520of%2520brain%2520monoacylglycerol%2520lipase%2520%2528MAGL%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D104%26epage%3D113%26doi%3D10.1016%2Fj.ejmech.2017.04.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawrylik, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noell, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span> <span> </span><span class="NLM_article-title">Azetidine and piperidine carbamates as efficient, covalent inhibitors of monoacylglycerol lipase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9860</span>– <span class="NLM_lpage">9873</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01531</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01531" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9860-9873&author=C.+R.+Butlerauthor=E.+M.+Beckauthor=A.+Harrisauthor=Z.+Huangauthor=L.+A.+McAllisterauthor=C.+W.+Am+Endeauthor=K.+Fennellauthor=T.+L.+Foleyauthor=K.+Fonsecaauthor=S.+J.+Hawrylikauthor=D.+S.+Johnsonauthor=J.+D.+Knafelsauthor=S.+Menteauthor=G.+S.+Noellauthor=J.+Panditauthor=T.+B.+Phillipsauthor=J.+R.+Piroauthor=B.+N.+Rogersauthor=T.+A.+Samadauthor=J.+Wangauthor=S.+Wanauthor=M.+A.+Brodney&title=Azetidine+and+piperidine+carbamates+as+efficient%2C+covalent+inhibitors+of+monoacylglycerol+lipase&doi=10.1021%2Facs.jmedchem.7b01531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Azetidine and Piperidine Carbamates as Efficient, Covalent Inhibitors of Monoacylglycerol Lipase</span></div><div class="casAuthors">Butler, Christopher R.; Beck, Elizabeth M.; Harris, Anthony; Huang, Zhen; McAllister, Laura A.; am Ende, Christopher W.; Fennell, Kimberly; Foley, Timothy L.; Fonseca, Kari; Hawrylik, Steven J.; Johnson, Douglas S.; Knafels, John D.; Mente, Scot; Noell, G. Stephen; Pandit, Jayvardhan; Phillips, Tracy B.; Piro, Justin R.; Rogers, Bruce N.; Samad, Tarek A.; Wang, Jane; Wan, Shuangyi; Brodney, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9860-9873</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is the main enzyme responsible for degrdn. of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the CNS.  MAGL catalyzes the conversion of 2-AG to arachidonic acid (AA), a precursor to the proinflammatory eicosannoids such as prostaglandins.  Herein the authors describe highly efficient MAGL inhibitors, identified through a parallel medicinal chem. approach that highlighted the improved efficiency of azetidine and piperidine-derived carbamates.  The discovery and optimization of 3-substituted azetidine carbamate irreversible inhibitors of MAGL were aided by the generation of inhibitor-bound MAGL crystal structures.  Compd. 6 (1,1,1,3,3,3-hexafluoropropan-2-yl 3-(1-phenyl-1H-pyrazol-3-yl)azetidine-1-carboxylate), a highly efficient and selective MAGL inhibitor against recombinant enzyme and in a cellular context, was tested in vivo and shown to elevate central 2-AG levels at a 10 mg/kg dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoRIXhdu0BLrVg90H21EOLACvtfcHk0liWTEJDc2FZxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqurzO&md5=b89f7d44f611dd84cd49a8d240ac26b0</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01531%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMcAllister%26aufirst%3DL.%2BA.%26aulast%3DAm%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DFennell%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DT.%2BL.%26aulast%3DFonseca%26aufirst%3DK.%26aulast%3DHawrylik%26aufirst%3DS.%2BJ.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DNoell%26aufirst%3DG.%2BS.%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DT.%2BB.%26aulast%3DPiro%26aufirst%3DJ.%2BR.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DSamad%26aufirst%3DT.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DS.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26atitle%3DAzetidine%2520and%2520piperidine%2520carbamates%2520as%2520efficient%252C%2520covalent%2520inhibitors%2520of%2520monoacylglycerol%2520lipase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9860%26epage%3D9873%26doi%3D10.1021%2Facs.jmedchem.7b01531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhouayek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minamimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondrechen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of 11C-Labeled azetidinecarboxylates for imaging monoacylglycerol lipase by PET imaging studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2278</span>– <span class="NLM_lpage">2291</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01400</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01400" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlOmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2278-2291&author=R.+Chengauthor=W.+Moriauthor=L.+Maauthor=M.+Alhouayekauthor=A.+Hatoriauthor=Y.+Zhangauthor=D.+Ogasawaraauthor=G.+Yuanauthor=Z.+Chenauthor=X.+Zhangauthor=H.+Shiauthor=T.+Yamasakiauthor=L.+Xieauthor=K.+Kumataauthor=M.+Fujinagaauthor=Y.+Nagaiauthor=T.+Minamimotoauthor=M.+Svenssonauthor=L.+Wangauthor=Y.+Duauthor=M.+J.+Ondrechenauthor=N.+Vasdevauthor=B.+F.+Cravattauthor=C.+Fowlerauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=In+vitro+and+in+vivo+evaluation+of+11C-Labeled+azetidinecarboxylates+for+imaging+monoacylglycerol+lipase+by+PET+imaging+studies&doi=10.1021%2Facs.jmedchem.7b01400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and in Vivo Evaluation of 11C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies</span></div><div class="casAuthors">Cheng, Ran; Mori, Wakana; Ma, Longle; Alhouayek, Mireille; Hatori, Akiko; Zhang, Yiding; Ogasawara, Daisuke; Yuan, Gengyang; Chen, Zhen; Zhang, Xiaofei; Shi, Hang; Yamasaki, Tomoteru; Xie, Lin; Kumata, Katsushi; Fujinaga, Masayuki; Nagai, Yuji; Minamimoto, Takafumi; Svensson, Mona; Wang, Lu; Du, Yunfei; Ondrechen, Mary Jo; Vasdev, Neil; Cravatt, Benjamin F.; Fowler, Christopher; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2278-2291</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is the principle enzyme for metabolizing endogenous cannabinoid ligand 2-arachidonoyglycerol (2-AG).  Blockade of MAGL increases 2-AG levels, resulting in subsequent activation of the endocannabinoid system, and has emerged as a novel therapeutic strategy to treat drug addiction, inflammation, and neurodegenerative diseases.  Herein we report a new series of MAGL inhibitors, which were radiolabeled by site-specific labeling technologies, including 11C-carbonylation and spirocyclic iodonium ylide (SCIDY) radiofluorination.  The lead compd. [11C]10 (MAGL-0519) demonstrated high specific binding and selectivity in vitro and in vivo.  We also obsd. unexpected washout kinetics with these irreversible radiotracers, in which in vivo evidence for turnover of the covalent residue was unveiled between MAGL and azetidine carboxylates.  This work may lead to new directions for drug discovery and PET tracer development based on azetidine carboxylate inhibitor scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm2LL5zxwjx7Vg90H21EOLACvtfcHk0ljRD54jOjrVGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlOmtb8%253D&md5=b2b4ddcfcccadac13be8d731127df7db</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01400%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DAlhouayek%26aufirst%3DM.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DMinamimoto%26aufirst%3DT.%26aulast%3DSvensson%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DOndrechen%26aufirst%3DM.%2BJ.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DFowler%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%252011C-Labeled%2520azetidinecarboxylates%2520for%2520imaging%2520monoacylglycerol%2520lipase%2520by%2520PET%2520imaging%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2278%26epage%3D2291%26doi%3D10.1021%2Facs.jmedchem.7b01400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafroth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of reversible and irreversible monoacylglycerol lipase positron emission tomography (PET) tracers using a ’tail switching’ strategy on a piperazinyl azetidine skeleton</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3336</span>– <span class="NLM_lpage">3353</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01778</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01778" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktV2mtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3336-3353&author=Z.+Chenauthor=W.+Moriauthor=X.+Dengauthor=R.+Chengauthor=D.+Ogasawaraauthor=G.+Zhangauthor=M.+A.+Schafrothauthor=K.+Dahlauthor=H.+Fuauthor=A.+Hatoriauthor=T.+Shaoauthor=Y.+Zhangauthor=T.+Yamasakiauthor=X.+Zhangauthor=J.+Rongauthor=Q.+Yuauthor=K.+Huauthor=M.+Fujinagaauthor=L.+Xieauthor=K.+Kumataauthor=Y.+Gouauthor=J.+Chenauthor=S.+Guauthor=L.+Baoauthor=L.+Wangauthor=T.+L.+Collierauthor=N.+Vasdevauthor=Y.+Shaoauthor=J.+A.+Maauthor=B.+F.+Cravattauthor=C.+Fowlerauthor=L.+Josephsonauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=Design%2C+synthesis+and+evaluation+of+reversible+and+irreversible+monoacylglycerol+lipase+positron+emission+tomography+%28PET%29+tracers+using+a+%E2%80%99tail+switching%E2%80%99+strategy+on+a+piperazinyl+azetidine+skeleton&doi=10.1021%2Facs.jmedchem.8b01778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a "Tail Switching" Strategy on a Piperazinyl Azetidine Skeleton</span></div><div class="casAuthors">Chen, Zhen; Mori, Wakana; Deng, Xiaoyun; Cheng, Ran; Ogasawara, Daisuke; Zhang, Genwei; Schafroth, Michael A.; Dahl, Kenneth; Fu, Hualong; Hatori, Akiko; Shao, Tuo; Zhang, Yiding; Yamasaki, Tomoteru; Zhang, Xiaofei; Rong, Jian; Yu, Qingzhen; Hu, Kuan; Fujinaga, Masayuki; Xie, Lin; Kumata, Katsushi; Gou, Yuancheng; Chen, Jingjin; Gu, Shuyin; Bao, Liang; Wang, Lu; Collier, Thomas Lee; Vasdev, Neil; Shao, Yihan; Ma, Jun-An; Cravatt, Benjamin F.; Fowler, Christopher; Josephson, Lee; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3336-3353</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a serine hydrolase that degrades 2-arachidonoylglycerol (2-AG) in the endocannabinoid system (eCB).  Selective inhibition of MAGL has emerged as a potential therapeutic approach for the treatment of diverse pathol. conditions, including chronic pain, inflammation, cancer, and neurodegeneration.  Herein, we disclose a novel array of reversible and irreversible MAGL inhibitors by means of "tail switching" on a piperazinyl azetidine scaffold.  We developed a lead irreversible-binding MAGL inhibitor 8 and reversible-binding compds. 17 and 37, which are amenable for radiolabeling with 11C or 18F. [11C]8 ([11C]MAGL-2-11) exhibited high brain uptake and excellent binding specificity in the brain toward MAGL.  Reversible radioligands [11C]17 ([11C]PAD) and [18F]37 ([18F]MAGL-4-11) also demonstrated excellent in vivo binding specificity toward MAGL in peripheral organs.  This work may pave the way for the development of MAGL-targeted positron emission tomog. tracers with tunability in reversible and irreversible binding mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq14JLjFrGKxrVg90H21EOLACvtfcHk0ljRD54jOjrVGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktV2mtbs%253D&md5=261c3ea3d090e90c7f3c23701a0c9c34</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01778%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DSchafroth%26aufirst%3DM.%2BA.%26aulast%3DDahl%26aufirst%3DK.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRong%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DS.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DJ.%2BA.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DFowler%26aufirst%3DC.%26aulast%3DJosephson%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520reversible%2520and%2520irreversible%2520monoacylglycerol%2520lipase%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520tracers%2520using%2520a%2520%25E2%2580%2599tail%2520switching%25E2%2580%2599%2520strategy%2520on%2520a%2520piperazinyl%2520azetidine%2520skeleton%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3336%26epage%3D3353%26doi%3D10.1021%2Facs.jmedchem.8b01778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neidhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, G.</span></span> <span> </span><span class="NLM_article-title">“Scaffold-Hopping” by topological pharmacophore search: a contribution to virtual screening</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2894</span>– <span class="NLM_lpage">2896</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1521-3773(19991004)38:19<2894::AID-ANIE2894>3.0.CO;2-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2F%28SICI%291521-3773%2819991004%2938%3A19%3C2894%3A%3AAID-ANIE2894%3E3.0.CO%3B2-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADyaK1MXmslKht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=2894-2896&author=G.+Schneiderauthor=W.+Neidhartauthor=T.+Gillerauthor=G.+Schmid&title=%E2%80%9CScaffold-Hopping%E2%80%9D+by+topological+pharmacophore+search%3A+a+contribution+to+virtual+screening&doi=10.1002%2F%28SICI%291521-3773%2819991004%2938%3A19%3C2894%3A%3AAID-ANIE2894%3E3.0.CO%3B2-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">"Scaffold-Hopping" by topological pharmacophore search: a contribution to virtual screening</span></div><div class="casAuthors">Schneider, Gisbert; Neidhart, Werner; Giller, Thomas; Schmid, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2894-2896</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">We present the successful application of a novel straightforward technique to "scaffold-hopping", i.e., identification of isofunctional mol. structures with significantly different mol. backbones.  The technique was applied to the prediction of novel cardiac T-type Ca2+ channel blocking agents using mibefradil as the seed structure.  The 12 highest-ranking mols. were tested using a cell culture assay for their ability to inhibit cellular Ca2+ influx.  One compd. (clopimozide) had an IC50 < 1 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgaa9cDF2whrVg90H21EOLACvtfcHk0ljgplBpL8CR2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmslKht78%253D&md5=460b2116abc32e54ba9eb3b712333eb9</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-3773%2819991004%2938%3A19%3C2894%3A%3AAID-ANIE2894%3E3.0.CO%3B2-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-3773%252819991004%252938%253A19%253C2894%253A%253AAID-ANIE2894%253E3.0.CO%253B2-F%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DGiller%26aufirst%3DT.%26aulast%3DSchmid%26aufirst%3DG.%26atitle%3D%25E2%2580%259CScaffold-Hopping%25E2%2580%259D%2520by%2520topological%2520pharmacophore%2520search%253A%2520a%2520contribution%2520to%2520virtual%2520screening%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1999%26volume%3D38%26spage%3D2894%26epage%3D2896%26doi%3D10.1002%2F%28SICI%291521-3773%2819991004%2938%3A19%3C2894%3A%3AAID-ANIE2894%3E3.0.CO%3B2-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpfe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in scaffold hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1246</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01437</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSks7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1238-1246&author=Y.+Huauthor=D.+Stumpfeauthor=J.+Bajorath&title=Recent+advances+in+scaffold+hopping&doi=10.1021%2Facs.jmedchem.6b01437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Scaffold Hopping</span></div><div class="casAuthors">Hu, Ye; Stumpfe, Dagmar; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1238-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Scaffold hopping refers to the computer-aided search for active compds. contg. different core structures, which is a topic of high interest in medicinal chem.  Herein foundations and caveats of scaffold hopping approaches are discussed and recent methodol. developments analyzed.  Despite the conceptual prevalence of pharmacophore methods for scaffold hopping, a variety of computational approaches have been successfully applied.  In recent years, scaffold hopping calcns. are increasingly carried out at the level of scaffolds rather than compds., and scaffold queries increasingly from chem. structures.  In addn., relationships between compds., scaffolds, and biol. activities are beginning to be globally explored, beyond individual applications.  Going forward, computational scaffold hopping is thought to benefit from the consideration of new scaffold concepts and the development of methods capable of guiding search calcns. toward scaffolds that are likely to represent potent compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreklFOuNfjw7Vg90H21EOLACvtfcHk0ljgplBpL8CR2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSks7%252FM&md5=a845ab13a7af0e397eedc94f7adcf870</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01437%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DStumpfe%26aufirst%3DD.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520in%2520scaffold%2520hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1238%26epage%3D1246%26doi%3D10.1021%2Facs.jmedchem.6b01437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary evaluation of a 11C-labeled piperidin-4-yl azetidine diamide for imaging monoacylglycerol lipase</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1004</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26966158" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=1004&author=L.+Wangauthor=M.+Fujinagaauthor=R.+Chengauthor=J.+Yuiauthor=Y.+Shimodaauthor=B.+Rotsteinauthor=Y.+Zhangauthor=N.+Vasdevauthor=M.+R.+Zhangauthor=S.+Liang&title=Synthesis+and+preliminary+evaluation+of+a+11C-labeled+piperidin-4-yl+azetidine+diamide+for+imaging+monoacylglycerol+lipase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DYui%26aufirst%3DJ.%26aulast%3DShimoda%26aufirst%3DY.%26aulast%3DRotstein%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520preliminary%2520evaluation%2520of%2520a%252011C-labeled%2520piperidin-4-yl%2520azetidine%2520diamide%2520for%2520imaging%2520monoacylglycerol%2520lipase%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2016%26volume%3D57%26spage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and evaluation of a novel monoacylglycerol lipase radiotracer: 1,1,1,3,3,3-hexafluoropropan-2-yl-3-(1-benzyl-1H-pyrazol-3-yl)azetidine-1-[<sup>11</sup>C] carboxylate</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3568</span>– <span class="NLM_lpage">3573</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.06.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.bmc.2019.06.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31278005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSmsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=3568-3573&author=W.+Moriauthor=A.+Hatoriauthor=Y.+Zhangauthor=Y.+Kuriharaauthor=T.+Yamasakiauthor=L.+Xieauthor=K.+Kumataauthor=K.+Huauthor=M.+Fujinagaauthor=M.+R.+Zhang&title=Radiosynthesis+and+evaluation+of+a+novel+monoacylglycerol+lipase+radiotracer%3A+1%2C1%2C1%2C3%2C3%2C3-hexafluoropropan-2-yl-3-%281-benzyl-1H-pyrazol-3-yl%29azetidine-1-%5B11C%5D+carboxylate&doi=10.1016%2Fj.bmc.2019.06.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and evaluation of a novel monoacylglycerol lipase radiotracer: 1,1,1,3,3,3-hexafluoropropan-2-yl-3-(1-benzyl-1H-pyrazol-3-yl)azetidine-1-[11C]carboxylate</span></div><div class="casAuthors">Mori, Wakana; Hatori, Akiko; Zhang, Yiding; Kurihara, Yusuke; Yamasaki, Tomoteru; Xie, Lin; Kumata, Katsushi; Hu, Kuan; Fujinaga, Masayuki; Zhang, Ming-Rong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3568-3573</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) into arachidonic acid (AA) and glycerol in the brain.  Because 2-AG and AA are endogenous biol. active ligands in the brain, the inhibition of MAGL is an attractive therapeutic target for neurodegenerative diseases.  In this study, to visualize MAGL via positron emission tomog. (PET), we report a new carbon-11-labeled radiotracer, namely 1,1,1,3,3,3-hexafluoropropan-2-yl-3-(1-benzyl-1H-pyrazol-3-yl)azetidine-1-[11C]carboxylate ([11C]6).  Compd. 6 exhibited high in vitro binding affinity (IC50 = 0.41 nM) to MAGL in the brain with a suitable lipophilicity (cLogD = 3.29). [11C]6 was synthesized by reacting 1,1,1,3,3,3-hexafluoropropanol (7) with [11C]phosgene ([11C]COCl2), followed by a reaction with 3-(1-benzyl-1H-pyrazol-3-yl)azetidine hydrochloride (8), which resulted in a 15.0 ± 6.8% radiochem. yield (decay-cor., n = 7) based on [11C]CO2 and a 45 min synthesis time from the end of bombardment.  A biodistribution study in mice showed high uptake of radioactivity in MAGL-rich organs, including the lungs, heart, and kidneys.  More than 90% of the total radioactivity was irreversibly bound in the brain homogenate of rats 5 min and 30 min after the radiotracer injection.  PET summation images of rat brains showed high radioactivity in all brain regions.  Pretreatment with 6 or MAGL-selective inhibitor JW642 significantly reduced the uptake of radioactivity in the brain. [11C]6 is a promising PET tracer which offers in vivo specific binding and selectivity for MAGL in rodent brains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5t0r8GBm6l7Vg90H21EOLACvtfcHk0ljgplBpL8CR2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSmsbbO&md5=5c6855f4a736513f1a37562f37bff574</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.06.037%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DW.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DKumata%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26atitle%3DRadiosynthesis%2520and%2520evaluation%2520of%2520a%2520novel%2520monoacylglycerol%2520lipase%2520radiotracer%253A%25201%252C1%252C1%252C3%252C3%252C3-hexafluoropropan-2-yl-3-%25281-benzyl-1H-pyrazol-3-yl%2529azetidine-1-%255B11C%255D%2520carboxylate%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D3568%26epage%3D3573%26doi%3D10.1016%2Fj.bmc.2019.06.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maresca, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildknegt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span> <span> </span><span class="NLM_article-title">Identification and development of an irreversible monoacylglycerol lipase (MAGL) positron emission tomography (PET) radioligand with high specificity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8532</span>– <span class="NLM_lpage">8543</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00847</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00847" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslSqsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8532-8543&author=L.+Zhangauthor=C.+R.+Butlerauthor=K.+P.+Marescaauthor=A.+Takanoauthor=S.+Nagauthor=Z.+Jiaauthor=R.+Arakawaauthor=J.+R.+Piroauthor=T.+Samadauthor=D.+L.+Smithauthor=D.+M.+Nasonauthor=S.+O%E2%80%99Neilauthor=L.+McAllisterauthor=K.+Schildknegtauthor=P.+Trapaauthor=T.+J.+McCarthyauthor=A.+Villalobosauthor=C.+Halldin&title=Identification+and+development+of+an+irreversible+monoacylglycerol+lipase+%28MAGL%29+positron+emission+tomography+%28PET%29+radioligand+with+high+specificity&doi=10.1021%2Facs.jmedchem.9b00847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Development of an Irreversible Monoacylglycerol Lipase (MAGL) Positron Emission Tomography (PET) Radioligand with High Specificity</span></div><div class="casAuthors">Zhang, Lei; Butler, Christopher R.; Maresca, Kevin P.; Takano, Akihiro; Nag, Sangram; Jia, Zhisheng; Arakawa, Ryosuke; Piro, Justin R.; Samad, Tarek; Smith, Deborah L.; Nason, Deane M.; O'Neil, Steven; McAllister, Laura; Schildknegt, Klaas; Trapa, Patrick; McCarthy, Timothy J.; Villalobos, Anabella; Halldin, Christer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8532-8543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL), a serine hydrolase extensively expressed throughout the brain, serves as a key gatekeeper regulating the tone of endocannabinoid signaling.  Preclinically, inhibition of MAGL is known to provide therapeutic benefits for a no. of neurol. disorders.  The availability of a MAGL-specific positron emission tomog. (PET) ligand would considerably facilitate the development and clin. characterization of MAGL inhibitors via noninvasive and quant. PET imaging.  Herein, we report the identification of the potent and selective irreversible MAGL inhibitor 7 (PF-06809247) as a suitable radioligand lead, which upon radiolabeling was found to exhibit a high level of MAGL specificity; this enabled cross-species measurement of MAGL brain expression (Bmax), assessment of in vivo binding in the rat, and nonhuman primate PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqln4bh3HqHSbVg90H21EOLACvtfcHk0li_xY0OciYUMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslSqsbfJ&md5=17513710756a393888768d92f327d172</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00847%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DMaresca%26aufirst%3DK.%2BP.%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DNag%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DZ.%26aulast%3DArakawa%26aufirst%3DR.%26aulast%3DPiro%26aufirst%3DJ.%2BR.%26aulast%3DSamad%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%26aulast%3DMcAllister%26aufirst%3DL.%26aulast%3DSchildknegt%26aufirst%3DK.%26aulast%3DTrapa%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DT.%2BJ.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DHalldin%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520development%2520of%2520an%2520irreversible%2520monoacylglycerol%2520lipase%2520%2528MAGL%2529%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520radioligand%2520with%2520high%2520specificity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8532%26epage%3D8543%26doi%3D10.1021%2Facs.jmedchem.9b00847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span>ClinicalTrials.gov.
Test re-test reliability of 11CPF-06809247 as a novel PET tacer. <a href="https://clinicaltrials.gov/ct2/show/NCT03100136" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03100136</a> (accessed Oct 8, 2010).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.%0ATest+re-test+reliability+of+11CPF-06809247+as+a+novel+PET+tacer.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03100136+%28accessed+Oct+8%2C+2010%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafroth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giffenig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papisov, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 18F-Labeled monoacylglycerol lipase inhibitors as novel positron emission tomography probes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8866</span>– <span class="NLM_lpage">8872</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00936</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00936" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKis7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8866-8872&author=Z.+Chenauthor=W.+Moriauthor=H.+Fuauthor=M.+A.+Schafrothauthor=A.+Hatoriauthor=T.+Shaoauthor=G.+Zhangauthor=R.+S.+Vanauthor=Y.+Zhangauthor=K.+Huauthor=M.+Fujinagaauthor=L.+Wangauthor=V.+Belovauthor=D.+Ogasawaraauthor=P.+Giffenigauthor=X.+Dengauthor=J.+Rongauthor=Q.+Yuauthor=X.+Zhangauthor=M.+I.+Papisovauthor=Y.+Shaoauthor=T.+L.+Collierauthor=J.+A.+Maauthor=B.+F.+Cravattauthor=L.+Josephsonauthor=M.+R.+Zhangauthor=S.+H.+Liang&title=Design%2C+synthesis%2C+and+evaluation+of+18F-Labeled+monoacylglycerol+lipase+inhibitors+as+novel+positron+emission+tomography+probes&doi=10.1021%2Facs.jmedchem.9b00936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of 18F-Labeled Monoacylglycerol Lipase Inhibitors as Novel Positron Emission Tomography Probes</span></div><div class="casAuthors">Chen, Zhen; Mori, Wakana; Fu, Hualong; Schafroth, Michael A.; Hatori, Akiko; Shao, Tuo; Zhang, Genwei; Van, Richard S.; Zhang, Yiding; Hu, Kuan; Fujinaga, Masayuki; Wang, Lu; Belov, Vasily; Ogasawara, Daisuke; Giffenig, Pilar; Deng, Xiaoyun; Rong, Jian; Yu, Qingzhen; Zhang, Xiaofei; Papisov, Mikhail I.; Shao, Yihan; Collier, Thomas L.; Ma, Jun-An; Cravatt, Benjamin F.; Josephson, Lee; Zhang, Ming-Rong; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8866-8872</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunction of monoacylglycerol lipase (MAGL) is assocd. with several psychopathol. disorders, including drug addiction and neurodegenerative diseases.  Herein we design, synthesize, and evaluate several irreversible fluorine-contg. MAGL inhibitors for positron emission tomog. (PET) ligand development.  Compd. 6 (identified from a therapeutic agent) was advanced for 18F-labeling via a novel spirocyclic iodonium ylide (SCIDY) strategy, which demonstrated high brain permeability and excellent specific binding.  This work supports further development of novel 18F-labeled MAGL PET probes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ9noubfh-w7Vg90H21EOLACvtfcHk0li_xY0OciYUMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKis7bF&md5=be7433643e89a96579a7be18198b5546</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00936%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMori%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DSchafroth%26aufirst%3DM.%2BA.%26aulast%3DHatori%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DVan%26aufirst%3DR.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBelov%26aufirst%3DV.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DGiffenig%26aufirst%3DP.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DRong%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPapisov%26aufirst%3DM.%2BI.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DCollier%26aufirst%3DT.%2BL.%26aulast%3DMa%26aufirst%3DJ.%2BA.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DJosephson%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%252018F-Labeled%2520monoacylglycerol%2520lipase%2520inhibitors%2520as%2520novel%2520positron%2520emission%2520tomography%2520probes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8866%26epage%3D8872%26doi%3D10.1021%2Facs.jmedchem.9b00936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrogna, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uccello, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of trifluoromethyl glycol carbamates as potent and selective covalent monoacylglycerol lipase (MAGL) inhibitors for treatment of neuroinflammation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3008</span>– <span class="NLM_lpage">3026</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00070</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslKlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3008-3026&author=L.+A.+McAllisterauthor=C.+R.+Butlerauthor=S.+Menteauthor=S.+V.+O%E2%80%99Neilauthor=K.+R.+Fonsecaauthor=J.+R.+Piroauthor=J.+A.+Cianfrognaauthor=T.+L.+Foleyauthor=A.+M.+Gilbertauthor=A.+R.+Harrisauthor=C.+J.+Helalauthor=D.+S.+Johnsonauthor=J.+I.+Montgomeryauthor=D.+M.+Nasonauthor=S.+Noellauthor=J.+Panditauthor=B.+N.+Rogersauthor=T.+A.+Samadauthor=C.+L.+Shafferauthor=R.+G.+da+Silvaauthor=D.+P.+Uccelloauthor=D.+Webbauthor=M.+A.+Brodney&title=Discovery+of+trifluoromethyl+glycol+carbamates+as+potent+and+selective+covalent+monoacylglycerol+lipase+%28MAGL%29+inhibitors+for+treatment+of+neuroinflammation&doi=10.1021%2Facs.jmedchem.8b00070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation</span></div><div class="casAuthors">McAllister, Laura A.; Butler, Christopher R.; Mente, Scot; O'Neil, Steven V.; Fonseca, Kari R.; Piro, Justin R.; Cianfrogna, Julie A.; Foley, Timothy L.; Gilbert, Adam M.; Harris, Anthony R.; Helal, Christopher J.; Johnson, Douglas S.; Montgomery, Justin I.; Nason, Deane M.; Noell, Stephen; Pandit, Jayvardhan; Rogers, Bruce N.; Samad, Tarek A.; Shaffer, Christopher L.; da Silva, Rafael G.; Uccello, Daniel P.; Webb, Damien; Brodney, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3008-3026</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) inhibition provides a potential treatment approach to neuroinflammation through modulation of both the endocannabinoid pathway and arachidonoyl signaling in the central nervous system (CNS).  Herein we report the discovery of compd. I (PF-06795071), a potent and selective covalent MAGL inhibitor, featuring a novel trifluoromethyl glycol leaving group that confers significant physicochem. property improvements as compared with earlier inhibitor series with more lipophilic leaving groups.  The design strategy focused on identifying an optimized leaving group that delivers MAGL potency, serine hydrolase selectivity, and CNS exposure while simultaneously reducing log D, improving soly., and minimizing chem. lability.  Compd. I achieves excellent CNS exposure, extended 2-AG elevation effect in vivo, and decreased brain inflammatory markers in response to an inflammatory challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVEF-xXUaFF7Vg90H21EOLACvtfcHk0lhwGFqbvFU_OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslKlurw%253D&md5=984babc4de306b698756e9c2a9fc5c8e</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00070%26sid%3Dliteratum%253Aachs%26aulast%3DMcAllister%26aufirst%3DL.%2BA.%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BV.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DPiro%26aufirst%3DJ.%2BR.%26aulast%3DCianfrogna%26aufirst%3DJ.%2BA.%26aulast%3DFoley%26aufirst%3DT.%2BL.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHarris%26aufirst%3DA.%2BR.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DMontgomery%26aufirst%3DJ.%2BI.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DNoell%26aufirst%3DS.%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DSamad%26aufirst%3DT.%2BA.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3Dda%2BSilva%26aufirst%3DR.%2BG.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26atitle%3DDiscovery%2520of%2520trifluoromethyl%2520glycol%2520carbamates%2520as%2520potent%2520and%2520selective%2520covalent%2520monoacylglycerol%2520lipase%2520%2528MAGL%2529%2520inhibitors%2520for%2520treatment%2520of%2520neuroinflammation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3008%26epage%3D3026%26doi%3D10.1021%2Facs.jmedchem.8b00070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic hypervalent iodine (III)-mediated radiofluorination of non-activated and hindered aromatics</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">4365</span>, <span class="refDoi"> DOI: 10.1038/ncomms5365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fncomms5365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=25007318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4365&author=B.+H.+Rotsteinauthor=N.+A.+Stephensonauthor=N.+Vasdevauthor=S.+H.+Liang&title=Spirocyclic+hypervalent+iodine+%28III%29-mediated+radiofluorination+of+non-activated+and+hindered+aromatics&doi=10.1038%2Fncomms5365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics</span></div><div class="casAuthors">Rotstein, Benjamin H.; Stephenson, Nickeisha A.; Vasdev, Neil; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4365</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An effective soln. that relied on the chem. of spirocyclic hypervalent iodine(III) complexes, which served as precursors for rapid, one-step regioselective radiofluorination with [18F]fluoride was described.  This methodol. proved to be efficient for radiolabeling a diverse range of non-activated functionalized arenes and heteroarenes, including arene substrates bearing electron-donating groups, bulky ortho functionalities, benzylic substituents and meta-substituted electron-withdrawing groups.  Polyfunctional mols. and a range of previously elusive 18F-labeled building blocks, compds. and radiopharmaceuticals were synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk9O3Tg0Uxr7Vg90H21EOLACvtfcHk0lhwGFqbvFU_OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVCiuro%253D&md5=4ae56df6f2c332f24beaece7097e77de</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1038%2Fncomms5365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms5365%26sid%3Dliteratum%253Aachs%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DStephenson%26aufirst%3DN.%2BA.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DSpirocyclic%2520hypervalent%2520iodine%2520%2528III%2529-mediated%2520radiofluorination%2520of%2520non-activated%2520and%2520hindered%2520aromatics%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D4365%26doi%3D10.1038%2Fncomms5365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Ortho-stabilized 18F-azido click agents and their application in PET imaging with single-stranded DNA aptamers</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">12777</span>– <span class="NLM_lpage">12781</span>, <span class="refDoi"> DOI: 10.1002/anie.201505927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fanie.201505927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVSju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=12777-12781&author=L.+Wangauthor=O.+Jacobsonauthor=D.+Avdicauthor=B.+H.+Rotsteinauthor=I.+D.+Weissauthor=L.+Collierauthor=X.+Chenauthor=N.+Vasdevauthor=S.+H.+Liang&title=Ortho-stabilized+18F-azido+click+agents+and+their+application+in+PET+imaging+with+single-stranded+DNA+aptamers&doi=10.1002%2Fanie.201505927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Ortho-Stabilized 18F-Azido Click Agents and their Application in PET Imaging with Single-Stranded DNA Aptamers</span></div><div class="casAuthors">Wang, Lu; Jacobson, Orit; Avdic, Din; Rotstein, Benjamin H.; Weiss, Ido D.; Collier, Lee; Chen, Xiaoyuan; Vasdev, Neil; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">12777-12781</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Azido 18F-arenes are important and versatile building blocks for the radiolabeling of biomols. via Huisgen cycloaddn. ("click chem.") for positron emission tomog. (PET).  However, routine access to such clickable agents is challenged by inefficient and/or poorly defined multistep radiochem. approaches.  A high-yielding direct radiofluorination for azido 18F-arenes was achieved through the development of an ortho-oxygen-stabilized iodonium deriv. (OID).  This OID strategy addresses an unmet need for a reliable azido 18F-arene clickable agent for bioconjugation reactions.  A ssDNA aptamer was radiolabeled with this agent and visualized in a xenograft mouse model of human colon cancer by PET, which demonstrates that this OID approach is a convenient and highly efficient way of labeling and tracking biomols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3SY-oFzg4xbVg90H21EOLACvtfcHk0lhwGFqbvFU_OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVSju7jM&md5=005856216ed8a236a3a643d6792681ec</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1002%2Fanie.201505927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201505927%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DAvdic%26aufirst%3DD.%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DWeiss%26aufirst%3DI.%2BD.%26aulast%3DCollier%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DOrtho-stabilized%252018F-azido%2520click%2520agents%2520and%2520their%2520application%2520in%2520PET%2520imaging%2520with%2520single-stranded%2520DNA%2520aptamers%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D12777%26epage%3D12781%26doi%3D10.1002%2Fanie.201505927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patteson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(III) ylides</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">4407</span>– <span class="NLM_lpage">4417</span>, <span class="refDoi"> DOI: 10.1039/C6SC00197A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1039%2FC6SC00197A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=27540460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC28Xksl2nt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=4407-4417&author=B.+H.+Rotsteinauthor=L.+Wangauthor=R.+Y.+Liuauthor=J.+Pattesonauthor=E.+E.+Kwanauthor=N.+Vasdevauthor=S.+H.+Liang&title=Mechanistic+studies+and+radiofluorination+of+structurally+diverse+pharmaceuticals+with+spirocyclic+iodonium%28III%29+ylides&doi=10.1039%2FC6SC00197A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium</span></div><div class="casAuthors">Rotstein, Benjamin H.; Wang, Lu; Liu, Richard Y.; Patteson, Jon; Kwan, Eugene E.; Vasdev, Neil; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4407-4417</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Synthesis of non-activated electron-rich and sterically hindered 18F-arenes remains a major challenge due to limitations of existing radiofluorination methodologies.  The mechanistic investigations of spirocyclic iodonium(III) ylide precursors for arene radiofluorination, including their reactivity, selectivity and stability with no-carrier-added [18F]fluoride.  Benchmark calcns. at the G2[ECP] level indicated that pseudorotation and reductive elimination at iodine(III) can be modeled well by appropriately selected dispersion-cor. d. functional methods.  Modeling of the reaction pathways showed that fluoride-iodonium(III) adduct intermediates were strongly activated and highly regioselective for reductive elimination of the desired [18F]fluoroarenes (difference in barriers, ΔΔG‡ > 25 kcal mol-1).  The advantage of spirocyclic auxiliaries was further supported by NMR spectroscopy studies, which bolster evidence for underlying decompn. processes which can be overcome for radiofluorination of iodonium(III) precursors.  Using a novel adamantyl auxiliary, sterically hindered iodonium ylides were developed to enable highly efficient radiofluorination of electron-rich arenes, including fragments of pharmaceutically relevant nitrogen-contg. heterocycles and tertiary amines.  Furthermore, this methodol. was applied for the synthesis of the radiopharmaceuticals 6-[18F]fluoro-meta-tyrosine ([18F]FMT, 11 ± 1% isolated radiochem. yield, non-decay-cor. (RCY, n.d.c.), n = 3), and meta-[18F]fluorobenzylguanidine ([18F]mFBG, 14 ± 1% isolated RCY, n.d.c., n = 3) which cannot be directly radiolabeled using conventional nucleophilic arom. substitution with [18F]fluoride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWHGHDrUUxvLVg90H21EOLACvtfcHk0lhwGFqbvFU_OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xksl2nt7c%253D&md5=2387e40f5ec7c24022aee848cc9e0436</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1039%2FC6SC00197A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6SC00197A%26sid%3Dliteratum%253Aachs%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DR.%2BY.%26aulast%3DPatteson%26aufirst%3DJ.%26aulast%3DKwan%26aufirst%3DE.%2BE.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DMechanistic%2520studies%2520and%2520radiofluorination%2520of%2520structurally%2520diverse%2520pharmaceuticals%2520with%2520spirocyclic%2520iodonium%2528III%2529%2520ylides%26jtitle%3DChem.%2520Sci.%26date%3D2016%26volume%3D7%26spage%3D4407%26epage%3D4417%26doi%3D10.1039%2FC6SC00197A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span> <span> </span><span class="NLM_article-title">Chemistry for positron emission tomography: recent advances in 11C-, 18F-, 13N-, and 15O-labeling reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2580</span>– <span class="NLM_lpage">2605</span>, <span class="refDoi"> DOI: 10.1002/anie.201805501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1002%2Fanie.201805501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=2580-2605&author=X.+Dengauthor=J.+Rongauthor=L.+Wangauthor=N.+Vasdevauthor=L.+Zhangauthor=L.+Josephsonauthor=S.+H.+Liang&title=Chemistry+for+positron+emission+tomography%3A+recent+advances+in+11C-%2C+18F-%2C+13N-%2C+and+15O-labeling+reactions&doi=10.1002%2Fanie.201805501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry for Positron Emission Tomography: Recent Advances in 11C-, 18F-, 13N-, and 15O-Labeling Reactions</span></div><div class="casAuthors">Deng, Xiaoyun; Rong, Jian; Wang, Lu; Vasdev, Neil; Zhang, Lei; Josephson, Lee; Liang, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2580-2605</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Positron emission tomog. (PET) is a mol. imaging technol. that provides quant. information about function and metab. in biol. processes in vivo for disease diagnosis and therapy assessment.  The broad application and rapid advances of PET has led to an increased demand for new radiochem. methods to synthesize highly specific mols. bearing positron-emitting radionuclides.  This Review provides an overview of commonly used labeling reactions through examples of clin. relevant PET tracers and highlights the most recent developments and breakthroughs over the past decade, with a focus on 11C, 18F, 13N, and 15O.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjYrPjeNgnYrVg90H21EOLACvtfcHk0lje-6PJuOevWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSjsbo%253D&md5=d18cd38e57253fffae7844c93b13588f</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1002%2Fanie.201805501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201805501%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DRong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DJosephson%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26atitle%3DChemistry%2520for%2520positron%2520emission%2520tomography%253A%2520recent%2520advances%2520in%252011C-%252C%252018F-%252C%252013N-%252C%2520and%252015O-labeling%2520reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D2580%26epage%3D2605%26doi%3D10.1002%2Fanie.201805501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span> <span> </span><span class="NLM_article-title">A novel 18F-labeled MAG lipase biomarker for differentiating brown and white adipose tissue in the lipid network</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=262-262&author=Z.+Chenauthor=R.+Chengauthor=J.+Yangauthor=T.+Shaoauthor=N.+Vasdevauthor=C.+Ranauthor=M.-R.+Zhangauthor=S.+Liang&title=A+novel+18F-labeled+MAG+lipase+biomarker+for+differentiating+brown+and+white+adipose+tissue+in+the+lipid+network"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DT.%26aulast%3DVasdev%26aufirst%3DN.%26aulast%3DRan%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.-R.%26aulast%3DLiang%26aufirst%3DS.%26atitle%3DA%2520novel%252018F-labeled%2520MAG%2520lipase%2520biomarker%2520for%2520differentiating%2520brown%2520and%2520white%2520adipose%2520tissue%2520in%2520the%2520lipid%2520network%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D262%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of (4 R)-1-{3-[2-(18F)Fluoro-4-methylpyridin-3-yl]phenyl}-4-[4-(1,3-thiazol-2-ylcarbo nyl)piperazin-1-yl]pyrrolidin-2-one ([<sup>18</sup>F]T-401) as a novel positron-emission tomography imaging agent for monoacylglycerol lipase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2362</span>– <span class="NLM_lpage">2375</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVSht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2362-2375&author=Y.+Hattoriauthor=K.+Aoyamaauthor=J.+Maedaauthor=N.+Arimuraauthor=Y.+Takahashiauthor=M.+Sasakiauthor=M.+Fujinagaauthor=C.+Sekiauthor=Y.+Nagaiauthor=K.+Kawamuraauthor=T.+Yamasakiauthor=M.+R.+Zhangauthor=M.+Higuchiauthor=T.+Koike&title=Design%2C+synthesis%2C+and+evaluation+of+%284+R%29-1-%7B3-%5B2-%2818F%29Fluoro-4-methylpyridin-3-yl%5Dphenyl%7D-4-%5B4-%281%2C3-thiazol-2-ylcarbo+nyl%29piperazin-1-yl%5Dpyrrolidin-2-one+%28%5B18F%5DT-401%29+as+a+novel+positron-emission+tomography+imaging+agent+for+monoacylglycerol+lipase&doi=10.1021%2Facs.jmedchem.8b01576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of (4R)-1-{3-[2-(18F)Fluoro-4-methylpyridin-3-yl]phenyl}-4-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]pyrrolidin-2-one ([18F]T-401) as a Novel Positron-Emission Tomography Imaging Agent for Monoacylglycerol Lipase</span></div><div class="casAuthors">Hattori, Yasushi; Aoyama, Kazunobu; Maeda, Jun; Arimura, Naoto; Takahashi, Yasuko; Sasaki, Masako; Fujinaga, Masayuki; Seki, Chie; Nagai, Yuji; Kawamura, Kazunori; Yamasaki, Tomoteru; Zhang, Ming-Rong; Higuchi, Makoto; Koike, Tatsuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2362-2375</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoacylglycerol lipase (MAGL) is a cytosolic serine hydrolase involved in endocannabinoid and inflammatory signaling.  Positron-emission tomog. (PET) imaging of MAGL serves to validate target engagement of therapeutic MAGL inhibitors as well as to investigate MAGL levels under normal and disease conditions.  However, PET radioligands with reversible binding kinetics for MAGL, which allow quant. assessment of MAGL, are hitherto unavailable.  In this study, we designed and synthesized fluoro-contg. PET probes starting from a recently identified piperazinyl pyrrolidine-2-one deriv. with reversible binding to MAGL.  By tailoring the lipophilicity of the mol. to optimize nonspecific binding and blood-brain barrier permeability, we successfully identified two compds. that show high uptake to regions enriched with MAGL.  PET imaging of wild-type and MAGL-deficient mice as well as a macaque monkey indicated that [18F]I ((4R)-1-{3-[2-(18F)fluoro-4-methylpyridin-3-yl]phenyl}-4-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]pyrrolidin-2-one, [18F]T-401) specifically binds to MAGL with adequate reversibility, yielding a high contrast for MAGL within an appropriate imaging time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppgW6fA1E8WLVg90H21EOLACvtfcHk0lje-6PJuOevWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVSht7k%253D&md5=4848fa8fce411e960b580b5bd007e0c9</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01576%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DY.%26aulast%3DAoyama%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DJ.%26aulast%3DArimura%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DM.%26aulast%3DFujinaga%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DC.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DM.%2BR.%26aulast%3DHiguchi%26aufirst%3DM.%26aulast%3DKoike%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520%25284%2520R%2529-1-%257B3-%255B2-%252818F%2529Fluoro-4-methylpyridin-3-yl%255Dphenyl%257D-4-%255B4-%25281%252C3-thiazol-2-ylcarbo%2520nyl%2529piperazin-1-yl%255Dpyrrolidin-2-one%2520%2528%255B18F%255DT-401%2529%2520as%2520a%2520novel%2520positron-emission%2520tomography%2520imaging%2520agent%2520for%2520monoacylglycerol%2520lipase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2362%26epage%3D2375%26doi%3D10.1021%2Facs.jmedchem.8b01576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor 1 positive allosteric modulators for posttraumatic stress disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnpp.2017.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=29192662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCrs7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=226-227&author=A.+Shekharauthor=G.+A.+Thakur&title=Cannabinoid+receptor+1+positive+allosteric+modulators+for+posttraumatic+stress+disorder&doi=10.1038%2Fnpp.2017.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid Receptor 1 Positive Allosteric Modulators for Posttraumatic Stress Disorder</span></div><div class="casAuthors">Shekhar, Anantha; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">226-227</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Post-traumatic stress disorder (PTSD) is a severe psychiatric disorder that develops in a subset of people following a traumatic event.  Exposure-based psychol. treatments and antidepressants are the current first-line treatments for PTSD symptoms.  However, many patients fail to receive effective treatments, drop out treatments, or are non-responsive to existing treatments (Watts et al, 2013), highlighting an urgent unmet need to develop novel therapeutics.  Part of the challenge in developing effective therapies has been the biol. heterogeneity in PTSD pathophysiol.  'Broad-spectrum' therapies such as antidepressants and standardized exposure therapies may not account for the biol. diversity of the underlying deficits in neurotransmitter mechanisms, stress resiliency, and learning deficits.  One of the novel targets that has emerged as being involved in PTSD with strong preclin. and human data is the endocannabinoid system.  The endocannabinoid system includes two principal cannabinoid receptors (CB1R and CB2R), their several endogenous ligands, including the two key ligands anandamide and 2- arachidonoylglycerol (2-AG), and enzymes responsible for endocannabinoid biosynthesis and inactivation.  Although there are some conflicting findings, perhaps due to differences in exptl. conditions, preclin. studies of fear disorder models generally support the concept that selective agonists of CB1R facilitate fear extinction.  Subjects with PTSD are reported to have significantly lower CB1R availability and reduced peripheral concn. of anandamide (Pietrzak et al, 2014; Neumeister et al, 2015) and appears to be assocd. with threat processing in trauma survivors (Pietrzak et al, 2014).  These data suggest that low anandamide levels and upregulation of endocannabinoid receptors in the amygdale-hippocampal-cortico-striatal circuitry could result in the enhanced reactivity to threat stimuli, and endogenous cannabinoid would ameliorate such responses (Neumeister et al, 2015).  Despite this strong mechanistic rationale, utilizing direct agonists of CB1R receptors has several disadvantages.  The CB1 receptors regulate many opposing functions in brain, esp. in the regulation of fear regulation circuitry and downregulation of receptors are seen after chronic exposure to agonists.  Agonists could also have adverse effects from off-target CB1 activation.  Therefore, alternative approaches to augment endocannabinoid signaling need to be explored.  One such promising approach is through inhibition of fatty acid amide hydrolase (FAAH) involved in endocannabinoid catabolism that would increase the availability of endogenously generated endocannabinoids (Gunduz-Cinar et al, 2013).  A second approach is to utilize pos. allosteric modulators (PAMs) that selectively increase the CB1R effects.  CB1R has allosteric sites spatially distinct from the orthosteric ligand-binding pocket, and engagement of CB1R by allosteric modulators induce a conformational change in the receptor that may be difficult to achieve with orthosteric ligands alone and thus one can 'fine-tune' the pharmacol. activity of the endogenous ligand.  Such compds. could offer not only enhanced CB1R selectivity, but also reduced receptor downregulation and inter-receptor promiscuity (Kulkarni et al, 2016).  One such compd. GAT211 increases CB1R effects, demonstrates good efficacy in rodent models of chronic pain without demonstrating acute tolerance, rewarding properties or dependence (Slivicki et al, 2017).  Our preliminary data show that GAT211 also enhances fear extinction in auditory cue-induced fear conditioning model and could potentially provide a novel approach to PTSD drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJLpQeI_DkbVg90H21EOLACvtfcHk0lgOh9z9fSQ_iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCrs7bM&md5=bec736b4161aca902cec0be97020c0f1</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.230%26sid%3Dliteratum%253Aachs%26aulast%3DShekhar%26aufirst%3DA.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DCannabinoid%2520receptor%25201%2520positive%2520allosteric%2520modulators%2520for%2520posttraumatic%2520stress%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D226%26epage%3D227%26doi%3D10.1038%2Fnpp.2017.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span> <span> </span><span class="NLM_article-title">Structure of an allosteric modulator bound to the CB1 cannabinoid receptor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1205</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0387-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41589-019-0387-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=31659318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCksLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1199-1205&author=Z.+Shaoauthor=W.+Yanauthor=K.+Chapmanauthor=K.+Rameshauthor=A.+J.+Ferrellauthor=J.+Yinauthor=X.+Wangauthor=Q.+Xuauthor=D.+M.+Rosenbaum&title=Structure+of+an+allosteric+modulator+bound+to+the+CB1+cannabinoid+receptor&doi=10.1038%2Fs41589-019-0387-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of an allosteric modulator bound to the CB1 cannabinoid receptor</span></div><div class="casAuthors">Shao, Zhenhua; Yan, Wei; Chapman, Karen; Ramesh, Karthik; Ferrell, Aaron J.; Yin, Jie; Wang, Xuehui; Xu, Qingping; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-1205</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The CB1 receptor mediates the central nervous system response to cannabinoids, and is a drug target for pain, anxiety and seizures.  CB1 also responds to allosteric modulators, which influence cannabinoid binding and efficacy.  To understand the mechanism of these compds., we solved the crystal structure of CB1 with the neg. allosteric modulator (NAM) ORG27569 and the agonist CP55940.  The structure reveals that the NAM binds to an extrahelical site within the inner leaflet of the membrane, which overlaps with a conserved site of cholesterol interaction in many G protein-coupled receptors (GPCRs).  The ternary structure with ORG27569 and CP55940 captures an intermediate state of the receptor, in which arom. residues at the base of the agonist-binding pocket adopt an inactive conformation despite the large contraction of the orthosteric pocket.  The structure illustrates a potential strategy for drug modulation of CB1 and other class A GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz52KMEDfkTbVg90H21EOLACvtfcHk0lgOh9z9fSQ_iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCksLnM&md5=58150bc1805c874c5dce7ed13fcf7c68</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0387-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0387-2%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DRamesh%26aufirst%3DK.%26aulast%3DFerrell%26aufirst%3DA.%2BJ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26atitle%3DStructure%2520of%2520an%2520allosteric%2520modulator%2520bound%2520to%2520the%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D1199%26epage%3D1205%26doi%3D10.1038%2Fs41589-019-0387-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerksen, R. J.</span></span> <span> </span><span class="NLM_article-title">Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1080/07391102.2019.1567384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1080%2F07391102.2019.1567384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30652534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFygs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=32-47&author=P.+Pandeyauthor=K.+K.+Royauthor=R.+J.+Doerksen&title=Negative+allosteric+modulators+of+cannabinoid+receptor+2%3A+protein+modeling%2C+binding+site+identification+and+molecular+dynamics+simulations+in+the+presence+of+an+orthosteric+agonist&doi=10.1080%2F07391102.2019.1567384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist</span></div><div class="casAuthors">Pandey, Pankaj; Roy, Kuldeep K.; Doerksen, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Selective activation of the cannabinoid receptor subtype 2 (CB2) shows promise for treating pain, inflammation, multiple sclerosis, cancer, ischemic/reperfusion injury and osteoporosis.  Target selectivity and off-target side effects are two major limiting factors for orthosteric ligands, and therefore, the search for allosteric modulators (AMs) is a widely used drug discovery approach.  To date, only a limited no. of neg. CB2 AMs have been identified, possessing only micromolar activity at best, and the CB2 receptor's allosteric site(s) are not well characterized.  Herein, we used computational approaches including receptor modeling, site mapping, docking, mol. dynamics (MD) simulations and binding free energy calcns. to predict, characterize and validate allosteric sites within the complex of the CB2 receptor with bound orthosteric agonist CP55,940.  After docking of known neg. CB2 allosteric modulators (NAMs), dihydro-gambogic acid (DHGA) and trans-β-caryophyllene (TBC) (note that TBC also shows agonist activity), at the predicted allosteric sites, the best total complex with CB2, CP55,940 and NAM was embedded into a hydrated lipid bilayer and subjected to a 200 ns MD simulation.  The presence of an AM affected the CB2-CP55,940 complex, altering the relative positioning of the toggle switch residues and promoting a strong π-π interaction between Phe1173.36 and Trp2586.48.  Binding of either TBC or DHGA to a putative allosteric pocket directly adjacent to the orthosteric ligand reduced the binding free energy of CP55,940, which is consistent with the expected effect of a neg. AM.  The identified allosteric sites present immense scope for the discovery of novel classes of CB2 AMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkASmOl3-otbVg90H21EOLACvtfcHk0lgOh9z9fSQ_iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFygs78%253D&md5=a34d458fdc37179e86836bc5c1cd7afd</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1080%2F07391102.2019.1567384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2019.1567384%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DP.%26aulast%3DRoy%26aufirst%3DK.%2BK.%26aulast%3DDoerksen%26aufirst%3DR.%2BJ.%26atitle%3DNegative%2520allosteric%2520modulators%2520of%2520cannabinoid%2520receptor%25202%253A%2520protein%2520modeling%252C%2520binding%2520site%2520identification%2520and%2520molecular%2520dynamics%2520simulations%2520in%2520the%2520presence%2520of%2520an%2520orthosteric%2520agonist%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2020%26volume%3D38%26spage%3D32%26epage%3D47%26doi%3D10.1080%2F07391102.2019.1567384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4805</span>, <span class="refDoi"> DOI: 10.1111/bph.13250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1111%2Fbph.13250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26218440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1CntL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=4790-4805&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=M.+E.+Kellyauthor=E.+M.+Denovan-Wright&title=Cannabidiol+is+a+negative+allosteric+modulator+of+the+cannabinoid+CB1+receptor&doi=10.1111%2Fbph.13250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor</span></div><div class="casAuthors">Laprairie, R. B.; Bagher, A. M.; Kelly, M. E. M.; Denovan-Wright, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4790-4805</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Cannabidiol has been reported to act as an antagonist at cannabinoid CB1 receptors.  We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through neg. allosteric modulation of CB1 receptors.  Exptl. Approach : Internalization of CB1 receptors, arrestin2 recruitment, and PLCβ3 and ERK1/2 phosphorylation, were quantified in HEK 293A cells heterologously expressing CB1 receptors and in the STHdhQ7/Q7 cell model of striatal neurons endogenously expressing CB1 receptors.  Cells were treated with 2-arachidonylglycerol or Δ9-tetrahydrocannabinol alone and in combination with different concns. of cannabidiol.  Key Results : Cannabidiol reduced the efficacy and potency of 2-arachidonylglycerol and Δ9-tetrahydrocannabinol on PLCβ3- and ERK1/2-dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdhQ7/Q7) expressing CB1 receptors.  By reducing arrestin2 recruitment to CB1 receptors, cannabidiol treatment prevented internalization of these receptors.  The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB1 receptor.  Conclusions and Implications : Cannabidiol behaved as a non-competitive neg. allosteric modulator of CB1 receptors.  Allosteric modulation, in conjunction with effects not mediated by CB1 receptors, may explain the in vivo effects of cannabidiol.  Allosteric modulators of CB1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects assocd. with orthosteric agonism or antagonism of these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCPkVL0nj1bLVg90H21EOLACvtfcHk0lh0yrBgaaYKpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1CntL7P&md5=312ae749b793eb27dc8d50e21aba4fe8</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1111%2Fbph.13250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13250%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DCannabidiol%2520is%2520a%2520negative%2520allosteric%2520modulator%2520of%2520the%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D4790%26epage%3D4805%26doi%3D10.1111%2Fbph.13250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborrini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poetz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertsch, J.</span></span> <span> </span><span class="NLM_article-title">Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">36944</span>– <span class="NLM_lpage">36967</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.382481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1074%2Fjbc.M112.382481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=22952224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=36944-36967&author=M.+Bauerauthor=A.+Chiccaauthor=M.+Tamborriniauthor=D.+Eisenauthor=R.+Lernerauthor=B.+Lutzauthor=O.+Poetzauthor=G.+Pluschkeauthor=J.+Gertsch&title=Identification+and+quantification+of+a+new+family+of+peptide+endocannabinoids+%28Pepcans%29+showing+negative+allosteric+modulation+at+CB1+receptors&doi=10.1074%2Fjbc.M112.382481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Quantification of a New Family of Peptide Endocannabinoids (Pepcans) Showing Negative Allosteric Modulation at CB1 Receptors</span></div><div class="casAuthors">Bauer, Mark; Chicca, Andrea; Tamborrini, Marco; Eisen, David; Lerner, Raissa; Lutz, Beat; Poetz, Oliver; Pluschke, Gerd; Gertsch, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">36944-36967</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The α-Hb-derived dodecapeptide RVD-hemopressin (RVDPVNFKLLSH) has been proposed to be an endogenous agonist for the cannabinoid receptor type 1 (CB1).  To study this peptide, we have raised mAbs against its C-terminal part.  Using an immunoaffinity mass spectrometry approach, a whole family of N-terminally extended peptides in addn. to RVD-Hpα were identified in rodent brain exts. and human and mouse plasma.  We designated these peptides Pepcan-12 (RVDPVNFKLLSH) to Pepcan-23 (SALSDLHAHKLRVDPVNFKLLSH), referring to peptide length.  The most abundant Pepcans found in the brain were tested for CB1 receptor binding.  In the classical radioligand displacement assay, Pepcan-12 was the most efficacious ligand but only partially displaced both [3H]CP 55,940 and [3H]WIN 55,212-2.  The data were fitted with the allosteric ternary complex model, revealing a cooperativity factor value α < 1, thus indicating a neg. allosteric modulation.  Dissocn. kinetic studies of [3H]CP 55,940 in the absence and presence of Pepcan-12 confirmed these results by showing increased dissocn. rate consts. induced by Pepcan-12.  A fluorescently labeled Pepcan-12 analog was synthesized to investigate the binding to CB1 receptors.  Competition binding studies revealed Ki values of several Pepcans in the nanomolar range.  Accordingly, using competitive ELISA, we found low nanomolar concns. of Pepcans in human plasma and ∼100 pmol/g in mouse brain.  Surprisingly, Pepcan-12 exhibited potent neg. allosteric modulation of the orthosteric agonist-induced cAMP accumulation, [35S]GTPγS binding, and CB1 receptor internalization.  Pepcans are the first endogenous allosteric modulators identified for CB1 receptors.  Given their abundance in the brain, Pepcans could play an important physiol. role in modulating endocannabinoid signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1hojsDy4as7Vg90H21EOLACvtfcHk0lh0yrBgaaYKpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqsrfP&md5=02f7eab97175b4b0bd4bed69be655aa0</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.382481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.382481%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DM.%26aulast%3DChicca%26aufirst%3DA.%26aulast%3DTamborrini%26aufirst%3DM.%26aulast%3DEisen%26aufirst%3DD.%26aulast%3DLerner%26aufirst%3DR.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DPoetz%26aufirst%3DO.%26aulast%3DPluschke%26aufirst%3DG.%26aulast%3DGertsch%26aufirst%3DJ.%26atitle%3DIdentification%2520and%2520quantification%2520of%2520a%2520new%2520family%2520of%2520peptide%2520endocannabinoids%2520%2528Pepcans%2529%2520showing%2520negative%2520allosteric%2520modulation%2520at%2520CB1%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D36944%26epage%3D36967%26doi%3D10.1074%2Fjbc.M112.382481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pamplona, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes de Lima, O.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarinho, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotjak, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calixto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimarães, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. N.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">21134</span>– <span class="NLM_lpage">21139</span>, <span class="refDoi"> DOI: 10.1073/pnas.1202906109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.1202906109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23150578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1eksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=21134-21139&author=F.+A.+Pamplonaauthor=J.+Ferreiraauthor=O.+Menezes+de+Limaauthor=F.+S.+Duarteauthor=A.+F.+Bentoauthor=S.+Fornerauthor=J.+G.+Villarinhoauthor=L.+Bellocchioauthor=C.+T.+Wotjakauthor=R.+Lernerauthor=K.+Monoryauthor=B.+Lutzauthor=C.+Canettiauthor=I.+Matiasauthor=J.+B.+Calixtoauthor=G.+Marsicanoauthor=M.+Z.+Guimar%C3%A3esauthor=R.+N.+Takahashi&title=Anti-inflammatory+lipoxin+A4+is+an+endogenous+allosteric+enhancer+of+CB1+cannabinoid+receptor&doi=10.1073%2Fpnas.1202906109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor</span></div><div class="casAuthors">Pamplona, Fabricio A.; Ferreira, Juliano; Menezes de Lima, Octavio, Jr.; Duarte, Filipe Silveira; Bento, Allisson Freire; Forner, Stefania; Villarinho, Jardel G.; Bellocchio, Luigi; Wotjak, Carsten T.; Lerner, Raissa; Monory, Krisztina; Lutz, Beat; Canetti, Claudio; Matias, Isabelle; Calixto, Joao Batista; Marsicano, Giovanni; Guimaraes, Marilia Z. P.; Takahashi, Reinaldo N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">21134-21139, S21134/1-S21134/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Allosteric modulation of G-protein-coupled receptors represents a key goal of current pharmacol.  In particular, endogenous allosteric modulators might represent important targets of interventions aimed at maximizing therapeutic efficacy and reducing side effects of drugs.  The anti-inflammatory lipid lipoxin A4 is an endogenous allosteric enhancer of the CB1 cannabinoid receptor.  Lipoxin A4 was detected in brain tissues, did not compete for the orthosteric binding site of the CB1 receptor (vs. 3H-SR141716A), and did not alter endocannabinoid metab. (as opposed to URB597 and MAFP), but it enhanced affinity of anandamide at the CB1 receptor, thereby potentiating the effects of this endocannabinoid both in vitro and in vivo.  In addn., lipoxin A4 displayed a CB1 receptor-dependent protective effect against β-amyloid (1-40)-induced spatial memory impairment in mice.  The discovery of lipoxins as a class of endogenous allosteric modulators of CB1 receptors may foster the therapeutic exploitation of the endocannabinoid system, in particular for the treatment of neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtolBezEx077Vg90H21EOLACvtfcHk0lh0yrBgaaYKpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1eksw%253D%253D&md5=594b68271d19309dcdc26f1c59738bdc</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1202906109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1202906109%26sid%3Dliteratum%253Aachs%26aulast%3DPamplona%26aufirst%3DF.%2BA.%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DMenezes%2Bde%2BLima%26aufirst%3DO.%26aulast%3DDuarte%26aufirst%3DF.%2BS.%26aulast%3DBento%26aufirst%3DA.%2BF.%26aulast%3DForner%26aufirst%3DS.%26aulast%3DVillarinho%26aufirst%3DJ.%2BG.%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DWotjak%26aufirst%3DC.%2BT.%26aulast%3DLerner%26aufirst%3DR.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DCanetti%26aufirst%3DC.%26aulast%3DMatias%26aufirst%3DI.%26aulast%3DCalixto%26aufirst%3DJ.%2BB.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DGuimar%25C3%25A3es%26aufirst%3DM.%2BZ.%26aulast%3DTakahashi%26aufirst%3DR.%2BN.%26atitle%3DAnti-inflammatory%2520lipoxin%2520A4%2520is%2520an%2520endogenous%2520allosteric%2520enhancer%2520of%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D21134%26epage%3D21139%26doi%3D10.1073%2Fpnas.1202906109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ignatowska-Jankowska, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damaj, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span> <span> </span><span class="NLM_article-title">A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2948</span>– <span class="NLM_lpage">2959</span>, <span class="refDoi"> DOI: 10.1038/npp.2015.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnpp.2015.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26052038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=2948-2959&author=B.+M.+Ignatowska-Jankowskaauthor=G.+L.+Baillieauthor=S.+Kinseyauthor=M.+Croweauthor=S.+Ghoshauthor=R.+A.+Owensauthor=I.+M.+Damajauthor=J.+Poklisauthor=J.+L.+Wileyauthor=M.+Zandaauthor=C.+Zanatoauthor=I.+R.+Greigauthor=A.+H.+Lichtmanauthor=R.+A.+Ross&title=A+cannabinoid+CB1+receptor-positive+allosteric+modulator+reduces+neuropathic+pain+in+the+mouse+with+no+psychoactive+effects&doi=10.1038%2Fnpp.2015.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects</span></div><div class="casAuthors">Ignatowska-Jankowska, Bogna M.; Baillie, Gemma L.; Kinsey, Steven; Crowe, Molly; Ghosh, Sudeshna; Owens, Robert A.; Damaj, Imad M.; Poklis, Justin; Wiley, Jenny L.; Zanda, Matteo; Zanato, Chiara; Greig, Iain R.; Lichtman, Aron H.; Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2948-2959</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The CB1 receptor represents a promising target for the treatment of several disorders including pain-related disease states.  However, therapeutic applications of Δ9-tetrahydrocannabinol and other CB1 orthosteric receptor agonists remain limited because of psychoactive side effects.  Pos. allosteric modulators (PAMs) offer an alternative approach to enhance CB1 receptor function for therapeutic gain with the promise of reduced side effects.  Here we describe the development of the novel synthetic CB1 PAM, 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011), which augments the in vitro and in vivo pharmacol. actions of the CB1 orthosteric agonists CP55,940 and N-arachidonoylethanolamine (AEA).  ZCZ011 potentiated binding of [3H]CP55,940 to the CB1 receptor as well as enhancing AEA-stimulated [35S]GTPγS binding in mouse brain membranes and β-arrestin recruitment and ERK phosphorylation in hCB1 cells.  In the whole animal, ZCZ011 is brain penetrant, increased the potency of these orthosteric agonists in mouse behavioral assays indicative of cannabimimetic activity, including antinociception, hypothermia, catalepsy, locomotor activity, and in the drug discrimination paradigm.  Administration of ZCZ011 alone was devoid of activity in these assays and did not produce a conditioned place preference or aversion, but elicited CB1 receptor-mediated antinociceptive effects in the chronic constriction nerve injury model of neuropathic pain and carrageenan model of inflammatory pain.  These data suggest that ZCZ011 acts as a CB1 PAM and provide the first proof of principle that CB1 PAMs offer a promising strategy to treat neuropathic and inflammatory pain with minimal or no cannabimimetic side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGrwc1SxmigLVg90H21EOLACvtfcHk0lgIuor-ZWrJMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jI&md5=353f294dc5044468997e98fb49711abf</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.148%26sid%3Dliteratum%253Aachs%26aulast%3DIgnatowska-Jankowska%26aufirst%3DB.%2BM.%26aulast%3DBaillie%26aufirst%3DG.%2BL.%26aulast%3DKinsey%26aufirst%3DS.%26aulast%3DCrowe%26aufirst%3DM.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DOwens%26aufirst%3DR.%2BA.%26aulast%3DDamaj%26aufirst%3DI.%2BM.%26aulast%3DPoklis%26aufirst%3DJ.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DZanda%26aufirst%3DM.%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DGreig%26aufirst%3DI.%2BR.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DA%2520cannabinoid%2520CB1%2520receptor-positive%2520allosteric%2520modulator%2520reduces%2520neuropathic%2520pain%2520in%2520the%2520mouse%2520with%2520no%2520psychoactive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2015%26volume%3D40%26spage%3D2948%26epage%3D2959%26doi%3D10.1038%2Fnpp.2015.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khurana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, D. A.</span></span> <span> </span><span class="NLM_article-title">Modulation of CB1 cannabinoid receptor by allosteric ligands: pharmacology and therapeutic opportunities</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuropharm.2017.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=28527758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVWhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=3-12&author=L.+Khuranaauthor=K.+Mackieauthor=D.+Piomelliauthor=D.+A.+Kendall&title=Modulation+of+CB1+cannabinoid+receptor+by+allosteric+ligands%3A+pharmacology+and+therapeutic+opportunities&doi=10.1016%2Fj.neuropharm.2017.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities</span></div><div class="casAuthors">Khurana, Leepakshi; Mackie, Ken; Piomelli, Daniele; Kendall, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-12</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cannabinoid pharmacol. has been intensely studied because of cannabis' pervasive medicinal and non-medicinal uses as well as for the therapeutic potential of cannabinoid-based drugs for the treatment of pain, anxiety, substance abuse, obesity, cancer and neurodegenerative disorders.  The identification of allosteric modulators of the cannabinoid receptor 1 (CB1) has given a new direction to the development of cannabinoid-based therapeutics due to the many advantages offered by targeting allosteric site(s).  Allosteric receptor modulators hold potential to develop subtype-specific and pathway-specific therapeutics.  Here we briefly discuss the first-generation of allosteric modulators of CB1 receptor, their structure-activity relationships, signaling pathways and the allosteric binding site(s) on the CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1NhrM0zr7WrVg90H21EOLACvtfcHk0lgIuor-ZWrJMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVWhtbk%253D&md5=b89f30916f32ae196b0c234f9d4ed385</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DKhurana%26aufirst%3DL.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DKendall%26aufirst%3DD.%2BA.%26atitle%3DModulation%2520of%2520CB1%2520cannabinoid%2520receptor%2520by%2520allosteric%2520ligands%253A%2520pharmacology%2520and%2520therapeutic%2520opportunities%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D124%26spage%3D3%26epage%3D12%26doi%3D10.1016%2Fj.neuropharm.2017.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dainese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelucci, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufrusine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fezza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fabritiis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid hydrolase FAAH is an allosteric enzyme</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2292</span>, <span class="refDoi"> DOI: 10.1038/s41598-020-59120-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41598-020-59120-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32041998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVagtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=2292&author=E.+Daineseauthor=S.+Oddiauthor=M.+Simonettiauthor=A.+Sabatucciauthor=C.+B.+Angelucciauthor=A.+Balloneauthor=B.+Dufrusineauthor=F.+Fezzaauthor=G.+De+Fabritiisauthor=M.+Maccarrone&title=The+endocannabinoid+hydrolase+FAAH+is+an+allosteric+enzyme&doi=10.1038%2Fs41598-020-59120-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid hydrolase FAAH is an allosteric enzyme</span></div><div class="casAuthors">Dainese, Enrico; Oddi, Sergio; Simonetti, Monica; Sabatucci, Annalaura; Angelucci, Clotilde B.; Ballone, Alice; Dufrusine, Beatrice; Fezza, Filomena; De Fabritiis, Gianni; Maccarrone, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2292</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Fatty acid amide hydrolase (FAAH) is a membrane-bound homodimeric enzyme that in vivo controls content and biol. activity of N-arachidonoylethanolamine (AEA) and other relevant bioactive lipids termed endocannabinoids.  Parallel orientation of FAAH monomers likely allows both subunits to simultaneously recruit and cleave substrates.  Here, we show full inhibition of human and rat FAAH by means of enzyme inhibitors used at a homodimer:inhibitor stoichiometric ratio of 1:1, implying that occupation of only one of the two active sites of FAAH is enough to fully block catalysis.  Single W445Y substitution in rat FAAH displayed the same activity as the wild-type, but failed to show full inhibition at the homodimer:inhibitor 1:1 ratio.  Instead, F432A mutant exhibited reduced specific activity but was fully inhibited at the homodimer:inhibitor 1:1 ratio.  Kinetic anal. of AEA hydrolysis by rat FAAH and its F432A mutant demonstrated a Hill coeff. of ∼1.6, that instead was ∼1.0 in the W445Y mutant.  Of note, also human FAAH catalyzed an allosteric hydrolysis of AEA, showing a Hill coeff. of ∼1.9.  Taken together, this study demonstrates an unprecedented allosterism of FAAH, and represents a case of communication between two enzyme subunits seemingly controlled by a single amino acid (W445) at the dimer interface.  In the light of extensive attempts and subsequent failures over the last decade to develop effective drugs for human therapy, these findings pave the way to the rationale design of new mols. that, by acting as pos. or neg. heterotropic effectors of FAAH, may control more efficiently its activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp46eQPj0TvObVg90H21EOLACvtfcHk0lgIuor-ZWrJMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVagtbw%253D&md5=328a4eb1c9832b343028943bc9141a8f</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1038%2Fs41598-020-59120-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-020-59120-1%26sid%3Dliteratum%253Aachs%26aulast%3DDainese%26aufirst%3DE.%26aulast%3DOddi%26aufirst%3DS.%26aulast%3DSimonetti%26aufirst%3DM.%26aulast%3DSabatucci%26aufirst%3DA.%26aulast%3DAngelucci%26aufirst%3DC.%2BB.%26aulast%3DBallone%26aufirst%3DA.%26aulast%3DDufrusine%26aufirst%3DB.%26aulast%3DFezza%26aufirst%3DF.%26aulast%3DDe%2BFabritiis%26aufirst%3DG.%26aulast%3DMaccarrone%26aufirst%3DM.%26atitle%3DThe%2520endocannabinoid%2520hydrolase%2520FAAH%2520is%2520an%2520allosteric%2520enzyme%26jtitle%3DSci.%2520Rep.%26date%3D2020%26volume%3D10%26spage%3D2292%26doi%3D10.1038%2Fs41598-020-59120-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, N.</span></span> <span> </span><span class="NLM_article-title">ABHD6: its place in endocannabinoid signaling and beyond</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2019.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.tips.2019.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30853109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Sis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=267-277&author=J.+K.+Caoauthor=J.+Kaplanauthor=N.+Stella&title=ABHD6%3A+its+place+in+endocannabinoid+signaling+and+beyond&doi=10.1016%2Fj.tips.2019.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">ABHD6: Its Place in Endocannabinoid Signaling and Beyond</span></div><div class="casAuthors">Cao, Jessica K.; Kaplan, Joshua; Stella, Nephi</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-277</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid (eCB) signaling system modulates neurotransmission and inflammation, among other physiol. functions.  Its newest member, α/β-hydrolase domain-contg. 6 (ABHD6), has emerged as a promising therapeutic target to treat several devastating diseases, including epilepsy.  Here, we review the mol. mechanisms that mediate and control eCB signaling and, within it, the specific role of ABHD6.  We also discuss how ABHD6 controls the abundance of addnl. lipids and the trafficking of ionotropic receptors to plasma membranes.  We finish with several unexplored questions regarding this novel enzyme.  Our current understanding of the mol. mechanism and biol. function of ABHD6 provides a strong foundation for the development of small-mol. therapeutics to treat devastating diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsu8ddxQw_fbVg90H21EOLACvtfcHk0lj7S2Bii6ajsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Sis70%253D&md5=b7ed26bafde16f34f3274afd4898bb55</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%2BK.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DStella%26aufirst%3DN.%26atitle%3DABHD6%253A%2520its%2520place%2520in%2520endocannabinoid%2520signaling%2520and%2520beyond%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26spage%3D267%26epage%3D277%26doi%3D10.1016%2Fj.tips.2019.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manterola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal-Chico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Samartín, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Rodríguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Puertas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matute, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mato, S.</span></span> <span> </span><span class="NLM_article-title">Re-examining the potential of targeting ABHD6 in multiple sclerosis: efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.08.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1016%2Fj.neuropharm.2018.08.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30171986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KktLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2018&pages=181-191&author=A.+Manterolaauthor=A.+Bernal-Chicoauthor=R.+Ciprianiauthor=A.+Ruizauthor=A.+P%C3%A9rez-Samart%C3%ADnauthor=M.+Moreno-Rodr%C3%ADguezauthor=K.-L.+Hsuauthor=B.+F.+Cravattauthor=J.+M.+Brownauthor=R.+Rodr%C3%ADguez-Puertasauthor=C.+Matuteauthor=S.+Mato&title=Re-examining+the+potential+of+targeting+ABHD6+in+multiple+sclerosis%3A+efficacy+of+systemic+and+peripherally+restricted+inhibitors+in+experimental+autoimmune+encephalomyelitis&doi=10.1016%2Fj.neuropharm.2018.08.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Manterola, Andrea; Bernal-Chico, Ana; Cipriani, Raffaela; Ruiz, Asier; Perez-Samartin, Alberto; Moreno-Rodriguez, Marta; Hsu, Ku-Lung; Cravatt, Benjamin F.; Brown, J. Mark; Rodriguez-Puertas, Rafael; Matute, Carlos; Mato, Susana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181-191</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">α/β-Hydrolase domain-contg. 6 (ABHD6) contributes to the hydrolysis of the major endocannabinoid 2-arachidonoylglycerol (2-AG) in the central nervous system (CNS) and in the periphery.  ABHD6 blockade has been proposed as novel strategy to treat multiple sclerosis (MS), based on the observation that the inhibitor WWL70 exerts protective anti-inflammatory effects in exptl. autoimmune encephalomyelitis (EAE).  According to recent data, WWL70 exhibits off-target anti-inflammatory activity in microglial cells and the potential of ABHD6 as drug target in MS remains controversial.  Here we further investigated the role of ABHD6 during autoimmune demyelination by comparing the efficacy of two novel inhibitors with different CNS permeability in vivo.  Preventive treatment with the systemically active inhibitor KT182 ameliorated the neurol. signs of EAE during the time-course of disease.  By contrast, administration of the peripherally restricted compd. KT203 was ineffective in attenuating EAE symptomatol.  Both inhibitors failed to improve corticospinal tract conduction latency and to attenuate inflammation at EAE recovery phase, despite being equally active at targeting brain ABHD6.  Chronic administration of KT182 was assocd. to a partial loss of brain CB1 receptor coupling ability, suggesting the engagement of CB1 receptor-mediated mechanisms during the EAE disease progression.  In cultured neurons, KT182 attenuated NMDA-stimulated excitotoxicity and mitochondrial calcium overload.  However, these protective effects were not attributable to ABHD6, as they were not mimicked by the alternative inhibitors KT203, KT195 and WWL70.  These results indicate that ABHD6 blockade exerts only modest therapeutic effects against autoimmune demyelination and call into question its utility as novel drug target in MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry8n8MXlD327Vg90H21EOLACvtfcHk0lj7S2Bii6ajsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KktLfN&md5=8e56796aad16813180c8c0f2f78da317</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.08.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.08.038%26sid%3Dliteratum%253Aachs%26aulast%3DManterola%26aufirst%3DA.%26aulast%3DBernal-Chico%26aufirst%3DA.%26aulast%3DCipriani%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez-Samart%25C3%25ADn%26aufirst%3DA.%26aulast%3DMoreno-Rodr%25C3%25ADguez%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DK.-L.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DRodr%25C3%25ADguez-Puertas%26aufirst%3DR.%26aulast%3DMatute%26aufirst%3DC.%26aulast%3DMato%26aufirst%3DS.%26atitle%3DRe-examining%2520the%2520potential%2520of%2520targeting%2520ABHD6%2520in%2520multiple%2520sclerosis%253A%2520efficacy%2520of%2520systemic%2520and%2520peripherally%2520restricted%2520inhibitors%2520in%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D141%26spage%3D181%26epage%3D191%26doi%3D10.1016%2Fj.neuropharm.2018.08.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichu, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vartabedian, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benthuysen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulanovskaya, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulce, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teijaro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1099</span>– <span class="NLM_lpage">1108</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0155-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41589-018-0155-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30420694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1SgurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1099-1108&author=D.+Ogasawaraauthor=T.-A.+Ichuauthor=V.+F.+Vartabedianauthor=J.+Benthuysenauthor=H.+Jingauthor=A.+Reedauthor=O.+A.+Ulanovskayaauthor=J.+J.+Hulceauthor=A.+Robertsauthor=S.+Brownauthor=H.+Rosenauthor=J.+R.+Teijaroauthor=B.+F.+Cravatt&title=Selective+blockade+of+the+lyso-PS+lipase+ABHD12+stimulates+immune+responses+in+vivo&doi=10.1038%2Fs41589-018-0155-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo</span></div><div class="casAuthors">Ogasawara, Daisuke; Ichu, Taka-Aki; Vartabedian, Vincent F.; Benthuysen, Jacqueline; Jing, Hui; Reed, Alex; Ulanovskaya, Olesya A.; Hulce, Jonathan J.; Roberts, Amanda; Brown, Steven; Rosen, Hugh; Teijaro, John R.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1099-1108</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">ABHD12 metabolizes bioactive lysophospholipids, including lysophosphatidylserine (lyso-PS).  Deleterious mutations in human ABHD12 cause the neurol. disease PHARC, and ABHD12-/- mice display PHARC-like phenotypes, including hearing loss, along with elevated brain lyso-PS and features of stimulated innate immune cell function.  Here, we develop a selective and in vivo-active inhibitor of ABHD12 termed DO264 and show that this compd. elevates lyso-PS in mouse brain and primary human macrophages.  Unlike ABHD12-/- mice, adult mice treated with DO264 exhibited minimal perturbations in auditory function.  On the other hand, both DO264-treated and ABHD12-/- mice displayed heightened immunol. responses to lymphocytic choriomeningitis virus (LCMV) clone 13 infection that manifested as severe lung pathol. with elevated proinflammatory chemokines.  These results reveal similarities and differences in the phenotypic impact of pharmacol. vs. genetic blockade of ABHD12 and point to a key role for this enzyme in regulating immunostimulatory lipid pathways in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp__z7e6AC5arVg90H21EOLACvtfcHk0lj7S2Bii6ajsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1SgurzM&md5=36064050300bdba18f0ef843284efa7b</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0155-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0155-8%26sid%3Dliteratum%253Aachs%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DIchu%26aufirst%3DT.-A.%26aulast%3DVartabedian%26aufirst%3DV.%2BF.%26aulast%3DBenthuysen%26aufirst%3DJ.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DA.%26aulast%3DUlanovskaya%26aufirst%3DO.%2BA.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DRoberts%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DTeijaro%26aufirst%3DJ.%2BR.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DSelective%2520blockade%2520of%2520the%2520lyso-PS%2520lipase%2520ABHD12%2520stimulates%2520immune%2520responses%2520in%2520vivo%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D1099%26epage%3D1108%26doi%3D10.1038%2Fs41589-018-0155-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span> <span> </span><span class="NLM_article-title">Diacylglycerol lipaseα (DAGLα) and DAGLβ cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1124/mol.113.085217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fmol.113.085217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23748223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=296-302&author=T.+Jainauthor=J.+Wager-Millerauthor=K.+Mackieauthor=A.+Straiker&title=Diacylglycerol+lipase%CE%B1+%28DAGL%CE%B1%29+and+DAGL%CE%B2+cooperatively+regulate+the+production+of+2-arachidonoyl+glycerol+in+autaptic+hippocampal+neurons&doi=10.1124%2Fmol.113.085217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Diacylglycerol lipaseα (DAGLα) and DAGLβ cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons</span></div><div class="casAuthors">Jain, Tarun; Wager-Miller, Jim; Mackie, Ken; Straiker, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-302</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cannabinoids are part of an endogenous signaling system consisting of cannabinoid receptors and endogenous cannabinoids as well as the enzymic machinery for their synthesis and degrdn.  Depolarization-induced suppression of excitation (DSE) is a form of cannabinoid CB1 receptor-mediated inhibition of synaptic transmission that involves the prodn. of the endogenous cannabinoid 2-arachidonoyl glycerol (2-AG).  Both diacylglycerol lipase α (DAGLα) and DAGLβ can produce 2-AG in vitro, but evidence from knockout animals argues strongly for a predominant, even exclusive, role for DAGLα in regulation of 2-AG-mediated synaptic plasticity.  What role, if any, might be played by DAGLβ remains largely unknown.  Cultured autaptic hippocampal neurons exhibit robust DSE.  With the ability to rapidly modulate expression of DAGLα and DAGLβ in these neurons with short hairpin RNA, they are well suited for a comparative study of the roles of each isoform in mediating DSE.  We find that RNA interference knockdown of DAGLα substantially reduces autaptic DSE, shifting the "depolarization-response curve" from an ED50 value of 1.7 s to 3.0 s.  Surprisingly, DAGLβ knockdown diminishes DSE as much or more (ED50 6.4 s), suggesting that DAGLβ is also responsible for a portion of 2-AG prodn. in autaptic neurons.  Similarly, the two DAGLs both contribute to the prodn. of 2-AG via group I metabotropic glutamate receptors.  Our results provide the first explicit evidence for a role of DAGLβ in modulating neurotransmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvnPTZAQNA-rVg90H21EOLACvtfcHk0lhx-Y1e6kzwbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsb7K&md5=c53f59e2025712b4e4333c1497bed9e6</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.085217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.085217%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DT.%26aulast%3DWager-Miller%26aufirst%3DJ.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DStraiker%26aufirst%3DA.%26atitle%3DDiacylglycerol%2520lipase%25CE%25B1%2520%2528DAGL%25CE%25B1%2529%2520and%2520DAGL%25CE%25B2%2520cooperatively%2520regulate%2520the%2520production%2520of%25202-arachidonoyl%2520glycerol%2520in%2520autaptic%2520hippocampal%2520neurons%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D296%26epage%3D302%26doi%3D10.1124%2Fmol.113.085217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adibekian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">999</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fnchembio.1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23103940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOmt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=999-1007&author=K.+L.+Hsuauthor=K.+Tsuboiauthor=A.+Adibekianauthor=H.+Pughauthor=K.+Masudaauthor=B.+F.+Cravatt&title=DAGL%CE%B2+inhibition+perturbs+a+lipid+network+involved+in+macrophage+inflammatory+responses&doi=10.1038%2Fnchembio.1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses</span></div><div class="casAuthors">Hsu, Ku-Lung; Tsuboi, Katsunori; Adibekian, Alexander; Pugh, Holly; Masuda, Kim; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">999-1007</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The endocannabinoid 2-arachidonoylglycerol (2-AG) is biosynthesized by diacylglycerol lipases DAGLα and DAGLβ.  Chem. probes to perturb DAGLs are needed to characterize endocannabinoid function in biol. processes.  Here we report a series of 1,2,3-triazole urea inhibitors, along with paired neg.-control and activity-based probes, for the functional anal. of DAGLβ in living systems.  Optimized inhibitors showed high selectivity for DAGLβ over other serine hydrolases, including DAGLα (∼60-fold selectivity), and the limited off-targets, such as ABHD6, were also inhibited by the neg.-control probe.  Using these agents and Daglb-/- mice, we show that DAGLβ inactivation lowers 2-AG, as well as arachidonic acid and eicosanoids, in mouse peritoneal macrophages in a manner that is distinct and complementary to disruption of cytosolic phospholipase-A2.  We obsd. a corresponding redn. in lipopolysaccharide-induced tumor necrosis factor-α release.  These findings indicate that DAGLβ is a key metabolic hub within a lipid network that regulates proinflammatory responses in macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdo9sqnvKCvLVg90H21EOLACvtfcHk0lhx-Y1e6kzwbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOmt7zL&md5=c4ce8861f2a5d73701d1ccdb76481da1</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1105%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DK.%2BL.%26aulast%3DTsuboi%26aufirst%3DK.%26aulast%3DAdibekian%26aufirst%3DA.%26aulast%3DPugh%26aufirst%3DH.%26aulast%3DMasuda%26aufirst%3DK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DDAGL%25CE%25B2%2520inhibition%2520perturbs%2520a%2520lipid%2520network%2520involved%2520in%2520macrophage%2520inflammatory%2520responses%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D999%26epage%3D1007%26doi%3D10.1038%2Fnchembio.1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viader, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggelaar, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Dulk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A. M. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soethoudt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Wel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Alavez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span> <span> </span><span class="NLM_article-title">Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1073/pnas.1522364112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1073%2Fpnas.1522364112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=26668358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWjtLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=26-33&author=D.+Ogasawaraauthor=H.+Dengauthor=A.+Viaderauthor=M.+P.+Baggelaarauthor=A.+Bremanauthor=H.+den+Dulkauthor=A.+M.+C.+H.+van+den+Nieuwendijkauthor=M.+Soethoudtauthor=T.+van+der+Welauthor=J.+Zhouauthor=H.+S.+Overkleeftauthor=M.+Sanchez-Alavezauthor=S.+Moriauthor=W.+Nguyenauthor=B.+Contiauthor=X.+Liuauthor=Y.+Chenauthor=Q.-s.+Liuauthor=B.+F.+Cravattauthor=M.+van+der%0AStelt&title=Rapid+and+profound+rewiring+of+brain+lipid+signaling+networks+by+acute+diacylglycerol+lipase+inhibition&doi=10.1073%2Fpnas.1522364112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition</span></div><div class="casAuthors">Ogasawara, Daisuke; Deng, Hui; Viader, Andreu; Baggelaar, Marc P.; Breman, Arjen; Dulk, Hans den; van den Nieuwendijk, Adriann M. C. H.; Soethoudt, Marjolein; van der Wel, Tom; Zhou, Juan; Overkleeft, Herman S.; Sanchez-Alavez, Manuel; Mo, Simone; Nguyen, William; Conti, Bruno; Liu, Xiaojie; Chen, Yao; Liu, Qing-song; Cravatt, Benjamin F.; van der Stelt, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-33</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Diacylglycerol lipases (DAGLα and DAGLβ) convert diacylglycerol to the endocannabinoid 2-arachidonoylglycerol.  Our understanding of DAGL function has been hindered by a lack of chem. probes that can perturb these enzymes in vivo.  Here, we report a set of centrally active DAGL inhibitors and a structurally related control probe and their use, in combination with chem. proteomics and lipidomics, to det. the impact of acute DAGL blockade on brain lipid networks in mice.  Within 2 h, DAGL inhibition produced a striking reorganization of bioactive lipids, including elevations in DAGs and redns. in endocannabinoids and eicosanoids.  We also found that DAGLα is a short half-life protein, and the inactivation of DAGLs disrupts cannabinoid receptor-dependent synaptic plasticity and impairs neuroinflammatory responses, including lipopolysaccharide-induced anapyrexia.  These findings illuminate the highly interconnected and dynamic nature of lipid signaling pathways in the brain and the central role that DAGL enzymes play in regulating this network.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDxeIZyBqtsbVg90H21EOLACvtfcHk0lhx-Y1e6kzwbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWjtLvP&md5=8c597387f8f8a14539bc2582d42d2d7d</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1522364112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1522364112%26sid%3Dliteratum%253Aachs%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DViader%26aufirst%3DA.%26aulast%3DBaggelaar%26aufirst%3DM.%2BP.%26aulast%3DBreman%26aufirst%3DA.%26aulast%3Dden%2BDulk%26aufirst%3DH.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%2BC.%2BH.%26aulast%3DSoethoudt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BWel%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DSanchez-Alavez%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DW.%26aulast%3DConti%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.-s.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26atitle%3DRapid%2520and%2520profound%2520rewiring%2520of%2520brain%2520lipid%2520signaling%2520networks%2520by%2520acute%2520diacylglycerol%2520lipase%2520inhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D26%26epage%3D33%26doi%3D10.1073%2Fpnas.1522364112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunduz-Cinar, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantae, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paloczi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donvito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Esbroeck, A. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Gracht, A. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotsogianni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Wel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soethoudt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, A. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Hurk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hankemeier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buczynski, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1038/s41589-020-0528-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41589-020-0528-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=32393901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVKhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=667-675&author=E.+D.+Mockauthor=M.+Mustafaauthor=O.+Gunduz-Cinarauthor=R.+Cinarauthor=G.+N.+Petrieauthor=V.+Kantaeauthor=X.+Diauthor=D.+Ogasawaraauthor=Z.+V.+Vargaauthor=J.+Palocziauthor=C.+Milianoauthor=G.+Donvitoauthor=A.+C.+M.+van+Esbroeckauthor=A.+M.+F.+van+der+Grachtauthor=I.+Kotsogianniauthor=J.+K.+Parkauthor=A.+Martellaauthor=T.+van+der%0AWelauthor=M.+Soethoudtauthor=M.+Jiangauthor=T.+J.+Wendelauthor=A.+P.+A.+Janssenauthor=A.+T.+Bakkerauthor=C.+M.+Donovanauthor=L.+I.+Castilloauthor=B.+I.+Floreaauthor=J.+Watauthor=H.+van+den+Hurkauthor=M.+Wittwerauthor=U.+Gretherauthor=A.+Holmesauthor=C.+A.+A.+van+Boeckelauthor=T.+Hankemeierauthor=B.+F.+Cravattauthor=M.+W.+Buczynskiauthor=M.+N.+Hillauthor=P.+Pacherauthor=A.+H.+Lichtmanauthor=M.+van+der%0AStelt&title=Discovery+of+a+NAPE-PLD+inhibitor+that+modulates+emotional+behavior+in+mice&doi=10.1038%2Fs41589-020-0528-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice</span></div><div class="casAuthors">Mock, Elliot D.; Mustafa, Mohammed; Gunduz-Cinar, Ozge; Cinar, Resat; Petrie, Gavin N.; Kantae, Vasudev; Di, Xinyu; Ogasawara, Daisuke; Varga, Zoltan V.; Paloczi, Janos; Miliano, Cristina; Donvito, Giulia; van Esbroeck, Annelot C. M.; van der Gracht, Anouk M. F.; Kotsogianni, Ioli; Park, Joshua K.; Martella, Andrea; van der Wel, Tom; Soethoudt, Marjolein; Jiang, Ming; Wendel, Tiemen J.; Janssen, Antonius P. A.; Bakker, Alexander T.; Donovan, Colleen M.; Castillo, Laura I.; Florea, Bogdan I.; Wat, Jesse; van den Hurk, Helma; Wittwer, Matthias; Grether, Uwe; Holmes, Andrew; van Boeckel, Constant A. A.; Hankemeier, Thomas; Cravatt, Benjamin F.; Buczynski, Matthew W.; Hill, Matthew N.; Pacher, Pal; Lichtman, Aron H.; van der Stelt, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-675</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: N-acylethanolamines (NAEs), which include the endocannabinoid anandamide, represent an important family of signaling lipids in the brain.  The lack of chem. probes that modulate NAE biosynthesis in living systems hamper the understanding of the biol. role of these lipids.  Using a high-throughput screen, chem. proteomics and targeted lipidomics, we report here the discovery and characterization of LEI-401 as a CNS-active N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) inhibitor.  LEI-401 reduced NAE levels in neuroblastoma cells and in the brain of freely moving mice, but not in NAPE-PLD KO cells and mice, resp.  LEI-401 activated the hypothalamus-pituitary-adrenal axis and impaired fear extinction, thereby emulating the effect of a cannabinoid CB1 receptor antagonist, which could be reversed by a fatty acid amide hydrolase inhibitor.  Our findings highlight the distinctive role of NAPE-PLD in NAE biosynthesis in the brain and suggest the presence of an endogenous NAE tone controlling emotional behavior. [graphic not available: see fulltext].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzC9MSWVmbH7Vg90H21EOLACvtfcHk0lgDWN-03OVOQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVKhs7g%253D&md5=093b78b3c98c31031915eea3bb596a18</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1038%2Fs41589-020-0528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-020-0528-7%26sid%3Dliteratum%253Aachs%26aulast%3DMock%26aufirst%3DE.%2BD.%26aulast%3DMustafa%26aufirst%3DM.%26aulast%3DGunduz-Cinar%26aufirst%3DO.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DPetrie%26aufirst%3DG.%2BN.%26aulast%3DKantae%26aufirst%3DV.%26aulast%3DDi%26aufirst%3DX.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3DVarga%26aufirst%3DZ.%2BV.%26aulast%3DPaloczi%26aufirst%3DJ.%26aulast%3DMiliano%26aufirst%3DC.%26aulast%3DDonvito%26aufirst%3DG.%26aulast%3Dvan%2BEsbroeck%26aufirst%3DA.%2BC.%2BM.%26aulast%3Dvan%2Bder%2BGracht%26aufirst%3DA.%2BM.%2BF.%26aulast%3DKotsogianni%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DMartella%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BWel%26aufirst%3DT.%26aulast%3DSoethoudt%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DWendel%26aufirst%3DT.%2BJ.%26aulast%3DJanssen%26aufirst%3DA.%2BP.%2BA.%26aulast%3DBakker%26aufirst%3DA.%2BT.%26aulast%3DDonovan%26aufirst%3DC.%2BM.%26aulast%3DCastillo%26aufirst%3DL.%2BI.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DWat%26aufirst%3DJ.%26aulast%3Dvan%2Bden%2BHurk%26aufirst%3DH.%26aulast%3DWittwer%26aufirst%3DM.%26aulast%3DGrether%26aufirst%3DU.%26aulast%3DHolmes%26aufirst%3DA.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3DHankemeier%26aufirst%3DT.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DBuczynski%26aufirst%3DM.%2BW.%26aulast%3DHill%26aufirst%3DM.%2BN.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520NAPE-PLD%2520inhibitor%2520that%2520modulates%2520emotional%2520behavior%2520in%2520mice%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D16%26spage%3D667%26epage%3D675%26doi%3D10.1038%2Fs41589-020-0528-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdullah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selley, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span> <span> </span><span class="NLM_article-title">Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1124%2Fjpet.112.201426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=23412396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlOgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2013&pages=492-501&author=S.+G.+Kinseyauthor=L.+E.+Wiseauthor=D.+Rameshauthor=R.+Abdullahauthor=D.+E.+Selleyauthor=B.+F.+Cravattauthor=A.+H.+Lichtman&title=Repeated+low-dose+administration+of+the+monoacylglycerol+lipase+inhibitor+JZL184+retains+cannabinoid+receptor+type+1-mediated+antinociceptive+and+gastroprotective+effects&doi=10.1124%2Fjpet.112.201426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects</span></div><div class="casAuthors">Kinsey, Steven G.; Wise, Laura E.; Ramesh, Divya; Abdullah, Rehab; Selley, Dana E.; Cravatt, Benjamin F.; Lichtman, Aron H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">492-501</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The monoacylglycerol lipase (MAGL) inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) produces antinociceptive and anti-inflammatory effects.  However, repeated administration of high-dose JZL184 (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacol. effects of cannabinoid receptor agonists, and cannabinoid receptor type 1 (CB1) downregulation and desensitization.  This functional CB1 receptor tolerance poses a hurdle in the development of MAGL inhibitors for therapeutic use.  Consequently, the present study tested whether repeated administration of low-dose JZL184 maintains its antinociceptive actions in the chronic constriction injury of the sciatic nerve neuropathic pain model and protective effects in a model of nonsteroidal anti-inflammatory drug-induced gastric hemorrhages.  Mice given daily injections of high-dose JZL184 (≥16 mg/kg) for 6 days displayed decreased CB1 receptor d. and function in the brain, as assessed in [3H]SR141716A binding and CP55,940 [(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol]-stimulated guanosine 5'-O-(3-[35S]thio)triphosphate binding assays, resp.  In contrast, normal CB1 receptor expression and function were maintained following repeated administration of low-dose JZL184 (≤8 mg/kg).  Likewise, the antinociceptive and gastroprotective effects of high-dose JZL184 underwent tolerance following repeated administration, but these effects were maintained following repeated low-dose JZL184 treatment.  Consistent with these observations, repeated high-dose JZL184, but not repeated low-dose JZL184, elicited cross-tolerance to the common pharmacol. effects of Δ9-tetrahydrocannabinol.  This same pattern of effects was found in a rimonabant [(5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide)]-pptd. withdrawal model of cannabinoid dependence.  Taken together, these results indicate that prolonged, partial MAGL inhibition maintains potentially beneficial antinociceptive and anti-inflammatory effects, without producing functional CB1 receptor tachyphylaxis/tolerance or cannabinoid dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZkkceF1Il2rVg90H21EOLACvtfcHk0lgDWN-03OVOQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlOgsL0%253D&md5=ea906c8140fa02a53729ff4fcbdcd8a8</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201426%26sid%3Dliteratum%253Aachs%26aulast%3DKinsey%26aufirst%3DS.%2BG.%26aulast%3DWise%26aufirst%3DL.%2BE.%26aulast%3DRamesh%26aufirst%3DD.%26aulast%3DAbdullah%26aufirst%3DR.%26aulast%3DSelley%26aufirst%3DD.%2BE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26atitle%3DRepeated%2520low-dose%2520administration%2520of%2520the%2520monoacylglycerol%2520lipase%2520inhibitor%2520JZL184%2520retains%2520cannabinoid%2520receptor%2520type%25201-mediated%2520antinociceptive%2520and%2520gastroprotective%2520effects%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D345%26spage%3D492%26epage%3D501%26doi%3D10.1124%2Fjpet.112.201426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotstein, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasdev, N.</span></span> <span> </span><span class="NLM_article-title">Facile 18F labeling of non-activated arenes via a spirocyclic iodonium(III) ylide method and its application in the synthesis of the mGluR5 PET radiopharmaceutical [<sup>18</sup>F]FPEB</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1038/s41596-019-0149-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=10.1038%2Fs41596-019-0149-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=30980032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12jsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1530-1545&author=S.+H.+Liangauthor=L.+Wangauthor=N.+A.+Stephensonauthor=B.+H.+Rotsteinauthor=N.+Vasdev&title=Facile+18F+labeling+of+non-activated+arenes+via+a+spirocyclic+iodonium%28III%29+ylide+method+and+its+application+in+the+synthesis+of+the+mGluR5+PET+radiopharmaceutical+%5B18F%5DFPEB&doi=10.1038%2Fs41596-019-0149-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Facile 18F labeling of non-activated arenes via a spirocyclic iodonium(III) ylide method and its application in the synthesis of the mGluR5 PET radiopharmaceutical [18F]FPEB</span></div><div class="casAuthors">Liang, Steven H.; Wang, Lu; Stephenson, Nickeisha A.; Rotstein, Benjamin H.; Vasdev, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1530-1545</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Non-activated (electron-rich and/or sterically hindered) arenes are prevalent chem. scaffolds in pharmaceuticals and positron emission tomog. (PET) diagnostics.  Despite substantial efforts to develop a general method to introduce 18F into these moieties for mol. imaging by PET, there is an urgent and unmet need for novel radiofluorination strategies that result in sufficiently labeled tracers to enable human imaging.  Herein, we describe an efficient method that relies on spirocyclic iodonium ylide (SCIDY) precursors for one-step and regioselective radiofluorination, as well as proof-of-concept translation to the radiosynthesis of a clin. useful PET tracer, 3-[18F]fluoro-5-[(pyridin-3-yl)ethynyl] benzonitrile ([18F]FPEB).  The protocol begins with the prepn. of a SCIDY precursor for FPEB, followed by radiosynthesis of [18F]FPEB, by either manual operation or an automated synthesis module. [18F]FPEB can be obtained in quantities >7.4 GBq (200 mCi), ready for injection (20 ± 5%, non-decay cor.), and has excellent chem. and radiochem. purity (>98%) as well as high molar activity (666 ± 51.8 GBq/μmol; 18 ± 1.4 Ci/μmol).  The total time for the synthesis and purifn. of the corresponding labeling SCIDY precursor is 10 h.  The subsequent radionuclide prodn., exptl. setup, 18F labeling, and formulation of a product that is ready for injection require 2 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNst5tL0zqK7Vg90H21EOLACvtfcHk0lgDWN-03OVOQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12jsrg%253D&md5=16cb676c294708a7c7c5a801ae220d92</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1038%2Fs41596-019-0149-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41596-019-0149-3%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStephenson%26aufirst%3DN.%2BA.%26aulast%3DRotstein%26aufirst%3DB.%2BH.%26aulast%3DVasdev%26aufirst%3DN.%26atitle%3DFacile%252018F%2520labeling%2520of%2520non-activated%2520arenes%2520via%2520a%2520spirocyclic%2520iodonium%2528III%2529%2520ylide%2520method%2520and%2520its%2520application%2520in%2520the%2520synthesis%2520of%2520the%2520mGluR5%2520PET%2520radiopharmaceutical%2520%255B18F%255DFPEB%26jtitle%3DNat.%2520Protoc.%26date%3D2019%26volume%3D14%26spage%3D1530%26epage%3D1545%26doi%3D10.1038%2Fs41596-019-0149-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01459&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01459%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01459" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679986f5c93e3c6a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
